WO2011034397A2 - Method for predicting drug targets and screening for drugs for pathogenic microorganisms using essential metabolites - Google Patents
Method for predicting drug targets and screening for drugs for pathogenic microorganisms using essential metabolites Download PDFInfo
- Publication number
- WO2011034397A2 WO2011034397A2 PCT/KR2010/006469 KR2010006469W WO2011034397A2 WO 2011034397 A2 WO2011034397 A2 WO 2011034397A2 KR 2010006469 W KR2010006469 W KR 2010006469W WO 2011034397 A2 WO2011034397 A2 WO 2011034397A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- essential
- metabolite
- phosphate
- metabolism
- metabolites
- Prior art date
Links
- 0 C*C(c(cc1*[O-])ccc1[N+][O-])=O Chemical compound C*C(c(cc1*[O-])ccc1[N+][O-])=O 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Definitions
- the present invention relates to a method for predicting a drug target and a drug search method of a pathogenic microorganism using computer system technology, and more specifically, selecting a target microorganism, constructing a metabolic network model of the selected microorganism, and then analyzing essential metabolite (metabolite). essentiality, removal of circulation metabolite, consideration of the number of reaction schemes, methods of predicting drug targets using irrelevance to host metabolism, and antimicrobial drugs from compounds with structural similarities to the selected essential metabolites. It relates to a method of screening.
- Pathogenic microorganisms can be very difficult and fatal to treat if they occur in people with weakened immune systems. Therefore, efforts to find a target for the development of effective anti-pathogenic drugs of pathogenic microorganisms are active.
- Metabolic flow analysis uses the mass balance and cell composition information of biochemical equations to obtain the ideal metabolic flow space that cells can reach, and aims to maximize or minimize specific objective functions through optimization methods (maximization of cell growth rate or specific perturbation). Minimization of metabolic regulation by
- metabolic flow analysis can generally be used to confirm the lethality of specific genes of a desired metabolite through strain improvement, and can be used to determine the metabolic network characteristics within the strain.
- various studies have been reported applying metabolic flow analysis methods to predict the flow changes in metabolic networks caused by the removal or addition of genes.
- metabolic flow analysis techniques can be used to look at the metabolism of complex microorganisms from a holistic perspective using partial metabolic information and to identify the effects of manipulation on specific genes on overall metabolic flow to accurately predict drug targets of pathogenic microorganisms. There is an urgent need for the development of such methods.
- the present inventors constructed a metabolic network model of the microbial pathogens Acinetobacter baumannii and Vibrio vulnificus , and then applied a metabolite analysis method to the metabolic model. Predict metabolites that are essential for growth, remove those of the current metabolite, and those that consume less than the required number of reaction metabolites, and the remaining essential metabolites and enzymes that consume them Theoretically discovered that only the missing ones could be selected and selected as potential candidates to predict efficient pathogen drug targets. Finally, compounds that are structurally similar to the essential metabolites selected were selected for anti-pathogenic candidates. The material was explored and the present invention was completed.
- An object of the present invention is to build a microbial metabolic network model structure, using the essential metabolite analysis (metabolite essentiality), distribution metabolite removal (currency metabolite) removal, considering the number of reactions, the relationship between the host metabolism,
- the present invention provides a method for screening an enzyme or a gene encoding the same as a drug target.
- Another object of the present invention is to provide a method for screening an enzyme or a gene encoding the enzyme that is a drug target of the genus Acinetobacter using the above method.
- Another object of the present invention is to provide a method for screening an enzyme or a gene encoding the enzyme that is a drug target of Vibrio genus microorganisms using the above method.
- Still another object of the present invention is to provide enzymes which are drug targets against Acinetobacter sp. Microorganisms obtained by the above method and gene groups encoding them.
- Still another object of the present invention is to provide drug target enzymes for Vibrio genus microorganisms and gene groups encoding them, which are obtained by the above method.
- Another object of the present invention is an enzyme of the selected microorganism; Or it provides a method of using the determined gene of the target microorganism as a drug target of the target microorganism.
- Another object of the present invention is to determine essential metabolites based on the structure of a particular microbial metabolic network model, using essential metabolite analysis, distribution metabolite removal, number of reaction schemes, and non-relevance to host metabolism.
- a structurally similar compound is selected from a compound library to provide a method for screening drugs that can inhibit the growth of a target microorganism through microbial growth inhibition experiments.
- Another object of the present invention is based on the structure of the metabolic network model of the genus Acinetobacter Baumani or Vibrio vulnificus , to analyze essential metabolites, remove distribution metabolites, consider the number of reaction schemes, and compare with host metabolism. Relevance is used to determine essential metabolites, and structurally similar compounds are selected from compound libraries using Tanimoto coefficients to screen for drugs that can inhibit the growth of target microorganisms through microbial pathogen growth inhibition experiments. To provide a method.
- acinetobacter Baumani obtained through the above method It is to provide a drug that can inhibit the growth of certain microorganisms, including the genus microorganism or Vibrio bulnipius genus and an antimicrobial composition containing the same.
- At least three or more enzymes are involved in the reaction scheme, and at the same time, at least two or more of the essential metabolites consume the corresponding metabolites.
- step (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite It provides a method for screening a drug target enzyme of a microorganism comprising the step of selecting an enzyme involved in the drug target enzyme of the target microorganism.
- the present invention provides a method for screening a drug target gene for a microorganism, characterized in that the gene group encoding the drug target enzyme of the selected microorganism is determined as a drug target gene of the target microorganism.
- the host may be a human, and the target microorganism is preferably Escherichia coli or pathogenic microorganism, and more preferably pathogenic microorganism.
- the metabolic network of the microorganism in step (a) is genomic level, and performing the step (b),
- Vjm is a metabolic flow value of the corresponding consumption equation
- the application of the linear programming is preferably made by reflecting all the nutrient conditions necessary for the growth of cells.
- the distribution metabolite having no specificity with the target microorganism in step (c) is also involved in other enzymatic reactions of the target microorganism and other organisms, and in step (d), at least three or more of the secondary essential metabolites At least two or more at the same time involved in the enzymatic reaction, it is preferable to determine the metabolite in the case of consuming the required metabolite as the third essential metabolite, and in step (f) the examination of the homology is carried out Gene sequences can be used. At this time, the examination of the homology may be performed using the BLASTP program or the BLAST program.
- the present invention provides the enzymes of the selected microorganism or gene groups encoding the same, and a method of using them as drug targets of the microorganism.
- step (e) selecting a compound candidate group having structural similarity to the essential metabolite in step (d) from the compound library by using Tanimoto coefficients;
- It provides a drug screening method for microorganisms, including.
- step (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
- step (g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (e) from the compound library by using a Tanimoto coefficient;
- screening drugs by administering each of the selected compound candidate groups to target microorganisms to determine whether they inhibit growth.
- It provides a method for screening a drug against a microorganism, including.
- step (c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter . Determining;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c); (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite enzymes involved in providing the Acinetobacter drug screening method of the target enzyme of the microorganism of the genus Acinetobacter (Acinetobacter), comprising the step of selecting the drug for the target enzyme in microorganisms (Acinetobacter).
- Acinetobacter Acinetobacter
- Acinetobacter baumannii Acinetobacter baumannii
- 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabo 3-dehydroquinate dehydratase (3-dehydroquinase), shikimate 5-dehydrogenase, quinate / shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno- Enzyme group of the genus Acinetobacter selected from the group
- step (c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite enzymes involved in including the step of selecting the drug target enzyme of the microorganism of the genus Vibrio (Vibrio), provides a screening method of Vibrio drug target of the enzyme in microorganisms (Vibrio).
- step (c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
- step (g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (f) from the compound library by using Tanimoto coefficients;
- (h) provides a drug screening method for by checking whether the growth inhibition by administering the selected compound candidate for each Vibrio (Vibrio) into the microorganism comprising the step of screening a drug, Vibrio (Vibrio) spp.
- the present invention also provides 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5-phosphate one or more Vibrio genus microbial enzymes selected from the group consisting of reductoisomerase, pyridoxine 5-phosphate synthase, and methods for using them as drug targets, and VV10567 and VV10580 genes encoding the enzymes obtained by the method , VV11175, VV11568, VV11644, VV11691 and VV11866, one or more Vibrio genus microbial genes selected from the group consisting of, and methods of using them as drug targets.
- the present invention is also screened according to the above method, and has a structure of Formula 1, Vibrio ( Vibrio ) It provides a compound having an antimicrobial activity against the genus microorganisms and an antimicrobial composition containing the same:
- FIG. 1 is a schematic diagram illustrating the concept of a microbial drug targeting methodology in accordance with the present invention
- A building a metabolic network of specific microorganisms
- B Primary essential metabolite prediction using essential metabolite analysis
- C removal of distribution metabolites
- D Consider the number of schemes involved in that metabolite
- E confirm presence in host metabolism
- F drug target enzyme and gene determination
- FIG. 2 is a schematic diagram illustrating the microbial growth inhibition experiment by selecting a compound similar to the structure of five fifth essential metabolites from the compound library as a drug candidate for Vibrio genus microorganisms.
- the present invention in one aspect, relates to a method for screening drug target enzymes or drug target genes encoding the microorganisms, in particular pathogenic microorganisms.
- the schematic process is shown in FIG.
- FIG. 1 illustrates the concept of an integrated drug targeting methodology in accordance with the present invention.
- a metabolic network of a particular microorganism is constructed (A), from which essential metabolite analysis is predicted using essential metabolite analysis based on metabolic flow analysis (B). From this, the elimination of circulating metabolites (C), the consideration of the number of reaction formulas involved in the metabolites (D), the confirmation of the presence of essential metabolites and their involved reactions in human metabolism (E), etc. Predict the most effective drug targets of the microorganism (F).
- step (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
- step (d) may be selectively applied to “step (c) and / or (e); and (f)". Therefore, in another aspect, the present invention relates to a method for determining an essential metabolite according to the method of each step.
- Step (f) is a step necessary to minimize adverse effects on the host of the drug, for example, the human body, and may shorten step (f) by performing steps (c) and (e). Therefore, in the case of performing step (f) in view of such efficiency, step (c) and step (e) can be selected individually or simultaneously. Most preferably, all the steps (c), (e) and (f) are performed.
- step (d) may alternatively be carried out as a method devised in the present invention to significantly reduce the number of drug targets more effectively.
- the method of one preferable aspect of this invention is as follows. That is, the present invention
- step (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the target microorganism.
- Acinetobacter genus microorganisms for example, Acinetobacter baumannii
- a method for screening drug target enzymes of the genus Acinetobacter comprising the following steps:
- step (c) Of the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter. Determining;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the microorganism of the genus Acinetobacter.
- step (d) may be selectively applied to the "step (c) and / or (e); and (f)".
- step (d) may be selectively applied to the "step (c) and / or (e); and (f)".
- Vibrio sp Microorganisms, for example, Vibrio vulnificus were used.
- Vibrio includes not only Vibrio bulnipius, but also Vibrio cholera, Vibrio hemoritis, and the like.
- a method for screening a drug target enzyme of Vibrio genus microorganism comprising the following steps:
- step (c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the microorganism of Vibrio genus.
- step (d) may be selectively applied to the "step (c) and / or (e); and (f)".
- step (d) may be selectively applied to the "step (c) and / or (e); and (f)".
- the present invention in another aspect, relates to a method for drug screening against a microorganism of the present invention.
- step (e) selecting a compound candidate group having structural similarity to the essential metabolite in step (d) from the compound library using the Tanimoto coefficient;
- step (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) have no homology with the host protein, determining the essential metabolites as the fifth essential metabolite;
- step (g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (e) from the compound library using a Tanimoto coefficient;
- screening drugs by administering each of the selected compound candidate groups to target microorganisms to determine whether they inhibit growth.
- Tanimoto coefficient through a known tool including a pipeline for selecting a compound having a structure similar to a specific substance It may be used, specifically characterized by selecting a compound candidate group having a Tanimoto coefficient of 0.5 to 1.
- the compound having a growth inhibitory effect of at least 80% compared to the control group is characterized by screening with a drug against the microorganism.
- Acinetobacter in microorganisms, such as one embodiment used the Acinetobacter baumannii (Acinetobacter baumannii). Accordingly, in one aspect of the present invention, there can be provided a method for drug screening of the genus Acinetobacter, comprising the following steps:
- step (c) Of the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter. Determining;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
- step (g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (f) from the compound library by using Tanimoto coefficients;
- Microorganisms for example, Vibrio vulnificus were used.
- a method for drug screening of Vibrio genus microorganisms comprising the following steps:
- step (c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
- step (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
- step (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
- step (f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
- step (g) selecting a candidate compound group having structural similarity to the fifth essential metabolite in step (f) from the compound library by using Tanimoto coefficient;
- Methodabolism means a series of activities related to the energy activities of living things. That is, a series of activities that synthesize various metabolites necessary for life's activities through various biosynthesis through digestion that absorbs energy sources from the outside and converts them into the energy forms that are most readily available to life. Included in The first of the biological networks studied is this "metabolic network".
- the first step in the present invention is to build a metabolic network of the target microorganism, to build a network consisting of all metabolites and reactive enzymes by collecting biochemical reactions occurring inside and outside the cell.
- the target microorganism for constructing the metabolic network may be Escherichia coli or pathogenic microorganism, and any pathogenic microorganism may be used without particular limitation.
- Acinetobacter Acinetobacter
- Acinetobacter baumannii Acinetobacter baumannii
- Vibrio Vibrio
- Vibrio nipi carcass Vibrio vulnificus
- a pathogenic microorganism is a microorganism having infectivity determined by pathogens, pathogens, pathogens, infectious pathways, and host susceptibility caused by toxins, enzymes, and other products produced by microorganisms, and may include various viruses, bacteria, and fungi. And they can be transmitted to various organisms such as animals and plants.
- a metabolic network of microorganisms is established.
- Acinetobacter baumannii (AB) is a gram-negative bacillus named after integrating two strains of Acinetobacter calcoaceticus and anitratus in the past, and has a wide range of bacteriological characteristics that make it possible to use various energy sources. It can be grown at or at pH and is found in samples taken from almost all soils and fresh water. Acinetobacter baumannii, which has this characteristic, has been reported as an important causative agent of hospital infections in many hospitals. Once hospital infections occur, they usually survive long-term in environments where bacteria are difficult to survive, resulting in high antibiotic resistance and resistance.
- A. baumannii Due to its characteristics, it is difficult to treat, and as a result, the mortality rate caused by the causative organism also increases, which has recently emerged as an important pathogen.
- A. baumannii is known to cause pneumonia associated with respirators, wound infections in burn patients, and sepsis.
- the Acinetobacter genus microbial metabolic network construction used in an example of the present invention can be made based on a gene group consisting of the following genes:
- Vibrio causes a variety of infections in humans as a kind of pathogenic microorganisms present in the sea and the estuary as a facultative anaerobic gram-negative bacilli, and are isolated from fresh water, rivers, ponds and lakes. More than 30 species belong to the genus Vibrio, 12 of which infect humans. Intestinal infections are the most common causative agents of V. cholerae and V. parahaemolyticus . Intestinal infections such as blood, wounds, eyes, ears, and bile can also occur. In Korea, Vibrio sepsis often occurs in summer, which is caused by V. vulnificus , which is mainly caused by cirrhosis and cancer patients and has a poor prognosis. .
- the Vibrio vulnificus is mainly found in estuaries and is a pathogenic microorganism that infects a variety of animals and seafood, including humans (Gulig et al., J. Mcirobiol., 43: 118, 2005). Ingestion of seafood infected with V. vulnificus or contact with the microorganisms of the human body can cause sepsis, gastroenteritis and wound infection. In particular, V. vulnificus is known to be very fast in human body when infected. Contact with the pathogen can cause death within 24 hours. It is known that mortality from sepsis is up to 75%, and mortality from wound infections is reported to be up to 50%.
- V. vulnificus the genome sequence translation of the two strains is completed (Chen et al., Genome Res. , 13: 2577, 2003), and therefore, the present inventors use partial metabolic flow analysis techniques.
- This study examined the metabolism of V. vulnificus from the whole point of view, not the strain manipulation, and found the possibility of developing a method to accurately predict the drug target of pathogenic microorganisms by identifying the effects of manipulation of specific genes on the overall metabolic flow.
- the Vibrio genus microbial metabolic network construction used in the example of the present invention may be made based on a gene group consisting of the following genes:
- metabolic flow analysis is performed on the established metabolic network of the microorganism, which is to determine the essential metabolite of the microorganism primarily (called a primary essential metabolite).
- the metabolic network of the constructed microorganism including all the metabolites constituting the constructed metabolic network model, the metabolic pathway of the metabolite and the stoichiometric matrix S in the metabolic pathway.
- S ij the stoichiometric coefficient of the i-th time in the j-th reaction metabolite
- the change in the metabolite concentration X over time can be represented as the sum of the flows of all metabolic reactions. Assuming that the amount of change of X with time is constant, i.e., if the amount of change of X is 0, the amount of change of the metabolite concentration with time under the quasi-steady state may be defined by Equation 1 above.
- the reaction scheme to be optimized ie maximized or minimized, is set as the objective function and the metabolic flow in the cell is predicted using linear programming (Kim et al., Mol Biosyst. 4 (2)). : 113, 2008).
- the cell growth rate is optimized by representing the constituents of the cells in matrix S and setting the scheme as the objective function. In other words, when applying the linear programming method, the objective function is set to maximize cell growth rate.
- the metabolic flow analysis should be carried out on the assumption that all the nutrients necessary for the cell to grow can be taken. This is because when pathogenic microorganisms grow in the host, various nutrients can be taken from the host.
- the enzyme reaction may appear to be essential only under certain conditions, but if metabolic flow analysis is applied on the assumption that all the nutrients can be ingested, it is possible to predict the essential enzyme reaction at all times.
- the nutrients used were 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2 -Oxoglutarate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, Betaine, Benzoate, Choline, Citrate, CO 2 , Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine, Formate, D-fructose, Fumarate, alpha-D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Gu
- the nutrients used were (S) -Lactate, (S) -Malate, 2-Oxoglutarate, 2-Phospho -D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, alpha, alpha-Trehalose, alpha-D-Glucose, Choline, Citrate, CO 2 , Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D-Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cystein
- the method of determining the cell growth rate according to a specific gene deletion uses a method of inactivating each corresponding reaction scheme. Suppressing these enzyme reactions is based on the assumption that it is impossible to consume or produce the specific metabolites involved in these enzymes, which will eventually stop the cell growth of the target microorganism.
- Suppressing these enzyme reactions is based on the assumption that it is impossible to consume or produce the specific metabolites involved in these enzymes, which will eventually stop the cell growth of the target microorganism.
- the present invention by defining the 'essentiality' of each metabolite and examining the properties of each metabolite, it is easy to identify the phenomenon of cell growth caused by the deletion of two or more genes. That is, the present invention provides a method of defining and using 'essentiality' of metabolites constituting the metabolic network of the target microorganism as follows.
- the 'essentiality' of metabolites is the effect of cells on the growth of cells when they are not consumed by metabolism.
- the rate of cell growth for each metabolite under certain conditions is determined by metabolic flow analysis.
- the necessity of metabolites can be determined by investigating (FIG. 4) (Kim et al., Proc. Natl. Acad. Sci. USA , 104: 13638, 2007).
- the metabolic flow value of the corresponding reaction equation is fixed to zero. In this case, if the growth rate of the cell is 0 is selected as an essential metabolite.
- V jm represents the metabolic flow value of the consumption equation.
- Essential metabolite analysis applies Equation 2 as an additional constraint while simultaneously blocking (deleting) all metabolic reactions consuming each metabolite in the stoichiometric matrix.
- the metabolic flow value of the consumption equation By fixing the metabolic flow value of the consumption equation to 0, the case where the cell growth rate is 0 is selected as an essential metabolite. In other words, if there is no metabolic flow of essential metabolite, the cells of the microorganism do not grow to determine the essentiality.
- the reason for not inactivating a metabolite produced without consuming a given metabolite is that the metabolite that produces the metabolite, even if the metabolite is non-essential Because it is also possible to produce other essential metabolites, if cell growth is inhibited due to inactivation of the metabolic reaction, it may be misunderstood that a non-essential metabolite is essential.
- the primary essential metabolite of AYE ( Acinetobacter baumannii AYE) obtained through metabolic flow analysis using Equation 1 and Equation 2 is (R) -4′-Phosphopantothenoyl-L-cysteine, (R ) -pantoate, (R) -Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Acyl-sn-glycerol 3-phosphate, 1-Deoxy-D-xylulose 5-phosphate, 2,3,4,5- Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine, 2-Amino-4-hydroxy-6 -(D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 2-Amino-4-hydroxy-6-
- the first essential metabolite of Vibrio vulnificus obtained through the metabolic flow analysis step using Equations 1 and 2 is (R) -4′-Phosphopantothenoyl-L-cysteine, (R) -pantoate, (R) -Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Deoxy-D-xylulose 5-phosphate, 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate, 2, 3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine (L-1 -Lysophosphatidylethanolamine), 2-Amino-4-hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropter
- circulation metabolite (currency metabolite) involved in a number of enzyme reactions of various organisms.
- Information on the metabolites in circulation is published in a paper published in Bioinformatics in 2003 (Ma and Zeng, Bioinformatics, 19: 1423, 2003), which do not have the specificity unique to the target microbial pathogen. Remove from the list of primary essential metabolites on the computer.
- the result of removing the distribution metabolite from the first essential metabolite was named as a second essential metabolite.
- At least two or more of the secondary essential metabolites are involved in the enzyme reaction, while at least two or more simultaneously name the metabolite when consuming the essential metabolite as the third essential metabolite.
- This method has the advantage of simultaneously targeting the consuming enzymes when using a metabolite analogue (metabolite analogue) as a drug.
- the biggest problem of anti-pathogen drugs is that the resistance of the pathogen to the drug occurs quickly, which is mainly caused by a single endogenous mutation of the enzyme target enzyme gene, thus the drug target gene group of the present invention.
- the combination has the advantage of being able to simultaneously target several places of the target microbial pathogen metabolism to minimize the resistance of the pathogen, and to reliably control the growth of the pathogen in the host.
- Acinetobacter Baumani or Vibrio Bulnipicus which is used as an embodiment in the present invention, is a kind of multi-drug resistant (MDR) infectious bacterium that is resistant to many drugs. It suggests that it may be an effective method for multidrug resistant pathogenic microorganisms.
- MDR multi-drug resistant
- the strategy is to ultimately disable the intake of essential metabolites from pathogens, thereby simultaneously inactivating all of the surrounding reactions, so even if the reactions are carried out by isoenzymes, it is not a problem.
- the remaining metabolites are named 5th essential metabolites.
- the host is a human
- the essential metabolites predicted through the metabolic flow analysis are further screened based on the homology between the enzymes and the host proteins related to their consumption equations to further reduce the number of possible essential metabolites. .
- drugs developed by targeting specific genes or enzymes act on the basis of the 'sequence' of the genes or enzymes. Therefore, if the genes or enzymes in these sequences are present in humans, the drugs also act on human proteins. May cause
- the genomic information of the host is preferable to use as a database.
- the BLASTP program may be used when using an amino acid sequence, or the BLAST program may be used when using a gene sequence.
- any data can be used as long as those skilled in the art can identify homology regardless of amino acid sequence or gene sequence.
- the present invention used the BLASTP program.
- the human genomic information is used as a database.
- the genes and amino acid sequences encoding all the enzymes consuming each of the essential metabolites further selected in the present invention are significantly different from those of the host protein, resulting in structurally different functionalities from the host protein. do.
- step (4-2) can be selectively applied to step (4-1) and / or step (4-3) and step (4-4). have.
- the pathogenic microorganism-specific essential metabolites can be finally determined, and the enzymes involved in these essential metabolites are determined as drug target enzyme groups.
- the enzymes involved in these essential metabolites are determined as drug target enzyme groups.
- Genes encoding drug target enzymes can be determined as a drug target gene family.
- the fifth essential metabolite of AYE ( Acinetobacter baumannii AYE) used in the example of the present invention is 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, D-Glutamate, 2,3-Dihydrodipicolinate, 2-Amino -4-hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 3-Dehydroshikimate, 1-Deoxy-D-xylulose 5-phosphate, 3-Dehydroquinate, 2-Dehydro- 3-deoxy-D-octonate, 4-Aminobenzoate and the like,
- Drug target enzymes involved in metabolism include 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase (3-dehydroquinase), shikimate 5-dehydrogenase, quinate / shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, dihydropter
- Drug target gene groups include ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, AYEYE95, ABAYE3176, ABA3, 355
- the fifth essential metabolite of Vibrio vulnificus used in one embodiment of the present invention is 1-deoxy-D-xylulose 5-phosphate, 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine , 2,3-dihydrodipicolinate, 4-aminobenzoate, D-glutamate and the like,
- Drug target enzymes involved in their metabolism include 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D -xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, etc.,
- VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, VV11866 and the like can be determined.
- the present invention provides a drug target enzyme candidate and a gene encoding the drug target enzyme of the above-described microorganisms or genes encoding the same, which are obtained by the screening method, which are involved in the metabolism of essential metabolites at each step. Provide gene families.
- step (d) drug target enzyme candidates involved in the primary essential metabolite determined by the metabolic flow analysis of step (b) and the gene group encoding the same; drug target enzyme candidates involved in the secondary essential metabolite determined by removing the circulation metabolite of step (c) and the gene group encoding the same;
- step (d) at least three or more enzyme reactions, and at least two or more at the same time the drug target enzyme candidates and genes encoding the enzymes involved in the selected third essential metabolite when the essential metabolite is consumed group; drug target enzyme candidates involved in the fourth essential metabolite determined by selecting only those not present in the metabolism of the host in step (e) and the gene group encoding the same;
- step (f) a drug target enzyme candidate involved in the fifth essential metabolite determined by selecting a case where there is no homology with the host protein among enzymes related to metabolism of the fourth essential metabolite and a gene group encoding the same.
- the present invention also relates to a method of using the determined enzyme group and the gene group encoding the same as the drug target of the target microorganism.
- a group of enzymes of -5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, or the gene groups VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, and VV11866 encoding the same can be used as drug targets of Vibrio vulnificus . Can be.
- the structure of the fifth essential metabolite or the final essential metabolite obtained by the above method can be used to select compounds having similar structures from the compound library as drug candidates.
- the Tanimoto coefficient is used.
- the microorganisms are treated to confirm whether the growth of the microorganisms is examined through experiments.
- the structural analogous compound inhibits at least 80% of the concentration of the microorganism relative to the highest concentration of the control standard microorganism that has not been treated with the compound, the structural analogous compound may be considered to be effective as an anti-pathogen drug candidate.
- MIC minimum microbial concentration
- Such drug target enzymes and drug target genes according to the present invention obtain only the next effective drug target candidate groups for pathogenic diseases, and are useful for the treatment and prevention of diseases caused by microbial pathogens.
- the present invention relates to an antimicrobial composition against Vibrio genus containing the compound of Formula 1, a derivative thereof, or a salt as an active ingredient. Furthermore, it includes all possible solvates, hydrates or racemates that can be prepared therefrom.
- Vibrio not only Vibrio bulnipius, but also Vibrio cholera, Vibrio hemoritis, and the like will be included.
- the antimicrobial means having the growth inhibitory ability of Vibrio uniphycus, and furthermore, is a concept including both growth and infection prevention, growth inhibition, and / or killing action.
- antimicrobial compositions include all forms of food, cosmetic or pharmaceutical compositions.
- the content of the drug in the composition of the present invention is 0.01% to 100% by weight.
- dragees, pills, gelatin capsules, syrups, gels which comprise a carrier which can be ingested directly with water or by any other known means, containing a dosage of 0.001 to 100% of the composition.
- supplements in the form of creams or peppermint drops This supplement additionally contains sweeteners, stabilizers, additives, flavors and pigments.
- the composition may be a cosmetic preparation containing a skin active compound known to those skilled in the art.
- the present invention also relates to a cosmetic composition containing the above preliminary composition.
- the content of the drug in the composition may comprise 0.01% by weight or more.
- Other cosmetically active ingredients may also be added.
- the composition can be added to the composition also emulsifiers, excipients, pigments, flavors or opacifiers.
- the composition may be a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a drug.
- the drug may also be prepared as a medicament by adding 0.01 to 100 parts by weight to one or more pharmaceutically acceptable carriers relative to the total weight.
- the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
- the composition may be prepared in the form of oral preparations, granules, powders, syrups, solutions, liquid extracts, emulsions, suspensions, acupuncture tablets, injections, capsules, creams, troches, pasta preparations, oral or It can be used parenterally.
- Dosage of the composition is a conventional dosage, for example, from 1 to 100 mg of the drug can be used per day.
- the dosage is not limited thereto, and may be differently applied depending on the age, sex, condition, absorbency of the active ingredient in the body, inactivation rate, type of disease, and the like.
- the present invention also relates to a disinfectant comprising a drug as an active ingredient.
- the disinfectant is a concept including all killing, growth or infection of pathogenic microorganisms, and antibacterial action. It is a natural disinfectant that is harmless to human body by applying strong sterilization function, sterilization of kitchen utensils (cutting board, knife, pot, chopsticks, cutlery, container, various utensils), personal cleaning products (oral cleaner, vaginal cleaner, soap, shampoo, Toothpaste), natural water disinfectant, such as sterilization disinfection of the environment surrounding the facility, including the cooling water sterilization disinfection of the air conditioner, air conditioner antibacterial filter, hospitals and homes. It can also be used as a disinfectant for water pipes, hot water tanks, water tanks, or humidifiers in hospitals and homes.
- salts may be used in the form of a pharmaceutically acceptable salt, and acid salts formed by pharmaceutically acceptable free acid are useful as salts.
- Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid and aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanes. Dioates, aromatic acids, aliphatic and
- non-toxic organic acids such as aromatic sulfonic acids.
- Such pharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, and iodide.
- the acid addition salts according to the present invention can be dissolved in conventional methods, for example, by dissolving Formula 1 or a derivative thereof in an excess aqueous solution of an acid, which salts are water-miscible organic solvents such as methanol, ethanol, acetone or acetonitrile. Can be prepared by precipitation.
- the acid or alcohol in the drug of Formula 1 and water may be heated, and then the mixture may be evaporated to dryness, or the precipitated salt may be manufactured by suction filtration.
- Bases can also be used to make pharmaceutically acceptable metal salts.
- Alkali metal or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium or calcium salt as the metal salt.
- Corresponding silver salts are also obtained by reacting alkali metal or alkaline earth metal salts with a suitable negative salt (eg, silver nitrate).
- the composition may be various oral or parenteral dosage forms when used as a pharmaceutical composition.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
- Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
- lubricants such as magnesium stearate, talc and the like are also used.
- Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- KEGG Kanehisa et al..Nucleic Acids Res , 34: D354, 2006
- TransportDB (Ren et al., PLoS Comput. Biol ., 1: e27, 2005)
- MetaCyc (Caspi et al. Nucleic Acids Res. , 36 (D623, 2008)
- the constructed metabolic network of A. baumanii AYE consists of 891 biochemical schemes and 778 metabolites, and the information of this metabolic network contains the following 650 gene information.
- the predicted drug targets were selected from these schemes.
- R035, R036, R044, R046, R052, R068, R069, R070, R071, R095, R108, R157, R160, R227, R239, R319, R320, R328, R329, R330, R346, R472, R608, R619, R621, R635, R649, R673, R745, R746, R747, and R748 are reactions without genes assigned to genomic information.
- the constructed metabolic network of V. vulnificus CMCP6 consists of 945 biochemical schemes and 765 metabolites, and the information of this metabolic network contains the following 672 gene information. The predicted drug targets were selected from these schemes.
- R002, R150, R196, R201, R233, R237, R238, R239, R240, R241, R413, R505, R619, R659, R660, R661, and R705 have no genes assigned to genomic information.
- the secondary essential metabolites were associated with at least three or more reaction schemes, but two or more reaction schemes were further selected only to consume those essential metabolites, thereby obtaining 97 tertiary essential metabolites.
- Example 2- (2) For the essential metabolite determined through metabolic flow analysis in Example 2- (2), those corresponding to the distribution metabolite were removed to obtain 162 secondary essential metabolites.
- ACACP ACCOA, ACP, AHHMP, AHTD, ARG, ASN, ASP, ASPSA, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CDPDG, CHOR, CYS, DALA, DATP, DCTP, DGLU, DGTP DHAP, DHDP, DHF, DHN, DHSK, DMK, DTMP, DTTP, DX5P, E4P, F6P, FMN, FUM, G1P, G3P, GL3P, GLY, GLYCOGEN, HIS, ILE, IPP, LEU, LYS, MALACP, MDAPIM, MET, MK, MKH2, NACN, OBUT, OIVAL, OPP, P5P, PABA, PE, PEP, PG, PHE, PHT, PPAACP, PPACOA, PRO, PRPP
- a total of 352 structure-like compounds having a Tanimoto coefficient of 0.5 to 1.0 were selected as drug candidates from the compound library.
- 100 ⁇ l was added to each well of a 100-well plate.
- Mueller Hinton's complex liquid medium was added, and metabolic microorganisms were cultured in each well.
- MIC minimal inhibitory concentration
- the present invention relates to a method for predicting a drug target of a microorganism and screening for a drug candidate compound capable of efficiently inhibiting microbial growth.
- the present invention is based on the results of essential metabolite analysis based on metabolic flow analysis, including pathogens. Only potential next effective drug target candidates for diseases caused by various microorganisms are obtained, which is useful for the treatment and prevention of diseases caused by the pathogen microorganisms. In particular, it is useful for the treatment and prevention of diseases caused by such pathogenic microorganisms by screening new drug compounds against pathogens that are multi-drug resistant, such as Acinetobacter Baumani, Vibrio Bulnipicus, and the like.
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method for predicting drug targets and screening for drugs for pathogenic microorganisms using essential metabolites. More particularly, the present invention relates to a method for screening for efficient drug target enzymes for pathogenic microorganisms or for drug target genes encoding the enzymes, and to a method for screening for drugs capable of inhibiting the growth of pathogenic microorganisms, wherein said methods comprise: selecting target microorganisms; constructing a metabolism network model for the selected microorganisms; predicting the metabolite that is essential for cell growth using a metabolite essentiality analysis; deleting a currency metabolite, and deleting an essential metabolite, the number of outgoing reactions of which is less than a reference number; and selecting the remaining essential metabolites and essential metabolites such that enzymes which consume the essential metabolites are not present in the metabolism of a host.
Description
본 발명은 컴퓨터 시스템 기법을 이용한 병원성 미생물의 약물 표적 예측 및 약물 탐색 방법에 관한 것으로, 보다 구체적으로는 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축한 후, 필수 대사산물 분석 (metabolite essentiality), 유통 대사산물(currency metabolite) 제거, 반응식의 개수 고려, 숙주 대사와의 비관련성을 이용하여 약물 표적들을 예측하는 방법 및 선별된 필수 대사산물과 구조적으로 유사성을 가진 화합물들로부터 항미생물체 약물을 스크리닝하는 방법에 관한 것이다.The present invention relates to a method for predicting a drug target and a drug search method of a pathogenic microorganism using computer system technology, and more specifically, selecting a target microorganism, constructing a metabolic network model of the selected microorganism, and then analyzing essential metabolite (metabolite). essentiality, removal of circulation metabolite, consideration of the number of reaction schemes, methods of predicting drug targets using irrelevance to host metabolism, and antimicrobial drugs from compounds with structural similarities to the selected essential metabolites. It relates to a method of screening.
병원성 미생물은 면역계(immune system)가 약화된 사람에게 발병할 경우에는 치료가 매우 힘들고 치명적인 결과를 불러 올 수 있다. 따라서 병원성 미생물의 효과적인 항 병원성 약물을 개발하기 위한 표적을 찾는 노력이 활발해져 가고 있다.Pathogenic microorganisms can be very difficult and fatal to treat if they occur in people with weakened immune systems. Therefore, efforts to find a target for the development of effective anti-pathogenic drugs of pathogenic microorganisms are active.
그러나 어떠한 유전자 산물이 이상적인 약물 표적이 되어 병원성 미생물을 사멸시킬 수 있는지를 확인하는 것은 어려운 일로서 병원성 미생물의 모든 단일 유전자를 결실시켜가며 해당 유전자의 치사성(lethality)을 확인하는 것은 기술적으로 힘든 일이다. 또한 약물 표적은 대부분 하나의 유전자가 아닌 복잡한 세포 구성 요소간의 상호작용에 의해 결정되며 각각의 유전자는 치사성이 없는 경우에도 복수의 유전자 결실에서 치사성이 나타나는 등 유전자 들 간의 조합을 고려할 경우 그 결과를 예측하는 것은 매우 어려워진다.However, it is difficult to determine which gene product is the ideal drug target to kill pathogenic microorganisms, and it is technically difficult to determine the lethality of the gene by deleting every single gene of the pathogenic microorganism. to be. In addition, drug targets are mostly determined by interactions between complex cellular components rather than a single gene, and each gene is considered to be lethal in multiple gene deletions even if it is not lethal. It becomes very difficult to predict.
따라서 병원성 미생물을 표적으로 삼는 효과적인 약물을 개발하기 위하여 미생물 세포 구성 요소들 간의 세포 기작과 상호작용을 이해하는 것이 매우 중요하다. 이에 게놈정보와 기능 유전체학의 발전을 통한 대사산물과 대사 네트워크의 구축은 세포 구성 요소를 구성하기 위한 유전자와 단백질들의 상호작용을 이해하고 대사 네트워크를 구성하여 효과적인 약물을 개발하는데 있어 그 중요성을 더하고 있다. Therefore, it is very important to understand the cellular mechanisms and interactions between microbial cell components in order to develop effective drugs that target pathogenic microorganisms. Therefore, the development of metabolites and metabolic networks through the development of genomic information and functional genomics has added the importance in understanding the interaction of genes and proteins to compose cellular components and constructing metabolic networks to develop effective drugs. .
실제로 게놈 정보를 통한 대사 네트워크 정보를 이용하여 병원성 미생물에서 포유동물의 세포에서 발견되지 않은 새로운 필수 대사 경로가 동정되는 경우 이러한 대사 특성을 표적으로 삼는 치료법을 개발하여 인체 세포에는 부작용을 유발하지 않으면서 병원성 세포만 특이적으로 공격하는 것이 가능해진다. 또한 병원성 미생물이 생존하는데 기존의 특정 대사 경로가 필수적이라는 사실이 규명된 경우 해당 대사 경로를 억제하는 약물을 개발하는 것이 가능하다. 병원성 미생물에 대한 약물이 개발된 경우 이와 유사한 화합물을 활용해 다른 유사한 병원성 미생물을 억제하는 약물이 쉽게 얻어질 수 있을 것으로 전망된다. Indeed, if metabolic network information through genomic information is used to identify new essential metabolic pathways that are not found in mammalian cells in pathogenic microorganisms, we have developed therapies that target these metabolic properties without causing adverse effects on human cells. Only pathogenic cells can be specifically attacked. It is also possible to develop drugs that inhibit these metabolic pathways if it is found that certain existing metabolic pathways are essential for survival of pathogenic microorganisms. When drugs against pathogenic microorganisms are developed, it is expected that drugs that inhibit other similar pathogenic microorganisms can be easily obtained using similar compounds.
대사 네트워크를 통한 분석 및 예측기술은 최근에야 급속하게 증가하는 게놈정보와 함께 그 가능성을 보이고 있다. 특히, 각 미생물의 대사 네트워크 모델들이 수학적 모델 및 최적화 기술 등과 결합되어 유전자의 제거 또는 추가 후에 일어나는 대사 네트워크의 반응을 예측하는 것이 가능해지고 있다 (Lee et al., Trends Biotechnol., 23:349, 2005). 또한 대사 네트워크를 이용한 대사흐름분석기법은 동적 정보를 필요로 하지 않음에도 세포의 이상적인 대사흐름을 보여주며 실제적으로 세포의 행동을 정확히 모사하고 예측할 수 있는 것으로 알려져 있다 (Papin, J. et al., Nat. Rev. Mol. Cell Biol., 6:99, 2005). Analytical and predictive techniques through metabolic networks have shown promise with rapidly growing genomic information. In particular, the metabolic network models of each microorganism have been combined with mathematical models and optimization techniques to make it possible to predict the response of the metabolic network after removal or addition of genes (Lee et al ., Trends Biotechnol ., 23: 349, 2005 ). In addition, metabolic flow analysis techniques using metabolic networks are known to show the ideal metabolic flow of cells even when dynamic information is not required and to accurately simulate and predict cell behavior (Papin, J. et al ., Nat. Rev. Mol. Cell Biol ., 6:99, 2005).
대사흐름분석은 생화학 반응식의 질량수지와 세포조성 정보만을 이용하여 세포가 도달 가능한 이상적인 대사 흐름 공간을 구하며 특정한 목적함수를 최적화 방법을 통하여 최대화 하거나 최소화 하는 것을 목적으로 한다(세포성장속도 최대화 또는 특정 섭동에 의한 대사 조절의 최소화 등). 그 밖에, 대사흐름분석은 일반적으로 균주개량을 통하여 원하는 대사산물의 특정 유전자의 치사성을 확인하기 위하여 사용될 수 있으며, 이를 이용하여 균주내부의 대사 네트워크 특성을 파악할 수 있다. 또한, 유전자의 제거 또는 추가에 의해 일어나는 대사 네트워크의 흐름변화 등을 예측하기 위해 대사흐름분석 방법을 응용한 다양한 연구가 보고되고 있다. Metabolic flow analysis uses the mass balance and cell composition information of biochemical equations to obtain the ideal metabolic flow space that cells can reach, and aims to maximize or minimize specific objective functions through optimization methods (maximization of cell growth rate or specific perturbation). Minimization of metabolic regulation by In addition, metabolic flow analysis can generally be used to confirm the lethality of specific genes of a desired metabolite through strain improvement, and can be used to determine the metabolic network characteristics within the strain. In addition, various studies have been reported applying metabolic flow analysis methods to predict the flow changes in metabolic networks caused by the removal or addition of genes.
당업계에서는 대사흐름분석 기법을 이용하여 부분적인 대사정보를 이용한 전체적인 관점에서 복잡한 미생물의 대사를 살펴보고 특정 유전자에 대한 조작이 전체 대사흐름에 미치는 영향들을 파악하여 병원성 미생물의 약물표적을 정확하게 예측할 수 있는 방법의 개발이 절실히 요구되고 있다.In the art, metabolic flow analysis techniques can be used to look at the metabolism of complex microorganisms from a holistic perspective using partial metabolic information and to identify the effects of manipulation on specific genes on overall metabolic flow to accurately predict drug targets of pathogenic microorganisms. There is an urgent need for the development of such methods.
이에 본 발명자들은 미생물 병원균인 아시네토박터 바우마니(Acinetobacter baumannii) 및 비브리오 불니피커스 (Vibrio vulnificus)의 대사 네트워크 모델을 구축한 후, 필수 대사산물 분석 (metabolite essentiality) 방법을 대사 모델에 적용하여 세포 성장에 필수적인 대사산물들을 예측하고, 이들 중 유통 대사산물(currency metabolite) 및 소비하는 반응식의 개수가 기준 미달인 필수 대사산물들 제거하고, 남은 필수 대사산물들과 이들을 소비하는 효소가 인간의 대사에 없는 것들만을 추가 선별하여, 차기 가능성 있는 후보군으로 추려내어 효율적인 병원균 약물 표적을 예측할 수 있음을 이론적으로 발견하고, 최종적으로 선별된 필수 대사산물과 구조적으로 유사한 화합물을 병원균 성장 억제 실험을 통해 항병원성 후보 물질을 탐색하고, 본 발명을 완성하였다.Therefore, the present inventors constructed a metabolic network model of the microbial pathogens Acinetobacter baumannii and Vibrio vulnificus , and then applied a metabolite analysis method to the metabolic model. Predict metabolites that are essential for growth, remove those of the current metabolite, and those that consume less than the required number of reaction metabolites, and the remaining essential metabolites and enzymes that consume them Theoretically discovered that only the missing ones could be selected and selected as potential candidates to predict efficient pathogen drug targets. Finally, compounds that are structurally similar to the essential metabolites selected were selected for anti-pathogenic candidates. The material was explored and the present invention was completed.
발명의 요약Summary of the Invention
본 발명의 목적은 특정 미생물 대사 네트워크 모델 구조를 바탕으로, 필수 대사산물 분석 (metabolite essentiality), 유통 대사산물(currency metabolite) 제거, 반응식의 개수 고려, 숙주 대사와의 비관련성을 이용하여, 상기 미생물의 약물 표적이 되는 효소 또는 이를 코딩하는 유전자를 스크리닝 하는 방법을 제공하는데 있다. An object of the present invention is to build a microbial metabolic network model structure, using the essential metabolite analysis (metabolite essentiality), distribution metabolite removal (currency metabolite) removal, considering the number of reactions, the relationship between the host metabolism, The present invention provides a method for screening an enzyme or a gene encoding the same as a drug target.
본 발명의 다른 목적은 상기 방법을 이용하여 아시네토박터 (Acinetobacter) 속 미생물의 약물 표적이 되는 효소 또는 이를 코딩하는 유전자를 스크리닝 하는 방법을 제공하는데 있다. Another object of the present invention is to provide a method for screening an enzyme or a gene encoding the enzyme that is a drug target of the genus Acinetobacter using the above method.
본 발명의 다른 목적은 상기 방법을 이용하여 비브리오 (Vibrio) 속 미생물의 약물 표적이 되는 효소 또는 이를 코딩하는 유전자를 스크리닝 하는 방법을 제공하는데 있다.Another object of the present invention is to provide a method for screening an enzyme or a gene encoding the enzyme that is a drug target of Vibrio genus microorganisms using the above method.
본 발명의 또 다른 목적은 상기 방법에 의해 수득되는, 아시네토박터 (Acinetobacter) 속 미생물에 대한 약물 표적이 되는 효소들 및 이들을 코딩하는 유전자군들을 제공하는데 있다.Still another object of the present invention is to provide enzymes which are drug targets against Acinetobacter sp. Microorganisms obtained by the above method and gene groups encoding them.
본 발명의 또 다른 목적은 상기 방법에 의해 수득되는, 비브리오 (Vibrio) 속 미생물에 대한 약물 표적 효소들 및 이들을 코딩하는 유전자군들을 제공하는데 있다.Still another object of the present invention is to provide drug target enzymes for Vibrio genus microorganisms and gene groups encoding them, which are obtained by the above method.
본 발명의 다른 목적은 상기 선정된 대상 미생물의 효소; 또는 상기 결정된 대상 미생물의 유전자를 대상 미생물의 약물 표적으로 이용하는 방법을 제공하는데 있다. Another object of the present invention is an enzyme of the selected microorganism; Or it provides a method of using the determined gene of the target microorganism as a drug target of the target microorganism.
본 발명의 또 다른 목적은 특정 미생물 대사 네트워크 모델 구조를 바탕으로, 필수 대사산물 분석, 유통 대사산물 제거, 반응식의 개수 고려, 숙주 대사와의 비관련성을 이용하여, 필수 대사산물을 결정하고, 이와 구조적으로 유사한 화합물을 화합물 라이브러리로부터 선별하여, 미생물 성장 억제 실험을 통해 대상 미생물의 성장을 억제할 수 있는 약물을 스크리닝 하는 방법을 제공하는데 있다. Another object of the present invention is to determine essential metabolites based on the structure of a particular microbial metabolic network model, using essential metabolite analysis, distribution metabolite removal, number of reaction schemes, and non-relevance to host metabolism. A structurally similar compound is selected from a compound library to provide a method for screening drugs that can inhibit the growth of a target microorganism through microbial growth inhibition experiments.
본 발명의 또 다른 목적은 아시네토박터 바우마니 또는 비브리오 불니피커스 (Vibrio vulnificus) 속 대사 네트워크 모델 구조를 바탕으로, 필수 대사산물 분석, 유통 대사산물 제거, 반응식의 개수 고려, 숙주 대사와의 비관련성을 이용하여, 필수 대사산물을 결정하고, 이와 구조적으로 유사한 화합물을 타니모토 계수를 이용하여 화합물 라이브러리로부터 선별하여, 미생물 병원균 성장 억제 실험을 통해 대상 미생물의 성장을 억제할 수 있는 약물을 스크리닝 하는 방법을 제공하는데 있다. Another object of the present invention is based on the structure of the metabolic network model of the genus Acinetobacter Baumani or Vibrio vulnificus , to analyze essential metabolites, remove distribution metabolites, consider the number of reaction schemes, and compare with host metabolism. Relevance is used to determine essential metabolites, and structurally similar compounds are selected from compound libraries using Tanimoto coefficients to screen for drugs that can inhibit the growth of target microorganisms through microbial pathogen growth inhibition experiments. To provide a method.
본 발명의 또 다른 목적은, 상기 방법을 통해 수득되는 아시네토박터 바우마니 속 미생물 또는 비브리오 불니피커스 속을 비롯한 특정 미생물의 성장을 억제할 수 있는 약물 및 이를 함유하는 항균 조성물을 제공하는데 있다. Another object of the present invention, acinetobacter Baumani obtained through the above method It is to provide a drug that can inhibit the growth of certain microorganisms, including the genus microorganism or Vibrio bulnipius genus and an antimicrobial composition containing the same.
상기 목적을 달성하기 위하여, 본 발명에서는 In order to achieve the above object, in the present invention
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, (c) of the primary essential metabolites determined in step (b),
대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하는 단계 및 숙주의 대사에 존재하지 않는 것들만을 선별하는 단계를, 각각 또는 모두 실시하는 단계Removing the circulation metabolite that has no specificity with the target microorganism and selecting only those that are not present in the host's metabolism, each or all
(d) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 최종 필수 대사산물로 결정하고, 상기 최종 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계를 포함하는, 미생물의 약물 표적 효소 스크리닝 방법을 제공한다. (d) If all the enzymes that consume the essential metabolites determined in the previous step do not have homology with the host protein, determine the essential metabolites as the final essential metabolite, and determine the enzymes involved in the final essential metabolite as the target microorganism. It provides a method for screening a drug target enzyme of a microorganism comprising the step of selecting a drug target enzyme of the.
특히, 상기 (c)단계 이후 결정된 필수 대사산물 중, 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 대사산물을 선별하는 단계를 추가로 수행할 수 있다. Particularly, among the essential metabolites determined after step (c), at least three or more enzymes are involved in the reaction scheme, and at the same time, at least two or more of the essential metabolites consume the corresponding metabolites. Can be.
가장 바람직하게는Most preferably
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응(d) of the secondary essential metabolites determined in step (c), involved enzymatic reaction
식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;Determining as a tertiary essential metabolite taking into account the number of formulas and the number of enzyme reactions consumed;
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계를 포함하는, 미생물의 약물 표적 효소 스크리닝 방법을 제공한다. (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite It provides a method for screening a drug target enzyme of a microorganism comprising the step of selecting an enzyme involved in the drug target enzyme of the target microorganism.
그리고, 상기 선정된 대상 미생물의 약물 표적 효소를 코딩하는 유전자군들을 대상 미생물의 약물 표적 유전자로 결정하는 것을 특징으로 하는, 미생물에 대한 약물 표적 유전자의 스크리닝 방법을 제공한다.In addition, the present invention provides a method for screening a drug target gene for a microorganism, characterized in that the gene group encoding the drug target enzyme of the selected microorganism is determined as a drug target gene of the target microorganism.
이 때, 상기 숙주는 인간일 수 있고, 상기 대상 미생물은 대장균 또는 병원성 미생물인 것이 바람직하고, 병원성 미생물인 것이 더욱 바람직하다. In this case, the host may be a human, and the target microorganism is preferably Escherichia coli or pathogenic microorganism, and more preferably pathogenic microorganism.
또한, (a)단계에서 미생물의 상기 대사 네트워크는 게놈 수준인 것이 바람직하고, (b)단계의 수행은, In addition, it is preferable that the metabolic network of the microorganism in step (a) is genomic level, and performing the step (b),
(i) 상기 구축된 미생물 대사 네트워크를 이하의 수학식으로 표현하여 선형(i) the constructed microbial metabolic network is expressed by the following equation
계획법을 이용하는 단계; 및Using programming; And
(여기서, S·v : 시간에 따른 X의 변화량, X: 대사산물의 농도, t: 시간)(Where S · v: change in X over time, X: concentration of metabolite, t: time)
(ii) 이하의 수학식2를 이용하여, 대사산물 소비 반응식의 대사흐름값을 0으(ii) Using the following Equation 2, the metabolite flow value of the metabolite consumption reaction equation is zero.
로 고정시킨 후 세포의 성장속도가 0인 경우를 1차 필수 대사산물로 결정하는 단계:Determining the first essential metabolite when the cell growth rate is 0 after fixation:
(여기서 jm은 각 대사산물의 소비 반응식; Vjm은 해당 소비 반응식의 대사흐름값)를 포함하여 이루어질 수 있다. (Where jm is a consumption equation of each metabolite; Vjm is a metabolic flow value of the corresponding consumption equation).
특히, 상기 선형계획법의 적용은 세포의 성장에 필요한 모든 영양분 조건을 반영하여 이루어지는 것이 바람직하다. In particular, the application of the linear programming is preferably made by reflecting all the nutrient conditions necessary for the growth of cells.
또한, (c)단계에서 대상 미생물과의 특이성이 없는 상기 유통 대사산물은 대상 미생물과 다른 생물체의 다른 효소 반응식에도 관여하는 것이고, (d)단계에서, 2차 필수 대사산물들 중 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 대사산물을 3차 필수 대사산물로 결정하는 것이 바람직하며, (f)단계에서 상기 상동관계의 검토는 아미노산 서열 또는 유전자 서열을 이용할 수 있다. 이 때, 상기 상동관계의 검토는 BLASTP 프로그램 또는 BLAST 프로그램을 이용하여 이루어질 수 있다. In addition, the distribution metabolite having no specificity with the target microorganism in step (c) is also involved in other enzymatic reactions of the target microorganism and other organisms, and in step (d), at least three or more of the secondary essential metabolites At least two or more at the same time involved in the enzymatic reaction, it is preferable to determine the metabolite in the case of consuming the required metabolite as the third essential metabolite, and in step (f) the examination of the homology is carried out Gene sequences can be used. At this time, the examination of the homology may be performed using the BLASTP program or the BLAST program.
그리고, 본 발명은 상기 선정된 대상 미생물의 효소들 또는 이를 코딩하는 유전자군들, 및 이들을 대상 미생물의 약물 표적으로 이용하는 방법을 제공한다.In addition, the present invention provides the enzymes of the selected microorganism or gene groups encoding the same, and a method of using them as drug targets of the microorganism.
또한, 본 발명은 In addition, the present invention
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, (c) of the primary essential metabolites determined in step (b),
대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하는 단계 및 숙주의 대사에 존재하지 않는 것들만을 선별하는 단계를, 각각 또는 모두 실시하는 단계;Removing a current metabolite having no specificity with the microorganism of interest and selecting only those that are not present in the host's metabolism, each or all;
(d) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 최종 필수 대사산물로 결정하는 단계;(d) if all enzymes consuming the essential metabolites determined in the previous step are not homologous to the host protein, determining those essential metabolites as the final essential metabolite;
(e) 상기 (d)단계에서 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 타니모토 계수를 이용하여 화합물 라이브러리에서 선별하는 단계; 및(e) selecting a compound candidate group having structural similarity to the essential metabolite in step (d) from the compound library by using Tanimoto coefficients; And
(f) 상기 선별된 화합물 후보군을 각각 대상 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계.(f) screening the drug by administering each of the selected compound candidate groups to the target microorganism to confirm growth inhibition.
를 포함하는, 미생물에 대한 약물 스크리닝 방법을 제공한다.It provides a drug screening method for microorganisms, including.
보다 바람직하게는, 본 발명은, More preferably, the present invention,
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계; (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정 하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
(g) 상기 (e)단계에서 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 타니모토 계수(Tanimoto coefficient)를 이용하여 화합물 라이브러리에서 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (e) from the compound library by using a Tanimoto coefficient; And
(h) 상기 선별된 화합물 후보군을 각각 대상 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계.(h) screening drugs by administering each of the selected compound candidate groups to target microorganisms to determine whether they inhibit growth.
를 포함하는, 미생물에 대한 약물의 스크리닝 방법을 제공한다.It provides a method for screening a drug against a microorganism, including.
또한, 본 발명은 In addition, the present invention
(a) 아시네토박터(Acinetobacter) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of the genus Acinetobacter ;
(b) 상기 구축된 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the first essential metabolism of the specific metabolites when the growth rate of the cell is 0 while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the Acinetobacter genus microbial metabolic network Determining the products;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 아시네토박터(Acinetobacter) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계; (c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter . Determining;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계; (e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및 (d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c); (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소로 선정하는 단계를 포함하는, 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소의 스크리닝 방법을 제공한다. (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite enzymes involved in providing the Acinetobacter drug screening method of the target enzyme of the microorganism of the genus Acinetobacter (Acinetobacter), comprising the step of selecting the drug for the target enzyme in microorganisms (Acinetobacter).
이 때, 아시네토박터(Acinetobacter) 속 미생물 중 아시네토박터 바우마니 (Acinetobacter baumannii)를 이용할 수 있다.In this case, you can use the Acinetobacter (Acinetobacter) microorganisms of the genus Acinetobacter baumannii (Acinetobacter baumannii).
또한, 본 발명은 상기 방법에 의해 수득된, In addition, the present invention obtained by the above method,
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase(3-dehydroquinase), shikimate 5-dehydrogenase, quinate/shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, 및 dihydropteroate synthase로 구성된 군에서 선택되는 아시네토박터(Acinetobacter)속 미생물의 효소군 및 이를 약물 표적으로 이용하는 방법과, 이들 효소를 코딩하는 유전자인 ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, ABAYE3176, ABAYE3395, ABAYE3524, ABAYE3568, ABAYE3612 및 ABAYE3616으로 구성된 군에서 선택되는 아시네토박터(Acinetobacter) 속 미생물의 유전자군 및 이를 약물 표적으로 이용하는 방법을 제공한다. 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabo 3-dehydroquinate dehydratase (3-dehydroquinase), shikimate 5-dehydrogenase, quinate / shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno- Enzyme group of the genus Acinetobacter selected from the group consisting of octulosonate cytidylyltransferase and dihydropteroate synthase, and methods of using the same as drug targets, and genes encoding these enzymes ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABA0945 , ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, ABAYE3176, ABAYE3395, ABAYE3524, ABAYE3568, ABAYE3 Provided are a gene group of Acinetobacter genus microorganisms selected from the group consisting of 612 and ABAYE3616 and methods of using the same as drug targets.
또한, 본 발명은 In addition, the present invention
(a) 비브리오(Vibrio) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of Vibrio genus microorganisms;
(b) 상기 구축된 비브리오(Vibrio) 속 미생물 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed Vibrio (Vibrio)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 비브리오(Vibrio) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 비브리오(Vibrio) 속 미생물의 약물 표적 효소로 선정하는 단계를 포함하는, 비브리오(Vibrio) 속 미생물의 약물 표적 효소의 스크리닝 방법을 제공한다. (f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite enzymes involved in including the step of selecting the drug target enzyme of the microorganism of the genus Vibrio (Vibrio), provides a screening method of Vibrio drug target of the enzyme in microorganisms (Vibrio).
또한, 본 발명은 In addition, the present invention
(a) 비브리오(Vibrio) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of Vibrio genus microorganisms;
(b) 상기 구축된 비브리오(Vibrio) 속 미생물 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed Vibrio (Vibrio)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 비브리오(Vibrio) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
(g) 상기 (f)단계에서 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 타니모토 계수를 이용하여 화합물 라이브러리에서 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (f) from the compound library by using Tanimoto coefficients; And
(h) 상기 선별된 화합물 후보군을 각각 비브리오(Vibrio) 속 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계를 포함하는, 비브리오(Vibrio) 속 미생물에 대한 약물 스크리닝 방법을 제공한다.(h) provides a drug screening method for by checking whether the growth inhibition by administering the selected compound candidate for each Vibrio (Vibrio) into the microorganism comprising the step of screening a drug, Vibrio (Vibrio) spp.
본 발명은 또한, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase로 구성된 군에서 선택되는 1종이상의, 비브리오(Vibrio) 속 미생물 효소들, 및 이들을 약물 표적으로 이용하는 방법과, 상기 방법에 의해 수득된 효소들을 코딩하는 유전자인 VV10567, VV10580, VV11175, VV11568, VV11644, VV11691 및 VV11866으로 구성된 군에서 선택되는 1종 이상의, 비브리오(Vibrio) 속 미생물 유전자들, 및 이들을 약물 표적으로 이용하는 방법을 제공한다. The present invention also provides 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5-phosphate one or more Vibrio genus microbial enzymes selected from the group consisting of reductoisomerase, pyridoxine 5-phosphate synthase, and methods for using them as drug targets, and VV10567 and VV10580 genes encoding the enzymes obtained by the method , VV11175, VV11568, VV11644, VV11691 and VV11866, one or more Vibrio genus microbial genes selected from the group consisting of, and methods of using them as drug targets.
본 발명은 또한, 상기 방법에 따라 스크리닝되고, 하기 화학식 1의 구조를 가지는, 비브리오(Vibrio) 속 미생물에 대한 항균능을 가지는 화합물 및 이를 함유하는 항균 조성물을 제공한다: The present invention is also screened according to the above method, and has a structure of Formula 1, Vibrio (Vibrio) It provides a compound having an antimicrobial activity against the genus microorganisms and an antimicrobial composition containing the same:
도 1은 본 발명에 따른, 미생물 약물 표적 방법론의 개념을 도시화한 개략도이다[A:특정 미생물의 대사 네트워크를 구축; B:필수 대사산물 분석을 이용한 1차 필수 대사산물 예측; C:유통 대사산물의 제거; D:해당 대사산물에 관여하는 반응식의 개수 고려; E:숙주 대사 내의 존재 여부 확인; F: 약물 표적 효소 및 유전자 결정]. 1 is a schematic diagram illustrating the concept of a microbial drug targeting methodology in accordance with the present invention [A: building a metabolic network of specific microorganisms; B: Primary essential metabolite prediction using essential metabolite analysis; C: removal of distribution metabolites; D: Consider the number of schemes involved in that metabolite; E: confirm presence in host metabolism; F: drug target enzyme and gene determination].
도 2는 비브리오(Vibrio) 속 미생물에 대한 약물 후보군으로써, 5개의 5차 필수 대사산물의 구조와 유사한 화합물을 화합물 라이브러리에서 선별하여 미생물 성장 억제 실험을 도시화한 개략도이다. FIG. 2 is a schematic diagram illustrating the microbial growth inhibition experiment by selecting a compound similar to the structure of five fifth essential metabolites from the compound library as a drug candidate for Vibrio genus microorganisms.
발명의 상세한 설명 및 구체적인 구현예Detailed Description of the Invention and Specific Embodiments
이하 본 발명을 구체적으로 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 일 관점에서, 미생물, 특히 병원성 미생물의 약물 표적 효소 또는 이를 코딩하는 약물 표적 유전자의 스크리닝 방법에 관한 것이다. 개략적인 과정은 도 1에 도시하고 있다.The present invention, in one aspect, relates to a method for screening drug target enzymes or drug target genes encoding the microorganisms, in particular pathogenic microorganisms. The schematic process is shown in FIG.
도 1에는 본 발명에 따른 통합 약물 표적 방법론의 개념을 도시한 것이다. 본 발명의 방법론에서는, 예를 들어, 특정 미생물의 대사 네트워크를 구축하고(A), 이로부터 대사흐름분석을 기반을 둔 필수 대사산물 분석을 이용하여 필수 대사산물을 예측한다(B). 그리고, 이로부터 유통 대사산물의 제거(C), 해당 대사산물에 관여하는 반응식의 개수 고려(D), 필수 대사산물 및 이들의 관여하는 반응식의 인간 대사 내의 존재 여부 등의 확인(E)을 통하여, 미생물의 가장 효과적인 약물 표적들을 예측한다(F). 1 illustrates the concept of an integrated drug targeting methodology in accordance with the present invention. In the methodology of the present invention, for example, a metabolic network of a particular microorganism is constructed (A), from which essential metabolite analysis is predicted using essential metabolite analysis based on metabolic flow analysis (B). From this, the elimination of circulating metabolites (C), the consideration of the number of reaction formulas involved in the metabolites (D), the confirmation of the presence of essential metabolites and their involved reactions in human metabolism (E), etc. Predict the most effective drug targets of the microorganism (F).
본 발명의 미생물의 약물 표적 효소 스크리닝 방법은 Drug target enzyme screening method of the microorganism of the present invention
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, (c) of the primary essential metabolites determined in step (b),
대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하는 단계 및 숙주의 대사에 존재하지 않는 것들만을 선별하는 단계를, 각각 또는 모두 실시하는 단계; 및Removing a current metabolite having no specificity with the microorganism of interest and selecting only those that are not present in the host's metabolism, each or all; And
(d) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 최종 필수 대사산물로 결정하고, 상기 최종 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계(d) If all the enzymes that consume the essential metabolites determined in the previous step do not have homology with the host protein, determine the essential metabolites as the final essential metabolite, and determine the enzymes involved in the final essential metabolite as the target microorganism. Selection as a drug target enzyme
를 포함하고, Including,
보다 구체적으로, 본 발명에 따른 약물 표적 효소 스크리닝 방법은, More specifically, the drug target enzyme screening method according to the present invention,
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
(d) 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물을 결정하는 단계;(d) determining the tertiary essential metabolite by considering the number of enzymatic reaction schemes involved and the number of enzymatic reaction schemes consumed;
(e) 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those that are not present in the host's metabolism to determine the fourth essential metabolite; And
(f) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계를 포함한다.(f) If all of the enzymes that consume the essential metabolites determined in the previous step do not have a homology with the host protein, determine those essential metabolites as the fifth essential metabolite and identify the enzymes involved in the fifth essential metabolite. Selecting a drug target enzyme of the subject microorganism.
이 때, 상기 방법에 있어서, 상기 "(c)단계 및/또는 (e)단계; 및 (f)단계"에 대하여 "(d)단계"는 선택적으로 적용할 수 있다. 따라서, 본 발명은 다른 관점에서, 상기 각 단계의 방법에 따른 필수 대사산물 결정방법에 관한 것이다. At this time, in the above method, "step (d)" may be selectively applied to "step (c) and / or (e); and (f)". Therefore, in another aspect, the present invention relates to a method for determining an essential metabolite according to the method of each step.
상기 (f)단계는 약물의 숙주, 예를 들어, 인체에 대한 부작용을 최소화하기 위하여 필요한 단계로서, (c)단계와 (e)단계를 수행함으로써 (f)단계를 시간적으로 단축시킬 수 있다. 따라서, 이런 효율성 관점에서 (f)단계를 수행하는 경우, (c)단계와 (e)단계는 각각 또는 동시 선택이 가능하다. 가장 바람직하게는 (c)단계, (e)단계 및 (f)단계 모두를 실시하는 경우이다. Step (f) is a step necessary to minimize adverse effects on the host of the drug, for example, the human body, and may shorten step (f) by performing steps (c) and (e). Therefore, in the case of performing step (f) in view of such efficiency, step (c) and step (e) can be selected individually or simultaneously. Most preferably, all the steps (c), (e) and (f) are performed.
그리고, 상기 (d)단계는 보다 효과적인 약물표적들만으로 그 개수를 현저히 줄이기 위해 본 발명에서 고안된 방법으로서 택일적으로 실시할 수 있다. 일반적으로, 필수 대사산물 분석을 통해서 예측된 필수 대사산물은 보통 100개 이상이고, 이들을 실험으로 모두 검증하기가 매우 어렵기 때문에, 이들의 개수를 줄일 필요가 있다. 그러므로, 본 발명에서는 특정 필수 대사산물을 병원균으로부터 제거했을 때의 효과를 극대화하기 위하여, 해당 필수 대사산물을 소비하는 반응식의 수를 고려하는 상기 (d)단계의 방법을 고안하였다. In addition, step (d) may alternatively be carried out as a method devised in the present invention to significantly reduce the number of drug targets more effectively. In general, there are usually more than 100 essential metabolites predicted through the analysis of essential metabolites, and it is very difficult to verify all of them experimentally, so the number of these needs to be reduced. Therefore, in the present invention, in order to maximize the effect of removing certain essential metabolites from the pathogen, the method of step (d) is devised in consideration of the number of reaction formulas that consume the essential metabolites.
즉, 본 발명은, 상기 단계들을 "(a)-(b)-(c)-(f)", "(a)-(b)-(e)-(f)", "(a)-(b)-(c)-(d)-(f)", "(a)-(b)-(d)-(e)-(f)" 또는 "(a)-(b)-(c)-(d)-(e)-(f)", 의 태양으로 당업자가 적절히 실시할 수 있다. 다만, 가장 바람직하게는 "(a)-(b)-(c)-(d)-(e)-(f)"의 태양으로 실시하는 것이다. That is, in the present invention, the steps are described as "(a)-(b)-(c)-(f)", "(a)-(b)-(e)-(f)", "(a)- (b)-(c)-(d)-(f) "," (a)-(b)-(d)-(e)-(f) "or" (a)-(b)-(c )-(d)-(e)-(f) ", which can be suitably implemented by those skilled in the art. However, most preferably, it implements in the aspect of "(a)-(b)-(c)-(d)-(e)-(f)".
따라서, 본 발명의 바람직한 일 태양의 방법은 이하와 같다. 즉, 본 발명은Therefore, the method of one preferable aspect of this invention is as follows. That is, the present invention
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계를 포함한다.(f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the target microorganism.
한편, 본 발명에서는 일 구체예로서 아시네토박터(Acinetobacter) 속 미생물, 예를 들어 아시네토박터 바우마니 (Acinetobacter baumannii)를 사용하였다. 따라서, 본 발명의 일 태양으로, 다음의 단계를 포함하는, 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소의 스크리닝 방법을 제공할 수 있다: Meanwhile, in the present invention, as a specific example, Acinetobacter genus microorganisms, for example, Acinetobacter baumannii, were used. Thus, in one aspect of the present invention, a method for screening drug target enzymes of the genus Acinetobacter may be provided, comprising the following steps:
(a) 아시네토박터(Acinetobacter) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of the genus Acinetobacter;
(b) 상기 구축된 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the first essential metabolism of the specific metabolites when the growth rate of the cell is 0 while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the Acinetobacter genus microbial metabolic network Determining the products;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 아시네토박터(Acinetobacter) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Of the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter. Determining;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소로 선정하는 단계.(f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the microorganism of the genus Acinetobacter.
이 때도 역시, 상기 "(c)단계 및/또는 (e)단계; 및 (f)단계"에 대하여 "(d)단계"는 선택적으로 적용할 수 있다. 구체적인 설명은 앞서 설명한 바와 같다.Also in this case, "step (d)" may be selectively applied to the "step (c) and / or (e); and (f)". The detailed description is as described above.
한편, 본 발명에서는 일 구체예로서 비브리오 속 미생물, 예를 들어 비브리오 불니피커스(Vibrio vulnificus )를 사용하였다. 하지만, 비브리오 속에는, 비브리오 불니피커스 뿐만 아니라, 비브리오 콜레라, 비브리오 헤모리티쿠스 등이 모두 포함된다. Meanwhile, in the present invention, Vibrio sp. Microorganisms, for example, Vibrio vulnificus were used. However, Vibrio includes not only Vibrio bulnipius, but also Vibrio cholera, Vibrio hemoritis, and the like.
본 발명의 일 태양으로, 다음의 단계를 포함하는, 비브리오 속 미생물의 약물 표적 효소의 스크리닝 방법을 제공할 수 있다: In one aspect of the present invention, a method for screening a drug target enzyme of Vibrio genus microorganism may be provided, comprising the following steps:
(a) 비브리오(Vibrio) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of Vibrio genus microorganisms;
(b) 상기 구축된 비브리오(Vibrio) 속 미생물 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed Vibrio (Vibrio)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 비브리오(Vibrio) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 비브리오(Vibrio) 속 미생물의 약물 표적 효소로 선정하는 단계.(f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the microorganism of Vibrio genus.
이 때도 역시, 상기 "(c)단계 및/또는 (e)단계; 및 (f)단계"에 대하여 "(d)단계"는 선택적으로 적용할 수 있다. 구체적인 설명은 앞서 설명한 바와 같다.Also in this case, "step (d)" may be selectively applied to the "step (c) and / or (e); and (f)". The detailed description is as described above.
본 발명은, 다른 관점에서, 본 발명의 미생물에 대한 약물 스크리닝 방법에 관한 것이다.The present invention, in another aspect, relates to a method for drug screening against a microorganism of the present invention.
본 발명의 미생물에 대한 약물 스크리닝 방법은, Drug screening method for a microorganism of the present invention,
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, (c) of the primary essential metabolites determined in step (b),
대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하는 단계 및 숙주의 대사에 존재하지 않는 것들만을 선별하는 단계를, 각각 또는 모두 실시하는 단계;Removing a current metabolite having no specificity with the microorganism of interest and selecting only those that are not present in the host's metabolism, each or all;
(d) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 최종 필수 대사산물로 결정하는 단계;(d) if all enzymes consuming the essential metabolites determined in the previous step are not homologous to the host protein, determining those essential metabolites as the final essential metabolite;
(e) 상기 (d)단계에서 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 타니모토 계수를 이용하여 화합물 라이브러리에서 선별하는 단계;및(e) selecting a compound candidate group having structural similarity to the essential metabolite in step (d) from the compound library using the Tanimoto coefficient; and
(f) 상기 선별된 화합물 후보군을 각각 대상 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계.(f) screening the drug by administering each of the selected compound candidate groups to the target microorganism to confirm growth inhibition.
를 포함하거나, 보다 구체적으로는, Or more specifically,
(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;
(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계; (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정 하는 단계;(f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) have no homology with the host protein, determining the essential metabolites as the fifth essential metabolite;
(g) 상기 (e)단계에서 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 타니모토 계수(Tanimoto coefficient)를 이용하여 화합물 라이브러리에서 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (e) from the compound library using a Tanimoto coefficient; And
(h) 상기 선별된 화합물 후보군을 각각 대상 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계를 포함한다.(h) screening drugs by administering each of the selected compound candidate groups to target microorganisms to determine whether they inhibit growth.
여기서, 상기 (g) 단계에서, 5차 필수 대사산물과 구조적으로 유사한 화합물 후보군을 선별하는데에는, 특정 물질과 유사한 구조의 화합물을 선별하는 pipeline 등을 비롯한 공지의 툴(tool)을 통한 타니모토 계수를 이용할 수 있으며, 구체적으로 타니모토 계수 0.5~ 1의 화합물 후보군을 선별하는 것을 특징으로 한다.Here, in the step (g), to select a compound candidate group structurally similar to the fifth essential metabolite, Tanimoto coefficient through a known tool including a pipeline for selecting a compound having a structure similar to a specific substance It may be used, specifically characterized by selecting a compound candidate group having a Tanimoto coefficient of 0.5 to 1.
상기 (h) 단계에서, 대상 미생물에 실제로 상기 선별된 화합물 후보군을 실제로 처리하여 배양한 결과, 대조군 대비 80% 이상의 성장 억제 효능을 가지는 화합물을 미생물에 대한 약물로 스크리닝하는 것을 특징으로 한다. In the step (h), as a result of actually treating and culturing the selected compound candidate group to the target microorganism, the compound having a growth inhibitory effect of at least 80% compared to the control group is characterized by screening with a drug against the microorganism.
한편, 본 발명에서는 일 구체예로서 아시네토박터(Acinetobacter) 속 미생물, 예를 들어 아시네토박터 바우마니 (Acinetobacter baumannii)를 사용하였다. 따라서, 본 발명의 일 태양으로, 다음의 단계를 포함하는, 아시네토박터(Acinetobacter) 속 미생물의 약물 스크리닝 방법을 제공할 수 있다: On the other hand, in the present invention, for Acinetobacter (Acinetobacter) in microorganisms, such as one embodiment used the Acinetobacter baumannii (Acinetobacter baumannii). Accordingly, in one aspect of the present invention, there can be provided a method for drug screening of the genus Acinetobacter, comprising the following steps:
(a) 아시네토박터(Acinetobacter) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) building a metabolic network model of the genus Acinetobacter ;
(b) 상기 구축된 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed acinetobacter (Acinetobacter)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 아시네토박터(Acinetobacter) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Of the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter. Determining;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
(g) 상기 (f)단계에서 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 타니모토 계수를 이용하여 화합물 라이브러리에서 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite in step (f) from the compound library by using Tanimoto coefficients; And
(h) 상기 화합물 후보군을 각각 아시네토박터(Acinetobacter) 속 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계.(h) by verifying whether the candidate compound for each of Acinetobacter (Acinetobacter) inhibited growth by administering a microorganism of the genus, comprising the steps of screening a drug.
한편, 본 발명에서는 일 구체예로서 비브리오 속 미생물, 예를 들어 비브리오 불니피커스(Vibrio vulnificus )를 사용하였다. 따라서, 본 발명의 일 태양으로, 다음의 단계를 포함하는, 비브리오 속 미생물의 약물 스크리닝 방법을 제공할 수 있다: Meanwhile, in the present invention, Vibrio sp. Microorganisms, for example, Vibrio vulnificus were used. Thus, in one aspect of the present invention, there can be provided a method for drug screening of Vibrio genus microorganisms, comprising the following steps:
(a) 비브리오(Vibrio) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of Vibrio genus microorganisms;
(b) 상기 구축된 비브리오(Vibrio) 속 미생물 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed Vibrio (Vibrio)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;
(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 비브리오(Vibrio) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;
(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);
(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And
(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;
(g) 상기 (f)단계에서 5차 필수 대사산물과 구조적 유사성을 가진화합물 후보군을 타니모토 계수를 이용하여 화합물 라이브러리에서 선별하는 단계; 및(g) selecting a candidate compound group having structural similarity to the fifth essential metabolite in step (f) from the compound library by using Tanimoto coefficient; And
(h) 상기 선별된 화합물 후보군을 각각 비브리오(Vibrio) 속 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계.(h) by checking whether the screening of candidate compounds administered to each Vibrio (Vibrio) in microbial growth inhibition, the method comprising screening a drug.
각 단계에 대한 구체적인 설명은 이하와 같다. 특히, 이하에서는 본 발명의 가장 바람직한 태양을 중심으로 기술한다.The detailed description of each step is as follows. In particular, the following description will focus on the most preferred aspects of the present invention.
(1) 대상 미생물의 대사 네트워크 구축(1) metabolic network construction of target microorganism
"대사(metabolism)"란 생물체의 에너지활동에 관련된 일련의 활동을 의미한다. 즉, 에너지원을 외부로부터 흡수하고, 이를 생명체가 이용하기 가장 용이한 형태의 에너지로 바꾸는 소화작용을 거쳐서 생명체의 활동에 필요한 여러 가지 대사산물을 다양한 생합성을 통하여 합성하는 일련의 활동이 모두 대사작용에 포함된다. 생체 네트워크 중 가장 먼저 연구된 것이 이러한 "대사 네트워크(metabolic network)"이다. "Metabolism" means a series of activities related to the energy activities of living things. That is, a series of activities that synthesize various metabolites necessary for life's activities through various biosynthesis through digestion that absorbs energy sources from the outside and converts them into the energy forms that are most readily available to life. Included in The first of the biological networks studied is this "metabolic network".
본 발명에서의 가장 첫 단계는 대상 미생물의 대사 네트워크 구축으로, 대상 미생물에 대해 세포내외에서 일어나는 생화학적 반응들을 모아 모든 대사 물질과 반응효소로 이루어진 네트워크를 구축한다. The first step in the present invention is to build a metabolic network of the target microorganism, to build a network consisting of all metabolites and reactive enzymes by collecting biochemical reactions occurring inside and outside the cell.
본 발명에 있어서, 상기 대사 네트워크를 구축하기 위한 대상 미생물로서는 대장균 또는 병원성 미생물일 수 있고, 특별한 제한 없이 모든 병원성 미생물을 사용할 수 있다. 본 발명의 일 구체예에서는 아시네토박터(Acinetobacter) 속 미생물, 예를 들어 아시네토박터 바우마니(Acinetobacter baumannii), 비브리오(Vibrio) 속 미생물, 예를 들어 비브리오 불니피커스(Vibrio vulnificus)를 사용하였다. In the present invention, the target microorganism for constructing the metabolic network may be Escherichia coli or pathogenic microorganism, and any pathogenic microorganism may be used without particular limitation. In one embodiment of the invention was used for Acinetobacter (Acinetobacter) in microorganisms, such as Acinetobacter baumannii (Acinetobacter baumannii), Vibrio (Vibrio) into the microorganism, for example, Vibrio nipi carcass (Vibrio vulnificus) .
'병원성 미생물'이란 미생물이 생성하는 독소, 효소 기타 생성물에 의해서 일어나는 병원성과 병원체, 병원소, 전염경로, 숙주감수성에 따라 결정되는 전염성을 갖고 있는 미생물로서, 각종 바이러스, 박테리아, 균류 등이 있을 수 있고, 이들은 동물, 식물 등 다양한 생물체에 전염될 수 있다.A pathogenic microorganism is a microorganism having infectivity determined by pathogens, pathogens, pathogens, infectious pathways, and host susceptibility caused by toxins, enzymes, and other products produced by microorganisms, and may include various viruses, bacteria, and fungi. And they can be transmitted to various organisms such as animals and plants.
본 발명의 방법에서는 우선, 미생물의 대사 네트워크를 구축한다. 이 때, 공지되어 있는 다양한 데이터베이스 및 실험결과를 이용하여 게놈 수준의 대사 네트워크를 구축하는 것이 바람직하다. 예를 들어, 유전자를 기반으로 네트워크를 구축할 수 있다. In the method of the present invention, first, a metabolic network of microorganisms is established. At this time, it is desirable to construct a genome-level metabolic network using various known databases and experimental results. For example, you can build a network based on genes.
본 발명의 일례에서는 아시네토박터 바우마니(Acinetobacter baumannii AYE)의 대사 네트워크 모델을 구축하여 이용하였다. 아시네토박터 바우마니(Acinetobacter baumannii,AB)는 과거의 Acinetobacter calcoaceticus와 anitratus의 두 균주를 통합하여 명명된 그람 음성 단간균으로, 에너지원을 다양하게 이용할 수 있는 세균학적 특징을 가지고 있어 넓은 범위의 온도와 pH에서 자랄 수 있으므로 거의 모든 토양과 민물에서 채취한 검체에서 발견된다. 이런 특징이 있는 Acinetobacter baumannii는 많은 병원에서 원내 감염의 중요한 원인균으로 보고되고 있는데, 일단 원내감염이 발생하면, 일반적으로 세균이 생존하기 어려운 환경에서도 장기간 생존할 수 있어, 높은 항생제 저항성과 저항성이 빠르게 발생하는 특성으로 인해 치료하기 힘들고 이로 인해 이 원인균으로 인한 사망률 또한 증가하여 최근 중요한 병원균으로 대두되고 있다. 성인에서는 A. baumannii가 인공 호흡기와 연관된 폐렴, 화상환자의 상처 감염, 패혈증을 발생시킨다고 알려져 있다.In one example of the present invention, a metabolic network model of Acinetobacter baumannii AYE was constructed and used. Acinetobacter baumannii (AB) is a gram-negative bacillus named after integrating two strains of Acinetobacter calcoaceticus and anitratus in the past, and has a wide range of bacteriological characteristics that make it possible to use various energy sources. It can be grown at or at pH and is found in samples taken from almost all soils and fresh water. Acinetobacter baumannii, which has this characteristic, has been reported as an important causative agent of hospital infections in many hospitals. Once hospital infections occur, they usually survive long-term in environments where bacteria are difficult to survive, resulting in high antibiotic resistance and resistance. Due to its characteristics, it is difficult to treat, and as a result, the mortality rate caused by the causative organism also increases, which has recently emerged as an important pathogen. In adults, A. baumannii is known to cause pneumonia associated with respirators, wound infections in burn patients, and sepsis.
본 발명의 일례에서 사용한 상기 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크 구축은 이하의 유전자로 구성된 유전자 군에 기반하여 이루어질 수 있다:The Acinetobacter genus microbial metabolic network construction used in an example of the present invention can be made based on a gene group consisting of the following genes:
ABAYE0014, ABAYE0022, ABAYE0023, ABAYE0028, ABAYE0036, ABAYE0043, ABAYE0056, ABAYE0058, ABAYE0059, ABAYE0064, ABAYE0067, ABAYE0068, ABAYE0075, ABAYE0076, ABAYE0078, ABAYE0079, ABAYE0081, ABAYE0082, ABAYE0084, ABAYE0089, ABAYE0090, ABAYE0091, ABAYE0093, ABAYE0095, ABAYE0096, ABAYE0098, ABAYE0102, ABAYE0104, ABAYE0109, ABAYE0116, ABAYE0127, ABAYE0128, ABAYE0129, ABAYE0144, ABAYE0147, ABAYE0148, ABAYE0149, ABAYE0150, ABAYE0154, ABAYE0157, ABAYE0158, ABAYE0166, ABAYE0167, ABAYE0168, ABAYE0175, ABAYE0179, ABAYE0200, ABAYE0209, ABAYE0210, ABAYE0243, ABAYE0244, ABAYE0250, ABAYE0253, ABAYE0254, ABAYE0262, ABAYE0264, ABAYE0277, ABAYE0283, ABAYE0284, ABAYE0285, ABAYE0295, ABAYE0296, ABAYE0298, ABAYE0299, ABAYE0310, ABAYE0312, ABAYE0313, ABAYE0325, ABAYE0332, ABAYE0351, ABAYE0352, ABAYE0353, ABAYE0354, ABAYE0355, ABAYE0356, ABAYE0367, ABAYE0368, ABAYE0377, ABAYE0378, ABAYE0379, ABAYE0381, ABAYE0397, ABAYE0405, ABAYE0435, ABAYE0436, ABAYE0465, ABAYE0470, ABAYE0476, ABAYE0479, ABAYE0480, ABAYE0482, ABAYE0483, ABAYE0489, ABAYE0491, ABAYE0497, ABAYE0505, ABAYE0524, ABAYE0577, ABAYE0588, ABAYE0604, ABAYE0605, ABAYE0607, ABAYE0608, ABAYE0613, ABAYE0614, ABAYE0615, ABAYE0619, ABAYE0624, ABAYE0625, ABAYE0628, ABAYE0629, ABAYE0634, ABAYE0638, ABAYE0663, ABAYE0674, ABAYE0676, ABAYE0682, ABAYE0691, ABAYE0697, ABAYE0698, ABAYE0699, ABAYE0708, ABAYE0709, ABAYE0716, ABAYE0722, ABAYE0740, ABAYE0749, ABAYE0757, ABAYE0758, ABAYE0763, ABAYE0773, ABAYE0774, ABAYE0775, ABAYE0776, ABAYE0777, ABAYE0780, ABAYE0781, ABAYE0782, ABAYE0783, ABAYE0784, ABAYE0788, ABAYE0800, ABAYE0801, ABAYE0807, ABAYE0811, ABAYE0812, ABAYE0816, ABAYE0817, ABAYE0818, ABAYE0824, ABAYE0826, ABAYE0849, ABAYE0850, ABAYE0853, ABAYE0854, ABAYE0860, ABAYE0861, ABAYE0877, ABAYE0885, ABAYE0888, ABAYE0889, ABAYE0899, ABAYE0911, ABAYE0912, ABAYE0915, ABAYE0916, ABAYE0923, ABAYE0931, ABAYE0933, ABAYE0935, ABAYE0945, ABAYE0951, ABAYE0958, ABAYE0962, ABAYE0966, ABAYE0969, ABAYE0977, ABAYE0980, ABAYE0982, ABAYE1010, ABAYE1011, ABAYE1026, ABAYE1027, ABAYE1028, ABAYE1030, ABAYE1039, ABAYE1047, ABAYE1052, ABAYE1066, ABAYE1067, ABAYE1083, ABAYE1094, ABAYE1098, ABAYE1103, ABAYE1104, ABAYE1106, ABAYE1113, ABAYE1114, ABAYE1115, ABAYE1118, ABAYE1119, ABAYE1123, ABAYE1126, ABAYE1127, ABAYE1128, ABAYE1138, ABAYE1141, ABAYE1142, ABAYE1145, ABAYE1147, ABAYE1171, ABAYE1199, ABAYE1204, ABAYE1206, ABAYE1207, ABAYE1209, ABAYE1223, ABAYE1278, ABAYE1280, ABAYE1295, ABAYE1296, ABAYE1354, ABAYE1356, ABAYE1362, ABAYE1366, ABAYE1367, ABAYE1380, ABAYE1385, ABAYE1386, ABAYE1387, ABAYE1388, ABAYE1389, ABAYE1391, ABAYE1411, ABAYE1413, ABAYE1417, ABAYE1418, ABAYE1425, ABAYE1427, ABAYE1432, ABAYE1445, ABAYE1453, ABAYE1455, ABAYE1456, ABAYE1457, ABAYE1458, ABAYE1460, ABAYE1463, ABAYE1465, ABAYE1466, ABAYE1469, ABAYE1477, ABAYE1510, ABAYE1513, ABAYE1514, ABAYE1520, ABAYE1522, ABAYE1526, ABAYE1537, ABAYE1538, ABAYE1539, ABAYE1544, ABAYE1546, ABAYE1562, ABAYE1563, ABAYE1567, ABAYE1569, ABAYE1571, ABAYE1577, ABAYE1580, ABAYE1581, ABAYE1585, ABAYE1586, ABAYE1587, ABAYE1599, ABAYE1613, ABAYE1625, ABAYE1636, ABAYE1637, ABAYE1646, ABAYE1649, ABAYE1650, ABAYE1653, ABAYE1658, ABAYE1667, ABAYE1668, ABAYE1669, ABAYE1672, ABAYE1675, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE1700, ABAYE1706, ABAYE1710, ABAYE1712, ABAYE1715, ABAYE1724, ABAYE1736, ABAYE1742, ABAYE1781, ABAYE1786, ABAYE1789, ABAYE1792, ABAYE1811, ABAYE1861, ABAYE1886, ABAYE1896, ABAYE1897, ABAYE1909, ABAYE1913, ABAYE1914, ABAYE1916, ABAYE1921, ABAYE1937, ABAYE1940, ABAYE1943, ABAYE1944, ABAYE1945, ABAYE1946, ABAYE1947, ABAYE1948, ABAYE1953, ABAYE1955, ABAYE1970, ABAYE1983, ABAYE1989, ABAYE1990, ABAYE1993, ABAYE1994, ABAYE2013, ABAYE2014, ABAYE2053, ABAYE2058, ABAYE2062, ABAYE2065, ABAYE2067, ABAYE2076, ABAYE2077, ABAYE2088, ABAYE2090, ABAYE2108, ABAYE2116, ABAYE2118, ABAYE2129, ABAYE2153, ABAYE2179, ABAYE2181, ABAYE2184, ABAYE2188, ABAYE2191, ABAYE2209, ABAYE2219, ABAYE2220, ABAYE2227, ABAYE2246, ABAYE2248, ABAYE2250, ABAYE2270, ABAYE2288, ABAYE2290, ABAYE2291, ABAYE2292, ABAYE2304, ABAYE2306, ABAYE2307, ABAYE2310, ABAYE2311, ABAYE2317, ABAYE2318, ABAYE2329, ABAYE2333, ABAYE2342, ABAYE2344, ABAYE2366, ABAYE2367, ABAYE2368, ABAYE2369, ABAYE2370, ABAYE2377, ABAYE2385, ABAYE2388, ABAYE2396, ABAYE2422, ABAYE2438, ABAYE2439, ABAYE2457, ABAYE2460, ABAYE2481, ABAYE2483, ABAYE2491, ABAYE2493, ABAYE2533, ABAYE2562, ABAYE2566, ABAYE2577, ABAYE2578, ABAYE2589, ABAYE2592, ABAYE2593, ABAYE2594, ABAYE2595, ABAYE2596, ABAYE2601, ABAYE2606, ABAYE2607, ABAYE2613, ABAYE2614, ABAYE2618, ABAYE2628, ABAYE2630, ABAYE2631, ABAYE2641, ABAYE2646, ABAYE2663, ABAYE2666, ABAYE2678, ABAYE2764, ABAYE2767, ABAYE2771, ABAYE2776, ABAYE2777, ABAYE2778, ABAYE2783, ABAYE2790, ABAYE2791, ABAYE2794, ABAYE2799, ABAYE2803, ABAYE2809, ABAYE2810, ABAYE2819, ABAYE2822, ABAYE2823, ABAYE2824, ABAYE2829, ABAYE2832, ABAYE2836, ABAYE2837, ABAYE2838, ABAYE2843, ABAYE2845, ABAYE2852, ABAYE2867, ABAYE2868, ABAYE2869, ABAYE2871, ABAYE2878, ABAYE2905, ABAYE2909, ABAYE2910, ABAYE2927, ABAYE2928, ABAYE2929, ABAYE2940, ABAYE2951, ABAYE2955, ABAYE2958, ABAYE2964, ABAYE2969, ABAYE2976, ABAYE2981, ABAYE2984, ABAYE2987, ABAYE2988, ABAYE2989, ABAYE2992, ABAYE2993, ABAYE3001, ABAYE3003, ABAYE3004, ABAYE3006, ABAYE3007, ABAYE3015, ABAYE3016, ABAYE3025, ABAYE3028, ABAYE3031, ABAYE3037, ABAYE3047, ABAYE3048, ABAYE3049, ABAYE3050, ABAYE3051, ABAYE3052, ABAYE3053, ABAYE3054, ABAYE3055, ABAYE3056, ABAYE3057, ABAYE3058, ABAYE3059, ABAYE3060, ABAYE3065, ABAYE3067, ABAYE3078, ABAYE3079, ABAYE3086, ABAYE3097, ABAYE3101, ABAYE3104, ABAYE3105, ABAYE3114, ABAYE3129, ABAYE3130, ABAYE3131, ABAYE3132, ABAYE3133, ABAYE3151, ABAYE3153, ABAYE3154, ABAYE3159, ABAYE3160, ABAYE3169, ABAYE3174, ABAYE3175, ABAYE3176, ABAYE3179, ABAYE3181, ABAYE3184, ABAYE3186, ABAYE3187, ABAYE3188, ABAYE3191, ABAYE3192, ABAYE3193, ABAYE3228, ABAYE3238, ABAYE3239, ABAYE3240, ABAYE3244, ABAYE3250, ABAYE3258, ABAYE3262, ABAYE3263, ABAYE3267, ABAYE3269, ABAYE3272, ABAYE3276, ABAYE3278, ABAYE3280, ABAYE3281, ABAYE3282, ABAYE3283, ABAYE3284, ABAYE3292, ABAYE3293, ABAYE3296, ABAYE3314, ABAYE3315, ABAYE3322, ABAYE3343, ABAYE3348, ABAYE3351, ABAYE3357, ABAYE3359, ABAYE3360, ABAYE3366, ABAYE3373, ABAYE3378, ABAYE3379, ABAYE3393, ABAYE3395, ABAYE3424, ABAYE3426, ABAYE3428, ABAYE3429, ABAYE3443, ABAYE3447, ABAYE3463, ABAYE3470, ABAYE3471, ABAYE3497, ABAYE3498, ABAYE3507, ABAYE3508, ABAYE3511, ABAYE3518, ABAYE3519, ABAYE3524, ABAYE3530, ABAYE3531, ABAYE3537, ABAYE3540, ABAYE3544, ABAYE3546, ABAYE3568, ABAYE3572, ABAYE3588, ABAYE3612, ABAYE3614, ABAYE3616, ABAYE3644, ABAYE3661, ABAYE3670, ABAYE3671, ABAYE3675, ABAYE3678, ABAYE3696, ABAYE3697, ABAYE3713, ABAYE3715, ABAYE3716, ABAYE3717, ABAYE3718, ABAYE3719, ABAYE3720, ABAYE3721, ABAYE3723, ABAYE3731, ABAYE3732, ABAYE3740, ABAYE3750, ABAYE3763, ABAYE3764, ABAYE3766, ABAYE3767, ABAYE3768, ABAYE3773, ABAYE3774, ABAYE3791, ABAYE3792, ABAYFE3793, ABAYE3795, ABAYE3796, ABAYE3797, ABAYE3800, ABAYE3801, ABAYE3802, ABAYE3803, ABAYE3804, ABAYE3807, ABAYE3814, ABAYE3815, ABAYE3823, ABAYE3825, ABAYE3834, ABAYE3835, ABAYE3839, ABAYE3846, ABAYE3851, ABAYE3852, ABAYE3871, ABAYE3872, ABAYE3885, ABAYE3887, p2ABAYE0004, p3ABAYE0020, p3ABAYE0024, p3ABAYE0029.ABAYE0014, ABAYE0022, ABAYE0023, ABAYE0028, ABAYE0036, ABAYE0043, ABAYE0056, ABAYE0058, ABAYE0059, ABAYE0064, ABAYE0067, ABAYE0068, ABAYE0075, ABAYE0076, ABAYE0078, ABAYE0079, ABAYE0081, ABAYE0082, ABAYE0084, ABAYE0089, ABAYE0090, ABAYE0091, ABAYE0093, ABAYE0095, ABAYE0096, ABAYE0098, ABAYE0102, ABAYE0104, ABAYE0109, ABAYE0116, ABAYE0127, ABAYE0128, ABAYE0129, ABAYE0144, ABAYE0147, ABAYE0148, ABAYE0149, ABAYE0150, ABAYE0154, ABAYE0157, ABAYE0158, ABAYE0166, ABAYE0167, ABAYE0168, ABAYE0175, ABAYE0179, ABAYE0200, ABAYE0209, ABAYE0210, ABAYE0243, ABAYE0244, ABAYE0250, ABAYE0253, ABAYE0254, ABAYE0262, ABAYE0264, ABAYE0277, ABAYE0283, ABAYE0284, ABAYE0285, ABAYE0295, ABAYE0296, ABAYE0298, ABAYE0299, ABAYE0310, ABAYE0312, ABAYE0313, ABAYE0325, ABAYE0332, ABAYE0351, ABAYE0352, ABAYE0353, ABAYE0354, ABAYE0355, ABAYE0356, ABAYE0367, ABAYE0368, ABAYE0377, ABAYE0378, ABAYE0379, ABAYE0381, ABAYE0397, ABAYE0405, ABAYE0435, ABAYE0436, ABAYE0465, ABAYE0470, ABAYE0476, ABAYE0479, ABAYE0480, ABAYE0482, ABAYE0483, ABAYE0489, ABAYE0491, ABAYE0497, ABAYE0505, ABAYE0524, ABAYE0577, ABAYE0588, ABAYE0604, ABAYE0605, ABAYE0607, ABAYE0608, ABAYE0613, ABAYE0614, ABAYE0615, ABAYE0619, ABAYE0624, ABAYE0625, ABAYE0628, ABAYE0629, ABAYE0634, ABAYE0638, ABAYE0663, ABAYE0674, ABAYE0676, ABAYE0682, ABAYE0691, ABAYE0697, ABAYE0698, ABAYE0699, ABAYE0708, ABAYE0709, ABAYE0716, ABAYE0722, ABAYE0740, ABAYE0749, ABAYE0757, ABAYE0758, ABAYE0763, ABAYE0773, ABAYE0774, ABAYE0775, ABAYE0776, ABAYE0777, ABAYE0780, ABAYE0781, ABAYE0782, ABAYE0783, ABAYE0784, ABAYE0788, ABAYE0800, ABAYE0801, ABAYE0807, ABAYE0811, ABAYE0812, ABAYE0816, ABAYE0817, ABAYE0818, ABAYE0824, ABAYE0826, ABAYE0849, ABAYE0850, ABAYE0853, ABAYE0854, ABAYE0860, ABAYE0861, ABAYE0877, ABAYE0885, ABAYE0888, ABAYE0889, ABAYE0899, ABAYE0911, ABAYE0912, ABAYE0915, ABAYE0916, ABAYE0923, ABAYE0931, ABAYE0933, ABAYE0935, ABAYE0945, ABAYE0951, ABAYE0958, ABAYE0962, ABAYE0966, ABAYE0969, ABAYE0977, ABAYE0980, ABAYE0982, ABAYE1010, ABAYE1011, ABAYE1026 , ABAYE1027, ABAYE1028, ABAYE1030, ABAYE1039, ABAYE1047, ABAYE1052, ABAYE1066, ABAYE1067, ABAYE1083, ABAYE1094, ABAYE1098, ABAYE1103, ABAYE1104, ABAYE1106, ABAYE1113, ABAYE1114, ABAYE1115, ABAYE1118, ABAYE1119, ABAYE1123, ABAYE1126, ABAYE1127, ABAYE1128, ABAYE1138, ABAYE1141 , ABAYE132, ABAYE1145, ABAYE1147, ABAYE1171, ABAYE1199, ABAYE1204, ABAYE1206, ABAYE1207, ABAYE1209, ABAYE1223, ABAYE1278, ABAYE1280, ABAYE1295, ABAYE1296, ABAYE1354, ABAYE136 ABAYE136 , ABAYE1391, ABAYE1411, ABAYE1413, ABAYE1417, ABAYE1418, ABAYE1425, ABAYE1427, ABAYE1432, ABAYE1445, ABAYE1453, ABAYE1455, ABAYE1456, ABAYE1457, ABAYE1458, ABAYE1460, ABAYE1463, ABAYE1465, ABAYE1466, ABAYE1469, ABAYE1477, ABAYE1510, ABAYE1513, ABAYE1514, ABAYE1520, ABAYE1522 , ABAYE1526, ABAYE1537, ABAYE1538, ABAYE1539, ABAYE1544, ABAYE1546, ABAYE1562, ABAYE1563, ABAYE1567, ABAYE1569, ABAYE1571, ABAYE1577, ABAYE1580, ABAYE1581, ABAYE1585, ABAYE158 6, ABAYE1587, ABAYE1599, ABAYE1613, ABAYE1625, ABAYE1636, ABAYE1637, ABAYE1646, ABAYE1649, ABAYE1650, ABAYE1653, ABAYE1658, ABAYE1667, ABAYE1668, ABAYE1669, ABAYE1672, ABAYE1675 ABAYE1724, ABAYE1736, ABAYE1742, ABAYE1781, ABAYE1786, ABAYE1789, ABAYE1792, ABAYE1811, ABAYE1861, ABAYE1886, ABAYE1896, ABAYE1897, ABAYE1909, ABAYE1913, ABAYE1914, ABAYE1916, ABAYE1921, ABAYE1937, ABAYE1940, ABAYE1943, ABAYE1944, ABAYE1945, ABAYE1946, ABAYE1947, ABAYE1948, ABAYE1953, ABAYE1955, ABAYE1970, ABAYE1983, ABAYE1989, ABAYE1990, ABAYE1993, ABAYE1994, ABAYE2013, ABAYE2014, ABAYE2053, ABAYE2058, ABAYE2062, ABAYE2065, ABAYE2067, ABAYE2076, ABAYE2077, ABAYE2077, ABAYE2077, ABAYE2077, ABAYE2077, ABAYE 2077 ABAYE2181, ABAYE2184, ABAYE2188, ABAYE2191, ABAYE2209, ABAYE2219, ABAYE2220, ABAYE2227, ABAYE2246, ABAYE2248, ABAYE2250, ABAYE2270, ABAYE2288, ABAYE2290, ABAYE2291, ABAYE2392, ABAYE2292 04, ABAYE2306, ABAYE2307, ABAYE2310, ABAYE2311, ABAYE2317, ABAYE2318, ABAYE2329, ABAYE2333, ABAYE2342, ABAYE2344, ABAYE2366, ABAYE2367, ABAYE2368, ABAYE2369, ABAYE2370, ABAYE2377, ABAYE2377, ABAYE2377 ABAYE2481, ABAYE2483, ABAYE2491, ABAYE2493, ABAYE2533, ABAYE2562, ABAYE2566, ABAYE2577, ABAYE2578, ABAYE2589, ABAYE2592, ABAYE2593, ABAYE2594, ABAYE2595, ABAYE2596, ABAYE2601, ABAYE2606, ABAYE2607, ABAYE2613, ABAYE2614, ABAYE2618, ABAYE2628, ABAYE2630, ABAYE2631, ABAYE2641, ABAYE2646, ABAYE2663, ABAYE2666, ABAYE2678, ABAYE2764, ABAYE2767, ABAYE2771, ABAYE2776, ABAYE2777, ABAYE2778, ABAYE2783, ABAYE2790, ABAYE2791, ABAYE2794, ABAYE2799, ABAYE2803, ABAYE2809, ABAYE2810, ABAYE2819, ABAYE2822, ABAYE2823, ABAYE2824, ABAYE2829, ABAYE2832, ABAYE2836, ABAYE2837, ABAYE2838, ABAYE2843, ABAYE2845, ABAYE2852, ABAYE2867, ABAYE2868, ABAYE2869, ABAYE2871, ABAYE2878, ABAYE2905, ABAYE2909, ABAYE2910, ABAYE2927, ABAYE2928, ABAYE2929, ABAYE2929 940, ABAYE2951, ABAYE2955, ABAYE2958, ABAYE2964, ABAYE2969, ABAYE2976, ABAYE2981, ABAYE2984, ABAYE2987, ABAYE2992, ABAYE2993, ABAYE3001, ABAYE300, ABA3300, ABA300 ABAYE3047, ABAYE3048, ABAYE3049, ABAYE3050, ABAYE3051, ABAYE3052, ABAYE3053, ABAYE3054, ABAYE3055, ABAYE3056, ABAYE3057, ABAYE3058, ABAYE3059, ABAYE3060, ABAYE3065, ABAYE3067, ABAYE3078, ABAYE3079, ABAYE3086, ABAYE3097, ABAYE3101, ABAYE3104, ABAYE3105, ABAYE3114, ABAYE3129, ABAYE3130, ABAYE3131, ABAYE3132, ABAYE3133, ABAYE3151, ABAYE3153, ABAYE3154, ABAYE3159, ABAYE3160, ABAYE3169, ABAYE3174, ABAYE3175, ABAYE3176, ABAYE3179, ABAYE3181, ABAYE3184, ABAYE3186, ABAYE3187, ABAYE3188, ABAYE3191, ABAYE3192, ABAYE3193, ABAYE3228, ABAYE3238, ABAYE3239, ABAYE3240, ABAYE3244, ABAYE3250, ABAYE3258, ABAYE3262, ABAYE3263, ABAYE3267, ABAYE3269, ABAYE3272, ABAYE3276, ABAYE3278, ABAYE3280, ABAYE3281, ABAYE3282, ABAYE3283, ABAYE3284, ABAYE3284 3292, ABAYE3293, ABAYE3296, ABAYE3314, ABAYE3315, ABAYE3322, ABAYE3343, ABAYE3348, ABAYE3351, ABAYE3357, ABAYE3359, ABAYE3360, ABAYE3366, ABAYE3373, ABAYE3378, ABAYE3379, ABA428 ABAYE3470, ABAYE3471, ABAYE3497, ABAYE3498, ABAYE3507, ABAYE3508, ABAYE3511, ABAYE3518, ABAYE3519, ABAYE3524, ABAYE3530, ABAYE3531, ABAYE3537, ABAYE3540, ABAYE3544, ABAYE3546, ABAYE3568, ABAYE3572, ABAYE3588, ABAYE3612, ABAYE3614, ABAYE3616, ABAYE3644, ABAYE3661, ABAYE3670, ABAYE3671, ABAYE3675, ABAYE3678, ABAYE3696, ABAYE3697, ABAYE3713, ABAYE3715, ABAYE3716, ABAYE3717, ABAYE3718, ABAYE3719, ABAYE3720, ABAYE3721, ABAYE3723, ABAYE3731, ABAYE3732, ABAYE3740, ABAYE3750, ABAYE3763, ABAYE3764, ABAYE3766, ABAYE3767, ABAYE3768, ABAYE3773, ABAYE3774, ABAYE3791, ABAYE3792, ABAYFE3793, ABAYE3795, ABAYE3796, ABAYE3797, ABAYE3800, ABAYE3801, ABAYE3802, ABAYE3803, ABAYE3804, ABAYE3807, ABAYE3814, ABAYE3815, ABAYE3823, ABAYE3825, ABAYE3825 YE3834, ABAYE3835, ABAYE3839, ABAYE3846, ABAYE3851, ABAYE3852, ABAYE3871, ABAYE3872, ABAYE3885, ABAYE3887, p2ABAYE0004, p3ABAYE0020, p3ABAYE0024, p3ABAYE0029.
본 발명의 일례에서는 비브리오 불니피커스(Vibrio vulnificus)의 대사 네트워크 모델을 구축하여 이용하였다. 병원성 미생물의 한 종류로서 인간에게 다양한 감염증을 일으키는 비브리오(Vibrio)는 통성 혐기성 그람음성 간균으로서 바다와 하구에 존재하며 담수, 강, 연못, 호수에서도 분리된다. Vibrio 속에는 30 균종 이상이 속해있으며 이 중 12 균종이 사람에게 감염을 일으킨다. 장내감염은 비브리오 콜레라(V. cholerae)와 비브리오 파라헤모리티쿠스 (V. parahaemolyticus)가 가장 흔한 원인균이다. 혈액, 창상, 눈, 귀, 담즙 등의 장외감염도 일으킬 수 있으며 우리나라에서는 여름철에 비브리오 패혈증이 종종 발생하는데, 이는 V. vulnificus에 의해 일어나는 것으로 간경화증, 암 환자 등에서 주로 발생하며 예후가 불량하다고 알려져 있다. In one example of the present invention, a metabolic network model of Vibrio vulnificus was constructed and used. Vibrio (Vibrio) causes a variety of infections in humans as a kind of pathogenic microorganisms present in the sea and the estuary as a facultative anaerobic gram-negative bacilli, and are isolated from fresh water, rivers, ponds and lakes. More than 30 species belong to the genus Vibrio, 12 of which infect humans. Intestinal infections are the most common causative agents of V. cholerae and V. parahaemolyticus . Intestinal infections such as blood, wounds, eyes, ears, and bile can also occur. In Korea, Vibrio sepsis often occurs in summer, which is caused by V. vulnificus , which is mainly caused by cirrhosis and cancer patients and has a poor prognosis. .
상기 비브리오 불니피커스(Vibrio vulnificus )는 주로 하구에서 발견되며, 인간을 비롯한 다양한 동물 및 해산물을 전염하는 병원균 미생물이다(Gulig et al., J. Mcirobiol., 43:118, 2005). V. vulnificus에 감염된 해산물을 섭취하거나 인체의 상처 부위가 상기 미생물과 접촉하면 패혈증, 위장염, 상처감염 등을 일으킬 수 있다. 특히 V. vulnificus은 인체에 감염되면 인체 내에서의 복제 속도가 매우 빠른 것으로 알려져 있다. 상기 병원균에 접촉되면 24시간 이내에 사망할 수 있다. 패혈증에 의한 사망률은 최고 75%에 달하는 것으로 알려져 있으며, 상처 감염에 의한 사망률은 최고 50%에 이르는 것으로 보고되고 있다. The Vibrio vulnificus is mainly found in estuaries and is a pathogenic microorganism that infects a variety of animals and seafood, including humans (Gulig et al., J. Mcirobiol., 43: 118, 2005). Ingestion of seafood infected with V. vulnificus or contact with the microorganisms of the human body can cause sepsis, gastroenteritis and wound infection. In particular, V. vulnificus is known to be very fast in human body when infected. Contact with the pathogen can cause death within 24 hours. It is known that mortality from sepsis is up to 75%, and mortality from wound infections is reported to be up to 50%.
특히, V. vulnificus의 경우 두 균주의 게놈 서열 해독이 완성된 상태(Chen et al., Genome Res., 13:2577, 2003)이므로, 본 발명자들은 대사흐름분석 기법을 이용하여 부분적인 대사정보를 이용한 균주조작이 아닌 전체적인 관점에서 V. vulnificus의 대사를 살펴보고 특정 유전자에 대한 조작이 전체 대사흐름에 미치는 영향들을 파악하여 병원성 미생물의 약물표적을 정확하게 예측할 수 있는 방법의 개발의 가능성을 발견하였다. Particularly, in the case of V. vulnificus , the genome sequence translation of the two strains is completed (Chen et al., Genome Res. , 13: 2577, 2003), and therefore, the present inventors use partial metabolic flow analysis techniques. This study examined the metabolism of V. vulnificus from the whole point of view, not the strain manipulation, and found the possibility of developing a method to accurately predict the drug target of pathogenic microorganisms by identifying the effects of manipulation of specific genes on the overall metabolic flow.
본 발명의 일례에서 사용한 상기 비브리오(Vibrio) 속 미생물 대사 네트워크 구축은 이하의 유전자로 구성된 유전자 군에 기반하여 이루어질 수 있다:The Vibrio genus microbial metabolic network construction used in the example of the present invention may be made based on a gene group consisting of the following genes:
VV10014, VV10053, VV10060, VV10061, VV10136, VV10143, VV10145, VV10154, VV10155, VV10156, VV10157, VV10158, VV10159, VV10160, VV10161, VV10162, VV10169, VV10176, VV10177, VV10179, VV10180, VV10183, VV10187, VV10188, VV10209, VV10212, VV10236, VV10246, VV10248, VV10249, VV10254, VV10256, VV10257, VV10265, VV10272, VV10286, VV10288, VV10289, VV10291, VV10314, VV10315, VV10316, VV10317, VV10319, VV10321, VV10322, VV10323, VV10325, VV10326, VV10329, VV10333, VV10340, VV10344, VV10366, VV10414, VV10418, VV10419, VV10426, VV10427, VV10430, VV10449, VV10450, VV10465, VV10484, VV10487, VV10494, VV10495, VV10504, VV10507, VV10508, VV10516, VV10526, VV10543, VV10544, VV10545, VV10553, VV10554, VV10555, VV10556, VV10558, VV10559, VV10565, VV10566, VV10567, VV10571, VV10577, VV10578, VV10580, VV10581, VV10582, VV10583, VV10591, VV10595, VV10596, VV10597, VV10610, VV10613, VV10623, VV10625, VV10638, VV10639, VV10641, VV10644, VV10647, VV10648, VV10649, VV10654, VV10655, VV10656, VV10657, VV10662, VV10665, VV10666, VV10673, VV10678, VV10679, VV10688, VV10705, VV10707, VV10708, VV10723, VV10725, VV10726, VV10727, VV10728, VV10774, VV10779, VV10780, VV10796, VV10797, VV10799, VV10803, VV10804, VV10808, VV10814, VV10815, VV10819, VV10828, VV10830, VV10831, VV10850, VV10852, VV10854, VV10881, VV10889, VV10894, VV10902, VV10907, VV10909, VV10933, VV10935, VV10940, VV10963, VV10964, VV10978, VV10981, VV10982, VV10989, VV10990, VV10992, VV11015, VV11016, VV11017, VV11018, VV11019, VV11020, VV11021, VV11022, VV11023, VV11028, VV11029, VV11030, VV11031, VV11032, VV11047, VV11053, VV11054, VV11056, VV11057, VV11077, VV11083, VV11099, VV11100, VV11102, VV11105, VV11120, VV11121, VV11122, VV11123, VV11126, VV11127, VV11141, VV11153, VV11163, VV11164, VV11165, VV11168, VV11175, VV11195, VV11197, VV11198, VV11199, VV11200, VV11218, VV11226, VV11227, VV11234, VV11235, VV11236, VV11237, VV11249, VV11257, VV11266, VV11267, VV11268, VV11269, VV11270, VV11276, VV11277, VV11281, VV11284, VV11291, VV11299, VV11306, VV11307, VV11311, VV11312, VV11313, VV11314, VV11315, VV11328, VV11342, VV11343, VV11345, VV11349, VV11353, VV11361, VV11364, VV11364*, VV11365, VV11366, VV11369, VV11370, VV11371, VV11372, VV11373, VV11374, VV11382, VV11383, VV11386, VV11393, VV11396, VV11402, VV11403, VV11404, VV11423, VV11424, VV11425, VV11428, VV11453, VV11461, VV11464, VV11465, VV11466, VV11467, VV11474, VV11485, VV11517, VV11519, VV11524, VV11530, VV11536, VV11537, VV11539, VV11540, VV11541, VV11546, VV11547, VV11552, VV11558, VV11568, VV11569, VV11575, VV11576, VV11578, VV11579, VV11582, VV11583, VV11584, VV11585, VV11593, VV11594, VV11600, VV11601, VV11602, VV11606, VV11608, VV11621, VV11622, VV11627, VV11630, VV11631, VV11632, VV11635, VV11636, VV11637, VV11642, VV11643, VV11644, VV11653, VV11654, VV11664, VV11678, VV11683, VV11691, VV11692, VV11698, VV11716, VV11725, VV11726, VV11727, VV11728, VV11730, VV11766, VV11767, VV11770, VV11771, VV11772, VV11773, VV11785, VV11787, VV11790, VV11799, VV11810, VV11838, VV11846, VV11855, VV11861, VV11865, VV11866, VV11870, VV11872, VV11873, VV11876, VV11883, VV11896, VV11897, VV11899, VV11900, VV11901, VV11912, VV11916, VV11975, VV11976, VV11978, VV11981, VV11986, VV11988, VV11989, VV11992, VV11993, VV11994, VV11997, VV12002, VV12016, VV12022, VV12064, VV12074, VV12075, VV12086, VV12088, VV12098, VV12116, VV12118, VV12126, VV12127, VV12131, VV12132, VV12156, VV12162, VV12163, VV12173, VV12200, VV12219, VV12220, VV12221, VV12227, VV12234, VV12248, VV12254, VV12257, VV12260, VV12265, VV12266, VV12341, VV12349, VV12355, VV12356, VV12357, VV12370, VV12371, VV12372, VV12374, VV12378, VV12379, VV12389, VV12390, VV12391, VV12392, VV12397, VV12448, VV12560, VV12590, VV12591, VV12592, VV12599, VV12614, VV12617, VV12618, VV12619, VV12620, VV12637, VV12641, VV12654, VV12682, VV12683, VV12684, VV12699, VV12702, VV12711, VV12730, VV12731, VV12732, VV12754, VV12755, VV12765, VV12768, VV12771, VV12772, VV12783, VV12785, VV12786, VV12787, VV12788, VV12797, VV12799, VV12801, VV12810, VV12813, VV12824, VV12826, VV12843, VV12871, VV12872, VV12888, VV12890, VV12907, VV12908, VV12910, VV12913, VV12914, VV12915, VV12916, VV12917, VV12918, VV12919, VV12920, VV12924, VV12928, VV12940, VV12942, VV12943, VV12944, VV12945, VV12946, VV12952, VV12977, VV12983, VV12992, VV12999, VV13002, VV13005, VV13006, VV13007, VV13009, VV13010, VV13011, VV13016, VV13018, VV13022, VV13025, VV13028, VV13035, VV13040, VV13041, VV13042, VV13050, VV13052, VV13060, VV13064, VV13065, VV13066, VV13067, VV13068, VV13069, VV13100, VV13111, VV13115, VV13135, VV13140, VV13153, VV13168, VV13169, VV13170, VV13172, VV13173, VV13174, VV20005, VV20010, VV20011, VV20012, VV20019, VV20053, VV20065, VV20117, VV20123, VV20148, VV20186, VV20188, VV20190, VV20198, VV20199, VV20200, VV20206, VV20214, VV20216, VV20217, VV20218, VV20237, VV20256, VV20280, VV20315, VV20316, VV20317, VV20330, VV20334, VV20337, VV20349, VV20367, VV20369, VV20370, VV20389, VV20390, VV20397, VV20398, VV20400, VV20407, VV20455, VV20456, VV20468, VV20469, VV20470, VV20471, VV20478, VV20488, VV20489, VV20490, VV20491, VV20493, VV20494, VV20496, VV20497, VV20498, VV20499, VV20500, VV20514, VV20515, VV20531, VV20532, VV20543, VV20552, VV20553, VV20558, VV20560, VV20561, VV20565, VV20566, VV20567, VV20568, VV20569, VV20712, VV20721, VV20730, VV20734, VV20735, VV20736, VV20741, VV20742, VV20752, VV20768, VV20789, VV20833, VV20835, VV20854, VV20869, VV20878, VV20903, VV20904, VV20905, VV20914, VV20966, VV20996, VV21024, VV21030, VV21050, VV21062, VV21064, VV21069, VV21070, VV21071, VV21072, VV21084, VV21085, VV21093, VV21094, VV21095, VV21118, VV21122, VV21136, VV21142, VV21180, VV21200, VV21204, VV21235, VV21237, VV21250, VV21251, VV21266, VV21287, VV21318, VV21327, VV21330, VV21348, VV21349, VV21352, VV21353, VV21356, VV21357, VV21373, VV21395, VV21412, VV21426, VV21432, VV21433, VV21457, VV21473, VV21484, VV21485, VV21520, VV21540, VV21596, VV21599, VV21615, VV21622, VV21635, VV21637, VV21651, VV21663, VV21664, VV21677, VV21687, VV21688.VV10014, VV10053, VV10060, VV10061, VV10136, VV10143, VV10145, VV10154, VV10155, VV10156, VV10157, VV10158, VV10159, VV10160, VV10161, VV10162, VV10169, VV10176, VV10177, VV10179, VV10180, VV10183, VV10187, VV10188, VV10209, VV10212, VV10236, VV10246, VV10248, VV10249, VV10254, VV10256, VV10257, VV10265, VV10272, VV10286, VV10288, VV10289, VV10291, VV10314, VV10315, VV10316, VV10317, VV10319 V103 V10326 V103 V10326 V103 V10326 VV10333, VV10340, VV10344, VV10366, VV10414, VV10418, VV10419, VV10426, VV10427, VV10430, VV10449, VV10450, VV10465, VV10484, VV10487, VV10494, VV10495, VV10504, VV10507, V10 V10 VV10553, VV10554, VV10555, VV10556, VV10558, VV10559, VV10565, VV10566, VV10567, VV10571, VV10577, VV10578, VV10580, VV10581, VV10582, VV10583, VV10591, VV10595, VV10596, V106 V106 V106 V106 V106 V106 VV10639, VV10641, VV10644, VV10647, VV10648, VV10649, VV10654, VV10655, VV10656, VV10657, VV10662, V V10665, VV10666, VV10673, VV10678, VV10679, VV10688, VV10705, VV10707, VV10708, VV10723, VV10725, VV10726, VV10727, VV10728, VV10774, VV10779, VV10780, VV10796, VV10797, V108 V1080 V10897 VV10819, VV10828, VV10830, VV10831, VV10850, VV10852, VV10854, VV10881, VV10889, VV10894, VV10902, VV10907, VV10909, VV10933, VV10935, VV10940, VV10963, VV10964, VV10978 109 VV11016, VV11017, VV11018, VV11019, VV11020, VV11021, VV11022, VV11023, VV11028, VV11029, VV11030, VV11031, VV11032, VV11047, VV11053, VV11054, VV11056, VV11057, VV11077, V11 V11 110, 110 VV11121, VV11122, VV11123, VV11126, VV11127, VV11141, VV11153, VV11163, VV11164, VV11165, VV11168, VV11175, VV11195, VV11197, VV11198, VV11199, VV11200, VV11218, VV11226, V112, V112, V112, V112 VV11257, VV11266, VV11267, VV11268, VV11269, VV11270, VV11276, VV11277, VV11281, VV11284, VV11291, VV 11299, VV11306, VV11307, VV11311, VV11312, VV11313, VV11314, VV11315, VV11328, VV11342, VV11343, VV11345, VV11349, VV11353, VV11361, VV11364, VV11364 *, VV11365, VV1 1373, VV11, 13, V11, 13, V11, 13, 11, 11 , VV11382, VV11383, VV11386, VV11393, VV11396, VV11402, VV11403, VV11404, VV11423, VV11424, VV11425, VV11428, VV11453, VV11461, VV11464, VV11465, VV11466, VV11467, VV11V V2424 V17 , VV11537, VV11539, VV11540, VV11541, VV11546, VV11547, VV11552, VV11558, VV11568, VV11569, VV11575, VV11576, VV11578, VV11579, VV11582, VV11583, VV11584, VV11585, VV115602, V11 V11 , VV11621, VV11622, VV11627, VV11630, VV11631, VV11632, VV11635, VV11636, VV11637, VV11642, VV11643, VV11644, VV11653, VV11654, VV11664, VV11678, VV11683, VV11691, VV11627, V117 , VV11730, VV11766, VV11767, VV11770, VV11771, VV11772, VV11773, VV11785, VV11787, VV11790, VV11799, VV 11810, VV11838, VV11846, VV11855, VV11861, VV11865, VV11866, VV11870, VV11872, VV11873, VV11876, VV11883, VV11896, VV11897, VV11899, VV11900, VV11901, VV11912, VV11916, V1976 V1 VV11989, VV11992, VV11993, VV11994, VV11997, VV12002, VV12016, VV12022, VV12064, VV12074, VV12075, VV12086, VV12088, VV12098, VV12116, VV12118, VV12126, VV12127, VV12131 V1212 VV12219, VV12220, VV12221, VV12227, VV12234, VV12248, VV12254, VV12257, VV12260, VV12265, VV12266, VV12341, VV12349, VV12355, VV12356, VV12357, VV12370, VV12371, VV12390 V123 V123 V123 V123 V123 VV12392, VV12397, VV12448, VV12560, VV12590, VV12591, VV12592, VV12599, VV12614, VV12617, VV12618, VV12619, VV12620, VV12637, VV12641, VV12654, VV12682, VV12683, VV12684, V127 126 VV12754, VV12755, VV12765, VV12768, VV12771, VV12772, VV12783, VV12785, VV12786, VV12787, VV12788, VV1 2797, VV12799, VV12801, VV12810, VV12813, VV12824, VV12826, VV12843, VV12871, VV12872, VV12888, VV12890, VV12907, VV12908, VV12910, VV12913, VV12914, VV12915, VV12916, VV12, V129V12 VV12940, VV12942, VV12943, VV12944, VV12945, VV12946, VV12952, VV12977, VV12983, VV12992, VV12999, VV13002, VV13005, VV13006, VV13007, VV13009, VV13010, VV13011, VV13016, V130, V130, V130, V130, V130 and V VV13041, VV13042, VV13050, VV13052, VV13060, VV13064, VV13065, VV13066, VV13067, VV13068, VV13069, VV13100, VV13111, VV13115, VV13135, VV13140, VV13153, VV13168, VV13169, V130, V131 VV20011, VV20012, VV20019, VV20053, VV20065, VV20117, VV20123, VV20148, VV20186, VV20188, VV20190, VV20198, VV20199, VV20200, VV20206, VV20214, VV20216, VV20217, VV20216, VV202 17, VV20218, V2020, V20 VV20330, VV20334, VV20337, VV20349, VV20367, VV20369, VV20370, VV20389, VV20390, VV20397, VV20398, VV20 400, VV20407, VV20455, VV20456, VV20468, VV20469, VV20470, VV20471, VV20478, VV20488, VV20489, VV20490, VV20491, VV20493, VV20494, VV20496, VV20497, VV20498, VV204, V15 V205 VV20552, VV20553, VV20558, VV20560, VV20561, VV20565, VV20566, VV20567, VV20568, VV20569, VV20712, VV20721, VV20730, VV20734, VV20735, VV20736, VV20741, VV20742, VV20752, V208 VV20878, VV20903, VV20904, VV20905, VV20914, VV20966, VV20996, VV21024, VV21030, VV21050, VV21062, VV21064, VV21069, VV21070, VV21071, VV21072, VV21084, VV21085, VV21093, V21 V21 V21 VV21180, VV21200, VV21204, VV21235, VV21237, VV21250, VV21251, VV21266, VV21287, VV21318, VV21327, VV21330, VV21348, VV21349, VV21352, VV21353, VV21356, VV21357, VV21373, V214, V214, V214 VV21473, VV21484, VV21485, VV21520, VV21540, VV21596, VV21599, VV21615, VV21622, VV21635, VV21637, VV216 51, VV21663, VV21664, VV21677, VV21687, VV21688.
따라서, 이하, 일부에서는 AYE (Acinetobacter baumannii AYE)의 대사 네트워크 모델 또는 비브리오 불니피커스(Vibrio vulnificus )의 대사 네트워크 모델을 구축한 경우를 예를 들어서 설명하기도 하였다. Therefore, in the following, the case where a metabolic network model of AYE ( Acinetobacter baumannii AYE) or a metabolic network model of Vibrio vulnificus was constructed was described as an example.
(2) 대사흐름분석의 실행(2) implementing metabolic flow analysis
다음으로, 상기 구축된 미생물의 대사 네트워크를 대상으로 대사흐름 분석을 실시하는데, 이는 상기 미생물의 필수 대사산물을 1차적으로 결정하기 위함이다(1차 필수 대사산물이라고 함). Next, metabolic flow analysis is performed on the established metabolic network of the microorganism, which is to determine the essential metabolite of the microorganism primarily (called a primary essential metabolite).
대사흐름 분석을 위해서, 구축된 미생물의 대사 네트워크를 수학적으로 표현할 필요가 있는데, 구축된 대사 네트워크 모델을 구성하고 있는 모든 대사산물, 상기 대사산물의 대사경로 및 상기 대사경로에서의 화학양론 매트릭스 S(stoichiometric matrix)(S
ij
, j 번째 반응에서 i 번째 대사산물의 시간에 따른 화학양론 계수)를 이용하여, 대사흐름 벡터( j , j 번째 대사반응의 대사흐름)를 계산할 수 있다.For metabolic flow analysis, it is necessary to mathematically express the metabolic network of the constructed microorganism, including all the metabolites constituting the constructed metabolic network model, the metabolic pathway of the metabolite and the stoichiometric matrix S in the metabolic pathway. using a stoichiometric matrix) (S ij, the stoichiometric coefficient of the i-th time in the j-th reaction metabolite), it is possible to calculate the metabolic flux vector (j, j metabolic flux of the first metabolic reaction).
수학식 1Equation 1
(여기서, S : 시간에 따른 X의 변화량, X: 대사산물의 농도, t: 시간)(here,S: Over timeXChange in,X= Concentration of metabolite,t: time)
이 때, 시간에 따른 대사산물 농도 X의 변화는 모든 대사 반응의 흐름의 합으로 나타낼 수 있다. 시간에 따른 X의 변화량이 일정하다고 가정하면, 즉 X의 변화량이 0인 경우, 준정상상태 가정 하에서 시간에 따른 대사산물 농도의 변화량은 상기 수학식 1로 정의될 수 있다.At this time, the change in the metabolite concentration X over time can be represented as the sum of the flows of all metabolic reactions. Assuming that the amount of change of X with time is constant, i.e., if the amount of change of X is 0, the amount of change of the metabolite concentration with time under the quasi-steady state may be defined by Equation 1 above.
상기 구성된 화학량론 매트릭스에서 최적화, 즉 최대화 또는 최소화 하고자 하는 반응식을 목적함수로 설정하고 선형계획법 (Linear programming)을 이용하여 세포 내의 대사흐름을 예측한다 (Kim et al., Mol Biosyst. 4(2):113, 2008). 본 발명의 일 구현예에서는 매트릭스 S에서 세포의 구성성분을 나타내고는 반응식을 목적함수로서 설정함으로써, 세포 성장 속도를 최적화한다. 즉, 선형계획법을 적용할 때, 목적함수를 세포 성장 속도가 최대화되는 것으로 설정한다. In the constructed stoichiometric matrix, the reaction scheme to be optimized, ie maximized or minimized, is set as the objective function and the metabolic flow in the cell is predicted using linear programming (Kim et al., Mol Biosyst. 4 (2)). : 113, 2008). In one embodiment of the present invention, the cell growth rate is optimized by representing the constituents of the cells in matrix S and setting the scheme as the objective function. In other words, when applying the linear programming method, the objective function is set to maximize cell growth rate.
한편, 상기 대사흐름분석은 세포가 성장하는 데에 필요한 모든 영양분을 섭취할 수 있다는 가정 하에 실행해야 한다. 병원성 미생물이 숙주 내에서 성장할 경우 숙주로부터 다양한 영양분을 섭취할 수 있기 때문이다. On the other hand, the metabolic flow analysis should be carried out on the assumption that all the nutrients necessary for the cell to grow can be taken. This is because when pathogenic microorganisms grow in the host, various nutrients can be taken from the host.
효소 반응식은 특정 조건에서만 필수적인 것으로 나타날 수 있으나, 상기 모든 영양분의 섭취가 가능하다는 가정 하에 대사흐름분석을 적용하면, 모든 조건에서 항시 필수적인 효소 반응식을 예측할 수 있다. The enzyme reaction may appear to be essential only under certain conditions, but if metabolic flow analysis is applied on the assumption that all the nutrients can be ingested, it is possible to predict the essential enzyme reaction at all times.
본 발명의 일례에서 사용한 AYE (Acinetobacter baumannii AYE)의 대사 네트워크를 기반으로 행한 대사흐름분석에 있어서, 사용된 영양분은 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2-Oxoglutarate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, Betaine, Benzoate, Choline, Citrate, CO2, Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine, Formate, D-fructose, Fumarate, alpha-D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Guanosine, L-Histidine, L-Homoserine, Isocitrate, L-Isoleucine, Isomaltose, L-Leucine, L-Lysine, (S)-Malate, L-Methionine, Maltose, D-Mannitol, N-Acetyl-D-glucosamine, Sodium, NH3, Nitrite, Nitrate, O2, L-Ornithine, L-Phenylalanine, Orthophosphate, L-Proline, Putrescine, L-Serine, (S)-Lactate, Sulfate, Spermidine, Succinate, Sucrose, L-Threonine, alpha,alpha-Trehalose, L-Tryptophan, Taurine, L-Tyrosine, Uracil, Urea, Uridine, L-Valine, Xanthine 등으로 구성된 군에서 선택될 수 있다. In metabolic flow analysis based on the metabolic network of AYE ( Acinetobacter baumannii AYE) used in an example of the present invention, the nutrients used were 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2 -Oxoglutarate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, Betaine, Benzoate, Choline, Citrate, CO 2 , Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine, Formate, D-fructose, Fumarate, alpha-D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Guanosine, L-Histidine, L-Histine Homoserine, Isocitrate, L-Isoleucine, Isomaltose, L-Leucine, L-Lysine, (S) -Malate, L-Methionine, Maltose, D-Mannitol, N-Acetyl-D-glucosamine, Sodium, NH 3 , Nitrite, Nitrate , O 2 , L-Ornithine, L-Phenylalanine, Orthophosphate, L-Proline, Putrescine, L-Serine, (S) -Lactate, Sulfate, Spermidine, Succinate, Sucrose, L-Threonine, alpha, alpha-Trehalose, L- Tryptophan, T It may be selected from the group consisting of aurine, L-Tyrosine, Uracil, Urea, Uridine, L-Valine, Xanthine and the like.
본 발명의 일례에서 사용한 비브리오 불니피커스(Vibrio vulnificus )의 대사 네트워크를 기반으로 행한 대사흐름분석에 있어서, 사용된 영양분은 (S)-Lactate, (S)-Malate, 2-Oxoglutarate, 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, alpha,alpha-Trehalose, alpha-D-Glucose, Choline, Citrate, CO2, Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D-Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, L-Homoserine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Ornithine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Maltose, Melibiose, N-Acetyl-D-glucosamine, NH3, Nitrate, Nitrite, Orthophosphate, Oxygen, Putrescine, sn-Glycerol 3-phosphate, Sodium, Spermidine, Succinate, Sucrose, Sulfate, Thiamin, Thymidine, Uracil, Urea, Uridine, Xanthine 등으로 구성된 군에서 선택될 수 있다. In metabolic flow analysis based on the metabolic network of Vibrio vulnificus used in one example of the present invention, the nutrients used were (S) -Lactate, (S) -Malate, 2-Oxoglutarate, 2-Phospho -D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, alpha, alpha-Trehalose, alpha-D-Glucose, Choline, Citrate, CO 2 , Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D-Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, L-Homoserine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Ornithine, L-Phenylalanine, L-Proline, L-Serine, L- Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Maltose, Melibiose, N-Acetyl-D-glucosamine, NH 3 , Nitrate, Nitrite, Orthophosphate, Oxygen, Putrescine, sn-Glycerol 3-phosphate, Sodium, Spermidine, Succinate, Sucrose, It can be selected from the group consisting of Sulfate, Thiamin, Thymidine, Uracil, Urea, Uridine, Xanthine and the like.
(3) 대사흐름분석을 이용한 필수 대사산물 분석 시뮬레이션 및 1차 필수 대사산물 예측(3) Simulation of essential metabolite analysis using metabolic flow analysis and prediction of first essential metabolite
일반적으로 기존의 대사흐름분석에서 특정 유전자 결실에 따른 세포 성장속도를 확인하는 방법은 각 해당 반응식을 불활성화 시키는 방법을 사용한다. 이들 효소 반응식을 억제하면 이 효소에 관여하는 특정 대사산물을 소비하거나 생산하는 것이 불가능하므로, 결국 대상 미생물의 세포 성장을 멈출 수 있을 것이라는 가정에 기반을 둔다. 그러나 이 경우 두개 이상의 유전자 결실에 따른 세포 성장 저하 현상을 확인하기 위해서는 실제로 두개 이상의 조합에 따른 경우를 모두 계산해야 하는 단점이 있어 왔다.In general, in the conventional metabolic flow analysis, the method of determining the cell growth rate according to a specific gene deletion uses a method of inactivating each corresponding reaction scheme. Suppressing these enzyme reactions is based on the assumption that it is impossible to consume or produce the specific metabolites involved in these enzymes, which will eventually stop the cell growth of the target microorganism. However, in this case, in order to identify the cell growth deterioration phenomenon caused by the deletion of two or more genes, there has been a disadvantage in that all cases of two or more combinations must be calculated.
이에 반하여, 본 발명에서는 각 대사산물의 '필수도(essentiality)'를 정의하여 각 대사산물의 특성을 살펴봄으로써 두 개 이상의 유전자 결실에 따른 세포 성장 저하 현상을 쉽게 확인할 수 있다. 즉, 본 발명에서는 대상 미생물의 대사 네트워크를 구성하는 대사산물들의 '필수도(essentiality)'를 이하와 같이 정의하고 사용하는 방법을 제공한다.On the contrary, in the present invention, by defining the 'essentiality' of each metabolite and examining the properties of each metabolite, it is easy to identify the phenomenon of cell growth caused by the deletion of two or more genes. That is, the present invention provides a method of defining and using 'essentiality' of metabolites constituting the metabolic network of the target microorganism as follows.
대사산물들의 '필수도(essentiality)'란 세포가 그 대사산물을 대사반응을 통해 소비하지 않을 때 세포의 성장에 미치는 영향으로서, 대사흐름분석을 통하여 일정 조건 하에 각 대사산물에 대한 세포의 성장 속도를 조사함으로써 대사산물의 필수도를 결정할 수 있다(도 4)(Kim et al., Proc. Natl. Acad. Sci. U S A, 104:13638, 2007). The 'essentiality' of metabolites is the effect of cells on the growth of cells when they are not consumed by metabolism. The rate of cell growth for each metabolite under certain conditions is determined by metabolic flow analysis. The necessity of metabolites can be determined by investigating (FIG. 4) (Kim et al., Proc. Natl. Acad. Sci. USA , 104: 13638, 2007).
따라서, 본 발명에서는 대상 미생물의 대사회로를 구성하는 대사산물들의 대사흐름분석 과정 중 각 대사산물을 소비하는 모든 대사반응을 불활성화시킨 상태에서, 즉 해당 소비반응식의 대사흐름값을 0으로 고정하고, 이때의 세포의 성장속도가 0인 경우를 필수 대사산물로 선별한다. Therefore, in the present invention, during the metabolic flow analysis process of the metabolites constituting the metabolic circuit of the target microorganism, all metabolic reactions consuming each metabolite are inactivated, that is, the metabolic flow value of the corresponding reaction equation is fixed to zero. In this case, if the growth rate of the cell is 0 is selected as an essential metabolite.
이를 수식으로 표현하면 이하와 같다.This is expressed as a formula below.
수학식 2Equation 2
여기서 j
m 은 각 대사산물의 소비 반응식이며, V
jm 은 해당 소비 반응식의 대사흐름값을 나타낸다. Where j m is the consumption equation of each metabolite and V jm represents the metabolic flow value of the consumption equation.
필수 대사산물 분석은 상기 대사흐름분석에서 사용한 수학식 1, 즉, 화학량론 매트릭스에서 각 대사산물을 소비하는 모든 대사반응을 동시에 차단(결실)시킨 상태에서 상기 수학식 2를 추가의 제한조건으로 적용하여, 해당 소비반응식의 대사흐름값을 0으로 고정시킨 후, 세포의 성장속도가 0인 경우를 필수 대사산물로 선별하는 것이다. 다시 말해, 필수 대사산물의 대사흐름이 없으면 상기 미생물의 세포는 성장하지 않는 점을 이용하여 필수도를 결정한다.Essential metabolite analysis applies Equation 2 as an additional constraint while simultaneously blocking (deleting) all metabolic reactions consuming each metabolite in the stoichiometric matrix. By fixing the metabolic flow value of the consumption equation to 0, the case where the cell growth rate is 0 is selected as an essential metabolite. In other words, if there is no metabolic flow of essential metabolite, the cells of the microorganism do not grow to determine the essentiality.
상기 필수도(essentiality)를 결정하기 위한 분석 과정 중, 주어진 대사산물을 소비하지 않고 생산하는 대사반응을 불활성화 시키지 않은 이유는 만약 대사산물이 non-essential이라고 하더라도, 그 대사산물을 생산하는 대사반응은 다른 필수적인 대사산물도 생산할 가능성이 있기 때문에, 상기 대사반응의 불활성화 때문에 세포성장이 억제된다면 그것은 원래 비필수적인(non-essential) 대사산물이 필수적이라고(essential) 잘못 이해될 수도 있기 때문이다. During the analytical process to determine the essentiality, the reason for not inactivating a metabolite produced without consuming a given metabolite is that the metabolite that produces the metabolite, even if the metabolite is non-essential Because it is also possible to produce other essential metabolites, if cell growth is inhibited due to inactivation of the metabolic reaction, it may be misunderstood that a non-essential metabolite is essential.
일례로, 상기 수학식 1 및 수학식 2를 이용한 대사흐름분석 단계를 거쳐 수득된 AYE (Acinetobacter baumannii AYE)의 1차 필수 대사산물로는 (R)-4'-Phosphopantothenoyl-L-cysteine, (R)-pantoate, (R)-Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Acyl-sn-glycerol 3-phosphate, 1-Deoxy-D-xylulose 5-phosphate, 2,3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4-(5'-phosphoribosylamino)-pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine, 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine triphosphate, 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate , 2-Dehydro-3-deoxy-D-octonate, 2-Dehydro-3-deoxy-D-octonate 8-phosphate, 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3-Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4,6-Dideoxy-4-oxo-dTDP-D-glucose, 4-amino-4-deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate, 5,10-Methylenetetrahydrofolate, 5-Amino-6-(5'-phosphoribitylamino)uracil, 5-Amino-6-(5'-phosphoribosylamino)uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H)-pyrimidinedione, 5-O-(1-Carboxyvinyl)-3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, Acetyl-[acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, ADP, all-trans-Octaprenyl diphosphate, alpha-D-Glucose, alpha-D-Glucose 6-phosphate, alpha-D-Mannose 1-phosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 1,6-bisphosphate, beta-D-Fructose 6-phosphate, beta-D-Glucose, beta-hydroxy dodecanoic acid, beta-hydroxy tetradecanoic acid, Cardiolipin (biomass component), CDP, CDP-diacylglycerol, Chorismate, CO2, CoA, Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, dADP, D-alanine, D-alanyl-D-alanine, D-Arabinose 5-phosphate, dATP, dCDP, dCTP, Deamino-NAD+, Decanoyl-[acyl-carrier protein], Dephospho-CoA, D-Erythrose 4-phosphate, dGDP, D-Glucosamine 1-phosphate, D-Glucosamine 6-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate, dGTP, Dihydrofolate, Dihydropteroate, D-Mannose 6-phosphate, DNA (biomass component), DNA 5-methylcytosine, Dodecanoyl-[acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTDP-4-dehydro-6-deoxy-L-mannose, dTDP-6-deoxy-L-mannose, dTDP-glucose, dTMP, dTTP, dUMP, Exopolysaccharide, Flavin adenine dinucleotide, FMN, GDP, GDP-mannose, Glycerone phosphate, Glycine, GMP, GTP, H2O2, HCO3, Heptadecanoyl-[acyl-carrier protein], Heptadecenoyl-[acyl-carrier protein], Hexadecanoyl-[acyl-carrier protein], Hexadecenoyl-[acyl-carrier protein], Iminoaspartate, IMP, Isochorismate, L,L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspartate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lipids other than phospholipid, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl-[acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminoheptanedioate, N6-(1,2-Dicarboxyethyl)-AMP, N-Acetyl-D-glucosamine 1-phosphate, NAD+, NADP+, NADPH, NH3, Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L-2,6-diaminopimelate, Octadecanoyl-[acyl-carrier protein], Octadecenoyl-[acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxygen, Pantetheine 4'-phosphate, Pentadecanoyl-[acyl-carrier protein], Peptidoglycan (biomass component), Peptidoglycan precursor, Phosphatidate, Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphoenolpyruvate, Phospholipids (biomass component), Propanoyl-[acyl-carrier protein], Propanoyl-CoA, Proteins , Pyridoxal, Pyridoxal 5'-phosphate, Pyridoxine, Pyridoxine 5'-phosphate, Pyruvate, Quinolinate, Riboflavin, RNA , S-Adenosyl-L-methionine, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl-[acyl-carrier protein], Tetrahydrofolate, Thioredoxin, Thioredoxin disulfide, Thymidine, Thymine, UDP, UDP-D-galactose, UDP-glucose, UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine, UDP-N-acetyl-D-galactosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-(glycyl)5-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, UTP, Xanthosine 5'-phosphate 등을 들 수 있다. For example, the primary essential metabolite of AYE ( Acinetobacter baumannii AYE) obtained through metabolic flow analysis using Equation 1 and Equation 2 is (R) -4′-Phosphopantothenoyl-L-cysteine, (R ) -pantoate, (R) -Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Acyl-sn-glycerol 3-phosphate, 1-Deoxy-D-xylulose 5-phosphate, 2,3,4,5- Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine, 2-Amino-4-hydroxy-6 -(D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 2-Amino-4-hydroxy-6- (erythro-1,2,3-trihydroxypropyl) dihydropteridine triphosphate, 2-Amino-4 -hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate, 2-Dehydro-3-deoxy-D-octonate, 2-Dehydro-3-deoxy- D-octonate 8-phosphate, 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-De hydroquinate, 3-Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4,6-Dideoxy-4-oxo-dTDP-D-glucose, 4-amino-4 -deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate, 5,10-Methylenetetrahydrofolate, 5-Amino-6- (5'-phosphoribitylamino) uracil, 5-Amino-6- (5'-phosphoribosylamino) uracil, 5 -Amino-6-ribitylamino-2,4 (1H, 3H) -pyrimidinedione, 5-O- (1-Carboxyvinyl) -3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl -8- (1-D-ribityl) lumazine, Acetyl- [acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, ADP, all-trans-Octaprenyl diphosphate, alpha-D-Glucose, alpha-D-Glucose 6-phosphate, alpha-D-Mannose 1-phosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 1,6-bisphosphate, beta-D-Fructose 6-phosphate, beta-D-Glucose, beta-hydroxy dodecanoic acid, beta-hydroxy tetradecanoic acid, Cardiolipin (biomass component), CDP, CDP-diacylglycerol, Chorismate, CO 2 , CoA, Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, dADP, D-alanine, D-alanyl-D-alanine, D-Arabinose 5-phosphate, dATP, dCDP, dCTP, Deamino-NAD +, Decanoyl- [acyl-carrier protein], Dephospho-CoA, D-Erythrose 4-phosphate, dGDP, D-Glucosamine 1-phosphate, D-Glucosamine 6-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate, dGTP, Dihydrofolate, Dihydropteroate, D-Mannose 6-phosphate, DNA (biomass component), DNA 5 -methylcytosine, Dodecanoyl- [acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTDP-4-dehydro-6-deoxy-L-mannose, dTDP-6-deoxy-L- mannose, dTDP-glucose, dTMP, dTTP, dUMP, Exopolysaccharide, Flavin adenine dinucleotide, FMN, GDP, GDP-mannose, Glycerone phosphate, Glycine, GMP, GTP, H 2 O 2 , HCO 3 , Heptadecanoyl- [acyl-carrier protein ], Heptadecenoyl- [acyl-carrier protein], Hexadecanoyl- [acyl-carrier protein], Hexadecenoyl- [acyl-carrier protein], Iminoaspartate, IMP, Isochorismate, L, L-2,6-Diaminopimelate, L-3,4 -Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspart ate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lipids other than phospholipid, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L- Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl- [acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminoheptanedioate, N6- ( 1,2-Dicarboxyethyl) -AMP, N-Acetyl-D-glucosamine 1-phosphate, NAD +, NADP +, NADPH, NH3, Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L -2,6-diaminopimelate, Octadecanoyl- [acyl-carrier protein], Octadecenoyl- [acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxygen , Pantetheine 4'-phosphate, Pentadecanoyl- [acyl-carrier protein], Peptidoglycan (biomass component), Peptidoglycan precursor, Phosphatidate, Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphosinospypymas s component), Propanoyl- [acyl-carrier protein], Propanoyl-CoA, Proteins, Pyridoxal, Pyridoxal 5'-phosphate, Pyridoxine, Pyridoxine 5'-phosphate, Pyruvate, Quinolinate, Riboflavin, RNA, S-Adenosyl-L-methionine , Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl- [acyl-carrier protein], Tetrahydrofolate, Thioredoxin, Thioredoxin disulfide, Thymidine, Thymine, UDP, UDP-D-galactose, UDP-glucose , UDP-N-acetyl-3- (1-carboxyvinyl) -D-glucosamine, UDP-N-acetyl-D-galactosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl -L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L -alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D -glutaminyl-meso-2,6-diaminopimeloyl- (glycyl) 5-D-alanyl-D-alanine, Undecaprenyl-diphosp ho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine)- L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D- alanyl-D-alanine, UTP, and Xanthosine 5'-phosphate.
일례로, 상기 수학식 1 및 수학식 2를 이용한 대사흐름분석 단계를 거쳐 수득된 비브리오 불니피커스(Vibrio vulnificus)의 1차 필수 대사산물로는 (R)-4'-Phosphopantothenoyl-L-cysteine, (R)-pantoate, (R)-Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Deoxy-D-xylulose 5-phosphate , 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate, 2,3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4-(5'-phosphoribosylamino)-pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine (L-1-Lysophosphatidylethanolamine), 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)-dihydropteridine triphosphate, 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate, 2-C-Methyl-D-erythritol 4-phosphate, 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate , 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-Phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3-Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4-(Cytidine 5'-diphospho)-2-C-methyl-D-erythritol, 4-amino-4-deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate (4-Phosphoerythronate), 5,10-Methylenetetrahydrofolate, 5-Amino-6-(5'-phosphoribitylamino)uracil, 5-Amino-6-(5'-phosphoribosylamino)uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H)-pyrimidinedione (4-(1-D-Ribitylamino)-5-amino-2,6-dihydroxypyrimidine (4-(1-D-Ribitylamino)-5-aminouracil)), 5-Methyltetrahydrofolate, 5-O-(1-Carboxyvinyl)-3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, Acetyl-[acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, Acyl-sn-glycerol 3-phosphate, ADP, ADP-D-glycero-D-manno-heptose, ADPglucose, ADP-L-glycero-D-manno-heptose, all-trans-Heptaprenyl diphosphate, all-trans-Hexaprenyl diphosphate, all-trans-Octaprenyl diphosphate, all-trans-Pentaprenyl diphosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 6-phosphate, CDP-diacylglycerol, Chorismate, CO2, CoA (coenzyme A), Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, D-alanine, D-alanyl-D-alanine, dATP, dCTP, Deamido-NAD+, Dephospho-CoA, D-Erythrose 4-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate ((2R)-2-Hydroxy-3-(phosphonooxy)-propanal), D-glycero-D-manno-Heptose 1,7-bisphosphate, D-glycero-D-manno-Heptose 1-phosphate, D-glycero-D-manno-Heptose 7-phosphate, dGTP, Dihydrofolate, Dihydropteroate, Dimethylallyl diphosphate, DNA (biomass component), Dodecanoyl-[acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTMP, dTTP, Flavin adenine dinucleotide (FAD), FMN (Riboflavin-5-phosphate, Flavin mononucleotide), Fumarate, GDP, Geranyl diphosphate, Geranylgeranyl diphosphate, Glycerone phosphate, Glycine, Glycogen, GMP, GTP, Hexadecanoyl-[acyl-carrier protein], Hexadecenoyl-[acyl-carrier protein], Iminoaspartate, Isochorismate, Isopentenyl diphosphate, L,L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspartate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl-[acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminopimelate, NAD+ (Nicotinamide adenine dinucleotide), NADH, NADP+ (Nicotinamide adenine dinucleotide phosphate), NADPH, NH3, Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L-2,6-diaminopimelate, Octadecanoyl-[acyl-carrier protein], Octadecenoyl-[acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxidized thioredoxin, Pantetheine 4'-phosphate, Pentadecanoyl-[acyl-carrier protein], Peptidoglycan (biomass component), Peptidoglycan precursor, Phosphatidate (1,2-Diacyl-sn-glycerol 3-phosphate), Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphoenolpyruvate, Phospholipids (biomass component), Propanoyl-[acyl-carrier protein] (Propionyl-[acyl-carrier protein]), Propanoyl-CoA (Propionyl-CoA), Proteins , Pyridoxine, Pyridoxine 5'-phosphate (Pyridoxine phosphate), Pyruvate, Quinolinate (Pyridine-2,3-dicarboxylate), Riboflavin, RNA , S-Adenosyl-L-methionine, Sedoheptulose 7-phosphate, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl-[acyl-carrier protein], Tetrahydrofolate, Thioredoxin, trans,trans-Farnesyl diphosphate, UDP, UDPglucose, UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-(glycyl)5-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, UTP 등을 들 수 있다. For example, the first essential metabolite of Vibrio vulnificus obtained through the metabolic flow analysis step using Equations 1 and 2 is (R) -4′-Phosphopantothenoyl-L-cysteine, (R) -pantoate, (R) -Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Deoxy-D-xylulose 5-phosphate, 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate, 2, 3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine (L-1 -Lysophosphatidylethanolamine), 2-Amino-4-hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 2-Amino-4-hydroxy-6- (erythro-1,2 , 3-trihydroxypropyl) -dihydropteridine triphosphate, 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate, 2-C-Methyl-D- erythritol 4-phosphate, 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate, 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-Phospho-4- (cy tidine 5'-diphospho) -2-C-methyl-D-erythritol, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3- Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4- (Cytidine 5'-diphospho) -2-C-methyl-D-erythritol, 4-amino-4 -deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate (4-Phosphoerythronate), 5,10-Methylenetetrahydrofolate, 5-Amino-6- (5'-phosphoribitylamino) uracil, 5-Amino-6- (5'- phosphoribosylamino) uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H) -pyrimidinedione (4- (1-D-Ribitylamino) -5-amino-2,6-dihydroxypyrimidine (4- (1-D- Ribitylamino) -5-aminouracil)), 5-Methyltetrahydrofolate, 5-O- (1-Carboxyvinyl) -3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl-8- (1 -D-ribityl) lumazine, Acetyl- [acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, Acyl-sn-glycerol 3-phosphate, ADP, ADP-D-glycero-D-manno-heptose, ADPglucose, ADP-L-glycero-D-manno-heptose, all-trans-Heptaprenyl diphosph ate, all-trans-Hexaprenyl diphosphate, all-trans-Octaprenyl diphosphate, all-trans-Pentaprenyl diphosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 6-phosphate, CDP-diacylglycerol, Chorismate, CO 2 , CoA (coenzyme A), Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, D-alanine, D-alanyl-D-alanine, dATP, dCTP, Deamido-NAD +, Dephospho-CoA, D-Erythrose 4-phosphate, D -Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate ((2R) -2-Hydroxy-3- (phosphonooxy) -propanal), D-glycero-D-manno-Heptose 1,7-bisphosphate, D -glycero-D-manno-Heptose 1-phosphate, D-glycero-D-manno-Heptose 7-phosphate, dGTP, Dihydrofolate, Dihydropteroate, Dimethylallyl diphosphate, DNA (biomass component), Dodecanoyl- [acyl-carrier protein], D Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTMP, dTTP, Flavin adenine dinucleotide (FAD), FMN (Riboflavin-5-phosphate, Flavin mononucleotide), Fumarate, GDP, Geranyl diphosphate, Geranylgeranyl diphosphate, Glycerone phosphate , Glycine, Glycogen, GMP, GTP, Hexadeca noyl- [acyl-carrier protein], Hexadecenoyl- [acyl-carrier protein], Iminoaspartate, Isochorismate, Isopentenyl diphosphate, L, L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspartate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lippolysaccharide, L-Isoleucine, L-Leucine, L -Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl- [acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminopimelate, NAD + (Nicotinamide adenine dinucleotide), NADH, NADP + (Nicotinamide adenine dinucleotide phosphate), NADPH, NH 3 , Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N -Succinyl-L-2,6-diaminopimelate, Octadecanoyl- [acyl-carrier protein], Octadecenoyl- [acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate -CoA, Oxidized thioredoxin, Pantetheine 4'-phosphate, Pentad ecanoyl- [acyl-carrier protein], Peptidoglycan (biomass component), Peptidoglycan precursor, Phosphatidate (1,2-Diacyl-sn-glycerol 3-phosphate), Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserophosphophosphate, Phosphophosphate, Phosphophosphate Propanoyl- [acyl-carrier protein] (Propionyl- [acyl-carrier protein]), Propanoyl-CoA (Propionyl-CoA), Proteins, Pyridoxine, Pyridoxine 5'-phosphate (Pyridoxine phosphate), Pyruvate, Quinolinate (Pyridine-2, 3-dicarboxylate), Riboflavin, RNA, S-Adenosyl-L-methionine, Sedoheptulose 7-phosphate, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl- [acyl-carrier protein], Tetrahydrofolate , Thioredoxin, trans, trans-Farnesyl diphosphate, UDP, UDPglucose, UDP-N-acetyl-3- (1-carboxyvinyl) -D-glucosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP- N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmu ramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl- diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl- (glycyl) 5-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl- ( N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutamyl -meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, UTP Etc. can be mentioned.
(4) 필수 대사산물의 추가 스크리닝 (4) Additional Screening of Essential Metabolites
4-1. 유통 대사산물(currency metabolite)의 제거4-1. Removal of Currency Metabolites
상기 (3)에서 결정된 필수 대사산물들 중에는 다양한 생물체의 다수 효소 반응식에 관여하는 이른바 유통 대사산물(currency metabolite)가 존재한다. 유통 대사사물들에 대한 정보는 2003년, Bioinformatics지에 발표된 논문(Ma and Zeng, Bioinformatics, 19:1423, 2003)에 게재되어 있으며, 이들은 대상 미생물 병원균만이 가지고 있는 특이성(specificity)를 가지고 있지 않기에 컴퓨터 상의 1차 필수 대사산물의 리스트에서 제거한다.Among the essential metabolites determined in (3), there is a so-called circulation metabolite (currency metabolite) involved in a number of enzyme reactions of various organisms. Information on the metabolites in circulation is published in a paper published in Bioinformatics in 2003 (Ma and Zeng, Bioinformatics, 19: 1423, 2003), which do not have the specificity unique to the target microbial pathogen. Remove from the list of primary essential metabolites on the computer.
1차 필수 대사산물에서 상기 유통 대사산물을 제거한 결과를 2차 필수 대사산물이라 명명하였다.The result of removing the distribution metabolite from the first essential metabolite was named as a second essential metabolite.
4-2. 다수의 반응식에 관여하는 필수 대사산물 선별4-2. Selection of essential metabolites involved in multiple reactions
상기 (4-1)에서 유통 대사산물(currency metabolite)을 제거하고 결정된 2차 필수 대사산물들 중에서, 최소 3개 이상의 반응식에 관여하며, 이들 반응식들 중에 최소 2개 이상은 해당 필수 대사산물을 소비하는 지를 조사한다. 그리고, 해당 기준을 만족하는 필수 대사산물들만을 선별한다.Among the secondary essential metabolites determined by removing the circulation metabolite in (4-1) above, at least three or more reactions are involved, and at least two or more of these reactions consume the corresponding metabolites. Investigate if you do. Only those essential metabolites that meet the criteria are selected.
즉, 2차 필수 대사산물들 중 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 대사산물을 3차 필수 대사산물이라고 명명한다. That is, at least two or more of the secondary essential metabolites are involved in the enzyme reaction, while at least two or more simultaneously name the metabolite when consuming the essential metabolite as the third essential metabolite.
이러한 방법은 대사산물 유사물질(metabolite analogue)을 약물로 사용할 경우, 상기 소비 효소들을 동시에 공략할 수 있는 장점이 있다. This method has the advantage of simultaneously targeting the consuming enzymes when using a metabolite analogue (metabolite analogue) as a drug.
통상적으로 항병원균 약물의 가장 큰 문제점은 약물에 대한 병원균의 내성이 금방 생긴다는 것이고, 이는 주로 약물 표적인 효소 유전자의 한 개의 변이(single endogenous mutation)에 의해서 일어나기 때문에, 본 발명의 약물 표적 유전자군으로 조합은 대상 미생물 병원균 대사의 여러 군데를 동시에 공략할 수 있어 상기 병원균의 내성을 최소화할 수 있고, 상기 병원균의 숙주 내 성장을 확실히 제어할 수 있다는 유리한 점이 있다. Typically, the biggest problem of anti-pathogen drugs is that the resistance of the pathogen to the drug occurs quickly, which is mainly caused by a single endogenous mutation of the enzyme target enzyme gene, thus the drug target gene group of the present invention. The combination has the advantage of being able to simultaneously target several places of the target microbial pathogen metabolism to minimize the resistance of the pathogen, and to reliably control the growth of the pathogen in the host.
특히, 본 발명에서 일 실시예로 사용한, 아시네토박터 바우마니 또는 비브리오 불니피커스는 다수의 약제에 내성을 보이는 다약제 내성(multi-drug resistant, MDR) 감염균의 일종으로, 본 발명의 방법은 이러한 다약제 내성 병원성 미생물에 대해 효과적 공략방법이 될 수 있음을 시사한다. In particular, Acinetobacter Baumani or Vibrio Bulnipicus, which is used as an embodiment in the present invention, is a kind of multi-drug resistant (MDR) infectious bacterium that is resistant to many drugs. It suggests that it may be an effective method for multidrug resistant pathogenic microorganisms.
4-3. 숙주의 대사에 존재하지 않는 필수 대사산물 선별4-3. Selection of essential metabolites that are not present in the host's metabolism
숙주가 약물로부터 받을 수 있는 부작용의 가능성을 최소화하기 위하여, 우선, 상기 (4-2)에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 대사산물들만을 선별하여 4차 필수 대사산물로 명명한다.In order to minimize the possibility of adverse reactions that the host may receive from the drug, firstly, only the metabolites which are not present in the metabolism of the host among the tertiary essential metabolites determined in the above (4-2) are selected and the fourth essential metabolites are selected. Named as
예를 들어, 숙주가 인간인 경우, (4-2)에서 결정된 3차 필수 대사산물들 중 인간의 대사에 존재하지 않는 대사산물들만을 선별한다.For example, if the host is human, only those metabolites that are not present in human metabolism are selected from the tertiary essential metabolites determined in (4-2).
4-4. 필수 대사산물들 중 소비하는 효소가 숙주에 없는 것들만을 선별4-4. Select only those enzymes that are not consumed among essential metabolites by the host
그리고, 추가로 상기 (4-3)에서 결정된 4차 필수 대사산물들 중 각각의 필수대사산물을 소비하는데 관련하는 모든 효소가 숙주 단백질과 상동관계가 없는 것들로만 이루어지는 경우의 필수 대사산물들을 선별하는 단계를 수행한다. 본 발명에서는 궁극적으로 필수 대사산물의 섭취를 병원균으로부터 불가능하게 하여 주변의 반응식을 모두 동시에 불활성화시키는 전략이므로, 설령 그 반응식들이 동질효소에 의해 진행된다 할지라도 문제되지 않는다.And further selecting essential metabolites when all the enzymes involved in consuming each of the essential metabolites from the fourth essential metabolites determined in (4-3) consist only of those not homologous to the host protein. Perform the steps. In the present invention, the strategy is to ultimately disable the intake of essential metabolites from pathogens, thereby simultaneously inactivating all of the surrounding reactions, so even if the reactions are carried out by isoenzymes, it is not a problem.
그 결과 남는 대사산물들을 5차 필수 대사산물로 명명한다. As a result, the remaining metabolites are named 5th essential metabolites.
예를 들어, 숙주가 인간인 경우, 4차 필수 대사산물들 중 이들을 소비하는 효소가 인체에 존재하지 않는 것, 즉 인간 단백질과 상동관계가 없는 대사산물들만을 5차 필수 대사산물로 선별한다. For example, if the host is a human, only those metabolites that do not have an enzyme in the human body that consumes any of the fourth essential metabolites, ie, have no homology with human proteins, are selected as the fifth essential metabolite.
이 단계에서는, 상기 대사흐름분석을 통해 예측된 필수 대사산물에 대해서, 이들의 소비 반응식과 관련하는 효소와 숙주 단백질간의 상동관계를 기준으로 추가 스크리닝하여 차기 가능성 있는 필수 대사산물의 수를 더욱 줄이게 된다. In this step, the essential metabolites predicted through the metabolic flow analysis are further screened based on the homology between the enzymes and the host proteins related to their consumption equations to further reduce the number of possible essential metabolites. .
특히, 특정 유전자나 효소를 표적으로 하여 개발된 약물은 그 유전자나의 효소의 '서열'에 기반하여 작용하므로, 이러한 서열의 유전자나 효소가 인간에도 존재할 경우, 상기 약물은 인간 단백질에도 작용하게 되어 부작용을 일으킬 수 있다.In particular, drugs developed by targeting specific genes or enzymes act on the basis of the 'sequence' of the genes or enzymes. Therefore, if the genes or enzymes in these sequences are present in humans, the drugs also act on human proteins. May cause
따라서, 만일 필수 대사산물 중 소비 반응식들의 효소가 한 개라도 숙주의 단백질과 통계적으로 유사할 경우, 해당 필수 대사산물 및 그의 소비 반응식은 더 이상 약물 표적으로서 고려하지 않는 것이다.Thus, if any of the enzymes in the consumption schemes in the essential metabolites are statistically similar to the protein of the host, the essential metabolites and their consumption schemes are no longer considered as drug targets.
이 단계에서, 상기 상동관계를 검토함에 있어서는 숙주의 게놈 정보를 데이터 베이스로 하는 것이 바람직하다. At this stage, in examining the homology, it is preferable to use the genomic information of the host as a database.
예를 들어, 아미노산 서열 이용시에는 BLASTP 프로그램을, 또는 유전자 서열 이용시에는 BLAST 프로그램을 사용할 수 있다. 다만, 아미노산 서열이든 유전자 서열이든 상관없이 당업자가 상동관계를 파악할 수 있는 데이터라면 어느 것이든 사용해도 무방하다. 본 발명의 일 구체예에서는 BLASTP 프로그램을 이용하였다. 숙주로서 인간을 대상으로 하는 경우, 인간의 게놈 정보를 데이터베이스로 이용한다.For example, the BLASTP program may be used when using an amino acid sequence, or the BLAST program may be used when using a gene sequence. However, any data can be used as long as those skilled in the art can identify homology regardless of amino acid sequence or gene sequence. In one embodiment of the present invention used the BLASTP program. When targeting a human as a host, the human genomic information is used as a database.
이 단계를 수행하면, 본 발명에서 추가로 선별된 각각의 필수 대사산물들을 소비하는 모든 효소를 코딩하는 유전자들 및 아미노산 서열들은 숙주 단백질의 것과 현저히 다르게 되며, 그 결과, 숙주 단백질과 구조적기능적으로 다르게 된다. By carrying out this step, the genes and amino acid sequences encoding all the enzymes consuming each of the essential metabolites further selected in the present invention are significantly different from those of the host protein, resulting in structurally different functionalities from the host protein. do.
이와 같은 상기 (4-3)과 본 (4-4) 과정은 상기 대사산물 유사물질을 약물로서 사용할 경우와 같이, 한 개의 약물로 동시에 여러 효소 소비 반응식을 억제하되, 숙주에게는 해당 단백질이 존재하지 않아 약물로부터 받을 수 있는 부작용의 가능성을 최소화하는 단계라고 할 수 있다. In the above (4-3) and the present (4-4) process, as in the case of using the metabolite analogue as a drug, one drug simultaneously suppresses several enzyme consumption reaction schemes, but the protein does not exist in the host. Therefore, it can be said to minimize the possibility of side effects that can be received from drugs.
이 때, 상기 방법에 있어서, 상기 "(4-1)단계 및/또는 (4-3)단계; 및 (4-4)단계"에 대하여 "(4-2)단계"는 선택적으로 적용할 수 있다. At this time, in the above method, step (4-2) can be selectively applied to step (4-1) and / or step (4-3) and step (4-4). have.
이상과 같은 단계를 거쳐, 병원성 미생물 특이적인 필수 대사산물을 최종적으로 결정할 수 있고, 이러한 필수 대사산물과 관여하는 효소들을 약물 표적 효소군으로 결정하게 된다. 또한, 이렇게 결정된 약물 표적 효소들을 코딩하는 유전자들을 약물 표적 유전자군으로 결정할 수 있다. Through the above steps, the pathogenic microorganism-specific essential metabolites can be finally determined, and the enzymes involved in these essential metabolites are determined as drug target enzyme groups. In addition, so determined Genes encoding drug target enzymes can be determined as a drug target gene family.
본 발명의 일례에서 사용한 AYE (Acinetobacter baumannii AYE)의 5차 필수 대사산물은 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, D-Glutamate, 2,3-Dihydrodipicolinate, 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, 3-Dehydroshikimate, 1-Deoxy-D-xylulose 5-phosphate, 3-Dehydroquinate, 2-Dehydro-3-deoxy-D-octonate, 4-Aminobenzoate 등이고, The fifth essential metabolite of AYE ( Acinetobacter baumannii AYE) used in the example of the present invention is 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, D-Glutamate, 2,3-Dihydrodipicolinate, 2-Amino -4-hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 3-Dehydroshikimate, 1-Deoxy-D-xylulose 5-phosphate, 3-Dehydroquinate, 2-Dehydro- 3-deoxy-D-octonate, 4-Aminobenzoate and the like,
이들의 대사에 관여하는 약물 표적 효소로는 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase(3-dehydroquinase), shikimate 5-dehydrogenase, quinate/shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, dihydropteroate synthase을 결정할 수 있고, Drug target enzymes involved in metabolism include 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase (3-dehydroquinase), shikimate 5-dehydrogenase, quinate / shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, dihydropteroate synthase,
약물 표적 유전자군으로는 ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, ABAYE3176, ABAYE3395, ABAYE3524, ABAYE3568, ABAYE3612 및 ABAYE3616을 결정할 수 있다. Drug target gene groups include ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, AYEYE95, ABAYE3176, ABA3, 355
본 발명의 일 례에서 사용한 비브리오 불니피커스(Vibrio vulnificus )의 5차 필수 대사산물은 1-deoxy-D-xylulose 5-phosphate, 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2,3-dihydrodipicolinate, 4-aminobenzoate, D-glutamate 등이고, The fifth essential metabolite of Vibrio vulnificus used in one embodiment of the present invention is 1-deoxy-D-xylulose 5-phosphate, 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine , 2,3-dihydrodipicolinate, 4-aminobenzoate, D-glutamate and the like,
이들의 대사에 관여하는 약물 표적 효소로는 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase 등을 결정할 수 있고, Drug target enzymes involved in their metabolism include 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D -xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, etc.,
약물 표적 유전자군으로는, VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, 및 VV11866 등을 결정할 수 있다. As the drug target gene group, VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, VV11866 and the like can be determined.
뿐만 아니라, 본 발명은 다른 관점에서, 상기 설명한 미생물의 약물 표적 효소 또는 이를 코딩하는 유전자를 스크리닝 방법에 따라 수득되는, 각 단계에서의 필수 대사산물의 대사에 관여하는 약물 표적 효소 후보 및 이를 코딩하는 유전자군을 제공한다. Furthermore, in another aspect, the present invention provides a drug target enzyme candidate and a gene encoding the drug target enzyme of the above-described microorganisms or genes encoding the same, which are obtained by the screening method, which are involved in the metabolism of essential metabolites at each step. Provide gene families.
즉, (b)단계의 대사흐름분석에 의해 결정한 1차 필수 대사산물과 관여하는 약물 표적 효소 후보 및 이를 코딩하는 유전자군; (c)단계의 유통 대사산물 (currency metabolite)을 제거하여 결정한 2차 필수 대사산물과 관여하는 약물 표적 효소 후보 및 이를 코딩하는 유전자군; (d)단계에서 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 선별하여 결정한 3차 필수 대사산물과 관여하는 약물 표적 효소 후보 및 이를 코딩하는 유전자군; (e)단계에서 숙주의 대사에 존재하지 않는 것들만을 선별하여 결정한 4차 필수 대사산물과 관여하는 약물 표적 효소 후보 및 이를 코딩하는 유전자군; 및 (f) 4차 필수 대사산물의 대사와 관련된 효소들 중 숙주 단백질과 상동관계가 없는 경우를 선별하여 결정한 5차 필수 대사산물과 관여하는 약물 표적 효소 후보 및 이를 코딩하는 유전자군을 제공한다. That is, drug target enzyme candidates involved in the primary essential metabolite determined by the metabolic flow analysis of step (b) and the gene group encoding the same; drug target enzyme candidates involved in the secondary essential metabolite determined by removing the circulation metabolite of step (c) and the gene group encoding the same; In step (d), at least three or more enzyme reactions, and at least two or more at the same time the drug target enzyme candidates and genes encoding the enzymes involved in the selected third essential metabolite when the essential metabolite is consumed group; drug target enzyme candidates involved in the fourth essential metabolite determined by selecting only those not present in the metabolism of the host in step (e) and the gene group encoding the same; And (f) a drug target enzyme candidate involved in the fifth essential metabolite determined by selecting a case where there is no homology with the host protein among enzymes related to metabolism of the fourth essential metabolite and a gene group encoding the same.
다른 관점에서, 본 발명은 또한 상기 결정된 효소군 및 이를 코딩하는 유전자군을 대상 미생물의 약물 표적으로 이용하는 방법에 관한 것이다.In another aspect, the present invention also relates to a method of using the determined enzyme group and the gene group encoding the same as the drug target of the target microorganism.
따라서, 일 태양으로, 상기 선정된 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase(3-dehydroquinase), shikimate 5-dehydrogenase, quinate/shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, dihydropteroate synthase의 효소군 또는 이를 코딩하는 ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, ABAYE3176, ABAYE3395, ABAYE3524, ABAYE3568, ABAYE3612, ABAYE3616의 유전자군을 AYE (Acinetobacter baumannii AYE)의 약물 표적으로 이용할 수 있다. Thus, in one aspect, the above-selected 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase (3-dehydroquinase), shikimate 5-dehydrogenase, quinate / shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5- Enzyme family of phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, dihydropteroate synthase, or ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE14 A, ABAYE 158 A, ABA YE 15BA The gene groups ABAYE3395, ABAYE3524, ABAYE3568, ABAYE3612, and ABAYE3616 can be used as drug targets of AYE ( Acinetobacter baumannii AYE).
또한, 다른 태양으로, 상기 선정된 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase의 효소군 또는, 이를 코딩하는 VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, 및 VV11866의 유전자군을 비브리오 불니피커스(Vibrio vulnificus )의 약물 표적으로 이용할 수 있다. Also, in another embodiment, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose selected above A group of enzymes of -5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, or the gene groups VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, and VV11866 encoding the same can be used as drug targets of Vibrio vulnificus . Can be.
(5) 5차 필수 대사산물의 구조를 이용한 약물 후보군 도출 및 미생물 성장 억제 실험을 통한 약물 스크리닝 (5) Drug screening through the derivation of drug candidate group and microbial growth inhibition experiment using the structure of the 5th essential metabolite
상기 방법으로 얻어지는 5차 필수 대사산물 또는 최종 필수 대사산물의 구조를 이용하여, 화합물 라이브러리로부터 구조가 유사한 화합물을 약물 후보군으로 선별할 수 있다. The structure of the fifth essential metabolite or the final essential metabolite obtained by the above method can be used to select compounds having similar structures from the compound library as drug candidates.
일 예로써, 비브리오 불니피커스의 경우, 상기 방법으로 얻은 5개의 5차 필수 대사산물의 구조를 이용하여 한국화합물은행에 있는 17만개 이상으로 구성된 화합물 라이브러리 또는 그 외의 다양한 화합물 라이브러리로부터 구조가 유사한 화합물만을 선별할 수 있다. As an example, in the case of Vibrio Buninipus, a compound having a similar structure from a compound library consisting of more than 170,000 compounds of the Korea Compound Bank or a variety of other compound libraries using the structure of five fifth essential metabolites obtained by the above method Only bays can be screened.
상기 최종 필수 대사산물 또는 5차 필수 대사산물과 구조적으로 유사한 화합물을 선별함에 있어서는, 타니모토 계수(Tanimoto coefficient)를 이용한다.In selecting a compound that is structurally similar to the final essential metabolite or the fifth essential metabolite, the Tanimoto coefficient is used.
타니모토 계수는 유사도를 측정하는 지표의 일종으로, T=c/(a+b+c)의 공식을 이용할 수 있으며, 여기서 c는 common bits이고, a는 분자 a의 unique bits number이며, b는 분자 b의 unique bits number이다. 이것은 molecular fingerprint를 이용하여 측정할 수 있다. 일반적으로, 매우 유사한 두 화합물 간의 타니모토 계수는 1에 가깝다. The Tanimoto coefficient is an index that measures similarity, and can use the formula T = c / (a + b + c), where c is common bits, a is unique bits number of molecule a, and b is unique of molecule b. bits number. This can be measured using molecular fingerprints. In general, the Tanimoto coefficient between two very similar compounds is close to one.
일반적으로, 이러한 구조적 유사한 화합물을 탐색하는 툴에는 Pipeleine Pilot 6.0 등 여러 가지 프로그램이 공지되어 있으며, 이들을 이용하여, 본 발명에서는 타니모토 계수 0.5를 기준으로 구조적 유사성을 가진 화합물을 선별하되, 바람직하게는, 0.5∼1의 타니모토 계수를 가지는 화합물을 구조가 유사한 약물 후보군으로 도출한다. In general, various programs such as Pipeleine Pilot 6.0 are known in the tool for searching for such structurally similar compounds. Using these, the present invention selects compounds having structural similarity based on the Tanimoto coefficient of 0.5, preferably , A compound having a Tanimoto coefficient of 0.5 to 1 is derived to a drug candidate group having a similar structure.
다음으로, 이들 선별된 약물 후보군을 가지고 실제로, 미생물에 처리하여 미생물의 성장 억제 여부를 실험을 통해 확인한다. Next, with these selected drug candidate groups, in fact, the microorganisms are treated to confirm whether the growth of the microorganisms is examined through experiments.
예컨대, 100-well plate의 각 well에는 100 ul의 Mueller Hinton이라는 복합 액체 배지를 넣으며, 대사 미생물을 각 well에서 배양한다. 배양은 20시간하며, 미생물의 농도는 매 시간마다 OD600를 측정해주는 BioScreen C를 이용한다. 유사 구조 화합물은 화합물 처리가 전혀 안된 대조 표준 미생물의 최고 농도 대비 미생물 농도의 80% 이상을 억제할 경우, 이 구조 유사 화합물은 항병원균 약물 후보군으로서 효력이 있다고 간주할 수 있다. For example, in each well of a 100-well plate, 100 ul of Mueller Hinton is placed in a complex liquid medium, and metabolic microorganisms are cultured in each well. Incubation is 20 hours, and the concentration of microorganisms is measured using BioScreen C, which measures OD600 every hour. If the analogous structural compound inhibits at least 80% of the concentration of the microorganism relative to the highest concentration of the control standard microorganism that has not been treated with the compound, the structural analogous compound may be considered to be effective as an anti-pathogen drug candidate.
본 발명의 일례에서, 비브리오 불니피커스의 경우, 구조 유사 물질인 약물 후보군은 한국화합물은행의 화합물 라이브러리에서 총 352개가 선별되었으며, 미생물 성장 억제 실험을 통하여 이들 중 가장 효력이 있는 구조 유사 물질로써, 선별된 약물은 화학식 1의 구조식을 가지는 화합물이다. In one example of the present invention, in the case of Vibrio Bulnipicus, a total of 352 drug candidates, which are structurally similar substances, were selected from the compound library of the Korea Compound Bank, and as the most effective structural analogues among them through a microbial growth inhibition experiment, The selected drug is a compound having the structural formula (I).
화학식 1Formula 1
이들은 MIC(미생물 최소 억제 농도)는 1~8, 바람직하게는, 1~2 ㎍/㎖일 수 있다. They may have a MIC (minimum microbial concentration) of 1 to 8, preferably 1 to 2 μg / ml.
이 화합물 이외에도, 이들의 유도체, 염 등의 형태 역시 비브리오 불니피커스에 대한 성장 억제능을 가질 수 있음은 당업자에게 자명할 것이다.In addition to these compounds, it will be apparent to those skilled in the art that their derivatives, salts, and the like may also have a growth inhibitory activity against Vibrio ulphipicus.
이와 같은 본 발명에 따른 약물 표적 효소 및 약물 표적 유전자들은 병원균에 의한 질병에 대한 차기 가능성 있는 효과적인 약물 표적 후보군들만을 얻게 되어 미생물 병원균체에 의한 질병의 치료 및 예방에 유용하다. Such drug target enzymes and drug target genes according to the present invention obtain only the next effective drug target candidate groups for pathogenic diseases, and are useful for the treatment and prevention of diseases caused by microbial pathogens.
따라서, 본 발명은 다른 관점에서, 상기 화학식 1의 화합물, 그 유도체, 또는 염을 유효성분으로 함유하는 비브리오 속에 대한 항균 조성물에 관한 것이다. 더 나아가, 이로부터 제조될 수 있는 가능한 용매화물, 수화물 또는 라세미체를 모두 포함한다. Therefore, in another aspect, the present invention relates to an antimicrobial composition against Vibrio genus containing the compound of Formula 1, a derivative thereof, or a salt as an active ingredient. Furthermore, it includes all possible solvates, hydrates or racemates that can be prepared therefrom.
여기서, 비브리오 속에는, 비브리오 불니피커스 뿐만 아니라, 비브리오 콜레라, 비브리오 헤모리티쿠스 등이 모두 포함될 것이다. Here, in Vibrio, not only Vibrio bulnipius, but also Vibrio cholera, Vibrio hemoritis, and the like will be included.
본 발명에서 항균이라 함은 비브리오 불니피커스의 성장 억제능을 가지는 것을 의미하며, 더 나아가, 성장 및 감염을 방지, 성장 억제, 및/또는 사멸작용을 모두 포함하는 개념이다. 이러한 항균 조성물은 식품, 화장품 또는 약제 조성물의 형태를 모두 포함한다. In the present invention, the antimicrobial means having the growth inhibitory ability of Vibrio uniphycus, and furthermore, is a concept including both growth and infection prevention, growth inhibition, and / or killing action. Such antimicrobial compositions include all forms of food, cosmetic or pharmaceutical compositions.
본 발명의 조성물에서 상기 약물의 함량은 0.01%~100 중량%이다. The content of the drug in the composition of the present invention is 0.01% to 100% by weight.
본 발명에 따라, 물과 함께 직접 섭취하거나 기타 임의의 공지 수단에 의해 섭취할 수 있는 담체를 포함하며, 상기 조성물의 0.001내지 100 %의 투여량을 함유하는 당의정, 환제, 젤라틴 캡슐, 시럽, 겔, 크림 또는 박하 드롭스의 형태인 보조 식품을 또한 들 수 있다. 이 보조 식품은 추가적으로 감미료, 안정화제, 첨가제, 풍미제 및 색소를 함유한다.In accordance with the invention, dragees, pills, gelatin capsules, syrups, gels, which comprise a carrier which can be ingested directly with water or by any other known means, containing a dosage of 0.001 to 100% of the composition. Also included are supplements in the form of creams or peppermint drops. This supplement additionally contains sweeteners, stabilizers, additives, flavors and pigments.
또한, 상기 조성물은 당업자에게 공지된 피부 활성 화합물을 함유하는 화장용 제제일 수 있다. 본 발명은 또한 상기한 예비 조성물을 함유하는 화장용 조성물에 관한 것이다. 이 경우, 조성물중 약물의 함량은 0.01 중량% 이상 을 포함할 수 있다. 기타 화장용 활성 성분을 첨가할 수도 있다. 조성물은 유화제, 부형제, 색소, 향 또는 불투명화제 또한 조성물에 첨가될 수 있다In addition, the composition may be a cosmetic preparation containing a skin active compound known to those skilled in the art. The present invention also relates to a cosmetic composition containing the above preliminary composition. In this case, the content of the drug in the composition may comprise 0.01% by weight or more. Other cosmetically active ingredients may also be added. The composition can be added to the composition also emulsifiers, excipients, pigments, flavors or opacifiers.
본 발명의 일례에서, 상기 조성물은 약리적으로 허용되는 담체와 약물을 포함하는 약제 조성물일 수 있다.In one example of the invention, the composition may be a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a drug.
또한 약물은 총 중량부에 대하여 0.01 내지 100 중량부로 약제학적으로 허용되는 1종 이상의 담체에 첨가하여 약제로 제조할 수 있다. 상기 담체로는 식염수, 완충 식염수, 물, 글리세롤 및 에탄올 등이 있으나 이에 한정되지않으며, 당해 기술 분야에 알려진 적합한 제제(Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA)는 모두 사용 가능하다.The drug may also be prepared as a medicament by adding 0.01 to 100 parts by weight to one or more pharmaceutically acceptable carriers relative to the total weight. The carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
상기 조성물은 경구제, 과립제, 산제, 시럽제, 액제, 유동엑스제, 유제, 현탁제, 침제, 정제, 주사제, 캅셀제, 크림제, 트로키제, 파스타제 등의 제형으로 제조할 수 있으며, 경구 또는 비경구로 사용될 수 있다. 상기 조성물의 투여량은 통상적인 투여량으로, 일예로 1일 1 내지 100 mg의 약물을 사용할 수 있다. 상기 투여량은 이에 한정되진 않으며, 환자의 연령, 성별, 상태, 체내에서 활성 성분의 흡수도, 불활성율, 및 질병 종류 등에 따라 달리 적용되는 것이 바람직하다.The composition may be prepared in the form of oral preparations, granules, powders, syrups, solutions, liquid extracts, emulsions, suspensions, acupuncture tablets, injections, capsules, creams, troches, pasta preparations, oral or It can be used parenterally. Dosage of the composition is a conventional dosage, for example, from 1 to 100 mg of the drug can be used per day. The dosage is not limited thereto, and may be differently applied depending on the age, sex, condition, absorbency of the active ingredient in the body, inactivation rate, type of disease, and the like.
본 발명은 또한 약물을 유효성분으로 포함하는 소독제에 관한 것이다. 본 발명에 있어서 소독제란 병원성 미생물의 사멸, 생육 또는 감염억제, 및 항균 작용을 모두 포함하는 개념이다. 강력한 살균소독 기능을 적용하여 인체에 무해한 천연살균소독제로서 주방용품(도마, 칼, 냄비, 젓가락, 수저, 용기, 각종 기구)의 살균소독, 개인 세정용품 (구강세정제, 질세정제, 비누, 삼푸, 치약), 냉방기의 냉각수 살균소독, 냉방기 항균필터, 병원 및 가정을 포함하는 시설물 주변환경의 살균소독 등 천연 살균소독제를 포함하나 이에 한정되는 것이 아니다. 또한, 병원 및 일반가정의 수도배관,온수탱크, 물탱크, 또는 가습기용 소독제로 사용될 수 있다. The present invention also relates to a disinfectant comprising a drug as an active ingredient. In the present invention, the disinfectant is a concept including all killing, growth or infection of pathogenic microorganisms, and antibacterial action. It is a natural disinfectant that is harmless to human body by applying strong sterilization function, sterilization of kitchen utensils (cutting board, knife, pot, chopsticks, cutlery, container, various utensils), personal cleaning products (oral cleaner, vaginal cleaner, soap, shampoo, Toothpaste), natural water disinfectant, such as sterilization disinfection of the environment surrounding the facility, including the cooling water sterilization disinfection of the air conditioner, air conditioner antibacterial filter, hospitals and homes. It can also be used as a disinfectant for water pipes, hot water tanks, water tanks, or humidifiers in hospitals and homes.
덧붙여, 상기 “염”이란 약학적으로 허용 가능한 염의 형태로 사용할 수 있으며, 염으로는 약학적으로 허용 가능한 유리산(free acid)에 의해 형성된 산 부가염이 유용하다. 산 부가염은 염산, 질산, 인산, 황산, 브롬화수소산, 요드화수소산, 아질산 또는 아인산과 같은 무기산류와 지방족 모노 및 디카르복실레이트, 페닐-치환된 알카노에이트, 하이드록시 알카노에이트 및 알칸디오에이트, 방향족 산류, 지방족 및In addition, the "salt" may be used in the form of a pharmaceutically acceptable salt, and acid salts formed by pharmaceutically acceptable free acid are useful as salts. Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid and aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanes. Dioates, aromatic acids, aliphatic and
방향족 설폰산류와 같은 무독성 유기산으로부터 얻는다. 이러한 약학적으로 무독한 염류로는 설페이트, 피로설페이트, 바이설페이트, 설파이트, 바이설파이트, 니트레이트, 포스페이트, 모노하이드로겐 포스페이트, 디하이드로겐 포스페이트, 메타포스페이트, 피로포스페이트 클로라이드, 브로마이드, 아이오다이드, 플루오라이드, 아세테이트, 프로피오네이트, 데카노에이트, 카프릴레이트, 아크릴레이트, 포메이트, 이소부티레이트, 카프레이트, 헵타노에이트, 프로피올레이트, 옥살레이트, 말로네이트, 석시네이트, 수베레이트, 세바케이트, 푸마레이트, 말리에이트, 부틴-1,4-디오에이트, 헥산-1,6-디오에이트, 벤조에이트, 클로로벤조에이트, 메틸벤조에이트, 디니트로 벤조에이트, 하이드록시벤조에이트, 메톡시벤조에이트, 프탈레이트, 테레프탈레이트, 벤젠설포네이트, 톨루엔설포네이트, 클로로벤젠설포네이트, 크실렌설포네이트, 페닐아세테이트, 페닐프로피오네이트, 페닐부티레이트, 시트레이트, 락테이트, β-하이드록시부티레이트, 글리콜레이트, 말레이트, 타트레이트, 메탄설포네이트, 프로판설포네이트, 나프탈렌-1-설포네이트, 나프탈렌-2-설포네이트 또는 만델레이트를 포함한다.Obtained from non-toxic organic acids such as aromatic sulfonic acids. Such pharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, and iodide. Id, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suverate , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, meth Oxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesul Nate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1- Sulfonates, naphthalene-2-sulfonates or mandelate.
본 발명에 따른 산 부가염은 통상의 방법, 예를 들면, 화학식 1 또는 그 유도체를 과량의 산 수용액 중에 용해시키고, 이 염을 수혼화성 유기 용매, 예를 들면 메탄올, 에탄올, 아세톤 또는 아세토니트릴을 사용하여 침전시켜서 제조할 수 있다.The acid addition salts according to the present invention can be dissolved in conventional methods, for example, by dissolving Formula 1 or a derivative thereof in an excess aqueous solution of an acid, which salts are water-miscible organic solvents such as methanol, ethanol, acetone or acetonitrile. Can be prepared by precipitation.
상기 화학식 1의 약물 및 물 중의 산 또는 알코올을 가열하고, 이어서 이 혼합물을 증발시켜서 건조시키거나 또는 석출된 염을 흡입 여과시켜 제조할 수도 있다.The acid or alcohol in the drug of Formula 1 and water may be heated, and then the mixture may be evaporated to dryness, or the precipitated salt may be manufactured by suction filtration.
또한, 염기를 사용하여 약학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리 토금속 염은 예를 들면 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해하고, 비용해 화합물 염을 여과하고, 여액을 증발, 건조시켜 얻는다. 이때, 금속 염으로는 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 제약상 적합하다. 또한, 이에 대응하는 은 염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 음염(예, 질산은)과 반응시켜 얻는다.Bases can also be used to make pharmaceutically acceptable metal salts. Alkali metal or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium or calcium salt as the metal salt. Corresponding silver salts are also obtained by reacting alkali metal or alkaline earth metal salts with a suitable negative salt (eg, silver nitrate).
상기 조성물은 약학적 조성물로 사용될 경우, 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The composition may be various oral or parenteral dosage forms when used as a pharmaceutical composition. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
실시예EXAMPLE
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
특히, 하기 실시예에서는 A. baumanii AYE 또는 V. vulnificus CMCP6을 모델시스템으로 이용한 약물 표적 스크리닝 방법에 대하여만 예시되어 있으나, A. baumanii AYE 또는 V. vulnificus CMCP6 이외의 다른 병원성 미생물의 경우에도 적용된다는 것은 본 명세서에 개시된 내용으로부터 당업자에게 자명하다.In particular, the following examples illustrate only drug target screening methods using A. baumanii AYE or V. vulnificus CMCP6 as a model system, but are applicable to other pathogenic microorganisms other than A. baumanii AYE or V. vulnificus CMCP6. It is apparent to those skilled in the art from the contents disclosed herein.
실시예 1 미생물 대사 네트워크의 구축Example 1 Construction of a Microbial Metabolic Network
(1) A. baumanii AYE의 대사 네트워크의 구축(1) Construction of the metabolic network of A. baumanii AYE
컴퓨터를 이용하여 A. baumanii AYE의 약물 표적을 예측하기 위하여 다양한 데이터베이스 및 실험결과를 이용하여 게놈 수준의 대사 네트워크를 구축하였다.To predict the drug target of A. baumanii AYE using a computer, a genome-level metabolic network was constructed using various databases and experimental results.
KEGG(Kanehisa et al.. Nucleic Acids Res, 34:D354, 2006), TransportDB(Ren et al., PLoS Comput. Biol., 1:e27, 2005), MetaCyc(Caspi et al. Nucleic Acids Res., 36:D623, 2008)을 토대로 초기 버전의 대사 네트워크를 구축하였으며 게놈 정보를 토대로 효소 반응식의 방향성, 유전자단백질의 상관관계를 명확히 하였다. KEGG (Kanehisa et al..Nucleic Acids Res , 34: D354, 2006), TransportDB (Ren et al., PLoS Comput. Biol ., 1: e27, 2005), MetaCyc (Caspi et al. Nucleic Acids Res. , 36 (D623, 2008), an early version of the metabolic network was established, and genomic information was used to clarify the relationship between the directionality and the gene protein of the enzyme reaction.
하기 표 1에 나타낸 바와 같이, 구축된 A. baumanii AYE의 대사 네트워크는 891개의 생화학 반응식과 778개의 대사산물로 구성되어 있고, 이러한 대사 네트워크의 정보는 하기 650개의 유전자 정보가 담겨 있다. 하기 예측되는 약물 표적은 이들 반응식들로부터 선별하였다. As shown in Table 1 below, the constructed metabolic network of A. baumanii AYE consists of 891 biochemical schemes and 778 metabolites, and the information of this metabolic network contains the following 650 gene information. The predicted drug targets were selected from these schemes.
표 1
Table 1
No. | Metabolism | EC Number | ORF | Reaction | Enzyme |
R001 | Glycolysis/ Gluconeogenesis | 5.1.3.3 | ABAYE2829 | GLC<-> bDGLC | aldose 1-epimerase |
R002 | Glycolysis/ Gluconeogenesis | 5.3.1.9 | ABAYE3801 | G6P<-> bDG6P | glucose-6-phosphate isomerase |
R003 | Glycolysis/ Gluconeogenesis | 5.3.1.9 | ABAYE3801 | G6P<-> F6P | glucose-6-phosphate isomerase |
R004 | Glycolysis/ Gluconeogenesis | 5.3.1.9 | ABAYE3801 | bDG6P<-> F6P | glucose-6-phosphate isomerase |
R005 | Glycolysis/ Gluconeogenesis | 5.4.2.2 | ABAYE2928 OR ABAYE3800 | G6P<-> G1P | phosphoglucomutase OR phosphomannomutase |
R006 | Glycolysis/ Gluconeogenesis | 3.1.3.11 | ABAYE0899 | FDP-> F6P + PI | fructose-1,6-bisphosphatase |
R007 | Glycolysis/ Gluconeogenesis | 4.1.2.13 | ABAYE2088 | FDP<-> G3P + DHAP | fructose-1,6-bisphosphate aldolase |
R008 | Glycolysis/ Gluconeogenesis | 5.3.1.1 | ABAYE3443 | DHAP<-> G3P | triosephosphate isomerase |
R009 | Glycolysis/ Gluconeogenesis | 1.2.1.12 | ABAYE0958 | G3P+ PI + NAD <-> NADH + 13PDG | glyceraldehyde3-phosphatedehydrogenase |
R010 | Glycolysis/ Gluconeogenesis | 2.7.2.3 | ABAYE2090 | 13PDG+ ADP <-> 3PG + ATP | phosphoglyceratekinase |
R011 | Glycolysis/ Gluconeogenesis | 5.4.2.1 | ABAYE3537 | 3PG<-> 2PG | phosphoglycerate mutase |
R012 | Glycolysis/ Gluconeogenesis | 4.2.1.11 | ABAYE1669 | 2PG<-> PEP | enolase |
R013 | Glycolysis/ Gluconeogenesis | 2.3.1.12 | ABAYE0158 OR ABAYE1946 | COA+ ADLIPO -> DLIPO + ACCOA | pyruvate dehydrogenase E2 component (dihydrolipoamideacetyltransferase) |
R014 | Glycolysis/ Gluconeogenesis | 1.8.1.4 | ABAYE0505 OR ABAYE0782 OR ABAYE1945 | DLIPO+ NAD -> LIPO + NADH | dihydrolipoamidedehydrogenase |
R015 | Glycolysis/ Gluconeogenesis | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | ATP+ AC + COA <-> AMP + PPI + ACCOA | acetyl-CoA synthetase |
R016 | Glycolysis/ Gluconeogenesis | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | ACAL+ NAD -> NADH + AC | aldehydedehydrogenase |
R017 | Glycolysis/ Gluconeogenesis | 1.1.1.1 | ABAYE0763 OR ABAYE1463 OR ABAYE1522 OR ABAYE1861 OR p2ABAYE0004 OR p3ABAYE0020 OR p3ABAYE0024 | ACAL+ NADH <-> ETH + NAD | alcohol dehydrogenase |
R018 | Glycolysis/ Gluconeogenesis | 4.1.1.1 | ABAYE1030 | ACAL+ THMPP <-> 2(HE)TPP | pyruvate decarboxylase/indolepyruvate decarboxylase |
R019 | TCA cycle | 2.3.3.1 | ABAYE0773 | ACCOA+ OA -> COA + CIT | citrate synthase |
R020 | TCA cycle | 4.2.1.3 | ABAYE1432 OR ABAYE3228 OR ABAYE3791 | CIT<-> ICIT | aconitate hydratase |
R021 | TCA cycle | 1.1.1.42 | ABAYE0980 OR ABAYE0982 | ICIT+ NADP -> NADPH + AKG + CO2 | isocitrate dehydrogenase |
R022 | TCA cycle | 1.2.4.2 | ABAYE0780 | AKG+ LIPO -> SDLIPO + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R023 | TCA cycle | 2.3.1.61 | ABAYE0781 | SDLIPO+ COA -> DLIPO + SUCCOA | 2-oxoglutaratedehydrogenaseE2component |
R024 | TCA cycle | 6.2.1.5 | ABAYE0783 AND ABAYE0784 | ADP + PI + SUCCOA <-> ATP + SUCC + COA | succinyl-CoAsynthetase |
R025 | TCA cycle | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | SUCC+ FAD -> FUM + FADH2 | succinatedehydrogenase |
R026 | TCA cycle | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | FUM+ MKH2 -> SUCC + MK | fumaratereductase |
R027 | TCA cycle | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | FUM+ DMKH2 -> SUCC + DMK | fumaratereductase |
R028 | TCA cycle | 4.2.1.2 | ABAYE1563 OR ABAYE3284 | FUM<-> MAL | fumaratehydratase |
R029 | TCA cycle | 1.1.1.37 | ABAYE0465 | MAL+ NAD <-> NADH + OA | malatedehydrogenase |
R030 | Pentose phosphate pathway | 5.1.3.1 | ABAYE3114 | RL5P<-> X5P | D-ribulose-5-phosphate 3-epimerase |
R031 | Pentose phosphate pathway | 5.3.1.6 | ABAYE1650 | RL5P<-> R5P | ribose 5-phosphate isomerase A |
R032 | Pentose phosphate pathway | 2.2.1.1 | ABAYE2116 OR (ABAYE2823 AND ABAYE2824) | R5P+ X5P <-> G3P + S7P | transketolase |
R033 | Pentose phosphate pathway | 2.2.1.1 | ABAYE2116 OR (ABAYE2823 AND ABAYE2824) | X5P+ E4P <-> F6P + G3P | transketolase |
R034 | Pentose phosphate pathway | 2.2.1.2 | ABAYE1510 | G3P+ S7P <-> E4P + F6P | transaldolase |
R035 | Pentose phosphate pathway | 4.1.2.4 | DR5P-> G3P + ACAL | deoxyribose-phosphatealdolase | |
R036 | Pentose phosphate pathway | 5.4.2.7 | DR1P<-> DR5P | phosphopentomutase | |
R037 | Pentose phosphate pathway | 4.1.2.14 | ABAYE3280 | KDPG-> PYR + G3P | bifunctional 4-hydroxy-2-oxoglutarate aldolase OR 2-dehydro-3-deoxyphosphogluconate aldolase |
R038 | Pentose phosphate pathway | 2.7.1.12 | ABAYE3278 | GLUC+ ATP -> D6PGC + ADP | gluconokinase |
R039 | Pentose phosphate pathway | 4.2.1.12 | ABAYE3281 | D6PGC-> KDPG | phosphogluconate dehydratase |
R040 | Pentose phosphate pathway | 5.4.2.2 | ABAYE2928 OR ABAYE3800 | R1P<-> R5P | phosphoglucomutase OR phosphomannomutase |
R041 | Pentose and glucuronate interconversions | 1.1.1.22 | ABAYE3802 | UDPG+2NAD<-> UDPGLUC + 2 NADH | UDP-glucose 6-dehydrogenase |
R042 | Fructose and mannose metabolism | 2.7.1.56 | ABAYE1613 | F1P+ ATP -> FDP + ADP | fructose-1-phosphate kinase |
R043 | Fructose and mannose metabolism | 4.1.2.13 | ABAYE2088 | F1P-> DHAP + T3 | fructose-bisphosphate aldolase |
R044 | Fructose and mannose metabolism | 5.3.1.8 | MAN6P<-> F6P | phosphomannoseisomerase | |
R045 | Fructose and mannose metabolism | 5.4.2.8 | ABAYE2928 OR ABAYE3800 | MAN6P<-> MAN1P | phosphomannomutase |
R046 | Fructose and mannose metabolism | 2.7.7.13 | GTP+ MAN1P <-> PPI + GDPMAN | nucleoside-diphosphate-sugarpyrophosphorylase | |
R047 | Fructose and mannose metabolism | 1.1.1.- | ABAYE0043 OR ABAYE0109 OR ABAYE0479 OR ABAYE1356 OR ABAYE2589 OR ABAYE2607 OR ABAYE2613 OR ABAYE2618 OR ABAYE2845 OR ABAYE3187 OR ABAYE3378 | S6P+ NADP <-> SB1P + NADPH | alcoholdehydrogenase |
R048 | Fructose and mannose metabolism | 4.1.2.17 | ABAYE3670 | FUCP<-> DHAP + LACAL | aldolase class II |
R049 | Galactose metabolism | 5.1.3.2 | ABAYE1562 OR ABAYE3804 | UDPG<-> UDPGAL | UDP-glucose4-epimerase |
R050 | Galactose metabolism | 2.7.7.9 | ABAYE3803 | G1P+ UTP <-> UDPG + PPI | UTP-glucose-1-phosphate uridylyltransferase |
R051 | Ascorbate and aldarate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | DGLUCL+ NAD <-> DGLUCA + NADH | aldehyde dehydrogenase |
R052 | Starch and sucrose metabolism | 3.2.1.93 | TRE6P-> GLC + G6P | trehalose-6-phosphate hydrolase | |
R053 | Starch and sucrose metabolism | 2.4.1.15 | ABAYE3007 | UDPG+ G6P <-> UDP + TRE6P | trehalose-6-phosphate synthase |
R054 | Starch and sucrose metabolism | 3.1.3.12 | ABAYE3006 | TRE6P-> TRE + PI | trehalose-6-phosphate phophatase, biosynthetic |
R055 | Aminosugars metabolism | 2.6.1.16 | ABAYE0089 | F6P+ GLN -> GLU + GA6P | glucosamine-fructose-6-phosphateaminotransferase |
R056 | Aminosugars metabolism | 5.4.2.10 | ABAYE0167 | GA6P<-> GA1P | phosphomannomutase |
R057 | Aminosugars metabolism | 2.3.1.157 | ABAYE0090 | ACCOA+ GA1P -> NAGA1P + COA | glucosamine-1-phosphateN-acetyltransferase |
R058 | Aminosugars metabolism | 2.7.7.23 | ABAYE0090 | UTP+ NAGA1P <-> UDPNAG + PPI | UDP-N-acetylglucosaminepyrophosphorylase |
R059 | Aminosugars metabolism | 5.1.3.14 | ABAYE0969 | UDPNAG<-> NADMA + UDP | UDP-N-acetylglucosamine2-epimerase |
R060 | Aminosugars metabolism | 5.1.3.14 | ABAYE0969 | UDPNAG<-> UDPNADMA | UDP-N-acetylglucosamine 2-epimerase |
R061 | Aminosugars metabolism | 1.1.1.- | ABAYE3815 | UDPNADMA+2NAD-> UDPNADMAU + 2 NADH | UDP-N-acetyl-D-mannosaminuronatedehydrogenase |
R062 | Aminosugars metabolism | 2.5.1.7 | ABAYE3133 | UDPNAG+ PEP -> UDPNAGEP + PI | UDP-N-acetylglucosamine enolpyruvyl transferase |
R063 | Aminosugars metabolism | 1.1.1.158 | ABAYE1526 | UDPNAGEP+ NADPH -> UDPNAM + NADP | UDP-N-acetylenolpyruvoylglucosamine reductase |
R064 | Aminosugars metabolism | 3.2.1.- | ABAYE2663 | GLCAMN<-> GLCA + GLCAMN | bifunctionalprotein[includes:lyticmureintransglycosylaseC,membrane-bound |
R065 | Aminosugars metabolism | 3.2.1.52 | ABAYE3272 | CHITB -> 2 NAGA | beta-N-acetyl-D-glucosaminidase |
R066 | Aminosugars metabolism | 5.1.3.7 | ABAYE3814 | UDPNAG<-> UDPAGLACA | NAD-dependent epimerase/dehydratase |
R067 | Nucleotide sugars metabolism | 5.1.3.2 | ABAYE1562 OR ABAYE3804 | DTDPGLU<-> DTDPGLAC | UDP-glucose4-epimerase |
R068 | Nucleotide sugars metabolism | 2.7.7.24 | G1P + DTTP -> DTDPGLU + PPI | glucose-1-phosphatethymidylyltransferase | |
R069 | Nucleotide sugars metabolism | 4.2.1.46 | DTDPGLU -> DTDP4O6DG | dTDP-glucose 4,6 dehydratase | |
R070 | Nucleotide sugars metabolism | 5.1.3.13 | DTDP4O6DG -> DTDP4ORMNS | dTDP-4-deoxyrhamnose-3,5-epimerase | |
R071 | Nucleotide sugars metabolism | 1.1.1.133 | DTDP4ORMNS + NADPH -> DTDPRMNS + NADP | dTDP-4-dehydrorhamnose reductase | |
R072 | Pyruvate metabolism | 2.7.9.2 | ABAYE1391 | ATP+ PYR -> AMP + PEP + PI | phosphoenolpyruvate synthase |
R073 | Pyruvate metabolism | 1.1.1.28 | ABAYE3796 | PYR+ NADH <-> LAC + NAD | D-lactatedehydrogenase |
R074 | Pyruvate metabolism | 2.3.1.8 | ABAYE1138 OR ABAYE3283 | ACCOA+ PI <-> ACETYLP + COA | phosphateacetyltransferase |
R075 | Pyruvate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | AAD+ COA <-> AMP + ACCOA | acetyl-CoA synthase |
R076 | Pyruvate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | ATP+ AC <-> PPI + AAD | acetyl-CoA synthetase |
R077 | Pyruvate metabolism | 2.7.2.1 | ABAYE3282 | ACETYLP+ ADP <-> AC + ATP | acetate kinase |
R078 | Pyruvate metabolism | 4.1.1.31 | ABAYE0028 | PEP+ CO2 -> OA + PI | phosphoenolpyruvatecarboxylase |
R079 | Pyruvate metabolism | 1.1.1.38 OR 1.1.1.40 | ABAYE3731 OR ABAYE1138 | MAL+ NAD <-> PYR + CO2 + NADH | malate dehydrogenase |
R080 | Pyruvate metabolism | 1.1.1.38 OR 1.1.1.40 | ABAYE3731 OR ABAYE1138 | MAL+ NADP <-> PYR + CO2 + NADPH | malate dehydrogenase |
R081 | Pyruvate metabolism | 2.3.3.9 | ABAYE2053 | ACCOA+ GLX -> MAL + COA | malatesynthase |
R082 | Pyruvate metabolism | 2.3.1.9 | ABAYE0629 OR ABAYE0638 OR ABAYE1916 OR ABAYE2307 | 2ACCOA-> COA + AACCOA | acetyl-CoA acetyltransferase |
R083 | Pyruvate metabolism | 4.4.1.5 | ABAYE1052 | RGT+ MTG <-> LTG | lactoylglutathione lyase |
R084 | Pyruvate metabolism | 3.1.2.6 | ABAYE1362 OR ABAYE1940 | LTG-> RGT + LAC | hydroxyacylglutathionehydrolaseGloB |
R085 | Pyruvate metabolism | 1.1.2.3 | ABAYE3797 | SLAC+2FERIC<-> PYR + 2 FEROC | L-lactate dehydrogenase, FMN linked |
R086 | Pyruvate metabolism | 1.1.99.16 | ABAYE2869 | MAL+ FAD -> FADH2 + OA | malate dehydrogenase |
R087 | Pyruvate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | ACAL+ NADP <-> AC + NADPH | aldehyde dehydrogenase |
R088 | Pyruvate metabolism | 1.2.4.1 | ABAYE0157 OR (ABAYE1947 AND ABAYE1948) | 2(HE)TPP+ LIPO <-> ADLIPO + THMPP | pyruvate dehydrogenase subunit E1 |
R089 | Pyruvate metabolism | 2.3.3.13 | ABAYE3292 | IPPMAL+ COA <-> ACCOA + OIVAL | 2-isopropylmalate synthase |
R090 | Pyruvate metabolism | 4.1.1.- | ABAYE1027 | PYR+ CO2 <-> HEDC | L-2,4-diaminobutyrate decarboxylase |
R091 | Pyruvate metabolism | 4.1.1.32 | ABAYE0818 | GTP+ OA <-> GDP + PEP + CO2 | phosphoenolpyruvatecarboxykinase[GTP](PEPcarboxykinase) |
R092 | Pyruvate metabolism | 4.1.1.32 | ABAYE0818 | ITP+ OA <-> IDP + PEP + CO2 | phosphoenolpyruvate carboxykinase [GTP] (PEP carboxykinase) |
R093 | Glyoxylate and dicarboxylate metabolism | 4.1.3.1 | ABAYE2783 | ICIT-> SUCC + GLX | isocitratelyase |
R094 | Glyoxylate and dicarboxylate metabolism | 1.2.1.2 | ABAYE0850 | FORMATE+ NAD -> CO2 + NADH | formate dehydrogenase |
R095 | Glyoxylate and dicarboxylate metabolism | 1.2.1.21 | GLAL+ NAD -> NADH + GLYCOLATE | glycolaldehyde dehydrogenase | |
R096 | Glyoxylate and dicarboxylate metabolism | 3.1.3.18 | ABAYE0081 OR ABAYE2988 OR ABAYE3373 OR ABAYE3498 OR ABAYE3835 | 2PPG-> GLYCOLATE + PI | phosphoglycolate phosphatase |
R097 | Glyoxylate and dicarboxylate metabolism | 1.1.1.60 | ABAYE1786 | DGLYCERATE+ NAD <-> HOPP + NADH | 2-hydroxy-3-oxopropionate reductase OR tartronate semialdehyde reductase |
R098 | Glyoxylate and dicarboxylate metabolism | 1.1.1.60 | ABAYE1786 | DGLYCERATE+ NADP <-> HOPP + NADPH | 2-hydroxy-3-oxopropionate reductase OR tartronate semialdehyde reductase |
R099 | Glyoxylate and dicarboxylate metabolism | 1.1.1.93 | ABAYE2964 | MTTA+ NAD <-> 2H3OSUCC + NADH | tartrate dehydrogenase/decarboxylase OR D-malate dehydrogenase [decarboxylating] |
R100 | Glyoxylate and dicarboxylate metabolism | 1.1.1.93 | ABAYE2964 | TTA+ NAD <-> 2H3OSUCC + NADH | tartratedehydrogenase/decarboxylase OR D-malatedehydrogenase[decarboxylating] |
R101 | Glyoxylate and dicarboxylate metabolism | 2.3.3.9 | ABAYE2053 | MAL+ COA <-> ACCOA + GLX | malate synthase G |
R102 | Glyoxylate and dicarboxylate metabolism | 5.3.1.22 | ABAYE3188 | HPYR<-> HOPP | hydroxypyruvate isomerase |
R103 | Propanoate metabolism | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 OR ABAYE3470 | 3HPCOA<-> PPCOA | enoyl-CoA hydratase/isomerase OR 3-methylglutaconyl-CoA hydratase |
R104 | Propanoate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | ATP+ PROPANOATE <-> PPI + PPA | acetyl-CoAsynthetase |
R105 | Propanoate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | PPA+ COA <-> AMP + PPACOA | propionyl-CoA synthetase |
R106 | Propanoate metabolism | 2.7.2.1 | ABAYE3282 | PROPANOATE+ ATP <-> PROPIONYLP + ADP | acetate kinase |
R107 | Propanoate metabolism | 2.3.1.8 | ABAYE1138 OR ABAYE3283 | PPACOA+ PI <-> PROPIONYLP + COA | phosphate acetyltransferase |
R108 | Propanoate metabolism | 2.3.1.54 | OBUT+ COA <-> PPACOA + FORMATE | formateacetyltransferase | |
R109 | Propanoate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 2P1A+ NAD -> PPN + NADH | aldehydedehydrogenase |
R110 | Propanoate metabolism | 2.3.3.5 | ABAYE3792 | 2MCIT+ COA <-> PPACOA + OA | 2-methylcitrate synthase |
R111 | Propanoate metabolism | 4.1.3.30 | ABAYE3793 | 3HB123TC<-> PYR + SUCC | methylisocitrate lyase |
R112 | Propanoate metabolism | 1.2.1.27 | ABAYE1296 OR ABAYE3768 | MMSA+ COA + NAD -> PPACOA + CO2 + NADH | methylmalonate-semialdehydedehydrogenase |
R113 | Propanoate metabolism | 1.3.99.3 | ABAYE0476 OR ABAYE2013 | PPACOA+ FAD <-> FADH2 + PPCOA | acyl-CoA dehydrogenase |
R114 | Propanoate metabolism | 4.1.1.4 | ABAYE1742 | AAC-> ACTN + CO2 | acetoacetate decarboxylase |
R115 | Propanoate metabolism | 6.4.1.3 | ABAYE0480 | ATP+ PPACOA + HCO3 <-> ADP + PI + MMALCOA | propionyl-CoA carboxylase |
R116 | Glycolysis/Gluconeogensis/Butanoate metabolism | 2.2.1.6 OR 4.1.1.1 OR 1.2.4.1 | (ABAYE2836 OR ABAYE3239 OR ABAYE3240) OR ABAYE1030 OR ABAYE0157 OR (ABAYE1947 AND ABAYE1948) | THMPP+ PYR -> 2(HE)TPP + CO2 | acetolactatesynthaseORpyruvatedehydrogenase |
R117 | Butanoate metabolism | 2.2.1.6 | ABAYE2836 OR ABAYE3239 OR ABAYE3240 | 2(HE)TPP+ PYR -> ACLAC + THMPP | acetolactate synthase |
R118 | Butanoate metabolism | 1.1.1.35 | ABAYE1411 OR ABAYE2460 OR ABAYE3470 | 3HBCOA+ NAD <-> AACCOA + NADH | 3-hydroxyacyl-CoAdehydrogenase |
R119 | Butanoate metabolism | 5.1.2.3 | ABAYE0628OR ABAYE3470 | 3HBCOA<-> R3HBCOA | 3-hydroxybutyryl-CoAepimerase |
R120 | Butanoate metabolism | 4.2.1.17 | ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764 | 3HBCOA<-> CCOA | enoyl-CoA hydratase/isomerase OR 3-methylglutaconyl-CoA hydratase |
R121 | Butanoate metabolism | 1.1.1.- | ABAYE0043 OR ABAYE0109 OR ABAYE0479 OR ABAYE1356 OR ABAYE2589 OR ABAYE2607 OR ABAYE2613 OR ABAYE2618 OR ABAYE2845 OR ABAYE3187 OR ABAYE3378 | 1BOH+ NAD <-> BUTANAL + NADH | alcoholdehydrogenase |
R122 | Butanoate metabolism | 1.2.1.16 | ABAYE0210 OR ABAYE2329 OR ABAYE2958 | SUCCSA+ NAD -> SUCC + NADH | succinate-semialdehyde dehydrogenase |
R123 | Butanoate metabolism | 1.2.1.16 | ABAYE0210 OR ABAYE2329 OR ABAYE2958 | SUCCSA+ NADP -> SUCC + NADPH | succinate-semialdehyde dehydrogenase |
R124 | Butanoate metabolism | 2.6.1.19 | ABAYE0209 | GABA+ AKG <-> SUCCSA + GLU | 4-aminobutyrateaminotransferase |
R125 | Butanoate metabolism | 4.1.3.4 | ABAYE2292 OR ABAYE2344 | 3H3MGCOA-> ACCOA + AAC | hydroxymethylglutaryl-CoA lyase |
R126 | Butanoate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 3B1A+ NAD -> 3BUT + NADH | aldehydedehydrogenase |
R127 | Butanoate metabolism | 1.1.1.157 | ABAYE2306 OR ABAYE2368 | 3HBCOA+ NADP <-> AACCOA + NADPH | 3-hydroxybutyryl-CoA dehydrogenase |
R128 | Butanoate metabolism | 1.1.1.30 | ABAYE1909 | 3HBUT+ NAD <-> AAC + NADH | 3-hydroxybutyrate dehydrogenase |
R129 | Butanoate metabolism | 1.1.1.4 | ABAYE1943 | 23BOH+ NAD <-> ACT + NADH | (R,R)-butanediol dehydrogenase |
R130 | Butanoate metabolism | 1.1.1.5 | ABAYE1944 | DAC+ NADH -> ACT + NAD | acetoin dehydrogenase (DAC reductase) |
R131 | Butanoate metabolism | 1.1.1.5 | ABAYE1944 | DAC+ NADPH -> ACT + NADP | acetoin dehydrogenase (DAC reductase) |
R132 | Butanoate metabolism | 1.1.1.83 | ABAYE2964 | RMAL+ NAD -> PYR + CO2 + NADH | tartrate dehydrogenase/decarboxylase OR D-malate dehydrogenase [decarboxylating] |
R133 | Butanoate metabolism | 2.8.3.5 | ABAYE1913 AND ABAYE1914 | SUCCOA+ AAC <-> SUCC + AACCOA | acetoacetyl-CoA transferase |
R134 | Inositol metabolism | 1.2.1.27 | ABAYE1296 OR ABAYE3768 | 3OPP+ COA + NAD -> ACCOA + CO2 + NADH | NAD-dependent aldehyde dehydrogenase |
R135 | Oxidative phosphorylation | 1.6.5.3 AND 1.6.99.3 | (ABAYE3048 AND ABAYE3049 AND ABAYE3050 AND ABAYE3051 AND ABAYE3052 AND ABAYE3053 AND ABAYE3054 AND ABAYE3055 AND ABAYE3056 AND ABAYE3057 AND ABAYE3058 AND ABAYE3059 AND ABAYE3060) AND (ABAYE0977 OR ABAYE1736) | NADH+ UQ -> NAD + UQH2 | NADH dehydrogenase |
R136 | Oxidative phosphorylation | 1.6.5.3 AND 1.6.99.3 | (ABAYE3048 AND ABAYE3049 AND ABAYE3050 AND ABAYE3051 AND ABAYE3052 AND ABAYE3053 AND ABAYE3054 AND ABAYE3055 AND ABAYE3056 AND ABAYE3057 AND ABAYE3058 AND ABAYE3059 AND ABAYE3060) AND (ABAYE0977 OR ABAYE1736) | NADH+ MK -> NAD + MKH2 | NADH dehydrogenase |
R137 | Oxidative phosphorylation | 1.6.5.3 AND 1.6.99.3 | (ABAYE3048 AND ABAYE3049 AND ABAYE3050 AND ABAYE3051 AND ABAYE3052 AND ABAYE3053 AND ABAYE3054 AND ABAYE3055 AND ABAYE3056 AND ABAYE3057 AND ABAYE3058 AND ABAYE3059 AND ABAYE3060) AND (ABAYE0977 OR ABAYE1736) | NADH+ DMK -> NAD + DMKH2 | NADH dehydrogenase |
R138 | Oxidative phosphorylation | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | FADH2+ UQ -> FAD + UQH2 | succinatedehydrogenase |
R139 | Oxidative phosphorylation | 2.5.1.- AND 1.10.3.- | ABAYE1385AND ABAYE1386 AND ABAYE1387 AND ABAYE1388 AND ABAYE1389 AND ((ABAYE1636 AND ABAYE1637) OR ABAYE2219 AND ABAYE2220)) | UQH2+0.5O2-> UQ + 2 Hxt | cytochrome complexes |
R140 | Oxidative phosphorylation | 3.6.1.1 | ABAYE3675 | PPI -> 2 PI | inorganic diphosphatase |
R141 | ATP synthesis | 3.6.3.14 | ABAYE3715 AND ABAYE3716 AND ABAYE3717 AND ABAYE3718 AND ABAYE3719 AND ABAYE3720 AND ABAYE3721 AND ABAYE3723 | ADP+ PI + 4 Hxt <-> ATP | ATP synthase |
R142 | Oxidative phosphorylation | 2.7.4.1 | ABAYE2803 | ATP+ PPI <-> ADP + PPPI | polyphosphate kinase |
R143 | Nitrogen metabolism | 4.2.1.1 | ABAYE0262 OR ABAYE2809 | CO2-> HCO3 | carbonic anhydrase |
R144 | Nitrogen metabolism | 1.7.99.4 | ABAYE1546 | NO3+ FEROC -> FERIC + NO2 | nitrate reductase |
R145 | Nitrogen metabolism | 1.7.1.4 | ABAYE1544 | NO2+3NADH->3NAD+ NH3 | nitrite reductase |
R146 | Nitrogen metabolism | 1.7.1.4 | ABAYE1544 | NO2+3NADPH->3NADP+ NH3 | nitrite reductase |
R147 | Nitrogen metabolism | 4.3.1.1 | ABAYE1921 | ASP<-> FUM + NH3 | aspartate ammonia-lyase |
R148 | Nitrogen metabolism | 1.13.11.32 | ABAYE0966 OR ABAYE2310 | O2 + 2 2NPRPN <-> 2 ACTN + 2 NO2 | 2-nitropropane dioxygenase |
R149 | Nitrogen metabolism | 1.14.12.1 | ABAYE1896 AND ABAYE1897 | AN+ O2 + NADH <-> CATECHOL + NH3 + CO2 + NAD | anthranilate dioxygenase |
R150 | Nitrogen metabolism | 1.14.12.1 | ABAYE1896 AND ABAYE1897 | AN+ O2 + NADPH <-> CATECHOL + NH3 + CO2 + NADP | anthranilate dioxygenase |
R151 | Nitrogen metabolism | 1.4.1.13 | ABAYE0298 AND ABAYE0299 | 2GLU+ NADP <-> GLN + AKG + NADPH | glutamate synthase |
R152 | Nitrogen metabolism | 1.4.1.13 | ABAYE0298 AND ABAYE0299 | 2GLU+ NAD <-> GLN + AKG + NADH | glutamate synthase |
R153 | Nitrogen metabolism | 1.4.1.3 OR 1.4.1.4 | ABAYE0351 OR ABAYE2764 | GLU+ NAD <-> AKG + NH3 + NADH | glutamate dehydrogenase (NAD(P)+) oxidoreductase protein |
R154 | Nitrogen metabolism | 1.4.1.3OR1.4.1.4 | ABAYE0351ORABAYE2764 | GLU+ NADP <-> AKG + NH3 + NADPH | glutamatedehydrogenase,NADP-specific |
R155 | Nitrogen metabolism | 1.4.99.1 | ABAYE1567 OR ABAYE3774 | DALA+ FAD <-> PYR + NH3 + FADH2 | D-amino acid dehydrogenase |
R156 | Sulfur metabolism | 2.7.7.4 | ABAYE2790 AND ABAYE2791 | SLF+ ATP -> PPI + APS | sulfateadenylyltransferase |
R157 | Sulfur metabolism | 2.7.1.25 | APS+ ATP -> ADP + PAPS | adenylylsulfate kinase | |
R158 | Sulfur metabolism | 1.8.4.8 | ABAYE0709 | PAPS+ RTHIO -> OTHIO + H2SO3 + PAP | 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase) |
R159 | Sulfur metabolism | 1.8.1.2 | ABAYE0634 OR ABAYE0682 | H2SO3+3NADPH-> H2S + 3 NADP | sulfite reductase (NADPH) |
R160 | Sulfur metabolism | 3.1.3.7 | PAP-> PI + AMP | 3',5'-bisphosphate nucleotidase | |
R161 | Sulfur metabolism | 1.8.1.2 | ABAYE0634 | SELT+3NADP-> SELD + 3 NADPH | sulfite reductase (NADPH) |
R162 | Fattyacidbiosynthesis | 6.4.1.2AND 6.3.4.14 | (ABAYE0614ORABAYE1537ORABAYE1538ORABAYE3153)AND(ABAYE1537ORABAYE2291ORABAYE2438) | ACCOA+ ATP + HCO3 -> MALCOA + ADP + PI | acetyl-CoA carboxylase |
R163 | Fattyacidbiosynthesis | 2.3.1.39 | ABAYE2227 OR ABAYE2993 | MALCOA+ ACP -> MALACP + COA | malonyl CoA-acyl carrier protein transacylase |
R164 | Fattyacidbiosynthesis | 2.3.1.180 | ABAYE2562 | ACCOA+ ACP -> ACACP + COA | 3-oxoacyl-[acyl-carrier-protein] synthase |
R165 | Fattyacidbiosynthesis | PPACOA+ ACP -> PPAACP + COA | malonyl CoA-acyl carrier protein transacylase | ||
R166 | Fattyacidbiosynthesis (nonanoic acid; c9:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+3MALACP+6NADPH->6NADP+ C090ACP + 3 CO2 + 3 ACP | synthesis of nonanoyl-[acyl-carrier protein] |
R167 | Fattyacidbiosynthesis (decanoic acid; c10:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+4MALACP+8NADPH->8NADP+ C100ACP + 4 CO2 + 4 ACP | synthesis of decanoyl-[acyl-carrier protein] |
R168 | Fattyacidbiosynthesis (undecanoic acid; c11:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+4MALACP+8NADPH->8NADP+ C110ACP + 4 CO2 + 4 ACP | synthesis of undecanoyl-[acyl-carrier protein] |
R169 | Fattyacidbiosynthesis (dodecanoic acid; c12:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+5MALACP+10NADPH->10NADP+ C120ACP + 5 CO2 + 5 ACP | synthesis of dodecanoyl-[acyl-carrier protein] |
R170 | Fattyacidbiosynthesis (tridecanoic acid; c13:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+5MALACP+10NADPH->10NADP+ C130ACP + 5 CO2 + 5 ACP | synthesis of tridecanoyl-[acyl-carrier protein] |
R171 | Fattyacidbiosynthesis (tetradecanoic acid; c14:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+6MALACP+12NADPH->12NADP+ C140ACP + 6 CO2 + 6 ACP | synthesis of tetradecanoyl-[acyl-carrier protein] |
R172 | Fattyacidbiosynthesis (pentadecanoic acid; c15:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+6MALACP+12NADPH->12NADP+ C150ACP + 6 CO2 + 6 ACP | synthesis of pentadecanoyl-[acyl-carrier protein] |
R173 | Fattyacidbiosynthesis (pentadecenoic acid; c15:1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+6MALACP+11NADPH->11NADP+ C151ACP + 6 CO2 + 6 ACP | synthesis of pentadecenoyl-[acyl-carrier protein] |
R174 | Fattyacidbiosynthesis (hexadecanoic acid; c16:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+7MALACP+14NADPH->14NADP+ C160ACP + 7 CO2 + 7 ACP | synthesis of hexadecanoyl-[acyl-carrier protein] |
R175 | Fattyacidbiosynthesis (hexadecenoic acid; c16:1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+7MALACP+13NADPH->13NADP+ C161ACP + 7 CO2 + 7 ACP | synthesis of hexadecenoyl-[acyl-carrier protein] |
R176 | Fattyacidbiosynthesis (heptadecanoic acid; c17:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+7MALACP+14NADPH->14NADP+ C170ACP + 7 CO2 + 7 ACP | synthesis of heptadecanoyl-[acyl-carrier protein] |
R177 | Fattyacidbiosynthesis (heptadecenoic acid; c17:1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+7MALACP+13NADPH->13NADP+ C171ACP + 7 CO2 + 7 ACP | synthesis of heptadecenoyl-[acyl-carrier protein] |
R178 | Fattyacidbiosynthesis (octadecanoic acid; c18:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+8MALACP+16NADPH->16NADP+ C180ACP + 8 CO2 + 8 ACP | synthesis of octadecanoyl-[acyl-carrier protein] |
R179 | Fattyacidbiosynthesis (octadecenoic acid; c18:1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+8MALACP+15NADPH->15NADP+ C181ACP + 8 CO2 + 8 ACP | synthesis of octadecenoyl-[acyl-carrier protein] |
R180 | Fattyacidbiosynthesis (nonadecanoic acid; c19:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+8MALACP+16NADPH->16NADP+ C190ACP + 8 CO2 + 8 ACP | synthesis of nonadecanoyl-[acyl-carrier protein] |
R181 | Fattyacidbiosynthesis (nonadecenoic acid; c19:1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP+8MALACP+15NADPH->15NADP+ C191ACP + 8 CO2 + 8 ACP | synthesis of nonadecenoyl-[acyl-carrier protein] |
R182 | Fattyacidbiosynthesis (eicosanoic acid; c20:0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP+9MALACP+18NADPH->18NADP+ C200ACP + 9 CO2 + 9 ACP | synthesis of eicosanoyl-[acyl-carrier protein] |
R183 | Fattyacidmetabolism (decanoic acid; c10:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C100+5COA+4FAD+4NAD+ ATP -> 5 ACCOA + 4 FADH2 + 4 NADH + AMP + PPI | oxidation of decanoic acid |
R184 | Fattyacidmetabolism (dodecanoic acid; c12:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C120+6COA+5FAD+5NAD+ ATP -> 6 ACCOA + 5 FADH2 + 5 NADH + AMP + PPI | oxidation of dodecanoic acid |
R185 | Fattyacidmetabolism (tetradecanoic acid; c14:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C140+7COA+6FAD+6NAD+ ATP -> 7 ACCOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of tetradecanoic acid |
R186 | Fattyacidmetabolism (pentadecanoic acid; c15:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C150+7COA+6FAD+6NAD+ ATP -> 6 ACCOA + PPACOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of pentadecanoic acid |
R187 | Fattyacidmetabolism (hexadecanoic acid; c16:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C160+8COA+7FAD+7NAD+ ATP -> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecanoic acid |
R188 | Fattyacidmetabolism (hexadecenoic acid; c16:1) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C161+8COA+7FAD+7NAD+ ATP -> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecenoic acid |
R189 | Fattyacidmetabolism (heptadecanoic acid; c17:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C170+8COA+7FAD+7NAD+ ATP -> 7 ACCOA + PPACOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of heptadecanoic acid |
R190 | Fattyacidmetabolism (heptadecenoic acid; c17:1) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C171+8COA+7FAD+7NAD+ ATP -> 7 ACCOA + PPACOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of heptadecenoic acid |
R191 | Fattyacidmetabolism (octadecanoic acid; c18:0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C180+9COA+8FAD+8NAD+ ATP -> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecanoic acid |
R192 | Fattyacidmetabolism (octadecenoic acid; c18:1) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678)ANDABAYE1145AND(ABAYE0436ORABAYE1204ORABAYE2631)AND(ABAYE1411ORABAYE2460ORABAYE3470)AND(ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764)ANDABAYE3097ANDABAYE3471 | C181+9COA+8FAD+8NAD+ ATP -> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecenoic acid |
R193 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C120ACP+ O2 + RRBRDX <-> C120OH + ORBRDX + ACP | terminal alkane-1-monooxygenase |
R194 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C120ACP+ O2 + FADH2 <-> C120OH + FAD + ACP | terminal alkane-1-monooxygenase |
R195 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C140ACP+ O2 + RRBRDX <-> C140OH + ORBRDX + ACP | terminal alkane-1-monooxygenase |
R196 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C140ACP+ O2 + FADH2 <-> C140OH + FAD + ACP | terminal alkane-1-monooxygenase |
R197 | Fatty acid metabolism | 1.1.1.1 | ABAYE0763 OR ABAYE1463 OR ABAYE1522 OR ABAYE1861 OR p2ABAYE0004 OR p3ABAYE0020 OR p3ABAYE0024 | CH3OR+ NAD <-> RCHO + NADH | alcohol dehydrogenase |
R198 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | RH+ RRBRDX + O2 <-> ORBRDX + CH3OR | terminal alkane-1-monooxygenase |
R199 | Fatty acid metabolism | 1.18.1.1OR1.18.1.3 | (ABAYE1067 OR ABAYE2799) OR ABAYE2843 | RRBRDX+ NAD <-> ORBRDX + NADH | rubredoxin-NAD(+)reductaseORferredoxinreductasecomponent(dioxygenase) |
R200 | Fatty acid metabolism | 1.18.1.3 | ABAYE2843 | RRBRDX+ NADP <-> ORBRDX + NADPH | ferredoxinreductasecomponent(dioxygenase) |
R201 | Fatty acid metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | RCHO+NAD<->0.015C100+0.048C120+0.003C140+0.003C150+0.281C160+0.192C161+0.017C170+0.016C171+0.008C180+0.375C181+0.041C120OH+ NADH | aldehyde dehydrogenase |
R202 | Fatty acid metabolism | 5.3.3.8 | ABAYE3470 | C121COA<-> C122COA | fattyoxidationcomplexalphasubunit |
R203 | Biosynthesis of steroids | 2.2.1.7 | ABAYE0381 | PYR+ G3P -> DX5P + CO2 | 1-deoxy-D-xylulose-5-phosphate synthase |
R204 | Biosynthesis of steroids | 1.1.1.267 | ABAYE1581 | DX5P+ NADPH -> MDE4P + NADP | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
R205 | Biosynthesis of steroids | 2.7.7.60 | ABAYE1672 | MDE4P+ CTP -> CDPMDE + PPI | 4-diphosphocytidyl-2-methyl-D-erythritol synthase |
R206 | Biosynthesis of steroids | 4.6.1.12 | ABAYE1569 | 2PCDPMDE-> MDECPP + CMP | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase |
R207 | Biosynthesis of steroids | 1.17.4.3 | ABAYE3263 | MDECPP+ NADH -> NAD + HMB4PP | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase |
R208 | Biosynthesis of steroids | 1.17.1.2 | ABAYE0313 | HMB4PP+ NADH -> NAD + IPP | 4-hydroxy-3-methylbut-2-enyl diphosphate reductase |
R209 | Biosynthesis of steroids | 2.5.1.10 | ABAYE0722 | DMPP+ IPP -> GPP + PPI | geranylgeranyl pyrophosphate synthase |
R210 | Biosynthesis of steroids | 2.5.1.10 | ABAYE0722 | GPP+ IPP -> FPP + PPI | geranylgeranyl pyrophosphate synthase |
R211 | Biosynthesis of steroids | GGPP+ IPP -> PPPP + PPI | dimethylallyltranstransferase | ||
R212 | Biosynthesis of steroids | HEPPP+ IPP -> OPP + PPI | trans-hexaprenyltranstransferase | ||
R213 | Glycerolipid metabolism | 2.7.1.31 | ABAYE0849 | 3PG+ ADP <-> DGLYCERATE + ATP | glycerate kinase |
R214 | Glycerolipid metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | NADH+ DGLYCERATE <-> T3 + NAD | aldehydedehydrogenase |
R215 | Glycerolipid metabolism | 2.7.1.30 | ABAYE0816 | GL+ ATP -> GL3P + ADP | glycerolkinase |
R216 | Glycerolipid metabolism | 3.1.1.3 | ABAYE0325 OR ABAYE2810 | DGR-> AGL + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | triacylglycerol lipase |
R217 | Glycerolipid metabolism | 3.1.1.3 | ABAYE0325 OR ABAYE2810 | TGL-> DGR + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | triacylglycerol lipase |
R218 | Glycerolipid metabolism | 2.3.1.15 | ABAYE0397 | GL3P+ACCOA-> AGL3P + COA | glycerol-3-phosphate acyltransferase |
R219 | Glycerolipid metabolism | 2.3.1.20 | ABAYE0708 | TGL+ COA -> DGR + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | bifunctional protein [wax ester synthase / acyl-CoA:diacylglycerol acyltransferase] |
R220 | Glycerophospholipid metabolism | 1.1.1.94 | ABAYE1223 | DHAP+ NADH -> GL3P + NAD | glycerol-3-phosphate dehydrogenase |
R221 | Glycerophospholipid metabolism | 1.1.1.94 | ABAYE1223 | DHAP+ NADPH -> GL3P + NADP | glycerol-3-phosphate dehydrogenase |
R222 | Glycerophospholipid metabolism | 1.1.99.5 | ABAYE0817 | DHAP+ UQH2 <-> GL3P + UQ | glycerol-3-phosphatedehydrogenase |
R223 | Glycerophospholipid metabolism | 1.1.99.5 | ABAYE0817 | DHAP+ MKH2 <-> GL3P + MK | glycerol-3-phosphatedehydrogenase |
R224 | Glycerophospholipid metabolism | 1.1.99.5 | ABAYE0817 | DHAP+ DMKH2 <-> GL3P + DMK | glycerol-3-phosphatedehydrogenase |
R225 | Glycerophospholipid metabolism | 2.3.1.- | ABAYE0497 OR ABAYE0625 OR ABAYE1513 OR ABAYE1675 OR ABAYE1715 OR ABAYE1811 OR ABAYE2153 OR ABAYE2367 OR ABAYE2457 OR ABAYE2483 OR ABAYE3572 OR ABAYE3588 OR ABAYE3697 OR ABAYE3807 | GL3P+ ACOA -> 2AGL3P + COA | acetyltransferase |
R226 | Glycerophospholipid metabolism | 2.3.1.15 | ABAYE0397 | GL3P+0.015C100ACP+0.048C120ACP+0.003C140ACP+0.003C150ACP+0.281C160ACP+0.192C161ACP+0.017C170ACP+0.016C171ACP+0.008C180ACP+0.375C181ACP+0.041C120OH-> AGL3P + 0.958 ACP | glycerol-3-phosphate O-acyltransferase |
R227 | Glycerophospholipid metabolism | 2.3.1.51 | AGL3P+0.015C100ACP+0.048C120ACP+0.003C140ACP+0.003C150ACP+0.281C160ACP+0.192C161ACP+0.017C170ACP+0.016C171ACP+0.008C180ACP+0.375C181ACP+0.041C120OH-> PA + 0.958 ACP | 1-acylglycerol-3-phosphate O-acyltransferase | |
R228 | Glycerophospholipid metabolism | 2.7.1.107 | ABAYE0824 | DGR+ ATP -> ADP + PA | diacylglycerol kinase |
R229 | Glycerophospholipid metabolism | 3.1.1.32 | ABAYE1646 | PC-> 2AG3PC + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | phospholipase |
R230 | Glycerophospholipid metabolism | 3.1.4.46 | ABAYE0604 OR ABAYE0826 | G3PC-> CHOLINE + GL3P | glycerophosphoryl diester phosphodiesterase |
R231 | Glycerophospholipid metabolism | 2.7.7.41 | ABAYE1580 | PA+ CTP <-> CDPDG + PPI | phosphatidate cytidylyltransferase |
R232 | Glycerophospholipid metabolism | 2.7.8.8 | ABAYE0470 | CDPDG+ SER <-> CMP + PS | phosphatidylserine synthase |
R233 | Glycerophospholipid metabolism | 3.1.1.32 | ABAYE1646 | PS-> 2AG3PS + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | phospholipase |
R234 | Glycerophospholipid metabolism | 4.1.1.65 | ABAYE0104 | PS-> PE + CO2 | phosphatidylserinedecarboxylase |
R235 | Glycerophospholipid metabolism | 3.1.1.32 | ABAYE1646 | PE-> 2AG3PE + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | phospholipase |
R236 | Glycerophospholipid metabolism | 3.1.4.46 | ABAYE0604 OR ABAYE0826 | G3PE-> ETHA + GL3P | glycerophosphoryl diester phosphodiesterase |
R237 | Glycerophospholipid metabolism | 2.7.8.5 | ABAYE3463 | CDPDG+ GL3P <-> CMP + PGP | CDP-diacylglycerol--glycerol-3-phosphate3-phosphatidyltransferase |
R238 | Glycerophospholipid metabolism | 3.1.3.27 | ABAYE0091 OR ABAYE0749 OR ABAYE3269 | PGP-> PI + PG | phosphatidylglycerophosphatase |
R239 | Glycerophospholipid metabolism | 2.7.8.- | CDPDG+ PG -> CMP + CL | cardiolipin synthase | |
R240 | Glycerophospholipid metabolism | 3.1.4.3 | ABAYE1520 OR ABAYE3825 | PC<-> DGR + CHOLINEP | phospholipase C precursor (phosphatidylcholine cholinephosphohydrolase) (phosphatidylcholine-hydrolyzing phospholipase C) |
R241 | Glycerophospholipid metabolism | 3.1.4.3 | ABAYE1520 OR ABAYE3825 | PE<-> DGR + ETHAP | phospholipase C precursor (phosphatidylcholine cholinephosphohydrolase) (phosphatidylcholine-hydrolyzing phospholipase C) |
R242 | Glycerophospholipid metabolism | 3.1.4.3 | ABAYE1520 OR ABAYE3825 | PG<-> DGR + GL3P | phospholipase C precursor (phosphatidylcholine cholinephosphohydrolase) (phosphatidylcholine-hydrolyzing phospholipase C) |
R243 | Glycerophospholipid metabolism | 4.3.1.7 | ABAYE1457 AND ABAYE1458 | ETHA<-> ACAL + NH3 | ethanolamine ammonia-lyase |
R244 | Purinemetabolism | 2.7.6.1 | ABAYE1789 OR ABAYE2981 | R5P+ ATP <-> PRPP + AMP | ribose-phosphate pyrophosphokinase |
R245 | Purine metabolism (De novo) | 2.4.2.14 | ABAYE1280 | PRPP+ GLN -> PRAM + PPI + GLU | amidophosphoribosyltransferase |
R246 | Purine metabolism (De novo) | 6.3.4.13 | ABAYE1366 | PRAM+ ATP + GLY <-> GAR + ADP + PI | phosphoribosylamine-glycine ligase |
R247 | Purine metabolism (De novo) | 2.1.2.2 | ABAYE0888 OR ABAYE2179 | GAR+ FTHF -> FGAR + THF | phosphoribosylglycinamideformyltransferase |
R248 | Purine metabolism (De novo) | 6.3.5.3 | ABAYE0912 | FGAR+ ATP + GLN -> FGAM + GLU + ADP + PI | phosphoribosylformylglycinamidine synthase |
R249 | Purine metabolism (De novo) | 6.3.3.1 | ABAYE0889 | FGAM+ ATP -> AIR + ADP + PI | phosphoribosylformylglycinamidine cyclo-ligase |
R250 | Purine metabolism (De novo) | 4.1.1.21 | ABAYE3871 AND ABAYE3872 | AIR+ CO2 + ATP -> CAIR + ADP + PI | phosphoribosylaminoimidazolecarboxylase |
R251 | Purine metabolism (De novo) | 6.3.2.6 | ABAYE0056 | CAIR+ ATP + ASP <-> SAICAR + ADP + PI | phosphoribosylaminoimidazole-succinocarboxamide synthase |
R252 | Purine metabolism (De novo) | 4.3.2.2 | ABAYE1039 | SAICAR<-> AICAR + FUM | adenylosuccinatelyase |
R253 | Purine metabolism (De novo) | 2.1.2.3 | ABAYE1367 | AICAR+ FTHF <-> PRFICA + THF | phosphoribosylaminoimidazolecarboxamide formyltransferase |
R254 | Purine metabolism (De novo) | 3.5.4.10 | ABAYE1367 | PRFICA<-> IMP | phosphoribosylaminoimidazolecarboxamide formyltransferase; IMP cyclohydrolase |
R255 | Purine metabolism (De novo) | 6.3.4.4 | ABAYE2592 | IMP+ GTP + ASP -> ASUC + GDP + PI | adenylosuccinatesynthase |
R256 | Purine metabolism (De novo) | 4.3.2.2 | ABAYE1039 | ASUC<-> FUM + AMP | adenylosuccinatelyase |
R257 | Purine metabolism (De novo) | 1.1.1.205 | ABAYE0166 | IMP+ NAD -> XMP + NADH | IMP dehydrogenase |
R258 | Purine metabolism (De novo) | 6.3.5.2 | ABAYE1456 OR ABAYE3740 | XMP+ ATP + GLN -> GMP + GLU + AMP + PPI | GMP synthetase |
R259 | Purine metabolism | 3.5.4.4 | ABAYE2601 OR ABAYE3101 | ADN-> INS + NH3 | adenosinedeaminase |
R260 | Purine metabolism | 3.5.4.4 | ABAYE2601 OR ABAYE3101 | DA<-> DIN + NH3 | adenosine deaminase |
R261 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | IMP-> INS + PI | 5'-nucleotidase |
R262 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | AMP-> ADN + PI | 5'-nucleotidase |
R263 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | XMP-> XTSINE + PI | 5'-nucleotidase |
R264 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | GMP-> GSN + PI | 5'-nucleotidase |
R265 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DAMP<-> DA + PI | 5'-nucleotidase |
R266 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DGMP<-> DG + PI | 5'-nucleotidase |
R267 | Purine metabolism | 2.7.4.8 | ABAYE0312 | DGMP+ ATP <-> DGDP + ADP | guanylatekinase |
R268 | Purine metabolism | 2.7.4.6 | ABAYE3267 | IDP+ ATP <-> ITP + ADP | nucleoside-diphosphate kinase |
R269 | Purine metabolism | 2.7.4.6 | ABAYE3267 | ATP+ DIDP <-> ADP + DITP | nucleoside-diphosphatekinase |
R270 | Purine metabolism | 2.4.2.8 | ABAYE3887 | HYXN+ PRPP -> PPI + IMP | hypoxanthinephosphoribosyltransferase |
R271 | Purine metabolism | 2.4.2.8 | ABAYE3887 | XAN+ PRPP -> PPI + XMP | hypoxanthine phosphoribosyltransferase |
R272 | Purine metabolism | 2.4.2.8 | ABAYE3887 | AMP+ PPI <-> AD + PRPP | hypoxanthine phosphoribosyltransferase |
R273 | Purine metabolism | 3.1.5.1 | ABAYE0911 | DGTP-> DG + PPPI | dGTPtriphosphohydrolase |
R274 | Purine metabolism | 2.7.6.5 | ABAYE3181 | ATP+ GTP -> pppGpp + AMP | GTPpyrophosphokinase |
R275 | Purine metabolism | 3.1.7.2 | ABAYE0310 | ppGpp<-> GDP + PPI | guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase |
R276 | Purine metabolism | 2.7.4.3 | ABAYE2767 | ATP+ AMP <-> 2 ADP | adenylate kinase |
R277 | Purine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | ADP+ RTHIO -> DADP + OTHIO | ribonucleoside-diphosphatereductase |
R278 | Purine metabolism | 2.7.4.6 | ABAYE3267 | DADP+ ATP <-> DATP + ADP | nucleoside-diphosphate kinase |
R279 | Purine metabolism | 2.7.4.8 | ABAYE0312 | GMP+ ATP <-> GDP + ADP | guanylate kinase |
R280 | Purine metabolism | 2.7.4.6 | ABAYE3267 | GDP+ ATP <-> GTP + ADP | nucleoside-diphosphate kinase |
R281 | Purine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | GDP+ RTHIO -> DGDP + OTHIO | ribonucleoside-diphosphatereductase |
R282 | Purine metabolism | 2.7.4.6 | ABAYE3267 | DGDP+ ATP <-> DGTP + ADP | nucleoside-diphosphate kinase |
R283 | Purine metabolism | 3.6.1.13 | ABAYE3519 | ARIB-> AMP + R5P | ADPribose ribophosphohydrolase |
R284 | Purine metabolism | 2.7.4.3 | ABAYE2767 | ATP+ DAMP <-> ADP + DADP | adenylate kinase |
R285 | Purine metabolism | 3.6.1.41 | ABAYE0491 | AppppA -> 2 ADP | bis(5'-nucleosyl)-tetraphosphatase |
R286 | Purine metabolism | 1.17.1.4 | ABAYE1114 AND ABAYE1115 | HYXN+ NAD <-> XAN + NADH | xanthine dehydrogenase |
R287 | Purine metabolism | 1.17.1.4 | ABAYE1114 AND ABAYE1115 | XAN+ NAD <-> URT + NADH | xanthine dehydrogenase |
R288 | Purine metabolism | 3.5.3.19 | ABAYE0127 | UDGLYCOLATE<-> GLX + 2 NH3 + CO2 | ureidoglycolate amidohydrolase(decarboxylating) |
R289 | Purine metabolism | 3.5.3.4 | ABAYE0128 | ALLNT<-> UDGLYCOLATE + UREA | allantoicase |
R290 | Purine metabolism | 3.5.4.3 | ABAYE2396 OR ABAYE3885 | GN<-> XAN + NH3 | guanine deaminase |
R291 | Purine metabolism | 3.6.1.11 | ABAYE3154 | pppGpp-> ppGpp + PI | exopolyphosphatase (exopolypase) |
R292 | Purine metabolism | 3.6.1.15 | ABAYE3296 | ATP<-> ADP + PI | hypotheticalprotein |
R293 | Purine metabolism | 3.6.1.19 | ABAYE3179 | DITP-> DIMP + PPI | nucleoside-triphosphate pyrophosphatase |
R294 | Purine metabolism | 3.6.1.19 | ABAYE3179 | GTP-> GMP + PPI | nucleoside-triphosphate pyrophosphatase |
R295 | Purine metabolism | 3.6.1.19 | ABAYE3179 | ITP-> IMP + PPI | nucleoside-triphosphate pyrophosphatase |
R296 | Purine metabolism | 3.6.1.19 | ABAYE3179 | XTP-> XMP + PPI | nucleoside-triphosphate pyrophosphatase |
R297 | Purine metabolism | 3.6.1.19 | ABAYE3179 | DGTP-> DGMP + PPI | nucleoside-triphosphate pyrophosphatase |
R298 | Purine metabolism | 4.1.1.- | ABAYE1027 | 5AI+ CO2 <-> 5A4ICA | L-2,4-diaminobutyrate decarboxylase |
R299 | Pyrimidine metabolism (De novo) | 2.1.3.2 | ABAYE2578 | CAP+ ASP -> CAASP + PI | aspartatecarbamoyltransferase |
R300 | Pyrimidine metabolism (De novo) | 3.5.2.3 | ABAYE2577 OR ABAYE2646 | CAASP<-> DOROA | dihydroorotase |
R301 | Pyrimidine metabolism (De novo) | 1.3.3.1 | ABAYE1278 | DOROA+ UQ <-> UQH2 + OROA | dihydroorotateoxidase |
R302 | Pyrimidine metabolism (De novo) | 1.3.3.1 | ABAYE1278 | DOROA+ MK <-> MKH2 + OROA | dihydroorotateoxidase |
R303 | Pyrimidine metabolism (De novo) | 2.4.2.10 | ABAYE0144 | OROA+ PRPP <-> PPI + OMP | orotatephosphoribosyltransferase |
R304 | Pyrimidine metabolism (De novo) | 4.1.1.23 | ABAYE2058 | OMP-> CO2 + UMP | orotidine-5'-phosphatedecarboxylase |
R305 | Pyrimidine metabolism (De novo) | 2.7.4.6 | ABAYE3267 | UDP+ ATP <-> UTP + ADP | nucleoside-diphosphate kinase |
R306 | Pyrimidine metabolism (De novo) | 6.3.4.2 | ABAYE1667 | UTP+ GLN + ATP -> GLU + CTP + ADP + PI | CTPsynthase |
R307 | Pyrimidine metabolism | 6.3.4.2 | ABAYE1667 | ATP+ UTP + NH3 -> ADP + PI + CTP | CTPsynthase |
R308 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | CDP+ ATP <-> CTP + ADP | nucleoside-diphosphate kinase |
R309 | Pyrimidine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | CDP+ RTHIO -> DCDP + OTHIO | ribonucleoside-diphosphate reductase |
R310 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | DCDP+ ATP <-> DCTP + ADP | nucleoside-diphosphate kinase |
R311 | Pyrimidine metabolism | 2.7.4.9 | ABAYE0933 | DTMP+ ATP <-> DTDP + ADP | thymidylatekinase |
R312 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | DTDP+ ATP <-> DTTP + ADP | nucleoside-diphosphate kinase |
R313 | Pyrimidine metabolism | 2.7.4.14 | ABAYE2062 | CMP+ ATP <-> ADP + CDP | cytidylatekinase |
R314 | Pyrimidine metabolism | 1.8.1.9 | ABAYE2940 OR ABAYE3661 | OTHIO+ NADPH -> RTHIO + NADP | thioredoxinreductase |
R315 | Pyrimidine metabolism | 2.7.4.14 | ABAYE2062 | DCMP+ ATP <-> ADP + DCDP | cytidylatekinase |
R316 | Pyrimidine metabolism | 2.4.2.9 | ABAYE3047 | URA+ PRPP <-> UMP + PPI | uracilphosphoribosyltransferase |
R317 | Pyrimidine metabolism | 4.2.1.70 | ABAYE1445 | URA+ R5P <-> PURI5P | pseudouridylate synthase |
R318 | Pyrimidine metabolism | 2.1.1.45 | ABAYE3314 | DUMP+ METTHF -> DHF + DTMP | thymidylatesynthase |
R319 | Pyrimidine metabolism | 2.4.2.1 OR 2.4.2.4 | DU+ PI -> URA + DR1P | purine-nucleosidephosphorylaseORthymidinephosphorylase | |
R320 | Pyrimidine metabolism | 2.4.2.4 | DT+ PI -> TM + DR1P | thymidinephosphorylase | |
R321 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | DUDP+ ATP <-> DUTP + ADP | nucleoside-diphosphate kinase |
R322 | Pyrimidine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | UDP+ RTHIO -> OTHIO + DUDP | ribonucleoside-diphosphate reductase |
R323 | Pyrimidine metabolism | 2.7.4.9 | ABAYE0933 | ATP+ DUMP <-> ADP + DUDP | thymidylatekinase |
R324 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | UMP-> URI + PI | 5'-nucleotidase |
R325 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | CMP-> CYTD + PI | 5'-nucleotidase |
R326 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DCMP-> DC + PI | 5'-nucleotidase |
R327 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DTMP-> DT + PI | 5'-nucleotidase |
R328 | Pyrimidine metabolism | 3.5.4.1 | 5MC<-> TM + NH3 | cytosinedeaminase | |
R329 | Pyrimidine metabolism | 3.5.4.1 | CT-> URA + NH3 | cytosinedeaminase | |
R330 | Pyrimidine metabolism | 3.5.4.5 | DC-> DU + NH3 | cytidinedeaminase | |
R331 | Pyrimidine metabolism | 2.7.4.14OR2.7.4.22 | ABAYE2062ORABAYE1577 | ATP+ UMP <-> ADP + UDP | cytidylate kinase OR uridylate kinase |
R332 | Pyrimidine metabolism | 3.5.4.13 | ABAYE3025 | CTP-> UTP + NH3 | deoxycytidine triphosphate deaminase |
R333 | Pyrimidine metabolism | 3.5.4.13 | ABAYE3025 | DCTP-> DUTP + NH3 | deoxycytidine triphosphate deaminase |
R334 | Pyrimidine metabolism | 3.6.1.19 | ABAYE3179 | UTP-> UMP + PPI | nucleoside-triphosphate pyrophosphatase |
R335 | Pyrimidine metabolism | 3.6.1.19 OR 3.6.1.23 | ABAYE3179ORABAYE2929 | DUTP-> DUMP + PPI | nucleoside-triphosphatepyrophosphatase OR deoxyuridine 5'-triphosphate nucleotidohydrolase |
R336 | Glutamate metabolism | 6.3.1.2 | ABAYE1126 OR ABAYE1425 | GLU+ NH3 + ATP -> GLN + ADP + PI | glutaminesynthetase |
R337 | Glutamate metabolism | 1.4.1.13 OR 1.4.1.14 | ABAYE0298 AND ABAYE0299 | GLN+ AKG + NADPH -> 2 GLU + NADP | glutamatesynthase |
R338 | Glutamate metabolism | 6.3.5.5 | ABAYE0800 AND ABAYE0801 | GLN+2ATP+ HCO3 -> GLU + CAP + 2 ADP + PI | carbamoyl-phosphate synthase |
R339 | Glutamate metabolism | 6.1.1.17 | ABAYE0277 | TRNAGLU+ GLU + ATP -> GLUTRNAGLU + PPI + AMP | glutamyl-tRNAsynthetase |
R340 | Glutamate metabolism | 6.1.1.18 | ABAYE1455 | ATP+ GLN + TRNAGLN -> AMP + PPI + GTRNA | glutaminyl-tRNAsynthetase |
R341 | Glutamate metabolism | 3.5.1.2 OR 3.5.1.38 | ABAYE2832 OR ABAYE2188 | GLN-> GLU + NH3 | glutaminase OR glutaminase-asparaginase |
R342 | Glutamate metabolism | 6.3.5.7 | ABAYE0697 AND ABAYE0698 AND ABAYE0699 | GTRNA+ GLU + PI + ADP <-> GLUTRNAGLN + GLN + ATP | aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase |
R343 | Alanine and aspartate metabolism | 2.6.1.1 | ABAYE0951 | OA+ GLU <-> ASP + AKG | aspartateaminotransferase |
R344 | Alanine and aspartate metabolism | 6.1.1.12 | ABAYE0588 | ATP+ ASP + TRNAASP -> AMP + PPI + ASPTRNAASP | aspartyl-tRNAsynthetase |
R345 | Alanine and aspartate metabolism | 6.1.1.7 | ABAYE2595 | ATP+ ALA + TRNAALA <-> AMP + PPI + ALATRNA | alanyl-tRNA synthetase |
R346 | Alanine and aspartate metabolism | 6.3.5.4 | ASP+ ATP + GLN -> GLU + ASN + AMP + PPI | asparaginesynthase | |
R347 | Alanine and aspartate metabolism | 3.5.1.1 OR 3.5.1.38 | ABAYE3351 OR ABAYE2188 | ASN-> ASP + NH3 | L-asparaginase I OR glutaminase-asparaginase |
R348 | Alanine and aspartate metabolism | 3.4.13.3 | ABAYE1209 | CNS-> bALA + HIS | aminoacyl-histidine dipeptidase (peptidase D) |
R349 | Alanine and aspartate metabolism | 1.4.3.16 | ABAYE0935 | ASP+ O2 -> OA + NH3 + H2O2 | L-aspartate oxidase |
R350 | Alanine and aspartate metabolism | 5.1.1.13 | ABAYE1354 | ASP<-> DASP | aspartate/glutamate racemase |
R351 | Alanine and aspartate metabolism | 6.3.5.6 | ABAYE0697 AND ABAYE0698 AND ABAYE0699 | ASNTRNAASN+ GLU + PI + ADP <-> ASPTRNAASN + GLN + ATP | aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase |
R352 | Glycine, serine and threonine metabolism | 2.7.2.4 | ABAYE2596 | ASP+ ATP -> ADP + BASP | aspartate kinase |
R353 | Glycine, serine and threonine metabolism | 1.2.1.11 | ABAYE3348 | BASP+ NADPH -> NADP + PI + ASPSA | aspartate-semialdehyde dehydrogenase |
R354 | Glycine, serine and threonine metabolism | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | ASPSA+ NADH <-> NAD + HSER | homoserinedehydrogenase |
R355 | Glycine, serine and threonine metabolism | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | ASPSA+ NADPH <-> NADP + HSER | homoserinedehydrogenase |
R356 | Glycine, serine and threonine metabolism | 2.7.1.39 | ABAYE0244 | HSER+ ATP -> ADP + PHSER | homoserine kinase |
R357 | Glycine, serine and threonine metabolism | 4.2.3.1 | ABAYE3531 | PHSER-> THR + PI | threonine synthase |
R358 | Glycine, serine and threonine metabolism | 1.1.1.95 | ABAYE0332 | 3PG+ NAD -> NADH + PHP | D-3-phosphoglycerate dehydrogenase |
R359 | Glycine, serine and threonine metabolism | 2.6.1.52 | ABAYE0877 | PHP+ GLU -> AKG + 3PSER | phosphoserine aminotransferase |
R360 | Glycine, serine and threonine metabolism | 3.1.3.3 | ABAYE0098 | 3PSER-> PI + SER | phosphoserinephosphatase |
R361 | Glycine, serine and threonine metabolism | 2.1.2.1 | ABAYE1171 | THF+ SER <-> GLY + METTHF | serine hydroxymethyltransferase |
R362 | Glycine, serine and threonine metabolism | 1.8.1.4 | ABAYE0505 OR ABAYE0782 OR ABAYE1945 | DHLIPOYLPROTEIN+ NAD -> NADH + LIPOYLPROTEIN | dihydrolipoamide dehydrogenase |
R363 | Glycine,serineandthreoninemetabolism | 4.3.1.17 OR 4.3.1.19 | ABAYE2377 OR (ABAYE0691 OR ABAYE1083 OR ABAYE1649) | SER<-> PYR + NH3 | L-serine ammonia-lyase |
R364 | Glycine,serineandthreoninemetabolism | 4.3.1.19 | ABAYE0691 OR ABAYE1083 OR ABAYE1649 | THR-> OBUT + NH3 | threoninedehydratase |
R365 | Glycine, serine and threonine metabolism | 6.1.1.3 | ABAYE3169 | ATP+ THR + TRNATHR -> AMP + PPI + THRTRNATHR | threonyl-tRNA synthetase |
R366 | Glycine, serine and threonine metabolism | 6.1.1.11 | ABAYE0757 | ATP+ SER + TRNASER -> AMP + PPI + SERTRNASER | seryl-tRNAsynthetase |
R367 | Glycine, serine and threonine metabolism | 6.1.1.14 | ABAYE0367 AND ABAYE0368 | ATP+ GLY + TRNAGLY -> AMP + PPI + GLYTRNAGLY | glycyl-tRNA synthetase |
R368 | Glycine, serine and threonine metabolism | 2.6.1.76 | ABAYE1026 | GLU+ ASPSA -> AKG + 24DAB | glutamate decarboxylase |
R369 | Glycine, serine and threonine metabolism | 1.1.99.1 | ABAYE2868 | BAL+ FAD -> FADH2 + BETAINE | choline dehydrogenase |
R370 | Glycine, serine and threonine metabolism | 1.2.1.8 | ABAYE1066 OR ABAYE2867 | BAL+ NAD -> BETAINE + NADH | NAD-dependent aldehyde dehydrogenase |
R371 | Glycine, serine and threonine metabolism | 1.1.1.- | ABAYE0043 OR ABAYE0109 OR ABAYE0479 OR ABAYE1356 OR ABAYE2589 OR ABAYE2607 OR ABAYE2613 OR ABAYE2618 OR ABAYE2845 OR ABAYE3187 OR ABAYE3378 | MTG+ NADPH -> HAC + NADP | alcohol dehydrogenase |
R372 | Glycine, serine and threonine metabolism | 1.4.3.21 | ABAYE1710 | AACTN+ O2 <-> MTG + NH3 + H2O2 | copper amine oxidase precursor (tyramine oxidase) (2-phenylethylamine oxidase) |
R373 | Glycine, serine and threonine metabolism | 4.3.1.18 | ABAYE2819 | DSER<-> PYR + NH3 | D-serine deaminase (dehydratase) |
R374 | Methionine metabolism | 4.4.1.8 | ABAYE0405 | LLCT-> HCYS + PYR + NH3 | cystathionine beta-lyase, PLP-dependent |
R375 | Methionine metabolism | 2.1.1.13 | ABAYE2822 | HCYS+ MTHF <-> THF + MET | methionine synthase I |
R376 | Methionine metabolism | 2.1.1.14 | ABAYE3079 | 5MTGLU+ HCYS -> TGLU + MET | 5-methyltetrahydropteroyltriglutamate-homocysteinemethyltransferase |
R377 | Methionine metabolism | 6.1.1.10 | ABAYE3031 | ATP+ MET + TRNAMET -> AMP + PPI + METTRNA | methionyl-tRNA synthetase |
R378 | Methionine metabolism | 2.1.2.9 | ABAYE0022 | METTRNA+ FTHF -> THF + FMETTRNA | methionyl-tRNA formyltransferase |
R379 | Methionine metabolism | 2.5.1.6 | ABAYE2118 | MET+ ATP -> PPI + PI + SAM | S-adenosylmethionine synthetase |
R380 | Methionine metabolism | 3.2.2.9 | ABAYE3028 OR ABAYE3846 | SAH<-> SRLH + AD | S-adenosylhomocysteine nucleosidase |
R381 | Methionine metabolism | 2.1.1.37 | ABAYE0084 | SAM+ CT <-> SAH + 5MC | cytosine-specific methyltransferase |
R382 | Methionine metabolism | 2.3.1.31 | ABAYE3293 | ACCOA+ HSER <-> COA + OAHSER | homoserine O-acetyltransferase |
R383 | Methionine metabolism | 2.5.1.- | ABAYE1970 | OSLHSER+ H2S <-> HCYS + SUCC | O-succinylhomoserine sulfhydrylase |
R384 | Methionine metabolism | 2.5.1.49 | ABAYE0264 | OAHSER+ H2S <-> HCYS + AC | homocysteine synthase |
R385 | Methionine metabolism | 2.5.1.49 | ABAYE0264 | OAHSER+ HO3S2 + RTHIO <-> HCYS + H2SO3 + OTHIO + AC | homocysteine synthase |
R386 | Cysteine metabolism | 4.4.1.8 | ABAYE0405 | H2S+ PYR + NH3 -> CYS | cystathioninebeta-lyase |
R387 | Cysteine metabolism | 4.4.1.8 | ABAYE0405 | CYST-> PYR + NH3 + TCYS | cystathioninebeta-lyase |
R388 | Cysteine metabolism | 2.3.1.30 | ABAYE2191 OR ABAYE2248 | SER+ ACCOA <-> COA + ASER | serine acetyltransferase |
R389 | Cysteine metabolism | 2.5.1.47 | ABAYE3184 OR ABAYE3696 | ASER+ H2S -> CYS + AC | cysteine synthase |
R390 | Cysteine metabolism | 2.5.1.47 OR 2.5.1.49 | ABAYE3184 OR ABAYE3696 OR ABAYE0264 | ASER+ HO3S2 + RTHIO -> CYS + H2SO3 + OTHIO + AC | cysteine synthase |
R391 | Cysteine metabolism | 2.5.1.47 | ABAYE3184 OR ABAYE3696 | ASER+ HO3S2 -> SSLCYS + AC | cysteine synthase |
R392 | Cysteine metabolism | 2.6.1.1 | ABAYE0951 | CYSTEATE+ AKG <-> 3SPYR + GLU | aspartate aminotransferase |
R393 | Cysteine metabolism | 2.6.1.1 | ABAYE0951 | 3SLALA+ AKG -> 3SFPYR + GLU | aspartate aminotransferase |
R394 | Cysteine metabolism | 2.6.1.1 | ABAYE0951 | MPYR+ GLU -> CYS + AKG | aspartate aminotransferase |
R395 | Cysteine metabolism | 4.3.1.17 | ABAYE2377 | SER-> 2AA | L-serine dehydratase |
R396 | Cysteine metabolism | 6.1.1.16 | ABAYE2493 | ATP+ CYS + TRNACYS -> AMP + PPI + CYSTRNACYS | cysteinyl-tRNA synthetase |
R397 | Cysteine metabolism | 4.4.1.15 | ABAYE3037 | DCYS<-> H2S + NH3 + PYR | D-cysteine desulfhydrase |
R398 | Valine, leucine and isoleucine degradation | 1.1.1.31 | ABAYE3767 | HIBUT+ NAD -> 3OPP + NADH | 3-hydroxyisobutyrate dehydrogenase |
R399 | Valine, leucine and isoleucine degradation | 1.3.99.3 OR 1.3.99.10 | (ABAYE0476 OR ABAYE2013) OR ABAYE2288 | 3MBCOA+ FAD <-> 3MCCOA + FADH2 | acyl-CoA dehydrogenase |
R400 | Valine, leucine and isoleucine degradation | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 | 3HIVCOA<-> 3MCCOA | enoyl-CoA hydratase |
R401 | Valine, leucine and isoleucine degradation | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 | 2MP2ECOA-> 3HIBCOA | enoyl-CoA hydratase |
R402 | Valine, leucine and isoleucine degradation | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 | 3H2MBCOA-> 2MB2ECOA | enoyl-CoA hydratase |
R403 | Valine, leucine and isoleucine degradation | 6.4.1.4 | ABAYE0483 | ATP+ 3MCCOA + HCO3 -> ADP + PI + 3MGCOA | 3-methylcrotonyl-CoA carboxylase |
R404 | Valine, leucine and isoleucine degradation | 1.1.1.35 | ABAYE1411 OR ABAYE2460 OR ABAYE3470 | HIBUT+ NAD <-> MMSA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R405 | Valine, leucine and isoleucine degradation | 1.1.1.35 | ABAYE1411 OR ABAYE2460 OR ABAYE3470 | 3H2MBCOA+ NAD <-> 2MAACCOA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R406 | Valine, leucine and isoleucine degradation | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | MMSA+ NAD -> MM + NADH | aldehyde dehydrogenase |
R407 | Valine, leucine and isoleucine degradation | 2.3.1.16 | ABAYE3471 | COA+ 2MAACCOA -> PPACOA + ACCOA | acetyl-CoA acyltransferase |
R408 | Valine, leucine and isoleucine degradation | 1.3.99.3 | ABAYE0476 OR ABAYE2013 | 2MPPACOA+ FAD <-> 2MP2ECOA + FADH2 | acyl-CoA dehydrogenase |
R409 | Valine, leucine and isoleucine degradation | 1.3.99.3 | ABAYE0476 OR ABAYE2013 | 2MBCOA+ FAD <-> 2MB2ECOA + FADH2 | acyl-CoA dehydrogenase |
R410 | Valine, leucine and isoleucine degradation | 2.6.1.18 | ABAYE1295 | ALA+ MMSA <-> PYR + AIBUT | omega-aminoacid--pyruvateaminotransferase(omega-APT)(beta-alanine--pyruvateaminotransferase) |
R411 | Valine, leucine and isoleucine degradation | 2.6.1.42 | ABAYE0577 | ILE+ AKG <-> 3MOP + GLU | branched-chain amino acid transferase |
R412 | Valine, leucine and isoleucine degradation | 2.6.1.42 | ABAYE0577 | LEU+ AKG <-> 4MOP + GLU | branched-chain amino acid transferase |
R413 | Valine,leucineandisoleucinebiosynthesis | 1.1.1.86 | ABAYE3238 | ACLAC+ NADPH -> NADP + DHMVA | acetohydroxy acid isomeroreductase |
R414 | Valine,leucineandisoleucinebiosynthesis | 4.2.1.9 | ABAYE0023 OR ABAYE1724 OR ABAYE1781 | DHMVA-> OIVAL | dihydroxy-acid dehydratase OR 6-phosphogluconate dehydratase |
R415 | Valine,leucineandisoleucinebiosynthesis | 2.6.1.42 | ABAYE0577 | OIVAL+ GLU <-> AKG + VAL | branched-chain amino acid aminotransferase |
R416 | Valine, leucine and isoleucine biosynthesis | 2.2.1.6 | ABAYE2836 OR (ABAYE3239 AND ABAYE3240) | OBUT+ 2(HE)TPP -> ABUT + THMPP | acetolactate synthase |
R417 | Valine, leucine and isoleucine biosynthesis | 1.1.1.86 | ABAYE3238 | ABUT+ NADPH -> NADP + DHMP | ketol-acid reductoisomerase |
R418 | Valine, leucine and isoleucine biosynthesis | 4.2.1.9 | ABAYE0023 OR ABAYE1724 OR ABAYE1781 | DHMP-> 3MOP | dihydroxy-acid dehydratase |
R419 | Valine, leucine and isoleucine biosynthesis | 2.6.1.42 | ABAYE0577 | 3MOP+ GLU <-> AKG + ILE | branched-chain amino acid aminotransferase |
R420 | Valine, leucine and isoleucine biosynthesis | 2.3.3.13 | ABAYE3292 | ACCOA+ OIVAL -> COA + IPPMAL | isopropylmalate synthase |
R421 | Valine, leucine and isoleucine biosynthesis | 4.2.1.33 | ABAYE3359 AND ABAYE3360 | IPPMAL<-> CBHCAP | 3-isopropylmalatedehydratase |
R422 | Valine, leucine and isoleucine biosynthesis | 1.1.1.85 | ABAYE3357 | CBHCAP+ NAD -> NADH + OICAP | isopropylmalatedehydrogenase |
R423 | Valine, leucine and isoleucine biosynthesis | OICAP-> 4MOP + CO2 | spontaneous | ||
R424 | Valine, leucine and isoleucine biosynthesis | 2.6.1.42 | ABAYE0577 | 4MOP+ GLU <-> AKG + LEU | branched-chain amino acid aminotransferase |
R425 | Valine, leucine and isoleucine biosynthesis | 6.1.1.4 | ABAYE3244 | ATP+ LEU + TRNALEU -> AMP + PPI + LEUTRNA | leucyl-tRNA synthetase |
R426 | Valine, leucine and isoleucine biosynthesis | 6.1.1.9 | ABAYE0740 | ATP+ VAL + TRNAVAL -> AMP + PPI + VALTRNAVAL | valyl-tRNA synthetase |
R427 | Valine, leucine and isoleucine biosynthesis | 6.1.1.5 | ABAYE3852 | ATP+ ILE + TRNAILE -> AMP + PPI + ILETRNAILE | isoleucyl-tRNA synthetase |
R428 | Lysine biosynthesis | 4.2.1.52 | ABAYE0058 OR ABAYE2388 OR ABAYE2878 OR ABAYE3671 | ASPSA+ PYR -> DHDP | dihydrodipicolinate synthase |
R429 | Lysine biosynthesis | 1.3.1.26 | ABAYE0036 | DHDP+ NADPH -> NADP + TDHDP | dihydrodipicolinate reductase |
R430 | Lysine biosynthesis | 1.3.1.26 | ABAYE0036 | DHDP+ NADH -> NAD + TDHDP | dihydrodipicolinate reductase |
R431 | Lysine biosynthesis | 2.3.1.117 | ABAYE0923 | TDHDP+ SUCCOA -> SAOPIM + COA | 2,3,4,5-tetrahydropyridine-2,6-carboxylate N-succinyltransferase |
R432 | Lysine biosynthesis | 2.6.1.17 | ABAYE2181 | SAOPIM+ GLU -> SDAPIM + AKG | succinyldiaminopimelate transaminase |
R433 | Lysine biosynthesis | 3.5.1.18 | ABAYE0676 | SDAPIM-> DAPIM + SUCC | succinyl-diaminopimelate desuccinylase |
R434 | Lysine biosynthesis | 5.1.1.7 | ABAYE0861 | DAPIM<-> MDAPIM | diaminopimelate epimerase |
R435 | Lysine biosynthesis | 4.1.1.20 | ABAYE0860 | MDAPIM-> LYS + CO2 | diaminopimelate decarboxylase |
R436 | Lysine biosynthesis | 6.1.1.6 | ABAYE0854 OR ABAYE2794 | ATP+ LYS + TRNALYS -> AMP + PPI + LYSTRNA | lysyl-tRNAsynthetase |
R437 | Lysine biosynthesis | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | HSER+ NAD <-> ASPSA + NADH | homoserine dehydrogenase |
R438 | Lysine biosynthesis | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | HSER+ NADP <-> ASPSA + NADPH | homoserine dehydrogenase |
R439 | Lysine biosynthesis | 1.2.1.11 | ABAYE3348 | ASPSA+ PI + NADP <-> BASP + NADPH | aspartate-semialdehyde dehydrogenase |
R440 | Lysine degradation | 1.2.4.2 | ABAYE0780 | 2OAD+ LIPO -> SGDHL + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R441 | Lysine degradation | 2.3.1.61 | ABAYE0781 | GLUTCOA+ DLIPO <-> COA + SGDHL | 2-oxoglutarate dehydrogenase E2 component |
R442 | Lysine degradation | 1.14.13.59 | ABAYE1094 | LYS+ O2 + NADPH <-> NHLYS + NADP | acinetobactinsiderophorebiosynthesisproteinORlysineN6-hydroxylase |
R443 | Lysine degradation | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 4TMABT+ NAD <-> 4TMABTO + NADH | aldehyde dehydrogenase |
R444 | Lysine degradation | 1.3.99.7 | ABAYE3097 | GLUTCOA<-> CCOA + CO2 | glutaryl-CoA dehydrogenase |
R445 | Arginine and proline metabolism | 2.3.1.109 | ABAYE0353 | SUCCOA+ ARG -> COA + N2SUCCARG | arginine succinyltransferase |
R446 | Arginine and proline metabolism | 6.1.1.19 | ABAYE3732 | ATP+ ARG + TRNAARG <-> AMP + PPI + ARGTRNAARG | arginyl-tRNA synthetase |
R447 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | P5C+ NAD -> NADH + GLU | bifunctional proline dehydrogenase OR delta-1-pyrroline-5-carboxylate dehydrogenase |
R448 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | P5C+ NADP -> NADPH + GLU | bifunctional proline dehydrogenase OR delta-1-pyrroline-5-carboxylate dehydrogenase |
R449 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | GLUGSAL+ NAD -> NADH + GLU | 1-pyrroline-5-carboxylate dehydrogenase |
R450 | Arginine and proline metabolism | 1.5.99.8 | ABAYE2108 | PRO+ FAD -> P5C + FADH2 | proline dehydrogenase |
R451 | Arginine and proline metabolism | 6.1.1.15 | ABAYE0663 | ATP+ PRO + TRNAPRO -> AMP + PPI + PROTRNAPRO | prolyl-tRNA synthetase |
R452 | Arginine and proline metabolism | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | L1P3H5C+ NADH -> 4HPRO + NAD | pyrroline-5-carboxylate reductase |
R453 | Arginine and proline metabolism | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | L1P3H5C+ NADPH -> 4HPRO + NADP | pyrroline-5-carboxylate reductase |
R454 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | L1P3H5C+ NAD -> E4HGLU + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R455 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | L1P3H5C+ NADP -> E4HGLU + NADPH | 1-pyrroline-5-carboxylate dehydrogenase |
R456 | Arginine and proline metabolism | 1.5.1.12 OR 1.5.99.8 | ABAYE2108 | E4HGLU+ NAD <-> 4HGLUSA + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R457 | Arginine and proline metabolism | 2.6.1.1 | ABAYE0951 | E4HGLU+ AKG -> HYDROXYAKG + GLU | aspartate aminotransferase |
R458 | Arginine and proline metabolism | 4.1.2.14 | ABAYE3280 | HYDROXYAKG<-> PYR + GLX | 4-hydroxy-2-oxoglutaratealdolase |
R459 | Arginine and proline metabolism | 1.2.1.71 | ABAYE0354 | N2SUCCGLU5SA+ NAD -> N2SUCCGLU + NADH | succinylglutamic semialdehyde dehydrogenase |
R460 | Arginine and proline metabolism | 2.6.1.81 | ABAYE0352 | SORN+ AKG -> N2SUCCGLU5SA + GLU | succinylornithine transaminase |
R461 | Arginine and proline metabolism | 3.5.1.96 | ABAYE0356 | N2SUCCGLU-> GLU + SUCC | succinylglutamate desuccinylase |
R462 | Arginine and proline metabolism | 3.5.3.23 | ABAYE0355 | N2SUCCARG-> SORN + CO2 + 2 NH3 | succinylarginine dihydrolase |
R463 | Arginine and proline metabolism | 3.5.3.3 | p3ABAYE0029 | CRTN<-> SCSN + UREA | creatinase(Creatineamidinohydrolase) |
R464 | Arginine and proline metabolism | 5.1.1.4 | ABAYE2385 | PRO<-> DPRO | prolineracemase |
R465 | Histidine metabolism | 2.4.2.17 | ABAYE2593 OR ABAYE3132 | PRPP+ ATP -> PPI + PRBATP | ATP phosphoribosyltransferase |
R466 | Histidine metabolism | 3.6.1.31 | ABAYE3428 | PRBATP-> PPI + PRBAMP | phosphoribosyl-ATP pyrophosphohydrolase |
R467 | Histidine metabolism | 3.5.4.19 | ABAYE3428 | PRBAMP-> PRFP | phosphoribosyl-AMP cyclohydrolase |
R468 | Histidine metabolism | 5.3.1.16 | ABAYE0250 | PRFP-> PRLP | phosphoribosylformimino-5-aminoimidazolecarboxamideribotideisomerase |
R469 | Histidine metabolism | 2.4.2.- OR 4.1.3.- | ABAYE0243 OR ABAYE0253 | PRLP+ GLN -> GLU + AICAR + DIMGP | imidazoleglycerolphosphatesynthaseOR glutamine amidotransferase |
R470 | Histidine metabolism | 4.2.1.19 | ABAYE0254 | DIMGP-> IMACP | imidazoleglycerol-phosphate dehydratase |
R471 | Histidine metabolism | 2.6.1.9 | ABAYE3130 | IMACP+ GLU -> AKG + HISOLP | histidinol-phosphate aminotransferase |
R472 | Histidine metabolism | 3.1.3.15 | HISOLP-> PI + HISOL | histidinol-phosphatase | |
R473 | Histidine metabolism | 1.1.1.23 | ABAYE3131 | HISOL+2NAD-> HIS + 2 NADH | histidinol dehydrogenase |
R474 | Histidine metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | HIS+ SAM -> NMHIS + SAH | N6-adenine-specific methylase |
R475 | Histidine metabolism | 6.1.1.21 | ABAYE3262 | ATP+ HIS + TRNAHIS -> AMP + PPI + HISTRNAHIS | histidyl-tRNA synthetase |
R476 | Histidine metabolism | 4.3.1.3 | ABAYE0076 | HIS-> UC + NH3 | histidine ammonia-lyase |
R477 | Histidine metabolism | 4.2.1.49 | ABAYE0075 | UC-> 4I5P | urocanate hydratase |
R478 | Histidine metabolism | 3.5.2.7 | ABAYE0078 | 4I5P-> NFGLU | imidazolonepropionase |
R479 | Histidine metabolism | 3.5.3.8 | ABAYE0079 | NFGLU-> GLU + FA | formiminoglutamase |
R480 | Histidine metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | I4AA+ NAD -> I4AC + NADH | aldehyde dehydrogenase |
R481 | Histidine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | 2H5P<-> O2 + 2 4I5P | flavin-binding family monooxygenase |
R482 | Histidine metabolism | 4.1.1.22 | ABAYE1098 | HIS<-> HIEA + CO2 | histidine decarboxylase |
R483 | Tyrosine metabolism | 5.3.3.10 | ABAYE1465 | 5CM2HM-> 5C2O3E | 5-carboxymethyl-2-hydroxymuconate isomerase |
R484 | Tyrosine metabolism | 2.6.1.1 | ABAYE0951 | AKG+ TYR <-> 4HPP + GLU | aspartate aminotransferase |
R485 | Tyrosine metabolism | 1.13.11.27 | ABAYE0064 | 4HPP+ O2 -> HOMOGEN + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R486 | Tyrosine metabolism | 5.2.1.2 | ABAYE0067 | 4MAAC-> 4FAAC | maleylacetoacetate isomerase |
R487 | Tyrosine metabolism | 1.1.1.1 | ABAYE0763 OR ABAYE1463 OR ABAYE1522 OR ABAYE1861 OR p2ABAYE0004 OR p3ABAYE0020 OR p3ABAYE0024 | 34DHPEG+ NAD <-> 34DHMA + NADH | alcohol dehydrogenase |
R488 | Tyrosine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | TRM+ O2 + NADH <-> DPM + NAD | flavin-bindingfamilymonooxygenase |
R489 | Tyrosine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | 4HPACALO+ NADPH + O2 <-> 4HMN + NADP | flavin-bindingfamilymonooxygenase |
R490 | Tyrosine metabolism | 1.14.13.3 | ABAYE3078 | 3HPA+ O2 + NADH <-> 34DHPA + NAD | flavoproteinoxidoreductase |
R491 | Tyrosine metabolism | 1.14.13.3 | ABAYE3078 | 4HPA+ O2 + NADH <-> 34DHPA + NAD | flavoproteinoxidoreductase |
R492 | Tyrosine metabolism | 1.4.3.21 | ABAYE1710 | TRM+ O2 <-> 4HPACAL + NH3 + H2O2 | copperamineoxidaseprecursor(tyramineoxidase)(2-phenylethylamineoxidase) |
R493 | Tyrosine metabolism | 1.4.3.21 | ABAYE1710 | DPM+ O2 <-> DHPACAL + NH3 + H2O2 | copper amine oxidase precursor (tyramine oxidase) (2-phenylethylamine oxidase) |
R494 | Tyrosine metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | MTRM+ SAM <-> HDN + SAH | O-methyltransferase protein |
R495 | Tyrosine metabolism | 2.3.1.- | ABAYE0497 OR ABAYE0625 OR ABAYE1513 OR ABAYE1675 OR ABAYE1715 OR ABAYE1811 OR ABAYE2153 OR ABAYE2367 OR ABAYE2457 OR ABAYE2483 OR ABAYE3572 OR ABAYE3588 OR ABAYE3697 OR ABAYE3807 | 4HPACOA+ GLY <-> 4HPAGLY + COA | acyltransferase OR acetyl transferase OR acyl-CoA thiolase OR beta-ketoadipyl CoA thiolase OR GCN5-related N-acetyltransferase |
R496 | Tyrosine metabolism | 2.6.1.9OR2.6.1.57 | ABAYE3130ORABAYE3795 | TYR+ AKG <-> 4HPP + GLU | histidinol-phosphate aminotransferase OR tyrosine aminotransferase |
R497 | Tyrosine metabolism | 3.7.1.2 | ABAYE0068 | AAC+ FUM <-> 4FAAC | fumarylacetoacetase (fumarylacetoacetate hydrolase) |
R498 | Tyrosine metabolism | 4.1.1.- | ABAYE1027 | HOMOGEN+ O2 + NADPH <-> GENAL + CO2 + NADP | L-2,4-diaminobutyrate decarboxylase |
R499 | Tyrosine metabolism | 4.1.1.- | ABAYE1027 | DHI+ CO2 <-> CDHDHI | L-2,4-diaminobutyrate decarboxylase |
R500 | Tyrosine metabolism | 4.1.1.- | ABAYE1027 | DPCHR<-> DHI + CO2 | L-2,4-diaminobutyrate decarboxylase |
R501 | Phenylalanine metabolism | 2.6.1.1 OR 2.6.1.9 OR 2.6.1.57 | ABAYE0951 OR ABAYE3130 OR ABAYE3795 | PHE+ AKG <-> PHPYR + GLU | aspartate aminotransferase |
R502 | Phenylalanine metabolism | 1.13.11.27 | ABAYE0064 | PHPYR+ O2 -> 2HPA + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R503 | Phenylalanine metabolism | 1.4.99.1 | ABAYE1567 OR ABAYE3774 | DPHE+ FAD -> PHPYR + FADH2 + NH3 | D-amino-acid dehydrogenase |
R504 | Phenylalanine metabolism | 1.11.1.7 | ABAYE0619 | PHE<-> PAA | antioxidantprotein |
R505 | Phenylalanine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | 2HPA<-> DHPA | flavin-bindingfamilymonooxygenase |
R506 | Phenylalanine metabolism | 1.2.1.39 | ABAYE1712 | PACAL+ NAD <-> PLA + NADH | phenylacetaldehydedehydrogenase |
R507 | Phenylalanine metabolism | 1.4.3.21 | ABAYE1710 | PEA+ O2 <-> PACAL + NH3 + H2O2 | copperamineoxidaseprecursor(tyramineoxidase)(2-phenylethylamineoxidase) |
R508 | Phenylalanine metabolism | 2.3.1.- | ABAYE0497 OR ABAYE0625 OR ABAYE1513 OR ABAYE1675 OR ABAYE1715 OR ABAYE1811 OR ABAYE2153 OR ABAYE2367 OR ABAYE2457 OR ABAYE2483 OR ABAYE3572 OR ABAYE3588 OR ABAYE3697 OR ABAYE3807 | PACOA+ GLY <-> PACGLY + COA | acyltransferase OR acetyl transferase OR acyl-CoA thiolase OR beta-ketoadipyl CoA thiolase OR GCN5-related N-acetyltransferase |
R509 | Phenylalanine metabolism | 3.5.1.32 | ABAYE3086 | HIPPRT<-> BZ + GLY | hydrolase |
R510 | Phenylalanine metabolism | 3.5.1.4 | ABAYE1700 OR ABAYE2422 | PAA<-> PLA + NH3 | amidase |
R511 | Phenylalanine metabolism | 6.2.1.30 | ABAYE2366 | ATP+ PLA + COA <-> AMP + PPI + PACOA | phenylacetate-coenzyme A ligase (phenylacetyl-CoA ligase) |
R512 | Tryptophan metabolism | 6.1.1.2 | ABAYE0788 | ATP+ TRP + TRNATRP -> AMP + PPI + TRPTRNATRP | tryptophanyl-tRNA synthetase |
R513 | Tryptophan metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 5HIAA+ NAD -> 5HIAC + NADH | aldehyde dehydrogenase |
R514 | Tryptophan metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | I3AA+ NAD -> I3AC + NADH | aldehyde dehydrogenase |
R515 | Tryptophan metabolism | 1.11.1.6 | ABAYE2270 OR ABAYE2342 OR ABAYE3366 | 23HAN+2O2-> CVN + 2 H2O2 | catalase |
R516 | Tryptophan metabolism | 1.2.4.2 | ABAYE0780 | 2OAD+ COA + NAD -> GLUTCOA + CO2 + NADH | 2-oxoglutarate dehydrogenase E1 component |
R517 | Tryptophan metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | AEIOH+ MTHF <-> MOT + THF | methyltransferase |
R518 | Tryptophan metabolism | 3.5.1.4 | ABAYE1700 OR ABAYE2422 | I3AAM<-> I3AC + NH3 | amidase |
R519 | Tryptophan metabolism | 3.7.1.3 | ABAYE1599 | FKYN<-> FAN + ALA | L-kynurenine hydrolase |
R520 | Tryptophan metabolism | 3.7.1.3 | ABAYE1599 | KYN<-> AN + ALA | L-kynurenine hydrolase |
R521 | Tryptophan metabolism | 3.7.1.3 | ABAYE1599 | HKYN<-> 3HAN + ALA | L-kynurenine hydrolase |
R522 | Tryptophan metabolism | 4.1.1.74 | ABAYE1030 | IPYR<-> I3AA + CO2 | pyruvatedecarboxylaseORindolepyruvatedecarboxylase |
R523 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.5.1.54 | ABAYE1658 OR ABAYE1989 | E4P+ PEP -> PI + 3DDAH7P | 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase |
R524 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.3.4 | ABAYE0296 | 3DDAH7P-> DQT + PI | 3-dehydroquinate synthetase |
R525 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.10 | ABAYE1539 OR ABAYE1682 | DQT<-> DHSK | 3-dehydroquinate dehydratase II OR catabolic 3-dehydroquinate dehydratase (3-dehydroquinase) |
R526 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.1.1.25 | ABAYE0377 | DHSK+ NADPH -> SME + NADP | shikimate5-dehydrogenase |
R527 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.7.1.71 | ABAYE0295 | SME+ ATP -> ADP + SME3P | shikimate kinase |
R528 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.5.1.19 | ABAYE1207 | SME3P+ PEP -> 3PSME + PI | 3-phosphoshikimate 1-carboxyvinyltransferase |
R529 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.3.5 | ABAYE1953 | 3PSME-> PI + CHOR | chorismate synthase |
R530 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.1.3.27 | ABAYE1123 OR ABAYE3497 | CHOR+ GLN -> GLU + PYR + AN | anthranilate synthase |
R531 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.1.3.27 | ABAYE1123 OR ABAYE3497 | CHOR+ NH3 -> AN + PYR | anthranilate synthase |
R532 | Phenylalanine,tyrosineandtryptophanbiosynthesis | 2.4.2.18 | ABAYE1119 | AN+ PRPP -> PPI + NPRAN | anthranilate phosphoribosyltransferase |
R533 | Phenylalanine,tyrosineandtryptophanbiosynthesis | 5.3.1.24 | ABAYE0607 | NPRAN-> CPAD5P | phosphoribosylanthranilate isomerase |
R534 | Phenylalanine,tyrosineandtryptophanbiosynthesis | 4.1.1.48 | ABAYE1118 | CPAD5P-> CO2 + IGP | indole-3-glycerolphosphatesynthase |
R535 | Phenylalanine,tyrosineandtryptophanbiosynthesis | 4.2.1.20 | ABAYE0608ORABAYE0613ORABAYE1955 | IGP+ SER -> G3P + TRP | tryptophansynthase |
R536 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.20 | ABAYE0608 OR ABAYE1955 | SER+ INDOLE -> TRP | tryptophansynthase |
R537 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.20 | ABAYE0613 | INDOLE+ G3P <-> IGP | tryptophansynthase |
R538 | Phenylalanine, tyrosine and tryptophan biosynthesis | 5.4.99.5 | ABAYE1206 OR ABAYE1477 | CHOR<-> PHEN | chorismatemutase |
R539 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.51 | ABAYE1206 | PHEN-> CO2 + PHPYR | prephenate dehydratase |
R540 | Phenylalanine, tyrosine and tryptophan biosynthesis | 6.1.1.20 | ABAYE3159 AND ABAYE3160 | ATP+ PHE + TRNAPHE -> AMP + PPI + PHETRNAPHE | phenylalanyl-tRNA synthetase |
R541 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.3.1.12 | ABAYE1207 | PHEN+ NAD -> 4HPP + CO2 + NADH | prephenatedehydrogenase |
R542 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.6.1.1 OR 2.6.1.9 OR 2.6.1.57 | ABAYE0951ORABAYE3130ORABAYE3795 | 4HPP+ GLU -> AKG + TYR | histidinol-phosphate aminotransferase |
R543 | Phenylalanine, tyrosine and tryptophan biosynthesis | 6.1.1.1 | ABAYE0014 | ATP+ TYR + TRNATYR -> AMP + PPI + TRYTRNATYR | tyrosyl-tRNA synthetase |
R544 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.51 | ABAYE1206 | AG-> PHE + CO2 | prephenate dehydratase |
R545 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.1.99.25 | ABAYE1685 | QNT+ PQQ <-> PQQH2 + DQT | quinate/shikimate dehydrogenase |
R546 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.1.99.25 | ABAYE1685 | SME+ PQQ <-> DHSK + PQQH2 | quinate/shikimate dehydrogenase |
R547 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.-(QuiC) | ABAYE1683 | DHSK<-> 34DHB | 3-dehydroshikimate dehydratase OR DHS dehydratase) |
R548 | Urea cycle and metabolism of amino groups | 2.7.2.11 | ABAYE0962 | GLU+ ATP -> ADP + GLUP | glutamate 5-kinase |
R549 | Urea cycle and metabolism of amino groups | 1.2.1.41 | ABAYE3276 | GLUP+ NADPH -> NADP + PI + GLUGSAL | gamma-glutamyl phosphate reductase |
R550 | Urea cycle and metabolism of amino groups | GLUGSAL<-> P5C | spontaneous | ||
R551 | Urea cycle and metabolism of amino groups | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | P5C+ NADPH <-> PRO + NADP | pyrroline-5-carboxylate reductase |
R552 | Urea cycle and metabolism of amino groups | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | PRO+ NAD <-> P5C + NADH | pyrroline-5-carboxylate reductase |
R553 | Urea cycle and metabolism of amino groups | 2.3.1.1 | ABAYE3105 OR ABAYE3839 | GLU+ ACCOA -> COA + NAGLU | amino-acid N-acetyltransferase |
R554 | Urea cycle and metabolism of amino groups | 2.7.2.8 | ABAYE2927 | NAGLU+ ATP -> ADP + NAGLUP | acetylglutamate kinase |
R555 | Urea cycle and metabolism of amino groups | 1.2.1.38 | ABAYE1653 | NAGLUP+ NADPH -> NADP + PI + NAGLUS | N-acetyl-gamma-glutamyl-phosphate reductase |
R556 | Urea cycle and metabolism of amino groups | 2.6.1.11 | ABAYE1625 | NAGLUS+ GLU -> AKG + NAORN | acetylornithine aminotransferase |
R557 | Urea cycle and metabolism of amino groups | 2.3.1.35 | ABAYE3105 | NAORN + GLU <-> ORN + NAGLU | bifunctional ornithine acetyltransferase/N-acetylglutamate synthase |
R558 | Urea cycle and metabolism of amino groups | 2.1.3.3 | ABAYE1571 | ORN+ CAP <-> CITR + PI | ornithine carbamoyltransferase |
R559 | Urea cycle and metabolism of amino groups | 6.3.4.5 | ABAYE2641 | CITR+ ASP + ATP <-> AMP + PPI + ARGSUCC | argininosuccinate synthase |
R560 | Urea cycle and metabolism of amino groups | 4.3.2.1 | ABAYE3511 | ARGSUCC<-> FUM + ARG | argininosuccinatelyase |
R561 | Urea cycle and metabolism of amino groups | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | N4AAB+ NAD <-> 4AABUT + NADH | aldehyde dehydrogenase |
R562 | Urea cycle and metabolism of amino groups | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 4AB+ NADP <-> GABA + NADPH | aldehyde dehydrogenase |
R563 | Urea cycle and metabolism of amino groups | 3.2.2.9 | ABAYE3028 OR ABAYE3846 | 5MTA<-> AD + 5MDR | 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase |
R564 | Urea cycle and metabolism of amino groups | 3.4.13.3 | ABAYE1209 | HCNS<-> GABA + HIS | aminoacyl-histidinedipeptidase |
R565 | Urea cycle and metabolism of amino groups | 3.5.1.4 | ABAYE1700 OR ABAYE2422 | 4GBTA<-> 4GBTR + NH3 | amidase |
R566 | Urea cycle and metabolism of amino groups | 3.5.1.5 | ABAYE2776 AND ABAYE2777 AND ABAYE2778 | UREA<-> CO2 + 2 NH3 | urease |
R567 | Urea cycle and metabolism of amino groups | 3.5.1.54 | ABAYE2439 | U1C <-> 2 CO2 + 2 NH3 | allophanate hydrolase |
R568 | beta-Alanine metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | bAPA+ NAD -> bALA + NADH | aldehyde dehydrogenase (NAD+) |
R569 | beta-Alanine metabolism | 1.4.3.21 | ABAYE1710 | 13DAP+ O2 <-> 3AP + NH3 + H2O2 | copperamineoxidaseprecursor(tyramineoxidase)(2-phenylethylamineoxidase) |
R570 | beta-Alanine metabolism | 2.6.1.18 | ABAYE1295 | ALA+3OPP<-> PYR + bALA | omega-amino acid--pyruvate aminotransferase (omega-APT) (beta-alanine--pyruvate aminotransferase) |
R571 | beta-Alanine metabolism | 2.6.1.19 | ABAYE0209 | bALA+ AKG <-> OPP + GLU | 4-aminobutyrateaminotransferase,PLP-dependent |
R572 | beta-Alanine metabolism | 4.1.1.11 | ABAYE2984 | ASP-> bALA + CO2 | aspartate 1-decarboxylase precursor |
R573 | Taurine and hypotaurine metabolism | 1.14.11.17 | ABAYE2209 | TR+ AKG + O2 -> H2SO3 + AAA + SUCC + CO2 | taurine dioxygenase |
R574 | Taurine and hypotaurine metabolism | 2.3.2.2 | ABAYE2905 | 5GLUPEPT+ TR -> PEPTIDE + GLUTR | gamma-glutamyltranspeptidaseprecursor |
R575 | Aminophosphonate metabolism | 2.6.1.37 | ABAYE2318 | (2AE)P+ PYR <-> PPAC + ALA | 2-aminoethylphosphonate-pyruvate transaminase |
R576 | Aminophosphonate metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | MCB+ PPAC -> 2HPP + VB12 | N6-adenine-specificmethylase |
R577 | Aminophosphonate metabolism | 2.7.8.- | ABAYE1103 OR ABAYE3258 OR ABAYE3750 | CMPAEP+ NAS <-> NASAEP + CMP | 4'-phosphopantetheinyl transferase |
R578 | Aminophosphonate metabolism | 3.11.1.1 | ABAYE2317 | PPAC<-> ACAL + PI | phosphonoacetaldehydephosphonohydrolase(phosphonatase) |
R579 | Selenoamino acid metabolism | 4.4.1.8 | ABAYE0405 | SLLCT-> SHCYS + NH3 + PYR | cystathionine beta-lyase |
R580 | Selenoamino acid metabolism | SHCYS-> SMET | |||
R581 | Selenoamino acid metabolism | 6.1.1.10 | ABAYE3031 | ATP+ SMET + TRNAMET -> AMP + PPI + SMETTRNAMET | methionyl-tRNA synthetase |
R582 | Selenoamino acid metabolism | 2.5.1.6 | ABAYE2118 | ATP+ SMET -> PI + PPI + SeASMET | S-adenosylmethionine synthetase |
R583 | Selenoamino acid metabolism | 2.5.1.47 | ABAYE3184 OR ABAYE3696 | ASER+ SELD -> SCYS + AC | cysteine synthase |
R584 | Selenoamino acid metabolism | 2.7.7.4 | ABAYE2790 AND ABAYE2791 | ATP+ SELNT <-> PPI + ASELNT | sulfateadenylyltransferase |
R585 | Selenoamino acid metabolism | 2.3.2.2 | ABAYE2905 | 5GLUPEPT+ MSCYS -> PEPTIDE + GGLUMSCYS | gamma-glutamyltranspeptidase precursor |
R586 | Selenoamino acid metabolism | 3.3.1.1 | ABAYE1142 | SASHCYS<-> ADN + SHCYS | S-adenosyl-L-homocysteinehydrolase |
R587 | Selenoamino acid metabolism | 4.4.1.16 | ABAYE2250 | SCYS+ FADH2 <-> SELD + ALA + FAD | cysteinedesulfurase1ORselenocysteinelyase |
R588 | Cyanoamino acid metabolism | 2.3.2.2 | ABAYE2905 | CALA+ GLU -> GLUBCALA | gamma-glutamyltranspeptidaseprecursor |
R589 | Cyanoamino acid metabolism | 2.3.2.2 | ABAYE2905 | APN+ GLU -> GAPN | gamma-glutamyltranspeptidaseprecursor |
R590 | D-Glutamine and D-glutamate metabolism | 3.5.1.2 OR 3.5.1.38 | ABAYE2832 OR ABAYE2188 | DGLN-> DGLU + NH3 | glutaminase OR glutaminase-asparaginase |
R591 | D-Glutamine and D-glutamate metabolism | 5.1.1.3 | ABAYE0082 OR ABAYE3395 | DGLU<-> GLU | glutamateracemase |
R592 | D-Alanine metabolism | 5.1.1.1 | ABAYE1380 OR ABAYE3773 | ALA<-> DALA | alanine racemase |
R593 | D-Alanine metabolism | 6.3.2.4 | ABAYE0150 | 2DALA+ ATP -> ALAALA + ADP + PI | D-alanine-D-alanineligase |
R594 | Glutathione metabolism | 3.4.11.1 OR 3.4.11.2 OR 3.4.13.3 | ABAYE3540 OR ABAYE1469 OR ABAYE1209 | CYSGLY-> CYS + GLY | aminopeptidaseA(EC:3.4.11.1)ORmembranealanylaminopeptidaseORaminoacyl-histidinedipeptidase(peptidaseD)(EC:3.4.13.3) |
R595 | Glutathione metabolism | 1.11.1.9 | ABAYE2184 OR ABAYE3713 | H2O2+2RGT<-> OGT | glutathione peroxidase |
R596 | Glutathione metabolism | 2.3.2.2 | ABAYE2905 | RGT-> CYSGLY + GLU | gamma-glutamyltranspeptidaseprecursor |
R597 | Glutathione metabolism | 6.3.2.2 | ABAYE0116 | ATP+ GLU + CYS <-> ADP + PI + GCYS | gamma-glutamate-cysteine ligase |
R598 | Glutathione metabolism | 6.3.2.3 | ABAYE0147 | ATP+ GCYS + GLY <-> ADP + PI + RGT | glutathione synthetase |
R599 | Lipopolysaccharide biosynthesis | 2.3.1.129 | ABAYE1587 | C140ACP+ UDPNAG -> ACP + UDPG2AA | UDP-N-acetylglucosamine acyltransferase |
R600 | Lipopolysaccharide biosynthesis | 3.5.1.- | ABAYE0154 | UDPG2AA-> UDPG2A + AC | UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase |
R601 | Lipopolysaccharide biosynthesis | 2.3.1.- | ABAYE1585 | UDPG2A+ C140ACP -> ACP + UDPG23A | UDP-3-O-[3-hydroxymyristoyl]glucosamineN-acyltransferase |
R602 | Lipopolysaccharide biosynthesis | 3.6.1.- | ABAYE1453 | UDPG23A-> UMP + LIPX | UDP-2,3-diacylglucosamine hydrolase |
R603 | Lipopolysaccharide biosynthesis | 2.4.1.182 | ABAYE1983 | LIPX+ UDPG23A -> UDP + DISAC1P | lipid-A-disaccharidesynthase |
R604 | Lipopolysaccharide biosynthesis | 2.7.1.130 | ABAYE2077 | DISAC1P+ ATP -> ADP + LIPIV | tetraacyldisaccharide 4'-kinase |
R605 | Lipopolysaccharide biosynthesis | 2.-.-.- | ABAYE0175 | LIPIV+ CMPKDO -> KDOLIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R606 | Lipopolysaccharide biosynthesis | 2.-.-.- | ABAYE0175 | KDOLIPIV+ CMPKDO -> K2LIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R607 | Lipopolysaccharide biosynthesis | 2.3.1.- | ABAYE0885 OR ABAYE3343 | C140ACP+ LK2LIPIV -> K2LIPA + ACP | lipidAbiosynthesis(KDO)2-(lauroyl)-lipidivaacyltransferase |
R608 | Lipopolysaccharide biosynthesis | 5.3.1.13 | RL5P<-> A5P | D-arabinose 5-phosphate isomerase | |
R609 | Lipopolysaccharide biosynthesis | 2.5.1.55 | ABAYE1668 | PEP+ A5P -> KDOP + PI | 2-dehydro-3-deoxyphosphooctonate aldolase (KDO 8-P synthase) |
R610 | Lipopolysaccharide biosynthesis | 3.1.3.45 | ABAYE2491 | KDOP-> KDO + PI | 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase |
R611 | Lipopolysaccharide biosynthesis | 2.7.7.38 | ABAYE2076 | KDO+ CTP -> PPI + CMPKDO | 3-deoxy-manno-octulosonatecytidylyltransferase |
R612 | Peptidoglycan biosynthesis | 6.3.2.8 | ABAYE0149 | UDPNAM+ ALA + ATP -> ADP + PI + UDPNAMA | UDP-N-acetylmuramate--alanine ligase |
R613 | Peptidoglycan biosynthesis | 6.3.2.9 | ABAYE3524 | UDPNAMA+ DGLU + ATP -> UDPNAMAG + ADP + PI | UDP-N-acetylmuramoylalanine--D-glutamate ligase |
R614 | Peptidoglycan biosynthesis | 6.3.2.13 | ABAYE0283 | UDPNAMAG+ MDAPIM + ATP -> UDPMNLADGMD + ADP + PI | UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase |
R615 | Peptidoglycan biosynthesis | 6.3.2.10 | ABAYE0284 | UDPMNLADGMD+ ALAALA + ATP -> UDPMNLADGMDDADA + ADP + PI | UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase |
R616 | Peptidoglycan biosynthesis | 2.7.8.13 | ABAYE0285 | UDPMNLADGMDDADA+ UDCP -> UPPMNLADGMDDADA + UMP | phospho-N-acetylmuramoyl-pentapeptide-transferase |
R617 | Peptidoglycan biosynthesis | 2.4.1.227 | ABAYE0148 | UPPMNLADGMDDADA+ UDPNAG -> UPPMN(GN)LADGMDDADA + UDP | UDP-N-acetylglucosamine--Nacetylmuramyl-(pentapeptide)pyrophosphoryl-undecaprenolN-acetylglucosaminetransferase |
R618 | Peptidoglycan biosynthesis | 6.3.1.2 | ABAYE1126 OR ABAYE1425 | UPPMN(GN)LADGMDDADA+ ATP + NH3 -> UPPMN(GN)LADGNMDDADA + ADP + PI | glutamine synthetase |
R619 | Peptidoglycan biosynthesis | 2.3.2.10 | 5GLY+ UPPMN(GN)LADGNMDDADA -> UPPMN(GN)LADGNMD(G)5DADA | L-Alanyl-tRNA:UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanineN6-alanyltransferase | |
R620 | Peptidoglycan biosynthesis | UPPMN(GN)LADGNMD(G)5DADA-> UDCPP + PPEPTIDO | |||
R621 | Peptidoglycan biosynthesis | 2.6.1.21 | PPEPTIDO+ DALA -> 0.9208 PEPTIDO + 0.8 DALAxt | D-Alanine:2-oxoglutarate aminotransferase | |
R622 | Peptidoglycan biosynthesis | 3.6.1.27 | ABAYE0716 | UDCPP-> UDCP + PI | undecaprenyl-diphosphatase |
R623 | Thiamine metabolism | thiC | ABAYE3518 | AIR-> AHM | thiamine biosynthesis protein ThiC |
R624 | Thiamine metabolism | 2.7.1.49 | ABAYE2989 | AHM+ ATP -> AHMP + ADP | hydroxymethylpyrimidine kinase |
R625 | Thiamine metabolism | 2.7.4.7 | ABAYE2989 | AHMP+ ATP -> AHMPP + ADP | phosphomethylpyrimidine kinase |
R626 | Thiamine metabolism | 2.5.1.3 | ABAYE1010 | THZP+ AHMPP -> THMP + PPI | thiamine-phosphate pyrophosphorylase |
R627 | Thiamine metabolism | 2.7.4.16 | ABAYE0093 | THMP+ ATP <-> THMPP + ADP | thiamine-monophosphatekinase |
R628 | Thiamine metabolism | 1.4.3.19 | ABAYE2910 | GLY<-> IGLY | D-aminoacidoxidase |
R629 | Thiamine metabolism | 2.7.1.50 | ABAYE1466 | ATP+ THZ <-> ADP + MPET | hydroxyethylthiazolekinase |
R630 | Thiamine metabolism | 3.5.99.2 | ABAYE0200 | THIAMIN<-> AHM + THZ | TenAfamilytranscriptionalactivator |
R631 | Thiamine metabolism | 3.6.1.15 | ABAYE3296 | THMPP<-> THMP + PI | nucleoside-triphosphatase |
R632 | Riboflavin metabolism | 3.5.4.25 | ABAYE0096 OR ABAYE0379 | GTP-> D6RP5P + FORMATE + PPI | GTP cyclohydrolase II |
R633 | Riboflavin metabolism | 3.5.4.26 | ABAYE3546 | D6RP5P-> A6RP5P + NH3 | diaminohydroxyphosphoribosylaminopyrimidine deaminase |
R634 | Riboflavin metabolism | 1.1.1.193 | ABAYE3546 | A6RP5P+ NADPH -> A6RP5P2 + NADP | 5-amino-6-(5-phosphoribosylamino)uracil reductase |
R635 | Riboflavin metabolism | 3.1.3- | A6RP5P2-> A6RP + PI | phosphatase | |
R636 | Riboflavin metabolism | RIBB | ABAYE0096 OR ABAYE2987 | RL5P-> DB4P + FORMATE | 3,4-dihydroxy-2-butanone 4-phosphate synthase |
R637 | Riboflavin metabolism | RIBH | ABAYE0095 | DB4P+ A6RP -> D8RL + PI | riboflavinsynthase |
R638 | Riboflavin metabolism | 2.5.1.9 | ABAYE3544 | 2D8RL-> RIBFLAV + A6RP | riboflavinsynthase |
R639 | Riboflavin metabolism | 2.7.1.26 | ABAYE3851 | RIBFLAV+ ATP -> FMN + ADP | riboflavin kinase |
R640 | Riboflavin metabolism | 2.7.7.2 | ABAYE3851 | FMN+ ATP -> FAD + PPI | FMN adenylyltransferase |
R641 | Riboflavin metabolism | 2.4.2.21 | ABAYE1993 | NACN+ DMB -> NAC + N1(5PADR)DMB | nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase |
R642 | Vitamin B6 metabolism | 1.2.1.72 | ABAYE2594 | E4P+ NAD <-> ER4P + NADH | D-erythrose 4-phosphate dehydrogenase |
R643 | Vitamin B6 metabolism | 1.1.1.290 | ABAYE0853 | ER4P+ NAD <-> OHB + NADH | erythronate-4-phosphate dehydrogenase |
R644 | Vitamin B6 metabolism | 2.6.1.52 | ABAYE0877 | OHB+ GLU <-> PHT + AKG | phosphoserine aminotransferase |
R645 | Vitamin B6 metabolism | 4.2.3.1 | ABAYE3531 | PHT-> 4HLT + PI | threonine synthase |
R646 | Vitamin B6 metabolism | 1.1.1.262 | ABAYE0489 | PHT+ NAD -> 3A2OP + NADH + CO2 | 4-hydroxythreonine-4-phosphate dehydrogenase |
R647 | Vitamin B6 metabolism | 2.6.99.2 | ABAYE0945 | 3A2OP+ DX5P -> P5P + PI | pyridoxine 5-phosphate synthase |
R648 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | P5P+ O2 -> PL5P + H2O2 | pyridoxamine 5'-phosphate oxidase |
R649 | Vitamin B6 metabolism | 3.1.3.- | PL5P-> PL + PI | phosphatase | |
R650 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | PDLA5P+ O2 -> PL5P + NH3 + H2O2 | pyridoxamine 5'-phosphate oxidase |
R651 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | PYRDX+ O2 <-> PL + H2O2 | pyridoxamine 5'-phosphate oxidase |
R652 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | PL+ O2 + NH3 <-> PDLA + H2O2 | pyridoxamine 5'-phosphate oxidase |
R653 | Nicotinate and nicotinamide metabolism | 1.4.3.16 | ABAYE0935 | ASP+ FUM -> IASP + SUCC | L-aspartateoxidase |
R654 | Nicotinate and nicotinamide metabolism | 1.4.3.16 | ABAYE0935 | ASP+ O2 -> IASP + H2O2 | L-aspartate oxidase |
R655 | Nicotinate and nicotinamide metabolism | NadA | ABAYE3104 | IASP+ DHAP -> QA + PI | quinolinate synthase |
R656 | Nicotinate and nicotinamide metabolism | 2.4.2.19 | ABAYE3823 | QA+ PRPP -> NACN + CO2 + PPI | nicotinate-nucleotide pyrophosphorylase (carboxylating) |
R657 | Nicotinate and nicotinamide metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | NACN-> NACD + PI | 5'-nucleotidase |
R658 | Nicotinate and nicotinamide metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | NAMN-> NAMD + PI | 5'-nucleotidase |
R659 | Nicotinate and nicotinamide metabolism | 2.4.2.11 | ABAYE0102 | NAC+ PRPP -> NACN + PPI | nicotinate phosphoribosyltransferase |
R660 | Nicotinate and nicotinamide metabolism | 2.7.7.1 OR 2.7.7.18 | ABAYE0916 OR ABAYE0916 | ATP+ NAMN <-> PPI + NAD | nicotinamide/nicotinate-nucleotide adenylyltransferase |
R661 | Nicotinate and nicotinamide metabolism | 2.7.7.1 OR 2.7.7.18 | ABAYE0916 OR ABAYE0916 | NACN+ ATP -> PPI + NAAD | nicotinate-nucleotide adenylyltransferase |
R662 | Nicotinate and nicotinamide metabolism | 6.3.5.1 | ABAYE2955 | NAAD+ ATP + GLN -> NAD + AMP + PPI + GLU | glutamine-dependentNAD(+)synthetase |
R663 | Nicotinate and nicotinamide metabolism | 3.5.1.19 | ABAYE0059 | NAM-> NAC + NH3 | nicotinamidase |
R664 | Nicotinate and nicotinamide metabolism | 1.6.1.2 | ABAYE3191 AND ABAYE3192 AND ABAYE3193 | NADP+ NADH -> NADPH + NAD | NAD(P)transhydrogenase |
R665 | Nicotinate and nicotinamide metabolism | 2.7.1.23 | ABAYE1199 | NAD+ ATP -> NADP + ADP | NAD kinase |
R666 | Nicotinate and nicotinamide metabolism | 1.6.1.1 | ABAYE1147 | NADPH+ NAD <-> NADP + NADH | NAD(P) transhydrogenase |
R667 | Nicotinate and nicotinamide metabolism | 1.4.1.21 | ABAYE2838 | ASP+ NAD <-> IASP + NADH | L-aspartate dehydrogenase |
R668 | Nicotinate and nicotinamide metabolism | 1.4.1.21 | ABAYE2838 | ASP+ NADP <-> IASP + NADPH | L-aspartatedehydrogenase |
R669 | Nicotinate and nicotinamide metabolism | 3.6.1.22 | ABAYE2666 | NAD<-> AMP + NAMN | NUDIX family NADH pyrophosphatase |
R670 | Nicotinate and nicotinamide metabolism | 3.6.1.22 | ABAYE2666 | NAAD<-> AMP + NACN | NUDIX family NADH pyrophosphatase |
R671 | Pantothenate and CoA biosynthesis | 2.2.1.6 | ABAYE2836 OR (ABAYE3239 AND ABAYE3240) | 2PYR-> ACLAC + CO2 | acetolactatesynthase |
R672 | Pantothenate and CoA biosynthesis | 2.1.2.11 | ABAYE3175 | OIVAL+ METTHF -> DHPANT + THF | 3-methyl-2-oxobutanoate hydroxymethyltransferase |
R673 | Pantothenate and CoA biosynthesis | 1.1.1.169 | DHPANT+ NADPH -> NADP + PANT | 2-dehydropantoate 2-reductase | |
R674 | Pantothenate and CoA biosynthesis | 6.3.2.1 | ABAYE3174 | PANT+ bALA + ATP -> AMP + PPI + PNTO | pantoate-beta-alanine ligase |
R675 | Pantothenate and CoA biosynthesis | 2.7.1.33 | ABAYE3016 | PNTO+ ATP -> ADP + 4PPNTO | pantothenate kinase |
R676 | Pantothenate and CoA biosynthesis | 2.7.1.33 | ABAYE3016 | ATP+ N(P)CYS -> ADP + 4PPNCYS | pantothenate kinase |
R677 | Pantothenate and CoA biosynthesis | 2.7.1.33 | ABAYE3016 | ATP+ PTT -> ADP + 4PPNTE | pantothenate kinase |
R678 | Pantothenate and CoA biosynthesis | 6.3.2.5 | ABAYE0524 | 4PPNTO+ CTP + CYS -> CMP + PPI + 4PPNCYS | phosphopantothenate-cysteine ligase |
R679 | Pantothenate and CoA biosynthesis | 4.1.1.36 | ABAYE0524 | 4PPNCYS-> CO2 + 4PPNTE | phosphopantothenoylcysteine decarboxylase |
R680 | Pantothenate and CoA biosynthesis | 2.7.7.3 | ABAYE2969 | 4PPNTE+ ATP -> PPI + DPCOA | pantetheine-phosphate adenylyltransferase |
R681 | Pantothenate and CoA biosynthesis | 2.7.1.24 | ABAYE3447 | DPCOA+ ATP -> ADP + COA | dephospho-CoA kinase |
R682 | Biotin metabolism | 2.3.1.47 | ABAYE3003 | ALA+ CHCOA <-> CO2 + COA + AONA | 8-amino-7-oxononanoate synthase |
R683 | Biotin metabolism | 2.6.1.62 | ABAYE3004 | SAM+ AONA <-> SAMOB + DANNA | adenosylmethionine-8-amino-7-oxononanoateaminotransferase |
R684 | Biotin metabolism | 6.3.3.3 | ABAYE3001 | CO2+ DANNA + ATP <-> DTB + PI + ADP | dethiobiotin synthetase |
R685 | Biotin metabolism | 2.8.1.6 | ABAYE2129 | DTB+ S -> BT | biotin synthase |
R686 | Biotin metabolism | 6.3.4.15 | ABAYE3015 | ATP+ BT -> PPI + B5AMP | biotin-[acetyl-CoA-carboxylase] ligase |
R687 | Biotin metabolism | 6.3.4.15 | ABAYE3015 | B5AMP+ A[C] -> AMP + H[C] | biotin-[acetyl-CoA-carboxylase] ligase |
R688 | Folate biosynthesis | 3.5.4.16 | ABAYE1113 | GTP-> FORMATE + AHTD | GTP cyclohydrolase I |
R689 | Folate biosynthesis | 3.6.1.- | ABAYE3429 | AHTD-> DHP + PPI + PI | recG-likehelicase |
R690 | Folate biosynthesis | 4.1.2.25 | ABAYE1417 | DHP-> AHHMP + GLAL | dihydroneopterin aldolase |
R691 | Folate biosynthesis | 2.7.6.3 | ABAYE1418 OR ABAYE3176 | AHHMP+ ATP -> AMP + AHHMD | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridinepyrophosphokinase |
R692 | Folate biosynthesis | 2.6.1.85 | ABAYE3129 | CHOR+ GLN -> ADCHOR + GLU | para-aminobenzoate synthase |
R693 | Folate biosynthesis | 4.1.3.38 | ABAYE0931 | ADCHOR-> PYR + PABA | 4-amino-4-deoxychorismate lyase |
R694 | Folate biosynthesis | 2.5.1.15 | ABAYE0807 OR ABAYE3568 OR ABAYE3612 OR ABAYE3616 | PABA+ AHHMD -> PPI + DHPT | dihydropteroate synthase |
R695 | Folate biosynthesis | 2.5.1.15 | ABAYE0807 OR ABAYE3568 OR ABAYE3612 OR ABAYE3616 | PABA+ AHHMP -> DHPT | dihydropteroate synthase |
R696 | Folate biosynthesis | 6.3.2.12 OR 6.3.2.17 | ABAYE0615 | DHPT+ ATP + GLU -> ADP + PI + DHF | dihydrofolate synthase |
R697 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF+ NADPH -> NADP + THF | dihydrofolate reductase |
R698 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF+ NADH -> NAD + THF | dihydrofolate reductase |
R699 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF+ NAD <-> FL + NADH | dihydrofolate reductase |
R700 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF+ NADP <-> FL + NADPH | dihydrofolate reductase |
R701 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | FL+ NADH -> THF + NAD | dihydrofolate reductase |
R702 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | FL+ NADPH -> THF + NADP | dihydrofolate reductase |
R703 | Folate biosynthesis | 6.3.2.17 | ABAYE0615 | THF+ ATP + GLU <-> ADP + PI + THFG | folylpolyglutamate synthase |
R704 | Folate biosynthesis | 4.2.3.12 | ABAYE2067 | AHTD-> PYTHP + PPPI | 6-pyruvoyl tetrahydrobiopterin synthase |
R705 | Folate biosynthesis | 3.1.3.1 | ABAYE0811 | AHTD<-> DHP + 3 PI | alkaline phosphatase D precursor |
R706 | One carbon pool by folate | 2.1.2.2 | ABAYE0888 OR ABAYE2179 | GAR+ METHF -> FGAR + THF | phosphoribosylglycinamide formyltransferase |
R707 | One carbon pool by folate | 3.5.4.9 | ABAYE0812 | METHF-> FTHF | bifunctionalprotein[includes:5,10-methylene-tetrahydrofolatedehydrogenase;5,10-methylene-tetrahydrofolatecyclohydrolase] |
R708 | One carbon pool by folate | 1.5.1.5 | ABAYE0812 | METTHF+ NADP <-> METHF + NADPH | bifunctionalprotein[includes:5,10-methylene-tetrahydrofolatedehydrogenase;5,10-methylene-tetrahydrofolatecyclohydrolase] |
R709 | One carbon pool by folate | 3.5.4.9 | ABAYE0812 | METHF<-> FTHF | bifunctionalprotein[includes:5,10-methylene-tetrahydrofolatedehydrogenase;5,10-methylene-tetrahydrofolatecyclohydrolase] |
R710 | One carbon pool by folate | 1.5.1.20 | ABAYE1141 OR ABAYE1792 | METTHF+ NADPH -> MTHF + NADP | methylenetetrahydrofolatereductase |
R711 | One carbon pool by folate | 1.5.1.20 | ABAYE1141 OR ABAYE1792 | METTHF+ FADH2 <-> MTHF + FAD | methylenetetrahydrofolatereductase |
R712 | One carbon pool by folate | 2.1.1.45 | ABAYE3314 | DUMP+ METTHF <-> DHF + DTMP | thymidylatesynthase |
R713 | One carbon pool by folate | 3.5.1.10 | ABAYE3322 | FTHF<-> FORMATE + THF | formyltetrahydrofolate deformylase |
R714 | One carbon pool by folate | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | THF+ NAD <-> DHF + NADH | dihydrofolate reductase |
R715 | One carbon pool by folate | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | THF+ NADP <-> DHF + NADPH | dihydrofolate reductase |
R716 | Porphyrin and chlorophyll metabolism | 1.2.1.70 | ABAYE2976 | GTRNA+ NADPH -> GSA + NADP | glutamyl-tRNA reductase |
R717 | Porphyrin and chlorophyll metabolism | 5.4.3.8 | ABAYE1011 | GSA-> ALAV | glutamate-1-semialdehyde aminotransferase |
R718 | Porphyrin and chlorophyll metabolism | 4.2.1.24 | ABAYE2909 | 2ALAV-> PBG | porphobilinogen synthase |
R719 | Porphyrin and chlorophyll metabolism | 2.5.1.61 | ABAYE3508 | 4PBG-> HMB + 4 NH3 | hydroxymethylbilane synthase |
R720 | Porphyrin and chlorophyll metabolism | 4.2.1.75 | ABAYE3507 | HMB-> UPRG | uroporphyrinogen-III synthase |
R721 | Porphyrin and chlorophyll metabolism | 2.1.1.107 | ABAYE0758 | 2SAM+ UPRG -> 2 SAH + PC2 | uroporphyrin-III C-methyltransferase |
R722 | Porphyrin and chlorophyll metabolism | 1.3.1.76 | ABAYE0758 | PC2+ NAD -> NADH + SHCL | precorrin-2 dehydrogenase |
R723 | Porphyrin and chlorophyll metabolism | 4.99.1.4 | ABAYE0758 | SHCL-> SHEME | sirohydrochlorin ferrochelatase |
R724 | Porphyrin and chlorophyll metabolism | 4.1.1.37 | ABAYE1106 | UPRG->4CO2+ CPP | uroporphyrinogen decarboxylase |
R725 | Porphyrin and chlorophyll metabolism | 1.3.99.22 | ABAYE0674 OR ABAYE3379 | CPP+2SAM-> PPHG + 2 CO2 + 2 MET + 2 DA | oxygen-independent coproporphyrinogen III oxidase |
R726 | Porphyrin and chlorophyll metabolism | 1.3.3.3 | ABAYE0378 | CPP+ O2 -> PPHG + 2 CO2 | coproporphyrinogen III oxidase |
R727 | Porphyrin and chlorophyll metabolism | 4.99.1.1 | ABAYE3393 | PPIX-> PTH | ferrochelatase |
R728 | Porphyrin and chlorophyll metabolism | 2.5.1.17 | ABAYE0605 | C(I)DA+ ATP -> ACDA + PPI + PI | cob(I)alamin adenosyltransferase |
R729 | Porphyrin and chlorophyll metabolism | 2.7.1.156 | ABAYE1994 | ADCBA+ ATP -> ADCBAP + ADP | adenosylcobinamidekinase |
R730 | Porphyrin and chlorophyll metabolism | 2.7.1.156 | ABAYE1994 | ADCBA+ GTP -> ADCBAP + GDP | adenosylcobinamidekinase |
R731 | Porphyrin and chlorophyll metabolism | 2.7.1.156 | ABAYE1994 | ADCBAP+ GTP -> AGDPCBA + PPI | adenosylcobinamide-phosphate guanylyltransferase |
R732 | Porphyrin and chlorophyll metabolism | 2.7.8.26 | ABAYE1990 | AGDPCBA+ ARBZ -> CBCO + GMP | adenosylcobinamide-GDP ribazoletransferase |
R733 | Porphyrin and chlorophyll metabolism | 2.5.1.17 | ABAYE0605 | ATP+ CBA <-> PPPI + ADCBA | cob(I)alamin adenosyltransferase |
R734 | Porphyrin and chlorophyll metabolism | 2.5.1.17 | ABAYE0605 | ATP+ C(I)A <-> PPPI + CBCO | cob(I)alamin adenosyltransferase |
R735 | Porphyrin and chlorophyll metabolism | 4.1.1.37 | ABAYE1106 | UPRGI<-> CPPI + 4 CO2 | uroporphyrinogen decarboxylase |
R736 | Porphyrin and chlorophyll metabolism | 2.5.1.- | ABAYE1385 | PTH<-> HEMEO | protohemeIXfarnesyltransferase |
R737 | Ubiquinone biosynthesis | 5.4.4.2 | ABAYE1104 | CHOR<-> ICHOR | menaquinone-specific isochorismate synthase |
R738 | Ubiquinone biosynthesis | 4.1.3.40 | ABAYE1127 | CHOR<-> 4HB + PYR | chorismate--pyruvate lyase |
R739 | Ubiquinone biosynthesis | 2.5.1.- | ABAYE1128 | OPP+ 4HB -> 3OP4HB + PPI | 4-hydroxybenzoate octaprenyltransferase |
R740 | Ubiquinone biosynthesis | UbiB | ABAYE3426 | 2OPP+ O2 + NADPH -> 2OP6HP + NADP | ubiquinone biosynthesis protein |
R741 | Ubiquinone biosynthesis | 2.1.1.64 | ABAYE3834 | 2OP6HP+ SAM -> 2OP6MP + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R742 | Ubiquinone biosynthesis | 1.14.13.- | ABAYE2678 | 2OP6MP+ O2 + NADPH -> 2OP6M14BQ + NADP | 2-octaprenyl-6-methoxyphynol hydroxylase |
R743 | Ubiquinone biosynthesis | 2.1.1.- | ABAYE3424 | 2OP6M14BQ+ SAM -> 2OP3M6M14BQ + SAH | 2-octaprenyl-6-methoxy-1,4-benzoquinone methylase |
R744 | Ubiquinone biosynthesis | 2.1.1.64 | ABAYE3834 | 2OP3M5H6M14BQ+ SAM -> UQ + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R745 | Ubiquinone biosynthesis | 2.5.1.64 | ICHOR+ AKG -> SHCHC + PYR + CO2 | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylatesynthase | |
R746 | Ubiquinone biosynthesis | 4.2.1.- | SHCHC-> OSB | O-succinylbenzoate-CoA synthase | |
R747 | Ubiquinone biosynthesis | 6.2.1.26 | OSB+ ATP + COA -> AMP + PPI + OSBCOA | O-succinylbenzoic acid--CoA ligase | |
R748 | Ubiquinone biosynthesis | 4.1.3.36 | OSBCOA-> DHN + COA | dihydroxynaphthoic acid synthase | |
R749 | Ubiquinone biosynthesis | 2.5.1.- | ABAYE1128 | DHN+ OPP -> PPI + CO2 + DMK | 4-hydroxybenzoate octaprenyltransferase |
R750 | Ubiquinone biosynthesis | 2.1.1.- | ABAYE3424 | DMK+ SAM -> MKH2 + SAH | menaquinone biosynthesis methyltransferase |
R751 | Ubiquinone biosynthesis | 2.1.1.- | ABAYE3424 | 2P14NQ+ SAM -> PQ + SAH | menaquinone biosynthesis methyltransferase |
R752 | Ubiquinone biosynthesis | 1.14.13.- | ABAYE1427 | 2HP3M6M14B+ O2 + NADPH <-> 2HP3M5H6M14B + NADP | ubiquinone biosynthesis protein |
R753 | Protein | 0.488ALA+0.281ARG+0.229ASN+0.229ASP+0.087CYS+0.25GLU+0.25GLN+0.582GLY+0.09HIS+0.276ILE+0.428LEU+0.326LYS+0.146MET+0.176PHE+0.21PRO+0.205SER+0.241THR+0.054TRP+0.131TYR+0.402VAL+40ATP->40ADP+40PI+ PROTEIN | |||
R754 | DNA | 2.7.7.7 | 0.987DATP+0.631DGTP+0.631DCTP+0.987DTTP+4.4ATP->4.4ADP+4.4PI+3.237PPI+ DNA | ||
R755 | RNA | 2.7.7.6 | 2.045ATP+0.920GTP+0.686CTP+0.689UTP->1.25ADP+1.25PI+3.091PPI+ RNA | ||
R756 | Phospholipid | 0.168CL+0.548PE+0.302PG+0.122AG3PE-> PHOSPHOLIPID | |||
R757 | Lipids | 0.058C100ACP+0.185C120ACP+0.013C140ACP+0.012C150ACP+1.082C160ACP+0.74C161ACP+0.067C170ACP+0.06C171ACP+0.032C180ACP+1.443C181ACP+0.157C120OH-> LIPID + 3.692 ACP | |||
R758 | Lipopolysaccharide biosynthesis | 0.182KDO+0.821bDGLC+0.656UDPGAL+0.018DTDPRMNS+0.365UDPNAG+0.255UDPAGLACA+0.037C120ACP+0.014C160ACP+0.079C120OH+0.009C180ACP+0.008C181ACP+0.071C140OH-> LPS + 1.276 UDP + 0.018 DTDP + 0.068 ACP | |||
R759 | 2.794DTDPRMNS+2.117bDGLC+0.265GDPMAN-> EXOPOLYS + 2.794 DTDP + 0.265 UDP | ||||
R760 | Cofactors and vitamins (CAV) | 0.163COA+0.159FAD+0.274FMN+0.405MK+0.188NAD+0.168NADP+0.739PYRDX+0.281THF-> CAV | |||
R761 | Biomass | 0.6PROTEIN+0.03DNA+0.19RNA+0.04PHOSPHOLIPID+0.02LIPID+0.005LPS+0.027PEPTIDO+0.038EXOPOLYS+0.03CAV+46ATP-> BIOMASS + 46 ADP + 46 PI | |||
R762 | Maintenance | ATP -> ADP + PI | |||
R763 | IMAL_transport | 3.6.1.- | IMALxt+ ATP <-> IMAL + PI + ADP | ||
R764 | FRU_transport | 2.7.1.69 | FRUxt+ PEP -> F1P + PYR | ||
R765 | GLC_transport | GLCxt + ATP -> GLC + ADP + PI | |||
R766 | GLUC_transport | GLUCxt+ Hxt -> GLUC | |||
R767 | MLT_transport | MLTxt+ ATP -> MLT + ADP + PI | |||
R768 | MNT_transport | MNTxt+ ATP -> MNT + ADP + PI | |||
R769 | NAGA_transport | NAGAxt+ ATP -> NAGA + ADP + PI | |||
R770 | SUC_transport | SUCxt+ ATP -> SUC + ADP + PI | |||
R771 | TRE_transport | TRExt+ ATP -> TRE + ADP + PI | |||
R772 | 2PG_transport | 2PGxt+ ATP -> 2PG + ADP + PI | |||
R773 | 3PG_transport | 3PGxt+ ATP -> 3PG + ADP + PI | |||
R774 | AC_transport | AC<-> ACxt + Hxt | |||
R775 | AKG_transport | AKGxt+ Hxt -> AKG | |||
R776 | AKG_transport | AKGxt+ Naxt -> AKG + Na | |||
R777 | CIT_transport | CITxt<-> CIT | |||
R778 | FORMATE_transport | FORMATE-> FORMATExt | |||
R779 | FUM_transport | FUMxt+ Hxt -> FUM | |||
R780 | FUM_transport | FUMxt+ Naxt -> FUM + Na | |||
R781 | FUM_transport | FUMxt+ SUCC <-> FUM + SUCCxt | |||
R782 | ICIT_transport | ICITxt+ Naxt -> ICIT + Na | |||
R783 | MAL_transport | MALxt+ Hxt -> MAL | |||
R784 | MAL_transport | MALxt+ Naxt -> MAL + Na | |||
R785 | MAL_transport | MALxt+ SUCC <-> MAL + SUCCxt | |||
R786 | SLAC_transport | SLACxt+ Hxt -> SLAC | |||
R787 | SUCC_transport | SUCCxt+ Hxt -> SUCC | |||
R788 | SUCC_transport | SUCCxt+ Naxt -> SUCC + Na | |||
R789 | GLYCOLATE_transport | GLYCOLATExt<-> GLYCOLATE | |||
R790 | ATP_transport | ATP<-> Hxt + ADP + PI | |||
R791 | CO2_transport | CO2xt<-> CO2 | |||
R792 | Na_transport | Naxt<-> Na + Hxt | |||
R793 | NH3_transport | NH3xt<-> NH3 | |||
R794 | NO2_transport | NO2-> NO2xt | |||
R795 | NO3_transport | NO3xt+ ATP -> NO3 + ADP + PI | |||
R796 | O2_transport | O2xt<-> O2 | |||
R797 | PI_transport | PIxt+ Hxt <-> PI | |||
R798 | PI_transport | PIxt+ ATP -> 2 PI + ADP | |||
R799 | SLF_transport | SLFxt+ Hxt -> SLF | |||
R800 | SLF_transport | SLFxt+ ATP -> SLF + ADP + PI | |||
R801 | ALA_transport | ALA+ Hxt <-> ALAxt | |||
R802 | ALA_transport | ALAxt+ ATP -> ALA + ADP + PI | |||
R803 | ALA_transport | ALAxt+ Hxt -> ALA | |||
R804 | ALA_transport | ALAxt+ Naxt -> ALA + Na | |||
R805 | ARG_transport | ARG+ Hxt <-> ARGxt | |||
R806 | ARG_transport | ARGxt+ ATP -> ARG + ADP + PI | |||
R807 | ARG_transport | ARGxt+ Hxt -> ARG | |||
R808 | ASN_transport | ASN+ Hxt <-> ASNxt | |||
R809 | ASN_transport | ASNxt+ ATP -> ASN + ADP + PI | |||
R810 | ASN_transport | ASNxt+ Hxt -> ASN | |||
R811 | ASP_transport | ASP+ Hxt <-> ASPxt | |||
R812 | ASP_transport | ASPxt+ ATP -> ASP + ADP + PI | |||
R813 | ASP_transport | ASPxt+ Hxt -> ASP | |||
R814 | CYS_transport | CYS+ Hxt <-> CYSxt | |||
R815 | CYS_transport | CYSxt+ ATP -> CYS + ADP + PI | |||
R816 | CYS_transport | CYSxt+ Hxt -> CYS | |||
R817 | DALA_transport | DALAxt+ Hxt -> DALA | |||
R818 | DGLU_transport | DGLUxt+ Hxt -> DGLU | |||
R819 | GLN_transport | GLN+ Hxt <-> GLNxt | |||
R820 | GLN_transport | GLNxt+ ATP -> GLN + ADP + PI | |||
R821 | GLN_transport | GLNxt+ Hxt -> GLN | |||
R822 | GLU_transport | GLU+ Hxt <-> GLUxt | |||
R823 | GLU_transport | GLUxt+ ATP -> GLU + ADP + PI | |||
R824 | GLU_transport | GLUxt+ Hxt -> GLU | |||
R825 | GLU_transport | GLUxt+ Naxt -> GLU + Na | |||
R826 | GLY_transport | GLY+ Hxt <-> GLYxt | |||
R827 | GLY_transport | GLYxt+ ATP -> GLY + ADP + PI | |||
R828 | GLY_transport | GLYxt+ Hxt -> GLY | |||
R829 | GLY_transport | GLYxt+ Naxt -> GLY + Na | |||
R830 | HIS_transport | HIS+ Hxt <-> HISxt | |||
R831 | HIS_transport | HISxt+ ATP -> HIS + ADP + PI | |||
R832 | HIS_transport | HISxt+ Hxt -> HIS | |||
R833 | ILE_transport | ILE+ Hxt <-> ILExt | |||
R834 | ILE_transport | ILExt+ ATP -> ILE + ADP + PI | |||
R835 | ILE_transport | ILExt+ Hxt -> ILE | |||
R836 | LEU_transport | LEU+ Hxt <-> LEUxt | |||
R837 | LEU_transport | LEUxt+ ATP -> LEU + ADP + PI | |||
R838 | LEU_transport | LEUxt+ Hxt -> LEU | |||
R839 | LYS_transport | LYS+ Hxt <-> LYSxt | |||
R840 | LYS_transport | LYS+ Hxt -> LYSxt | |||
R841 | LYS_transport | LYSxt+ ATP -> LYS + ADP + PI | |||
R842 | LYS_transport | LYSxt+ Hxt -> LYS | |||
R843 | MET_transport | MET+ Hxt <-> METxt | |||
R844 | MET_transport | METxt+ ATP -> MET + ADP + PI | |||
R845 | MET_transport | METxt+ Hxt -> MET | |||
R846 | PHE_transport | PHE+ Hxt <-> PHExt | |||
R847 | PHE_transport | PHExt+ ATP -> PHE + ADP + PI | |||
R848 | PHE_transport | PHExt+ Hxt -> PHE | |||
R849 | PRO_transport | PRO+ Hxt <-> PROxt | |||
R850 | PRO_transport | PROxt+ ATP -> PRO + ADP + PI | |||
R851 | PRO_transport | PROxt+ Hxt -> PRO | |||
R852 | PRO_transport | PROxt+ Naxt -> PRO + Na | |||
R853 | SER_transport | SER+ Hxt <-> SERxt | |||
R854 | SER_transport | SERxt+ ATP -> SER + ADP + PI | |||
R855 | SER_transport | SERxt+ Hxt -> SER | |||
R856 | THR_transport | THR+ Hxt <-> THRxt | |||
R857 | THR_transport | THRxt+ ATP -> THR + ADP + PI | |||
R858 | THR_transport | THRxt+ Hxt -> THR | |||
R859 | TRP_transport | TRP+ Hxt <-> TRPxt | |||
R860 | TRP_transport | TRPxt+ ATP -> TRP + ADP + PI | |||
R861 | TRP_transport | TRPxt+ Hxt -> TRP | |||
R862 | TYR_transport | TYR+ Hxt <-> TYRxt | |||
R863 | TYR_transport | TYRxt+ ATP -> TYR + ADP + PI | |||
R864 | TYR_transport | TYRxt+ Hxt -> TYR | |||
R865 | VAL_transport | VAL+ Hxt <-> VALxt | |||
R866 | VAL_transport | VALxt+ ATP -> VAL + ADP + PI | |||
R867 | VAL_transport | VALxt+ Hxt -> VAL | |||
R868 | DSER_transport | DSERxt + Hxt -> DSER | |||
R869 | ARG_transport | ARGxt + ORN <-> ARG + ORNxt | |||
R870 | HSER_transport | HSER+ Hxt <-> HSERxt | |||
R871 | ORN_transport | ORNxt+ ATP -> ORN + ADP + PI | |||
R872 | PTRC_transport | PTRCxt+ ATP -> PTRC + ADP + PI | |||
R873 | SPRMD_transport | SPRMDxt+ ATP -> SPRMD + ADP + PI | |||
R874 | UREA_transport | UREAxt+ ATP -> UREA + ADP + PI | |||
R875 | CHOLINE_transport | CHOLINExt+ Hxt -> CHOLINE | |||
R876 | ADN_transport | ADNxt+ Hxt -> ADN | |||
R877 | CYTD_transport | CYTDxt+ Hxt -> CYTD | |||
R878 | DA_transport | DAxt+ Hxt -> DA | |||
R879 | DC_transport | DCxt+ Hxt -> DC | |||
R880 | DG_transport | DGxt+ Hxt -> DG | |||
R881 | DT_transport | DTxt+ Hxt -> DT | |||
R882 | DU_transport | DUxt+ Hxt -> DU | |||
R883 | GSN_transport | GSNxt+ Hxt -> GSN | |||
R884 | URI_transport | URIxt+ Hxt -> URI | |||
R885 | CT_transport | CTxt+ Hxt -> CT | |||
R886 | XAN_transport | XANxt+ Hxt -> XAN | |||
R887 | URA_transport | URAxt+ Hxt -> URA | |||
R888 | TR_transport | TRxt + ATP -> TR + ADP + PI | |||
R889 | ETHA_transport | ETHAxt + Hxt -> ETHA | |||
R890 | BETAINE_transport | BETAINExt + Hxt -> BETAINE | |||
R891 | BZ_transport | BZxt + Hxt -> BZ |
No. | Metabolism | EC Number | ORF | Reaction | Enzyme |
R001 | Glycolysis / Gluconeogenesis | 5.1.3.3 | ABAYE2829 | GLC <-> bDGLC | aldose 1-epimerase |
R002 | Glycolysis / Gluconeogenesis | 5.3.1.9 | ABAYE3801 | G6P <-> bDG6P | glucose-6-phosphate isomerase |
R003 | Glycolysis / Gluconeogenesis | 5.3.1.9 | ABAYE3801 | G6P <-> F6P | glucose-6-phosphate isomerase |
R004 | Glycolysis / Gluconeogenesis | 5.3.1.9 | ABAYE3801 | bDG6P <-> F6P | glucose-6-phosphate isomerase |
R005 | Glycolysis / Gluconeogenesis | 5.4.2.2 | ABAYE2928 OR ABAYE3800 | G6P <-> G1P | phosphoglucomutase OR phosphomannomutase |
R006 | Glycolysis / Gluconeogenesis | 3.1.3.11 | ABAYE0899 | FDP-> F6P + PI | fructose-1,6-bisphosphatase |
R007 | Glycolysis / Gluconeogenesis | 4.1.2.13 | ABAYE2088 | FDP <-> G3P + DHAP | fructose-1,6-bisphosphate aldolase |
R008 | Glycolysis / Gluconeogenesis | 5.3.1.1 | ABAYE3443 | DHAP <-> G3P | triosephosphate isomerase |
R009 | Glycolysis / Gluconeogenesis | 1.2.1.12 | ABAYE0958 | G3P + PI + NAD <-> NADH + 13PDG | glyceraldehyde3-phosphatedehydrogenase |
R010 | Glycolysis / Gluconeogenesis | 2.7.2.3 | ABAYE2090 | 13PDG + ADP <-> 3PG + ATP | phosphoglyceratekinase |
R011 | Glycolysis / Gluconeogenesis | 5.4.2.1 | ABAYE3537 | 3PG <-> 2PG | phosphoglycerate mutase |
R012 | Glycolysis / Gluconeogenesis | 4.2.1.11 | ABAYE1669 | 2PG <-> PEP | enolase |
R013 | Glycolysis / Gluconeogenesis | 2.3.1.12 | ABAYE0158 OR ABAYE1946 | COA + ADLIPO-> DLIPO + ACCOA | pyruvate dehydrogenase E2 component (dihydrolipoamideacetyltransferase) |
R014 | Glycolysis / Gluconeogenesis | 1.8.1.4 | ABAYE0505 OR ABAYE0782 OR ABAYE1945 | DLIPO + NAD-> LIPO + NADH | dihydrolipoamidedehydrogenase |
R015 | Glycolysis / Gluconeogenesis | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | ATP + AC + COA <-> AMP + PPI + ACCOA | acetyl-CoA synthetase |
R016 | Glycolysis / Gluconeogenesis | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | ACAL + NAD-> NADH + AC | aldehydedehydrogenase |
R017 | Glycolysis / Gluconeogenesis | 1.1.1.1 | ABAYE0763 OR ABAYE1463 OR ABAYE1522 OR ABAYE1861 OR p2ABAYE0004 OR p3ABAYE0020 OR p3ABAYE0024 | ACAL + NADH <-> ETH + NAD | alcohol dehydrogenase |
R018 | Glycolysis / Gluconeogenesis | 4.1.1.1 | ABAYE1030 | ACAL + THMPP <-> 2 (HE) TPP | pyruvate decarboxylase / indolepyruvate decarboxylase |
R019 | TCA cycle | 2.3.3.1 | ABAYE0773 | ACCOA + OA-> COA + CIT | citrate synthase |
R020 | TCA cycle | 4.2.1.3 | ABAYE1432 OR ABAYE3228 OR ABAYE3791 | CIT <-> ICIT | aconitate hydratase |
R021 | TCA cycle | 1.1.1.42 | ABAYE0980 OR ABAYE0982 | ICIT + NADP-> NADPH + AKG + CO2 | isocitrate dehydrogenase |
R022 | TCA cycle | 1.2.4.2 | ABAYE0780 | AKG + LIPO-> SDLIPO + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R023 | TCA cycle | 2.3.1.61 | ABAYE0781 | SDLIPO + COA-> DLIPO + SUCCOA | 2-oxoglutaratedehydrogenaseE2component |
R024 | TCA cycle | 6.2.1.5 | ABAYE0783 AND ABAYE0784 | ADP + PI + SUCCOA <-> ATP + SUCC + COA | succinyl-CoAsynthetase |
R025 | TCA cycle | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | SUCC + FAD-> FUM + FADH2 | succinatedehydrogenase |
R026 | TCA cycle | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | FUM + MKH2-> SUCC + MK | fumaratereductase |
R027 | TCA cycle | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | FUM + DMKH2-> SUCC + DMK | fumaratereductase |
R028 | TCA cycle | 4.2.1.2 | ABAYE1563 OR ABAYE3284 | FUM <-> MAL | fumaratehydratase |
R029 | TCA cycle | 1.1.1.37 | ABAYE0465 | MAL + NAD <-> NADH + OA | malatedehydrogenase |
R030 | Pentose phosphate pathway | 5.1.3.1 | ABAYE3114 | RL5P <-> X5P | D-ribulose-5-phosphate 3-epimerase |
R031 | Pentose phosphate pathway | 5.3.1.6 | ABAYE1650 | RL5P <-> R5P | ribose 5-phosphate isomerase A |
R032 | Pentose phosphate pathway | 2.2.1.1 | ABAYE2116 OR (ABAYE2823 AND ABAYE2824) | R5P + X5P <-> G3P + S7P | transketolase |
R033 | Pentose phosphate pathway | 2.2.1.1 | ABAYE2116 OR (ABAYE2823 AND ABAYE2824) | X5P + E4P <-> F6P + G3P | transketolase |
R034 | Pentose phosphate pathway | 2.2.1.2 | ABAYE1510 | G3P + S7P <-> E4P + F6P | transaldolase |
R035 | Pentose phosphate pathway | 4.1.2.4 | DR5P-> G3P + ACAL | deoxyribose-phosphatealdolase | |
R036 | Pentose phosphate pathway | 5.4.2.7 | DR1P <-> DR5P | phosphopentomutase | |
R037 | Pentose phosphate pathway | 4.1.2.14 | ABAYE3280 | KDPG-> PYR + G3P | bifunctional 4-hydroxy-2-oxoglutarate aldolase OR 2-dehydro-3-deoxyphosphogluconate aldolase |
R038 | Pentose phosphate pathway | 2.7.1.12 | ABAYE3278 | GLUC + ATP-> D6PGC + ADP | gluconokinase |
R039 | Pentose phosphate pathway | 4.2.1.12 | ABAYE3281 | D6PGC-> KDPG | phosphogluconate dehydratase |
R040 | Pentose phosphate pathway | 5.4.2.2 | ABAYE2928 OR ABAYE3800 | R1P <-> R5P | phosphoglucomutase OR phosphomannomutase |
R041 | Pentose and glucuronate interconversions | 1.1.1.22 | ABAYE3802 | UDPG + 2NAD <-> UDPGLUC + 2 NADH | UDP-glucose 6-dehydrogenase |
R042 | Fructose and mannose metabolism | 2.7.1.56 | ABAYE1613 | F1P + ATP-> FDP + ADP | fructose-1-phosphate kinase |
R043 | Fructose and mannose metabolism | 4.1.2.13 | ABAYE2088 | F1P-> DHAP + T3 | fructose-bisphosphate aldolase |
R044 | Fructose and mannose metabolism | 5.3.1.8 | MAN6P <-> F6P | phosphomannoseisomerase | |
R045 | Fructose and mannose metabolism | 5.4.2.8 | ABAYE2928 OR ABAYE3800 | MAN6P <-> MAN1P | phosphomannomutase |
R046 | Fructose and mannose metabolism | 2.7.7.13 | GTP + MAN1P <-> PPI + GDPMAN | nucleoside-diphosphate-sugarpyrophosphorylase | |
R047 | Fructose and mannose metabolism | 1.1.1.- | ABAYE0043 OR ABAYE0109 OR ABAYE0479 OR ABAYE1356 OR ABAYE2589 OR ABAYE2607 OR ABAYE2613 OR ABAYE2618 OR ABAYE2845 OR ABAYE3187 OR ABAYE3378 | S6P + NADP <-> SB1P + NADPH | alcoholdehydrogenase |
R048 | Fructose and mannose metabolism | 4.1.2.17 | ABAYE3670 | FUCP <-> DHAP + LACAL | aldolase class II |
R049 | Galactose metabolism | 5.1.3.2 | ABAYE1562 OR ABAYE3804 | UDPG <-> UDPGAL | UDP-glucose4-epimerase |
R050 | Galactose metabolism | 2.7.7.9 | ABAYE3803 | G1P + UTP <-> UDPG + PPI | UTP-glucose-1-phosphate uridylyltransferase |
R051 | Ascorbate and aldarate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | DGLUCL + NAD <-> DGLUCA + NADH | aldehyde dehydrogenase |
R052 | Starch and sucrose metabolism | 3.2.1.93 | TRE6P-> GLC + G6P | trehalose-6-phosphate hydrolase | |
R053 | Starch and sucrose metabolism | 2.4.1.15 | ABAYE3007 | UDPG + G6P <-> UDP + TRE6P | trehalose-6-phosphate synthase |
R054 | Starch and sucrose metabolism | 3.1.3.12 | ABAYE3006 | TRE6P-> TRE + PI | trehalose-6-phosphate phophatase, biosynthetic |
R055 | Aminosugars metabolism | 2.6.1.16 | ABAYE0089 | F6P + GLN-> GLU + GA6P | glucosamine-fructose-6-phosphateaminotransferase |
R056 | Aminosugars metabolism | 5.4.2.10 | ABAYE0167 | GA6P <-> GA1P | phosphomannomutase |
R057 | Aminosugars metabolism | 2.3.1.157 | ABAYE0090 | ACCOA + GA1P-> NAGA1P + COA | glucosamine-1-phosphateN-acetyltransferase |
R058 | Aminosugars metabolism | 2.7.7.23 | ABAYE0090 | UTP + NAGA1P <-> UDPNAG + PPI | UDP-N-acetylglucosaminepyrophosphorylase |
R059 | Aminosugars metabolism | 5.1.3.14 | ABAYE0969 | UDPNAG <-> NADMA + UDP | UDP-N-acetylglucosamine2-epimerase |
R060 | Aminosugars metabolism | 5.1.3.14 | ABAYE0969 | UDPNAG <-> UDPNADMA | UDP-N-acetylglucosamine 2-epimerase |
R061 | Aminosugars metabolism | 1.1.1.- | ABAYE3815 | UDPNADMA + 2NAD-> UDPNADMAU + 2 NADH | UDP-N-acetyl-D-mannosaminuronatedehydrogenase |
R062 | Aminosugars metabolism | 2.5.1.7 | ABAYE3133 | UDPNAG + PEP-> UDPNAGEP + PI | UDP-N-acetylglucosamine enolpyruvyl transferase |
R063 | Aminosugars metabolism | 1.1.1.158 | ABAYE1526 | UDPNAGEP + NADPH-> UDPNAM + NADP | UDP-N-acetylenolpyruvoylglucosamine reductase |
R064 | Aminosugars metabolism | 3.2.1.- | ABAYE2663 | GLCAMN <-> GLCA + GLCAMN | bifunctionalprotein [includes: lyticmureintransglycosylaseC, membrane-bound |
R065 | Aminosugars metabolism | 3.2.1.52 | ABAYE3272 | CHITB-> 2 NAGA | beta-N-acetyl-D-glucosaminidase |
R066 | Aminosugars metabolism | 5.1.3.7 | ABAYE3814 | UDPNAG <-> UDPAGLACA | NAD-dependent epimerase / dehydratase |
R067 | Nucleotide sugars metabolism | 5.1.3.2 | ABAYE1562 OR ABAYE3804 | DTDPGLU <-> DTDPGLAC | UDP-glucose4-epimerase |
R068 | Nucleotide sugars metabolism | 2.7.7.24 | G1P + DTTP-> DTDPGLU + PPI | glucose-1-phosphatethymidylyltransferase | |
R069 | Nucleotide sugars metabolism | 4.2.1.46 | DTDPGLU-> DTDP4O6DG | dTDP-glucose 4,6 dehydratase | |
R070 | Nucleotide sugars metabolism | 5.1.3.13 | DTDP4O6DG-> DTDP4ORMNS | dTDP-4-deoxyrhamnose-3,5-epimerase | |
R071 | Nucleotide sugars metabolism | 1.1.1.133 | DTDP4ORMNS + NADPH-> DTDPRMNS + NADP | dTDP-4-dehydrorhamnose reductase | |
R072 | Pyruvate metabolism | 2.7.9.2 | ABAYE1391 | ATP + PYR-> AMP + PEP + PI | phosphoenolpyruvate synthase |
R073 | Pyruvate metabolism | 1.1.1.28 | ABAYE3796 | PYR + NADH <-> LAC + NAD | D-lactatedehydrogenase |
R074 | Pyruvate metabolism | 2.3.1.8 | ABAYE1138 OR ABAYE3283 | ACCOA + PI <-> ACETYLP + COA | phosphateacetyltransferase |
R075 | Pyruvate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | AAD + COA <-> AMP + ACCOA | acetyl-CoA synthase |
R076 | Pyruvate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | ATP + AC <-> PPI + AAD | acetyl-CoA synthetase |
R077 | Pyruvate metabolism | 2.7.2.1 | ABAYE3282 | ACETYLP + ADP <-> AC + ATP | acetate kinase |
R078 | Pyruvate metabolism | 4.1.1.31 | ABAYE0028 | PEP + CO2-> OA + PI | phosphoenolpyruvatecarboxylase |
R079 | Pyruvate metabolism | 1.1.1.38 OR 1.1.1.40 | ABAYE3731 OR ABAYE1138 | MAL + NAD <-> PYR + CO2 + NADH | malate dehydrogenase |
R080 | Pyruvate metabolism | 1.1.1.38 OR 1.1.1.40 | ABAYE3731 OR ABAYE1138 | MAL + NADP <-> PYR + CO2 + NADPH | malate dehydrogenase |
R081 | Pyruvate metabolism | 2.3.3.9 | ABAYE2053 | ACCOA + GLX-> MAL + COA | malatesynthase |
R082 | Pyruvate metabolism | 2.3.1.9 | ABAYE0629 OR ABAYE0638 OR ABAYE1916 OR ABAYE2307 | 2ACCOA-> COA + AACCOA | acetyl-CoA acetyltransferase |
R083 | Pyruvate metabolism | 4.4.1.5 | ABAYE1052 | RGT + MTG <-> LTG | lactoylglutathione lyase |
R084 | Pyruvate metabolism | 3.1.2.6 | ABAYE1362 OR ABAYE1940 | LTG-> RGT + LAC | hydroxyacylglutathionehydrolaseGloB |
R085 | Pyruvate metabolism | 1.1.2.3 | ABAYE3797 | SLAC + 2FERIC <-> PYR + 2 FEROC | L-lactate dehydrogenase, FMN linked |
R086 | Pyruvate metabolism | 1.1.99.16 | ABAYE2869 | MAL + FAD-> FADH2 + OA | malate dehydrogenase |
R087 | Pyruvate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | ACAL + NADP <-> AC + NADPH | aldehyde dehydrogenase |
R088 | Pyruvate metabolism | 1.2.4.1 | ABAYE0157 OR (ABAYE1947 AND ABAYE1948) | 2 (HE) TPP + LIPO <-> ADLIPO + THMPP | pyruvate dehydrogenase subunit E1 |
R089 | Pyruvate metabolism | 2.3.3.13 | ABAYE3292 | IPPMAL + COA <-> ACCOA + OIVAL | 2-isopropylmalate synthase |
R090 | Pyruvate metabolism | 4.1.1.- | ABAYE1027 | PYR + CO2 <-> HEDC | L-2,4-diaminobutyrate decarboxylase |
R091 | Pyruvate metabolism | 4.1.1.32 | ABAYE0818 | GTP + OA <-> GDP + PEP + CO2 | phosphoenolpyruvatecarboxykinase [GTP] (PEPcarboxykinase) |
R092 | Pyruvate metabolism | 4.1.1.32 | ABAYE0818 | ITP + OA <-> IDP + PEP + CO2 | phosphoenolpyruvate carboxykinase [GTP] (PEP carboxykinase) |
R093 | Glyoxylate and dicarboxylate metabolism | 4.1.3.1 | ABAYE2783 | ICIT-> SUCC + GLX | isocitratelyase |
R094 | Glyoxylate and dicarboxylate metabolism | 1.2.1.2 | ABAYE0850 | FORMATE + NAD-> CO2 + NADH | formate dehydrogenase |
R095 | Glyoxylate and dicarboxylate metabolism | 1.2.1.21 | GLAL + NAD-> NADH + GLYCOLATE | glycolaldehyde dehydrogenase | |
R096 | Glyoxylate and dicarboxylate metabolism | 3.1.3.18 | ABAYE0081 OR ABAYE2988 OR ABAYE3373 OR ABAYE3498 OR ABAYE3835 | 2PPG-> GLYCOLATE + PI | phosphoglycolate phosphatase |
R097 | Glyoxylate and dicarboxylate metabolism | 1.1.1.60 | ABAYE1786 | DGLYCERATE + NAD <-> HOPP + NADH | 2-hydroxy-3-oxopropionate reductase OR tartronate semialdehyde reductase |
R098 | Glyoxylate and dicarboxylate metabolism | 1.1.1.60 | ABAYE1786 | DGLYCERATE + NADP <-> HOPP + NADPH | 2-hydroxy-3-oxopropionate reductase OR tartronate semialdehyde reductase |
R099 | Glyoxylate and dicarboxylate metabolism | 1.1.1.93 | ABAYE2964 | MTTA + NAD <-> 2H3OSUCC + NADH | tartrate dehydrogenase / decarboxylase OR D-malate dehydrogenase [decarboxylating] |
R100 | Glyoxylate and dicarboxylate metabolism | 1.1.1.93 | ABAYE2964 | TTA + NAD <-> 2H3OSUCC + NADH | tartratedehydrogenase / decarboxylase OR D-malatedehydrogenase [decarboxylating] |
R101 | Glyoxylate and dicarboxylate metabolism | 2.3.3.9 | ABAYE2053 | MAL + COA <-> ACCOA + GLX | malate synthase G |
R102 | Glyoxylate and dicarboxylate metabolism | 5.3.1.22 | ABAYE3188 | HPYR <-> HOPP | hydroxypyruvate isomerase |
R103 | Propanoate metabolism | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 OR ABAYE3470 | 3HPCOA <-> PPCOA | enoyl-CoA hydratase / isomerase OR 3-methylglutaconyl-CoA hydratase |
R104 | Propanoate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | ATP + PROPANOATE <-> PPI + PPA | acetyl-CoAsynthetase |
R105 | Propanoate metabolism | 6.2.1.1 | ABAYE0179 OR ABAYE1413 OR ABAYE3766 | PPA + COA <-> AMP + PPACOA | propionyl-CoA synthetase |
R106 | Propanoate metabolism | 2.7.2.1 | ABAYE3282 | PROPANOATE + ATP <-> PROPIONYLP + ADP | acetate kinase |
R107 | Propanoate metabolism | 2.3.1.8 | ABAYE1138 OR ABAYE3283 | PPACOA + PI <-> PROPIONYLP + COA | phosphate acetyltransferase |
R108 | Propanoate metabolism | 2.3.1.54 | OBUT + COA <-> PPACOA + FORMATE | formateacetyltransferase | |
R109 | Propanoate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 2P1A + NAD-> PPN + NADH | aldehydedehydrogenase |
R110 | Propanoate metabolism | 2.3.3.5 | ABAYE3792 | 2MCIT + COA <-> PPACOA + OA | 2-methylcitrate synthase |
R111 | Propanoate metabolism | 4.1.3.30 | ABAYE3793 | 3HB123TC <-> PYR + SUCC | methylisocitrate lyase |
R112 | Propanoate metabolism | 1.2.1.27 | ABAYE1296 OR ABAYE3768 | MMSA + COA + NAD-> PPACOA + CO2 + NADH | methylmalonate-semialdehydedehydrogenase |
R113 | Propanoate metabolism | 1.3.99.3 | ABAYE0476 OR ABAYE2013 | PPACOA + FAD <-> FADH2 + PPCOA | acyl-CoA dehydrogenase |
R114 | Propanoate metabolism | 4.1.1.4 | ABAYE1742 | AAC-> ACTN + CO2 | acetoacetate decarboxylase |
R115 | Propanoate metabolism | 6.4.1.3 | ABAYE0480 | ATP + PPACOA + HCO3 <-> ADP + PI + MMALCOA | propionyl-CoA carboxylase |
R116 | Glycolysis / Gluconeogensis / Butanoate metabolism | 2.2.1.6 OR 4.1.1.1 OR 1.2.4.1 | (ABAYE2836 OR ABAYE3239 OR ABAYE3240) OR ABAYE1030 OR ABAYE0157 OR (ABAYE1947 AND ABAYE1948) | THMPP + PYR-> 2 (HE) TPP + CO2 | acetolactatesynthaseORpyruvatedehydrogenase |
R117 | Butanoate metabolism | 2.2.1.6 | ABAYE2836 OR ABAYE3239 OR ABAYE3240 | 2 (HE) TPP + PYR-> ACLAC + THMPP | acetolactate synthase |
R118 | Butanoate metabolism | 1.1.1.35 | ABAYE1411 OR ABAYE2460 OR ABAYE3470 | 3HBCOA + NAD <-> AACCOA + NADH | 3-hydroxyacyl-CoAdehydrogenase |
R119 | Butanoate metabolism | 5.1.2.3 | ABAYE0628OR ABAYE3470 | 3HBCOA <-> R3HBCOA | 3-hydroxybutyryl-CoAepimerase |
R120 | Butanoate metabolism | 4.2.1.17 | ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764 | 3HBCOA <-> CCOA | enoyl-CoA hydratase / isomerase OR 3-methylglutaconyl-CoA hydratase |
R121 | Butanoate metabolism | 1.1.1.- | ABAYE0043 OR ABAYE0109 OR ABAYE0479 OR ABAYE1356 OR ABAYE2589 OR ABAYE2607 OR ABAYE2613 OR ABAYE2618 OR ABAYE2845 OR ABAYE3187 OR ABAYE3378 | 1BOH + NAD <-> BUTANAL + NADH | alcoholdehydrogenase |
R122 | Butanoate metabolism | 1.2.1.16 | ABAYE0210 OR ABAYE2329 OR ABAYE2958 | SUCCSA + NAD-> SUCC + NADH | succinate-semialdehyde dehydrogenase |
R123 | Butanoate metabolism | 1.2.1.16 | ABAYE0210 OR ABAYE2329 OR ABAYE2958 | SUCCSA + NADP-> SUCC + NADPH | succinate-semialdehyde dehydrogenase |
R124 | Butanoate metabolism | 2.6.1.19 | ABAYE0209 | GABA + AKG <-> SUCCSA + GLU | 4-aminobutyrateaminotransferase |
R125 | Butanoate metabolism | 4.1.3.4 | ABAYE2292 OR ABAYE2344 | 3H3MGCOA-> ACCOA + AAC | hydroxymethylglutaryl-CoA lyase |
R126 | Butanoate metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 3B1A + NAD-> 3BUT + NADH | aldehydedehydrogenase |
R127 | Butanoate metabolism | 1.1.1.157 | ABAYE2306 OR ABAYE2368 | 3HBCOA + NADP <-> AACCOA + NADPH | 3-hydroxybutyryl-CoA dehydrogenase |
R128 | Butanoate metabolism | 1.1.1.30 | ABAYE1909 | 3HBUT + NAD <-> AAC + NADH | 3-hydroxybutyrate dehydrogenase |
R129 | Butanoate metabolism | 1.1.1.4 | ABAYE1943 | 23BOH + NAD <-> ACT + NADH | (R, R) -butanediol dehydrogenase |
R130 | Butanoate metabolism | 1.1.1.5 | ABAYE1944 | DAC + NADH-> ACT + NAD | acetoin dehydrogenase (DAC reductase) |
R131 | Butanoate metabolism | 1.1.1.5 | ABAYE1944 | DAC + NADPH-> ACT + NADP | acetoin dehydrogenase (DAC reductase) |
R132 | Butanoate metabolism | 1.1.1.83 | ABAYE2964 | RMAL + NAD-> PYR + CO2 + NADH | tartrate dehydrogenase / decarboxylase OR D-malate dehydrogenase [decarboxylating] |
R133 | Butanoate metabolism | 2.8.3.5 | ABAYE1913 AND ABAYE1914 | SUCCOA + AAC <-> SUCC + AACCOA | acetoacetyl-CoA transferase |
R134 | Inositol metabolism | 1.2.1.27 | ABAYE1296 OR ABAYE3768 | 3OPP + COA + NAD-> ACCOA + CO2 + NADH | NAD-dependent aldehyde dehydrogenase |
R135 | Oxidative phosphorylation | 1.6.5.3 AND 1.6.99.3 | (ABAYE3048 AND ABAYE3049 AND ABAYE3050 AND ABAYE3051 AND ABAYE3052 AND ABAYE3053 AND ABAYE3054 AND ABAYE3055 AND ABAYE3056 AND ABAYE3057 AND ABAYE3058 AND ABAYE3059 AND ABAYE3060) AND (ABAYE0977 OR ABAYE1736) | NADH + UQ-> NAD + UQH2 | NADH dehydrogenase |
R136 | Oxidative phosphorylation | 1.6.5.3 AND 1.6.99.3 | (ABAYE3048 AND ABAYE3049 AND ABAYE3050 AND ABAYE3051 AND ABAYE3052 AND ABAYE3053 AND ABAYE3054 AND ABAYE3055 AND ABAYE3056 AND ABAYE3057 AND ABAYE3058 AND ABAYE3059 AND ABAYE3060) AND (ABAYE0977 OR ABAYE1736) | NADH + MK-> NAD + MKH2 | NADH dehydrogenase |
R137 | Oxidative phosphorylation | 1.6.5.3 AND 1.6.99.3 | (ABAYE3048 AND ABAYE3049 AND ABAYE3050 AND ABAYE3051 AND ABAYE3052 AND ABAYE3053 AND ABAYE3054 AND ABAYE3055 AND ABAYE3056 AND ABAYE3057 AND ABAYE3058 AND ABAYE3059 AND ABAYE3060) AND (ABAYE0977 OR ABAYE1736) | NADH + DMK-> NAD + DMKH2 | NADH dehydrogenase |
R138 | Oxidative phosphorylation | 1.3.99.1 | ABAYE0774 AND ABAYE0775 AND ABAYE0776 AND ABAYE0777 | FADH2 + UQ-> FAD + UQH2 | succinatedehydrogenase |
R139 | Oxidative phosphorylation | 2.5.1.- AND 1.10.3.- | ABAYE1385AND ABAYE1386 AND ABAYE1387 AND ABAYE1388 AND ABAYE1389 AND ((ABAYE1636 AND ABAYE1637) OR ABAYE2219 AND ABAYE2220) | UQH2 + 0.5O2-> UQ + 2 Hxt | cytochrome complexes |
R140 | Oxidative phosphorylation | 3.6.1.1 | ABAYE3675 | PPI-> 2 PI | inorganic diphosphatase |
R141 | ATP synthesis | 3.6.3.14 | ABAYE3715 AND ABAYE3716 AND ABAYE3717 AND ABAYE3718 AND ABAYE3719 AND ABAYE3720 AND ABAYE3721 AND ABAYE3723 | ADP + PI + 4 Hxt <-> ATP | ATP synthase |
R142 | Oxidative phosphorylation | 2.7.4.1 | ABAYE2803 | ATP + PPI <-> ADP + PPPI | polyphosphate kinase |
R143 | Nitrogen metabolism | 4.2.1.1 | ABAYE0262 OR ABAYE2809 | CO2-> HCO3 | carbonic anhydrase |
R144 | Nitrogen metabolism | 1.7.99.4 | ABAYE1546 | NO3 + FEROC-> FERIC + NO2 | nitrate reductase |
R145 | Nitrogen metabolism | 1.7.1.4 | ABAYE1544 | NO2 + 3NADH-> 3NAD + NH3 | nitrite reductase |
R146 | Nitrogen metabolism | 1.7.1.4 | ABAYE1544 | NO2 + 3NADPH-> 3NADP + NH3 | nitrite reductase |
R147 | Nitrogen metabolism | 4.3.1.1 | ABAYE1921 | ASP <-> FUM + NH3 | aspartate ammonia-lyase |
R148 | Nitrogen metabolism | 1.13.11.32 | ABAYE0966 OR ABAYE2310 | O2 + 2 2NPRPN <-> 2 ACTN + 2 NO2 | 2-nitropropane dioxygenase |
R149 | Nitrogen metabolism | 1.14.12.1 | ABAYE1896 AND ABAYE1897 | AN + O2 + NADH <-> CATECHOL + NH3 + CO2 + NAD | anthranilate dioxygenase |
R150 | Nitrogen metabolism | 1.14.12.1 | ABAYE1896 AND ABAYE1897 | AN + O2 + NADPH <-> CATECHOL + NH3 + CO2 + NADP | anthranilate dioxygenase |
R151 | Nitrogen metabolism | 1.4.1.13 | ABAYE0298 AND ABAYE0299 | 2GLU + NADP <-> GLN + AKG + NADPH | glutamate synthase |
R152 | Nitrogen metabolism | 1.4.1.13 | ABAYE0298 AND ABAYE0299 | 2GLU + NAD <-> GLN + AKG + NADH | glutamate synthase |
R153 | Nitrogen metabolism | 1.4.1.3 OR 1.4.1.4 | ABAYE0351 OR ABAYE2764 | GLU + NAD <-> AKG + NH3 + NADH | glutamate dehydrogenase (NAD (P) +) oxidoreductase protein |
R154 | Nitrogen metabolism | 1.4.1.3 OR 1.4.1.4 | ABAYE0351ORABAYE2764 | GLU + NADP <-> AKG + NH3 + NADPH | glutamatedehydrogenase, NADP-specific |
R155 | Nitrogen metabolism | 1.4.99.1 | ABAYE1567 OR ABAYE3774 | DALA + FAD <-> PYR + NH3 + FADH2 | D-amino acid dehydrogenase |
R156 | Sulfur metabolism | 2.7.7.4 | ABAYE2790 AND ABAYE2791 | SLF + ATP-> PPI + APS | sulfateadenylyltransferase |
R157 | Sulfur metabolism | 2.7.1.25 | APS + ATP-> ADP + PAPS | adenylylsulfate kinase | |
R158 | Sulfur metabolism | 1.8.4.8 | ABAYE0709 | PAPS + RTHIO-> OTHIO + H2SO3 + PAP | 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase) |
R159 | Sulfur metabolism | 1.8.1.2 | ABAYE0634 OR ABAYE0682 | H2SO3 + 3NADPH-> H2S + 3 NADP | sulfite reductase (NADPH) |
R160 | Sulfur metabolism | 3.1.3.7 | PAP-> PI + AMP | 3 ', 5'-bisphosphate nucleotidase | |
R161 | Sulfur metabolism | 1.8.1.2 | ABAYE0634 | SELT + 3NADP-> SELD + 3 NADPH | sulfite reductase (NADPH) |
R162 | Fattyacidbiosynthesis | 6.4.1.2 AND 6.3.4.14 | (ABAYE0614ORABAYE1537ORABAYE1538ORABAYE3153) AND (ABAYE1537ORABAYE2291ORABAYE2438) | ACCOA + ATP + HCO3-> MALCOA + ADP + PI | acetyl-CoA carboxylase |
R163 | Fattyacidbiosynthesis | 2.3.1.39 | ABAYE2227 OR ABAYE2993 | MALCOA + ACP-> MALACP + COA | malonyl CoA-acyl carrier protein transacylase |
R164 | Fattyacidbiosynthesis | 2.3.1.180 | ABAYE2562 | ACCOA + ACP-> ACACP + COA | 3-oxoacyl- [acyl-carrier-protein] synthase |
R165 | Fattyacidbiosynthesis | PPACOA + ACP-> PPAACP + COA | malonyl CoA-acyl carrier protein transacylase | ||
R166 | Fattyacidbiosynthesis (nonanoic acid; c9: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 3MALACP + 6NADPH-> 6NADP + C090ACP + 3 CO2 + 3 ACP | synthesis of nonanoyl- [acyl-carrier protein] |
R167 | Fattyacidbiosynthesis (decanoic acid; c10: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 4MALACP + 8NADPH-> 8NADP + C100ACP + 4 CO2 + 4 ACP | synthesis of decanoyl- [acyl-carrier protein] |
R168 | Fattyacidbiosynthesis (undecanoic acid; c11: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 4MALACP + 8NADPH-> 8NADP + C110ACP + 4 CO2 + 4 ACP | synthesis of undecanoyl- [acyl-carrier protein] |
R169 | Fattyacidbiosynthesis (dodecanoic acid; c12: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 5MALACP + 10NADPH-> 10NADP + C120ACP + 5 CO2 + 5 ACP | synthesis of dodecanoyl- [acyl-carrier protein] |
R170 | Fattyacidbiosynthesis (tridecanoic acid; c13: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 5MALACP + 10NADPH-> 10NADP + C130ACP + 5 CO2 + 5 ACP | synthesis of tridecanoyl- [acyl-carrier protein] |
R171 | Fattyacidbiosynthesis (tetradecanoic acid; c14: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 6MALACP + 12NADPH-> 12NADP + C140ACP + 6 CO2 + 6 ACP | synthesis of tetradecanoyl- [acyl-carrier protein] |
R172 | Fattyacidbiosynthesis (pentadecanoic acid; c15: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 6MALACP + 12NADPH-> 12NADP + C150ACP + 6 CO2 + 6 ACP | synthesis of pentadecanoyl- [acyl-carrier protein] |
R173 | Fattyacidbiosynthesis (pentadecenoic acid; c15: 1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 6MALACP + 11NADPH-> 11NADP + C151ACP + 6 CO2 + 6 ACP | synthesis of pentadecenoyl- [acyl-carrier protein] |
R174 | Fattyacidbiosynthesis (hexadecanoic acid; c16: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 7MALACP + 14NADPH-> 14NADP + C160ACP + 7 CO2 + 7 ACP | synthesis of hexadecanoyl- [acyl-carrier protein] |
R175 | Fattyacidbiosynthesis (hexadecenoic acid; c16: 1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 7MALACP + 13NADPH-> 13NADP + C161ACP + 7 CO2 + 7 ACP | synthesis of hexadecenoyl- [acyl-carrier protein] |
R176 | Fattyacidbiosynthesis (heptadecanoic acid; c17: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 7MALACP + 14NADPH-> 14NADP + C170ACP + 7 CO2 + 7 ACP | synthesis of heptadecanoyl- [acyl-carrier protein] |
R177 | Fattyacidbiosynthesis (heptadecenoic acid; c17: 1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 7MALACP + 13NADPH-> 13NADP + C171ACP + 7 CO2 + 7 ACP | synthesis of heptadecenoyl- [acyl-carrier protein] |
R178 | Fattyacidbiosynthesis (octadecanoic acid; c18: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 8MALACP + 16NADPH-> 16NADP + C180ACP + 8 CO2 + 8 ACP | synthesis of octadecanoyl- [acyl-carrier protein] |
R179 | Fattyacidbiosynthesis (octadecenoic acid; c18: 1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 8MALACP + 15NADPH-> 15NADP + C181ACP + 8 CO2 + 8 ACP | synthesis of octadecenoyl- [acyl-carrier protein] |
R180 | Fattyacidbiosynthesis (nonadecanoic acid; c19: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 8MALACP + 16NADPH-> 16NADP + C190ACP + 8 CO2 + 8 ACP | synthesis of nonadecanoyl- [acyl-carrier protein] |
R181 | Fattyacidbiosynthesis (nonadecenoic acid; c19: 1) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | PPAACP + 8MALACP + 15NADPH-> 15NADP + C191ACP + 8 CO2 + 8 ACP | synthesis of nonadecenoyl- [acyl-carrier protein] |
R182 | Fattyacidbiosynthesis (eicosanoic acid; c20: 0) | 1.1.1.100AND1.3.1.9AND2.3.1.41AND 2.3.1.180 AND 4.2.1.- | (ABAYE1514 OR ABAYE1706 OR ABAYE2246 OR ABAYE2992) AND ABAYE3250 AND ABAYE2951 AND ABAYE2562 AND ABAYE1586 | ACACP + 9MALACP + 18NADPH-> 18NADP + C200ACP + 9 CO2 + 9 ACP | synthesis of eicosanoyl- [acyl-carrier protein] |
R183 | Fattyacidmetabolism (decanoic acid; c10: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C100 + 5COA + 4FAD + 4NAD + ATP-> 5 ACCOA + 4 FADH2 + 4 NADH + AMP + PPI | oxidation of decanoic acid |
R184 | Fattyacidmetabolism (dodecanoic acid; c12: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C120 + 6COA + 5FAD + 5NAD + ATP-> 6 ACCOA + 5 FADH2 + 5 NADH + AMP + PPI | oxidation of dodecanoic acid |
R185 | Fattyacidmetabolism (tetradecanoic acid; c14: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C140 + 7COA + 6FAD + 6NAD + ATP-> 7 ACCOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of tetradecanoic acid |
R186 | Fattyacidmetabolism (pentadecanoic acid; c15: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C150 + 7COA + 6FAD + 6NAD + ATP-> 6 ACCOA + PPACOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of pentadecanoic acid |
R187 | Fattyacidmetabolism (hexadecanoic acid; c16: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C160 + 8COA + 7FAD + 7NAD + ATP-> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecanoic acid |
R188 | Fattyacidmetabolism (hexadecenoic acid; c16: 1) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C161 + 8COA + 7FAD + 7NAD + ATP-> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecenoic acid |
R189 | Fattyacidmetabolism (heptadecanoic acid; c17: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C170 + 8COA + 7FAD + 7NAD + ATP-> 7 ACCOA + PPACOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of heptadecanoic acid |
R190 | Fattyacidmetabolism (heptadecenoic acid; c17: 1) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C171 + 8COA + 7FAD + 7NAD + ATP-> 7 ACCOA + PPACOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of heptadecenoic acid |
R191 | Fattyacidmetabolism (octadecanoic acid; c18: 0) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C180 + 9COA + 8FAD + 8NAD + ATP-> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecanoic acid |
R192 | Fattyacidmetabolism (octadecenoic acid; c18: 1) | 6.2.1.3AND1.3.99.-AND1.3.99.3AND1.3.99.13AND4.2.1.17AND1.1.1.35AND2.3.1.16AND2.3.1.9AND 1.3.99.7 | (ABAYE2630ORABAYE3678) ANDABAYE1145AND (ABAYE0436ORABAYE1204ORABAYE2631) AND (ABAYE1411ORABAYE2460ORABAYE3470) AND (ABAYE0482ORABAYE0915ORABAYE2065ORABAYE2290ORABAYE2304ORABAYE2311ORABAYE2369ORABAYE2370ORABAYE2628ORABAYE2852ORABAYE3186ORABAYE3470ORABAYE3763ORABAYE3764) ANDABAYE3097ANDABAYE3471 | C181 + 9COA + 8FAD + 8NAD + ATP-> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecenoic acid |
R193 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C120ACP + O2 + RRBRDX <-> C120OH + ORBRDX + ACP | terminal alkane-1-monooxygenase |
R194 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C120ACP + O2 + FADH2 <-> C120OH + FAD + ACP | terminal alkane-1-monooxygenase |
R195 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C140ACP + O2 + RRBRDX <-> C140OH + ORBRDX + ACP | terminal alkane-1-monooxygenase |
R196 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | C140ACP + O2 + FADH2 <-> C140OH + FAD + ACP | terminal alkane-1-monooxygenase |
R197 | Fatty acid metabolism | 1.1.1.1 | ABAYE0763 OR ABAYE1463 OR ABAYE1522 OR ABAYE1861 OR p2ABAYE0004 OR p3ABAYE0020 OR p3ABAYE0024 | CH3OR + NAD <-> RCHO + NADH | alcohol dehydrogenase |
R198 | Fatty acid metabolism | 1.14.15.3 | ABAYE2014 | RH + RRBRDX + O2 <-> ORBRDX + CH3OR | terminal alkane-1-monooxygenase |
R199 | Fatty acid metabolism | 1.18.1.1OR1.18.1.3 | (ABAYE1067 OR ABAYE2799) OR ABAYE2843 | RRBRDX + NAD <-> ORBRDX + NADH | rubredoxin-NAD (+) reductase ORferredoxinreductasecomponent (dioxygenase) |
R200 | Fatty acid metabolism | 1.18.1.3 | ABAYE2843 | RRBRDX + NADP <-> ORBRDX + NADPH | ferredoxinreductasecomponent (dioxygenase) |
R201 | Fatty acid metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | RCHO + NAD <-> 0.015C100 + 0.048C120 + 0.003C140 + 0.003C150 + 0.281C160 + 0.192C161 + 0.017C170 + 0.016C171 + 0.008C180 + 0.375C181 + 0.041C120OH + NADH | aldehyde dehydrogenase |
R202 | Fatty acid metabolism | 5.3.3.8 | ABAYE3470 | C121COA <-> C122COA | fattyoxidationcomplexalphasubunit |
R203 | Biosynthesis of steroids | 2.2.1.7 | ABAYE0381 | PYR + G3P-> DX5P + CO2 | 1-deoxy-D-xylulose-5-phosphate synthase |
R204 | Biosynthesis of steroids | 1.1.1.267 | ABAYE1581 | DX5P + NADPH-> MDE4P + NADP | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
R205 | Biosynthesis of steroids | 2.7.7.60 | ABAYE1672 | MDE4P + CTP-> CDPMDE + PPI | 4-diphosphocytidyl-2-methyl-D-erythritol synthase |
R206 | Biosynthesis of steroids | 4.6.1.12 | ABAYE1569 | 2PCDPMDE-> MDECPP + CMP | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase |
R207 | Biosynthesis of steroids | 1.17.4.3 | ABAYE3263 | MDECPP + NADH-> NAD + HMB4PP | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase |
R208 | Biosynthesis of steroids | 1.17.1.2 | ABAYE0313 | HMB4PP + NADH-> NAD + IPP | 4-hydroxy-3-methylbut-2-enyl diphosphate reductase |
R209 | Biosynthesis of steroids | 2.5.1.10 | ABAYE0722 | DMPP + IPP-> GPP + PPI | geranylgeranyl pyrophosphate synthase |
R210 | Biosynthesis of steroids | 2.5.1.10 | ABAYE0722 | GPP + IPP-> FPP + PPI | geranylgeranyl pyrophosphate synthase |
R211 | Biosynthesis of steroids | GGPP + IPP-> PPPP + PPI | dimethylallyltranstransferase | ||
R212 | Biosynthesis of steroids | HEPPP + IPP-> OPP + PPI | trans-hexaprenyltranstransferase | ||
R213 | Glycerolipid metabolism | 2.7.1.31 | ABAYE0849 | 3PG + ADP <-> DGLYCERATE + ATP | glycerate kinase |
R214 | Glycerolipid metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | NADH + DGLYCERATE <-> T3 + NAD | aldehydedehydrogenase |
R215 | Glycerolipid metabolism | 2.7.1.30 | ABAYE0816 | GL + ATP-> GL3P + ADP | glycerolkinase |
R216 | Glycerolipid metabolism | 3.1.1.3 | ABAYE0325 OR ABAYE2810 | DGR-> AGL + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | triacylglycerol lipase |
R217 | Glycerolipid metabolism | 3.1.1.3 | ABAYE0325 OR ABAYE2810 | TGL-> DGR + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | triacylglycerol lipase |
R218 | Glycerolipid metabolism | 2.3.1.15 | ABAYE0397 | GL3P + ACCOA-> AGL3P + COA | glycerol-3-phosphate acyltransferase |
R219 | Glycerolipid metabolism | 2.3.1.20 | ABAYE0708 | TGL + COA-> DGR + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | bifunctional protein [wax ester synthase / acyl-CoA: diacylglycerol acyltransferase] |
R220 | Glycerophospholipid metabolism | 1.1.1.94 | ABAYE1223 | DHAP + NADH-> GL3P + NAD | glycerol-3-phosphate dehydrogenase |
R221 | Glycerophospholipid metabolism | 1.1.1.94 | ABAYE1223 | DHAP + NADPH-> GL3P + NADP | glycerol-3-phosphate dehydrogenase |
R222 | Glycerophospholipid metabolism | 1.1.99.5 | ABAYE0817 | DHAP + UQH2 <-> GL3P + UQ | glycerol-3-phosphatedehydrogenase |
R223 | Glycerophospholipid metabolism | 1.1.99.5 | ABAYE0817 | DHAP + MKH2 <-> GL3P + MK | glycerol-3-phosphatedehydrogenase |
R224 | Glycerophospholipid metabolism | 1.1.99.5 | ABAYE0817 | DHAP + DMKH2 <-> GL3P + DMK | glycerol-3-phosphatedehydrogenase |
R225 | Glycerophospholipid metabolism | 2.3.1.- | ABAYE0497 OR ABAYE0625 OR ABAYE1513 OR ABAYE1675 OR ABAYE1715 OR ABAYE1811 OR ABAYE2153 OR ABAYE2367 OR ABAYE2457 OR ABAYE2483 OR ABAYE3572 OR ABAYE3588 OR ABAYE3697 OR ABAYE3807 | GL3P + ACOA-> 2AGL3P + COA | acetyltransferase |
R226 | Glycerophospholipid metabolism | 2.3.1.15 | ABAYE0397 | GL3P + 0.015C100ACP + 0.048C120ACP + 0.003C140ACP + 0.003C150ACP + 0.281C160ACP + 0.192C161ACP + 0.017C170ACP + 0.016C171ACP + 0.008C180ACP + 0.375C181ACP + 0.041C120OH-> AGL3P + 0.958 ACP | glycerol-3-phosphate O-acyltransferase |
R227 | Glycerophospholipid metabolism | 2.3.1.51 | AGL3P + 0.015C100ACP + 0.048C120ACP + 0.003C140ACP + 0.003C150ACP + 0.281C160ACP + 0.192C161ACP + 0.017C170ACP + 0.016C171ACP + 0.008C180ACP + 0.375C181ACP + 0.041C120OH-> PA + 0.958 ACP | 1-acylglycerol-3-phosphate O-acyltransferase | |
R228 | Glycerophospholipid metabolism | 2.7.1.107 | ABAYE0824 | DGR + ATP-> ADP + PA | diacylglycerol kinase |
R229 | Glycerophospholipid metabolism | 3.1.1.32 | ABAYE1646 | PC-> 2AG3PC + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | phospholipase |
R230 | Glycerophospholipid metabolism | 3.1.4.46 | ABAYE0604 OR ABAYE0826 | G3PC-> CHOLINE + GL3P | glycerophosphoryl diester phosphodiesterase |
R231 | Glycerophospholipid metabolism | 2.7.7.41 | ABAYE1580 | PA + CTP <-> CDPDG + PPI | phosphatidate cytidylyltransferase |
R232 | Glycerophospholipid metabolism | 2.7.8.8 | ABAYE0470 | CDPDG + SER <-> CMP + PS | phosphatidylserine synthase |
R233 | Glycerophospholipid metabolism | 3.1.1.32 | ABAYE1646 | PS-> 2AG3PS + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | phospholipase |
R234 | Glycerophospholipid metabolism | 4.1.1.65 | ABAYE0104 | PS-> PE + CO2 | phosphatidylserinedecarboxylase |
R235 | Glycerophospholipid metabolism | 3.1.1.32 | ABAYE1646 | PE-> 2AG3PE + 0.015 C100 + 0.048 C120 + 0.003 C140 + 0.003 C150 + 0.281 C160 + 0.192 C161 + 0.017 C170 + 0.016 C171 + 0.008 C180 + 0.375 C181 + 0.041 C120OH | phospholipase |
R236 | Glycerophospholipid metabolism | 3.1.4.46 | ABAYE0604 OR ABAYE0826 | G3PE-> ETHA + GL3P | glycerophosphoryl diester phosphodiesterase |
R237 | Glycerophospholipid metabolism | 2.7.8.5 | ABAYE3463 | CDPDG + GL3P <-> CMP + PGP | CDP-diacylglycerol--glycerol-3-phosphate3-phosphatidyltransferase |
R238 | Glycerophospholipid metabolism | 3.1.3.27 | ABAYE0091 OR ABAYE0749 OR ABAYE3269 | PGP-> PI + PG | phosphatidylglycerophosphatase |
R239 | Glycerophospholipid metabolism | 2.7.8.- | CDPDG + PG-> CMP + CL | cardiolipin synthase | |
R240 | Glycerophospholipid metabolism | 3.1.4.3 | ABAYE1520 OR ABAYE3825 | PC <-> DGR + CHOLINEP | phospholipase C precursor (phosphatidylcholine cholinephosphohydrolase) (phosphatidylcholine-hydrolyzing phospholipase C) |
R241 | Glycerophospholipid metabolism | 3.1.4.3 | ABAYE1520 OR ABAYE3825 | PE <-> DGR + ETHAP | phospholipase C precursor (phosphatidylcholine cholinephosphohydrolase) (phosphatidylcholine-hydrolyzing phospholipase C) |
R242 | Glycerophospholipid metabolism | 3.1.4.3 | ABAYE1520 OR ABAYE3825 | PG <-> DGR + GL3P | phospholipase C precursor (phosphatidylcholine cholinephosphohydrolase) (phosphatidylcholine-hydrolyzing phospholipase C) |
R243 | Glycerophospholipid metabolism | 4.3.1.7 | ABAYE1457 AND ABAYE1458 | ETHA <-> ACAL + NH3 | ethanolamine ammonia-lyase |
R244 | Purinemetabolism | 2.7.6.1 | ABAYE1789 OR ABAYE2981 | R5P + ATP <-> PRPP + AMP | ribose-phosphate pyrophosphokinase |
R245 | Purine metabolism (De novo) | 2.4.2.14 | ABAYE1280 | PRPP + GLN-> PRAM + PPI + GLU | amidophosphoribosyltransferase |
R246 | Purine metabolism (De novo) | 6.3.4.13 | ABAYE1366 | PRAM + ATP + GLY <-> GAR + ADP + PI | phosphoribosylamine-glycine ligase |
R247 | Purine metabolism (De novo) | 2.1.2.2 | ABAYE0888 OR ABAYE2179 | GAR + FTHF-> FGAR + THF | phosphoribosylglycinamideformyltransferase |
R248 | Purine metabolism (De novo) | 6.3.5.3 | ABAYE0912 | FGAR + ATP + GLN-> FGAM + GLU + ADP + PI | phosphoribosylformylglycinamidine synthase |
R249 | Purine metabolism (De novo) | 6.3.3.1 | ABAYE0889 | FGAM + ATP-> AIR + ADP + PI | phosphoribosylformylglycinamidine cyclo-ligase |
R250 | Purine metabolism (De novo) | 4.1.1.21 | ABAYE3871 AND ABAYE3872 | AIR + CO2 + ATP-> CAIR + ADP + PI | phosphoribosylaminoimidazolecarboxylase |
R251 | Purine metabolism (De novo) | 6.3.2.6 | ABAYE0056 | CAIR + ATP + ASP <-> SAICAR + ADP + PI | phosphoribosylaminoimidazole-succinocarboxamide synthase |
R252 | Purine metabolism (De novo) | 4.3.2.2 | ABAYE1039 | SAICAR <-> AICAR + FUM | adenylosuccinatelyase |
R253 | Purine metabolism (De novo) | 2.1.2.3 | ABAYE1367 | AICAR + FTHF <-> PRFICA + THF | phosphoribosylaminoimidazolecarboxamide formyltransferase |
R254 | Purine metabolism (De novo) | 3.5.4.10 | ABAYE1367 | PRFICA <-> IMP | phosphoribosylaminoimidazolecarboxamide formyltransferase; IMP cyclohydrolase |
R255 | Purine metabolism (De novo) | 6.3.4.4 | ABAYE2592 | IMP + GTP + ASP-> ASUC + GDP + PI | adenylosuccinatesynthase |
R256 | Purine metabolism (De novo) | 4.3.2.2 | ABAYE1039 | ASUC <-> FUM + AMP | adenylosuccinatelyase |
R257 | Purine metabolism (De novo) | 1.1.1.205 | ABAYE0166 | IMP + NAD-> XMP + NADH | IMP dehydrogenase |
R258 | Purine metabolism (De novo) | 6.3.5.2 | ABAYE1456 OR ABAYE3740 | XMP + ATP + GLN-> GMP + GLU + AMP + PPI | GMP synthetase |
R259 | Purine metabolism | 3.5.4.4 | ABAYE2601 OR ABAYE3101 | ADN-> INS + NH3 | adenosinedeaminase |
R260 | Purine metabolism | 3.5.4.4 | ABAYE2601 OR ABAYE3101 | DA <-> DIN + NH3 | adenosine deaminase |
R261 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | IMP-> INS + PI | 5'-nucleotidase |
R262 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | AMP-> ADN + PI | 5'-nucleotidase |
R263 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | XMP-> XTSINE + PI | 5'-nucleotidase |
R264 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | GMP-> GSN + PI | 5'-nucleotidase |
R265 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DAMP <-> DA + PI | 5'-nucleotidase |
R266 | Purine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DGMP <-> DG + PI | 5'-nucleotidase |
R267 | Purine metabolism | 2.7.4.8 | ABAYE0312 | DGMP + ATP <-> DGDP + ADP | guanylatekinase |
R268 | Purine metabolism | 2.7.4.6 | ABAYE3267 | IDP + ATP <-> ITP + ADP | nucleoside-diphosphate kinase |
R269 | Purine metabolism | 2.7.4.6 | ABAYE3267 | ATP + DIDP <-> ADP + DITP | nucleoside-diphosphatekinase |
R270 | Purine metabolism | 2.4.2.8 | ABAYE3887 | HYXN + PRPP-> PPI + IMP | hypoxanthinephosphoribosyltransferase |
R271 | Purine metabolism | 2.4.2.8 | ABAYE3887 | XAN + PRPP-> PPI + XMP | hypoxanthine phosphoribosyltransferase |
R272 | Purine metabolism | 2.4.2.8 | ABAYE3887 | AMP + PPI <-> AD + PRPP | hypoxanthine phosphoribosyltransferase |
R273 | Purine metabolism | 3.1.5.1 | ABAYE0911 | DGTP-> DG + PPPI | dGTPtriphosphohydrolase |
R274 | Purine metabolism | 2.7.6.5 | ABAYE3181 | ATP + GTP-> pppGpp + AMP | GTPpyrophosphokinase |
R275 | Purine metabolism | 3.1.7.2 | ABAYE0310 | ppGpp <-> GDP + PPI | guanosine-3 ', 5'-bis (diphosphate) 3'-pyrophosphohydrolase |
R276 | Purine metabolism | 2.7.4.3 | ABAYE2767 | ATP + AMP <-> 2 ADP | adenylate kinase |
R277 | Purine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | ADP + RTHIO-> DADP + OTHIO | ribonucleoside-diphosphatereductase |
R278 | Purine metabolism | 2.7.4.6 | ABAYE3267 | DADP + ATP <-> DATP + ADP | nucleoside-diphosphate kinase |
R279 | Purine metabolism | 2.7.4.8 | ABAYE0312 | GMP + ATP <-> GDP + ADP | guanylate kinase |
R280 | Purine metabolism | 2.7.4.6 | ABAYE3267 | GDP + ATP <-> GTP + ADP | nucleoside-diphosphate kinase |
R281 | Purine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | GDP + RTHIO-> DGDP + OTHIO | ribonucleoside-diphosphatereductase |
R282 | Purine metabolism | 2.7.4.6 | ABAYE3267 | DGDP + ATP <-> DGTP + ADP | nucleoside-diphosphate kinase |
R283 | Purine metabolism | 3.6.1.13 | ABAYE3519 | ARIB-> AMP + R5P | ADPribose ribophosphohydrolase |
R284 | Purine metabolism | 2.7.4.3 | ABAYE2767 | ATP + DAMP <-> ADP + DADP | adenylate kinase |
R285 | Purine metabolism | 3.6.1.41 | ABAYE0491 | AppppA-> 2 ADP | bis (5'-nucleosyl) -tetraphosphatase |
R286 | Purine metabolism | 1.17.1.4 | ABAYE1114 AND ABAYE1115 | HYXN + NAD <-> XAN + NADH | xanthine dehydrogenase |
R287 | Purine metabolism | 1.17.1.4 | ABAYE1114 AND ABAYE1115 | XAN + NAD <-> URT + NADH | xanthine dehydrogenase |
R288 | Purine metabolism | 3.5.3.19 | ABAYE0127 | UDGLYCOLATE <-> GLX + 2 NH3 + CO2 | ureidoglycolate amidohydrolase (decarboxylating) |
R289 | Purine metabolism | 3.5.3.4 | ABAYE0128 | ALLNT <-> UDGLYCOLATE + UREA | allantoicase |
R290 | Purine metabolism | 3.5.4.3 | ABAYE2396 OR ABAYE3885 | GN <-> XAN + NH3 | guanine deaminase |
R291 | Purine metabolism | 3.6.1.11 | ABAYE3154 | pppGpp-> ppGpp + PI | exopolyphosphatase (exopolypase) |
R292 | Purine metabolism | 3.6.1.15 | ABAYE3296 | ATP <-> ADP + PI | hypotheticalprotein |
R293 | Purine metabolism | 3.6.1.19 | ABAYE3179 | DITP-> DIMP + PPI | nucleoside-triphosphate pyrophosphatase |
R294 | Purine metabolism | 3.6.1.19 | ABAYE3179 | GTP-> GMP + PPI | nucleoside-triphosphate pyrophosphatase |
R295 | Purine metabolism | 3.6.1.19 | ABAYE3179 | ITP-> IMP + PPI | nucleoside-triphosphate pyrophosphatase |
R296 | Purine metabolism | 3.6.1.19 | ABAYE3179 | XTP-> XMP + PPI | nucleoside-triphosphate pyrophosphatase |
R297 | Purine metabolism | 3.6.1.19 | ABAYE3179 | DGTP-> DGMP + PPI | nucleoside-triphosphate pyrophosphatase |
R298 | Purine metabolism | 4.1.1.- | ABAYE1027 | 5AI + CO2 <-> 5A4ICA | L-2,4-diaminobutyrate decarboxylase |
R299 | Pyrimidine metabolism (De novo) | 2.1.3.2 | ABAYE2578 | CAP + ASP-> CAASP + PI | aspartatecarbamoyltransferase |
R300 | Pyrimidine metabolism (De novo) | 3.5.2.3 | ABAYE2577 OR ABAYE2646 | CAASP <-> DOROA | dihydroorotase |
R301 | Pyrimidine metabolism (De novo) | 1.3.3.1 | ABAYE1278 | DOROA + UQ <-> UQH2 + OROA | dihydroorotateoxidase |
R302 | Pyrimidine metabolism (De novo) | 1.3.3.1 | ABAYE1278 | DOROA + MK <-> MKH2 + OROA | dihydroorotateoxidase |
R303 | Pyrimidine metabolism (De novo) | 2.4.2.10 | ABAYE0144 | OROA + PRPP <-> PPI + OMP | orotatephosphoribosyltransferase |
R304 | Pyrimidine metabolism (De novo) | 4.1.1.23 | ABAYE2058 | OMP-> CO2 + UMP | orotidine-5'-phosphatedecarboxylase |
R305 | Pyrimidine metabolism (De novo) | 2.7.4.6 | ABAYE3267 | UDP + ATP <-> UTP + ADP | nucleoside-diphosphate kinase |
R306 | Pyrimidine metabolism (De novo) | 6.3.4.2 | ABAYE1667 | UTP + GLN + ATP-> GLU + CTP + ADP + PI | CTPsynthase |
R307 | Pyrimidine metabolism | 6.3.4.2 | ABAYE1667 | ATP + UTP + NH3-> ADP + PI + CTP | CTPsynthase |
R308 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | CDP + ATP <-> CTP + ADP | nucleoside-diphosphate kinase |
R309 | Pyrimidine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | CDP + RTHIO-> DCDP + OTHIO | ribonucleoside-diphosphate reductase |
R310 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | DCDP + ATP <-> DCTP + ADP | nucleoside-diphosphate kinase |
R311 | Pyrimidine metabolism | 2.7.4.9 | ABAYE0933 | DTMP + ATP <-> DTDP + ADP | thymidylatekinase |
R312 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | DTDP + ATP <-> DTTP + ADP | nucleoside-diphosphate kinase |
R313 | Pyrimidine metabolism | 2.7.4.14 | ABAYE2062 | CMP + ATP <-> ADP + CDP | cytidylatekinase |
R314 | Pyrimidine metabolism | 1.8.1.9 | ABAYE2940 OR ABAYE3661 | OTHIO + NADPH-> RTHIO + NADP | thioredoxinreductase |
R315 | Pyrimidine metabolism | 2.7.4.14 | ABAYE2062 | DCMP + ATP <-> ADP + DCDP | cytidylatekinase |
R316 | Pyrimidine metabolism | 2.4.2.9 | ABAYE3047 | URA + PRPP <-> UMP + PPI | uracilphosphoribosyltransferase |
R317 | Pyrimidine metabolism | 4.2.1.70 | ABAYE1445 | URA + R5P <-> PURI5P | pseudouridylate synthase |
R318 | Pyrimidine metabolism | 2.1.1.45 | ABAYE3314 | DUMP + METTHF-> DHF + DTMP | thymidylatesynthase |
R319 | Pyrimidine metabolism | 2.4.2.1 OR 2.4.2.4 | DU + PI-> URA + DR1P | purine-nucleosidephosphorylase ORthymidinephosphorylase | |
R320 | Pyrimidine metabolism | 2.4.2.4 | DT + PI-> TM + DR1P | thymidinephosphorylase | |
R321 | Pyrimidine metabolism | 2.7.4.6 | ABAYE3267 | DUDP + ATP <-> DUTP + ADP | nucleoside-diphosphate kinase |
R322 | Pyrimidine metabolism | 1.17.4.1 | ABAYE3065 AND ABAYE3067 | UDP + RTHIO-> OTHIO + DUDP | ribonucleoside-diphosphate reductase |
R323 | Pyrimidine metabolism | 2.7.4.9 | ABAYE0933 | ATP + DUMP <-> ADP + DUDP | thymidylatekinase |
R324 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | UMP-> URI + PI | 5'-nucleotidase |
R325 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | CMP-> CYTD + PI | 5'-nucleotidase |
R326 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DCMP-> DC + PI | 5'-nucleotidase |
R327 | Pyrimidine metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | DTMP-> DT + PI | 5'-nucleotidase |
R328 | Pyrimidine metabolism | 3.5.4.1 | 5MC <-> TM + NH3 | cytosinedeaminase | |
R329 | Pyrimidine metabolism | 3.5.4.1 | CT-> URA + NH3 | cytosinedeaminase | |
R330 | Pyrimidine metabolism | 3.5.4.5 | DC-> DU + NH3 | cytidinedeaminase | |
R331 | Pyrimidine metabolism | 2.7.4.14 OR2.7.4.22 | ABAYE2062ORABAYE1577 | ATP + UMP <-> ADP + UDP | cytidylate kinase OR uridylate kinase |
R332 | Pyrimidine metabolism | 3.5.4.13 | ABAYE3025 | CTP-> UTP + NH3 | deoxycytidine triphosphate deaminase |
R333 | Pyrimidine metabolism | 3.5.4.13 | ABAYE3025 | DCTP-> DUTP + NH3 | deoxycytidine triphosphate deaminase |
R334 | Pyrimidine metabolism | 3.6.1.19 | ABAYE3179 | UTP-> UMP + PPI | nucleoside-triphosphate pyrophosphatase |
R335 | Pyrimidine metabolism | 3.6.1.19 OR 3.6.1.23 | ABAYE3179ORABAYE2929 | DUTP-> DUMP + PPI | nucleoside-triphosphatepyrophosphatase OR deoxyuridine 5'-triphosphate nucleotidohydrolase |
R336 | Glutamate metabolism | 6.3.1.2 | ABAYE1126 OR ABAYE1425 | GLU + NH3 + ATP-> GLN + ADP + PI | glutaminesynthetase |
R337 | Glutamate metabolism | 1.4.1.13 OR 1.4.1.14 | ABAYE0298 AND ABAYE0299 | GLN + AKG + NADPH-> 2 GLU + NADP | glutamatesynthase |
R338 | Glutamate metabolism | 6.3.5.5 | ABAYE0800 AND ABAYE0801 | GLN + 2ATP + HCO3-> GLU + CAP + 2 ADP + PI | carbamoyl-phosphate synthase |
R339 | Glutamate metabolism | 6.1.1.17 | ABAYE0277 | TRNAGLU + GLU + ATP-> GLUTRNAGLU + PPI + AMP | glutamyl-tRNAsynthetase |
R340 | Glutamate metabolism | 6.1.1.18 | ABAYE1455 | ATP + GLN + TRNAGLN-> AMP + PPI + GTRNA | glutaminyl-tRNAsynthetase |
R341 | Glutamate metabolism | 3.5.1.2 OR 3.5.1.38 | ABAYE2832 OR ABAYE2188 | GLN-> GLU + NH3 | glutaminase OR glutaminase-asparaginase |
R342 | Glutamate metabolism | 6.3.5.7 | ABAYE0697 AND ABAYE0698 AND ABAYE0699 | GTRNA + GLU + PI + ADP <-> GLUTRNAGLN + GLN + ATP | aspartyl / glutamyl-tRNA (Asn / Gln) amidotransferase |
R343 | Alanine and aspartate metabolism | 2.6.1.1 | ABAYE0951 | OA + GLU <-> ASP + AKG | aspartateaminotransferase |
R344 | Alanine and aspartate metabolism | 6.1.1.12 | ABAYE0588 | ATP + ASP + TRNAASP-> AMP + PPI + ASPTRNAASP | aspartyl-tRNAsynthetase |
R345 | Alanine and aspartate metabolism | 6.1.1.7 | ABAYE2595 | ATP + ALA + TRNAALA <-> AMP + PPI + ALATRNA | alanyl-tRNA synthetase |
R346 | Alanine and aspartate metabolism | 6.3.5.4 | ASP + ATP + GLN-> GLU + ASN + AMP + PPI | asparaginesynthase | |
R347 | Alanine and aspartate metabolism | 3.5.1.1 OR 3.5.1.38 | ABAYE3351 OR ABAYE2188 | ASN-> ASP + NH3 | L-asparaginase I OR glutaminase-asparaginase |
R348 | Alanine and aspartate metabolism | 3.4.13.3 | ABAYE1209 | CNS-> bALA + HIS | aminoacyl-histidine dipeptidase (peptidase D) |
R349 | Alanine and aspartate metabolism | 1.4.3.16 | ABAYE0935 | ASP + O2-> OA + NH3 + H2O2 | L-aspartate oxidase |
R350 | Alanine and aspartate metabolism | 5.1.1.13 | ABAYE1354 | ASP <-> DASP | aspartate / glutamate racemase |
R351 | Alanine and aspartate metabolism | 6.3.5.6 | ABAYE0697 AND ABAYE0698 AND ABAYE0699 | ASNTRNAASN + GLU + PI + ADP <-> ASPTRNAASN + GLN + ATP | aspartyl / glutamyl-tRNA (Asn / Gln) amidotransferase |
R352 | Glycine, serine and threonine metabolism | 2.7.2.4 | ABAYE2596 | ASP + ATP-> ADP + BASP | aspartate kinase |
R353 | Glycine, serine and threonine metabolism | 1.2.1.11 | ABAYE3348 | BASP + NADPH-> NADP + PI + ASPSA | aspartate-semialdehyde dehydrogenase |
R354 | Glycine, serine and threonine metabolism | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | ASPSA + NADH <-> NAD + HSER | homoserinedehydrogenase |
R355 | Glycine, serine and threonine metabolism | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | ASPSA + NADPH <-> NADP + HSER | homoserinedehydrogenase |
R356 | Glycine, serine and threonine metabolism | 2.7.1.39 | ABAYE0244 | HSER + ATP-> ADP + PHSER | homoserine kinase |
R357 | Glycine, serine and threonine metabolism | 4.2.3.1 | ABAYE3531 | PHSER-> THR + PI | threonine synthase |
R358 | Glycine, serine and threonine metabolism | 1.1.1.95 | ABAYE0332 | 3PG + NAD-> NADH + PHP | D-3-phosphoglycerate dehydrogenase |
R359 | Glycine, serine and threonine metabolism | 2.6.1.52 | ABAYE0877 | PHP + GLU-> AKG + 3PSER | phosphoserine aminotransferase |
R360 | Glycine, serine and threonine metabolism | 3.1.3.3 | ABAYE0098 | 3PSER-> PI + SER | phosphoserinephosphatase |
R361 | Glycine, serine and threonine metabolism | 2.1.2.1 | ABAYE1171 | THF + SER <-> GLY + METTHF | serine hydroxymethyltransferase |
R362 | Glycine, serine and threonine metabolism | 1.8.1.4 | ABAYE0505 OR ABAYE0782 OR ABAYE1945 | DHLIPOYLPROTEIN + NAD-> NADH + LIPOYLPROTEIN | dihydrolipoamide dehydrogenase |
R363 | Glycine, serineandthreoninemetabolism | 4.3.1.17 OR 4.3.1.19 | ABAYE2377 OR (ABAYE0691 OR ABAYE1083 OR ABAYE1649) | SER <-> PYR + NH3 | L-serine ammonia-lyase |
R364 | Glycine, serineandthreoninemetabolism | 4.3.1.19 | ABAYE0691 OR ABAYE1083 OR ABAYE1649 | THR-> OBUT + NH3 | threoninedehydratase |
R365 | Glycine, serine and threonine metabolism | 6.1.1.3 | ABAYE3169 | ATP + THR + TRNATHR-> AMP + PPI + THRTRNATHR | threonyl-tRNA synthetase |
R366 | Glycine, serine and threonine metabolism | 6.1.1.11 | ABAYE0757 | ATP + SER + TRNASER-> AMP + PPI + SERTRNASER | seryl-tRNAsynthetase |
R367 | Glycine, serine and threonine metabolism | 6.1.1.14 | ABAYE0367 AND ABAYE0368 | ATP + GLY + TRNAGLY-> AMP + PPI + GLYTRNAGLY | glycyl-tRNA synthetase |
R368 | Glycine, serine and threonine metabolism | 2.6.1.76 | ABAYE1026 | GLU + ASPSA-> AKG + 24DAB | glutamate decarboxylase |
R369 | Glycine, serine and threonine metabolism | 1.1.99.1 | ABAYE2868 | BAL + FAD-> FADH2 + BETAINE | choline dehydrogenase |
R370 | Glycine, serine and threonine metabolism | 1.2.1.8 | ABAYE1066 OR ABAYE2867 | BAL + NAD-> BETAINE + NADH | NAD-dependent aldehyde dehydrogenase |
R371 | Glycine, serine and threonine metabolism | 1.1.1.- | ABAYE0043 OR ABAYE0109 OR ABAYE0479 OR ABAYE1356 OR ABAYE2589 OR ABAYE2607 OR ABAYE2613 OR ABAYE2618 OR ABAYE2845 OR ABAYE3187 OR ABAYE3378 | MTG + NADPH-> HAC + NADP | alcohol dehydrogenase |
R372 | Glycine, serine and threonine metabolism | 1.4.3.21 | ABAYE1710 | AACTN + O2 <-> MTG + NH3 + H2O2 | copper amine oxidase precursor (tyramine oxidase) (2-phenylethylamine oxidase) |
R373 | Glycine, serine and threonine metabolism | 4.3.1.18 | ABAYE2819 | DSER <-> PYR + NH3 | D-serine deaminase (dehydratase) |
R374 | Methionine metabolism | 4.4.1.8 | ABAYE0405 | LLCT-> HCYS + PYR + NH3 | cystathionine beta-lyase, PLP-dependent |
R375 | Methionine metabolism | 2.1.1.13 | ABAYE2822 | HCYS + MTHF <-> THF + MET | methionine synthase I |
R376 | Methionine metabolism | 2.1.1.14 | ABAYE3079 | 5MTGLU + HCYS-> TGLU + MET | 5-methyltetrahydropteroyltriglutamate-homocysteinemethyltransferase |
R377 | Methionine metabolism | 6.1.1.10 | ABAYE3031 | ATP + MET + TRNAMET-> AMP + PPI + METTRNA | methionyl-tRNA synthetase |
R378 | Methionine metabolism | 2.1.2.9 | ABAYE0022 | METTRNA + FTHF-> THF + FMETTRNA | methionyl-tRNA formyltransferase |
R379 | Methionine metabolism | 2.5.1.6 | ABAYE2118 | MET + ATP-> PPI + PI + SAM | S-adenosylmethionine synthetase |
R380 | Methionine metabolism | 3.2.2.9 | ABAYE3028 OR ABAYE3846 | SAH <-> SRLH + AD | S-adenosylhomocysteine nucleosidase |
R381 | Methionine metabolism | 2.1.1.37 | ABAYE0084 | SAM + CT <-> SAH + 5MC | cytosine-specific methyltransferase |
R382 | Methionine metabolism | 2.3.1.31 | ABAYE3293 | ACCOA + HSER <-> COA + OAHSER | homoserine O-acetyltransferase |
R383 | Methionine metabolism | 2.5.1.- | ABAYE1970 | OSLHSER + H2S <-> HCYS + SUCC | O-succinylhomoserine sulfhydrylase |
R384 | Methionine metabolism | 2.5.1.49 | ABAYE0264 | OAHSER + H2S <-> HCYS + AC | homocysteine synthase |
R385 | Methionine metabolism | 2.5.1.49 | ABAYE0264 | OAHSER + HO3S2 + RTHIO <-> HCYS + H2SO3 + OTHIO + AC | homocysteine synthase |
R386 | Cysteine metabolism | 4.4.1.8 | ABAYE0405 | H2S + PYR + NH3-> CYS | cystathioninebeta-lyase |
R387 | Cysteine metabolism | 4.4.1.8 | ABAYE0405 | CYST-> PYR + NH3 + TCYS | cystathioninebeta-lyase |
R388 | Cysteine metabolism | 2.3.1.30 | ABAYE2191 OR ABAYE2248 | SER + ACCOA <-> COA + ASER | serine acetyltransferase |
R389 | Cysteine metabolism | 2.5.1.47 | ABAYE3184 OR ABAYE3696 | ASER + H2S-> CYS + AC | cysteine synthase |
R390 | Cysteine metabolism | 2.5.1.47 OR 2.5.1.49 | ABAYE3184 OR ABAYE3696 OR ABAYE0264 | ASER + HO3S2 + RTHIO-> CYS + H2SO3 + OTHIO + AC | cysteine synthase |
R391 | Cysteine metabolism | 2.5.1.47 | ABAYE3184 OR ABAYE3696 | ASER + HO3S2-> SSLCYS + AC | cysteine synthase |
R392 | Cysteine metabolism | 2.6.1.1 | ABAYE0951 | CYSTEATE + AKG <-> 3SPYR + GLU | aspartate aminotransferase |
R393 | Cysteine metabolism | 2.6.1.1 | ABAYE0951 | 3SLALA + AKG-> 3SFPYR + GLU | aspartate aminotransferase |
R394 | Cysteine metabolism | 2.6.1.1 | ABAYE0951 | MPYR + GLU-> CYS + AKG | aspartate aminotransferase |
R395 | Cysteine metabolism | 4.3.1.17 | ABAYE2377 | SER-> 2AA | L-serine dehydratase |
R396 | Cysteine metabolism | 6.1.1.16 | ABAYE2493 | ATP + CYS + TRNACYS-> AMP + PPI + CYSTRNACYS | cysteinyl-tRNA synthetase |
R397 | Cysteine metabolism | 4.4.1.15 | ABAYE3037 | DCYS <-> H2S + NH3 + PYR | D-cysteine desulfhydrase |
R398 | Valine, leucine and isoleucine degradation | 1.1.1.31 | ABAYE3767 | HIBUT + NAD-> 3OPP + NADH | 3-hydroxyisobutyrate dehydrogenase |
R399 | Valine, leucine and isoleucine degradation | 1.3.99.3 OR 1.3.99.10 | (ABAYE0476 OR ABAYE2013) OR ABAYE2288 | 3MBCOA + FAD <-> 3MCCOA + FADH2 | acyl-CoA dehydrogenase |
R400 | Valine, leucine and isoleucine degradation | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 | 3HIVCOA <-> 3MCCOA | enoyl-CoA hydratase |
R401 | Valine, leucine and isoleucine degradation | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 | 2MP2ECOA-> 3HIBCOA | enoyl-CoA hydratase |
R402 | Valine, leucine and isoleucine degradation | 4.2.1.17 | ABAYE0482 OR ABAYE0915 OR ABAYE2065 OR ABAYE2290 OR ABAYE2304 OR ABAYE2311 OR ABAYE2369 OR ABAYE2370 OR ABAYE2628 OR ABAYE2852 OR ABAYE3186 OR ABAYE3763 OR ABAYE3764 | 3H2MBCOA-> 2MB2ECOA | enoyl-CoA hydratase |
R403 | Valine, leucine and isoleucine degradation | 6.4.1.4 | ABAYE0483 | ATP + 3MCCOA + HCO3-> ADP + PI + 3MGCOA | 3-methylcrotonyl-CoA carboxylase |
R404 | Valine, leucine and isoleucine degradation | 1.1.1.35 | ABAYE1411 OR ABAYE2460 OR ABAYE3470 | HIBUT + NAD <-> MMSA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R405 | Valine, leucine and isoleucine degradation | 1.1.1.35 | ABAYE1411 OR ABAYE2460 OR ABAYE3470 | 3H2MBCOA + NAD <-> 2MAACCOA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R406 | Valine, leucine and isoleucine degradation | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | MMSA + NAD-> MM + NADH | aldehyde dehydrogenase |
R407 | Valine, leucine and isoleucine degradation | 2.3.1.16 | ABAYE3471 | COA + 2MAACCOA-> PPACOA + ACCOA | acetyl-CoA acyltransferase |
R408 | Valine, leucine and isoleucine degradation | 1.3.99.3 | ABAYE0476 OR ABAYE2013 | 2MPPACOA + FAD <-> 2MP2ECOA + FADH2 | acyl-CoA dehydrogenase |
R409 | Valine, leucine and isoleucine degradation | 1.3.99.3 | ABAYE0476 OR ABAYE2013 | 2MBCOA + FAD <-> 2MB2ECOA + FADH2 | acyl-CoA dehydrogenase |
R410 | Valine, leucine and isoleucine degradation | 2.6.1.18 | ABAYE1295 | ALA + MMSA <-> PYR + AIBUT | omega-aminoacid--pyruvateaminotransferase (omega-APT) (beta-alanine--pyruvateaminotransferase) |
R411 | Valine, leucine and isoleucine degradation | 2.6.1.42 | ABAYE0577 | ILE + AKG <-> 3MOP + GLU | branched-chain amino acid transferase |
R412 | Valine, leucine and isoleucine degradation | 2.6.1.42 | ABAYE0577 | LEU + AKG <-> 4MOP + GLU | branched-chain amino acid transferase |
R413 | Valine, leucineandisoleucinebiosynthesis | 1.1.1.86 | ABAYE3238 | ACLAC + NADPH-> NADP + DHMVA | acetohydroxy acid isomeroreductase |
R414 | Valine, leucineandisoleucinebiosynthesis | 4.2.1.9 | ABAYE0023 OR ABAYE1724 OR ABAYE1781 | DHMVA-> OIVAL | dihydroxy-acid dehydratase OR 6-phosphogluconate dehydratase |
R415 | Valine, leucineandisoleucinebiosynthesis | 2.6.1.42 | ABAYE0577 | OIVAL + GLU <-> AKG + VAL | branched-chain amino acid aminotransferase |
R416 | Valine, leucine and isoleucine biosynthesis | 2.2.1.6 | ABAYE2836 OR (ABAYE3239 AND ABAYE3240) | OBUT + 2 (HE) TPP-> ABUT + THMPP | acetolactate synthase |
R417 | Valine, leucine and isoleucine biosynthesis | 1.1.1.86 | ABAYE3238 | ABUT + NADPH-> NADP + DHMP | ketol-acid reductoisomerase |
R418 | Valine, leucine and isoleucine biosynthesis | 4.2.1.9 | ABAYE0023 OR ABAYE1724 OR ABAYE1781 | DHMP-> 3MOP | dihydroxy-acid dehydratase |
R419 | Valine, leucine and isoleucine biosynthesis | 2.6.1.42 | ABAYE0577 | 3MOP + GLU <-> AKG + ILE | branched-chain amino acid aminotransferase |
R420 | Valine, leucine and isoleucine biosynthesis | 2.3.3.13 | ABAYE3292 | ACCOA + OIVAL-> COA + IPPMAL | isopropylmalate synthase |
R421 | Valine, leucine and isoleucine biosynthesis | 4.2.1.33 | ABAYE3359 AND ABAYE3360 | IPPMAL <-> CBHCAP | 3-isopropylmalatedehydratase |
R422 | Valine, leucine and isoleucine biosynthesis | 1.1.1.85 | ABAYE3357 | CBHCAP + NAD-> NADH + OICAP | isopropylmalatedehydrogenase |
R423 | Valine, leucine and isoleucine biosynthesis | OICAP-> 4MOP + CO2 | spontaneous | ||
R424 | Valine, leucine and isoleucine biosynthesis | 2.6.1.42 | ABAYE0577 | 4MOP + GLU <-> AKG + LEU | branched-chain amino acid aminotransferase |
R425 | Valine, leucine and isoleucine biosynthesis | 6.1.1.4 | ABAYE3244 | ATP + LEU + TRNALEU-> AMP + PPI + LEUTRNA | leucyl-tRNA synthetase |
R426 | Valine, leucine and isoleucine biosynthesis | 6.1.1.9 | ABAYE0740 | ATP + VAL + TRNAVAL-> AMP + PPI + VALTRNAVAL | valyl-tRNA synthetase |
R427 | Valine, leucine and isoleucine biosynthesis | 6.1.1.5 | ABAYE3852 | ATP + ILE + TRNAILE-> AMP + PPI + ILETRNAILE | isoleucyl-tRNA synthetase |
R428 | Lysine biosynthesis | 4.2.1.52 | ABAYE0058 OR ABAYE2388 OR ABAYE2878 OR ABAYE3671 | ASPSA + PYR-> DHDP | dihydrodipicolinate synthase |
R429 | Lysine biosynthesis | 1.3.1.26 | ABAYE0036 | DHDP + NADPH-> NADP + TDHDP | dihydrodipicolinate reductase |
R430 | Lysine biosynthesis | 1.3.1.26 | ABAYE0036 | DHDP + NADH-> NAD + TDHDP | dihydrodipicolinate reductase |
R431 | Lysine biosynthesis | 2.3.1.117 | ABAYE0923 | TDHDP + SUCCOA-> SAOPIM + COA | 2,3,4,5-tetrahydropyridine-2,6-carboxylate N-succinyltransferase |
R432 | Lysine biosynthesis | 2.6.1.17 | ABAYE2181 | SAOPIM + GLU-> SDAPIM + AKG | succinyldiaminopimelate transaminase |
R433 | Lysine biosynthesis | 3.5.1.18 | ABAYE0676 | SDAPIM-> DAPIM + SUCC | succinyl-diaminopimelate desuccinylase |
R434 | Lysine biosynthesis | 5.1.1.7 | ABAYE0861 | DAPIM <-> MDAPIM | diaminopimelate epimerase |
R435 | Lysine biosynthesis | 4.1.1.20 | ABAYE0860 | MDAPIM-> LYS + CO2 | diaminopimelate decarboxylase |
R436 | Lysine biosynthesis | 6.1.1.6 | ABAYE0854 OR ABAYE2794 | ATP + LYS + TRNALYS-> AMP + PPI + LYSTRNA | lysyl-tRNAsynthetase |
R437 | Lysine biosynthesis | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | HSER + NAD <-> ASPSA + NADH | homoserine dehydrogenase |
R438 | Lysine biosynthesis | 1.1.1.3 | ABAYE1937 OR ABAYE3530 | HSER + NADP <-> ASPSA + NADPH | homoserine dehydrogenase |
R439 | Lysine biosynthesis | 1.2.1.11 | ABAYE3348 | ASPSA + PI + NADP <-> BASP + NADPH | aspartate-semialdehyde dehydrogenase |
R440 | Lysine degradation | 1.2.4.2 | ABAYE0780 | 2OAD + LIPO-> SGDHL + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R441 | Lysine degradation | 2.3.1.61 | ABAYE0781 | GLUTCOA + DLIPO <-> COA + SGDHL | 2-oxoglutarate dehydrogenase E2 component |
R442 | Lysine degradation | 1.14.13.59 | ABAYE1094 | LYS + O2 + NADPH <-> NHLYS + NADP | acinetobactinsiderophorebiosynthesisproteinORlysineN6-hydroxylase |
R443 | Lysine degradation | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 4TMABT + NAD <-> 4TMABTO + NADH | aldehyde dehydrogenase |
R444 | Lysine degradation | 1.3.99.7 | ABAYE3097 | GLUTCOA <-> CCOA + CO2 | glutaryl-CoA dehydrogenase |
R445 | Arginine and proline metabolism | 2.3.1.109 | ABAYE0353 | SUCCOA + ARG-> COA + N2SUCCARG | arginine succinyltransferase |
R446 | Arginine and proline metabolism | 6.1.1.19 | ABAYE3732 | ATP + ARG + TRNAARG <-> AMP + PPI + ARGTRNAARG | arginyl-tRNA synthetase |
R447 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | P5C + NAD-> NADH + GLU | bifunctional proline dehydrogenase OR delta-1-pyrroline-5-carboxylate dehydrogenase |
R448 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | P5C + NADP-> NADPH + GLU | bifunctional proline dehydrogenase OR delta-1-pyrroline-5-carboxylate dehydrogenase |
R449 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | GLUGSAL + NAD-> NADH + GLU | 1-pyrroline-5-carboxylate dehydrogenase |
R450 | Arginine and proline metabolism | 1.5.99.8 | ABAYE2108 | PRO + FAD-> P5C + FADH2 | proline dehydrogenase |
R451 | Arginine and proline metabolism | 6.1.1.15 | ABAYE0663 | ATP + PRO + TRNAPRO-> AMP + PPI + PROTRNAPRO | prolyl-tRNA synthetase |
R452 | Arginine and proline metabolism | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | L1P3H5C + NADH-> 4HPRO + NAD | pyrroline-5-carboxylate reductase |
R453 | Arginine and proline metabolism | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | L1P3H5C + NADPH-> 4HPRO + NADP | pyrroline-5-carboxylate reductase |
R454 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | L1P3H5C + NAD-> E4HGLU + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R455 | Arginine and proline metabolism | 1.5.1.12 | ABAYE2108 | L1P3H5C + NADP-> E4HGLU + NADPH | 1-pyrroline-5-carboxylate dehydrogenase |
R456 | Arginine and proline metabolism | 1.5.1.12 OR 1.5.99.8 | ABAYE2108 | E4HGLU + NAD <-> 4HGLUSA + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R457 | Arginine and proline metabolism | 2.6.1.1 | ABAYE0951 | E4HGLU + AKG-> HYDROXYAKG + GLU | aspartate aminotransferase |
R458 | Arginine and proline metabolism | 4.1.2.14 | ABAYE3280 | HYDROXYAKG <-> PYR + GLX | 4-hydroxy-2-oxoglutaratealdolase |
R459 | Arginine and proline metabolism | 1.2.1.71 | ABAYE0354 | N2SUCCGLU5SA + NAD-> N2SUCCGLU + NADH | succinylglutamic semialdehyde dehydrogenase |
R460 | Arginine and proline metabolism | 2.6.1.81 | ABAYE0352 | SORN + AKG-> N2SUCCGLU5SA + GLU | succinylornithine transaminase |
R461 | Arginine and proline metabolism | 3.5.1.96 | ABAYE0356 | N2SUCCGLU-> GLU + SUCC | succinylglutamate desuccinylase |
R462 | Arginine and proline metabolism | 3.5.3.23 | ABAYE0355 | N2SUCCARG-> SORN + CO2 + 2 NH3 | succinylarginine dihydrolase |
R463 | Arginine and proline metabolism | 3.5.3.3 | p3ABAYE0029 | CRTN <-> SCSN + UREA | creatinase (Creatineamidinohydrolase) |
R464 | Arginine and proline metabolism | 5.1.1.4 | ABAYE2385 | PRO <-> DPRO | prolineracemase |
R465 | Histidine metabolism | 2.4.2.17 | ABAYE2593 OR ABAYE3132 | PRPP + ATP-> PPI + PRBATP | ATP phosphoribosyltransferase |
R466 | Histidine metabolism | 3.6.1.31 | ABAYE3428 | PRBATP-> PPI + PRBAMP | phosphoribosyl-ATP pyrophosphohydrolase |
R467 | Histidine metabolism | 3.5.4.19 | ABAYE3428 | PRBAMP-> PRFP | phosphoribosyl-AMP cyclohydrolase |
R468 | Histidine metabolism | 5.3.1.16 | ABAYE0250 | PRFP-> PRLP | phosphoribosylformimino-5-aminoimidazolecarboxamideribotideisomerase |
R469 | Histidine metabolism | 2.4.2.- OR 4.1.3.- | ABAYE0243 OR ABAYE0253 | PRLP + GLN-> GLU + AICAR + DIMGP | imidazoleglycerolphosphatesynthaseOR glutamine amidotransferase |
R470 | Histidine metabolism | 4.2.1.19 | ABAYE0254 | DIMGP-> IMACP | imidazoleglycerol-phosphate dehydratase |
R471 | Histidine metabolism | 2.6.1.9 | ABAYE3130 | IMACP + GLU-> AKG + HISOLP | histidinol-phosphate aminotransferase |
R472 | Histidine metabolism | 3.1.3.15 | HISOLP-> PI + HISOL | histidinol-phosphatase | |
R473 | Histidine metabolism | 1.1.1.23 | ABAYE3131 | HISOL + 2NAD-> HIS + 2 NADH | histidinol dehydrogenase |
R474 | Histidine metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | HIS + SAM-> NMHIS + SAH | N6-adenine-specific methylase |
R475 | Histidine metabolism | 6.1.1.21 | ABAYE3262 | ATP + HIS + TRNAHIS-> AMP + PPI + HISTRNAHIS | histidyl-tRNA synthetase |
R476 | Histidine metabolism | 4.3.1.3 | ABAYE0076 | HIS-> UC + NH3 | histidine ammonia-lyase |
R477 | Histidine metabolism | 4.2.1.49 | ABAYE0075 | UC-> 4I5P | urocanate hydratase |
R478 | Histidine metabolism | 3.5.2.7 | ABAYE0078 | 4I5P-> NFGLU | imidazolonepropionase |
R479 | Histidine metabolism | 3.5.3.8 | ABAYE0079 | NFGLU-> GLU + FA | formiminoglutamase |
R480 | Histidine metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | I4AA + NAD-> I4AC + NADH | aldehyde dehydrogenase |
R481 | Histidine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | 2H5P <-> O2 + 2 4I5P | flavin-binding family monooxygenase |
R482 | Histidine metabolism | 4.1.1.22 | ABAYE1098 | HIS <-> HIEA + CO2 | histidine decarboxylase |
R483 | Tyrosine metabolism | 5.3.3.10 | ABAYE1465 | 5CM2HM-> 5C2O3E | 5-carboxymethyl-2-hydroxymuconate isomerase |
R484 | Tyrosine metabolism | 2.6.1.1 | ABAYE0951 | AKG + TYR <-> 4HPP + GLU | aspartate aminotransferase |
R485 | Tyrosine metabolism | 1.13.11.27 | ABAYE0064 | 4HPP + O2-> HOMOGEN + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R486 | Tyrosine metabolism | 5.2.1.2 | ABAYE0067 | 4MAAC-> 4FAAC | maleylacetoacetate isomerase |
R487 | Tyrosine metabolism | 1.1.1.1 | ABAYE0763 OR ABAYE1463 OR ABAYE1522 OR ABAYE1861 OR p2ABAYE0004 OR p3ABAYE0020 OR p3ABAYE0024 | 34DHPEG + NAD <-> 34DHMA + NADH | alcohol dehydrogenase |
R488 | Tyrosine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | TRM + O2 + NADH <-> DPM + NAD | flavin-bindingfamilymonooxygenase |
R489 | Tyrosine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | 4HPACALO + NADPH + O2 <-> 4HMN + NADP | flavin-bindingfamilymonooxygenase |
R490 | Tyrosine metabolism | 1.14.13.3 | ABAYE3078 | 3HPA + O2 + NADH <-> 34DHPA + NAD | flavoproteinoxidoreductase |
R491 | Tyrosine metabolism | 1.14.13.3 | ABAYE3078 | 4HPA + O2 + NADH <-> 34DHPA + NAD | flavoproteinoxidoreductase |
R492 | Tyrosine metabolism | 1.4.3.21 | ABAYE1710 | TRM + O2 <-> 4HPACAL + NH3 + H2O2 | copperamineoxidaseprecursor (tyramineoxidase) (2-phenylethylamineoxidase) |
R493 | Tyrosine metabolism | 1.4.3.21 | ABAYE1710 | DPM + O2 <-> DHPACAL + NH3 + H2O2 | copper amine oxidase precursor (tyramine oxidase) (2-phenylethylamine oxidase) |
R494 | Tyrosine metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | MTRM + SAM <-> HDN + SAH | O-methyltransferase protein |
R495 | Tyrosine metabolism | 2.3.1.- | ABAYE0497 OR ABAYE0625 OR ABAYE1513 OR ABAYE1675 OR ABAYE1715 OR ABAYE1811 OR ABAYE2153 OR ABAYE2367 OR ABAYE2457 OR ABAYE2483 OR ABAYE3572 OR ABAYE3588 OR ABAYE3697 OR ABAYE3807 | 4HPACOA + GLY <-> 4HPAGLY + COA | acyltransferase OR acetyl transferase OR acyl-CoA thiolase OR beta-ketoadipyl CoA thiolase OR GCN5-related N-acetyltransferase |
R496 | Tyrosine metabolism | 2.6.1.9 OR 2.6.1.57 | ABAYE3130ORABAYE3795 | TYR + AKG <-> 4HPP + GLU | histidinol-phosphate aminotransferase OR tyrosine aminotransferase |
R497 | Tyrosine metabolism | 3.7.1.2 | ABAYE0068 | AAC + FUM <-> 4FAAC | fumarylacetoacetase (fumarylacetoacetate hydrolase) |
R498 | Tyrosine metabolism | 4.1.1.- | ABAYE1027 | HOMOGEN + O2 + NADPH <-> GENAL + CO2 + NADP | L-2,4-diaminobutyrate decarboxylase |
R499 | Tyrosine metabolism | 4.1.1.- | ABAYE1027 | DHI + CO2 <-> CDHDHI | L-2,4-diaminobutyrate decarboxylase |
R500 | Tyrosine metabolism | 4.1.1.- | ABAYE1027 | DPCHR <-> DHI + CO2 | L-2,4-diaminobutyrate decarboxylase |
R501 | Phenylalanine metabolism | 2.6.1.1 OR 2.6.1.9 OR 2.6.1.57 | ABAYE0951 OR ABAYE3130 OR ABAYE3795 | PHE + AKG <-> PHPYR + GLU | aspartate aminotransferase |
R502 | Phenylalanine metabolism | 1.13.11.27 | ABAYE0064 | PHPYR + O2-> 2HPA + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R503 | Phenylalanine metabolism | 1.4.99.1 | ABAYE1567 OR ABAYE3774 | DPHE + FAD-> PHPYR + FADH2 + NH3 | D-amino-acid dehydrogenase |
R504 | Phenylalanine metabolism | 1.11.1.7 | ABAYE0619 | PHE <-> PAA | antioxidantprotein |
R505 | Phenylalanine metabolism | 1.14.13.- | ABAYE0129 OR ABAYE0435 OR ABAYE2606 OR ABAYE2614 | 2HPA <-> DHPA | flavin-bindingfamilymonooxygenase |
R506 | Phenylalanine metabolism | 1.2.1.39 | ABAYE1712 | PACAL + NAD <-> PLA + NADH | phenylacetaldehydedehydrogenase |
R507 | Phenylalanine metabolism | 1.4.3.21 | ABAYE1710 | PEA + O2 <-> PACAL + NH3 + H2O2 | copperamineoxidaseprecursor (tyramineoxidase) (2-phenylethylamineoxidase) |
R508 | Phenylalanine metabolism | 2.3.1.- | ABAYE0497 OR ABAYE0625 OR ABAYE1513 OR ABAYE1675 OR ABAYE1715 OR ABAYE1811 OR ABAYE2153 OR ABAYE2367 OR ABAYE2457 OR ABAYE2483 OR ABAYE3572 OR ABAYE3588 OR ABAYE3697 OR ABAYE3807 | PACOA + GLY <-> PACGLY + COA | acyltransferase OR acetyl transferase OR acyl-CoA thiolase OR beta-ketoadipyl CoA thiolase OR GCN5-related N-acetyltransferase |
R509 | Phenylalanine metabolism | 3.5.1.32 | ABAYE3086 | HIPPRT <-> BZ + GLY | hydrolase |
R510 | Phenylalanine metabolism | 3.5.1.4 | ABAYE1700 OR ABAYE2422 | PAA <-> PLA + NH3 | amidase |
R511 | Phenylalanine metabolism | 6.2.1.30 | ABAYE2366 | ATP + PLA + COA <-> AMP + PPI + PACOA | phenylacetate-coenzyme A ligase (phenylacetyl-CoA ligase) |
R512 | Tryptophan metabolism | 6.1.1.2 | ABAYE0788 | ATP + TRP + TRNATRP-> AMP + PPI + TRPTRNATRP | tryptophanyl-tRNA synthetase |
R513 | Tryptophan metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 5HIAA + NAD-> 5HIAC + NADH | aldehyde dehydrogenase |
R514 | Tryptophan metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | I3AA + NAD-> I3AC + NADH | aldehyde dehydrogenase |
R515 | Tryptophan metabolism | 1.11.1.6 | ABAYE2270 OR ABAYE2342 OR ABAYE3366 | 23HAN + 2O2-> CVN + 2 H2O2 | catalase |
R516 | Tryptophan metabolism | 1.2.4.2 | ABAYE0780 | 2OAD + COA + NAD-> GLUTCOA + CO2 + NADH | 2-oxoglutarate dehydrogenase E1 component |
R517 | Tryptophan metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | AEIOH + MTHF <-> MOT + THF | methyltransferase |
R518 | Tryptophan metabolism | 3.5.1.4 | ABAYE1700 OR ABAYE2422 | I3AAM <-> I3AC + NH3 | amidase |
R519 | Tryptophan metabolism | 3.7.1.3 | ABAYE1599 | FKYN <-> FAN + ALA | L-kynurenine hydrolase |
R520 | Tryptophan metabolism | 3.7.1.3 | ABAYE1599 | KYN <-> AN + ALA | L-kynurenine hydrolase |
R521 | Tryptophan metabolism | 3.7.1.3 | ABAYE1599 | HKYN <-> 3HAN + ALA | L-kynurenine hydrolase |
R522 | Tryptophan metabolism | 4.1.1.74 | ABAYE1030 | IPYR <-> I3AA + CO2 | pyruvatedecarboxylaseORindolepyruvatedecarboxylase |
R523 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.5.1.54 | ABAYE1658 OR ABAYE1989 | E4P + PEP-> PI + 3DDAH7P | 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase |
R524 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.3.4 | ABAYE0296 | 3DDAH7P-> DQT + PI | 3-dehydroquinate synthetase |
R525 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.10 | ABAYE1539 OR ABAYE1682 | DQT <-> DHSK | 3-dehydroquinate dehydratase II OR catabolic 3-dehydroquinate dehydratase (3-dehydroquinase) |
R526 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.1.1.25 | ABAYE0377 | DHSK + NADPH-> SME + NADP | shikimate5-dehydrogenase |
R527 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.7.1.71 | ABAYE0295 | SME + ATP-> ADP + SME3P | shikimate kinase |
R528 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.5.1.19 | ABAYE1207 | SME3P + PEP-> 3PSME + PI | 3-phosphoshikimate 1-carboxyvinyltransferase |
R529 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.3.5 | ABAYE1953 | 3PSME-> PI + CHOR | chorismate synthase |
R530 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.1.3.27 | ABAYE1123 OR ABAYE3497 | CHOR + GLN-> GLU + PYR + AN | anthranilate synthase |
R531 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.1.3.27 | ABAYE1123 OR ABAYE3497 | CHOR + NH3-> AN + PYR | anthranilate synthase |
R532 | Phenylalanine, tyrosineandtryptophanbiosynthesis | 2.4.2.18 | ABAYE1119 | AN + PRPP-> PPI + NPRAN | anthranilate phosphoribosyltransferase |
R533 | Phenylalanine, tyrosineandtryptophanbiosynthesis | 5.3.1.24 | ABAYE0607 | NPRAN-> CPAD5P | phosphoribosylanthranilate isomerase |
R534 | Phenylalanine, tyrosineandtryptophanbiosynthesis | 4.1.1.48 | ABAYE1118 | CPAD5P-> CO2 + IGP | indole-3-glycerolphosphatesynthase |
R535 | Phenylalanine, tyrosineandtryptophanbiosynthesis | 4.2.1.20 | ABAYE0608ORABAYE0613ORABAYE1955 | IGP + SER-> G3P + TRP | tryptophansynthase |
R536 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.20 | ABAYE0608 OR ABAYE1955 | SER + INDOLE-> TRP | tryptophansynthase |
R537 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.20 | ABAYE0613 | INDOLE + G3P <-> IGP | tryptophansynthase |
R538 | Phenylalanine, tyrosine and tryptophan biosynthesis | 5.4.99.5 | ABAYE1206 OR ABAYE1477 | CHOR <-> PHEN | chorismatemutase |
R539 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.51 | ABAYE1206 | PHEN-> CO2 + PHPYR | prephenate dehydratase |
R540 | Phenylalanine, tyrosine and tryptophan biosynthesis | 6.1.1.20 | ABAYE3159 AND ABAYE3160 | ATP + PHE + TRNAPHE-> AMP + PPI + PHETRNAPHE | phenylalanyl-tRNA synthetase |
R541 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.3.1.12 | ABAYE1207 | PHEN + NAD-> 4HPP + CO2 + NADH | prephenatedehydrogenase |
R542 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2.6.1.1 OR 2.6.1.9 OR 2.6.1.57 | ABAYE0951ORABAYE3130ORABAYE3795 | 4HPP + GLU-> AKG + TYR | histidinol-phosphate aminotransferase |
R543 | Phenylalanine, tyrosine and tryptophan biosynthesis | 6.1.1.1 | ABAYE0014 | ATP + TYR + TRNATYR-> AMP + PPI + TRYTRNATYR | tyrosyl-tRNA synthetase |
R544 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1.51 | ABAYE1206 | AG-> PHE + CO2 | prephenate dehydratase |
R545 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.1.99.25 | ABAYE1685 | QNT + PQQ <-> PQQH2 + DQT | quinate / shikimate dehydrogenase |
R546 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1.1.99.25 | ABAYE1685 | SME + PQQ <-> DHSK + PQQH2 | quinate / shikimate dehydrogenase |
R547 | Phenylalanine, tyrosine and tryptophan biosynthesis | 4.2.1 .- (QuiC) | ABAYE1683 | DHSK <-> 34DHB | 3-dehydroshikimate dehydratase OR DHS dehydratase) |
R548 | Urea cycle and metabolism of amino groups | 2.7.2.11 | ABAYE0962 | GLU + ATP-> ADP + GLUP | glutamate 5-kinase |
R549 | Urea cycle and metabolism of amino groups | 1.2.1.41 | ABAYE3276 | GLUP + NADPH-> NADP + PI + GLUGSAL | gamma-glutamyl phosphate reductase |
R550 | Urea cycle and metabolism of amino groups | GLUGSAL <-> P5C | spontaneous | ||
R551 | Urea cycle and metabolism of amino groups | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | P5C + NADPH <-> PRO + NADP | pyrroline-5-carboxylate reductase |
R552 | Urea cycle and metabolism of amino groups | 1.5.1.2 | ABAYE2533 OR ABAYE3151 | PRO + NAD <-> P5C + NADH | pyrroline-5-carboxylate reductase |
R553 | Urea cycle and metabolism of amino groups | 2.3.1.1 | ABAYE3105 OR ABAYE3839 | GLU + ACCOA-> COA + NAGLU | amino-acid N-acetyltransferase |
R554 | Urea cycle and metabolism of amino groups | 2.7.2.8 | ABAYE2927 | NAGLU + ATP-> ADP + NAGLUP | acetylglutamate kinase |
R555 | Urea cycle and metabolism of amino groups | 1.2.1.38 | ABAYE1653 | NAGLUP + NADPH-> NADP + PI + NAGLUS | N-acetyl-gamma-glutamyl-phosphate reductase |
R556 | Urea cycle and metabolism of amino groups | 2.6.1.11 | ABAYE1625 | NAGLUS + GLU-> AKG + NAORN | acetylornithine aminotransferase |
R557 | Urea cycle and metabolism of amino groups | 2.3.1.35 | ABAYE3105 | NAORN + GLU <-> ORN + NAGLU | bifunctional ornithine acetyltransferase / N-acetylglutamate synthase |
R558 | Urea cycle and metabolism of amino groups | 2.1.3.3 | ABAYE1571 | ORN + CAP <-> CITR + PI | ornithine carbamoyltransferase |
R559 | Urea cycle and metabolism of amino groups | 6.3.4.5 | ABAYE2641 | CITR + ASP + ATP <-> AMP + PPI + ARGSUCC | argininosuccinate synthase |
R560 | Urea cycle and metabolism of amino groups | 4.3.2.1 | ABAYE3511 | ARGSUCC <-> FUM + ARG | argininosuccinatelyase |
R561 | Urea cycle and metabolism of amino groups | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | N4AAB + NAD <-> 4AABUT + NADH | aldehyde dehydrogenase |
R562 | Urea cycle and metabolism of amino groups | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | 4AB + NADP <-> GABA + NADPH | aldehyde dehydrogenase |
R563 | Urea cycle and metabolism of amino groups | 3.2.2.9 | ABAYE3028 OR ABAYE3846 | 5MTA <-> AD + 5MDR | 5'-methylthioadenosine / S-adenosylhomocysteine nucleosidase |
R564 | Urea cycle and metabolism of amino groups | 3.4.13.3 | ABAYE1209 | HCNS <-> GABA + HIS | aminoacyl-histidinedipeptidase |
R565 | Urea cycle and metabolism of amino groups | 3.5.1.4 | ABAYE1700 OR ABAYE2422 | 4GBTA <-> 4GBTR + NH3 | amidase |
R566 | Urea cycle and metabolism of amino groups | 3.5.1.5 | ABAYE2776 AND ABAYE2777 AND ABAYE2778 | UREA <-> CO2 + 2 NH3 | urease |
R567 | Urea cycle and metabolism of amino groups | 3.5.1.54 | ABAYE2439 | U1C <-> 2 CO2 + 2 NH3 | allophanate hydrolase |
R568 | beta-Alanine metabolism | 1.2.1.3 | ABAYE1028 OR ABAYE1460 OR ABAYE2333 OR ABAYE2837 | bAPA + NAD-> bALA + NADH | aldehyde dehydrogenase (NAD +) |
R569 | beta-Alanine metabolism | 1.4.3.21 | ABAYE1710 | 13DAP + O2 <-> 3AP + NH3 + H2O2 | copperamineoxidaseprecursor (tyramineoxidase) (2-phenylethylamineoxidase) |
R570 | beta-Alanine metabolism | 2.6.1.18 | ABAYE1295 | ALA + 3OPP <-> PYR + bALA | omega-amino acid--pyruvate aminotransferase (omega-APT) (beta-alanine--pyruvate aminotransferase) |
R571 | beta-Alanine metabolism | 2.6.1.19 | ABAYE0209 | bALA + AKG <-> OPP + GLU | 4-aminobutyrateaminotransferase, PLP-dependent |
R572 | beta-Alanine metabolism | 4.1.1.11 | ABAYE2984 | ASP-> bALA + CO2 | aspartate 1-decarboxylase precursor |
R573 | Taurine and hypotaurine metabolism | 1.14.11.17 | ABAYE2209 | TR + AKG + O2-> H2SO3 + AAA + SUCC + CO2 | taurine dioxygenase |
R574 | Taurine and hypotaurine metabolism | 2.3.2.2 | ABAYE2905 | 5GLUPEPT + TR-> PEPTIDE + GLUTR | gamma-glutamyltranspeptidaseprecursor |
R575 | Aminophosphonate metabolism | 2.6.1.37 | ABAYE2318 | (2AE) P + PYR <-> PPAC + ALA | 2-aminoethylphosphonate-pyruvate transaminase |
R576 | Aminophosphonate metabolism | 2.1.1.- | ABAYE0624 OR ABAYE2481 OR ABAYE2566 OR ABAYE2771 OR ABAYE2871 | MCB + PPAC-> 2HPP + VB12 | N6-adenine-specificmethylase |
R577 | Aminophosphonate metabolism | 2.7.8.- | ABAYE1103 OR ABAYE3258 OR ABAYE3750 | CMPAEP + NAS <-> NASAEP + CMP | 4'-phosphopantetheinyl transferase |
R578 | Aminophosphonate metabolism | 3.11.1.1 | ABAYE2317 | PPAC <-> ACAL + PI | phosphonoacetaldehydephosphonohydrolase (phosphonatase) |
R579 | Selenoamino acid metabolism | 4.4.1.8 | ABAYE0405 | SLLCT-> SHCYS + NH3 + PYR | cystathionine beta-lyase |
R580 | Selenoamino acid metabolism | SHCYS-> SMET | |||
R581 | Selenoamino acid metabolism | 6.1.1.10 | ABAYE3031 | ATP + SMET + TRNAMET-> AMP + PPI + SMETTRNAMET | methionyl-tRNA synthetase |
R582 | Selenoamino acid metabolism | 2.5.1.6 | ABAYE2118 | ATP + SMET-> PI + PPI + SeASMET | S-adenosylmethionine synthetase |
R583 | Selenoamino acid metabolism | 2.5.1.47 | ABAYE3184 OR ABAYE3696 | ASER + SELD-> SCYS + AC | cysteine synthase |
R584 | Selenoamino acid metabolism | 2.7.7.4 | ABAYE2790 AND ABAYE2791 | ATP + SELNT <-> PPI + ASELNT | sulfateadenylyltransferase |
R585 | Selenoamino acid metabolism | 2.3.2.2 | ABAYE2905 | 5GLUPEPT + MSCYS-> PEPTIDE + GGLUMSCYS | gamma-glutamyltranspeptidase precursor |
R586 | Selenoamino acid metabolism | 3.3.1.1 | ABAYE1142 | SASHCYS <-> ADN + SHCYS | S-adenosyl-L-homocysteinehydrolase |
R587 | Selenoamino acid metabolism | 4.4.1.16 | ABAYE2250 | SCYS + FADH2 <-> SELD + ALA + FAD | cysteinedesulfurase1ORselenocysteinelyase |
R588 | Cyanoamino acid metabolism | 2.3.2.2 | ABAYE2905 | CALA + GLU-> GLUBCALA | gamma-glutamyltranspeptidaseprecursor |
R589 | Cyanoamino acid metabolism | 2.3.2.2 | ABAYE2905 | APN + GLU-> GAPN | gamma-glutamyltranspeptidaseprecursor |
R590 | D-Glutamine and D-glutamate metabolism | 3.5.1.2 OR 3.5.1.38 | ABAYE2832 OR ABAYE2188 | DGLN-> DGLU + NH3 | glutaminase OR glutaminase-asparaginase |
R591 | D-Glutamine and D-glutamate metabolism | 5.1.1.3 | ABAYE0082 OR ABAYE3395 | DGLU <-> GLU | glutamateracemase |
R592 | D-Alanine metabolism | 5.1.1.1 | ABAYE1380 OR ABAYE3773 | ALA <-> DALA | alanine racemase |
R593 | D-Alanine metabolism | 6.3.2.4 | ABAYE0150 | 2DALA + ATP-> ALAALA + ADP + PI | D-alanine-D-alanineligase |
R594 | Glutathione metabolism | 3.4.11.1 OR 3.4.11.2 OR 3.4.13.3 | ABAYE3540 OR ABAYE1469 OR ABAYE1209 | CYSGLY-> CYS + GLY | aminopeptidase A (EC: 3.4.11.1) ormembranealanylaminopeptidase |
R595 | Glutathione metabolism | 1.11.1.9 | ABAYE2184 OR ABAYE3713 | H2O2 + 2RGT <-> OGT | glutathione peroxidase |
R596 | Glutathione metabolism | 2.3.2.2 | ABAYE2905 | RGT-> CYSGLY + GLU | gamma-glutamyltranspeptidaseprecursor |
R597 | Glutathione metabolism | 6.3.2.2 | ABAYE0116 | ATP + GLU + CYS <-> ADP + PI + GCYS | gamma-glutamate-cysteine ligase |
R598 | Glutathione metabolism | 6.3.2.3 | ABAYE0147 | ATP + GCYS + GLY <-> ADP + PI + RGT | glutathione synthetase |
R599 | Lipopolysaccharide biosynthesis | 2.3.1.129 | ABAYE1587 | C140ACP + UDPNAG-> ACP + UDPG2AA | UDP-N-acetylglucosamine acyltransferase |
R600 | Lipopolysaccharide biosynthesis | 3.5.1.- | ABAYE0154 | UDPG2AA-> UDPG2A + AC | UDP-3-O- [3-hydroxymyristoyl] N-acetylglucosamine deacetylase |
R601 | Lipopolysaccharide biosynthesis | 2.3.1.- | ABAYE1585 | UDPG2A + C140ACP-> ACP + UDPG23A | UDP-3-O- [3-hydroxymyristoyl] glucosamine N-acyltransferase |
R602 | Lipopolysaccharide biosynthesis | 3.6.1.- | ABAYE1453 | UDPG23A-> UMP + LIPX | UDP-2,3-diacylglucosamine hydrolase |
R603 | Lipopolysaccharide biosynthesis | 2.4.1.182 | ABAYE1983 | LIPX + UDPG23A-> UDP + DISAC1P | lipid-A-disaccharide synthase |
R604 | Lipopolysaccharide biosynthesis | 2.7.1.130 | ABAYE2077 | DISAC1P + ATP-> ADP + LIPIV | tetraacyldisaccharide 4'-kinase |
R605 | Lipopolysaccharide biosynthesis | 2.-.-.- | ABAYE0175 | LIPIV + CMPKDO-> KDOLIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R606 | Lipopolysaccharide biosynthesis | 2.-.-.- | ABAYE0175 | KDOLIPIV + CMPKDO-> K2LIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R607 | Lipopolysaccharide biosynthesis | 2.3.1.- | ABAYE0885 OR ABAYE3343 | C140ACP + LK2LIPIV-> K2LIPA + ACP | lipidAbiosynthesis (KDO) 2- (lauroyl) -lipidivaacyltransferase |
R608 | Lipopolysaccharide biosynthesis | 5.3.1.13 | RL5P <-> A5P | D-arabinose 5-phosphate isomerase | |
R609 | Lipopolysaccharide biosynthesis | 2.5.1.55 | ABAYE1668 | PEP + A5P-> KDOP + PI | 2-dehydro-3-deoxyphosphooctonate aldolase (KDO 8-P synthase) |
R610 | Lipopolysaccharide biosynthesis | 3.1.3.45 | ABAYE2491 | KDOP-> KDO + PI | 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase |
R611 | Lipopolysaccharide biosynthesis | 2.7.7.38 | ABAYE2076 | KDO + CTP-> PPI + CMPKDO | 3-deoxy-manno-octulosonatecytidylyltransferase |
R612 | Peptidoglycan biosynthesis | 6.3.2.8 | ABAYE0149 | UDPNAM + ALA + ATP-> ADP + PI + UDPNAMA | UDP-N-acetylmuramate--alanine ligase |
R613 | Peptidoglycan biosynthesis | 6.3.2.9 | ABAYE3524 | UDPNAMA + DGLU + ATP-> UDPNAMAG + ADP + PI | UDP-N-acetylmuramoylalanine--D-glutamate ligase |
R614 | Peptidoglycan biosynthesis | 6.3.2.13 | ABAYE0283 | UDPNAMAG + MDAPIM + ATP-> UDPMNLADGMD + ADP + PI | UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase |
R615 | Peptidoglycan biosynthesis | 6.3.2.10 | ABAYE0284 | UDPMNLADGMD + ALAALA + ATP-> UDPMNLADGMDDADA + ADP + PI | UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase |
R616 | Peptidoglycan biosynthesis | 2.7.8.13 | ABAYE0285 | UDPMNLADGMDDADA + UDCP-> UPPMNLADGMDDADA + UMP | phospho-N-acetylmuramoyl-pentapeptide-transferase |
R617 | Peptidoglycan biosynthesis | 2.4.1.227 | ABAYE0148 | UPPMNLADGMDDADA + UDPNAG-> UPPMN (GN) LADGMDDADA + UDP | UDP-N-acetylglucosamine--Nacetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenolN-acetylglucosaminetransferase |
R618 | Peptidoglycan biosynthesis | 6.3.1.2 | ABAYE1126 OR ABAYE1425 | UPPMN (GN) LADGMDDADA + ATP + NH3-> UPPMN (GN) LADGNMDDADA + ADP + PI | glutamine synthetase |
R619 | Peptidoglycan biosynthesis | 2.3.2.10 | 5GLY + UPPMN (GN) LADGNMDDADA-> UPPMN (GN) LADGNMD (G) 5DADA | L-Alanyl-tRNA: UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanineN6-alanyltransferase | |
R620 | Peptidoglycan biosynthesis | UPPMN (GN) LADGNMD (G) 5DADA-> UDCPP + PPEPTIDO | |||
R621 | Peptidoglycan biosynthesis | 2.6.1.21 | PPEPTIDO + DALA-> 0.9208 PEPTIDO + 0.8 DALAxt | D-Alanine: 2-oxoglutarate aminotransferase | |
R622 | Peptidoglycan biosynthesis | 3.6.1.27 | ABAYE0716 | UDCPP-> UDCP + PI | undecaprenyl-diphosphatase |
R623 | Thiamine metabolism | thiC | ABAYE3518 | AIR-> AHM | thiamine biosynthesis protein ThiC |
R624 | Thiamine metabolism | 2.7.1.49 | ABAYE2989 | AHM + ATP-> AHMP + ADP | hydroxymethylpyrimidine kinase |
R625 | Thiamine metabolism | 2.7.4.7 | ABAYE2989 | AHMP + ATP-> AHMPP + ADP | phosphomethylpyrimidine kinase |
R626 | Thiamine metabolism | 2.5.1.3 | ABAYE1010 | THZP + AHMPP-> THMP + PPI | thiamine-phosphate pyrophosphorylase |
R627 | Thiamine metabolism | 2.7.4.16 | ABAYE0093 | THMP + ATP <-> THMPP + ADP | thiamine-monophosphatekinase |
R628 | Thiamine metabolism | 1.4.3.19 | ABAYE2910 | GLY <-> IGLY | D-aminoacidoxidase |
R629 | Thiamine metabolism | 2.7.1.50 | ABAYE1466 | ATP + THZ <-> ADP + MPET | hydroxyethylthiazolekinase |
R630 | Thiamine metabolism | 3.5.99.2 | ABAYE0200 | THIAMIN <-> AHM + THZ | TenAfamilytranscriptionalactivator |
R631 | Thiamine metabolism | 3.6.1.15 | ABAYE3296 | THMPP <-> THMP + PI | nucleoside-triphosphatase |
R632 | Riboflavin metabolism | 3.5.4.25 | ABAYE0096 OR ABAYE0379 | GTP-> D6RP5P + FORMATE + PPI | GTP cyclohydrolase II |
R633 | Riboflavin metabolism | 3.5.4.26 | ABAYE3546 | D6RP5P-> A6RP5P + NH3 | diaminohydroxyphosphoribosylaminopyrimidine deaminase |
R634 | Riboflavin metabolism | 1.1.1.193 | ABAYE3546 | A6RP5P + NADPH-> A6RP5P2 + NADP | 5-amino-6- (5-phosphoribosylamino) uracil reductase |
R635 | Riboflavin metabolism | 3.1.3- | A6RP5P2-> A6RP + PI | phosphatase | |
R636 | Riboflavin metabolism | RIBB | ABAYE0096 OR ABAYE2987 | RL5P-> DB4P + FORMATE | 3,4-dihydroxy-2-butanone 4-phosphate synthase |
R637 | Riboflavin metabolism | RIBH | ABAYE0095 | DB4P + A6RP-> D8RL + PI | riboflavinsynthase |
R638 | Riboflavin metabolism | 2.5.1.9 | ABAYE3544 | 2D8RL-> RIBFLAV + A6RP | riboflavinsynthase |
R639 | Riboflavin metabolism | 2.7.1.26 | ABAYE3851 | RIBFLAV + ATP-> FMN + ADP | riboflavin kinase |
R640 | Riboflavin metabolism | 2.7.7.2 | ABAYE3851 | FMN + ATP-> FAD + PPI | FMN adenylyltransferase |
R641 | Riboflavin metabolism | 2.4.2.21 | ABAYE1993 | NACN + DMB-> NAC + N1 (5PADR) DMB | nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase |
R642 | Vitamin B6 metabolism | 1.2.1.72 | ABAYE2594 | E4P + NAD <-> ER4P + NADH | D-erythrose 4-phosphate dehydrogenase |
R643 | Vitamin B6 metabolism | 1.1.1.290 | ABAYE0853 | ER4P + NAD <-> OHB + NADH | erythronate-4-phosphate dehydrogenase |
R644 | Vitamin B6 metabolism | 2.6.1.52 | ABAYE0877 | OHB + GLU <-> PHT + AKG | phosphoserine aminotransferase |
R645 | Vitamin B6 metabolism | 4.2.3.1 | ABAYE3531 | PHT-> 4HLT + PI | threonine synthase |
R646 | Vitamin B6 metabolism | 1.1.1.262 | ABAYE0489 | PHT + NAD-> 3A2OP + NADH + CO2 | 4-hydroxythreonine-4-phosphate dehydrogenase |
R647 | Vitamin B6 metabolism | 2.6.99.2 | ABAYE0945 | 3A2OP + DX5P-> P5P + PI | pyridoxine 5-phosphate synthase |
R648 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | P5P + O2-> PL5P + H2O2 | pyridoxamine 5'-phosphate oxidase |
R649 | Vitamin B6 metabolism | 3.1.3.- | PL5P-> PL + PI | phosphatase | |
R650 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | PDLA5P + O2-> PL5P + NH3 + H2O2 | pyridoxamine 5'-phosphate oxidase |
R651 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | PYRDX + O2 <-> PL + H2O2 | pyridoxamine 5'-phosphate oxidase |
R652 | Vitamin B6 metabolism | 1.4.3.5 | ABAYE0168 | PL + O2 + NH3 <-> PDLA + H2O2 | pyridoxamine 5'-phosphate oxidase |
R653 | Nicotinate and nicotinamide metabolism | 1.4.3.16 | ABAYE0935 | ASP + FUM-> IASP + SUCC | L-aspartateoxidase |
R654 | Nicotinate and nicotinamide metabolism | 1.4.3.16 | ABAYE0935 | ASP + O2-> IASP + H2O2 | L-aspartate oxidase |
R655 | Nicotinate and nicotinamide metabolism | NadA | ABAYE3104 | IASP + DHAP-> QA + PI | quinolinate synthase |
R656 | Nicotinate and nicotinamide metabolism | 2.4.2.19 | ABAYE3823 | QA + PRPP-> NACN + CO2 + PPI | nicotinate-nucleotide pyrophosphorylase (carboxylating) |
R657 | Nicotinate and nicotinamide metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | NACN-> NACD + PI | 5'-nucleotidase |
R658 | Nicotinate and nicotinamide metabolism | 3.1.3.5 | ABAYE1047 OR ABAYE1886 | NAMN-> NAMD + PI | 5'-nucleotidase |
R659 | Nicotinate and nicotinamide metabolism | 2.4.2.11 | ABAYE0102 | NAC + PRPP-> NACN + PPI | nicotinate phosphoribosyltransferase |
R660 | Nicotinate and nicotinamide metabolism | 2.7.7.1 OR 2.7.7.18 | ABAYE0916 OR ABAYE0916 | ATP + NAMN <-> PPI + NAD | nicotinamide / nicotinate-nucleotide adenylyltransferase |
R661 | Nicotinate and nicotinamide metabolism | 2.7.7.1 OR 2.7.7.18 | ABAYE0916 OR ABAYE0916 | NACN + ATP-> PPI + NAAD | nicotinate-nucleotide adenylyltransferase |
R662 | Nicotinate and nicotinamide metabolism | 6.3.5.1 | ABAYE2955 | NAAD + ATP + GLN-> NAD + AMP + PPI + GLU | glutamine-dependentNAD (+) synthetase |
R663 | Nicotinate and nicotinamide metabolism | 3.5.1.19 | ABAYE0059 | NAM-> NAC + NH3 | nicotinamidase |
R664 | Nicotinate and nicotinamide metabolism | 1.6.1.2 | ABAYE3191 AND ABAYE3192 AND ABAYE3193 | NADP + NADH-> NADPH + NAD | NAD (P) transhydrogenase |
R665 | Nicotinate and nicotinamide metabolism | 2.7.1.23 | ABAYE1199 | NAD + ATP-> NADP + ADP | NAD kinase |
R666 | Nicotinate and nicotinamide metabolism | 1.6.1.1 | ABAYE1147 | NADPH + NAD <-> NADP + NADH | NAD (P) transhydrogenase |
R667 | Nicotinate and nicotinamide metabolism | 1.4.1.21 | ABAYE2838 | ASP + NAD <-> IASP + NADH | L-aspartate dehydrogenase |
R668 | Nicotinate and nicotinamide metabolism | 1.4.1.21 | ABAYE2838 | ASP + NADP <-> IASP + NADPH | L-aspartatedehydrogenase |
R669 | Nicotinate and nicotinamide metabolism | 3.6.1.22 | ABAYE2666 | NAD <-> AMP + NAMN | NUDIX family NADH pyrophosphatase |
R670 | Nicotinate and nicotinamide metabolism | 3.6.1.22 | ABAYE2666 | NAAD <-> AMP + NACN | NUDIX family NADH pyrophosphatase |
R671 | Pantothenate and CoA biosynthesis | 2.2.1.6 | ABAYE2836 OR (ABAYE3239 AND ABAYE3240) | 2PYR-> ACLAC + CO2 | acetolactatesynthase |
R672 | Pantothenate and CoA biosynthesis | 2.1.2.11 | ABAYE3175 | OIVAL + METTHF-> DHPANT + THF | 3-methyl-2-oxobutanoate hydroxymethyltransferase |
R673 | Pantothenate and CoA biosynthesis | 1.1.1.169 | DHPANT + NADPH-> NADP + PANT | 2-dehydropantoate 2-reductase | |
R674 | Pantothenate and CoA biosynthesis | 6.3.2.1 | ABAYE3174 | PANT + bALA + ATP-> AMP + PPI + PNTO | pantoate-beta-alanine ligase |
R675 | Pantothenate and CoA biosynthesis | 2.7.1.33 | ABAYE3016 | PNTO + ATP-> ADP + 4PPNTO | pantothenate kinase |
R676 | Pantothenate and CoA biosynthesis | 2.7.1.33 | ABAYE3016 | ATP + N (P) CYS-> ADP + 4PPNCYS | pantothenate kinase |
R677 | Pantothenate and CoA biosynthesis | 2.7.1.33 | ABAYE3016 | ATP + PTT-> ADP + 4PPNTE | pantothenate kinase |
R678 | Pantothenate and CoA biosynthesis | 6.3.2.5 | ABAYE0524 | 4PPNTO + CTP + CYS-> CMP + PPI + 4PPNCYS | phosphopantothenate-cysteine ligase |
R679 | Pantothenate and CoA biosynthesis | 4.1.1.36 | ABAYE0524 | 4PPNCYS-> CO2 + 4PPNTE | phosphopantothenoylcysteine decarboxylase |
R680 | Pantothenate and CoA biosynthesis | 2.7.7.3 | ABAYE2969 | 4PPNTE + ATP-> PPI + DPCOA | pantetheine-phosphate adenylyltransferase |
R681 | Pantothenate and CoA biosynthesis | 2.7.1.24 | ABAYE3447 | DPCOA + ATP-> ADP + COA | dephospho-CoA kinase |
R682 | Biotin metabolism | 2.3.1.47 | ABAYE3003 | ALA + CHCOA <-> CO2 + COA + AONA | 8-amino-7-oxononanoate synthase |
R683 | Biotin metabolism | 2.6.1.62 | ABAYE3004 | SAM + AONA <-> SAMOB + DANNA | adenosylmethionine-8-amino-7-oxononanoateaminotransferase |
R684 | Biotin metabolism | 6.3.3.3 | ABAYE3001 | CO2 + DANNA + ATP <-> DTB + PI + ADP | dethiobiotin synthetase |
R685 | Biotin metabolism | 2.8.1.6 | ABAYE2129 | DTB + S-> BT | biotin synthase |
R686 | Biotin metabolism | 6.3.4.15 | ABAYE3015 | ATP + BT-> PPI + B5AMP | biotin- [acetyl-CoA-carboxylase] ligase |
R687 | Biotin metabolism | 6.3.4.15 | ABAYE3015 | B5AMP + A [C]-> AMP + H [C] | biotin- [acetyl-CoA-carboxylase] ligase |
R688 | Folate biosynthesis | 3.5.4.16 | ABAYE1113 | GTP-> FORMATE + AHTD | GTP cyclohydrolase I |
R689 | Folate biosynthesis | 3.6.1.- | ABAYE3429 | AHTD-> DHP + PPI + PI | recG-likehelicase |
R690 | Folate biosynthesis | 4.1.2.25 | ABAYE1417 | DHP-> AHHMP + GLAL | dihydroneopterin aldolase |
R691 | Folate biosynthesis | 2.7.6.3 | ABAYE1418 OR ABAYE3176 | AHHMP + ATP-> AMP + AHHMD | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridinepyrophosphokinase |
R692 | Folate biosynthesis | 2.6.1.85 | ABAYE3129 | CHOR + GLN-> ADCHOR + GLU | para-aminobenzoate synthase |
R693 | Folate biosynthesis | 4.1.3.38 | ABAYE0931 | ADCHOR-> PYR + PABA | 4-amino-4-deoxychorismate lyase |
R694 | Folate biosynthesis | 2.5.1.15 | ABAYE0807 OR ABAYE3568 OR ABAYE3612 OR ABAYE3616 | PABA + AHHMD-> PPI + DHPT | dihydropteroate synthase |
R695 | Folate biosynthesis | 2.5.1.15 | ABAYE0807 OR ABAYE3568 OR ABAYE3612 OR ABAYE3616 | PABA + AHHMP-> DHPT | dihydropteroate synthase |
R696 | Folate biosynthesis | 6.3.2.12 OR 6.3.2.17 | ABAYE0615 | DHPT + ATP + GLU-> ADP + PI + DHF | dihydrofolate synthase |
R697 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF + NADPH-> NADP + THF | dihydrofolate reductase |
R698 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF + NADH-> NAD + THF | dihydrofolate reductase |
R699 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF + NAD <-> FL + NADH | dihydrofolate reductase |
R700 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | DHF + NADP <-> FL + NADPH | dihydrofolate reductase |
R701 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | FL + NADH-> THF + NAD | dihydrofolate reductase |
R702 | Folate biosynthesis | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | FL + NADPH-> THF + NADP | dihydrofolate reductase |
R703 | Folate biosynthesis | 6.3.2.17 | ABAYE0615 | THF + ATP + GLU <-> ADP + PI + THFG | folylpolyglutamate synthase |
R704 | Folate biosynthesis | 4.2.3.12 | ABAYE2067 | AHTD-> PYTHP + PPPI | 6-pyruvoyl tetrahydrobiopterin synthase |
R705 | Folate biosynthesis | 3.1.3.1 | ABAYE0811 | AHTD <-> DHP + 3 PI | alkaline phosphatase D precursor |
R706 | One carbon pool by folate | 2.1.2.2 | ABAYE0888 OR ABAYE2179 | GAR + METHF-> FGAR + THF | phosphoribosylglycinamide formyltransferase |
R707 | One carbon pool by folate | 3.5.4.9 | ABAYE0812 | METHF-> FTHF | bifunctionalprotein [includes: 5,10-methylene-tetrahydrofolatedehydrogenase; 5,10-methylene-tetrahydrofolatecyclohydrolase] |
R708 | One carbon pool by folate | 1.5.1.5 | ABAYE0812 | METTHF + NADP <-> METHF + NADPH | bifunctionalprotein [includes: 5,10-methylene-tetrahydrofolatedehydrogenase; 5,10-methylene-tetrahydrofolatecyclohydrolase] |
R709 | One carbon pool by folate | 3.5.4.9 | ABAYE0812 | METHF <-> FTHF | bifunctionalprotein [includes: 5,10-methylene-tetrahydrofolatedehydrogenase; 5,10-methylene-tetrahydrofolatecyclohydrolase] |
R710 | One carbon pool by folate | 1.5.1.20 | ABAYE1141 OR ABAYE1792 | METTHF + NADPH-> MTHF + NADP | methylenetetrahydrofolatereductase |
R711 | One carbon pool by folate | 1.5.1.20 | ABAYE1141 OR ABAYE1792 | METTHF + FADH2 <-> MTHF + FAD | methylenetetrahydrofolatereductase |
R712 | One carbon pool by folate | 2.1.1.45 | ABAYE3314 | DUMP + METTHF <-> DHF + DTMP | thymidylatesynthase |
R713 | One carbon pool by folate | 3.5.1.10 | ABAYE3322 | FTHF <-> FORMATE + THF | formyltetrahydrofolate deformylase |
R714 | One carbon pool by folate | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | THF + NAD <-> DHF + NADH | dihydrofolate reductase |
R715 | One carbon pool by folate | 1.5.1.3 | ABAYE3315 OR ABAYE3614 OR ABAYE3644 | THF + NADP <-> DHF + NADPH | dihydrofolate reductase |
R716 | Porphyrin and chlorophyll metabolism | 1.2.1.70 | ABAYE2976 | GTRNA + NADPH-> GSA + NADP | glutamyl-tRNA reductase |
R717 | Porphyrin and chlorophyll metabolism | 5.4.3.8 | ABAYE1011 | GSA-> ALAV | glutamate-1-semialdehyde aminotransferase |
R718 | Porphyrin and chlorophyll metabolism | 4.2.1.24 | ABAYE2909 | 2ALAV-> PBG | porphobilinogen synthase |
R719 | Porphyrin and chlorophyll metabolism | 2.5.1.61 | ABAYE3508 | 4PBG-> HMB + 4 NH3 | hydroxymethylbilane synthase |
R720 | Porphyrin and chlorophyll metabolism | 4.2.1.75 | ABAYE3507 | HMB-> UPRG | uroporphyrinogen-III synthase |
R721 | Porphyrin and chlorophyll metabolism | 2.1.1.107 | ABAYE0758 | 2SAM + UPRG-> 2 SAH + PC2 | uroporphyrin-III C-methyltransferase |
R722 | Porphyrin and chlorophyll metabolism | 1.3.1.76 | ABAYE0758 | PC2 + NAD-> NADH + SHCL | precorrin-2 dehydrogenase |
R723 | Porphyrin and chlorophyll metabolism | 4.99.1.4 | ABAYE0758 | SHCL-> SHEME | sirohydrochlorin ferrochelatase |
R724 | Porphyrin and chlorophyll metabolism | 4.1.1.37 | ABAYE1106 | UPRG-> 4CO2 + CPP | uroporphyrinogen decarboxylase |
R725 | Porphyrin and chlorophyll metabolism | 1.3.99.22 | ABAYE0674 OR ABAYE3379 | CPP + 2SAM-> PPHG + 2 CO2 + 2 MET + 2 DA | oxygen-independent coproporphyrinogen III oxidase |
R726 | Porphyrin and chlorophyll metabolism | 1.3.3.3 | ABAYE0378 | CPP + O2-> PPHG + 2 CO2 | coproporphyrinogen III oxidase |
R727 | Porphyrin and chlorophyll metabolism | 4.99.1.1 | ABAYE3393 | PPIX-> PTH | ferrochelatase |
R728 | Porphyrin and chlorophyll metabolism | 2.5.1.17 | ABAYE0605 | C (I) DA + ATP-> ACDA + PPI + PI | cob (I) alamin adenosyltransferase |
R729 | Porphyrin and chlorophyll metabolism | 2.7.1.156 | ABAYE1994 | ADCBA + ATP-> ADCBAP + ADP | adenosylcobinamidekinase |
R730 | Porphyrin and chlorophyll metabolism | 2.7.1.156 | ABAYE1994 | ADCBA + GTP-> ADCBAP + GDP | adenosylcobinamidekinase |
R731 | Porphyrin and chlorophyll metabolism | 2.7.1.156 | ABAYE1994 | ADCBAP + GTP-> AGDPCBA + PPI | adenosylcobinamide-phosphate guanylyltransferase |
R732 | Porphyrin and chlorophyll metabolism | 2.7.8.26 | ABAYE1990 | AGDPCBA + ARBZ-> CBCO + GMP | adenosylcobinamide-GDP ribazoletransferase |
R733 | Porphyrin and chlorophyll metabolism | 2.5.1.17 | ABAYE0605 | ATP + CBA <-> PPPI + ADCBA | cob (I) alamin adenosyltransferase |
R734 | Porphyrin and chlorophyll metabolism | 2.5.1.17 | ABAYE0605 | ATP + C (I) A <-> PPPI + CBCO | cob (I) alamin adenosyltransferase |
R735 | Porphyrin and chlorophyll metabolism | 4.1.1.37 | ABAYE1106 | UPRGI <-> CPPI + 4 CO2 | uroporphyrinogen decarboxylase |
R736 | Porphyrin and chlorophyll metabolism | 2.5.1.- | ABAYE1385 | PTH <-> HEMEO | protohemeIXfarnesyltransferase |
R737 | Ubiquinone biosynthesis | 5.4.4.2 | ABAYE1104 | CHOR <-> ICHOR | menaquinone-specific isochorismate synthase |
R738 | Ubiquinone biosynthesis | 4.1.3.40 | ABAYE1127 | CHOR <-> 4HB + PYR | chorismate--pyruvate lyase |
R739 | Ubiquinone biosynthesis | 2.5.1.- | ABAYE1128 | OPP + 4HB-> 3OP4HB + PPI | 4-hydroxybenzoate octaprenyltransferase |
R740 | Ubiquinone biosynthesis | Ubib | ABAYE3426 | 2OPP + O2 + NADPH-> 2OP6HP + NADP | ubiquinone biosynthesis protein |
R741 | Ubiquinone biosynthesis | 2.1.1.64 | ABAYE3834 | 2OP6HP + SAM-> 2OP6MP + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R742 | Ubiquinone biosynthesis | 1.14.13.- | ABAYE2678 | 2OP6MP + O2 + NADPH-> 2OP6M14BQ + NADP | 2-octaprenyl-6-methoxyphynol hydroxylase |
R743 | Ubiquinone biosynthesis | 2.1.1.- | ABAYE3424 | 2OP6M14BQ + SAM-> 2OP3M6M14BQ + SAH | 2-octaprenyl-6-methoxy-1,4-benzoquinone methylase |
R744 | Ubiquinone biosynthesis | 2.1.1.64 | ABAYE3834 | 2OP3M5H6M14BQ + SAM-> UQ + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R745 | Ubiquinone biosynthesis | 2.5.1.64 | ICHOR + AKG-> SHCHC + PYR + CO2 | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylatesynthase | |
R746 | Ubiquinone biosynthesis | 4.2.1.- | SHCHC-> OSB | O-succinylbenzoate-CoA synthase | |
R747 | Ubiquinone biosynthesis | 6.2.1.26 | OSB + ATP + COA-> AMP + PPI + OSBCOA | O-succinylbenzoic acid--CoA ligase | |
R748 | Ubiquinone biosynthesis | 4.1.3.36 | OSBCOA-> DHN + COA | dihydroxynaphthoic acid synthase | |
R749 | Ubiquinone biosynthesis | 2.5.1.- | ABAYE1128 | DHN + OPP-> PPI + CO2 + DMK | 4-hydroxybenzoate octaprenyltransferase |
R750 | Ubiquinone biosynthesis | 2.1.1.- | ABAYE3424 | DMK + SAM-> MKH2 + SAH | menaquinone biosynthesis methyltransferase |
R751 | Ubiquinone biosynthesis | 2.1.1.- | ABAYE3424 | 2P14NQ + SAM-> PQ + SAH | menaquinone biosynthesis methyltransferase |
R752 | Ubiquinone biosynthesis | 1.14.13.- | ABAYE1427 | 2HP3M6M14B + O2 + NADPH <-> 2HP3M5H6M14B + NADP | ubiquinone biosynthesis protein |
R753 | Protein | 0.488ALA + 0.281ARG + 0.229ASN + 0.229ASP + 0.087CYS + 0.25GLU + 0.25GLN + 0.582GLY + 0.09HIS + 0.276ILE + 0.428LEU + 0.326LYS + 0.146MET + 0.176PHE + 0.21PRO + 0.205SER + 0.241THR + 0.054TRP + 0.131TYR + 0.402VAL + 40ATP-> 40ADP + 40PI + PROTEIN | |||
R754 | DNA | 2.7.7.7 | 0.987DATP + 0.631DGTP + 0.631DCTP + 0.987DTTP + 4.4ATP-> 4.4ADP + 4.4PI + 3.237PPI + DNA | ||
R755 | RNA | 2.7.7.6 | 2.045ATP + 0.920GTP + 0.686CTP + 0.689UTP-> 1.25ADP + 1.25PI + 3.091PPI + RNA | ||
R756 | Phospholipid | 0.168CL + 0.548PE + 0.302PG + 0.122AG3PE-> PHOSPHOLIPID | |||
R757 | Lipids | 0.058C100ACP + 0.185C120ACP + 0.013C140ACP + 0.012C150ACP + 1.082C160ACP + 0.74C161ACP + 0.067C170ACP + 0.06C171ACP + 0.032C180ACP + 1.443C181ACP + 0.157C120OH-> LIPID + 3.692 ACP | |||
R758 | Lipopolysaccharide biosynthesis | 0.182KDO + 0.821bDGLC + 0.656UDPGAL + 0.018DTDPRMNS + 0.365UDPNAG + 0.255UDPAGLACA + 0.037C120ACP + 0.014C160ACP + 0.079C120OH + 0.009C180ACP + 0.008C181ACP + 0.071C140OH-> LPS + 1.276 UDP + 0.018 DTDP + 0.068 ACP | |||
R759 | 2.794DTDPRMNS + 2.117bDGLC + 0.265GDPMAN-> EXOPOLYS + 2.794 DTDP + 0.265 UDP | ||||
R760 | Cofactors and vitamins (CAV) | 0.163COA + 0.159FAD + 0.274FMN + 0.405MK + 0.188NAD + 0.168NADP + 0.739PYRDX + 0.281THF-> CAV | |||
R761 | Biomass | 0.6PROTEIN + 0.03DNA + 0.19RNA + 0.04PHOSPHOLIPID + 0.02LIPID + 0.005LPS + 0.027PEPTIDO + 0.038EXOPOLYS + 0.03CAV + 46ATP-> BIOMASS + 46 ADP + 46 PI | |||
R762 | Maintenance | ATP-> ADP + PI | |||
R763 | IMAL_transport | 3.6.1.- | IMALxt + ATP <-> IMAL + PI + ADP | ||
R764 | FRU_transport | 2.7.1.69 | FRUxt + PEP-> F1P + PYR | ||
R765 | GLC_transport | GLCxt + ATP-> GLC + ADP + PI | |||
R766 | GLUC_transport | GLUCxt + Hxt-> GLUC | |||
R767 | MLT_transport | MLTxt + ATP-> MLT + ADP + PI | |||
R768 | MNT_transport | MNTxt + ATP-> MNT + ADP + PI | |||
R769 | NAGA_transport | NAGAxt + ATP-> NAGA + ADP + PI | |||
R770 | SUC_transport | SUCxt + ATP-> SUC + ADP + PI | |||
R771 | TRE_transport | TRExt + ATP-> TRE + ADP + PI | |||
R772 | 2PG_transport | 2PGxt + ATP-> 2PG + ADP + PI | |||
R773 | 3PG_transport | 3PGxt + ATP-> 3PG + ADP + PI | |||
R774 | AC_transport | AC <-> ACxt + Hxt | |||
R775 | AKG_transport | AKGxt + Hxt-> AKG | |||
R776 | AKG_transport | AKGxt + Naxt-> AKG + Na | |||
R777 | CIT_transport | CITxt <-> CIT | |||
R778 | FORMATE_transport | FORMATE-> FORMATExt | |||
R779 | FUM_transport | FUMxt + Hxt-> FUM | |||
R780 | FUM_transport | FUMxt + Naxt-> FUM + Na | |||
R781 | FUM_transport | FUMxt + SUCC <-> FUM + SUCCxt | |||
R782 | ICIT_transport | ICITxt + Naxt-> ICIT + Na | |||
R783 | MAL_transport | MALxt + Hxt-> MAL | |||
R784 | MAL_transport | MALxt + Naxt-> MAL + Na | |||
R785 | MAL_transport | MALxt + SUCC <-> MAL + SUCCxt | |||
R786 | SLAC_transport | SLACxt + Hxt-> SLAC | |||
R787 | SUCC_transport | SUCCxt + Hxt-> SUCC | |||
R788 | SUCC_transport | SUCCxt + Naxt-> SUCC + Na | |||
R789 | GLYCOLATE_transport | GLYCOLATExt <-> GLYCOLATE | |||
R790 | ATP_transport | ATP <-> Hxt + ADP + PI | |||
R791 | CO2_transport | CO2xt <-> CO2 | |||
R792 | Na_transport | Naxt <-> Na + Hxt | |||
R793 | NH3_transport | NH3xt <-> NH3 | |||
R794 | NO2_transport | NO2-> NO2xt | |||
R795 | NO3_transport | NO3xt + ATP-> NO3 + ADP + PI | |||
R796 | O2_transport | O2xt <-> O2 | |||
R797 | PI_transport | PIxt + Hxt <-> PI | |||
R798 | PI_transport | PIxt + ATP-> 2 PI + ADP | |||
R799 | SLF_transport | SLFxt + Hxt-> SLF | |||
R800 | SLF_transport | SLFxt + ATP-> SLF + ADP + PI | |||
R801 | ALA_transport | ALA + Hxt <-> ALAxt | |||
R802 | ALA_transport | ALAxt + ATP-> ALA + ADP + PI | |||
R803 | ALA_transport | ALAxt + Hxt-> ALA | |||
R804 | ALA_transport | ALAxt + Naxt-> ALA + Na | |||
R805 | ARG_transport | ARG + Hxt <-> ARGxt | |||
R806 | ARG_transport | ARGxt + ATP-> ARG + ADP + PI | |||
R807 | ARG_transport | ARGxt + Hxt-> ARG | |||
R808 | ASN_transport | ASN + Hxt <-> ASNxt | |||
R809 | ASN_transport | ASNxt + ATP-> ASN + ADP + PI | |||
R810 | ASN_transport | ASNxt + Hxt-> ASN | |||
R811 | ASP_transport | ASP + Hxt <-> ASPxt | |||
R812 | ASP_transport | ASPxt + ATP-> ASP + ADP + PI | |||
R813 | ASP_transport | ASPxt + Hxt-> ASP | |||
R814 | CYS_transport | CYS + Hxt <-> CYSxt | |||
R815 | CYS_transport | CYSxt + ATP-> CYS + ADP + PI | |||
R816 | CYS_transport | CYSxt + Hxt-> CYS | |||
R817 | DALA_transport | DALAxt + Hxt-> DALA | |||
R818 | DGLU_transport | DGLUxt + Hxt-> DGLU | |||
R819 | GLN_transport | GLN + Hxt <-> GLNxt | |||
R820 | GLN_transport | GLNxt + ATP-> GLN + ADP + PI | |||
R821 | GLN_transport | GLNxt + Hxt-> GLN | |||
R822 | GLU_transport | GLU + Hxt <-> GLUxt | |||
R823 | GLU_transport | GLUxt + ATP-> GLU + ADP + PI | |||
R824 | GLU_transport | GLUxt + Hxt-> GLU | |||
R825 | GLU_transport | GLUxt + Naxt-> GLU + Na | |||
R826 | GLY_transport | GLY + Hxt <-> GLYxt | |||
R827 | GLY_transport | GLYxt + ATP-> GLY + ADP + PI | |||
R828 | GLY_transport | GLYxt + Hxt-> GLY | |||
R829 | GLY_transport | GLYxt + Naxt-> GLY + Na | |||
R830 | HIS_transport | HIS + Hxt <-> HISxt | |||
R831 | HIS_transport | HISxt + ATP-> HIS + ADP + PI | |||
R832 | HIS_transport | HISxt + Hxt-> HIS | |||
R833 | ILE_transport | ILE + Hxt <-> ILExt | |||
R834 | ILE_transport | ILExt + ATP-> ILE + ADP + PI | |||
R835 | ILE_transport | ILExt + Hxt-> ILE | |||
R836 | LEU_transport | LEU + Hxt <-> LEUxt | |||
R837 | LEU_transport | LEUxt + ATP-> LEU + ADP + PI | |||
R838 | LEU_transport | LEUxt + Hxt-> LEU | |||
R839 | LYS_transport | LYS + Hxt <-> LYSxt | |||
R840 | LYS_transport | LYS + Hxt-> LYSxt | |||
R841 | LYS_transport | LYSxt + ATP-> LYS + ADP + PI | |||
R842 | LYS_transport | LYSxt + Hxt-> LYS | |||
R843 | MET_transport | MET + Hxt <-> METxt | |||
R844 | MET_transport | METxt + ATP-> MET + ADP + PI | |||
R845 | MET_transport | METxt + Hxt-> MET | |||
R846 | PHE_transport | PHE + Hxt <-> PHExt | |||
R847 | PHE_transport | PHExt + ATP-> PHE + ADP + PI | |||
R848 | PHE_transport | PHExt + Hxt-> PHE | |||
R849 | PRO_transport | PRO + Hxt <-> PROxt | |||
R850 | PRO_transport | PROxt + ATP-> PRO + ADP + PI | |||
R851 | PRO_transport | PROxt + Hxt-> PRO | |||
R852 | PRO_transport | PROxt + Naxt-> PRO + Na | |||
R853 | SER_transport | SER + Hxt <-> SERxt | |||
R854 | SER_transport | SERxt + ATP-> SER + ADP + PI | |||
R855 | SER_transport | SERxt + Hxt-> SER | |||
R856 | THR_transport | THR + Hxt <-> THRxt | |||
R857 | THR_transport | THRxt + ATP-> THR + ADP + PI | |||
R858 | THR_transport | THRxt + Hxt-> THR | |||
R859 | TRP_transport | TRP + Hxt <-> TRPxt | |||
R860 | TRP_transport | TRPxt + ATP-> TRP + ADP + PI | |||
R861 | TRP_transport | TRPxt + Hxt-> TRP | |||
R862 | TYR_transport | TYR + Hxt <-> TYRxt | |||
R863 | TYR_transport | TYRxt + ATP-> TYR + ADP + PI | |||
R864 | TYR_transport | TYRxt + Hxt-> TYR | |||
R865 | VAL_transport | VAL + Hxt <-> VALxt | |||
R866 | VAL_transport | VALxt + ATP-> VAL + ADP + PI | |||
R867 | VAL_transport | VALxt + Hxt-> VAL | |||
R868 | DSER_transport | DSERxt + Hxt-> DSER | |||
R869 | ARG_transport | ARGxt + ORN <-> ARG + ORNxt | |||
R870 | HSER_transport | HSER + Hxt <-> HSERxt | |||
R871 | ORN_transport | ORNxt + ATP-> ORN + ADP + PI | |||
R872 | PTRC_transport | PTRCxt + ATP-> PTRC + ADP + PI | |||
R873 | SPRMD_transport | SPRMDxt + ATP-> SPRMD + ADP + PI | |||
R874 | UREA_transport | UREAxt + ATP-> UREA + ADP + PI | |||
R875 | CHOLINE_transport | CHOLINExt + Hxt-> CHOLINE | |||
R876 | ADN_transport | ADNxt + Hxt-> ADN | |||
R877 | CYTD_transport | CYTDxt + Hxt-> CYTD | |||
R878 | DA_transport | DAxt + Hxt-> DA | |||
R879 | DC_transport | DCxt + Hxt-> DC | |||
R880 | DG_transport | DGxt + Hxt-> DG | |||
R881 | DT_transport | DTxt + Hxt-> DT | |||
R882 | DU_transport | DUxt + Hxt-> DU | |||
R883 | GSN_transport | GSNxt + Hxt-> GSN | |||
R884 | URI_transport | URIxt + Hxt-> URI | |||
R885 | CT_transport | CTxt + Hxt-> CT | |||
R886 | XAN_transport | XANxt + Hxt-> XAN | |||
R887 | URA_transport | URAxt + Hxt-> URA | |||
R888 | TR_transport | TRxt + ATP-> TR + ADP + PI | |||
R889 | ETHA_transport | ETHAxt + Hxt-> ETHA | |||
R890 | BETAINE_transport | BETAINExt + Hxt-> BETAINE | |||
R891 | BZ_transport | BZxt + Hxt-> BZ |
(여기서, 상기 R035, R036, R044, R046, R052, R068, R069, R070, R071, R095, R108, R157, R160, R227, R239, R319, R320, R328, R329, R330, R346, R472, R608, R619, R621, R635, R649, R673, R745, R746, R747, R748은 게놈 정보에 할당된 유전자가 없는 반응식)Here, R035, R036, R044, R046, R052, R068, R069, R070, R071, R095, R108, R157, R160, R227, R239, R319, R320, R328, R329, R330, R346, R472, R608, R619, R621, R635, R649, R673, R745, R746, R747, and R748 are reactions without genes assigned to genomic information.)
표 2 대사산물
TABLE 2 <u> Metabolites </ u>
Metabolite abbreviations | Metabolite names |
(2AE)P | (2-Aminoethyl)phosphonate |
13DAP | 1,3-Diaminopropane; Trimethylenediamine; 1,3-Propanediamine; Propane-1,3-diamine |
13PDG | 3-Phospho-D-glyceroyl phosphate |
1BOH | 1-Butanol |
2(HE)TPP | 2-(alpha-Hydroxyethyl)thiamine diphosphate |
23BOH | (R,R)-Butane-2,3-diol; (R,R)-2,3-Butanediol; (R,R)-2,3-Butylene glycol |
24DAB | L-2,4-Diaminobutanoate |
2AA | 2-Aminoacrylate |
2AG3PC | 2-Acyl-sn-glycero-3-phosphocholine |
2AG3PE | 2-Acyl-sn-glycero-3-phosphoethanolamine; L-1-Lysophosphatidylethanolamine |
2AG3PS | 2-Acyl-sn-glycero-3-phosphoserine |
2AGL3P | 2-Acyl-sn-glycerol 3-phosphate |
2H3OSUCC | 2-Hydroxy-3-oxosuccinate; Oxaloglycolate |
2HP3M5H6M14B | 2-Hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone |
2HP3M6M14B | 2-Hexaprenyl-3-methyl-6-methoxy-1,4-benzoquinone |
2HPA | 2-Hydroxyphenylacetate |
2HPP | 2-Hydroxypropylphosphonate |
2MAACCOA | 2-Methylacetoacetyl-CoA |
2MB2ECOA | 2-Methylbut-2-enoyl-CoA |
2MBCOA | (S)-2-Methylbutanoyl-CoA |
2MCIT | 2-Methylcitrate |
2MP2ECOA | 2-Methylprop-2-enoyl-CoA |
2MPPACOA | 2-Methylpropanoyl-CoA |
2NPRPN | 2-Nitropropane |
2OAD | 2-Oxoadipate |
2OP3M5H6M14BQ | 2-Octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone |
2OP3M6M14BQ | 2-Octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone |
2OP6HP | 2-Octaprenyl-6-hydroxyphenol |
2OP6M14BQ | 2-Octaprenyl-6-methoxy-1,4-benzoquinone |
2OP6MP | 2-Octaprenyl-6-methoxyphenol |
2OPP | 2-Octaprenylphenol |
2P14NQ | 2-Phytyl-1,4-naphthoquinone |
2P1A | 2-Propyn-1-al |
2PCDPMDE | 2-Phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol |
2PG | 2-Phospho-D-glycerate |
2PPG | 2-Phosphoglycolate |
34DHB | 3,4-Dihydroxybenzoate; 3,4-Dihydroxybenzoic acid;; Protocatechuate; Protocatechuic acid |
34DHMA | 3,4-Dihydroxymandelaldehyde |
34DHPA | 3,4-Dihydroxyphenylacetate |
34DHPEG | 3,4-Dihydroxyphenylethyleneglycol |
3A2OP | 3-Amino-2-oxopropyl phosphate |
3AP | 3-Aminopropanal; beta-Aminopropion aldehyde |
3B1A | 3-Butyn-1-al |
3BUT | 3-Butynoate |
3DDAH7P | 2-Dehydro-3-deoxy-D-arabino-heptonate7-phosphate |
3H2MBCOA | (2S,3S)-3-Hydroxy-2-methylbutanoyl-CoA |
3H3MGCOA | (S)-3-Hydroxy-3-methylglutaryl-CoA |
3HAN | 3-Hydroxyanthranilate |
3HB123TC | (2S,3R)-3-Hydroxybutane-1,2,3-tricarboxylate |
3HBCOA | (S)-3-Hydroxybutanoyl-CoA |
3HBUT | (R)-3-Hydroxybutanoate;(R)-3-Hydroxybutyricacid |
3HIBCOA | (S)-3-Hydroxyisobutyryl-CoA |
3HIVCOA | 3-Hydroxyisovaleryl-CoA |
3HPA | 3-Hydroxyphenylacetate |
3HPCOA | 3-Hydroxypropionyl-CoA |
3MBCOA | 3-Methylbutanoyl-CoA |
3MCCOA | 3-Methylcrotonyl-CoA |
3MGCOA | 3-Methylglutaconyl-CoA |
3MOP | (S)-3-Methyl-2-oxopentanoic acid; (S)-3-Methyl-2-oxopentanoate; (3S)-3-Methyl-2-oxopentanoic acid; (3S)-3-Methyl-2-oxopentanoate |
3OP4HB | 3-Octaprenyl-4-hydroxybenzoate |
3OPP | 3-Oxopropanoate; Malonate semialdehyde |
3PG | 3-Phospho-D-glycerate |
3PSER | 3-Phosphoserine |
3PSME | 5-O-(1-Carboxyvinyl)-3-phosphoshikimate |
3SFPYR | 3-Sulfinylpyruvate |
3SLALA | 3-Sulfino-L-alanine |
3SPYR | 3-Sulfopyruvate |
4AABUT | 4-Acetamidobutanoate |
4AB | 4-Aminobutanal |
4FAAC | 4-Fumarylacetoacetate |
4GBTA | 4-Guanidinobutanamide |
4GBTR | 4-Guanidinobutanoate; 4-Guanidinobutyric acid |
4HB | 4-Hydroxybenzoate |
4HGLUSA | L-4-Hydroxyglutamate semialdehyde |
4HLT | 4-Hydroxy-L-threonine |
4HMN | 4-Hydroxymandelonitrile |
4HPA | 4-Hydroxyphenylacetate |
4HPACAL | 4-Hydroxyphenylacetaldehyde; 2-(4-Hydroxyphenyl)acetaldehyde |
4HPACALO | (Z)-4-Hydroxyphenylacetaldehyde-oxime |
4HPACOA | 4-Hydroxyphenylacetyl-CoA |
4HPAGLY | 4-Hydroxyphenylacetylglycine |
4HPP | 3-(4-Hydroxyphenyl)pyruvate |
4HPRO | trans-4-Hydroxy-L-proline |
4I5P | 4-Imidazolone-5-propanoate |
4MAAC | 4-Maleylacetoacetate |
4MOP | 4-Methyl-2-oxopentanoate |
4PPNCYS | (R)-4'-Phosphopantothenoyl-L-cysteine |
4PPNTE | Pantetheine 4'-phosphate |
4PPNTO | D-4'-Phosphopantothenate |
4TMABT | 4-Trimethylammoniobutanal |
4TMABTO | 4-Trimethylammoniobutanoate |
5A4ICA | 5-Amino-4-imidazole carboxylate |
5AI | 5-Aminoimidazole; Aminoimidazole; 4-Aminoimidazole |
5C2O3E | 5-Carboxy-2-oxohept-3-enedioate |
5CM2HM | 5-Carboxymethyl-2-hydroxymuconate |
5GLUPEPT | (5-L-Glutamyl)-peptide |
5HIAA | 5-Hydroxyindoleacetaldehyde |
5HIAC | 5-Hydroxyindoleacetate |
5MC | DNA 5-methylcytosine; DNA containing 5-methylcytosine; 5-Methylcytosine (in DNA) |
5MDR | 5-Methylthio-D-ribose |
5MTA | 5'-Methylthioadenosine |
5MTGLU | 5-Methyltetrahydropteroyltri-L-glutamate |
A[C] | Apo-[carboxylase] |
A5P | D-Arabinose 5-phosphate |
A6RP | 5-Amino-6-ribitylamino-2,4 (1H, 3H)-pyrimidinedione; 4-(1-D-Ribitylamino)-5-amino-2,6-dihydroxypyrimidine; 4-(1-D-Ribitylamino)-5-aminouracil |
A6RP5P | 5-Amino-6-(5'-phosphoribosylamino)uracil |
A6RP5P2 | 5-Amino-6-(5'-phosphoribitylamino)uracil |
AAA | Aminoacetaldehyde |
AAC | Acetoacetate |
AACCOA | Acetoacetyl-CoA |
AACTN | Aminoacetone; 1-Amino-2-propanone |
AAD | Acetyl adenylate |
ABUT | (S)-2-Aceto-2-hydroxybutanoate |
AC | Acetate |
ACACP | Acetyl-[acyl-carrier protein] |
ACAL | Acetaldehyde |
ACCOA | Acetyl-CoA |
ACDA | Adenosyl cobyrinate a,c diamide |
ACETYLP | Acetyl phosphate |
ACLAC | 2-Acetolactate |
ACOA | Acyl-CoA |
ACP | Acyl-carrier protein |
ACT | (R)-Acetoin; (R)-2-Acetoin; (R)-3-Hydroxy-2-butanone; (R)-Dimethylketol; (R)-3-Hydroxybutan-2-one |
ACTN | Acetone; Dimethyl ketone; 2-Propanone |
AD | Adenine |
ADCBA | Adenosyl cobinamide |
ADCBAP | Adenosyl cobinamide phosphate |
ADCHOR | 4-amino-4-deoxychorismate |
ADLIPO | 6-S-Acetyldihydrolipoamide; [Dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine; S-Acetyldihydrolipoamide-E |
ADN | Adenosine |
ADP | ADP |
AEIOH | 3-(2-Aminoethyl)-1H-indol-5-ol; Serotonin; 5-Hydroxytryptamine; Enteramine |
AG | L-Arogenate |
AGDPCBA | Adenosine-GDP-cobinamide |
AGL | Acylglycerol |
AGL3P | 1-Acyl-sn-glycerol 3-phosphate |
AHHMD | 2-Amino-7,8-dihydro-4-hydroxy-6-(diphosphooxymethyl)pteridine |
AHHMP | 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine |
AHM | 4-Amino-5-hydroxymethyl-2-methylpyrimidine |
AHMP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-phosphate |
AHMPP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-pyrophosphate |
AHTD | 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine triphosphate; 6-(L-erythro-1,2-Dihydroxypropyl 3-triphosphate)-7,8-dihydropterin; 6-[(1S,2R)-1,2-Dihydroxy-3-triphosphooxypropyl]-7,8-dihydropterin; 7,8-Dihydroneopterin 3'-triphosphate |
AIBUT | L-3-Amino-isobutanoate; (S)-3-Amino-isobutyrate; L-3-Amino-isobutyrate; (S)-3-Amino-isobutanoate; (S)-3-Amino-2-methylpropanoate |
AICAR | 1-(5'-Phosphoribosyl)-5-amino-4-imidazolecarboxamide |
AIR | Aminoimidazole ribotide |
AKG | 2-Oxoglutarate |
ALA | L-Alanine |
ALAALA | D-alanyl-D-alanine |
ALATRNA | L-Alanyl-tRNA |
ALAV | D-Aminolevulinate |
ALLNT | Allantoate; Allantoic acid |
AMP | AMP |
AN | Anthranilate |
AONA | 8-amino-7-oxononanoate |
APN | beta-Aminopropionitrile; 3-Aminopropiononitrile |
AppppA | P1,P4-Bis(5'-adenosyl) tetraphosphate |
APS | Adenylylsulfate; Adenylyl sulfate; Adenosine 5'-phosphosulfate; APS; 5'-Adenylyl sulfate |
ARBZ | alpha-Ribazole; N1-(alpha-D-ribosyl)-5,6-dimethylbenzimidazole |
ARG | L-Arginine |
ARGSUCC | N-(L-Arginino)succinate |
ARGTRNAARG | L-Arginyl-tRNA(Arg) |
ARIB | ADPribose |
ASELNT | Adenylylselenate |
ASER | O-Acetyl-L-serine |
ASN | L-Asparagine |
ASNTRNAASN | L-Asparaginyl-tRNA(Asn) |
ASP | L-Aspartate |
ASPSA | L-Aspartate 4-semialdehyde |
ASPTRNAASN | L-Aspartyl-tRNA(Asn) |
ASPTRNAASP | L-Aspartyl-tRNA(Asp) |
ASUC | N6-(1,2-Dicarboxyethyl)-AMP |
ATP | ATP |
B5AMP | Biotinyl-5'-AMP |
BAL | Betaine aldehyde |
bALA | beta-Alanine |
bAPA | beta-Aminopropion aldehyde |
BASP | 4-Phospho-L-aspartate |
bDG6P | beta-D-Glucose 6-phosphate |
bDGLC | beta-D-Glucose |
BETAINE | Betaine; Glycine betaine |
BT | Biotin |
BUTANAL | Butanal |
BZ | Benzoate; Benzoic acid; Benzenecarboxylic acid; Phenylformic acid; Dracylic acid |
C(I)A | Cob(I)alamin; Cbl; Vitamin B12s |
C(I)DA | Cob(I)yrinate a,c diamide |
C090ACP | Nonanoyl-[acyl-carrier protein] |
C100 | Decanoic acid |
C100ACP | Decanoyl-[acyl-carrier protein] |
C110ACP | Undecanoyl-[acyl-carrier protein] |
C120 | Dodecanoic acid |
C120ACP | Dodecanoyl-[acyl-carrier protein] |
C120OH | beta-hydroxy dodecanoic acid |
C121COA | cis,cis-3,6-Dodecadienoyl-CoA |
C122COA | trans,cis-Lauro-2,6-dienoyl-CoA |
C130ACP | Tridecanoyl-[acyl-carrier protein] |
C140 | Tetradecanoic acid |
C140ACP | Tetradecanoyl-[acyl-carrier protein] |
C140OH | beta-hydroxy tetradecanoic acid |
C150 | Pentadecanoic acid |
C150ACP | Pentadecanoyl-[acyl-carrier protein] |
C151ACP | Pentadecenoyl-[acyl-carrier protein] |
C160 | Hexadecanoic acid |
C160ACP | Hexadecanoyl-[acyl-carrier protein] |
C161 | Hexadecenoic acid |
C161ACP | Hexadecenoyl-[acyl-carrier protein] |
C170 | Heptadecanoic acid |
C170ACP | Heptadecanoyl-[acyl-carrier protein] |
C171 | Heptadecenoic acid |
C171ACP | Heptadecenoyl-[acyl-carrier protein] |
C180 | Octadecanoic acid |
C180ACP | Octadecanoyl-[acyl-carrier protein] |
C181 | Octadecenoic acid |
C181ACP | Octadecenoyl-[acyl-carrier protein] |
C190ACP | Nonadecanoyl-[acyl-carrier protein] |
C191ACP | Nonadecenoyl-[acyl-carrier protein] |
C200ACP | Eicosanoyl-[acyl-carrier protein] |
CAASP | N-Carbamoyl-L-aspartate |
CAIR | 1-(5-Phospho-D-ribosyl)-5-amino-4-imidazolecarboxylate |
CALA | 3-Cyano-L-alanine; L-3-Cyanoalanine; L-beta-Cyanoalanine |
CAP | Carbamoyl phosphate |
CATECHOL | Catechol; 1,2-Benzenediol; o-Benzenediol; 1,2-Dihydroxybenzene; Brenzcatechin; Pyrocatechol |
CAV | Cofactors and vitamins |
CBA | Cobinamide |
CBCO | Cobamide coenzyme |
CBHCAP | 3-Isopropylmalate |
CCOA | Crotonoyl-CoA |
CDHDHI | 2-Carboxy-2,3-dihydro-5,6-dihydroxyindole |
CDP | CDP |
CDPDG | CDP-diacylglycerol |
CDPMDE | 4-(Cytidine5'-diphospho)-2-C-methyl-D-erythritol |
CH3OR | Primary alcohol |
CHCOA | 6-carboxyhexanoyl-CoA; Pimeloyl-CoA |
CHITB | Chitobiose |
CHOLINE | Choline |
CHOLINEP | Choline phosphate; Phosphorylcholine; Phosphocholine; O-Phosphocholine |
CHOR | Chorismate |
CIT | Citrate |
CITR | L-Citrulline |
CL | Cardiolipin (biomass component) |
CMP | CMP |
CMPAEP | CMP-2-aminoethylphosphonate; CMPciliatine |
CMPKDO | CMP-2-keto-3-deoxyoctanoate |
CNS | Carnosine |
CO2 | CO2 |
COA | CoA; coenzyme A |
CPAD5P | 1-(2-Carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate |
CPP | Coproporphyrinogen III |
CPPI | Coproporphyrinogen I |
CRTN | Creatine; alpha-Methylguanidino acetic acid; Methylglycocyamine |
CT | DNA cytosine; Cytosine (in DNA) |
CTP | CTP |
CVN | Cinnavalininate |
CYS | L-Cysteine |
CYSGLY | Cys-Gly; L-Cysteinylglycine |
CYST | L-Cystine |
CYSTEATE | L-Cysteate |
CYSTRNACYS | L-Cysteinyl-tRNA(Cys) |
CYTD | Cytidine |
D6PGC | 6-Phospho-D-gluconate |
D6RP5P | 2,5-Diamino-6-hydroxy-4-(5'-phosphoribosylamino)-pyrimidine |
D8RL | 6,7-Dimethyl-8-(1-D-ribityl)lumazine |
DA | Deoxyadenosine |
DAC | Diacetyl; Biacetyl; Dimethylglyoxal; 2,3-Butanedione |
DADP | dADP |
DALA | D-alanine |
DAMP | dAMP |
DANNA | 7,8-Diaminononanoate |
DAPIM | L,L-2,6-Diaminopimelate |
DASP | D-Aspartate |
DATP | dATP |
DB4P | L-3,4-Dihydroxy-2-butanone 4-phosphate |
DC | Deoxycytidine |
DCDP | dCDP |
DCMP | dCMP |
DCTP | dCTP |
DCYS | D-Cysteine; D-Amino-3-mercaptopropionic acid |
DG | Deoxyguanosine |
DGDP | dGDP |
DGLN | D-Glutamine |
DGLU | D-Glutamate |
DGLUCA | D-Glucarate |
DGLUCL | D-Glucuronolactone |
DGLYCERATE | D-glycerate |
DGMP | dGMP |
DGR | 1,2-Diacyl-sn-glycerol; 1,2-Diacylglycerol |
DGTP | dGTP |
DHAP | Glycerone phosphate |
DHDP | 2,3-Dihydrodipicolinate |
DHF | Dihydrofolate |
DHI | 5,6-Dihydroxyindole |
DHLIPOYLPROTEIN | Dihydrolipoylprotein |
DHMP | (R)-2,3-dihydroxy-3-methylpentanoate |
DHMVA | (R)-2,3-dihydroxy-3-methylbutanoate |
DHN | 1,4-dihydroxy-2-naphthoate |
DHP | 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine |
DHPA | 2,6-Dihydroxyphenylacetate |
DHPACAL | 3,4-Dihydroxyphenylacetaldehyde; Protocatechuatealdehyde |
DHPANT | 2-Dehydropantoate |
DHPT | Dihydropteroate |
DHSK | 3-Dehydroshikimate |
DIDP | dIDP |
DIMGP | D-erythro-1-(Imidazol-4-yl)glycerol 3-phosphate |
DIMP | 2'-Deoxyinosine 5'-phosphate; dIMP |
DIN | Deoxyinosine |
DISAC1P | 2,3-bis(3-hydroxytetradecanoyl)-D-glucosaminyl-1,6-beta-D-2,3-bis(3-hydroxytetradecanoyl)-beta-D-glucosaminyl 1-phosphate or dissacharide 1-P |
DITP | dITP |
DLIPO | Enzyme N6-(dihydrolipoyl)lysine; Dihydrolipoamide-E |
DMB | Dimethylbenzimidazole |
DMK | 2-Demethylmenaquinone |
DMKH2 | 2-Demethylmenaquinol |
DMPP | Dimethylallyl diphosphate |
DNA | DNA (biomass component) |
DOROA | (S)-Dihydroorotate |
DPCHR | L-Dopachrome; 2-L-Carboxy-2,3-dihydroindole-5,6-quinone |
DPCOA | Dephospho-CoA |
DPHE | D-Phenylalanine |
DPM | Dopamine; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 3,4-Dihydroxyphenethylamine; 2-(3,4-Dihydroxyphenyl)ethylamine |
DPRO | D-Proline |
DQT | 3-Dehydroquinate |
DR1P | 2-Deoxy-D-ribose 1-phosphate |
DR5P | 2-Deoxy-D-ribose 5-phosphate |
DSER | D-Serine |
DT | Thymidine |
DTB | Dethiobiotin |
DTDP | dTDP |
DTDP4O6DG | 4,6-Dideoxy-4-oxo-dTDP-D-glucose; dTDP-4-oxo-6-deoxy-D-glucose; dTDP-4-dehydro-6-deoxy-D-glucose; dTDP-4-dehydro-6-deoxy-alpha-D-glucose; dTDP-4-oxo-6-deoxy-alpha-D-glucose; dTDP-4-dehydro-6-deoxy-alpha-D-galactose; dTDP-4-dehydro-6-deoxy-D-galactose |
DTDP4ORMNS | dTDP-4-dehydro-6-deoxy-L-mannose; dTDP-4-oxo-6-deoxy-L-mannose; dTDP-4-oxo-L-rhamnose |
DTDPGLAC | dTDPgalactose |
DTDPGLU | dTDP-glucose; dTDP-D-glucose; dTDP-alpha-D-glucose |
DTDPRMNS | dTDP-6-deoxy-L-mannose; dTDP-L-rhamnose |
DTMP | dTMP |
DTTP | dTTP |
DU | Deoxyuridine |
DUDP | dUDP |
DUMP | dUMP |
DUTP | dUTP |
DX5P | 1-Deoxy-D-xylulose 5-phosphate |
E4HGLU | L-erythro-4-Hydroxyglutamate |
E4P | D-Erythrose 4-phosphate |
ER4P | 4-Phospho-D-erythronate; 4-Phosphoerythronate |
ETH | Ethanol |
ETHA | Ethanolamine |
ETHAP | Ethanolamine phosphate; O-Phosphorylethanolamine; Phosphoethanolamine; O-Phosphoethanolamine |
EXOPOLYS | Exopolysaccharide |
F1P | D-Fructose 1-phosphate |
F6P | beta-D-Fructose 6-phosphate |
FA | Formamide |
FAD | Flavin adenine dinucleotide; FAD |
FADH2 | FADH2 |
FAN | Formylanthranilate; N-Formylanthranilate; 2-(Formylamino)-benzoic acid |
FDP | beta-D-Fructose 1,6-bisphosphate |
FERIC | Ferricytochrome c |
FEROC | Ferrocytochrome c |
FGAM | 2-(Formamido)-N1-(5'-phosphoribosyl)acetamidine |
FGAR | 5'-Phosphoribosyl-N-formylglycinamide |
FKYN | L-Formylkynurenine; N-Formyl-L-kynurenine; N-Formylkynurenine |
FL | Folate |
FMETTRNA | N-Formylmethionyl-tRNA |
FMN | FMN; Riboflavin-5-phosphate; Flavin mononucleotide |
FORMATE | Formate |
FPP | trans,trans-Farnesyl diphosphate |
FTHF | 10-Formyltetrahydrofolate |
FUCP | L-Fuculose 1-phosphate |
FUM | Fumarate |
G1P | D-Glucose 1-phosphate |
G3P | D-Glyceraldehyde3-phosphate; (2R)-2-Hydroxy-3-(phosphonooxy)-propanal |
G3PC | sn-glycero-3-Phosphocholine |
G3PE | sn-glycero-3-Phosphoethanolamine |
G6P | alpha-D-Glucose 6-phosphate |
GA1P | D-Glucosamine 1-phosphate |
GA6P | D-Glucosamine 6-phosphate |
GABA | 4-Aminobutanoate |
GAPN | gamma-Glutamyl-beta-aminopropiononitrile; gamma-Glutamyl-3-aminopropiononitrile |
GAR | 5'-Phosphoribosylglycinamide |
GCYS | gamma-L-Glutamyl-L-cysteine |
GDP | GDP |
GDPMAN | GDP-mannose |
GENAL | Gentisate aldehyde |
GGLUMSCYS | gamma-Glutamyl-Se-methylselenocysteine |
GGPP | Geranylgeranyl diphosphate |
GL | Glycerol |
GL3P | sn-Glycerol 3-phosphate |
GLAL | Glycolaldehyde |
GLC | alpha-D-Glucose |
GLCA | D-Glucosamine; Chitosamine; 2-Amino-2-deoxy-D-glucose |
GLCAMN | D-Glucosaminide |
GLN | L-Glutamine |
GLU | L-Glutamate |
GLUBCALA | gamma-Glutamyl-beta-cyanoalanine |
GLUC | D-Gluconate |
GLUGSAL | L-Glutamate 5-semialdehyde |
GLUP | alpha-D-Glutamyl phosphate |
GLUTCOA | Glutaryl-CoA |
GLUTR | 5-L-Glutamyl-taurine |
GLUTRNAGLN | L-Glutamyl-tRNA(Gln) |
GLUTRNAGLU | L-Glutamyl-tRNA(Glu) |
GLX | Glyoxylate |
GLY | Glycine |
GLYCOLATE | Glycolate |
GLYTRNAGLY | Glycyl-tRNA(Gly) |
GMP | GMP |
GN | Guanine |
GPP | Geranyl diphosphate |
GSA | Glutamate-1-semialdehyde |
GSN | Guanosine |
GTP | GTP |
GTRNA | Glutaminyl-tRNA |
H[C] | Holo-[carboxylase] |
H2O2 | H2O2 |
H2S | Hydrogen sulfide |
H2SO3 | Sulfite |
H5P | Hydantoin-5-propionate; Hydantoin-propionate |
HAC | Hydroxyacetone |
HCNS | Homocarnosine |
HCO3 | HCO3 |
HCYS | L-Homocysteine |
HDN | Hordenine; 4-[2-(Dimethylamino)ethyl]phenol |
HEDC | 2-Hydroxyethylenedicarboxylate; enol-Oxaloacetate; enol-Oxaloacetic acid; 2-Hydroxybut-2-enedioic acid |
HEMEO | Heme O |
HEPPP | all-trans-Heptaprenyl diphosphate |
HIBUT | (S)-3-Hydroxyisobutyrate |
HIEA | 1H-Imidazole-4-ethanamine; Histamine; 2-(4-Imidazolyl)ethylamine |
HIPPRT | Hippurate; Hippuric acid; N-Benzoylglycine; Benzoylaminoacetic acid |
HIS | L-Histidine |
HISOL | L-Histidinol |
HISOLP | L-Histidinol phosphate |
HISTRNAHIS | L-Histidyl-tRNA(His) |
HKYN | 3-Hydroxy-L-kynurenine |
HMB | Hydroxymethylbilane |
HMB4PP | 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate |
HO3S2 | Thiosulfate |
HOMOGEN | Homogentisate |
HOPP | 2-Hydroxy-3-oxopropanoate; Tartronate semialdehyde |
HPYR | Hydroxypyruvate; Hydroxypyruvic acid; 3-Hydroxypyruvate; 3-Hydroxypyruvic acid |
HSER | L-Homoserine |
Hxt | External proton |
HYDROXYAKG | D-4-Hydroxy-2-oxoglutarate |
HYXN | Hypoxanthine |
I3AA | Indole-3-acetaldehyde |
I3AAM | Indole-3-acetamide |
I3AC | Indole-3-acetate |
I4AA | Imidazole-4-acetaldehyde |
I4AC | Imidazole-4-acetate |
IASP | Iminoaspartate |
ICHOR | Isochorismate |
ICIT | Isocitrate |
IDP | IDP |
IGLY | Iminoglycine; Iminoacetic acid |
IGP | Indoleglycerol phosphate |
ILE | L-Isoleucine |
ILETRNAILE | L-Isoleucyl-tRNA(Ile) |
IMACP | 3-(Imidazol-4-yl)-2-oxopropyl phosphate |
IMAL | Isomaltose |
IMP | IMP |
INDOLE | Indole |
INS | Inosine |
IPP | Isopentenyl diphosphate |
IPPMAL | 2-Isopropylmalate; (2S)-2-Isopropylmalate; 3-Carboxy-3-hydroxy-4-methylpentanoate; 3-Carboxy-3-hydroxy-isocaproate; 3-Carboxy-3-hydroxyisocaproate; 2-Hydroxy-2-isopropylbutanedioate; 3-Hydroxy-4-methyl-3-carboxypentanoate |
IPYR | Indolepyruvate; Indolepyruvic acid; (Indol-3-yl)pyruvate; Indole-3-pyruvate; 3-(Indol-3-yl)pyruvate |
ITP | ITP |
K2LIPA | KDO2-lipid (A); Di[3-deoxy-D-manno-octulosonyl]-lipid A |
K2LIPIV | KDO2-lipid IV(A); Di[3-deoxy-D-manno-octulosonyl]-lipid IV(A); |
KDO | 2-Dehydro-3-deoxy-D-octonate |
KDOLIPIV | KDO-lipid IV(A) |
KDOP | 2-Dehydro-3-deoxy-D-octonate 8-phosphate |
KDPG | 2-Dehydro-3-deoxy-6-phospho-D-gluconate |
KYN | L-Kynurenine; 3-Anthraniloyl-L-alanine |
L1P3H5C | L-1-Pyrroline-3-hydroxy-5-carboxylate |
LAC | (R)-Lactate, D-Lactate |
LACAL | (S)-Lactaldehyde; L-Lactaldehyde; L-2-Hydroxypropionaldehyde |
LEU | L-Leucine |
LEUTRNA | L-Leucyl-tRNA |
LIPID | Lipids other than phospholipid |
LIPIV | Lipid IV(A) |
LIPO | Enzyme N6-(lipoyl)lysine; Lipoamide-E |
LIPOYLPROTEIN | Lipoylprotein |
LIPX | Lipid X |
LK2LIPIV | Lauroyl-KDO2-lipid IV(A) |
LLCT | L-Cystathionine |
LPS | Lippolysaccharide |
LTG | (R)-S-Lactoylglutathione |
LYS | L-Lysine |
LYSTRNA | L-Lysyl-tRNA |
MAL | (S)-Malate |
MALACP | Malonyl-[acyl-carrier protein] |
MALCOA | Malonyl-CoA |
MAN1P | alpha-D-Mannose 1-phosphate |
MAN6P | D-Mannose 6-phosphate |
MCB | Methylcobalamin |
MDAPIM | meso-2,6-Diaminoheptanedioate; meso-2,6-Diaminopimelate; meso-2,6-Diaminopimelic acid; meso-Diaminoheptanedioate |
MDE4P | 2-C-Methyl-D-erythritol 4-phosphate |
MDECPP | 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate |
MET | L-Methionine |
METHF | 5,10-Methenyltetrahydrofolate |
METTHF | 5,10-Methylenetetrahydrofolate |
METTRNA | L-Methionyl-tRNA |
MK | menaquinone |
MKH2 | menaquinol |
MLT | Maltose |
MM | Methylmalonate |
MMALCOA | (S)-Methylmalonyl-CoA; (S)-Methylmalonyl-coenzyme A; (2S)-Methylmalonyl-CoA; D-Methylmalonyl-CoA |
MMSA | (S)-Methylmalonate semialdehyde |
MNT | D-Mannitol |
MOT | 5-Methoxytryptamine; 5-MeOT |
MPET | 4-Methyl-5-(2-phosphoethyl)-thiazole; 4-Methyl-5-(2-phosphono-oxyethyl)-thiazole |
MPYR | Mercaptopyruvate |
MSCYS | Se-Methylselenocysteine |
MTG | Methylglyoxal |
MTHF | 5-Methyltetrahydrofolate |
MTRM | N-Methyltyramine |
MTTA | meso-Tartaric acid; meso-Tartrate |
N(P)CYS | N-((R)-Pantothenoyl)-L-cysteine |
N1(5PADR)DMB | N1-(5-Phospho-alpha-D-ribosyl)-5,6-dimethylbenzimidazole |
N2SUCCARG | N2-Succinyl-L-arginine |
N2SUCCGLU | N-Succinyl-L-glutamate; (2S)-2-(3-Carboxypropanoylamino)pentanedioic acid |
N2SUCCGLU5SA | N-Succinyl-L-glutamate 5-semialdehyde; (2S)-2-(3-Carboxypropanoylamino)-5-oxopentanoic acid |
N4AAB | N4-Acetylaminobutanal |
Na | Sodium |
NAAD | Deamino-NAD+; Deamido-NAD+; Deamido-NAD |
NAC | Nicotinate |
NACD | Nicotinate D-ribonucleoside |
NACN | Nicotinate D-ribonucleotide |
NAD | NAD+; Nicotinamide adenine dinucleotide |
NADH | NADH |
NADMA | N-Acetyl-D-mannosamine |
NADP | NADP+; Nicotinamide adenine dinucleotide phosphate |
NADPH | NADPH |
NAGA | N-Acetyl-D-glucosamine |
NAGA1P | N-Acetyl-D-glucosamine 1-phosphate |
NAGLU | N-Acetyl-L-glutamate |
NAGLUP | N-Acetyl-L-glutamate 5-phosphate |
NAGLUS | N-Acetyl-L-glutamate 5-semialdehyde |
NAM | Nicotinamide |
NAMD | N-Ribosylnicotinamide |
NAMN | Nicotinamide D-ribonucleotide |
NAORN | N2-Acetyl-L-ornithine |
NAS | N-Acylsphingosine; Ceramide |
NASAEP | Ceramide 2-aminoethylphosphonate; Ceramide ciliatine |
NFGLU | N-Formimino-L-glutamate |
NH3 | NH3 |
NHLYS | N6-Hydroxy-L-lysine |
NMHIS | N(pi)-Methyl-L-Histidine |
NO2 | Nitrite |
NO3 | Nitrate |
NPRAN | N-(5-Phospho-D-ribosyl)anthranilate |
O2 | Oxygen |
OA | Oxaloacetate |
OAHSER | O-Acetyl-L-homoserine |
OBUT | 2-Oxobutanoate |
OGT | Oxidized glutathione; Glutathione disulfide; Oxiglutatione |
OHB | 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate |
OICAP | 3-Carboxy-4-methyl-2-oxopentanoate |
OIVAL | 3-Methyl-2-oxobutanoic acid |
OMP | Orotidine 5'-phosphate |
OPP | all-trans-Octaprenyl diphosphate |
ORBRDX | Oxidized rubredoxin |
ORN | L-Ornithine |
OROA | Orotate |
OSB | O-succinylbenzoate |
OSBCOA | O-succinylbenzoate-CoA |
OSLHSER | O-Succinyl-L-homoserine |
OTHIO | Thioredoxin disulfide; Oxidized thioredoxin; Thioredoxin sulfide |
P5C | (S)-1-Pyrroline-5-carboxylate |
P5P | Pyridoxine 5'-phosphate; Pyridoxine phosphate |
PA | Phosphatidate; 1,2-Diacyl-sn-glycerol 3-phosphate |
PAA | 2-Phenylacetamide |
PABA | 4-Aminobenzoate |
PACAL | Phenylacetaldehyde; alpha-Tolualdehyde |
PACGLY | Phenylacetylglycine |
PACOA | Phenylacetyl-CoA |
PANT | (R)-pantoate |
PAP | Adenosine 3',5'-bisphosphate |
PAPS | 3'-Phosphoadenylyl sulfate |
PBG | Porphobilinogen |
PC | Phosphatidylcholine |
PC2 | Percorrin 2 |
PDLA | Pyridoxamine |
PDLA5P | Pyridoxamine-5-phosphate |
PE | Phosphatidylethanolamine |
PEA | Phenethylamine; 2-Phenylethylamine; beta-Phenylethylamine; Phenylethylamine |
PEP | Phosphoenolpyruvate |
PEPTIDE | Peptide |
PEPTIDO | Peptidoglycan (biomass component) |
PG | Phosphatidylglycerol |
PGP | Phosphatidylglycerophosphate |
PHE | L-Phenylalanine |
PHEN | Prephenate |
PHETRNAPHE | L-Phenylalanyl-tRNA(Phe) |
PHOSPHOLIPID | Phospholipids (biomass component) |
PHP | 3-Phosphonooxypyruvate |
PHPYR | Phenylpyruvate |
PHSER | O-Phospho-L-homoserine |
PHT | O-Phospho-4-hydroxy-L-threonine |
PI | Orthophosphate |
PL | Pyridoxal |
PL5P | Pyridoxal 5'-phosphate |
PLA | Phenylacetic acid; Benzylformic acid; Phenylacetate; Benzeneacetiic acid |
PNTO | (R)-Pantothenate; Pantothenate |
PPA | Propinol adenylate |
PPAACP | Propanoyl-[acyl-carrier protein]; Propionyl-[acyl-carrier protein] |
PPAC | Phosphonoacetaldehyde |
PPACOA | Propanoyl-CoA; Propionyl-CoA |
PPCOA | Propenoyl-CoA; Acryloyl-CoA |
PPEPTIDO | Peptidoglycan precursor |
ppGpp | Guanosine 3',5'-bis(diphosphate) |
PPHG | Protoporphyrinogen IX |
PPI | Pyrophosphate; Diphosphate |
PPIX | Protoporphyrin IX |
PPN | Propynoate |
pppGpp | Guanosine 3'-diphosphate 5'-triphosphate |
PPPI | Triphosphate |
PPPP | all-trans-Pentaprenyl diphosphate |
PQ | Phylloquinone |
PQQ | Pyrrolo-quinolinequinone;Pyrroloquinoline-quinone;Pyrroloquinolinequinone;4,5-Dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylate |
PQQH2 | Reduced pyrroloquinoline-quinone |
PRAM | 5-Phosphoribosylamine |
PRBAMP | N1-(5-Phospho-D-ribosyl)-AMP |
PRBATP | N1-(5-Phospho-D-ribosyl)-ATP |
PRFICA | 1-(5'-Phosphoribosyl)-5-formamido-4-imidazolecarboxamide |
PRFP | 5-(5-Phospho-D-ribosylaminoformimino)-1-(5-phosphoribosyl)-imidazole-4-carboxamide |
PRLP | N-(5'-Phospho-D-1'-ribulosylformimino)-5-amino-1-(5"-phospho-D-ribosyl)-4-imidazolecarboxamide |
PRO | L-Proline |
PROPANOATE | Propanoate |
PROPIONYLP | Propanoyl phosphate |
PROTEIN | Proteins |
PROTRNAPRO | L-Prolyl-tRNA(Pro) |
PRPP | 5-Phospho-alpha-D-ribose 1-diphosphate |
PS | Phosphatidylserine |
PTH | Heme; Haem; Protoheme; Heme B; Protoheme IX |
PTRC | Putrescine |
PTT | Pantetheine |
PURI5P | Pseudouridine 5'-phosphate |
PYR | Pyruvate |
PYRDX | Pyridoxine |
PYTHP | 6-Pyruvoyltetrahydropterin |
QA | Quinolinate; Pyridine-2,3-dicarboxylate |
QNT | Quinate; Quinic acid; Kinic acid; Chinic acid; L-Quinic acid; L-Quinate; (-)-Quinic acid |
R1P | D-Ribose 1-phosphate; alpha-D-Ribose 1-phosphate; Ribose 1-phosphate |
R3HBCOA | (R)-3-Hydroxybutanoyl-CoA |
R5P | D-Ribose 5-phosphate |
RCHO | Aldehyde |
RGT | Glutathione |
RH | Alkane |
RIBFLAV | Riboflavin |
RL5P | D-Ribulose 5-phosphate |
RMAL | (R)-Malate; D-Malate; D-Malic acid |
RNA | RNA |
RRBRDX | Reduced rubredoxin |
RTHIO | Thioredoxin |
S | Sulfur |
S6P | Sorbitol 6-phosphate |
S7P | Sedoheptulose 7-phosphate |
SAH | S-Adenosyl-L-homocysteine |
SAICAR | 1-(5'-Phosphoribosyl)-5-amino-4-(N-succinocarboxamide)-imidazole |
SAM | S-Adenosyl-L-methionine |
SAMOB | S-adenosyl-4-methylthio-2-oxobutanoate |
SAOPIM | N-Succinyl-2-amino-6-oxopimelate |
SASHCYS | Se-Adenosylselenohomocysteine |
SB1P | Sorbose 1-phosphate |
SCSN | Sarcosine; N-Methylglycine |
SCYS | Selenocysteine |
SDAPIM | N-Succinyl-L-2,6-diaminopimelate |
SDLIPO | S-Succinyldihydrolipoamide |
SeASMET | Se-Adenosylselenomethionine |
SELD | Selenide |
SELNT | Selenate |
SELT | Selenite |
SER | L-Serine |
SERTRNASER | L-Seryl-tRNA(Ser) |
SGDHL | S-Glutaryldihydrolipoamide |
SHCHC | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate |
SHCL | Sirohydrochlorin |
SHCYS | Selenohomocysteine |
SHEME | Siroheme |
SLAC | (S)-Lactate |
SLF | Sulfate |
SLLCT | Selenocystathionine |
SME | Shikimate |
SME3P | Shikimate 3-phosphate |
SMET | Selenomethionine |
SMETTRNAMET | Selenomethionyl-tRNA(Met) |
SORN | N2-Succinyl-L-ornithine; (2S)-5-Amino-2-(3-carboxypropanoylamino)pentanoic acid |
SPRMD | Spermidine |
SRLH | S-Ribosyl-L-homocysteine |
SSLCYS | S-Sulfo-L-cysteine |
SUC | Sucrose |
SUCC | Succinate |
SUCCOA | Succinyl-CoA |
SUCCSA | Succinate semialdehyde |
T3 | D-Glyceraldehyde |
TCYS | Thiocysteine |
TDHDP | 2,3,4,5-Tetrahydrodipicolinate |
TGL | Triacylglycerol |
TGLU | Tetrahydropteroyltri-L-glutamate |
THF | Tetrahydrofolate |
THFG | Tetrahydrofolyl-[Glu](n) |
THIAMIN | Thiamin |
THMP | Thiamin monophosphate |
THMPP | Thiamin diphosphate |
THR | L-Threonine |
THRTRNATHR | L-Threonyl-tRNA(Thr) |
THZ | 5-(2-Hydroxyethyl)-4-methylthiazole; 4-Methyl-5-(2'-hydroxyethyl)-thiazole; 4-Methyl-5-(2-hydroxyethyl)-thiazole |
THZP | 4-Methyl-5-(beta-hydroxyethyl)thiazole phosphate |
TM | Thymine |
TR | Taurine |
TRE | alpha,alpha-Trehalose |
TRE6P | alpha,alpha'-Trehalose 6-phosphate |
TRM | Tyramine; 2-(p-Hydroxyphenyl)ethylamine |
TRNAALA | tRNA(Ala) |
TRNAARG | tRNA(Arg) |
TRNAASP | tRNA(Asp) |
TRNACYS | tRNA(Cys) |
TRNAGLN | tRNA(Gln) |
TRNAGLU | tRNA(Glu) |
TRNAGLY | tRNA(Gly) |
TRNAHIS | tRNA(His) |
TRNAILE | tRNA(Ile) |
TRNALEU | tRNA(Leu) |
TRNALYS | tRNA(Lys) |
TRNAMET | tRNA(Met) |
TRNAPHE | tRNA(Phe) |
TRNAPRO | tRNA(Pro) |
TRNASER | tRNA(Ser) |
TRNATHR | tRNA(Thr) |
TRNATRP | tRNA(Trp) |
TRNATYR | tRNA(Tyr) |
TRNAVAL | tRNA(Val) |
TRP | L-Tryptophan |
TRPTRNATRP | L-Tryptophanyl-tRNA(Trp) |
TRYTRNATYR | L-Tyrosyl-tRNA(Tyr) |
TTA | (R,R)-Tartaric acid; (R,R)-Tartrate; L-Tartaric acid; Tartaric acid; Tartrate; 2,3-Dihydroxybutanedioic acid; (2R,3R)-Tartaric acid; (+)-Tartaric acid |
TYR | L-Tyrosine |
U1C | Urea-1-carboxylate; Allophanate; Allophanic acid |
UC | Urocanate |
UDCP | Undecaprenyl phosphate |
UDCPP | Undecaprenyl diphosphate |
UDGLYCOLATE | (-)-Ureidoglycolate; (S)-Ureidoglycolate |
UDP | UDP |
UDPAGLACA | UDP-N-acetyl-D-galactosamine |
UDPG | UDP-glucose |
UDPG23A | UDP-2,3-bis(3-hydroxytetradecanoyl)glucosamine |
UDPG2A | UDP-3-O-(3-hydroxytetradecanoyl)glucosamine |
UDPG2AA | UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine |
UDPGAL | UDP-D-galactose |
UDPGLUC | UDP-glucuronate |
UDPMNLADGMD | UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate |
UDPMNLADGMDDADA | UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine |
UDPNADMA | UDP-N-acetyl-D-mannosamine |
UDPNADMAU | UDP-N-acetyl-D-mannosaminouronate |
UDPNAG | UDP-N-acetyl-D-glucosamine |
UDPNAGEP | UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine |
UDPNAM | UDP-N-acetylmuramate |
UDPNAMA | UDP-N-acetylmuramoyl-L-alanine |
UDPNAMAG | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate |
UMP | UMP |
UPPMN(GN)LADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMN(GN)LADGNMD(G)5DADA | Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-(glycyl)5-D-alanyl-D-alanine |
UPPMN(GN)LADGNMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMNLADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPRG | Uroporphyrinogen III |
UPRGI | Uroporphyrinogen I |
UQ | Ubiquinone |
UQH2 | Ubiquinol |
URA | Uracil |
UREA | Urea |
URI | Uridine |
URT | Urate; Uric acid |
UTP | UTP |
VAL | L-Valine |
VALTRNAVAL | L-Valyl-tRNA(Val) |
VB12 | Vitamin B12 |
X5P | D-Xylulose 5-phosphate |
XAN | Xanthine |
XMP | Xanthosine 5'-phosphate |
XTP | XTP |
XTSINE | Xanthosine |
BIOMASS | Cell biomass |
FRUxt | External D-fructose |
Metabolite abbreviations | Metabolite names |
(2AE) P | (2-Aminoethyl) phosphonate |
13DAP | 1,3-Diaminopropane; Trimethylenediamine; 1,3-Propanediamine; Propane-1,3-diamine |
13PDG | 3-Phospho-D-glyceroyl phosphate |
1BOH | 1-Butanol |
2 (HE) TPP | 2- (alpha-Hydroxyethyl) thiamine diphosphate |
23BOH | (R, R) -Butane-2,3-diol; (R, R) -2,3-Butanediol; (R, R) -2,3-Butylene glycol |
24DAB | L-2,4-Diaminobutanoate |
2AA | 2-Aminoacrylate |
2AG3PC | 2-Acyl-sn-glycero-3-phosphocholine |
2AG3PE | 2-Acyl-sn-glycero-3-phosphoethanolamine; L-1-Lysophosphatidylethanolamine |
2AG3PS | 2-Acyl-sn-glycero-3-phosphoserine |
2AGL3P | 2-Acyl-sn-glycerol 3-phosphate |
2H3OSUCC | 2-Hydroxy-3-oxosuccinate; Oxaloglycolate |
2HP3M5H6M14B | 2-Hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone |
2HP3M6M14B | 2-Hexaprenyl-3-methyl-6-methoxy-1,4-benzoquinone |
2HPA | 2-Hydroxyphenylacetate |
2HPP | 2-Hydroxypropylphosphonate |
2MAACCOA | 2-Methylacetoacetyl-CoA |
2MB2ECOA | 2-Methylbut-2-enoyl-CoA |
2MBCOA | (S) -2-Methylbutanoyl-CoA |
2MCIT | 2-Methylcitrate |
2MP2ECOA | 2-Methylprop-2-enoyl-CoA |
2MPPACOA | 2-Methylpropanoyl-CoA |
2NPRPN | 2-Nitropropane |
2OAD | 2-Oxoadipate |
2OP3M5H6M14BQ | 2-Octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone |
2OP3M6M14BQ | 2-Octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone |
2OP6HP | 2-Octaprenyl-6-hydroxyphenol |
2OP6M14BQ | 2-Octaprenyl-6-methoxy-1,4-benzoquinone |
2OP6MP | 2-Octaprenyl-6-methoxyphenol |
2OPP | 2-Octaprenylphenol |
2P14NQ | 2-Phytyl-1,4-naphthoquinone |
2P1A | 2-Propyn-1-al |
2PCDPMDE | 2-Phospho-4- (cytidine 5'-diphospho) -2-C-methyl-D-erythritol |
2PG | 2-Phospho-D-glycerate |
2PPG | 2-Phosphoglycolate |
34DHB | 3,4-Dihydroxybenzoate; 3,4-Dihydroxybenzoic acid ;; Protocatechuate; Protocatechuic acid |
34DHMA | 3,4-Dihydroxymandelaldehyde |
34DHPA | 3,4-Dihydroxyphenylacetate |
34DHPEG | 3,4-Dihydroxyphenylethyleneglycol |
3A2OP | 3-Amino-2-oxopropyl phosphate |
3AP | 3-Aminopropanal; beta-Aminopropion aldehyde |
3B1A | 3-Butyn-1-al |
3BUT | 3-Butynoate |
3DDAH7P | 2-Dehydro-3-deoxy-D-arabino-heptonate7-phosphate |
3H2MBCOA | (2S, 3S) -3-Hydroxy-2-methylbutanoyl-CoA |
3H3MGCOA | (S) -3-Hydroxy-3-methylglutaryl-CoA |
3HAN | 3-Hydroxyanthranilate |
3HB123TC | (2S, 3R) -3-Hydroxybutane-1,2,3-tricarboxylate |
3HBCOA | (S) -3-Hydroxybutanoyl-CoA |
3HBUT | (R) -3-Hydroxybutanoate; (R) -3-Hydroxybutyricacid |
3HIBCOA | (S) -3-Hydroxyisobutyryl-CoA |
3HIVCOA | 3-Hydroxyisovaleryl-CoA |
3HPA | 3-Hydroxyphenylacetate |
3HPCOA | 3-Hydroxypropionyl-CoA |
3MBCOA | 3-Methylbutanoyl-CoA |
3MCCOA | 3-Methylcrotonyl-CoA |
3MGCOA | 3-Methylglutaconyl-CoA |
3MOP | (S) -3-Methyl-2-oxopentanoic acid; (S) -3-Methyl-2-oxopentanoate; (3S) -3-Methyl-2-oxopentanoic acid; (3S) -3-Methyl-2-oxopentanoate |
3OP4HB | 3-Octaprenyl-4-hydroxybenzoate |
3OPP | 3-Oxopropanoate; Malonate semialdehyde |
3PG | 3-Phospho-D-glycerate |
3PSER | 3-Phosphoserine |
3PSME | 5-O- (1-Carboxyvinyl) -3-phosphoshikimate |
3SFPYR | 3-Sulfinylpyruvate |
3SLALA | 3-Sulfino-L-alanine |
3SPYR | 3-Sulfopyruvate |
4AABUT | 4-Acetamidobutanoate |
4AB | 4-Aminobutanal |
4FAAC | 4-Fumarylacetoacetate |
4GBTA | 4-Guanidinobutanamide |
4 GBTR | 4-Guanidinobutanoate; 4-Guanidinobutyric acid |
4HB | 4-Hydroxybenzoate |
4HGLUSA | L-4-Hydroxyglutamate semialdehyde |
4HLT | 4-Hydroxy-L-threonine |
4HMN | 4-Hydroxymandelonitrile |
4HPA | 4-Hydroxyphenylacetate |
4HPACAL | 4-Hydroxyphenylacetaldehyde; 2- (4-Hydroxyphenyl) acetaldehyde |
4HPACALO | (Z) -4-Hydroxyphenylacetaldehyde-oxime |
4HPACOA | 4-Hydroxyphenylacetyl-CoA |
4HPAGLY | 4-Hydroxyphenylacetylglycine |
4HPP | 3- (4-Hydroxyphenyl) pyruvate |
4HPRO | trans-4-Hydroxy-L-proline |
4I5P | 4-Imidazolone-5-propanoate |
4MAAC | 4-Maleylacetoacetate |
4MOP | 4-Methyl-2-oxopentanoate |
4PPNCYS | (R) -4'-Phosphopantothenoyl-L-cysteine |
4PPNTE | Pantetheine 4'-phosphate |
4PPNTO | D-4'-Phosphopantothenate |
4TMABT | 4-Trimethylammoniobutanal |
4TMABTO | 4-Trimethylammoniobutanoate |
5A4ICA | 5-Amino-4-imidazole carboxylate |
5AI | 5-Aminoimidazole; Aminoimidazole; 4-Aminoimidazole |
5C2O3E | 5-Carboxy-2-oxohept-3-enedioate |
5CM2HM | 5-Carboxymethyl-2-hydroxymuconate |
5GLUPEPT | (5-L-Glutamyl) -peptide |
5HIAA | 5-Hydroxyindoleacetaldehyde |
5HIAC | 5-Hydroxyindoleacetate |
5MC | DNA 5-methylcytosine; DNA containing 5-methylcytosine; 5-Methylcytosine (in DNA) |
5MDR | 5-Methylthio-D-ribose |
5MTA | 5'-Methylthioadenosine |
5MTGLU | 5-Methyltetrahydropteroyltri-L-glutamate |
A [C] | Apo- [carboxylase] |
A5P | D-Arabinose 5-phosphate |
A6RP | 5-Amino-6-ribitylamino-2,4 (1H, 3H) -pyrimidinedione; 4- (1-D-Ribitylamino) -5-amino-2,6-dihydroxypyrimidine; 4- (1-D-Ribitylamino) -5-aminouracil |
A6RP5P | 5-Amino-6- (5'-phosphoribosylamino) uracil |
A6RP5P2 | 5-Amino-6- (5'-phosphoribitylamino) uracil |
AAA | Aminoacetaldehyde |
AAC | Acetoacetate |
AACCOA | Acetoacetyl-CoA |
AACTN | Aminoacetone; 1-Amino-2-propanone |
AAD | Acetyl adenylate |
ABUT | (S) -2-Aceto-2-hydroxybutanoate |
AC | Acetate |
ACACP | Acetyl- [acyl-carrier protein] |
ACAL | Acetaldehyde |
ACCOA | Acetyl-CoA |
ACDA | Adenosyl cobyrinate a, c diamide |
ACETYLP | Acetyl phosphate |
ACLAC | 2-Acetolactate |
ACOA | Acyl-CoA |
ACP | Acyl-carrier protein |
ACT | (R) -Acetoin; (R) -2-Acetoin; (R) -3-Hydroxy-2-butanone; (R) -Dimethylketol; (R) -3-Hydroxybutan-2-one |
ACTN | Acetone; Dimethyl ketone; 2-Propanone |
AD | Adenine |
ADCBA | Adenosyl cobinamide |
ADCBAP | Adenosyl cobinamide phosphate |
ADCHOR | 4-amino-4-deoxychorismate |
ADLIPO | 6-S-Acetyldihydrolipoamide; [Dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine; S-Acetyldihydrolipoamide-E |
ADN | Adenosine |
ADP | ADP |
AEIOH | 3- (2-Aminoethyl) -1H-indol-5-ol; Serotonin; 5-Hydroxytryptamine; Enteramine |
AG | L-Arogenate |
AGDPCBA | Adenosine-GDP-cobinamide |
AGL | Acylglycerol |
AGL3P | 1-Acyl-sn-glycerol 3-phosphate |
AHHMD | 2-Amino-7,8-dihydro-4-hydroxy-6- (diphosphooxymethyl) pteridine |
AHHMP | 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine |
AHM | 4-Amino-5-hydroxymethyl-2-methylpyrimidine |
AHMP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-phosphate |
AHMPP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-pyrophosphate |
AHTD | 2-Amino-4-hydroxy-6- (erythro-1,2,3-trihydroxypropyl) dihydropteridine triphosphate; 6- (L-erythro-1,2-Dihydroxypropyl 3-triphosphate) -7,8-dihydropterin; 6-[(1S, 2R) -1,2-Dihydroxy-3-triphosphooxypropyl] -7,8-dihydropterin; 7,8-Dihydroneopterin 3'-triphosphate |
AIBUT | L-3-Amino-isobutanoate; (S) -3-Amino-isobutyrate; L-3-Amino-isobutyrate; (S) -3-Amino-isobutanoate; (S) -3-Amino-2-methylpropanoate |
AICAR | 1- (5'-Phosphoribosyl) -5-amino-4-imidazolecarboxamide |
AIR | Aminoimidazole ribotide |
AKG | 2-Oxoglutarate |
ALA | L-Alanine |
ALAALA | D-alanyl-D-alanine |
ALATRNA | L-Alanyl-tRNA |
ALAV | D-Aminolevulinate |
ALLNT | Allantoate; Allantoic acid |
AMP | AMP |
AN | Anthranilate |
AONA | 8-amino-7-oxononanoate |
APN | beta-Aminopropionitrile; 3-Aminopropiononitrile |
AppppA | P1, P4-Bis (5'-adenosyl) tetraphosphate |
APS | Adenylylsulfate; Adenylyl sulfate; Adenosine 5'-phosphosulfate;APS;5'-Adenylyl sulfate |
ARBZ | alpha-Ribazole; N1- (alpha-D-ribosyl) -5,6-dimethylbenzimidazole |
ARG | L-Arginine |
ARGSUCC | N- (L-Arginino) succinate |
ARGTRNAARG | L-Arginyl-tRNA (Arg) |
ARIB | ADPribose |
ASELNT | Adenylylselenate |
ASER | O-Acetyl-L-serine |
ASN | L-Asparagine |
ASNTRNAASN | L-Asparaginyl-tRNA (Asn) |
ASP | L-Aspartate |
ASPSA | L-Aspartate 4-semialdehyde |
ASPTRNAASN | L-Aspartyl-tRNA (Asn) |
ASPTRNAASP | L-Aspartyl-tRNA (Asp) |
ASUC | N6- (1,2-Dicarboxyethyl) -AMP |
ATP | ATP |
B5AMP | Biotinyl-5'-AMP |
BAL | Betaine aldehyde |
bALA | beta-Alanine |
bAPA | beta-Aminopropion aldehyde |
BASP | 4-Phospho-L-aspartate |
bDG6P | beta-D-Glucose 6-phosphate |
bDGLC | beta-D-Glucose |
BETAINE | Betaine; Glycine betaine |
BT | Biotin |
BUTANAL | Butanal |
BZ | Benzoate; Benzoic acid; Benzenecarboxylic acid; Phenylformic acid; Dracylic acid |
C (I) A | Cob (I) alamin; Cbl; Vitamin b12s |
C (I) DA | Cob (I) yrinate a, c diamide |
C090ACP | Nonanoyl- [acyl-carrier protein] |
C100 | Decanoic acid |
C100ACP | Decanoyl- [acyl-carrier protein] |
C110ACP | Undecanoyl- [acyl-carrier protein] |
C120 | Dodecanoic acid |
C120ACP | Dodecanoyl- [acyl-carrier protein] |
C120OH | beta-hydroxy dodecanoic acid |
C121COA | cis, cis-3,6-Dodecadienoyl-CoA |
C122COA | trans, cis-Lauro-2,6-dienoyl-CoA |
C130ACP | Tridecanoyl- [acyl-carrier protein] |
C140 | Tetradecanoic acid |
C140ACP | Tetradecanoyl- [acyl-carrier protein] |
C140OH | beta-hydroxy tetradecanoic acid |
C150 | Pentadecanoic acid |
C150ACP | Pentadecanoyl- [acyl-carrier protein] |
C151ACP | Pentadecenoyl- [acyl-carrier protein] |
C160 | Hexadecanoic acid |
C160ACP | Hexadecanoyl- [acyl-carrier protein] |
C161 | Hexadecenoic acid |
C161ACP | Hexadecenoyl- [acyl-carrier protein] |
C170 | Heptadecanoic acid |
C170ACP | Heptadecanoyl- [acyl-carrier protein] |
C171 | Heptadecenoic acid |
C171ACP | Heptadecenoyl- [acyl-carrier protein] |
C180 | Octadecanoic acid |
C180ACP | Octadecanoyl- [acyl-carrier protein] |
C181 | Octadecenoic acid |
C181ACP | Octadecenoyl- [acyl-carrier protein] |
C190ACP | Nonadecanoyl- [acyl-carrier protein] |
C191ACP | Nonadecenoyl- [acyl-carrier protein] |
C200ACP | Eicosanoyl- [acyl-carrier protein] |
CAASP | N-Carbamoyl-L-aspartate |
CAIR | 1- (5-Phospho-D-ribosyl) -5-amino-4-imidazolecarboxylate |
CALA | 3-Cyano-L-alanine; L-3-Cyanoalanine; L-beta-Cyanoalanine |
CAP | Carbamoyl phosphate |
CATECHOL | Catechol; 1,2-Benzenediol; o-Benzenediol; 1,2-Dihydroxybenzene; Brenzcatechin; Pyrocatechol |
CAV | Cofactors and vitamins |
CBA | Cobinamide |
CBCO | Cobamide coenzyme |
CBHCAP | 3-Isopropylmalate |
CCOA | Crotonoyl-coa |
CDHDHI | 2-Carboxy-2,3-dihydro-5,6-dihydroxyindole |
CDP | CDP |
CDPDG | CDP-diacylglycerol |
CDPMDE | 4- (Cytidine5'-diphospho) -2-C-methyl-D-erythritol |
CH3OR | Primary alcohol |
CHCOA | 6-carboxyhexanoyl-CoA; Pimeloyl-coa |
CHITB | Chitobiose |
CHOLINE | Choline |
CHOLINEP | Choline phosphate; Phosphorylcholine; Phosphocholine; O-Phosphocholine |
CHOR | Chorismate |
CIT | Citrate |
CITR | L-Citrulline |
CL | Cardiolipin (biomass component) |
CMP | CMP |
CMPAEP | CMP-2-aminoethylphosphonate; CMPciliatine |
CMPKDO | CMP-2-keto-3-deoxyoctanoate |
CNS | Carnosine |
CO2 | CO2 |
COA | CoA; coenzyme A |
CPAD5P | 1- (2-Carboxyphenylamino) -1-deoxy-D-ribulose 5-phosphate |
CPP | Coproporphyrinogen III |
CPPI | Coproporphyrinogen I |
CRTN | Creatine; alpha-Methylguanidino acetic acid; Methylglycocyamine |
CT | DNA cytosine; Cytosine (in DNA) |
CTP | CTP |
CVN | Cinnavalininate |
CYS | L-Cysteine |
CYSGLY | Cys-Gly; L-Cysteinylglycine |
CYST | L-Cystine |
CYSTEATE | L-Cysteate |
CYSTRNACYS | L-Cysteinyl-tRNA (Cys) |
CYTD | Cytidine |
D6PGC | 6-Phospho-D-gluconate |
D6RP5P | 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine |
D8RL | 6,7-Dimethyl-8- (1-D-ribityl) lumazine |
DA | Deoxyadenosine |
DAC | Diacetyl; Biacetyl; Dimethylglyoxal; 2,3-Butanedione |
DADP | dADP |
DALA | D-alanine |
DAMP | dAMP |
Danna | 7,8-Diaminononanoate |
DAPIM | L, L-2,6-Diaminopimelate |
DASP | D-Aspartate |
DATP | dATP |
DB4P | L-3,4-Dihydroxy-2-butanone 4-phosphate |
DC | Deoxycytidine |
DCDP | dCDP |
DCMP | dCMP |
DCTP | dCTP |
DCYS | D-Cysteine; D-Amino-3-mercaptopropionic acid |
DG | Deoxyguanosine |
DGDP | dGDP |
DGLN | D-Glutamine |
DGLU | D-Glutamate |
DGLUCA | D-Glucarate |
DGLUCL | D-Glucuronolactone |
DGLYCERATE | D-glycerate |
DGMP | dGMP |
DGR | 1,2-Diacyl-sn-glycerol; 1,2-Diacylglycerol |
DGTP | dGTP |
DHAP | Glycerone phosphate |
DHDP | 2,3-Dihydrodipicolinate |
DHF | Dihydrofolate |
DHI | 5,6-Dihydroxyindole |
DHLIPOYLPROTEIN | Dihydrolipoylprotein |
DHMP | (R) -2,3-dihydroxy-3-methylpentanoate |
DHMVA | (R) -2,3-dihydroxy-3-methylbutanoate |
DHN | 1,4-dihydroxy-2-naphthoate |
DHP | 2-Amino-4-hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine |
DHPA | 2,6-Dihydroxyphenylacetate |
DHPACAL | 3,4-Dihydroxyphenylacetaldehyde; Protocatechuatealdehyde |
DHPANT | 2-Dehydropantoate |
DHPT | Dihydropteroate |
DHSK | 3-Dehydroshikimate |
DIDP | dIDP |
DIMGP | D-erythro-1- (Imidazol-4-yl) glycerol 3-phosphate |
DIMP | 2'-Deoxyinosine 5'-phosphate; dIMP |
DIN | Deoxyinosine |
DISAC1P | 2,3-bis (3-hydroxytetradecanoyl) -D-glucosaminyl-1,6-beta-D-2,3-bis (3-hydroxytetradecanoyl) -beta-D-glucosaminyl 1-phosphate or dissacharide 1-P |
DITP | dITP |
DLIPO | Enzyme N6- (dihydrolipoyl) lysine; Dihydrolipoamide-E |
DMB | Dimethylbenzimidazole |
DMK | 2-Demethylmenaquinone |
DMKH2 | 2-Demethylmenaquinol |
DMPP | Dimethylallyl diphosphate |
DNA | DNA (biomass component) |
DOROA | (S) -Dihydroorotate |
DPCHR | L-Dopachrome; 2-L-Carboxy-2,3-dihydroindole-5,6-quinone |
DPCOA | Dephospho-CoA |
DPHE | D-Phenylalanine |
DPM | Dopamine; 4- (2-Aminoethyl) -1,2-benzenediol; 4- (2-Aminoethyl) benzene-1,2-diol; 3,4-Dihydroxyphenethylamine; 2- (3,4-Dihydroxyphenyl) ethylamine |
DPRO | D-Proline |
DQT | 3-Dehydroquinate |
DR1P | 2-Deoxy-D-ribose 1-phosphate |
DR5P | 2-Deoxy-D-ribose 5-phosphate |
DSER | D-Serine |
DT | Thymidine |
DTB | Dethiobiotin |
DTDP | dTDP |
DTDP4O6DG | 4,6-Dideoxy-4-oxo-dTDP-D-glucose; dTDP-4-oxo-6-deoxy-D-glucose; dTDP-4-dehydro-6-deoxy-D-glucose; dTDP-4-dehydro-6-deoxy-alpha-D-glucose; dTDP-4-oxo-6-deoxy-alpha-D-glucose; dTDP-4-dehydro-6-deoxy-alpha-D-galactose; dTDP-4-dehydro-6-deoxy-D-galactose |
DTDP4ORMNS | dTDP-4-dehydro-6-deoxy-L-mannose; dTDP-4-oxo-6-deoxy-L-mannose; dTDP-4-oxo-L-rhamnose |
DTDPGLAC | dTDPgalactose |
DTDPGLU | dTDP-glucose; dTDP-D-glucose; dTDP-alpha-D-glucose |
DTDPRMNS | dTDP-6-deoxy-L-mannose; dTDP-L-rhamnose |
DTMP | dTMP |
DTTP | dTTP |
DU | Deoxyuridine |
DUDP | dUDP |
DUMP | dUMP |
DUTP | dUTP |
DX5P | 1-Deoxy-D-xylulose 5-phosphate |
E4HGLU | L-erythro-4-Hydroxyglutamate |
E4P | D-Erythrose 4-phosphate |
ER4P | 4-Phospho-D-erythronate; 4-Phosphoerythronate |
ETH | Ethanol |
ETHA | Ethanolamine |
ETHAP | Ethanolamine phosphate; O-Phosphorylethanolamine; Phosphoethanolamine; O-Phosphoethanolamine |
EXOPOLYS | Exopolysaccharide |
F1P | D-Fructose 1-phosphate |
F6P | beta-D-Fructose 6-phosphate |
FA | Formamide |
FAD | Flavin adenine dinucleotide; FAD |
FADH2 | FADH2 |
FAN | Formylanthranilate; N-Formylanthranilate; 2- (Formylamino) -benzoic acid |
FDP | beta-D-Fructose 1,6-bisphosphate |
FERIC | Ferricytochrome c |
FEROC | Ferrocytochrome c |
FGAM | 2- (Formamido) -N1- (5'-phosphoribosyl) acetamidine |
FGAR | 5'-Phosphoribosyl-N-formylglycinamide |
FKYN | L-Formylkynurenine; N-Formyl-L-kynurenine; N-Formylkynurenine |
FL | Folate |
FMETTRNA | N-Formylmethionyl-tRNA |
FMN | FMN; Riboflavin-5-phosphate; Flavin mononucleotide |
FORMATE | Formate |
FPP | trans, trans-Farnesyl diphosphate |
FTHF | 10-Formyltetrahydrofolate |
FUCP | L-Fuculose 1-phosphate |
FUM | Fumarate |
G1P | D-Glucose 1-phosphate |
G3P | D-Glyceraldehyde3-phosphate; (2R) -2-Hydroxy-3- (phosphonooxy) -propanal |
G3PC | sn-glycero-3-Phosphocholine |
G3PE | sn-glycero-3-Phosphoethanolamine |
G6P | alpha-D-Glucose 6-phosphate |
GA1P | D-Glucosamine 1-phosphate |
GA6P | D-Glucosamine 6-phosphate |
GABA | 4-Aminobutanoate |
GAPN | gamma-Glutamyl-beta-aminopropiononitrile; gamma-Glutamyl-3-aminopropiononitrile |
GAR | 5'-Phosphoribosylglycinamide |
GCYS | gamma-L-Glutamyl-L-cysteine |
GDP | GDP |
GDPMAN | GDP-mannose |
GENAL | Gentisate aldehyde |
GGLUMSCYS | gamma-Glutamyl-Se-methylselenocysteine |
GGPP | Geranylgeranyl diphosphate |
GL | Glycerol |
GL3P | sn-Glycerol 3-phosphate |
GLAL | Glycolaldehyde |
GLC | alpha-D-Glucose |
GLCA | D-Glucosamine; Chitosamine; 2-Amino-2-deoxy-D-glucose |
GLCAMN | D-Glucosaminide |
GLN | L-Glutamine |
GLU | L-Glutamate |
GLUBCALA | gamma-Glutamyl-beta-cyanoalanine |
GLUC | D-Gluconate |
GLUGSAL | L-Glutamate 5-semialdehyde |
GLUP | alpha-D-Glutamyl phosphate |
GLUTCOA | Glutaryl-CoA |
GLUTR | 5-L-Glutamyl-taurine |
GLUTRNAGLN | L-Glutamyl-tRNA (Gln) |
GLUTRNAGLU | L-Glutamyl-tRNA (Glu) |
GLX | Glyoxylate |
GLY | Glycine |
GLYCOLATE | Glycolate |
GLYTRNAGLY | Glycyl-tRNA (Gly) |
GMP | GMP |
GN | Guanine |
GPP | Geranyl diphosphate |
GSA | Glutamate-1-semialdehyde |
GSN | Guanosine |
GTP | GTP |
GTRNA | Glutaminyl-tRNA |
H [C] | Holo- [carboxylase] |
H2O2 | H2O2 |
H2S | Hydrogen sulfide |
H2SO3 | Sulfite |
H5P | Hydantoin-5-propionate; Hydantoin-propionate |
HAC | Hydroxyacetone |
HCNS | Homocarnosine |
HCO3 | HCO3 |
HCYS | L-Homocysteine |
HDN | Hordenine; 4- [2- (Dimethylamino) ethyl] phenol |
HEDC | 2-Hydroxyethylenedicarboxylate; enol-Oxaloacetate; enol-Oxaloacetic acid; 2-Hydroxybut-2-enedioic acid |
HEMEO | Heme o |
HEPPP | all-trans-Heptaprenyl diphosphate |
HIBUT | (S) -3-Hydroxyisobutyrate |
HIEA | 1H-Imidazole-4-ethanamine; Histamine; 2- (4-Imidazolyl) ethylamine |
HIPPRT | Hippurate; Hippuric acid; N-Benzoylglycine; Benzoylaminoacetic acid |
HIS | L-Histidine |
HISOL | L-Histidinol |
HISOLP | L-Histidinol phosphate |
HISTRNAHIS | L-Histidyl-tRNA (His) |
HKYN | 3-Hydroxy-L-kynurenine |
HMB | Hydroxymethylbilane |
HMB4PP | 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate |
HO3S2 | Thiosulfate |
HOMOGEN | Homogentisate |
HOPP | 2-Hydroxy-3-oxopropanoate; Tartronate semialdehyde |
HPYR | Hydroxypyruvate; Hydroxypyruvic acid; 3-Hydroxypyruvate; 3-Hydroxypyruvic acid |
HSER | L-Homoserine |
Hxt | External proton |
HYDROXYAKG | D-4-Hydroxy-2-oxoglutarate |
HYXN | Hypoxanthine |
I3AA | Indole-3-acetaldehyde |
I3AAM | Indole-3-acetamide |
I3AC | Indole-3-acetate |
I4AA | Imidazole-4-acetaldehyde |
I4AC | Imidazole-4-acetate |
IASP | Iminoaspartate |
ICHOR | Isochorismate |
ICIT | Isocitrate |
IDP | IDP |
IGLY | Iminoglycine; Iminoacetic acid |
IGP | Indoleglycerol phosphate |
ILE | L-Isoleucine |
ILETRNAILE | L-Isoleucyl-tRNA (Ile) |
IMACP | 3- (Imidazol-4-yl) -2-oxopropyl phosphate |
IMAL | Isomaltose |
IMP | IMP |
INDOLE | Indole |
INS | Inosine |
IPP | Isopentenyl diphosphate |
IPPMAL | 2-Isopropylmalate; (2S) -2-Isopropylmalate; 3-Carboxy-3-hydroxy-4-methylpentanoate; 3-Carboxy-3-hydroxy-isocaproate; 3-Carboxy-3-hydroxyisocaproate; 2-Hydroxy-2-isopropylbutanedioate; 3-Hydroxy-4-methyl-3-carboxypentanoate |
IPYR | Indolepyruvate; Indolepyruvic acid; (Indol-3-yl) pyruvate; Indole-3-pyruvate; 3- (Indol-3-yl) pyruvate |
ITP | ITP |
K2LIPA | KDO2-lipid (A); Di [3-deoxy-D-manno-octulosonyl] -lipid A |
K2LIPIV | KDO2-lipid IV (A); Di [3-deoxy-D-manno-octulosonyl] -lipid IV (A); |
KDO | 2-Dehydro-3-deoxy-D-octonate |
KDOLIPIV | KDO-lipid IV (A) |
KDOP | 2-Dehydro-3-deoxy-D-octonate 8-phosphate |
KDPG | 2-Dehydro-3-deoxy-6-phospho-D-gluconate |
KYN | L-Kynurenine; 3-Anthraniloyl-L-alanine |
L1P3H5C | L-1-Pyrroline-3-hydroxy-5-carboxylate |
LAC | (R) -Lactate, D-Lactate |
LACAL | (S) -Lactaldehyde; L-Lactaldehyde; L-2-Hydroxypropionaldehyde |
LEU | L-Leucine |
LEUTRNA | L-Leucyl-tRNA |
LIPID | Lipids other than phospholipid |
LIPIV | Lipid IV (A) |
LIPO | Enzyme N6- (lipoyl) lysine; Lipoamide-E |
LIPOYLPROTEIN | Lipoylprotein |
LIPX | Lipid X |
LK2LIPIV | Lauroyl-KDO2-lipid IV (A) |
LLCT | L-Cystathionine |
LPS | Lippolysaccharide |
LTG | (R) -S-Lactoylglutathione |
LYS | L-Lysine |
LYSTRNA | L-Lysyl-tRNA |
MAL | (S) -Malate |
MALACP | Malonyl- [acyl-carrier protein] |
MALCOA | Malonyl-CoA |
MAN1P | alpha-D-Mannose 1-phosphate |
MAN6P | D-Mannose 6-phosphate |
MCB | Methylcobalamin |
MDAPIM | meso-2,6-Diaminoheptanedioate; meso-2,6-Diaminopimelate; meso-2,6-Diaminopimelic acid; meso-Diaminoheptanedioate |
MDE4P | 2-C-Methyl-D-erythritol 4-phosphate |
MDECPP | 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate |
MET | L-Methionine |
METHF | 5,10-Methenyltetrahydrofolate |
METTHF | 5,10-Methylenetetrahydrofolate |
METTRNA | L-Methionyl-tRNA |
MK | menaquinone |
MKH2 | menaquinol |
MLT | Maltose |
MM | Methylmalonate |
MMALCOA | (S) -Methylmalonyl-CoA; (S) -Methylmalonyl-coenzyme A; (2S) -Methylmalonyl-CoA; D-Methylmalonyl-CoA |
MMSA | (S) -Methylmalonate semialdehyde |
MNT | D-Mannitol |
MOT | 5-Methoxytryptamine; 5-MeOT |
MPET | 4-Methyl-5- (2-phosphoethyl) -thiazole; 4-Methyl-5- (2-phosphono-oxyethyl) -thiazole |
MPYR | Meraptopyruvate |
MSCYS | Se-Methylselenocysteine |
MTG | Methylglyoxal |
MTHF | 5-Methyltetrahydrofolate |
MTRM | N-Methyltyramine |
MTTA | meso-Tartaric acid; meso-Tartrate |
N (P) CYS | N-((R) -Pantothenoyl) -L-cysteine |
N1 (5PADR) DMB | N1- (5-Phospho-alpha-D-ribosyl) -5,6-dimethylbenzimidazole |
N2SUCCARG | N2-Succinyl-L-arginine |
N2SUCCGLU | N-Succinyl-L-glutamate; (2S) -2- (3-Carboxypropanoylamino) pentanedioic acid |
N2SUCCGLU5SA | N-Succinyl-L-glutamate 5-semialdehyde; (2S) -2- (3-Carboxypropanoylamino) -5-oxopentanoic acid |
N4AAB | N4-Acetylaminobutanal |
Na | Sodium |
NAAD | Deamino-NAD +; Deamido-NAD +; Deamido-NAD |
NAC | Nicotinate |
NACD | Nicotinate D-ribonucleoside |
NACN | Nicotinate D-ribonucleotide |
NAD | NAD +; Nicotinamide adenine dinucleotide |
NADH | NADH |
NADMA | N-Acetyl-D-mannosamine |
NADP | NADP +; Nicotinamide adenine dinucleotide phosphate |
NADPH | NADPH |
NAGA | N-Acetyl-D-glucosamine |
NAGA1P | N-Acetyl-D-glucosamine 1-phosphate |
NAGLU | N-Acetyl-L-glutamate |
NAGLUP | N-Acetyl-L-glutamate 5-phosphate |
NAGLUS | N-Acetyl-L-glutamate 5-semialdehyde |
NAM | Nicotinamide |
NAMD | N-Ribosylnicotinamide |
NAMN | Nicotinamide D-ribonucleotide |
NAORN | N2-Acetyl-L-ornithine |
NAS | N-Acylsphingosine; Ceramide |
NASAEP | Ceramide 2-aminoethylphosphonate; Ceramide ciliatine |
NFGLU | N-Formimino-L-glutamate |
NH3 | NH3 |
NHLYS | N6-Hydroxy-L-lysine |
NMHIS | N (pi) -Methyl-L-Histidine |
NO2 | Nitrite |
NO3 | Nitrate |
NPRAN | N- (5-Phospho-D-ribosyl) anthranilate |
O2 | Oxygen |
OA | Oxaloacetate |
OAHSER | O-Acetyl-L-homoserine |
OBUT | 2-Oxobutanoate |
OGT | Oxidized glutathione; Glutathione disulfide; Oxiglutatione |
OHB | 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate |
OICAP | 3-Carboxy-4-methyl-2-oxopentanoate |
OIVAL | 3-Methyl-2-oxobutanoic acid |
OMP | Orotidine 5'-phosphate |
OPP | all-trans-Octaprenyl diphosphate |
ORBRDX | Oxidized rubredoxin |
ORN | L-Ornithine |
OROA | Orrotate |
OSB | O-succinylbenzoate |
OSBCOA | O-succinylbenzoate-CoA |
OSLHSER | O-Succinyl-L-homoserine |
OTHIO | Thioredoxin disulfide; Oxidized thioredoxin; Thioredoxin sulfide |
P5C | (S) -1-Pyrroline-5-carboxylate |
P5P | Pyridoxine 5'-phosphate; Pyridoxine phosphate |
PA | Phosphatidate; 1,2-Diacyl-sn-glycerol 3-phosphate |
PAA | 2-Phenylacetamide |
PABA | 4-Aminobenzoate |
PACAL | Phenylacetaldehyde; alpha-Tolualdehyde |
PACGLY | Phenylacetylglycine |
PACOA | Phenylacetyl-CoA |
PANT | (R) -pantoate |
PAP | Adenosine 3 ', 5'-bisphosphate |
PAPS | 3'-Phosphoadenylyl sulfate |
PBG | Porphobilinogen |
PC | Phosphatidylcholine |
PC2 | Percorrin 2 |
PDLA | Pyridoxamine |
PDLA5P | Pyridoxamine-5-phosphate |
PE | Phosphatidylethanolamine |
PEA | Phenethylamine; 2-Phenylethylamine; beta-Phenylethylamine; Phenylethylamine |
PEP | Phosphoenolpyruvate |
PEPTIDE | Peptide |
PEPTIDO | Peptidoglycan (biomass component) |
PG | Phosphatidylglycerol |
PGP | Phosphatidylglycerophosphate |
PHE | L-Phenylalanine |
PHEN | Prephenate |
PHETRNAPHE | L-Phenylalanyl-tRNA (Phe) |
PHOSPHOLIPID | Phospholipids (biomass component) |
PHP | 3-Phosphonooxypyruvate |
PHPYR | Phenylpyruvate |
PHSER | O-Phospho-L-homoserine |
PHT | O-Phospho-4-hydroxy-L-threonine |
PI | Orthophosphate |
PL | Pyridoxal |
PL5P | Pyridoxal 5'-phosphate |
PLA | Phenylacetic acid; Benzylformic acid; Phenylacetate; Benzeneacetiic acid |
PNTO | (R) -Pantothenate; Pantothenate |
PPA | Propinol adenylate |
PPAACP | Propanoyl- [acyl-carrier protein]; Propionyl- [acyl-carrier protein] |
PPAC | Phosphonoacetaldehyde |
PPACOA | Propanoyl-CoA; Propionyl-coa |
PPCOA | Propenoyl-CoA; Acryloyl-coa |
PPEPTIDO | Peptidoglycan precursor |
ppGpp | Guanosine 3 ', 5'-bis (diphosphate) |
PPHG | Protoporphyrinogen IX |
PPI | Pyrophosphate; Diphosphate |
PPIX | Protoporphyrin IX |
PPN | Propynoate |
pppGpp | Guanosine 3'-diphosphate 5'-triphosphate |
PPPI | Triphosphate |
PPPP | all-trans-Pentaprenyl diphosphate |
PQ | Phylloquinone |
PQQ | Pyrrolo-quinolinequinone; Pyrroloquinoline-quinone; Pyrroloquinolinequinone; 4,5-Dioxo-4,5-dihydro-1H-pyrrolo [2,3-f] quinoline-2,7,9-tricarboxylate |
PQQH2 | Reduced pyrroloquinoline-quinone |
PRAM | 5-Phosphoribosylamine |
PRBAMP | N1- (5-Phospho-D-ribosyl) -AMP |
PRBATP | N1- (5-Phospho-D-ribosyl) -ATP |
PRFICA | 1- (5'-Phosphoribosyl) -5-formamido-4-imidazolecarboxamide |
PRFP | 5- (5-Phospho-D-ribosylaminoformimino) -1- (5-phosphoribosyl) -imidazole-4-carboxamide |
PRLP | N- (5'-Phospho-D-1'-ribulosylformimino) -5-amino-1- (5 "-phospho-D-ribosyl) -4-imidazolecarboxamide |
PRO | L-Proline |
PROPANOATE | Propanoate |
PROPIONYLP | Propanoyl phosphate |
PROTEIN | Proteins |
PROTRNAPRO | L-Prolyl-tRNA (Pro) |
PRPP | 5-Phospho-alpha-D-ribose 1-diphosphate |
PS | Phosphatidylserine |
PTH | Heme; Haem; Protoheme; Heme B; Protoheme IX |
PTRC | Putrescine |
PTT | Pantetheine |
PURI5P | Pseudouridine 5'-phosphate |
PYR | Pyruvate |
PYRDX | Pyridoxine |
PYTHP | 6-Pyruvoyltetrahydropterin |
QA | Quinolinate; Pyridine-2,3-dicarboxylate |
QNT | Quinate; Quinic acid; Kinic acid; Chinic acid; L-Quinic acid; L-Quinate; (-)-Quinic acid |
R1P | D-Ribose 1-phosphate; alpha-D-Ribose 1-phosphate; Ribose 1-phosphate |
R3HBCOA | (R) -3-Hydroxybutanoyl-CoA |
R5P | D-Ribose 5-phosphate |
RCHO | Aldehyde |
RGT | Glutathione |
RH | Alkane |
RIBFLAV | Riboflavin |
RL5P | D-Ribulose 5-phosphate |
RMAL | (R) -Malate; D-Malate; D-Malic acid |
RNA | RNA |
RRBRDX | Reduced rubredoxin |
RTHIO | Thioredoxin |
S | Sulfur |
S6P | Sorbitol 6-phosphate |
S7P | Sedoheptulose 7-phosphate |
SAH | S-Adenosyl-L-homocysteine |
SAICAR | 1- (5'-Phosphoribosyl) -5-amino-4- (N-succinocarboxamide) -imidazole |
SAM | S-Adenosyl-L-methionine |
SAMOB | S-adenosyl-4-methylthio-2-oxobutanoate |
SAOPIM | N-Succinyl-2-amino-6-oxopimelate |
SASHCYS | Se-adenosylselenohomocysteine |
SB1P | Sorbose 1-phosphate |
SCSN | Sarcosine; N-Methylglycine |
SCYS | Selenocysteine |
SDAPIM | N-Succinyl-L-2,6-diaminopimelate |
SDLIPO | S-Succinyldihydrolipoamide |
SeASMET | Se-Adenosylselenomethionine |
SELD | Selenide |
SELNT | Selenate |
SELT | Selenite |
SER | L-Serine |
SERTRNASER | L-Seryl-tRNA (Ser) |
SGDHL | S-Glutaryldihydrolipoamide |
SHCHC | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate |
SHCL | Sirohydrochlorin |
SHCYS | Selenohomocysteine |
SHEME | Siroheme |
SLAC | (S) -Lactate |
SLF | Sulfate |
SLLCT | Selenocystathionine |
SME | Shikimate |
SME3P | Shikimate 3-phosphate |
SMET | Selenomethionine |
SMETTRNAMET | Selenomethionyl-tRNA (Met) |
SORN | N2-Succinyl-L-ornithine; (2S) -5-Amino-2- (3-carboxypropanoylamino) pentanoic acid |
SPRMD | Spermidine |
SRLH | S-Ribosyl-L-homocysteine |
SSLCYS | S-Sulfo-L-cysteine |
SUC | Sucrose |
SUCC | Succinate |
SUCCOA | Succinyl-CoA |
SUCCSA | Succinate semialdehyde |
T3 | D-Glyceraldehyde |
TCYS | Thiocysteine |
TDHDP | 2,3,4,5-Tetrahydrodipicolinate |
TGL | Triacylglycerol |
TGLU | Tetrahydropteroyltri-L-glutamate |
THF | Tetrahydrofolate |
THFG | Tetrahydrofolyl- [Glu] (n) |
THIAMIN | Thiamin |
THMP | Thiamin monophosphate |
THMPP | Thiamin diphosphate |
THR | L-Threonine |
THRTRNATHR | L-Threonyl-tRNA (Thr) |
THZ | 5- (2-Hydroxyethyl) -4-methylthiazole; 4-Methyl-5- (2'-hydroxyethyl) -thiazole; 4-Methyl-5- (2-hydroxyethyl) -thiazole |
THZP | 4-Methyl-5- (beta-hydroxyethyl) thiazole phosphate |
TM | Thymine |
TR | Taurine |
TRE | alpha, alpha-Trehalose |
TRE6P | alpha, alpha'-Trehalose 6-phosphate |
TRM | Tyramine; 2- (p-Hydroxyphenyl) ethylamine |
TRNAALA | tRNA (Ala) |
TRNAARG | tRNA (Arg) |
TRNAASP | tRNA (Asp) |
TRNACYS | tRNA (Cys) |
TRNAGLN | tRNA (Gln) |
TRNAGLU | tRNA (Glu) |
TRNAGLY | tRNA (Gly) |
TRNAHIS | tRNA (His) |
TRNAILE | tRNA (Ile) |
TRNALEU | tRNA (Leu) |
TRNALYS | tRNA (Lys) |
TRNAMET | tRNA (Met) |
TRNAPHE | tRNA (Phe) |
TRNAPRO | tRNA (Pro) |
TRNASER | tRNA (Ser) |
TRNATHR | tRNA (Thr) |
TRNATRP | tRNA (Trp) |
TRNATYR | tRNA (Tyr) |
TRNAVAL | tRNA (Val) |
TRP | L-Tryptophan |
TRPTRNATRP | L-Tryptophanyl-tRNA (Trp) |
TRYTRNATYR | L-Tyrosyl-tRNA (Tyr) |
TTA | (R, R) -Tartaric acid; (R, R) -Tartrate; L-Tartaric acid; Tartaric acid; Tartrate; 2,3-Dihydroxybutanedioic acid; (2R, 3R) -Tartaric acid; (+)-Tartaric acid |
TYR | L-Tyrosine |
U1C | Urea-1-carboxylate; Allophanate; Allophanic acid |
UC | Urocanate |
UDCP | Undecaprenyl phosphate |
UDCPP | Undecaprenyl diphosphate |
UDGLYCOLATE | (-)-Ureidoglycolate; (S) -Ureidoglycolate |
UDP | UDP |
UDPAGLACA | UDP-N-acetyl-D-galactosamine |
UDPG | UDP-glucose |
UDPG23A | UDP-2,3-bis (3-hydroxytetradecanoyl) glucosamine |
UDPG2A | UDP-3-O- (3-hydroxytetradecanoyl) glucosamine |
UDPG2AA | UDP-3-O- (3-hydroxytetradecanoyl) -N-acetylglucosamine |
UDPGAL | UDP-D-galactose |
UDPGLUC | UDP-glucuronate |
UDPMNLADGMD | UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate |
UDPMNLADGMDDADA | UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine |
UDPNADMA | UDP-N-acetyl-D-mannosamine |
UDPNADMAU | UDP-N-acetyl-D-mannosaminouronate |
UDPNAG | UDP-N-acetyl-D-glucosamine |
UDPNAGEP | UDP-N-acetyl-3- (1-carboxyvinyl) -D-glucosamine |
UDPNAM | UDP-N-acetylmuramate |
UDPNAMA | UDP-N-acetylmuramoyl-L-alanine |
UDPNAMAG | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate |
UMP | UMP |
UPPMN (GN) LADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMN (GN) LADGNMD (G) 5DADA | Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl- (glycyl) 5-D-alanyl-D-alanine |
UPPMN (GN) LADGNMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMNLADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPRG | Uroporphyrinogen III |
UPRGI | Uroporphyrinogen I |
UQ | Ubiquinone |
UQH2 | Ubiquinol |
URA | Uracil |
UREA | Urea |
URI | Uridine |
URT | Urate; Uric acid |
UTP | UTP |
VAL | L-Valine |
VALTRNAVAL | L-Valyl-tRNA (Val) |
VB12 | Vitamin b12 |
X5P | D-Xylulose 5-phosphate |
XAN | Xanthine |
XMP | Xanthosine 5'-phosphate |
XTP | XTP |
XTSINE | Xanthosine |
BIOMASS | Cell biomass |
FRUxt | External D-fructose |
(2) V. Vulnicus CMCP6의 대사 네트워크의 구축(2) Construction of the metabolic network of V. Vulnicus CMCP6
컴퓨터를 이용하여 V. vulnificus CMCP6의 약물 표적을 예측하기 위하여 다양한 데이터베이스 및 실험결과를 이용하여 게놈 수준의 대사 네트워크를 구축하였다.To predict the drug target of V. vulnificus CMCP6 using a computer, a genome-level metabolic network was constructed using various databases and experimental results.
KEGG(Kanehisa et al.. Nucleic Acids Res, 34:D354, 2006), TransportDB(Ren et al., PLoS Comput. Biol., 1:e27, 2005), MetaCyc(Caspi et al. Nucleic Acids Res., 36:D623, 2008)을 토대로 초기 버전의 대사 네트워크를 구축하였으며 게놈 정보를 토대로 효소 반응식의 방향성, 유전자단백질의 상관관계를 명확히 하였다. KEGG (Kanehisa et al. Nucleic Acids Res, 34: D354, 2006), TransportDB (Ren et al., PLoS Comput. Biol. , 1: e27, 2005), MetaCyc (Caspi et al. Nucleic Acids Res ., 36 (D623, 2008), an early version of the metabolic network was established, and based on genomic information, the relationship between the directionality and the gene protein of the enzyme reaction was clarified.
하기 표 3에 나타낸 바와 같이, 구축된 V. vulnificus CMCP6의 대사 네트워크는 945개의 생화학 반응식과 765개의 대사산물로 구성되어 있고, 이러한 대사 네트워크의 정보는 하기 672개의 유전자 정보가 담겨 있다. 하기 예측되는 약물 표적은 이들 반응식들로부터 선별하였다. As shown in Table 3 below, the constructed metabolic network of V. vulnificus CMCP6 consists of 945 biochemical schemes and 765 metabolites, and the information of this metabolic network contains the following 672 gene information. The predicted drug targets were selected from these schemes.
표 3
TABLE 3
Reaction ID | Metabolism | ORF | EC Number | Reaction | Enzyme |
R001 | Glycolysis/ Gluconeogenesis | VV11773 | 5.1.3.3 | GLC <-> bDGLC | aldose 1-epimerase |
R002 | Glycolysis/ Gluconeogenesis | 2.7.1.2 | GLC + ATP <-> ADP + G6P | glucokinase | |
R003 | Glycolysis/ Gluconeogenesis | VV11396 | 5.3.1.9 | G6P <-> bDG6P | glucose-6-phosphate isomerase |
R004 | Glycolysis/ Gluconeogenesis | VV11485 OR VV21050 | 3.2.1.86 | A6P -> HQ + bDG6P | 6-phospho-beta-glucosidase |
R005 | Glycolysis/ Gluconeogenesis | VV11396 | 5.3.1.9 | G6P <-> F6P | glucose-6-phosphate isomerase |
R006 | Glycolysis/ Gluconeogenesis | VV11396 | 5.3.1.9 | bDG6P <-> F6P | glucose-6-phosphate isomerase |
R007 | Glycolysis/ Gluconeogenesis | VV10169 | 5.4.2.2 | G6P <-> G1P | phosphoglucomutase |
R008 | Glycolysis/ Gluconeogenesis | VV11257 | 2.7.1.11 | F6P + ATP -> FDP + ADP | 6-phosphofructokinase |
R009 | Glycolysis/ Gluconeogenesis | VV10707 OR VV11349 | 3.1.3.11 | FDP -> F6P + PI | fructose-bisphosphatase |
R010 | Glycolysis/ Gluconeogenesis | VV11541 | 4.1.2.13 | FDP <-> G3P + DHAP | fructose-bisphosphate aldolase |
R011 | Glycolysis/ Gluconeogenesis | VV11343 | 5.3.1.1 | DHAP <-> G3P | triosephosphate isomerase |
R012 | Glycolysis/ Gluconeogenesis | VV11141 OR VV13140 | 1.2.1.12 | G3P+PI+NAD<-> NADH + 13PDG | glyceraldehyde3-phosphatedehydrogenase |
R013 | Glycolysis/ Gluconeogenesis | VV11540 | 2.7.2.3 | 13PDG + ADP <-> 3PG + ATP | phosphoglyceratekinase |
R014 | Glycolysis/ Gluconeogenesis | VV12711 | 3.6.1.7 | 13PDG + ADP -> 3PG + ATP | acylphosphatase |
R015 | Glycolysis/ Gluconeogenesis | VV11281 | 5.4.2.1 | 3PG <-> 2PG | phosphoglycerate mutase |
R016 | Glycolysis/ Gluconeogenesis | VV11579 | 4.2.1.11 | 2PG <-> PEP | enolase |
R017 | Glycolysis/ Gluconeogenesis | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | PEP + ADP -> PYR + ATP | pyruvate kinase |
R018 | Glycolysis/ Gluconeogenesis | VV21457 | 1.1.1.27 | SLAC + NAD <-> PYR + NADH | L-lactate dehydrogenase |
R019 | Glycolysis/ Gluconeogenesis | VV11630 OR (VV20469 AND VV20470) | 1.2.4.1 | PYR + LIPO -> ADLIPO + CO2 | pyruvate dehydrogenase E1 component |
R020 | Glycolysis/ Gluconeogenesis | VV11631 AND VV20471 | 2.3.1.12 | COA + ADLIPO -> DLIPO + ACCOA | pyruvate dehydrogenase E2 component (dihydrolipoamideacetyltransferase) |
R021 | Glycolysis/ Gluconeogenesis | VV11632 | 1.8.1.4 | DLIPO + NAD -> LIPO + NADH | dihydrolipoamidedehydrogenase |
R022 | Glycolysis/ Gluconeogenesis | VV11237 OR VV20456 | 6.2.1.1 | ATP + AC + COA <-> AMP + PPI + ACCOA | acetyl-CoA synthetase |
R023 | Glycolysis/ Gluconeogenesis | VV20869 | 1.2.1.3 | ACAL + NAD -> NADH + AC | aldehydedehydrogenase |
R024 | Glycolysis/ Gluconeogenesis | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | ACAL + NADH <-> ETH + NAD | alcohol dehydrogenase |
R025 | TCA cycle | VV10162 | 2.3.3.1 | ACCOA + OA -> COA + CIT | citrate synthase |
R026 | TCA cycle | VV12730 OR VV11653 | 4.2.1.3 | CIT <-> ICIT | aconitate hydratase |
R027 | TCA cycle | VV12118 | 1.1.1.42 | ICIT + NADP -> NADPH + AKG + CO2 | isocitrate dehydrogenase |
R028 | TCA cycle | VV10157 | 1.2.4.2 | AKG + LIPO -> SDLIPO + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R029 | TCA cycle | VV10156 | 2.3.1.61 | SDLIPO + COA -> DLIPO + SUCCOA | 2-oxoglutaratedehydrogenaseE2component |
R030 | TCA cycle | VV10154 AND VV10155 | 6.2.1.5 | ADP + PI + SUCCOA <-> ATP + SUCC + COA | succinyl-CoAsynthetase |
R031 | TCA cycle | VV10158 AND VV10159 AND VV10160 AND VV10161 | 1.3.99.1 | SUCC + FAD -> FUM + FADH2 | succinatedehydrogenase |
R032 | TCA cycle | VV11266 AND VV11267 AND VV11268 AND VV11269 | 1.3.99.1 | FUM + MKH2 -> SUCC + MK | fumaratereductase |
R033 | TCA cycle | VV11266 AND VV11267 AND VV11268 AND VV11269 | 1.3.99.1 | FUM + DMKH2 -> SUCC + DMK | fumaratereductase |
R034 | TCA cycle | VV12266 | 4.2.1.2 | FUM <-> MAL | fumaratehydratase |
R035 | TCA cycle | VV10673 | 1.1.1.37 | MAL + NAD <-> NADH + OA | malatedehydrogenase |
R036 | Pentose phosphate pathway | VV12684 | 1.1.1.49 | G6P + NADP -> D6PGL + NADPH | glucose-6-phosphate1-dehydrogenase |
R037 | Pentose phosphate pathway | VV12684 | 1.1.1.49 | G6P + NAD -> D6PGL + NADH | glucose-6-phosphate 1-dehydrogenase |
R038 | Pentose phosphate pathway | VV12683 | 3.1.1.31 | D6PGL -> D6PGC | 6-phosphogluconolactonase |
R039 | Pentose phosphate pathway | VV12682 | 1.1.1.44 | D6PGC + NADP -> NADPH + CO2 + RL5P | 6-phosphogluconatedehydrogenase |
R040 | Pentose phosphate pathway | VV11386 | 5.1.3.1 | RL5P <-> X5P | ribulose-phosphate3-epimerase |
R041 | Pentose phosphate pathway | VV11547 | 5.3.1.6 | RL5P <-> R5P | ribose 5-phosphate isomerase A |
R042 | Pentose phosphate pathway | VV20065 | 2.7.1.15 | RIB + ATP -> R5P + ADP | ribokinase |
R043 | Pentose phosphate pathway | VV11727 OR VV10169 | 5.4.2.7 OR 5.4.2.2 | R1P <-> R5P | phosphopentomutase |
R044 | Pentose phosphate pathway | VV11537 OR VV20553 | 2.2.1.1 | R5P + X5P <-> G3P + S7P | transketolase |
R045 | Pentose phosphate pathway | VV11537 OR VV20553 | 2.2.1.1 | X5P + E4P <-> F6P + G3P | transketolase |
R046 | Pentose phosphate pathway | VV20552 | 2.2.1.2 | G3P + S7P <-> E4P + F6P | transaldolase |
R047 | Pentose phosphate pathway | VV11725 | 4.1.2.4 | DR5P -> G3P + ACAL | deoxyribose-phosphatealdolase |
R048 | Pentose phosphate pathway | VV20065 | 2.7.1.15 | DRIB + ATP -> DR5P + ADP | ribokinase |
R049 | Pentose phosphate pathway | VV11727 | 5.4.2.7 | DR1P <-> DR5P | phosphopentomutase |
R050 | Pentose phosphate pathway | VV11102 OR VV20904 OR VV21072 | 4.1.2.14 | KDPG -> PYR + G3P | 2-dehydro-3-deoxyphosphogluconate aldolase |
R051 | Pentose phosphate pathway | VV20905 OR VV21071 | 2.7.1.45 | KDG + ATP -> KDPG + ADP | 2-dehydro-3-deoxygluconokinase |
R052 | Pentose phosphate pathway | VV11100 | 2.7.1.12 | GLUC + ATP -> D6PGC + ADP | gluconokinase |
R053 | Pentose phosphate pathway | VV11099 | 4.2.1.12 | D6PGC->KDPG | phosphogluconate dehydratase |
R054 | Pentose and glucuronate interconversions | VV21070 | 5.3.1.12 | DGALAC -> DTAGA | glucuronateisomerase |
R055 | Pentose and glucuronate interconversions | VV20914 OR VV21093 | 1.1.1.125 | KDG + NAD <-> DDOH + NADH | 2-deoxy-D-gluconate3-dehydrogenase |
R056 | Pentose and glucuronate interconversions | VV21064 | 4.2.1.8 | KDG<->DMAN | mannonatedehydratase |
R057 | Pentose and glucuronate interconversions | VV21069 | 1.1.1.57 | DMAN + NAD <-> DFRUC + NADH | mannonate oxidoreductase |
R058 | Pentose and glucuronate interconversions | VV21070 | 5.3.1.12 | DGLUC <-> DFRUC | glucuronateisomerase |
R059 | Pentose and glucuronate interconversions | VV10774 | 1.1.1.22 | UDPG + 2 NAD <-> UDPGLUC + 2 NADH | UDPglucose6-dehydrogenase |
R060 | Fructose and mannose metabolism | VV20199 | 2.7.1.56 | F1P + ATP -> FDP + ADP | fructose-1-phosphate kinase |
R061 | Fructose and mannose metabolism | VV11541 | 4.1.2.13 | F1P -> DHAP + T3 | fructose-bisphosphate aldolase |
R062 | Fructose and mannose metabolism | VV20514 OR VV20515 OR VV21348 | 5.3.1.8 | MAN6P <-> F6P | phosphomannoseisomerase |
R063 | Fructose and mannose metabolism | VV11664 OR VV20569 | 5.4.2.8 | MAN6P <-> MAN1P | phosphomannomutase |
R064 | Fructose and mannose metabolism | VV10804 | 2.7.7.13 | GTP + MAN1P <-> PPI + GDPMAN | nucleoside-diphosphate-sugarpyrophosphorylase |
R065 | Fructose and mannose metabolism | VV10639 | 1.1.1.17 | MNT1P + NAD -> F6P + NADH | mannitol-1-phosphate5-dehydrogenase |
R066 | Fructose and mannose metabolism | VV11978 OR VV20752 | 3.1.3.- | F2P <-> FRU + PI | phosphohistidinephosphatase |
R067 | Fructose and mannose metabolism | VV12826 | 1.1.1.- | S6P + NADP <-> SB1P + NADPH | alcoholdehydrogenase |
R068 | Galactose metabolism | VV11772 | 2.7.1.6 | GLAC + ATP -> GAL1P + ADP | galactokinase |
R069 | Galactose metabolism | VV21094 | 2.7.7.12 | UDPG + GAL1P <-> G1P + UDPGAL | galactose-1-phosphate uridylyltransferase |
R070 | Galactose metabolism | VV11342 OR VV11770 OR VV21095 | 5.1.3.2 | UDPG <-> UDPGAL | UDP-glucose4-epimerase |
R071 | Galactose metabolism | VV11771 | 2.7.7.10 | UTP + GAL1P <-> PPI + UDPGAL | galactose-1-phosphateuridylyltransferase |
R072 | Galactose metabolism | VV11428 | 2.7.7.9 | G1P + UTP <-> UDPG + PPI | UDPglucose-1-phosphate uridylyltransferase |
R073 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | RAF -> GLAC + SUC | alpha-galactosidase |
R074 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | STACHYOSE->RAF+GLAC | alpha-galactosidase |
R075 | Galactose metabolism | VV12890 OR VV21330 OR (VV12227) | 3.2.1.22 OR (3.2.1.20) | MELI -> GLC + GLAC | alpha-galactosidase |
R076 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | EPM <-> MAN + GLAC | alpha-galactosidase |
R077 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | GGL <-> GL + GLAC | alpha-galactosidase |
R078 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | MELT <-> SOT + GLAC | alpha-galactosidase |
R079 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | GALACTINOL -> MI + GLAC | alpha-galactosidase |
R080 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | G6GG -> GLAC + MELI | alpha-galactosidase |
R081 | Galactose metabolism | (VV11766 AND VV11767) OR VV21327 | 3.2.1.23 | LACTOSE -> GLAC + GLC | beta-galactosidase |
R082 | Galactose metabolism | (VV11766 AND VV11767) OR VV21327 | 3.2.1.23 | LACTOSE + PI -> L6P | beta-galactosidase |
R083 | Galactose metabolism | (VV11766 AND VV11767) OR VV21327 | 3.2.1.23 | 3KL <-> 3KBDG + bDGLC | beta-galactosidase |
R084 | Galactose metabolism | VV11257 OR VV21024 | 2.7.1.11 OR 2.7.1.144 | T6P + ATP <-> T16B + ADP | 6-phosphofructokinase |
R085 | Galactose metabolism | VV12826 | 1.1.1.- | 3KBDG + NADP <-> bGLAC + NADPH | alcoholdehydrogenase |
R086 | Ascorbate and aldarate metabolism | VV20869 | 1.2.1.3 | DGLUCL + NAD <-> DGLUCA + NADH | aldehyde dehydrogenase |
R087 | Ascorbate and aldarate metabolism | VV21085 | 5.1.3.22 | LXYLULOSE5P -> LRIBULOSE5P | L-xylulose-5-phosphate3-epimerase |
R088 | Ascorbate and aldarate metabolism | VV21084 | 4.1.1.85 | 3DG6P -> LXYLULOSE5P + CO2 | 3-hexulose-6-phosphatesynthase |
R089 | Ascorbate and aldarate metabolism | VV12826 | 1.1.1.- | 2D3DDX+NAD<->5H24DP+NADH | alcoholdehydrogenase |
R090 | Starch and sucrose metabolism | VV12131 OR VV20214 | 2.7.7.27 | ATP + G1P -> PPI + ADPG | glucose-1-phosphateadenylyltransferase |
R091 | Starch and sucrose metabolism | VV12132 | 2.4.1.21 | ADPG -> ADP + GLYCOGEN | glycogen synthase |
R092 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | GLYCOGEN + PI -> G1P | glucanphosphorylase |
R093 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | MLTPT + PI <-> G1P + MLTTTR | maltodextrin phosphorylase |
R094 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | MLTHX + PI <-> G1P + MLTPT | maltodextrin phosphorylase |
R095 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | MLTHPT + PI <-> G1P + MLTHX | maltodextrin phosphorylase |
R096 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTTR -> GLC + MLTTTR | 4-alpha-glucanotransferase |
R097 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTTTR -> GLC + MLTPT | 4-alpha-glucanotransferase |
R098 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTPT -> GLC + MLTHX | 4-alpha-glucanotransferase |
R099 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTHX -> GLC + MLTHPT | 4-alpha-glucanotransferase |
R100 | Starch and sucrose metabolism | VV20256 | 3.2.1.10 | IMAL -> 2 GLC | glycosidase |
R101 | Starch and sucrose metabolism | VV12227 | 3.2.1.20 | SUC -> GLC + FRU | glycosidases |
R102 | Starch and sucrose metabolism | VV21287 | 3.2.1.21 | CB -> 2 bDGLC | beta-glucosidase |
R103 | Starch and sucrose metabolism | VV10288 | 3.2.1.93 | TRE6P -> GLC + G6P | trehalose-6-phosphate hydrolase |
R104 | Starch and sucrose metabolism | VV20400 OR VV20903 OR VV21622 | 3.2.1.1 | STA -> DEXTRIN + STA | alpha-amylase |
R105 | Aminosugars metabolism | VV10641 | 2.6.1.16 | F6P + GLN -> GLU + GA6P | glucosamine-fructose-6-phosphateaminotransferase |
R106 | Aminosugars metabolism | VV21200 | 3.5.99.6 | GA6P -> NH3 + F6P | glucosamine-6-phosphate isomerase |
R107 | Aminosugars metabolism | VV10180 OR VV20736 | 3.5.1.25 | NAGA6P <-> GA6P + AC | N-acetylglucosamine-6-phosphatedeacetylase |
R108 | Aminosugars metabolism | VV11692 | 5.4.2.10 | GA6P <-> GA1P | phosphomannomutase |
R109 | Aminosugars metabolism | VV11023 | 2.3.1.157 | ACCOA + GA1P -> NAGA1P + COA | glucosamine-1-phosphateN-acetyltransferase |
R110 | Aminosugars metabolism | VV11023 | 2.7.7.23 | UTP + NAGA1P <-> UDPNAG + PPI | UDP-N-acetylglucosaminepyrophosphorylase |
R111 | Aminosugars metabolism | VV10780 | 5.1.3.14 | UDPNAG <-> NADMA + UDP | UDP-N-acetylglucosamine2-epimerase |
R112 | Aminosugars metabolism | VV10780 | 5.1.3.14 | UDPNAG <-> UDPNADMA | UDP-N-acetylglucosamine 2-epimerase |
R113 | Aminosugars metabolism | VV10779 | 1.1.1.- | UDPNADMA + 2 NAD -> UDPNADMAU + 2 NADH | UDP-N-acetyl-D-mannosaminuronatedehydrogenase |
R114 | Aminosugars metabolism | VV20730 | 4.1.3.3 | NANEU <-> NADMA + PYR | N-acetylneuraminate lyase |
R115 | Aminosugars metabolism | VV10808 | 2.5.1.56 | NANEU + PI <-> NADMA + PEP | N-acetylneuraminate synthase |
R116 | Aminosugars metabolism | VV11978 | 3.1.3.- | NADMA + PI <-> NADMA6P | phosphohistidinephosphataseSixA |
R117 | Aminosugars metabolism | VV20735 | 2.7.1.60 | ATP + NADMA -> ADP + NADMA6P | N-acetylmannosaminekinase |
R118 | Aminosugars metabolism | VV20734 | 5.1.3.9 | NAGA6P <-> NADMA6P | N-acetylmannosamine-6-phosphateepimerase |
R119 | Aminosugars metabolism | VV10808 | 2.5.1.56 | NANEU9P + PI <-> NADMA6P + PEP | N-acetylneuraminate synthase |
R120 | Aminosugars metabolism | VV11453 OR VV13018 | 3.1.4.- | NADMA + UDP <-> UDPNADMA | ribonuclease |
R121 | Aminosugars metabolism | VV10679 | 2.5.1.7 | UDPNAG + PEP -> UDPNAGEP + PI | UDP-N-acetylglucosamine enolpyruvyl transferase |
R122 | Aminosugars metabolism | VV11197 | 1.1.1.158 | UDPNAGEP + NADPH -> UDPNAM + NADP | UDP-N-acetylenolpyruvoylglucosamine reductase |
R123 | Aminosugars metabolism | VV10803 | 2.7.7.43 | CTP + NANEU <-> PPI + CMPNANEU | CMP-N-acetylneuraminic acid synthetase |
R124 | Aminosugars metabolism | VV10803 | 2.7.7.43 | CTP + NGNEU <-> PPI + CMPNGNEU | CMP-N-acetylneuraminic acid synthetase |
R125 | Nucleotide sugars metabolism | VV12826 | 1.1.1.- | UDPGAL + 2 NAD -> UDPDGALAC + 2 NADH | alcoholdehydrogenase |
R126 | Nucleotide sugars metabolism | VV12826 | 1.1.1.- | DTDPGLU + 2 NADP -> DTDPDGLUC + 2 NADPH | alcoholdehydrogenase |
R127 | Nucleotide sugars metabolism | VV11342 OR VV11770 OR VV21095 | 5.1.3.2 | DTDPGLU <-> DTDPGLAC | UDP-glucose4-epimerase |
R128 | Pyruvate metabolism | VV20005 | 2.7.9.2 | ATP + PYR -> AMP + PEP + PI | phosphoenolpyruvate synthase |
R129 | Pyruvate metabolism | VV12200 | 1.1.1.28 | PYR + NADH <-> LAC + NAD | D-lactatedehydrogenase |
R130 | Pyruvate metabolism | VV12220 | 2.3.1.8 | ACCOA + PI <-> ACETYLP + COA | phosphateacetyltransferase |
R131 | Pyruvate metabolism | VV11237 OR VV20456 | 6.2.1.1 | AAD + COA <-> AMP + ACCOA | acetyl-CoA synthase |
R132 | Pyruvate metabolism | VV11237 OR VV20456 | 6.2.1.1 | ATP + AC <-> PPI + AAD | acetyl-CoA synthetase |
R133 | Pyruvate metabolism | VV12221 OR VV20148 | 2.7.2.1 | ACETYLP + ADP <-> AC + ATP | acetate kinase |
R134 | Pyruvate metabolism | VV12711 | 3.6.1.7 | ACETYLP -> AC + PI | acylphosphatase |
R135 | Pyruvate metabolism | VV11369 | 4.1.1.31 | PEP + CO2 -> OA + PI | phosphoenolpyruvatecarboxylase |
R136 | Pyruvate metabolism | VV10881 | 4.1.1.49 | OA + ATP <-> PEP + ADP + CO2 | phosphoenolpyruvatecarboxykinase |
R137 | Pyruvate metabolism | VV11361 OR VV12801 | 1.1.1.38 | MAL + NAD <-> PYR + CO2 + NADH | malate dehydrogenase |
R138 | Pyruvate metabolism | VV11600 AND VV11601 AND VV11602 | 4.1.1.3 | MAL + NADP <-> PYR + CO2 + NADPH | oxaloacetate decarboxylase |
R139 | Pyruvate metabolism | VV11600 AND VV11601 AND VV11602 | 4.1.1.3 | OA -> PYR + CO2 | oxaloacetate decarboxylase |
R140 | Pyruvate metabolism | VV12098 | 2.3.1.54 | ACCOA + FORMATE <-> COA + PYR | formateacetyltransferase |
R141 | Pyruvate metabolism | VV10450 | 2.3.3.9 | ACCOA + GLX -> MAL + COA | malatesynthase |
R142 | Pyruvate metabolism | VV20494 OR VV20741 | 2.3.1.9 | 2 ACCOA -> COA + AACCOA | acetyl-CoA acetyltransferase |
R143 | Pyruvate metabolism | VV20123 | 4.2.3.3 | DHAP -> MTG + PI | methylglyoxalsynthase |
R144 | Pyruvate metabolism | VV12016 OR VV13100 | 4.4.1.5 | RGT + MTG <-> LTG | lactoylglutathione lyase |
R145 | Pyruvate metabolism | VV11883 | 3.1.2.6 | LTG -> RGT + LAC | hydroxyacylglutathionehydrolaseGloB |
R146 | Pyruvate metabolism | VV13111 | 1.2.1.10 | ACAL + COA + NAD <-> ACCOA + NADH | acetaldehydedehydrogenase |
R147 | Glyoxylate and dicarboxylate metabolism | VV10449 | 4.1.3.1 | ICIT -> SUCC + GLX | isocitratelyase |
R148 | Glyoxylate and dicarboxylate metabolism | VV12590 AND VV12591 AND VV12592 | 1.2.1.2 | FORMATE+NAD->CO2+NADH | formate dehydrogenase |
R149 | Glyoxylate and dicarboxylate metabolism | VV20216 AND VV20217 | 6.3.4.3 | THF + FORMATE + ATP -> ADP + PI + FTHF | formate-tetrahydrofolate ligase |
R150 | Glyoxylate and dicarboxylate metabolism | 1.2.1.21 | GLAL + NAD -> NADH + GLYCOLATE | glycolaldehyde dehydrogenase | |
R151 | Glyoxylate and dicarboxylate metabolism | VV11306 | 3.1.3.18 | 2PPG -> GLYCOLATE + PI | phosphoglycolate phosphatase |
R152 | Propanoate metabolism | VV21663 | 2.6.1.19 | bALA + AKG <-> 3OPP + GLU | 4-aminobutyrateaminotransferase |
R153 | Propanoate metabolism | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3HPCOA <-> PPCOA | enoyl-CoAhydratase |
R154 | Propanoate metabolism | VV11237 OR VV20456 | 6.2.1.1 OR 6.2.1.17 | ATP + PROPANOATE <-> PPI + PPA | acetyl-CoAsynthetase |
R155 | Propanoate metabolism | VV11237 OR VV20456 | 6.2.1.1 OR 6.2.1.17 | PPA + COA <-> AMP + PPACOA | propionyl-CoA synthetase |
R156 | Propanoate metabolism | VV12221 OR VV20148 | 2.7.2.1 | PROPANOATE + ATP <-> PROPIONYLP + ADP | acetate kinase |
R157 | Propanoate metabolism | VV12220 | 2.3.1.8 | PPACOA + PI <-> PROPIONYLP + COA | phosphate acetyltransferase |
R158 | Propanoate metabolism | VV12098 | 2.3.1.54 | OBUT + COA <-> PPACOA + FORMATE | formateacetyltransferase |
R159 | Propanoate metabolism | VV21457 | 1.1.1.27 | 2HBA + NAD -> OBUT + NADH | L-lactate dehydrogenase |
R160 | Propanoate metabolism | VV20869 | 1.2.1.3 | 2P1A + NAD -> PPN + NADH | aldehydedehydrogenase |
R161 | Propanoate metabolism | VV12731 | 2.3.3.5 | 2MCIT + COA <-> PPACOA + OA | 2-methylcitrate synthase |
R162 | Propanoate metabolism | VV12732 | 4.1.3.30 | 3HB123TC <-> PYR + SUCC | methylisocitrate lyase |
R163 | Propanoate metabolism | VV20493 | 1.2.1.27 | MMSA + COA + NAD -> PPACOA + CO2 + NADH | methylmalonate-semialdehydedehydrogenase |
R164 | Butanoate metabolism | (VV10647 AND VV10648) OR (VV11031 AND VV11032) OR VV11630 OR (VV20469 AND VV20470) | 2.2.1.6 OR 1.2.4.1 | THMPP + PYR -> 2(HE)TPP + CO2 | acetolactatesynthaseORpyruvatedehydrogenase |
R165 | Butanoate metabolism | (VV10647 AND VV10648) OR (VV11031 AND VV11032) | 2.2.1.6 | 2(HE)TPP + PYR -> ACLAC + THMPP | acetolactate synthase |
R166 | Butanoate metabolism | VV10981 OR VV11976 | 1.1.1.35 | 3HBCOA + NAD <-> AACCOA + NADH | 3-hydroxyacyl-CoAdehydrogenase |
R167 | Butanoate metabolism | VV20742 | 1.1.1.36 | R3HBCOA + NADP <-> AACCOA + NADPH | acetoacetyl-CoAreductase |
R168 | Butanoate metabolism | VV10981 OR VV11976 | 5.1.2.3 | 3HBCOA <-> R3HBCOA | 3-hydroxybutyryl-CoAepimerase |
R169 | Butanoate metabolism | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3HBCOA <-> CCOA | enoyl-CoAhydratase |
R170 | Butanoate metabolism | VV13111 | 1.2.1.10 | BUTANAL + COA + NAD -> C040COA + NADH | acetaldehydedehydrogenase |
R171 | Butanoate metabolism | VV12826 | 1.1.1.- | 1BOH + NAD <-> BUTANAL + NADH | alcoholdehydrogenase |
R172 | Butanoate metabolism | VV21266 | 1.2.1.16 | SUCCSA + NAD -> SUCC + NADH | aldehydedehydrogenase |
R173 | Butanoate metabolism | VV21266 | 1.2.1.16 | SUCCSA + NADP -> SUCC + NADPH | aldehydedehydrogenase |
R174 | Butanoate metabolism | VV21663 | 2.6.1.19 | GABA + AKG <-> SUCCSA + GLU | 4-aminobutyrateaminotransferase |
R175 | Butanoate metabolism | VV20499 AND VV20500 | 4.1.3.4 | 3H3MGCOA -> ACCOA + AAC | hydroxymethylglutaryl-CoA lyase |
R176 | Butanoate metabolism | VV20869 | 1.2.1.3 | 3B1A + NAD -> 3BUT + NADH | aldehydedehydrogenase |
R177 | Inositol metabolism | VV20493 | 1.2.1.27 | 3OPP + COA + NAD -> ACCOA + CO2 + NADH | NAD-dependent aldehyde dehydrogenase |
R178 | Oxidative phosphorylation | VV12074 AND VV12075 | 1.6.5.3 AND 1.6.99.3 | NADH + UQ -> NAD + UQH2 | NADH dehydrogenase |
R179 | Oxidative phosphorylation | VV12074 AND VV12075 | 1.6.5.3 AND 1.6.99.3 | NADH + MK -> NAD + MKH2 | NADH dehydrogenase |
R180 | Oxidative phosphorylation | VV12074 AND VV12075 | 1.6.5.3 AND 1.6.99.3 | NADH + DMK -> NAD + DMKH2 | NADH dehydrogenase |
R181 | Oxidative phosphorylation | VV10158 AND VV10159 AND VV10160 AND VV10161 | 1.3.99.1 | FADH2 + UQ -> FAD + UQH2 | succinatedehydrogenase |
R182 | Oxidative phosphorylation | VV10595 AND VV10596 AND VV10597 AND VV12162 AND VV12163 AND VV12617 AND VV12618 AND VV12619 AND VV12620 AND VV20560 AND VV20561 AND VV20565 AND VV20566 AND VV20567 AND VV20568 | 1.9.3.1 AND 1.10.2.2 AND 1.10.3.- | UQH2 + 0.5 O2 -> UQ + 2 Hxt | cytochrome complexes |
R183 | Oxidative phosphorylation | VV10708 OR VV12888 | 3.6.1.1 | PPI -> 2 PI | inorganic diphosphatase |
R184 | ATP synthesis | VV11015 AND VV11016 AND VV11017 AND VV11018 AND VV11019 AND VV11020 AND VV11021 AND VV11022 | 3.6.3.14 | ADP + PI + 4 Hxt <-> ATP | ATP synthase |
R185 | Nitrogen metabolism | VV20190 | 2.1.2.10 | METTHF + NH3 + CO2 + NADH -> GLY + THF + NAD | aminomethyltransferase |
R186 | Nitrogen metabolism | VV11637 OR VV21520 | 4.2.1.1 | CO2 -> H2CO3 | carbonic anhydrase |
R187 | Nitrogen metabolism | VV20398 OR VV20721 | 1.7.99.4 | NO3 + FEROC -> FERIC + NO2 | nitrate reductase |
R188 | Nitrogen metabolism | (VV20369 AND VV20370) OR (VV20389 AND VV20390) | 1.7.1.4 | NO2 + 3 NADH -> 3 NAD + NH3 | nitrite reductase |
R189 | Nitrogen metabolism | (VV20369 AND VV20370) OR (VV20389 AND VV20390) | 1.7.1.4 | NO2 + 3 NADPH -> 3 NADP + NH3 | nitrite reductase |
R190 | Nitrogen metabolism | VV13035 | 1.7.2.2 | NO2 + 6 FEROC -> NH3 + 6 FERIC | formate-dependent nitrite reductase |
R191 | Nitrogen metabolism | VV11249 | 4.3.1.1 | ASP <-> FUM + NH3 | aspartate ammonia-lyase |
R192 | Sulfur metabolism | VV10725 AND VV10726 | 2.7.7.4 | SLF + ATP -> PPI + APS | sulfateadenylyltransferase |
R193 | Sulfur metabolism | VV10723 | 2.7.1.25 | APS + ATP -> ADP + PAPS | adenylylsulfate kinase |
R194 | Sulfur metabolism | VV11404 | 1.8.4.8 | PAPS + RTHIO -> OTHIO + H2SO3 + PAP | 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase) |
R195 | Sulfur metabolism | VV11402 AND VV11403 | 1.8.1.2 | H2SO3 + 3 NADPH -> H2S + 3 NADP | sulfite reductase (NADPH) |
R196 | Sulfur metabolism | 3.1.3.7 | PAP -> PI + AMP | 3',5'-bisphosphate nucleotidase | |
R197 | Sulfur metabolism | VV11402 AND VV11403 | 1.8.1.2 | SELT + 3 NADP -> SELD + 3 NADPH | sulfite reductase (NADPH) |
R198 | Fattyacidbiosynthesis | VV11234 AND VV11235 AND VV11876 AND VV11993 | 6.4.1.2AND 6.3.4.14 | ACCOA + ATP + CO2 -> MALCOA + ADP + PI | acetyl-CoA carboxylase |
R199 | Fattyacidbiosynthesis | VV13010 | 2.3.1.39 | MALCOA + ACP -> MALACP + COA | malonyl CoA-acyl carrier protein transacylase |
R200 | Fattyacidbiosynthesis | VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349 | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 | ACCOA + ACP -> ACACP + COA | 3-oxoacyl-[acyl-carrier-protein] synthase |
Reaction ID | Metabolism | ORF | EC Number | Reaction | Enzyme |
R001 | Glycolysis / Gluconeogenesis | VV11773 | 5.1.3.3 | GLC <-> bDGLC | aldose 1-epimerase |
R002 | Glycolysis / Gluconeogenesis | 2.7.1.2 | GLC + ATP <-> ADP + G6P | glucokinase | |
R003 | Glycolysis / Gluconeogenesis | VV11396 | 5.3.1.9 | G6P <-> bDG6P | glucose-6-phosphate isomerase |
R004 | Glycolysis / Gluconeogenesis | VV11485 OR VV21050 | 3.2.1.86 | A6P-> HQ + bDG6P | 6-phospho-beta-glucosidase |
R005 | Glycolysis / Gluconeogenesis | VV11396 | 5.3.1.9 | G6P <-> F6P | glucose-6-phosphate isomerase |
R006 | Glycolysis / Gluconeogenesis | VV11396 | 5.3.1.9 | bDG6P <-> F6P | glucose-6-phosphate isomerase |
R007 | Glycolysis / Gluconeogenesis | VV10169 | 5.4.2.2 | G6P <-> G1P | phosphoglucomutase |
R008 | Glycolysis / Gluconeogenesis | VV11257 | 2.7.1.11 | F6P + ATP-> FDP + ADP | 6-phosphofructokinase |
R009 | Glycolysis / Gluconeogenesis | VV10707 OR VV11349 | 3.1.3.11 | FDP-> F6P + PI | fructose-bisphosphatase |
R010 | Glycolysis / Gluconeogenesis | VV11541 | 4.1.2.13 | FDP <-> G3P + DHAP | fructose-bisphosphate aldolase |
R011 | Glycolysis / Gluconeogenesis | VV11343 | 5.3.1.1 | DHAP <-> G3P | triosephosphate isomerase |
R012 | Glycolysis / Gluconeogenesis | VV11141 OR VV13140 | 1.2.1.12 | G3P + PI + NAD <-> NADH + 13PDG | glyceraldehyde3-phosphatedehydrogenase |
R013 | Glycolysis / Gluconeogenesis | VV11540 | 2.7.2.3 | 13PDG + ADP <-> 3PG + ATP | phosphoglyceratekinase |
R014 | Glycolysis / Gluconeogenesis | VV12711 | 3.6.1.7 | 13PDG + ADP-> 3PG + ATP | acylphosphatase |
R015 | Glycolysis / Gluconeogenesis | VV11281 | 5.4.2.1 | 3PG <-> 2PG | phosphoglycerate mutase |
R016 | Glycolysis / Gluconeogenesis | VV11579 | 4.2.1.11 | 2PG <-> PEP | enolase |
R017 | Glycolysis / Gluconeogenesis | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | PEP + ADP-> PYR + ATP | pyruvate kinase |
R018 | Glycolysis / Gluconeogenesis | VV21457 | 1.1.1.27 | SLAC + NAD <-> PYR + NADH | L-lactate dehydrogenase |
R019 | Glycolysis / Gluconeogenesis | VV11630 OR (VV20469 AND VV20470) | 1.2.4.1 | PYR + LIPO-> ADLIPO + CO2 | pyruvate dehydrogenase E1 component |
R020 | Glycolysis / Gluconeogenesis | VV11631 AND VV20471 | 2.3.1.12 | COA + ADLIPO-> DLIPO + ACCOA | pyruvate dehydrogenase E2 component (dihydrolipoamideacetyltransferase) |
R021 | Glycolysis / Gluconeogenesis | VV11632 | 1.8.1.4 | DLIPO + NAD-> LIPO + NADH | dihydrolipoamidedehydrogenase |
R022 | Glycolysis / Gluconeogenesis | VV11237 OR VV20456 | 6.2.1.1 | ATP + AC + COA <-> AMP + PPI + ACCOA | acetyl-CoA synthetase |
R023 | Glycolysis / Gluconeogenesis | VV20869 | 1.2.1.3 | ACAL + NAD-> NADH + AC | aldehydedehydrogenase |
R024 | Glycolysis / Gluconeogenesis | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | ACAL + NADH <-> ETH + NAD | alcohol dehydrogenase |
R025 | TCA cycle | VV10162 | 2.3.3.1 | ACCOA + OA-> COA + CIT | citrate synthase |
R026 | TCA cycle | VV12730 OR VV11653 | 4.2.1.3 | CIT <-> ICIT | aconitate hydratase |
R027 | TCA cycle | VV12118 | 1.1.1.42 | ICIT + NADP-> NADPH + AKG + CO2 | isocitrate dehydrogenase |
R028 | TCA cycle | VV10157 | 1.2.4.2 | AKG + LIPO-> SDLIPO + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R029 | TCA cycle | VV10156 | 2.3.1.61 | SDLIPO + COA-> DLIPO + SUCCOA | 2-oxoglutaratedehydrogenaseE2component |
R030 | TCA cycle | VV10154 AND VV10155 | 6.2.1.5 | ADP + PI + SUCCOA <-> ATP + SUCC + COA | succinyl-CoAsynthetase |
R031 | TCA cycle | VV10158 AND VV10159 AND VV10160 AND VV10161 | 1.3.99.1 | SUCC + FAD-> FUM + FADH2 | succinatedehydrogenase |
R032 | TCA cycle | VV11266 AND VV11267 AND VV11268 AND VV11269 | 1.3.99.1 | FUM + MKH2-> SUCC + MK | fumaratereductase |
R033 | TCA cycle | VV11266 AND VV11267 AND VV11268 AND VV11269 | 1.3.99.1 | FUM + DMKH2-> SUCC + DMK | fumaratereductase |
R034 | TCA cycle | VV12266 | 4.2.1.2 | FUM <-> MAL | fumaratehydratase |
R035 | TCA cycle | VV10673 | 1.1.1.37 | MAL + NAD <-> NADH + OA | malatedehydrogenase |
R036 | Pentose phosphate pathway | VV12684 | 1.1.1.49 | G6P + NADP-> D6PGL + NADPH | glucose-6-phosphate1-dehydrogenase |
R037 | Pentose phosphate pathway | VV12684 | 1.1.1.49 | G6P + NAD-> D6PGL + NADH | glucose-6-phosphate 1-dehydrogenase |
R038 | Pentose phosphate pathway | VV12683 | 3.1.1.31 | D6PGL-> D6PGC | 6-phosphogluconolactonase |
R039 | Pentose phosphate pathway | VV12682 | 1.1.1.44 | D6PGC + NADP-> NADPH + CO2 + RL5P | 6-phosphogluconatedehydrogenase |
R040 | Pentose phosphate pathway | VV11386 | 5.1.3.1 | RL5P <-> X5P | ribulose-phosphate3-epimerase |
R041 | Pentose phosphate pathway | VV11547 | 5.3.1.6 | RL5P <-> R5P | ribose 5-phosphate isomerase A |
R042 | Pentose phosphate pathway | VV20065 | 2.7.1.15 | RIB + ATP-> R5P + ADP | ribokinase |
R043 | Pentose phosphate pathway | VV11727 OR VV10169 | 5.4.2.7 OR 5.4.2.2 | R1P <-> R5P | phosphopentomutase |
R044 | Pentose phosphate pathway | VV11537 OR VV20553 | 2.2.1.1 | R5P + X5P <-> G3P + S7P | transketolase |
R045 | Pentose phosphate pathway | VV11537 OR VV20553 | 2.2.1.1 | X5P + E4P <-> F6P + G3P | transketolase |
R046 | Pentose phosphate pathway | VV20552 | 2.2.1.2 | G3P + S7P <-> E4P + F6P | transaldolase |
R047 | Pentose phosphate pathway | VV11725 | 4.1.2.4 | DR5P-> G3P + ACAL | deoxyribose-phosphatealdolase |
R048 | Pentose phosphate pathway | VV20065 | 2.7.1.15 | DRIB + ATP-> DR5P + ADP | ribokinase |
R049 | Pentose phosphate pathway | VV11727 | 5.4.2.7 | DR1P <-> DR5P | phosphopentomutase |
R050 | Pentose phosphate pathway | VV11102 OR VV20904 OR VV21072 | 4.1.2.14 | KDPG-> PYR + G3P | 2-dehydro-3-deoxyphosphogluconate aldolase |
R051 | Pentose phosphate pathway | VV20905 OR VV21071 | 2.7.1.45 | KDG + ATP-> KDPG + ADP | 2-dehydro-3-deoxygluconokinase |
R052 | Pentose phosphate pathway | VV11100 | 2.7.1.12 | GLUC + ATP-> D6PGC + ADP | gluconokinase |
R053 | Pentose phosphate pathway | VV11099 | 4.2.1.12 | D6PGC-> KDPG | phosphogluconate dehydratase |
R054 | Pentose and glucuronate interconversions | VV21070 | 5.3.1.12 | DGALAC-> DTAGA | glucuronateisomerase |
R055 | Pentose and glucuronate interconversions | VV20914 OR VV21093 | 1.1.1.125 | KDG + NAD <-> DDOH + NADH | 2-deoxy-D-gluconate3-dehydrogenase |
R056 | Pentose and glucuronate interconversions | VV21064 | 4.2.1.8 | KDG <-> DMAN | mannonatedehydratase |
R057 | Pentose and glucuronate interconversions | VV21069 | 1.1.1.57 | DMAN + NAD <-> DFRUC + NADH | mannonate oxidoreductase |
R058 | Pentose and glucuronate interconversions | VV21070 | 5.3.1.12 | DGLUC <-> DFRUC | glucuronateisomerase |
R059 | Pentose and glucuronate interconversions | VV10774 | 1.1.1.22 | UDPG + 2 NAD <-> UDPGLUC + 2 NADH | UDPglucose6-dehydrogenase |
R060 | Fructose and mannose metabolism | VV20199 | 2.7.1.56 | F1P + ATP-> FDP + ADP | fructose-1-phosphate kinase |
R061 | Fructose and mannose metabolism | VV11541 | 4.1.2.13 | F1P-> DHAP + T3 | fructose-bisphosphate aldolase |
R062 | Fructose and mannose metabolism | VV20514 OR VV20515 OR VV21348 | 5.3.1.8 | MAN6P <-> F6P | phosphomannoseisomerase |
R063 | Fructose and mannose metabolism | VV11664 OR VV20569 | 5.4.2.8 | MAN6P <-> MAN1P | phosphomannomutase |
R064 | Fructose and mannose metabolism | VV10804 | 2.7.7.13 | GTP + MAN1P <-> PPI + GDPMAN | nucleoside-diphosphate-sugarpyrophosphorylase |
R065 | Fructose and mannose metabolism | VV10639 | 1.1.1.17 | MNT1P + NAD-> F6P + NADH | mannitol-1-phosphate5-dehydrogenase |
R066 | Fructose and mannose metabolism | VV11978 OR VV20752 | 3.1.3.- | F2P <-> FRU + PI | phosphohistidinephosphatase |
R067 | Fructose and mannose metabolism | VV12826 | 1.1.1.- | S6P + NADP <-> SB1P + NADPH | alcoholdehydrogenase |
R068 | Galactose metabolism | VV11772 | 2.7.1.6 | GLAC + ATP-> GAL1P + ADP | galactokinase |
R069 | Galactose metabolism | VV21094 | 2.7.7.12 | UDPG + GAL1P <-> G1P + UDPGAL | galactose-1-phosphate uridylyltransferase |
R070 | Galactose metabolism | VV11342 OR VV11770 OR VV21095 | 5.1.3.2 | UDPG <-> UDPGAL | UDP-glucose4-epimerase |
R071 | Galactose metabolism | VV11771 | 2.7.7.10 | UTP + GAL1P <-> PPI + UDPGAL | galactose-1-phosphateuridylyltransferase |
R072 | Galactose metabolism | VV11428 | 2.7.7.9 | G1P + UTP <-> UDPG + PPI | UDPglucose-1-phosphate uridylyltransferase |
R073 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | RAF-> GLAC + SUC | alpha-galactosidase |
R074 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | STACHYOSE-> RAF + GLAC | alpha-galactosidase |
R075 | Galactose metabolism | VV12890 OR VV21330 OR (VV12227) | 3.2.1.22 OR (3.2.1.20) | MELI-> GLC + GLAC | alpha-galactosidase |
R076 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | EPM <-> MAN + GLAC | alpha-galactosidase |
R077 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | GGL <-> GL + GLAC | alpha-galactosidase |
R078 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | MELT <-> SOT + GLAC | alpha-galactosidase |
R079 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | GALACTINOL-> MI + GLAC | alpha-galactosidase |
R080 | Galactose metabolism | VV12890 OR VV21330 | 3.2.1.22 | G6GG-> GLAC + MELI | alpha-galactosidase |
R081 | Galactose metabolism | (VV11766 AND VV11767) OR VV21327 | 3.2.1.23 | LACTOSE-> GLAC + GLC | beta-galactosidase |
R082 | Galactose metabolism | (VV11766 AND VV11767) OR VV21327 | 3.2.1.23 | LACTOSE + PI-> L6P | beta-galactosidase |
R083 | Galactose metabolism | (VV11766 AND VV11767) OR VV21327 | 3.2.1.23 | 3KL <-> 3KBDG + bDGLC | beta-galactosidase |
R084 | Galactose metabolism | VV11257 OR VV21024 | 2.7.1.11 OR 2.7.1.144 | T6P + ATP <-> T16B + ADP | 6-phosphofructokinase |
R085 | Galactose metabolism | VV12826 | 1.1.1.- | 3KBDG + NADP <-> bGLAC + NADPH | alcoholdehydrogenase |
R086 | Ascorbate and aldarate metabolism | VV20869 | 1.2.1.3 | DGLUCL + NAD <-> DGLUCA + NADH | aldehyde dehydrogenase |
R087 | Ascorbate and aldarate metabolism | VV21085 | 5.1.3.22 | LXYLULOSE5P-> LRIBULOSE5P | L-xylulose-5-phosphate3-epimerase |
R088 | Ascorbate and aldarate metabolism | VV21084 | 4.1.1.85 | 3DG6P-> LXYLULOSE5P + CO2 | 3-hexulose-6-phosphatesynthase |
R089 | Ascorbate and aldarate metabolism | VV12826 | 1.1.1.- | 2D3DDX + NAD <-> 5H24DP + NADH | alcoholdehydrogenase |
R090 | Starch and sucrose metabolism | VV12131 OR VV20214 | 2.7.7.27 | ATP + G1P-> PPI + ADPG | glucose-1-phosphateadenylyltransferase |
R091 | Starch and sucrose metabolism | VV12132 | 2.4.1.21 | ADPG-> ADP + GLYCOGEN | glycogen synthase |
R092 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | GLYCOGEN + PI-> G1P | glucanphosphorylase |
R093 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | MLTPT + PI <-> G1P + MLTTTR | maltodextrin phosphorylase |
R094 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | MLTHX + PI <-> G1P + MLTPT | maltodextrin phosphorylase |
R095 | Starch and sucrose metabolism | VV21250 | 2.4.1.1 | MLTHPT + PI <-> G1P + MLTHX | maltodextrin phosphorylase |
R096 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTTR-> GLC + MLTTTR | 4-alpha-glucanotransferase |
R097 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTTTR-> GLC + MLTPT | 4-alpha-glucanotransferase |
R098 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTPT-> GLC + MLTHX | 4-alpha-glucanotransferase |
R099 | Starch and sucrose metabolism | VV21251 | 2.4.1.25 | MLT + MLTHX-> GLC + MLTHPT | 4-alpha-glucanotransferase |
R100 | Starch and sucrose metabolism | VV20256 | 3.2.1.10 | IMAL-> 2 GLC | glycosidase |
R101 | Starch and sucrose metabolism | VV12227 | 3.2.1.20 | SUC-> GLC + FRU | glycosidases |
R102 | Starch and sucrose metabolism | VV21287 | 3.2.1.21 | CB-> 2 bDGLC | beta-glucosidase |
R103 | Starch and sucrose metabolism | VV10288 | 3.2.1.93 | TRE6P-> GLC + G6P | trehalose-6-phosphate hydrolase |
R104 | Starch and sucrose metabolism | VV20400 OR VV20903 OR VV21622 | 3.2.1.1 | STA-> DEXTRIN + STA | alpha-amylase |
R105 | Aminosugars metabolism | VV10641 | 2.6.1.16 | F6P + GLN-> GLU + GA6P | glucosamine-fructose-6-phosphateaminotransferase |
R106 | Aminosugars metabolism | VV21200 | 3.5.99.6 | GA6P-> NH3 + F6P | glucosamine-6-phosphate isomerase |
R107 | Aminosugars metabolism | VV10180 OR VV20736 | 3.5.1.25 | NAGA6P <-> GA6P + AC | N-acetylglucosamine-6-phosphatedeacetylase |
R108 | Aminosugars metabolism | VV11692 | 5.4.2.10 | GA6P <-> GA1P | phosphomannomutase |
R109 | Aminosugars metabolism | VV11023 | 2.3.1.157 | ACCOA + GA1P-> NAGA1P + COA | glucosamine-1-phosphateN-acetyltransferase |
R110 | Aminosugars metabolism | VV11023 | 2.7.7.23 | UTP + NAGA1P <-> UDPNAG + PPI | UDP-N-acetylglucosaminepyrophosphorylase |
R111 | Aminosugars metabolism | VV10780 | 5.1.3.14 | UDPNAG <-> NADMA + UDP | UDP-N-acetylglucosamine2-epimerase |
R112 | Aminosugars metabolism | VV10780 | 5.1.3.14 | UDPNAG <-> UDPNADMA | UDP-N-acetylglucosamine 2-epimerase |
R113 | Aminosugars metabolism | VV10779 | 1.1.1.- | UDPNADMA + 2 NAD-> UDPNADMAU + 2 NADH | UDP-N-acetyl-D-mannosaminuronatedehydrogenase |
R114 | Aminosugars metabolism | VV20730 | 4.1.3.3 | NANEU <-> NADMA + PYR | N-acetylneuraminate lyase |
R115 | Aminosugars metabolism | VV10808 | 2.5.1.56 | NANEU + PI <-> NADMA + PEP | N-acetylneuraminate synthase |
R116 | Aminosugars metabolism | VV11978 | 3.1.3.- | NADMA + PI <-> NADMA6P | phosphohistidinephosphataseSixA |
R117 | Aminosugars metabolism | VV20735 | 2.7.1.60 | ATP + NADMA-> ADP + NADMA6P | N-acetylmannosaminekinase |
R118 | Aminosugars metabolism | VV20734 | 5.1.3.9 | NAGA6P <-> NADMA6P | N-acetylmannosamine-6-phosphateepimerase |
R119 | Aminosugars metabolism | VV10808 | 2.5.1.56 | NANEU9P + PI <-> NADMA6P + PEP | N-acetylneuraminate synthase |
R120 | Aminosugars metabolism | VV11453 OR VV13018 | 3.1.4.- | NADMA + UDP <-> UDPNADMA | ribonuclease |
R121 | Aminosugars metabolism | VV10679 | 2.5.1.7 | UDPNAG + PEP-> UDPNAGEP + PI | UDP-N-acetylglucosamine enolpyruvyl transferase |
R122 | Aminosugars metabolism | VV11197 | 1.1.1.158 | UDPNAGEP + NADPH-> UDPNAM + NADP | UDP-N-acetylenolpyruvoylglucosamine reductase |
R123 | Aminosugars metabolism | VV10803 | 2.7.7.43 | CTP + NANEU <-> PPI + CMPNANEU | CMP-N-acetylneuraminic acid synthetase |
R124 | Aminosugars metabolism | VV10803 | 2.7.7.43 | CTP + NGNEU <-> PPI + CMPNGNEU | CMP-N-acetylneuraminic acid synthetase |
R125 | Nucleotide sugars metabolism | VV12826 | 1.1.1.- | UDPGAL + 2 NAD-> UDPDGALAC + 2 NADH | alcoholdehydrogenase |
R126 | Nucleotide sugars metabolism | VV12826 | 1.1.1.- | DTDPGLU + 2 NADP-> DTDPDGLUC + 2 NADPH | alcoholdehydrogenase |
R127 | Nucleotide sugars metabolism | VV11342 OR VV11770 OR VV21095 | 5.1.3.2 | DTDPGLU <-> DTDPGLAC | UDP-glucose4-epimerase |
R128 | Pyruvate metabolism | VV20005 | 2.7.9.2 | ATP + PYR-> AMP + PEP + PI | phosphoenolpyruvate synthase |
R129 | Pyruvate metabolism | VV12200 | 1.1.1.28 | PYR + NADH <-> LAC + NAD | D-lactatedehydrogenase |
R130 | Pyruvate metabolism | VV12220 | 2.3.1.8 | ACCOA + PI <-> ACETYLP + COA | phosphateacetyltransferase |
R131 | Pyruvate metabolism | VV11237 OR VV20456 | 6.2.1.1 | AAD + COA <-> AMP + ACCOA | acetyl-CoA synthase |
R132 | Pyruvate metabolism | VV11237 OR VV20456 | 6.2.1.1 | ATP + AC <-> PPI + AAD | acetyl-CoA synthetase |
R133 | Pyruvate metabolism | VV12221 OR VV20148 | 2.7.2.1 | ACETYLP + ADP <-> AC + ATP | acetate kinase |
R134 | Pyruvate metabolism | VV12711 | 3.6.1.7 | ACETYLP-> AC + PI | acylphosphatase |
R135 | Pyruvate metabolism | VV11369 | 4.1.1.31 | PEP + CO2-> OA + PI | phosphoenolpyruvatecarboxylase |
R136 | Pyruvate metabolism | VV10881 | 4.1.1.49 | OA + ATP <-> PEP + ADP + CO2 | phosphoenolpyruvatecarboxykinase |
R137 | Pyruvate metabolism | VV11361 OR VV12801 | 1.1.1.38 | MAL + NAD <-> PYR + CO2 + NADH | malate dehydrogenase |
R138 | Pyruvate metabolism | VV11600 AND VV11601 AND VV11602 | 4.1.1.3 | MAL + NADP <-> PYR + CO2 + NADPH | oxaloacetate decarboxylase |
R139 | Pyruvate metabolism | VV11600 AND VV11601 AND VV11602 | 4.1.1.3 | OA-> PYR + CO2 | oxaloacetate decarboxylase |
R140 | Pyruvate metabolism | VV12098 | 2.3.1.54 | ACCOA + FORMATE <-> COA + PYR | formateacetyltransferase |
R141 | Pyruvate metabolism | VV10450 | 2.3.3.9 | ACCOA + GLX-> MAL + COA | malatesynthase |
R142 | Pyruvate metabolism | VV20494 OR VV20741 | 2.3.1.9 | 2 ACCOA-> COA + AACCOA | acetyl-CoA acetyltransferase |
R143 | Pyruvate metabolism | VV20123 | 4.2.3.3 | DHAP-> MTG + PI | methylglyoxalsynthase |
R144 | Pyruvate metabolism | VV12016 OR VV13100 | 4.4.1.5 | RGT + MTG <-> LTG | lactoylglutathione lyase |
R145 | Pyruvate metabolism | VV11883 | 3.1.2.6 | LTG-> RGT + LAC | hydroxyacylglutathionehydrolaseGloB |
R146 | Pyruvate metabolism | VV13111 | 1.2.1.10 | ACAL + COA + NAD <-> ACCOA + NADH | acetaldehydedehydrogenase |
R147 | Glyoxylate and dicarboxylate metabolism | VV10449 | 4.1.3.1 | ICIT-> SUCC + GLX | isocitratelyase |
R148 | Glyoxylate and dicarboxylate metabolism | VV12590 AND VV12591 AND VV12592 | 1.2.1.2 | FORMATE + NAD-> CO2 + NADH | formate dehydrogenase |
R149 | Glyoxylate and dicarboxylate metabolism | VV20216 AND VV20217 | 6.3.4.3 | THF + FORMATE + ATP-> ADP + PI + FTHF | formate-tetrahydrofolate ligase |
R150 | Glyoxylate and dicarboxylate metabolism | 1.2.1.21 | GLAL + NAD-> NADH + GLYCOLATE | glycolaldehyde dehydrogenase | |
R151 | Glyoxylate and dicarboxylate metabolism | VV11306 | 3.1.3.18 | 2PPG-> GLYCOLATE + PI | phosphoglycolate phosphatase |
R152 | Propanoate metabolism | VV21663 | 2.6.1.19 | bALA + AKG <-> 3OPP + GLU | 4-aminobutyrateaminotransferase |
R153 | Propanoate metabolism | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3HPCOA <-> PPCOA | enoyl-CoAhydratase |
R154 | Propanoate metabolism | VV11237 OR VV20456 | 6.2.1.1 OR 6.2.1.17 | ATP + PROPANOATE <-> PPI + PPA | acetyl-CoAsynthetase |
R155 | Propanoate metabolism | VV11237 OR VV20456 | 6.2.1.1 OR 6.2.1.17 | PPA + COA <-> AMP + PPACOA | propionyl-CoA synthetase |
R156 | Propanoate metabolism | VV12221 OR VV20148 | 2.7.2.1 | PROPANOATE + ATP <-> PROPIONYLP + ADP | acetate kinase |
R157 | Propanoate metabolism | VV12220 | 2.3.1.8 | PPACOA + PI <-> PROPIONYLP + COA | phosphate acetyltransferase |
R158 | Propanoate metabolism | VV12098 | 2.3.1.54 | OBUT + COA <-> PPACOA + FORMATE | formateacetyltransferase |
R159 | Propanoate metabolism | VV21457 | 1.1.1.27 | 2HBA + NAD-> OBUT + NADH | L-lactate dehydrogenase |
R160 | Propanoate metabolism | VV20869 | 1.2.1.3 | 2P1A + NAD-> PPN + NADH | aldehydedehydrogenase |
R161 | Propanoate metabolism | VV12731 | 2.3.3.5 | 2MCIT + COA <-> PPACOA + OA | 2-methylcitrate synthase |
R162 | Propanoate metabolism | VV12732 | 4.1.3.30 | 3HB123TC <-> PYR + SUCC | methylisocitrate lyase |
R163 | Propanoate metabolism | VV20493 | 1.2.1.27 | MMSA + COA + NAD-> PPACOA + CO2 + NADH | methylmalonate-semialdehydedehydrogenase |
R164 | Butanoate metabolism | (VV10647 AND VV10648) OR (VV11031 AND VV11032) OR VV11630 OR (VV20469 AND VV20470) | 2.2.1.6 OR 1.2.4.1 | THMPP + PYR-> 2 (HE) TPP + CO2 | acetolactatesynthaseORpyruvatedehydrogenase |
R165 | Butanoate metabolism | (VV10647 AND VV10648) OR (VV11031 AND VV11032) | 2.2.1.6 | 2 (HE) TPP + PYR-> ACLAC + THMPP | acetolactate synthase |
R166 | Butanoate metabolism | VV10981 OR VV11976 | 1.1.1.35 | 3HBCOA + NAD <-> AACCOA + NADH | 3-hydroxyacyl-CoAdehydrogenase |
R167 | Butanoate metabolism | VV20742 | 1.1.1.36 | R3HBCOA + NADP <-> AACCOA + NADPH | acetoacetyl-CoAreductase |
R168 | Butanoate metabolism | VV10981 OR VV11976 | 5.1.2.3 | 3HBCOA <-> R3HBCOA | 3-hydroxybutyryl-CoAepimerase |
R169 | Butanoate metabolism | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3HBCOA <-> CCOA | enoyl-CoAhydratase |
R170 | Butanoate metabolism | VV13111 | 1.2.1.10 | BUTANAL + COA + NAD-> C040COA + NADH | acetaldehydedehydrogenase |
R171 | Butanoate metabolism | VV12826 | 1.1.1.- | 1BOH + NAD <-> BUTANAL + NADH | alcoholdehydrogenase |
R172 | Butanoate metabolism | VV21266 | 1.2.1.16 | SUCCSA + NAD-> SUCC + NADH | aldehydedehydrogenase |
R173 | Butanoate metabolism | VV21266 | 1.2.1.16 | SUCCSA + NADP-> SUCC + NADPH | aldehydedehydrogenase |
R174 | Butanoate metabolism | VV21663 | 2.6.1.19 | GABA + AKG <-> SUCCSA + GLU | 4-aminobutyrateaminotransferase |
R175 | Butanoate metabolism | VV20499 AND VV20500 | 4.1.3.4 | 3H3MGCOA-> ACCOA + AAC | hydroxymethylglutaryl-CoA lyase |
R176 | Butanoate metabolism | VV20869 | 1.2.1.3 | 3B1A + NAD-> 3BUT + NADH | aldehydedehydrogenase |
R177 | Inositol metabolism | VV20493 | 1.2.1.27 | 3OPP + COA + NAD-> ACCOA + CO2 + NADH | NAD-dependent aldehyde dehydrogenase |
R178 | Oxidative phosphorylation | VV12074 AND VV12075 | 1.6.5.3 AND 1.6.99.3 | NADH + UQ-> NAD + UQH2 | NADH dehydrogenase |
R179 | Oxidative phosphorylation | VV12074 AND VV12075 | 1.6.5.3 AND 1.6.99.3 | NADH + MK-> NAD + MKH2 | NADH dehydrogenase |
R180 | Oxidative phosphorylation | VV12074 AND VV12075 | 1.6.5.3 AND 1.6.99.3 | NADH + DMK-> NAD + DMKH2 | NADH dehydrogenase |
R181 | Oxidative phosphorylation | VV10158 AND VV10159 AND VV10160 AND VV10161 | 1.3.99.1 | FADH2 + UQ-> FAD + UQH2 | succinatedehydrogenase |
R182 | Oxidative phosphorylation | VV10595 AND VV10596 AND VV10597 AND VV12162 AND VV12163 AND VV12617 AND VV12618 AND VV12619 AND VV12620 AND VV20560 AND VV20561 AND VV20565 AND VV20566 AND VV20567 AND VV20568 | 1.9.3.1 AND 1.10.2.2 AND 1.10.3.- | UQH2 + 0.5 O2-> UQ + 2 Hxt | cytochrome complexes |
R183 | Oxidative phosphorylation | VV10708 OR VV12888 | 3.6.1.1 | PPI-> 2 PI | inorganic diphosphatase |
R184 | ATP synthesis | VV11015 AND VV11016 AND VV11017 AND VV11018 AND VV11019 AND VV11020 AND VV11021 AND VV11022 | 3.6.3.14 | ADP + PI + 4 Hxt <-> ATP | ATP synthase |
R185 | Nitrogen metabolism | VV20190 | 2.1.2.10 | METTHF + NH3 + CO2 + NADH-> GLY + THF + NAD | aminomethyltransferase |
R186 | Nitrogen metabolism | VV11637 OR VV21520 | 4.2.1.1 | CO2-> H2CO3 | carbonic anhydrase |
R187 | Nitrogen metabolism | VV20398 OR VV20721 | 1.7.99.4 | NO3 + FEROC-> FERIC + NO2 | nitrate reductase |
R188 | Nitrogen metabolism | (VV20369 AND VV20370) OR (VV20389 AND VV20390) | 1.7.1.4 | NO2 + 3 NADH-> 3 NAD + NH3 | nitrite reductase |
R189 | Nitrogen metabolism | (VV20369 AND VV20370) OR (VV20389 AND VV20390) | 1.7.1.4 | NO2 + 3 NADPH-> 3 NADP + NH3 | nitrite reductase |
R190 | Nitrogen metabolism | VV13035 | 1.7.2.2 | NO2 + 6 FEROC-> NH3 + 6 FERIC | formate-dependent nitrite reductase |
R191 | Nitrogen metabolism | VV11249 | 4.3.1.1 | ASP <-> FUM + NH3 | aspartate ammonia-lyase |
R192 | Sulfur metabolism | VV10725 AND VV10726 | 2.7.7.4 | SLF + ATP-> PPI + APS | sulfateadenylyltransferase |
R193 | Sulfur metabolism | VV10723 | 2.7.1.25 | APS + ATP-> ADP + PAPS | adenylylsulfate kinase |
R194 | Sulfur metabolism | VV11404 | 1.8.4.8 | PAPS + RTHIO-> OTHIO + H2SO3 + PAP | 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase) |
R195 | Sulfur metabolism | VV11402 AND VV11403 | 1.8.1.2 | H2SO3 + 3 NADPH-> H2S + 3 NADP | sulfite reductase (NADPH) |
R196 | Sulfur metabolism | 3.1.3.7 | PAP-> PI + AMP | 3 ', 5'-bisphosphate nucleotidase | |
R197 | Sulfur metabolism | VV11402 AND VV11403 | 1.8.1.2 | SELT + 3 NADP-> SELD + 3 NADPH | sulfite reductase (NADPH) |
R198 | Fattyacidbiosynthesis | VV11234 AND VV11235 AND VV11876 AND VV11993 | 6.4.1.2 AND 6.3.4.14 | ACCOA + ATP + CO2-> MALCOA + ADP + PI | acetyl-CoA carboxylase |
R199 | Fattyacidbiosynthesis | VV13010 | 2.3.1.39 | MALCOA + ACP-> MALACP + COA | malonyl CoA-acyl carrier protein transacylase |
R200 | Fattyacidbiosynthesis | VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349 | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 | ACCOA + ACP-> ACACP + COA | 3-oxoacyl- [acyl-carrier-protein] synthase |
표 4
Table 4
R201 | Fattyacidbiosynthesis | PPACOA + ACP -> PPAACP + COA | malonyl CoA-acyl carrier protein transacylase | ||
R202 | Fattyacidbiosynthesis (nonanoic acid; c9:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP+3MALACP+6NADPH->6NADP+C090ACP+3CO2+3ACP | synthesis of nonanoyl-[acyl-carrier protein] |
R203 | Fattyacidbiosynthesis (decanoic acid; c10:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP+4MALACP+8NADPH->8NADP+C100ACP+4CO2+4ACP | synthesis of decanoyl-[acyl-carrier protein] |
R204 | Fattyacidbiosynthesis (undecanoic acid; c11:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP+4MALACP+8NADPH->8NADP+C110ACP+4CO2+4ACP | synthesis of undecanoyl-[acyl-carrier protein] |
R205 | Fattyacidbiosynthesis (dodecanoic acid; c12:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP+5MALACP+10NADPH->10NADP+C120ACP+5CO2+5ACP | synthesis of dodecanoyl-[acyl-carrier protein] |
R206 | Fattyacidbiosynthesis (tridecanoic acid; c13:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP+5MALACP+10NADPH->10NADP+C130ACP+5CO2+5ACP | synthesis of tridecanoyl-[acyl-carrier protein] |
R207 | Fattyacidbiosynthesis (tetradecanoic acid; c14:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 6 MALACP + 12 NADPH -> 12 NADP + C140ACP + 6 CO2 + 6 ACP | synthesis of tetradecanoyl-[acyl-carrier protein] |
R208 | Fattyacidbiosynthesis (pentadecanoic acid; c15:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 6 MALACP + 12 NADPH -> 12 NADP + C150ACP + 6 CO2 + 6 ACP | synthesis of pentadecanoyl-[acyl-carrier protein] |
R209 | Fattyacidbiosynthesis (pentadecenoic acid; c15:1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 6 MALACP + 11 NADPH -> 11 NADP + C151ACP + 6 CO2 + 6 ACP | synthesis of pentadecenoyl-[acyl-carrier protein] |
R210 | Fattyacidbiosynthesis (hexadecanoic acid; c16:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 7 MALACP + 14 NADPH -> 14 NADP + C160ACP + 7 CO2 + 7 ACP | synthesis of hexadecanoyl-[acyl-carrier protein] |
R211 | Fattyacidbiosynthesis (hexadecenoic acid; c16:1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP+7MALACP+13NADPH->13NADP+C161ACP+7CO2 + 7 ACP | synthesis of hexadecenoyl-[acyl-carrier protein] |
R212 | Fattyacidbiosynthesis (heptadecanoic acid; c17:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 7 MALACP + 14 NADPH -> 14 NADP + C170ACP + 7 CO2 + 7 ACP | synthesis of heptadecanoyl-[acyl-carrier protein] |
R213 | Fattyacidbiosynthesis (heptadecenoic acid; c17:1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 7 MALACP + 13 NADPH -> 13 NADP + C171ACP + 7 CO2 + 7 ACP | synthesis of heptadecenoyl-[acyl-carrier protein] |
R214 | Fattyacidbiosynthesis (octadecanoic acid; c18:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP+8MALACP+16NADPH->16NADP+C180ACP+8CO2+8ACP | synthesis of octadecanoyl-[acyl-carrier protein] |
R215 | Fattyacidbiosynthesis (octadecenoic acid; c18:1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 8 MALACP + 15 NADPH -> 15 NADP + C181ACP + 8 CO2 + 8 ACP | synthesis of octadecenoyl-[acyl-carrier protein] |
R216 | Fattyacidbiosynthesis (nonadecanoic acid; c19:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 8 MALACP + 16 NADPH -> 16 NADP + C190ACP + 8 CO2 + 8 ACP | synthesis of nonadecanoyl-[acyl-carrier protein] |
R217 | Fattyacidbiosynthesis (nonadecenoic acid; c19:1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 8 MALACP + 15 NADPH -> 15 NADP + C191ACP + 8 CO2 + 8 ACP | synthesis of nonadecenoyl-[acyl-carrier protein] |
R218 | Fattyacidbiosynthesis (eicosanoic acid; c20:0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP+9MALACP+18NADPH->18NADP+C200ACP+9CO2+9ACP | synthesis of eicosanoyl-[acyl-carrier protein] |
R219 | Fattyacidmetabolism (dodecanoic acid; c12:0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C120 + 6 COA + 5 FAD + 5 NAD + ATP -> 6 ACCOA + 5 FADH2 + 5 NADH + AMP + PPI | oxidation of dodecanoic acid |
R220 | Fattyacidmetabolism (tetradecanoic acid; c14:0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C140 + 7 COA + 6 FAD + 6 NAD + ATP -> 7 ACCOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of tetradecanoic acid |
R221 | Fattyacidmetabolism (pentadecanoic acid; c15:0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C150+7COA+6FAD+6NAD+ ATP -> 6 ACCOA + PPACOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of pentadecanoic acid |
R222 | Fattyacidmetabolism (hexadecanoic acid; c16:0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C160 + 8 COA + 7 FAD + 7 NAD + ATP -> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecanoic acid |
R223 | Fattyacidmetabolism (hexadecenoic acid; c16:1) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C161 + 8 COA + 7 FAD + 7 NAD + ATP -> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecenoic acid |
R224 | Fattyacidmetabolism (octadecanoic acid; c18:0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C180 + 9 COA + 8 FAD + 8 NAD + ATP -> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecanoic acid |
R225 | Fattyacidmetabolism (octadecenoic acid; c18:1) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C181 + 9 COA + 8 FAD + 8 NAD + ATP -> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecenoic acid |
R226 | Biosynthesis of steroids | VV10315 | 2.2.1.7 | PYR + G3P -> DX5P + CO2 | 1-deoxy-D-xylulose-5-phosphate synthase |
R227 | Biosynthesis of steroids | VV11866 | 1.1.1.267 | DX5P + NADPH -> MDE4P + NADP | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
R228 | Biosynthesis of steroids | VV11582 | 2.7.7.60 | MDE4P + CTP -> CDPMDE + PPI | 4-diphosphocytidyl-2-methyl-D-erythritol synthase |
R229 | Biosynthesis of steroids | VV10256 | 2.7.1.148 | CDPMDE + ATP -> 2PCDPMDE + ADP | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase |
R230 | Biosynthesis of steroids | VV11583 | 4.6.1.12 | 2PCDPMDE -> MDECPP + CMP | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase |
R231 | Biosynthesis of steroids | VV10427 | 1.17.4.3 | MDECPP + NADH -> NAD + HMB4PP | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase |
R232 | Biosynthesis of steroids | VV10504 | 1.17.1.2 | HMB4PP + NADH -> NAD + IPP | 4-hydroxy-3-methylbut-2-enyl diphosphate reductase |
R233 | Biosynthesis of steroids | 5.3.3.2 | IPP <-> DMPP | isopentenyl-diphosphate D-isomerase | |
R234 | Biosynthesis of steroids | VV10314 | 2.5.1.10 | DMPP + IPP -> GPP + PPI | geranylgeranyl pyrophosphate synthase |
R235 | Biosynthesis of steroids | VV10314 | 2.5.1.10 | GPP + IPP -> FPP + PPI | geranylgeranyl pyrophosphate synthase |
R236 | Biosynthesis of steroids | VV20117 | 1.1.1.34 | 3H3MGCOA + 2 NADPH -> MVLN + COA + 2 NADP | 3-hydroxy-3-methylglutaryl-CoA reductase |
R237 | Biosynthesis of steroids | 2.5.1.29 | FPP + IPP -> GGPP + PPI | farnesyltranstransferase | |
R238 | Biosynthesis of steroids | GGPP + IPP -> PPPP + PPI | dimethylallyltranstransferase | ||
R239 | Biosynthesis of steroids | 2.5.1.33 | PPPP + IPP -> HPPP + PPI | trans-pentaprenyltranstransferase | |
R240 | Biosynthesis of steroids | 2.5.1.30 | HPPP + IPP -> HEPPP + PPI | trans-hexaprenyltranstransferase | |
R241 | Biosynthesis of steroids | HEPPP + IPP -> OPP + PPI | trans-hexaprenyltranstransferase | ||
R242 | Glycerolipid metabolism | VV11654 | 2.7.1.31 | 3PG + ADP <-> DGLYCERATE + ATP | glycerate kinase |
R243 | Glycerolipid metabolism | VV20869 | 1.2.1.3 | NADH + DGLYCERATE <-> T3 + NAD | aldehydedehydrogenase |
R244 | Glycerolipid metabolism | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | T3 + NADH <-> GL + NAD | alcohol dehydrogenase |
R245 | Glycerolipid metabolism | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | T3 + NADPH <-> GL + NADP | alcohol dehydrogenase |
R246 | Glycerolipid metabolism | VV11787 | 2.7.1.30 | GL + ATP -> GL3P + ADP | glycerolkinase |
R247 | Glycerolipid metabolism | VV12349 | 3.1.1.3 | DGR -> AGL + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | triacylglycerol lipase |
R248 | Glycerolipid metabolism | VV12349 | 3.1.1.3 | TGL -> DGR + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | triacylglycerol lipase |
R249 | Glycerophospholipid metabolism | VV11277 | 1.1.1.94 | DHAP + NADH -> GL3P + NAD | glycerol-3-phosphate dehydrogenase |
R250 | Glycerophospholipid metabolism | VV11277 | 1.1.1.94 | DHAP + NADPH -> GL3P + NADP | glycerol-3-phosphate dehydrogenase |
R251 | Glycerophospholipid metabolism | VV11785 OR (VV20010 AND VV20011 AND VV20012) | 1.1.99.5 | DHAP + UQH2 <-> GL3P + UQ | glycerol-3-phosphatedehydrogenase |
R252 | Glycerophospholipid metabolism | VV11785 OR (VV20010 AND VV20011 AND VV20012) | 1.1.99.5 | DHAP + MKH2 <-> GL3P + MK | glycerol-3-phosphatedehydrogenase |
R253 | Glycerophospholipid metabolism | VV11785 OR (VV20010 AND VV20011 AND VV20012) | 1.1.99.5 | DHAP + DMKH2 <-> GL3P + DMK | glycerol-3-phosphatedehydrogenase |
R254 | Glycerophospholipid metabolism | VV11374 OR VV21136 OR VV21651 | 2.3.1.- | GL3P + ACOA -> 2AGL3P + COA | acetyltransferase |
R255 | Glycerophospholipid metabolism | VV11165 | 2.3.1.15 | GL3P+ 0.052 C120ACP + 0.182 C140ACP + 0.05 C150ACP + 0.39 C160ACP + 0.24 C161ACP + 0.01 C180ACP + 0.076 C181ACP -> AGL3P + ACP | glycerol-3-phosphate O-acyltransferase |
R256 | Glycerophospholipid metabolism | VV10678 OR VV12699 | 2.3.1.51 | AGL3P + 0.052 C120ACP + 0.182 C140ACP + 0.05 C150ACP + 0.39 C160ACP + 0.24 C161ACP + 0.01 C180ACP + 0.076 C181ACP -> PA + ACP | 1-acylglycerol-3-phosphate O-acyltransferase |
R257 | Glycerophospholipid metabolism | VV10815 OR VV21412 | 2.7.1.107 | DGR + ATP -> ADP + PA | diacylglycerol kinase |
R258 | Glycerophospholipid metabolism | VV12799 | 3.1.1.32 | PC -> 2AG3PC + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | phospholipase |
R259 | Glycerophospholipid metabolism | VV12754 OR VV20407 | 3.1.4.46 | G3PC -> CHOLINE + GL3P | glycerophosphoryl diester phosphodiesterase |
R260 | Glycerophospholipid metabolism | VV11865 | 2.7.7.41 | PA + CTP <-> CDPDG + PPI | phosphatidate cytidylyltransferase |
R261 | Glycerophospholipid metabolism | VV11195 | 2.7.8.8 | CDPDG + SER <-> CMP + PS | phosphatidylserine synthase |
R262 | Glycerophospholipid metabolism | VV12799 | 3.1.1.32 | PS->2AG3PS+ 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | phospholipase |
R263 | Glycerophospholipid metabolism | VV11284 | 4.1.1.65 | PS -> PE + CO2 | phosphatidylserinedecarboxylase |
R264 | Glycerophospholipid metabolism | VV12799 | 3.1.1.32 | PE->2AG3PE+ 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | phospholipase |
R265 | Glycerophospholipid metabolism | VV12754 OR VV20407 | 3.1.4.46 | G3PE -> ETHA + GL3P | glycerophosphoryl diester phosphodiesterase |
R266 | Glycerophospholipid metabolism | VV13052 | 2.7.8.5 | CDPDG + GL3P <-> CMP + PGP | CDP-diacylglycerol--glycerol-3-phosphate3-phosphatidyltransferase |
R267 | Glycerophospholipid metabolism | VV10316 OR VV21432 | 3.1.3.27 | PGP -> PI + PG | phosphatidylglycerophosphatase |
R268 | Glycerophospholipid metabolism | VV12871 | 2.7.8.- | CDPDG + PG -> CMP + CL | cardiolipin synthase |
R269 | Purinemetabolism | VV10257 | 2.7.6.1 | R5P + ATP <-> PRPP + AMP | ribose-phosphate pyrophosphokinase |
R270 | Purine metabolism (De novo) | VV11997 | 2.4.2.14 | PRPP + GLN -> PRAM + PPI + GLU | amidophosphoribosyltransferase |
R271 | Purine metabolism (De novo) | VV11226 | 6.3.4.13 | PRAM + ATP + GLY <-> GAR + ADP + PI | phosphoribosylamine-glycine ligase |
R272 | Purine metabolism (De novo) | VV11899 | 2.1.2.2 | GAR + FTHF -> FGAR + THF | phosphoribosylglycinamideformyltransferase |
R273 | Purine metabolism (De novo) | VV10340 | 6.3.5.3 | FGAR + ATP + GLN -> FGAM + GLU + ADP + PI | phosphoribosylformylglycinamidine synthase |
R274 | Purine metabolism (De novo) | VV11900 | 6.3.3.1 | FGAM + ATP -> AIR + ADP + PI | phosphoribosylformylglycinamidine cyclo-ligase |
R275 | Purine metabolism (De novo) | VV11053 AND VV11054 | 4.1.1.21 | AIR + CO2 + ATP -> CAIR + ADP + PI | phosphoribosylaminoimidazolecarboxylase |
R276 | Purine metabolism (De novo) | VV12797 | 6.3.2.6 | CAIR + ATP + ASP <-> SAICAR + ADP + PI | phosphoribosylaminoimidazole-succinocarboxamide synthase |
R277 | Purine metabolism (De novo) | VV12928 | 4.3.2.2 | SAICAR <-> AICAR + FUM | adenylosuccinatelyase |
R278 | Purine metabolism (De novo) | VV11227 | 2.1.2.3 | AICAR + FTHF <-> PRFICA + THF | phosphoribosylaminoimidazolecarboxamide formyltransferase |
R279 | Purine metabolism (De novo) | VV11227 | 2.1.2.3 | PRFICA <-> IMP | phosphoribosylaminoimidazolecarboxamide formyltransferase; IMP cyclohydrolase |
R280 | Purine metabolism (De novo) | VV11299 OR VV20768 | 6.3.4.4 | IMP + GTP + ASP -> ASUC + GDP + PI | adenylosuccinatesynthase |
R281 | Purine metabolism (De novo) | VV12928 | 4.3.2.2 | ASUC <-> FUM + AMP | adenylosuccinatelyase |
R282 | Purine metabolism (De novo) | VV10419 | 1.1.1.205 | IMP + NAD -> XMP + NADH | IMP dehydrogenase |
R283 | Purine metabolism (De novo) | VV10418 | 6.3.5.2 | XMP + ATP + GLN -> GMP + GLU + AMP + PPI | GMPsynthase |
R284 | Purine metabolism | VV20712 | 1.7.1.7 | GMP + NADPH -> IMP + NH3 + NADP | GMP reductase |
R285 | Purine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cAMP -> 3AMP | 2',3'-cyclic-nucleotide2'-phosphodiesterase |
R286 | Purine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cGMP -> 3GMP | 2',3'-cyclic-nucleotide2'-phosphodiesterase |
R287 | Purine metabolism | VV12924 OR VV20218 | 2.7.1.73 | ATP + INS <-> ADP + IMP | inosinekinase |
R288 | Purine metabolism | VV12924 OR VV20218 | 2.7.1.73 | ATP + GSN <-> ADP + GMP | guanosine kinase |
R289 | Purine metabolism | VV20468 | 3.5.4.4 | ADN -> INS + NH3 | adenosinedeaminase |
R290 | Purine metabolism | VV20468 | 3.5.4.4 | DA <-> DIN + NH3 | adenosine deaminase |
R291 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | IMP -> INS + PI | 5'-nucleotidase |
R292 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | AMP -> ADN + PI | 5'-nucleotidase |
R293 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | XMP -> XTSINE + PI | 5'-nucleotidase |
R294 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | GMP -> GSN + PI | 5'-nucleotidase |
R295 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DAMP <-> DA + PI | 5'-nucleotidase |
R296 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DGMP <-> DG + PI | 5'-nucleotidase |
R297 | Purine metabolism | VV11726 | 2.4.2.4 | DIN + PI -> HYXN + DR1P | thymidinephosphorylase |
R298 | Purine metabolism | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | DATP + PYR <-> DADP + PEP | pyruvatekinase |
R299 | Purine metabolism | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | GTP + PYR <-> GDP + PEP | pyruvatekinase |
R300 | Purine metabolism | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | DGDP + PEP -> DGTP + PYR | pyruvatekinase |
R301 | Purine metabolism | VV11123 | 4.6.1.1 | ATP -> cAMP + PPI | adenylatecyclase |
R302 | Purine metabolism | VV11123 | 4.6.1.1 | GTP -> cGMP + PPI | adenylatecyclase |
R303 | Purine metabolism | VV10850 | 2.7.4.8 | DGMP + ATP <-> DGDP + ADP | guanylatekinase |
R304 | Purine metabolism | VV10430 | 2.7.4.6 | IDP + ATP <-> ITP + ADP | nucleoside-diphosphate kinase |
R305 | Purine metabolism | VV10430 | 2.7.4.6 | ATP + DIDP <-> ADP + DITP | nucleoside-diphosphatekinase |
R306 | Purine metabolism | VV12002 | 2.4.2.7 | AICAR + PPI <-> 5A4IC + PRPP | adenine phosphoribosyltransferase |
R307 | Purine metabolism | VV12002 | 2.4.2.7 | AD+PRPP->PPI+AMP | adenine phosphoribosyltransferase |
R308 | Purine metabolism | VV12002 | 2.4.2.7 | GN + PRPP -> PPI + GMP | adenine phosphoribosyltransferase |
R309 | Purine metabolism | VV11635 AND VV11636 | 2.4.2.8 | HYXN + PRPP -> PPI + IMP | hypoxanthinephosphoribosyltransferase |
R310 | Purine metabolism | VV11635 AND VV11636 | 2.4.2.8 | XAN + PRPP -> PPI + XMP | hypoxanthine phosphoribosyltransferase |
R311 | Purine metabolism | VV11635 AND VV11636 | 2.4.2.8 | AMP + PPI <-> AD + PRPP | hypoxanthine phosphoribosyltransferase |
R312 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | DIN+PI<->HYXN+DR1P | purine-nucleoside phosphorylase |
R313 | Purine metabolism | VV11728 OR VV21540 OR VV11726 | 2.4.2.1 OR 2.4.2.4 | DA + PI <-> AD + DR1P | purine-nucleosidephosphorylaseORthymidinephosphorylase |
R314 | Purine metabolism | VV11728 OR VV21540 OR VV11726 | 2.4.2.1 OR 2.4.2.4 | DG + PI <-> GN + DR1P | purine-nucleosidephosphorylaseORthymidinephosphorylase |
R315 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | HYXN + R1P <-> INS + PI | purine-nucleoside phosphorylase |
R316 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | AD + R1P <-> PI + ADN | purine-nucleoside phosphorylase |
R317 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | GN + R1P <-> PI + GSN | purine-nucleoside phosphorylase |
R318 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | XAN + R1P <-> PI + XTSINE | purine-nucleoside phosphorylase |
R319 | Purine metabolism | VV10014 | 3.1.5.1 | DGTP -> DG + H5P3O10 | dGTPtriphosphohydrolase |
R320 | Purine metabolism | VV11575 AND VV11576 | 2.7.6.5 | ATP + GTP -> pppGpp + AMP | GTPpyrophosphokinase |
R321 | Purine metabolism | VV10852 | 3.1.7.2 | ppGpp <-> GDP + PPI | guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase |
R322 | Purine metabolism | VV10188 | 2.7.4.3 | ATP + AMP <-> 2 ADP | adenylate kinase |
R323 | Purine metabolism | VV13041 AND VV13042 | 1.17.4.1 | ADP + RTHIO -> DADP + OTHIO | ribonucleoside-diphosphatereductase |
R324 | Purine metabolism | VV10430 | 2.7.4.6 | DADP + ATP <-> DATP + ADP | nucleoside-diphosphate kinase |
R325 | Purine metabolism | VV10850 | 2.7.4.8 | GMP + ATP <-> GDP + ADP | guanylate kinase |
R326 | Purine metabolism | VV10430 | 2.7.4.6 | GDP + ATP <-> GTP + ADP | nucleoside-diphosphate kinase |
R327 | Purine metabolism | VV13041 AND VV13042 | 1.17.4.1 | GDP + RTHIO -> DGDP + OTHIO | ribonucleoside-diphosphatereductase |
R328 | Purine metabolism | VV10430 | 2.7.4.6 | DGDP + ATP <-> DGTP + ADP | nucleoside-diphosphate kinase |
R329 | Purine metabolism | VV10610 | 3.6.1.13 | ARIB -> AMP + R5P | ADPribose ribophosphohydrolase |
R330 | Purine metabolism | VV20337 | 1.17.4.2 | ATP + RTHIO -> DATP + OTHIO | ribonucleoside-triphosphatereductase |
R331 | Purine metabolism | VV20337 | 1.17.4.2 | GTP + RTHIO -> DGTP + OTHIO | ribonucleoside-triphosphatereductase |
R332 | Purine metabolism | VV10188 | 2.7.4.3 | ATP + DAMP <-> ADP + DADP | adenylate kinase |
R333 | Purine metabolism | VV10329 OR VV11635 AND VV11636 | 2.4.2.22 OR 2.4.2.8 | GMP + PPI <-> GN + PRPP | xanthine-guaninephosphoribosyltransferaseORhypoxanthinephosphoribosyltransferase |
R334 | Purine metabolism | VV10329 | 2.4.2.22 | XMP + PPI <-> XAN + PRPP | xanthine-guanine phosphoribosyltransferase |
R335 | Purine metabolism | VV10465 OR VV10940 | 3.6.1.11 OR 3.6.1.40 | pppGpp <-> ppGpp + PI | exopolyphosphatase |
R336 | Purine metabolism | VV10665 | 3.6.1.41 | AppppA -> 2 ADP | bis(5'-nucleosyl)-tetraphosphatase |
R337 | Pyrimidine metabolism (De novo) | VV11464 AND VV11465 | 2.1.3.2 | CAP + ASP -> CAASP + PI | aspartatecarbamoyltransferase |
R338 | Pyrimidine metabolism (De novo) | VV21596 | 3.5.2.3 | CAASP <-> DOROA | dihydroorotase |
R339 | Pyrimidine metabolism (De novo) | VV12637 | 1.3.3.1 | DOROA + UQ <-> UQH2 + OROA | dihydroorotateoxidase |
R340 | Pyrimidine metabolism (De novo) | VV12637 | 1.3.3.1 | DOROA + MK <-> MKH2 + OROA | dihydroorotateoxidase |
R341 | Pyrimidine metabolism (De novo) | VV10831 | 2.4.2.10 | OROA + PRPP <-> PPI + OMP | orotatephosphoribosyltransferase |
R342 | Pyrimidine metabolism (De novo) | VV12977 | 4.1.1.23 | OMP -> CO2 + UMP | orotidine-5'-phosphatedecarboxylase |
R343 | Pyrimidine metabolism (De novo) | VV12983 OR VV11861 | 2.7.4.14 OR 2.7.4.22 | ATP + UMP <-> ADP + UDP | cytidylate kinase OR uridylate kinase |
R344 | Pyrimidine metabolism (De novo) | VV10430 | 2.7.4.6 | UDP + ATP <-> UTP + ADP | nucleoside-diphosphate kinase |
R345 | Pyrimidine metabolism (De novo) | VV11578 | 6.3.4.2 | UTP + GLN + ATP -> GLU + CTP + ADP + PI | CTPsynthase |
R346 | Pyrimidine metabolism | VV11578 | 6.3.4.2 | ATP + UTP + NH3 -> ADP + PI + CTP | CTPsynthase |
R347 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | CDP + ATP <-> CTP + ADP | nucleoside-diphosphate kinase |
R348 | Pyrimidine metabolism | VV13041 AND VV13042 | 1.17.4.1 | CDP + RTHIO -> DCDP + OTHIO | ribonucleoside-diphosphate reductase |
R349 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | DCDP + ATP <-> DCTP + ADP | nucleoside-diphosphate kinase |
R350 | Pyrimidine metabolism | VV12907 | 2.7.1.21 | DT + ATP -> ADP + DTMP | thymidinekinase |
R351 | Pyrimidine metabolism | VV13002 | 2.7.4.9 | DTMP + ATP <-> DTDP + ADP | thymidylatekinase |
R352 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | DTDP + ATP <-> DTTP + ADP | nucleoside-diphosphate kinase |
R353 | Pyrimidine metabolism | VV12983 | 2.7.4.14 | CMP + ATP <-> ADP + CDP | cytidylatekinase |
R354 | Pyrimidine metabolism | VV12810 | 1.8.1.9 | OTHIO + NADPH -> RTHIO + NADP | thioredoxinreductase |
R355 | Pyrimidine metabolism | VV12983 | 2.7.4.14 | DCMP + ATP <-> ADP + DCDP | cytidylatekinase |
R356 | Pyrimidine metabolism | VV12907 | 2.7.1.21 | DU + ATP -> DUMP + ADP | thymidinekinase |
R357 | Pyrimidine metabolism | VV11901 | 2.4.2.9 | URA + PRPP <-> UMP + PPI | uracilphosphoribosyltransferase |
R358 | Pyrimidine metabolism | VV10246 OR VV10484 OR VV11461 OR VV11584 OR VV11698 OR VV11855 OR VV11992 OR VV12116 OR VV12843 OR VV13016 OR VV13060 OR VV21318 | 4.2.1.70 | URA + R5P <-> PURI5P | pseudouridylate synthase |
R359 | Pyrimidine metabolism | VV10516 | 2.1.1.45 | DUMP + METTHF -> DHF + DTMP | thymidylatesynthase |
R360 | Pyrimidine metabolism | VV11728 OR VV21540 OR VV11726 | 2.4.2.1 OR 2.4.2.4 | DU + PI -> URA + DR1P | purine-nucleosidephosphorylaseORthymidinephosphorylase |
R361 | Pyrimidine metabolism | VV11726 | 2.4.2.4 | DT + PI -> TM + DR1P | thymidinephosphorylase |
R362 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | DUDP + ATP <-> DUTP + ADP | nucleoside-diphosphate kinase |
R363 | Pyrimidine metabolism | VV13041 AND VV13042 | 1.17.4.1 | UDP + RTHIO -> OTHIO + DUDP | ribonucleoside-diphosphate reductase |
R364 | Pyrimidine metabolism | VV20337 | 1.17.4.2 | UTP + RTHIO -> DUTP + OTHIO | ribonucleoside-triphosphatereductase |
R365 | Pyrimidine metabolism | VV20337 | 1.17.4.2 | CTP + RTHIO -> DCTP + OTHIO | ribonucleoside-triphosphatereductase |
R366 | Pyrimidine metabolism | VV13002 | 2.7.4.9 | ATP + DUMP <-> ADP + DUDP | thymidylatekinase |
R367 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ATP + CYTD -> ADP + CMP | uridinekinase |
R368 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ATP + URI -> ADP + UMP | uridinekinase |
R369 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DATP + CYTD -> DADP + CMP | uridinekinase |
R370 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DATP + URI -> DADP + UMP | uridinekinase |
R371 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DCTP + CYTD -> DCDP + CMP | uridinekinase |
R372 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DCTP + URI -> DCDP + UMP | uridinekinase |
R373 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DGTP + CYTD -> DGDP + CMP | uridinekinase |
R374 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DGTP + URI -> DGDP + UMP | uridinekinase |
R375 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DTTP + CYTD -> DTDP + CMP | uridinekinase |
R376 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DTTP + URI -> DTDP + UMP | uridinekinase |
R377 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DUTP + CYTD -> DUDP + CMP | uridinekinase |
R378 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DUTP + URI -> DUDP + UMP | uridinekinase |
R379 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | GTP + CYTD -> GDP + CMP | uridinekinase |
R380 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | GTP + URI -> GDP + UMP | uridinekinase |
R381 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ITP + CYTD -> IDP + CMP | uridinekinase |
R382 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ITP + URI -> IDP + UMP | uridinekinase |
R383 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | UTP + CYTD -> UDP + CMP | uridinekinase |
R384 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | UTP + URI -> UDP + UMP | uridinekinase |
R385 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | UMP -> URI + PI | 5'-nucleotidase |
R386 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | CMP -> CYTD + PI | 5'-nucleotidase |
R387 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DCMP -> DC + PI | 5'-nucleotidase |
R388 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DTMP -> DT + PI | 5'-nucleotidase |
R389 | Pyrimidine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cCMP -> 3CMP | 2',3'-cyclic-nucleotide2'-phosphodiesterase |
R390 | Pyrimidine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cUMP -> 3UMP | 2',3'-cyclic-nucleotide2'-phosphodiesterase |
R391 | Pyrimidine metabolism | VV20789 | 3.5.4.1 | 5MC <-> TM + NH3 | cytosinedeaminase |
R392 | Pyrimidine metabolism | VV20789 | 3.5.4.1 | CT -> URA + NH3 | cytosinedeaminase |
R393 | Pyrimidine metabolism | VV12379 | 3.5.4.5 | DC -> DU + NH3 | cytidinedeaminase |
R394 | Pyrimidine metabolism | VV12379 | 3.5.4.5 | CYTD -> URI + NH3 | cytidinedeaminase |
R395 | Pyrimidine metabolism | VV20531 | 3.5.4.12 | DCMP -> DUMP + NH3 | deoxycytidylatedeaminase |
R396 | Pyrimidine metabolism | VV12064 OR VV21373 | 2.4.2.3 | URI + PI <-> URA + R1P | uridinephosphorylase |
R397 | Glutamate metabolism | VV10889 | 6.3.1.2 | GLU + NH3 + ATP -> GLN + ADP + PI | glutaminesynthetase |
R398 | Glutamate metabolism | VV10553 AND VV10554 AND VV10555 AND VV10556 | 1.4.1.13 | GLN + AKG + NADPH -> 2 GLU + NADP | glutamatesynthase |
R399 | Glutamate metabolism | VV12356 AND VV12357 OR VV12824 | 4.1.1.19 OR 4.1.1.15 | GLU -> GABA + CO2 | biosyntheticargininedecarboxylaseORglutamatedecarboxylase |
R400 | Glutamate metabolism | VV10565 AND VV10566 | 6.3.5.5 | GLN + 2 ATP + CO2 -> GLU + CAP + 2 ADP + PI | carbamoyl-phosphate synthase |
R201 | Fattyacidbiosynthesis | PPACOA + ACP-> PPAACP + COA | malonyl CoA-acyl carrier protein transacylase | ||
R202 | Fattyacidbiosynthesis (nonanoic acid; c9: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 3MALACP + 6NADPH-> 6NADP + C090ACP + 3CO2 + 3ACP | synthesis of nonanoyl- [acyl-carrier protein] |
R203 | Fattyacidbiosynthesis (decanoic acid; c10: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 4MALACP + 8NADPH-> 8NADP + C100ACP + 4CO2 + 4ACP | synthesis of decanoyl- [acyl-carrier protein] |
R204 | Fattyacidbiosynthesis (undecanoic acid; c11: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 4MALACP + 8NADPH-> 8NADP + C110ACP + 4CO2 + 4ACP | synthesis of undecanoyl- [acyl-carrier protein] |
R205 | Fattyacidbiosynthesis (dodecanoic acid; c12: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 5MALACP + 10NADPH-> 10NADP + C120ACP + 5CO2 + 5ACP | synthesis of dodecanoyl- [acyl-carrier protein] |
R206 | Fattyacidbiosynthesis (tridecanoic acid; c13: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 5MALACP + 10NADPH-> 10NADP + C130ACP + 5CO2 + 5ACP | synthesis of tridecanoyl- [acyl-carrier protein] |
R207 | Fattyacidbiosynthesis (tetradecanoic acid; c14: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 6 MALACP + 12 NADPH-> 12 NADP + C140ACP + 6 CO2 + 6 ACP | synthesis of tetradecanoyl- [acyl-carrier protein] |
R208 | Fattyacidbiosynthesis (pentadecanoic acid; c15: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 6 MALACP + 12 NADPH-> 12 NADP + C150ACP + 6 CO2 + 6 ACP | synthesis of pentadecanoyl- [acyl-carrier protein] |
R209 | Fattyacidbiosynthesis (pentadecenoic acid; c15: 1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 6 MALACP + 11 NADPH-> 11 NADP + C151ACP + 6 CO2 + 6 ACP | synthesis of pentadecenoyl- [acyl-carrier protein] |
R210 | Fattyacidbiosynthesis (hexadecanoic acid; c16: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 7 MALACP + 14 NADPH-> 14 NADP + C160ACP + 7 CO2 + 7 ACP | synthesis of hexadecanoyl- [acyl-carrier protein] |
R211 | Fattyacidbiosynthesis (hexadecenoic acid; c16: 1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 7MALACP + 13NADPH-> 13NADP + C161ACP + 7CO2 + 7 ACP | synthesis of hexadecenoyl- [acyl-carrier protein] |
R212 | Fattyacidbiosynthesis (heptadecanoic acid; c17: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 7 MALACP + 14 NADPH-> 14 NADP + C170ACP + 7 CO2 + 7 ACP | synthesis of heptadecanoyl- [acyl-carrier protein] |
R213 | Fattyacidbiosynthesis (heptadecenoic acid; c17: 1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 7 MALACP + 13 NADPH-> 13 NADP + C171ACP + 7 CO2 + 7 ACP | synthesis of heptadecenoyl- [acyl-carrier protein] |
R214 | Fattyacidbiosynthesis (octadecanoic acid; c18: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 8MALACP + 16NADPH-> 16NADP + C180ACP + 8CO2 + 8ACP | synthesis of octadecanoyl- [acyl-carrier protein] |
R215 | Fattyacidbiosynthesis (octadecenoic acid; c18: 1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 8 MALACP + 15 NADPH-> 15 NADP + C181ACP + 8 CO2 + 8 ACP | synthesis of octadecenoyl- [acyl-carrier protein] |
R216 | Fattyacidbiosynthesis (nonadecanoic acid; c19: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 8 MALACP + 16 NADPH-> 16 NADP + C190ACP + 8 CO2 + 8 ACP | synthesis of nonadecanoyl- [acyl-carrier protein] |
R217 | Fattyacidbiosynthesis (nonadecenoic acid; c19: 1) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | PPAACP + 8 MALACP + 15 NADPH-> 15 NADP + C191ACP + 8 CO2 + 8 ACP | synthesis of nonadecenoyl- [acyl-carrier protein] |
R218 | Fattyacidbiosynthesis (eicosanoic acid; c20: 0) | (VV10061 OR VV11846 OR VV11986 OR VV13006 OR VV13007 OR VV13011 OR VV20349) AND (VV10060 AND VV13009 AND VV20488) | 2.3.1.41 AND 2.3.1.179 AND 2.3.1.180 AND 1.1.1.100 | ACACP + 9MALACP + 18NADPH-> 18NADP + C200ACP + 9CO2 + 9ACP | synthesis of eicosanoyl- [acyl-carrier protein] |
R219 | Fattyacidmetabolism (dodecanoic acid; c12: 0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C120 + 6 COA + 5 FAD + 5 NAD + ATP-> 6 ACCOA + 5 FADH2 + 5 NADH + AMP + PPI | oxidation of dodecanoic acid |
R220 | Fattyacidmetabolism (tetradecanoic acid; c14: 0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C140 + 7 COA + 6 FAD + 6 NAD + ATP-> 7 ACCOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of tetradecanoic acid |
R221 | Fattyacidmetabolism (pentadecanoic acid; c15: 0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C150 + 7COA + 6FAD + 6NAD + ATP-> 6 ACCOA + PPACOA + 6 FADH2 + 6 NADH + AMP + PPI | oxidation of pentadecanoic acid |
R222 | Fattyacidmetabolism (hexadecanoic acid; c16: 0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C160 + 8 COA + 7 FAD + 7 NAD + ATP-> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecanoic acid |
R223 | Fattyacidmetabolism (hexadecenoic acid; c16: 1) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C161 + 8 COA + 7 FAD + 7 NAD + ATP-> 8 ACCOA + 7 FADH2 + 7 NADH + AMP + PPI | oxidation of hexadecenoic acid |
R224 | Fattyacidmetabolism (octadecanoic acid; c18: 0) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C180 + 9 COA + 8 FAD + 8 NAD + ATP-> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecanoic acid |
R225 | Fattyacidmetabolism (octadecenoic acid; c18: 1) | (VV10136 OR VV10649) AND VV11896 AND (VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498) AND (VV10982 OR VV11975) | 6.2.1.3AND1.3.99.-AND4.2.1.17AND1.1.1.35AND2.3.1.16 | C181 + 9 COA + 8 FAD + 8 NAD + ATP-> 9 ACCOA + 8 FADH2 + 8 NADH + AMP + PPI | oxidation of octadecenoic acid |
R226 | Biosynthesis of steroids | VV10315 | 2.2.1.7 | PYR + G3P-> DX5P + CO2 | 1-deoxy-D-xylulose-5-phosphate synthase |
R227 | Biosynthesis of steroids | VV11866 | 1.1.1.267 | DX5P + NADPH-> MDE4P + NADP | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
R228 | Biosynthesis of steroids | VV11582 | 2.7.7.60 | MDE4P + CTP-> CDPMDE + PPI | 4-diphosphocytidyl-2-methyl-D-erythritol synthase |
R229 | Biosynthesis of steroids | VV10256 | 2.7.1.148 | CDPMDE + ATP-> 2PCDPMDE + ADP | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase |
R230 | Biosynthesis of steroids | VV11583 | 4.6.1.12 | 2PCDPMDE-> MDECPP + CMP | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase |
R231 | Biosynthesis of steroids | VV10427 | 1.17.4.3 | MDECPP + NADH-> NAD + HMB4PP | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase |
R232 | Biosynthesis of steroids | VV10504 | 1.17.1.2 | HMB4PP + NADH-> NAD + IPP | 4-hydroxy-3-methylbut-2-enyl diphosphate reductase |
R233 | Biosynthesis of steroids | 5.3.3.2 | IPP <-> DMPP | isopentenyl-diphosphate D-isomerase | |
R234 | Biosynthesis of steroids | VV10314 | 2.5.1.10 | DMPP + IPP-> GPP + PPI | geranylgeranyl pyrophosphate synthase |
R235 | Biosynthesis of steroids | VV10314 | 2.5.1.10 | GPP + IPP-> FPP + PPI | geranylgeranyl pyrophosphate synthase |
R236 | Biosynthesis of steroids | VV20117 | 1.1.1.34 | 3H3MGCOA + 2 NADPH-> MVLN + COA + 2 NADP | 3-hydroxy-3-methylglutaryl-CoA reductase |
R237 | Biosynthesis of steroids | 2.5.1.29 | FPP + IPP-> GGPP + PPI | farnesyltranstransferase | |
R238 | Biosynthesis of steroids | GGPP + IPP-> PPPP + PPI | dimethylallyltranstransferase | ||
R239 | Biosynthesis of steroids | 2.5.1.33 | PPPP + IPP-> HPPP + PPI | trans-pentaprenyltranstransferase | |
R240 | Biosynthesis of steroids | 2.5.1.30 | HPPP + IPP-> HEPPP + PPI | trans-hexaprenyltranstransferase | |
R241 | Biosynthesis of steroids | HEPPP + IPP-> OPP + PPI | trans-hexaprenyltranstransferase | ||
R242 | Glycerolipid metabolism | VV11654 | 2.7.1.31 | 3PG + ADP <-> DGLYCERATE + ATP | glycerate kinase |
R243 | Glycerolipid metabolism | VV20869 | 1.2.1.3 | NADH + DGLYCERATE <-> T3 + NAD | aldehydedehydrogenase |
R244 | Glycerolipid metabolism | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | T3 + NADH <-> GL + NAD | alcohol dehydrogenase |
R245 | Glycerolipid metabolism | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | T3 + NADPH <-> GL + NADP | alcohol dehydrogenase |
R246 | Glycerolipid metabolism | VV11787 | 2.7.1.30 | GL + ATP-> GL3P + ADP | glycerolkinase |
R247 | Glycerolipid metabolism | VV12349 | 3.1.1.3 | DGR-> AGL + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | triacylglycerol lipase |
R248 | Glycerolipid metabolism | VV12349 | 3.1.1.3 | TGL-> DGR + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | triacylglycerol lipase |
R249 | Glycerophospholipid metabolism | VV11277 | 1.1.1.94 | DHAP + NADH-> GL3P + NAD | glycerol-3-phosphate dehydrogenase |
R250 | Glycerophospholipid metabolism | VV11277 | 1.1.1.94 | DHAP + NADPH-> GL3P + NADP | glycerol-3-phosphate dehydrogenase |
R251 | Glycerophospholipid metabolism | VV11785 OR (VV20010 AND VV20011 AND VV20012) | 1.1.99.5 | DHAP + UQH2 <-> GL3P + UQ | glycerol-3-phosphatedehydrogenase |
R252 | Glycerophospholipid metabolism | VV11785 OR (VV20010 AND VV20011 AND VV20012) | 1.1.99.5 | DHAP + MKH2 <-> GL3P + MK | glycerol-3-phosphatedehydrogenase |
R253 | Glycerophospholipid metabolism | VV11785 OR (VV20010 AND VV20011 AND VV20012) | 1.1.99.5 | DHAP + DMKH2 <-> GL3P + DMK | glycerol-3-phosphatedehydrogenase |
R254 | Glycerophospholipid metabolism | VV11374 OR VV21136 OR VV21651 | 2.3.1.- | GL3P + ACOA-> 2AGL3P + COA | acetyltransferase |
R255 | Glycerophospholipid metabolism | VV11165 | 2.3.1.15 | GL3P + 0.052 C120ACP + 0.182 C140ACP + 0.05 C150ACP + 0.39 C160ACP + 0.24 C161ACP + 0.01 C180ACP + 0.076 C181ACP-> AGL3P + ACP | glycerol-3-phosphate O-acyltransferase |
R256 | Glycerophospholipid metabolism | VV10678 OR VV12699 | 2.3.1.51 | AGL3P + 0.052 C120ACP + 0.182 C140ACP + 0.05 C150ACP + 0.39 C160ACP + 0.24 C161ACP + 0.01 C180ACP + 0.076 C181ACP-> PA + ACP | 1-acylglycerol-3-phosphate O-acyltransferase |
R257 | Glycerophospholipid metabolism | VV10815 OR VV21412 | 2.7.1.107 | DGR + ATP-> ADP + PA | diacylglycerol kinase |
R258 | Glycerophospholipid metabolism | VV12799 | 3.1.1.32 | PC-> 2AG3PC + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | phospholipase |
R259 | Glycerophospholipid metabolism | VV12754 OR VV20407 | 3.1.4.46 | G3PC-> CHOLINE + GL3P | glycerophosphoryl diester phosphodiesterase |
R260 | Glycerophospholipid metabolism | VV11865 | 2.7.7.41 | PA + CTP <-> CDPDG + PPI | phosphatidate cytidylyltransferase |
R261 | Glycerophospholipid metabolism | VV11195 | 2.7.8.8 | CDPDG + SER <-> CMP + PS | phosphatidylserine synthase |
R262 | Glycerophospholipid metabolism | VV12799 | 3.1.1.32 | PS-> 2AG3PS + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | phospholipase |
R263 | Glycerophospholipid metabolism | VV11284 | 4.1.1.65 | PS-> PE + CO2 | phosphatidylserinedecarboxylase |
R264 | Glycerophospholipid metabolism | VV12799 | 3.1.1.32 | PE-> 2AG3 PE + 0.052 C120 + 0.182 C140 + 0.05 C150 + 0.39 C160 + 0.24 C161 + 0.01 C180 + 0.076 C181 | phospholipase |
R265 | Glycerophospholipid metabolism | VV12754 OR VV20407 | 3.1.4.46 | G3PE-> ETHA + GL3P | glycerophosphoryl diester phosphodiesterase |
R266 | Glycerophospholipid metabolism | VV13052 | 2.7.8.5 | CDPDG + GL3P <-> CMP + PGP | CDP-diacylglycerol--glycerol-3-phosphate3-phosphatidyltransferase |
R267 | Glycerophospholipid metabolism | VV10316 OR VV21432 | 3.1.3.27 | PGP-> PI + PG | phosphatidylglycerophosphatase |
R268 | Glycerophospholipid metabolism | VV12871 | 2.7.8.- | CDPDG + PG-> CMP + CL | cardiolipin synthase |
R269 | Purinemetabolism | VV10257 | 2.7.6.1 | R5P + ATP <-> PRPP + AMP | ribose-phosphate pyrophosphokinase |
R270 | Purine metabolism (De novo) | VV11997 | 2.4.2.14 | PRPP + GLN-> PRAM + PPI + GLU | amidophosphoribosyltransferase |
R271 | Purine metabolism (De novo) | VV11226 | 6.3.4.13 | PRAM + ATP + GLY <-> GAR + ADP + PI | phosphoribosylamine-glycine ligase |
R272 | Purine metabolism (De novo) | VV11899 | 2.1.2.2 | GAR + FTHF-> FGAR + THF | phosphoribosylglycinamideformyltransferase |
R273 | Purine metabolism (De novo) | VV10340 | 6.3.5.3 | FGAR + ATP + GLN-> FGAM + GLU + ADP + PI | phosphoribosylformylglycinamidine synthase |
R274 | Purine metabolism (De novo) | VV11900 | 6.3.3.1 | FGAM + ATP-> AIR + ADP + PI | phosphoribosylformylglycinamidine cyclo-ligase |
R275 | Purine metabolism (De novo) | VV11053 AND VV11054 | 4.1.1.21 | AIR + CO2 + ATP-> CAIR + ADP + PI | phosphoribosylaminoimidazolecarboxylase |
R276 | Purine metabolism (De novo) | VV12797 | 6.3.2.6 | CAIR + ATP + ASP <-> SAICAR + ADP + PI | phosphoribosylaminoimidazole-succinocarboxamide synthase |
R277 | Purine metabolism (De novo) | VV12928 | 4.3.2.2 | SAICAR <-> AICAR + FUM | adenylosuccinatelyase |
R278 | Purine metabolism (De novo) | VV11227 | 2.1.2.3 | AICAR + FTHF <-> PRFICA + THF | phosphoribosylaminoimidazolecarboxamide formyltransferase |
R279 | Purine metabolism (De novo) | VV11227 | 2.1.2.3 | PRFICA <-> IMP | phosphoribosylaminoimidazolecarboxamide formyltransferase; IMP cyclohydrolase |
R280 | Purine metabolism (De novo) | VV11299 OR VV20768 | 6.3.4.4 | IMP + GTP + ASP-> ASUC + GDP + PI | adenylosuccinatesynthase |
R281 | Purine metabolism (De novo) | VV12928 | 4.3.2.2 | ASUC <-> FUM + AMP | adenylosuccinatelyase |
R282 | Purine metabolism (De novo) | VV10419 | 1.1.1.205 | IMP + NAD-> XMP + NADH | IMP dehydrogenase |
R283 | Purine metabolism (De novo) | VV10418 | 6.3.5.2 | XMP + ATP + GLN-> GMP + GLU + AMP + PPI | GMPsynthase |
R284 | Purine metabolism | VV20712 | 1.7.1.7 | GMP + NADPH-> IMP + NH3 + NADP | GMP reductase |
R285 | Purine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cAMP-> 3AMP | 2 ', 3'-cyclic-nucleotide2'-phosphodiesterase |
R286 | Purine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cGMP-> 3GMP | 2 ', 3'-cyclic-nucleotide2'-phosphodiesterase |
R287 | Purine metabolism | VV12924 OR VV20218 | 2.7.1.73 | ATP + INS <-> ADP + IMP | inosinekinase |
R288 | Purine metabolism | VV12924 OR VV20218 | 2.7.1.73 | ATP + GSN <-> ADP + GMP | guanosine kinase |
R289 | Purine metabolism | VV20468 | 3.5.4.4 | ADN-> INS + NH3 | adenosinedeaminase |
R290 | Purine metabolism | VV20468 | 3.5.4.4 | DA <-> DIN + NH3 | adenosine deaminase |
R291 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | IMP-> INS + PI | 5'-nucleotidase |
R292 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | AMP-> ADN + PI | 5'-nucleotidase |
R293 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | XMP-> XTSINE + PI | 5'-nucleotidase |
R294 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | GMP-> GSN + PI | 5'-nucleotidase |
R295 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DAMP <-> DA + PI | 5'-nucleotidase |
R296 | Purine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DGMP <-> DG + PI | 5'-nucleotidase |
R297 | Purine metabolism | VV11726 | 2.4.2.4 | DIN + PI-> HYXN + DR1P | thymidinephosphorylase |
R298 | Purine metabolism | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | DATP + PYR <-> DADP + PEP | pyruvatekinase |
R299 | Purine metabolism | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | GTP + PYR <-> GDP + PEP | pyruvatekinase |
R300 | Purine metabolism | VV10644 OR VV12992 OR VV20206 | 2.7.1.40 | DGDP + PEP-> DGTP + PYR | pyruvatekinase |
R301 | Purine metabolism | VV11123 | 4.6.1.1 | ATP-> cAMP + PPI | adenylatecyclase |
R302 | Purine metabolism | VV11123 | 4.6.1.1 | GTP-> cGMP + PPI | adenylatecyclase |
R303 | Purine metabolism | VV10850 | 2.7.4.8 | DGMP + ATP <-> DGDP + ADP | guanylatekinase |
R304 | Purine metabolism | VV10430 | 2.7.4.6 | IDP + ATP <-> ITP + ADP | nucleoside-diphosphate kinase |
R305 | Purine metabolism | VV10430 | 2.7.4.6 | ATP + DIDP <-> ADP + DITP | nucleoside-diphosphatekinase |
R306 | Purine metabolism | VV12002 | 2.4.2.7 | AICAR + PPI <-> 5A4IC + PRPP | adenine phosphoribosyltransferase |
R307 | Purine metabolism | VV12002 | 2.4.2.7 | AD + PRPP-> PPI + AMP | adenine phosphoribosyltransferase |
R308 | Purine metabolism | VV12002 | 2.4.2.7 | GN + PRPP-> PPI + GMP | adenine phosphoribosyltransferase |
R309 | Purine metabolism | VV11635 AND VV11636 | 2.4.2.8 | HYXN + PRPP-> PPI + IMP | hypoxanthinephosphoribosyltransferase |
R310 | Purine metabolism | VV11635 AND VV11636 | 2.4.2.8 | XAN + PRPP-> PPI + XMP | hypoxanthine phosphoribosyltransferase |
R311 | Purine metabolism | VV11635 AND VV11636 | 2.4.2.8 | AMP + PPI <-> AD + PRPP | hypoxanthine phosphoribosyltransferase |
R312 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | DIN + PI <-> HYXN + DR1P | purine-nucleoside phosphorylase |
R313 | Purine metabolism | VV11728 OR VV21540 OR VV11726 | 2.4.2.1 OR 2.4.2.4 | DA + PI <-> AD + DR1P | purine-nucleosidephosphorylase ORthymidinephosphorylase |
R314 | Purine metabolism | VV11728 OR VV21540 OR VV11726 | 2.4.2.1 OR 2.4.2.4 | DG + PI <-> GN + DR1P | purine-nucleosidephosphorylase ORthymidinephosphorylase |
R315 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | HYXN + R1P <-> INS + PI | purine-nucleoside phosphorylase |
R316 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | AD + R1P <-> PI + ADN | purine-nucleoside phosphorylase |
R317 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | GN + R1P <-> PI + GSN | purine-nucleoside phosphorylase |
R318 | Purine metabolism | VV11728 OR VV21540 | 2.4.2.1 | XAN + R1P <-> PI + XTSINE | purine-nucleoside phosphorylase |
R319 | Purine metabolism | VV10014 | 3.1.5.1 | DGTP-> DG + H5P3O10 | dGTPtriphosphohydrolase |
R320 | Purine metabolism | VV11575 AND VV11576 | 2.7.6.5 | ATP + GTP-> pppGpp + AMP | GTPpyrophosphokinase |
R321 | Purine metabolism | VV10852 | 3.1.7.2 | ppGpp <-> GDP + PPI | guanosine-3 ', 5'-bis (diphosphate) 3'-pyrophosphohydrolase |
R322 | Purine metabolism | VV10188 | 2.7.4.3 | ATP + AMP <-> 2 ADP | adenylate kinase |
R323 | Purine metabolism | VV13041 AND VV13042 | 1.17.4.1 | ADP + RTHIO-> DADP + OTHIO | ribonucleoside-diphosphatereductase |
R324 | Purine metabolism | VV10430 | 2.7.4.6 | DADP + ATP <-> DATP + ADP | nucleoside-diphosphate kinase |
R325 | Purine metabolism | VV10850 | 2.7.4.8 | GMP + ATP <-> GDP + ADP | guanylate kinase |
R326 | Purine metabolism | VV10430 | 2.7.4.6 | GDP + ATP <-> GTP + ADP | nucleoside-diphosphate kinase |
R327 | Purine metabolism | VV13041 AND VV13042 | 1.17.4.1 | GDP + RTHIO-> DGDP + OTHIO | ribonucleoside-diphosphatereductase |
R328 | Purine metabolism | VV10430 | 2.7.4.6 | DGDP + ATP <-> DGTP + ADP | nucleoside-diphosphate kinase |
R329 | Purine metabolism | VV10610 | 3.6.1.13 | ARIB-> AMP + R5P | ADPribose ribophosphohydrolase |
R330 | Purine metabolism | VV20337 | 1.17.4.2 | ATP + RTHIO-> DATP + OTHIO | ribonucleoside-triphosphatereductase |
R331 | Purine metabolism | VV20337 | 1.17.4.2 | GTP + RTHIO-> DGTP + OTHIO | ribonucleoside-triphosphatereductase |
R332 | Purine metabolism | VV10188 | 2.7.4.3 | ATP + DAMP <-> ADP + DADP | adenylate kinase |
R333 | Purine metabolism | VV10329 OR VV11635 AND VV11636 | 2.4.2.22 OR 2.4.2.8 | GMP + PPI <-> GN + PRPP | xanthine-guaninephosphoribosyltransferase ORhypoxanthinephosphoribosyltransferase |
R334 | Purine metabolism | VV10329 | 2.4.2.22 | XMP + PPI <-> XAN + PRPP | xanthine-guanine phosphoribosyltransferase |
R335 | Purine metabolism | VV10465 OR VV10940 | 3.6.1.11 OR 3.6.1.40 | pppGpp <-> ppGpp + PI | exopolyphosphatase |
R336 | Purine metabolism | VV10665 | 3.6.1.41 | AppppA-> 2 ADP | bis (5'-nucleosyl) -tetraphosphatase |
R337 | Pyrimidine metabolism (De novo) | VV11464 AND VV11465 | 2.1.3.2 | CAP + ASP-> CAASP + PI | aspartatecarbamoyltransferase |
R338 | Pyrimidine metabolism (De novo) | VV21596 | 3.5.2.3 | CAASP <-> DOROA | dihydroorotase |
R339 | Pyrimidine metabolism (De novo) | VV12637 | 1.3.3.1 | DOROA + UQ <-> UQH2 + OROA | dihydroorotateoxidase |
R340 | Pyrimidine metabolism (De novo) | VV12637 | 1.3.3.1 | DOROA + MK <-> MKH2 + OROA | dihydroorotateoxidase |
R341 | Pyrimidine metabolism (De novo) | VV10831 | 2.4.2.10 | OROA + PRPP <-> PPI + OMP | orotatephosphoribosyltransferase |
R342 | Pyrimidine metabolism (De novo) | VV12977 | 4.1.1.23 | OMP-> CO2 + UMP | orotidine-5'-phosphatedecarboxylase |
R343 | Pyrimidine metabolism (De novo) | VV12983 OR VV11861 | 2.7.4.14 OR 2.7.4.22 | ATP + UMP <-> ADP + UDP | cytidylate kinase OR uridylate kinase |
R344 | Pyrimidine metabolism (De novo) | VV10430 | 2.7.4.6 | UDP + ATP <-> UTP + ADP | nucleoside-diphosphate kinase |
R345 | Pyrimidine metabolism (De novo) | VV11578 | 6.3.4.2 | UTP + GLN + ATP-> GLU + CTP + ADP + PI | CTPsynthase |
R346 | Pyrimidine metabolism | VV11578 | 6.3.4.2 | ATP + UTP + NH3-> ADP + PI + CTP | CTPsynthase |
R347 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | CDP + ATP <-> CTP + ADP | nucleoside-diphosphate kinase |
R348 | Pyrimidine metabolism | VV13041 AND VV13042 | 1.17.4.1 | CDP + RTHIO-> DCDP + OTHIO | ribonucleoside-diphosphate reductase |
R349 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | DCDP + ATP <-> DCTP + ADP | nucleoside-diphosphate kinase |
R350 | Pyrimidine metabolism | VV12907 | 2.7.1.21 | DT + ATP-> ADP + DTMP | thymidinekinase |
R351 | Pyrimidine metabolism | VV13002 | 2.7.4.9 | DTMP + ATP <-> DTDP + ADP | thymidylatekinase |
R352 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | DTDP + ATP <-> DTTP + ADP | nucleoside-diphosphate kinase |
R353 | Pyrimidine metabolism | VV12983 | 2.7.4.14 | CMP + ATP <-> ADP + CDP | cytidylatekinase |
R354 | Pyrimidine metabolism | VV12810 | 1.8.1.9 | OTHIO + NADPH-> RTHIO + NADP | thioredoxinreductase |
R355 | Pyrimidine metabolism | VV12983 | 2.7.4.14 | DCMP + ATP <-> ADP + DCDP | cytidylatekinase |
R356 | Pyrimidine metabolism | VV12907 | 2.7.1.21 | DU + ATP-> DUMP + ADP | thymidinekinase |
R357 | Pyrimidine metabolism | VV11901 | 2.4.2.9 | URA + PRPP <-> UMP + PPI | uracilphosphoribosyltransferase |
R358 | Pyrimidine metabolism | VV10246 OR VV10484 OR VV11461 OR VV11584 OR VV11698 OR VV11855 OR VV11992 OR VV12116 OR VV12843 OR VV13016 OR VV13060 OR VV21318 | 4.2.1.70 | URA + R5P <-> PURI5P | pseudouridylate synthase |
R359 | Pyrimidine metabolism | VV10516 | 2.1.1.45 | DUMP + METTHF-> DHF + DTMP | thymidylatesynthase |
R360 | Pyrimidine metabolism | VV11728 OR VV21540 OR VV11726 | 2.4.2.1 OR 2.4.2.4 | DU + PI-> URA + DR1P | purine-nucleosidephosphorylase ORthymidinephosphorylase |
R361 | Pyrimidine metabolism | VV11726 | 2.4.2.4 | DT + PI-> TM + DR1P | thymidinephosphorylase |
R362 | Pyrimidine metabolism | VV10430 | 2.7.4.6 | DUDP + ATP <-> DUTP + ADP | nucleoside-diphosphate kinase |
R363 | Pyrimidine metabolism | VV13041 AND VV13042 | 1.17.4.1 | UDP + RTHIO-> OTHIO + DUDP | ribonucleoside-diphosphate reductase |
R364 | Pyrimidine metabolism | VV20337 | 1.17.4.2 | UTP + RTHIO-> DUTP + OTHIO | ribonucleoside-triphosphatereductase |
R365 | Pyrimidine metabolism | VV20337 | 1.17.4.2 | CTP + RTHIO-> DCTP + OTHIO | ribonucleoside-triphosphatereductase |
R366 | Pyrimidine metabolism | VV13002 | 2.7.4.9 | ATP + DUMP <-> ADP + DUDP | thymidylatekinase |
R367 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ATP + CYTD-> ADP + CMP | uridinekinase |
R368 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ATP + URI-> ADP + UMP | uridinekinase |
R369 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DATP + CYTD-> DADP + CMP | uridinekinase |
R370 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DATP + URI-> DADP + UMP | uridinekinase |
R371 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DCTP + CYTD-> DCDP + CMP | uridinekinase |
R372 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DCTP + URI-> DCDP + UMP | uridinekinase |
R373 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DGTP + CYTD-> DGDP + CMP | uridinekinase |
R374 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DGTP + URI-> DGDP + UMP | uridinekinase |
R375 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DTTP + CYTD-> DTDP + CMP | uridinekinase |
R376 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DTTP + URI-> DTDP + UMP | uridinekinase |
R377 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DUTP + CYTD-> DUDP + CMP | uridinekinase |
R378 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | DUTP + URI-> DUDP + UMP | uridinekinase |
R379 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | GTP + CYTD-> GDP + CMP | uridinekinase |
R380 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | GTP + URI-> GDP + UMP | uridinekinase |
R381 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ITP + CYTD-> IDP + CMP | uridinekinase |
R382 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | ITP + URI-> IDP + UMP | uridinekinase |
R383 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | UTP + CYTD-> UDP + CMP | uridinekinase |
R384 | Pyrimidine metabolism | VV13025 | 2.7.1.48 | UTP + URI-> UDP + UMP | uridinekinase |
R385 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | UMP-> URI + PI | 5'-nucleotidase |
R386 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | CMP-> CYTD + PI | 5'-nucleotidase |
R387 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DCMP-> DC + PI | 5'-nucleotidase |
R388 | Pyrimidine metabolism | VV10248 OR VV20237 | 3.1.3.5 | DTMP-> DT + PI | 5'-nucleotidase |
R389 | Pyrimidine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cCMP-> 3CMP | 2 ', 3'-cyclic-nucleotide2'-phosphodiesterase |
R390 | Pyrimidine metabolism | VV10728 OR VV12771 | 3.1.4.16 | 23cUMP-> 3UMP | 2 ', 3'-cyclic-nucleotide2'-phosphodiesterase |
R391 | Pyrimidine metabolism | VV20789 | 3.5.4.1 | 5MC <-> TM + NH3 | cytosinedeaminase |
R392 | Pyrimidine metabolism | VV20789 | 3.5.4.1 | CT-> URA + NH3 | cytosinedeaminase |
R393 | Pyrimidine metabolism | VV12379 | 3.5.4.5 | DC-> DU + NH3 | cytidinedeaminase |
R394 | Pyrimidine metabolism | VV12379 | 3.5.4.5 | CYTD-> URI + NH3 | cytidinedeaminase |
R395 | Pyrimidine metabolism | VV20531 | 3.5.4.12 | DCMP-> DUMP + NH3 | deoxycytidylatedeaminase |
R396 | Pyrimidine metabolism | VV12064 OR VV21373 | 2.4.2.3 | URI + PI <-> URA + R1P | uridinephosphorylase |
R397 | Glutamate metabolism | VV10889 | 6.3.1.2 | GLU + NH3 + ATP-> GLN + ADP + PI | glutaminesynthetase |
R398 | Glutamate metabolism | VV10553 AND VV10554 AND VV10555 AND VV10556 | 1.4.1.13 | GLN + AKG + NADPH-> 2 GLU + NADP | glutamatesynthase |
R399 | Glutamate metabolism | VV12356 AND VV12357 OR VV12824 | 4.1.1.19 OR 4.1.1.15 | GLU-> GABA + CO2 | biosyntheticargininedecarboxylaseORglutamatedecarboxylase |
R400 | Glutamate metabolism | VV10565 AND VV10566 | 6.3.5.5 | GLN + 2 ATP + CO2-> GLU + CAP + 2 ADP + PI | carbamoyl-phosphate synthase |
표 5
Table 5
R401 | Glutamate metabolism | VV11606 | 6.3.2.2 | ATP + GLU + CYS -> ADP + PI + GCYS | glutamate--cysteine ligase |
R402 | Glutamate metabolism | VV10236 | 6.1.1.17 | TRNAGLU + GLU + ATP -> GLUTRNAGLU + PPI + AMP | glutamyl-tRNAsynthetase |
R403 | Glutamate metabolism | VV10176 AND VV10177 | 6.1.1.18 | ATP + GLN + TRNAGLN -> AMP + PPI + GTRNA | glutaminyl-tRNAsynthetase |
R404 | Glutamate metabolism | VV11530 OR VV21204 | 6.3.2.3 | ATP + GCYS + GLY -> ADP + PI + RGT | glutathionesynthase |
R405 | Glutamate metabolism | VV11105 | 1.8.1.7 | NAD + 2 RGT <-> OGT + NADH | glutathione reductase |
R406 | Glutamate metabolism | VV11105 | 1.8.1.7 | NADP + 2 RGT <-> OGT + NADPH | glutathione reductase |
R407 | Alanine and aspartate metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | OA + GLU <-> ASP + AKG | aspartateaminotransferase |
R408 | Alanine and aspartate metabolism | VV12156 | 6.1.1.12 | ATP + ASP + TRNAASP -> AMP + PPI + ASPTRNAASP | aspartyl-tRNAsynthetase |
R409 | Alanine and aspartate metabolism | VV11593 | 6.1.1.7 | ATP + ALA + TRNAALA <-> AMP + PPI + ALATRNA | alanyl-tRNA synthetase |
R410 | Alanine and aspartate metabolism | VV12254 | 6.1.1.22 | ATP + ASN + TRNAASN -> AMP + PPI + ASNTRNAASN | asparaginyl-tRNAsynthetase |
R411 | Alanine and aspartate metabolism | VV10183 | 6.3.5.4 | ASP + ATP + GLN -> GLU + ASN + AMP + PPI | asparaginesynthase |
R412 | Alanine and aspartate metabolism | VV11328 OR VV13135 | 3.5.1.1 | ASN -> ASP + NH3 | L-asparaginase |
R413 | Alanine and aspartate metabolism | 2.6.1.2 | PYR + GLU <-> AKG + ALA | alanine dehydrogenase | |
R414 | Alanine and aspartate metabolism | VV12824 | 4.1.1.15 | ASP -> bALA + CO2 | glutamate decarboxylase |
R415 | Alanine and aspartate metabolism | VV10333 | 3.4.13.3 | CNS -> bALA + HIS | aminoacylhistidinedipeptidase |
R416 | Glycine, serine and threonine metabolism | VV10545 OR VV11365 OR VV11424 OR VV11594 | 2.7.2.4 | ASP + ATP -> ADP + BASP | aspartate kinase |
R417 | Glycine, serine and threonine metabolism | VV11989 OR VV13115 | 1.2.1.11 | BASP + NADPH -> NADP + PI + ASPSA | aspartate-semialdehyde dehydrogenase |
R418 | Glycine, serine and threonine metabolism | VV10545 OR VV11365 | 1.1.1.3 | ASPSA + NADH <-> NAD + HSER | homoserinedehydrogenase |
R419 | Glycine, serine and threonine metabolism | VV10545 OR VV11365 | 1.1.1.3 | ASPSA + NADPH <-> NADP + HSER | homoserinedehydrogenase |
R420 | Glycine, serine and threonine metabolism | VV10544 | 2.7.1.39 | HSER + ATP -> ADP + PHSER | homoserine kinase |
R421 | Glycine, serine and threonine metabolism | VV10543 | 4.2.3.1 | PHSER -> THR + PI | threonine synthase |
R422 | Glycine, serine and threonine metabolism | VV11546 | 1.1.1.95 | 3PG + NAD -> NADH + PHP | D-3-phosphoglycerate dehydrogenase |
R423 | Glycine, serine and threonine metabolism | VV12813 | 2.6.1.52 | PHP + GLU -> AKG + 3PSER | phosphoserine aminotransferase |
R424 | Glycine, serine and threonine metabolism | VV11730 | 3.1.3.3 | 3PSER -> PI + SER | phosphoserinephosphatase |
R425 | Glycine, serine and threonine metabolism | VV10286 OR VV20188 | 2.1.2.1 | THF + SER <-> GLY + METTHF | serine hydroxymethyltransferase |
R426 | Glycine, serine and threonine metabolism | VV20053 | 4.1.2.5 | THR <-> GLY + ACAL | threoninealdolase |
R427 | Glycine, serine and threonine metabolism | VV20053 | 4.1.2.5 | ATHR <-> GLY + ACAL | threoninealdolase |
R428 | Glycine, serine and threonine metabolism | VV21484 | 2.3.1.29 | ACCOA + GLY <-> COA + 2A3OB | 2-amino-3-ketobutyrate coenzyme A ligase |
R429 | Glycine, serine and threonine metabolism | VV21485 | 1.1.1.103 | THR + NAD -> 2A3OB + NADH | threonine 3-dehydrogenase |
R430 | Glycine, serine and threonine metabolism | VV20190 | 2.1.2.10 | THF + SAP -> METTHF + NH3 + DHLIPOYLPROTEIN | aminomethyltransferase |
R431 | Glycine, serine and threonine metabolism | VV20186 | 1.4.4.2 | GLY + LIPOYLPROTEIN -> SAP + CO2 | glycine cleavage system protein P |
R432 | Glycine, serine and threonine metabolism | VV11632 | 1.8.1.4 | DHLIPOYLPROTEIN + NAD -> NADH + LIPOYLPROTEIN | dihydrolipoamide dehydrogenase |
R433 | Glycine, serine and threonine metabolism | VV12260 OR VV21677 | 4.3.1.17 | SER -> PYR + NH3 | L-serine dehydratase 1 |
R434 | Glycine,serineandthreoninemetabolism | VV11028 | 4.3.1.19 | SER <-> PYR + NH3 | serine deaminase |
R435 | Glycine,serineandthreoninemetabolism | VV11028 | 4.3.1.19 | THR -> OBUT + NH3 | threoninedehydratase |
R436 | Glycine, serine and threonine metabolism | VV12378 | 2.1.2.- | THMNP + SER <-> MTHMNP + GLY | phosphoribosylglycinamide formyltransferase 2 |
R437 | Glycine, serine and threonine metabolism | VV12397 | 6.1.1.3 | ATP + THR + TRNATHR -> AMP + PPI + THRTRNATHR | threonyl-tRNA synthetase |
R438 | Glycine, serine and threonine metabolism | VV12946 | 6.1.1.11 | ATP + SER + TRNASER -> AMP + PPI + SERTRNASER | seryl-tRNAsynthetase |
R439 | Glycine, serine and threonine metabolism | VV10989 AND VV10990 | 6.1.1.14 | ATP + GLY + TRNAGLY -> AMP + PPI + GLYTRNAGLY | glycyl-tRNA synthetase |
R440 | Glycine, serine and threonine metabolism | VV13050 | 2.6.1.76 | GLU + ASPSA -> AKG + 24DAB | glutamate decarboxylase |
R441 | Glycine, serine and threonine metabolism | VV21688 | 1.1.99.1 | BAL + FAD -> FADH2 + BETAINE | choline dehydrogenase |
R442 | Glycine, serine and threonine metabolism | VV21687 | 1.2.1.8 | BAL + NAD -> BETAINE + NADH | NAD-dependent aldehyde dehydrogenase |
R443 | Glycine, serine and threonine metabolism | VV12826 | 1.1.1.- | MTG + NADPH -> HAC + NADP | alcohol dehydrogenase |
R444 | Methionine metabolism | VV12772 | 2.3.1.46 | HSER + SUCCOA <-> OSLHSER + COA | homoserine O-succinyltransferase |
R445 | Methionine metabolism | VV11364 | 2.5.1.48 | CYS + OSLHSER -> LLCT + SUCC | cystathionine beta-lyase |
R446 | Methionine metabolism | VV11364 | 2.5.1.48 | OSLHSER + H2S -> HCYS + SUCC | cystathionine beta-lyase |
R447 | Methionine metabolism | VV11364 | 2.5.1.48 | OSLHSER -> SUCC + OBUT + NH3 | cystathionine beta-lyase |
R448 | Methionine metabolism | VV11364 | 2.5.1.48 | OAHSER + CYS <-> LLCT + AC | cystathionine beta-lyase |
R449 | Methionine metabolism | VV11364 | 2.5.1.48 | OAHSER + H2S -> HCYS + AC | cystathionine beta-lyase |
R450 | Methionine metabolism | VV11364 | 2.5.1.48 | OAHSER + HO3S2 + RTHIO -> HCYS + H2SO3 + OTHIO + AC | cystathionine beta-lyase |
R451 | Methionine metabolism | VV12872 | 4.4.1.8 | LLCT -> HCYS + PYR + NH3 | cystathionine beta-lyase |
R452 | Methionine metabolism | VV11423 | 2.1.1.13 | HCYS + MTHF <-> THF + MET | methionine synthase I |
R453 | Methionine metabolism | VV12219 OR VV20996 | 2.1.1.14 | 5MTGLU + HCYS -> TGLU + MET | 5-methyltetrahydropteroyltriglutamate-homocysteinemethyltransferase |
R454 | Methionine metabolism | VV11608 | 4.4.1.21 | SRLH <-> RIB + HCYS | luxS protein involved in autoinducer AI2 synthesis |
R455 | Methionine metabolism | VV13028 | 6.1.1.10 | ATP + MET + TRNAMET -> AMP + PPI + METTRNA | methionyl-tRNA synthetase |
R456 | Methionine metabolism | VV11047 | 2.1.2.9 | METTRNA + FTHF -> THF + FMETTRNA | methionyl-tRNA formyltransferase |
R457 | Methionine metabolism | VV11536 | 2.5.1.6 | MET + ATP -> PPI + PI + SAM | S-adenosylmethionine synthetase |
R458 | Methionine metabolism | VV10558 | 3.2.2.9 | SAH <-> SRLH + AD | S-adenosylhomocysteine nucleosidase |
R459 | Cysteine metabolism | VV12872 | 4.4.1.8 | H2S + PYR + NH3 -> CYS | cystathioninebeta-lyase |
R460 | Cysteine metabolism | VV12872 | 4.4.1.8 | CYST -> PYR + NH3 + TCYS | cystathioninebeta-lyase |
R461 | Cysteine metabolism | VV11276 | 2.3.1.30 | SER + ACCOA <-> COA + ASER | serine O-acetyltransferase |
R462 | Cysteine metabolism | VV10209 OR VV13153 | 2.5.1.47 | ASER + H2S -> CYS + AC | cysteine synthase |
R463 | Cysteine metabolism | VV21457 | 1.1.1.27 | MPYR + NADH -> 3MLAC + NAD | L-lactate dehydrogenase |
R464 | Cysteine metabolism | VV10209 OR VV13153 | 2.5.1.47 | ASER + HO3S2 + RTHIO -> CYS + H2SO3 + OTHIO + AC | cysteine synthase |
R465 | Cysteine metabolism | VV10209 OR VV13153 OR VV11364* | 2.5.1.47 OR 2.5.1.48* | ASER + HO3S2 -> SSLCYS + AC | cysteine synthase |
R466 | Cysteine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | CYSTEATE + AKG <-> 3SPYR + GLU | aspartate aminotransferase |
R467 | Cysteine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | 3SLALA + AKG -> 3SFPYR + GLU | aspartate aminotransferase |
R468 | Cysteine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | MPYR + GLU -> CYS + AKG | aspartate aminotransferase |
R469 | Cysteine metabolism | VV12260 OR VV21677 | 4.3.1.17 | SER -> 2AA | L-serine dehydratase |
R470 | Cysteine metabolism | VV12908 | 6.1.1.16 | ATP + CYS + TRNACYS -> AMP + PPI + CYSTRNACYS | cysteinyl-tRNA synthetase |
R471 | Valine, leucine and isoleucine degradation | VV20489 OR VV21637 | 1.1.1.31 | HIBUT + NAD -> 3OPP + NADH | 3-hydroxyisobutyrate dehydrogenase |
R472 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | S(3MB)DHL + COA -> 3MBCOA + DLIPO | acetyltransferase |
R473 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | OIVAL + LIPO -> S(2MP)DHL + CO2 | acetyltransferase |
R474 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | S(2MP)DHL + COA -> 2MPPACOA + DLIPO | acetyltransferase |
R475 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | S(2MB)DHL + COA -> 2MBCOA + DLIPO | acetyltransferase |
R476 | Valine, leucine and isoleucine degradation | VV20496 | 1.3.99.10 | 3MBCOA + FAD -> 3MCCOA + FADH2 | acyl-CoA dehydrogenase |
R477 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3HIVCOA <-> 3MCCOA | enoyl-CoA hydratase |
R478 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 2MP2ECOA -> 3HIBCOA | enoyl-CoA hydratase |
R479 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3H2MBCOA -> 2MB2ECOA | enoyl-CoA hydratase |
R480 | Valine, leucine and isoleucine degradation | VV20497 | 6.4.1.4 | ATP + 3MCCOA + HCO3 -> ADP + PI + 3MGCOA | 3-methylcrotonyl-CoA carboxylase |
R481 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 | 1.1.1.35 | HIBUT + NAD <-> MMSA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R482 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 | 1.1.1.35 | 3H2MBCOA + NAD <-> 2MAACCOA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R483 | Valine, leucine and isoleucine degradation | VV20869 | 1.2.1.3 | MMSA + NAD -> MM + NADH | aldehyde dehydrogenase |
R484 | Valine, leucine and isoleucine degradation | VV10982 OR VV11975 | 2.3.1.16 | COA + 2MAACCOA -> PPACOA + ACCOA | acetyl-CoA acyltransferase |
R485 | Valine,leucineandisoleucinebiosynthesis | VV11077 | 1.1.1.86 | ACLAC + NADPH -> NADP + DHMVA | ketol-acid reductoisomerase |
R486 | Valine,leucineandisoleucinebiosynthesis | VV11029 | 4.2.1.9 | DHMVA -> OIVAL | dihydroxy-acid dehydratase |
R487 | Valine,leucineandisoleucinebiosynthesis | VV11030 | 2.6.1.42 | OIVAL + GLU <-> AKG + VAL | branched-chain amino acid aminotransferase |
R488 | Valine, leucine and isoleucine biosynthesis | VV10992 | 2.6.1.66 | OIVAL + ALA -> VAL + PYR | valine-pyruvate aminotransferase |
R489 | Valine, leucine and isoleucine biosynthesis | (VV10647 AND VV10648) OR (VV11031 AND VV11032) | 2.2.1.6 | OBUT + 2(HE)TPP -> ABUT + THMPP | acetolactate synthase |
R490 | Valine, leucine and isoleucine biosynthesis | VV11077 | 1.1.1.86 | ABUT + NADPH -> NADP + DHMP | ketol-acid reductoisomerase |
R491 | Valine, leucine and isoleucine biosynthesis | VV11029 | 4.2.1.9 | DHMP -> 3MOP | dihydroxy-acid dehydratase |
R492 | Valine, leucine and isoleucine biosynthesis | VV11030 | 2.6.1.42 | 3MOP + GLU <-> AKG + ILE | branched-chain amino acid aminotransferase |
R493 | Valine, leucine and isoleucine biosynthesis | VV10654 | 2.3.3.13 | ACCOA + OIVAL -> COA + IPPMAL | isopropylmalate synthase |
R494 | Valine, leucine and isoleucine biosynthesis | VV10656 AND VV10657 | 4.2.1.33 | IPPMAL <-> CBHCAP | 3-isopropylmalatedehydratase |
R495 | Valine, leucine and isoleucine biosynthesis | VV10655 | 1.1.1.85 | CBHCAP + NAD -> NADH + OICAP | isopropylmalatedehydrogenase |
R496 | Valine, leucine and isoleucine biosynthesis | OICAP -> 4MOP + CO2 | spontaneous | ||
R497 | Valine, leucine and isoleucine biosynthesis | VV11030 | 2.6.1.42 | 4MOP + GLU <-> AKG + LEU | branched-chain amino acid aminotransferase |
R498 | Valine, leucine and isoleucine biosynthesis | VV10272 | 6.1.1.4 | ATP + LEU + TRNALEU -> AMP + PPI + LEUTRNA | leucyl-tRNA synthetase |
R499 | Valine, leucine and isoleucine biosynthesis | VV11474 | 6.1.1.9 | ATP + VAL + TRNAVAL -> AMP + PPI + VALTRNAVAL | valyl-tRNA synthetase |
R500 | Valine, leucine and isoleucine biosynthesis | VV10507 | 6.1.1.5 | ATP + ILE + TRNAILE -> AMP + PPI + ILETRNAILE | isoleucyl-tRNA synthetase |
R501 | Lysine biosynthesis | VV11912 | 4.2.1.52 | ASPSA + PYR -> DHDP | dihydrodipicolinate synthase |
R502 | Lysine biosynthesis | VV10567 | 1.3.1.26 | DHDP + NADPH -> NADP + TDHDP | dihydrodipicolinate reductase |
R503 | Lysine biosynthesis | VV10567 | 1.3.1.26 | DHDP + NADH -> NAD + TDHDP | dihydrodipicolinate reductase |
R504 | Lysine biosynthesis | VV11790 | 2.3.1.117 | TDHDP + SUCCOA -> SAOPIM + COA | tetrahydrodipicolinate N-succinyltransferase |
R505 | Lysine biosynthesis | 2.6.1.17 | SAOPIM + GLU -> SDAPIM + AKG | succinyldiaminopimelate transaminase | |
R506 | Lysine biosynthesis | VV11916 | 3.5.1.18 | SDAPIM -> DAPIM + SUCC | succinyl-diaminopimelate desuccinylase |
R507 | Lysine biosynthesis | VV11127 | 5.1.1.7 | DAPIM <-> MDAPIM | diaminopimelate epimerase |
R508 | Lysine biosynthesis | VV11126 | 4.1.1.20 | MDAPIM -> LYS + CO2 | diaminopimelate decarboxylase |
R509 | Lysine biosynthesis | VV10526 OR VV11270 | 6.1.1.6 | ATP + LYS + TRNALYS -> AMP + PPI + LYSTRNA | lysyl-tRNAsynthetase |
R510 | Lysine degradation | VV10157 | 1.2.4.2 | 2OAD + LIPO -> SGDHL + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R511 | Lysine degradation | VV10156 | 2.3.1.61 | GLUTCOA + DLIPO <-> COA + SGDHL | 2-oxoglutarate dehydrogenase E2 component |
R512 | Arginine and proline metabolism | VV11467 | 3.5.3.6 | ARG -> CITR + NH3 | arginine deiminase |
R513 | Arginine and proline metabolism | VV11314 | 2.3.1.109 | SUCCOA + ARG <-> COA + N2SUCCARG | arginineN-succinyltransferase |
R514 | Arginine and proline metabolism | VV10145 | 6.1.1.19 | ATP + ARG + TRNAARG <-> AMP + PPI + ARGTRNAARG | arginyl-tRNA synthetase |
R515 | Arginine and proline metabolism | VV21030 OR VV21235 | 4.1.1.17 | ORN -> PTRC + CO2 | diaminopimelate decarboxylase |
R516 | Arginine and proline metabolism | VV12355 | 3.5.3.11 | AGMATINE -> PTRC + UREA | agmatinase |
R517 | Arginine and proline metabolism | VV12356 AND VV12357 | 4.1.1.19 | ARG -> AGMATINE + CO2 | biosynthetic arginine decarboxylase |
R518 | Arginine and proline metabolism | VV11315 | 1.2.1.- | N2SUCCGLU5SA + NAD <-> N2SUCCGLU + NADH | aldehydedehydrogenase |
R519 | Arginine and proline metabolism | VV12783 | 3.5.1.- | N2SUCCGLU -> GLU + SUCC | succinylglutamate desuccinylase |
R520 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | P5C + NAD -> NADH + GLU | 1-pyrroline-5-carboxylatedehydrogenase |
R521 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | P5C + NADP -> NADPH + GLU | 1-pyrroline-5-carboxylatedehydrogenase |
R522 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | GLUGSAL + NAD -> NADH + GLU | 1-pyrroline-5-carboxylate dehydrogenase |
R523 | Arginine and proline metabolism | VV21118 | 1.5.99.8 | PRO + FAD -> P5C + FADH2 | proline dehydrogenase |
R524 | Arginine and proline metabolism | VV11838 | 6.1.1.15 | ATP + PRO + TRNAPRO -> AMP + PPI + PROTRNAPRO | prolyl-tRNA synthetase |
R525 | Arginine and proline metabolism | VV21118 | 1.5.99.8 OR 1.5.1.12 | 4HPRO + FAD -> L1P3H5C + FADH2 | proline dehydrogenase |
R526 | Arginine and proline metabolism | VV11524 | 1.5.1.2 | L1P3H5C + NADH -> 4HPRO + NAD | pyrroline-5-carboxylate reductase |
R527 | Arginine and proline metabolism | VV11524 | 1.5.1.2 | L1P3H5C + NADPH -> 4HPRO + NADP | pyrroline-5-carboxylate reductase |
R528 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | L1P3H5C + NAD -> E4HGLU + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R529 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | L1P3H5C + NADP -> E4HGLU + NADPH | 1-pyrroline-5-carboxylate dehydrogenase |
R530 | Arginine and proline metabolism | VV21118 | 1.5.1.12 OR 1.5.99.8 | E4HGLU + NAD <-> 4HGLUSA + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R531 | Arginine and proline metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | E4HGLU + AKG -> HYDROXYAKG + GLU | aspartate aminotransferase |
R532 | Arginine and proline metabolism | VV11102 OR VV20904 OR VV21072 | 4.1.2.14 | HYDROXYAKG <-> PYR + GLX | 4-hydroxy-2-oxoglutaratealdolase |
R533 | Arginine and proline metabolism | VV20869 | 1.2.1.3 | N4AAB + NAD -> 4AABUT + NADH | aldehyde dehydrogenase |
R534 | Arginine and proline metabolism | VV20869 | 1.2.1.3 | 4AB + NADP -> GABA + NADPH | aldehyde dehydrogenase |
R535 | Arginine and proline metabolism | VV21635 | 2.5.1.16 | SAMA + PTRC -> 5MTA + SPRMD | spermidine synthase |
R536 | Arginine and proline metabolism | VV10333 | 3.4.13.3 | HCNS -> GABA + HIS | aminoacylhistidinedipeptidase |
R537 | Arginine and proline metabolism | VV10558 | 3.2.2.16 | 5MTA -> AD + 5MDR | 5'-methylthioadenosine nucleosidase |
R538 | Arginine and proline metabolism | VV11600 AND VV11601 AND VV11602 OR VV11102 OR VV20904 OR VV21072 | 4.1.1.3 OR 4.1.3.16 | HYDROXYAKG -> PYR + GLX | oxaloacetatedecarboxylaseOR4-hydroxy-2-oxoglutaratealdolase |
R539 | Histidine metabolism | VV12920 | 2.4.2.17 | PRPP + ATP -> PPI + PRBATP | ATP phosphoribosyltransferase |
R540 | Histidine metabolism | VV12913 | 3.6.1.31 | PRBATP -> PPI + PRBAMP | phosphoribosyl-ATP pyrophosphohydrolase |
R541 | Histidine metabolism | VV12913 | 3.5.4.19 | PRBAMP -> PRFP | phosphoribosyl-AMP cyclohydrolase |
R542 | Histidine metabolism | VV12915 | 5.3.1.16 | PRFP -> PRLP | phosphoribosylformimino-5-aminoimidazolecarboxamideribotideisomerase |
R543 | Histidine metabolism | VV12914 AND VV12916 | 2.4.2.- | PRLP + GLN -> GLU + AICAR + DIMGP | imidazoleglycerol-phosphatesynthase/glutamineamidotransferase |
R544 | Histidine metabolism | VV12917 | 4.2.1.19 | DIMGP -> IMACP | imidazoleglycerol-phosphate dehydratase |
R545 | Histidine metabolism | VV12918 | 2.6.1.9 | IMACP + GLU -> AKG + HISOLP | histidinol-phosphate aminotransferase |
R546 | Histidine metabolism | VV12917 | 3.1.3.15 | HISOLP -> PI + HISOL | histidinol-phosphatase |
R547 | Histidine metabolism | VV12919 | 1.1.1.23 | HISOL+2NAD->HIS+2NADH | histidinol dehydrogenase |
R548 | Histidine metabolism | VV11153 | 2.1.1.- | HIS + SAM -> NMHIS + SAH | N6-adenine-specific methylase |
R549 | Histidine metabolism | VV10426 | 6.1.1.21 | ATP + HIS + TRNAHIS -> AMP + PPI + HISTRNAHIS | histidyl-tRNA synthetase |
R550 | Histidine metabolism | VV10053 OR VV12389 | 4.3.1.3 | HIS -> UC + NH3 | histidine ammonia-lyase |
R551 | Histidine metabolism | VV12390 | 4.2.1.49 | UC -> 4I5P | urocanate hydratase |
R552 | Histidine metabolism | VV12392 | 3.5.2.7 | 4I5P -> NFGLU | imidazolonepropionase |
R553 | Histidine metabolism | VV12391 | 3.5.3.8 | NFGLU -> GLU + FA | formiminoglutamase |
R554 | Histidine metabolism | VV20869 | 1.2.1.3 | I4AA + NAD -> I4AC + NADH | aldehyde dehydrogenase |
R555 | Tyrosine metabolism | VV11345 | 5.3.3.10 | 5CM2HM -> 5C2O3E | 5-carboxymethyl-2-hydroxymuconate isomerase |
R556 | Tyrosine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | AKG + TYR <-> 4HPP + GLU | aspartate aminotransferase |
R557 | Tyrosine metabolism | VV12768 | 1.13.11.27 | 4HPP + O2 -> HOMOGEN + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R558 | Tyrosine metabolism | VV12765 | 5.2.1.2 | 4MAAC -> 4FAAC | maleylacetoacetate isomerase |
R559 | Tyrosine metabolism | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | 34DHPEG + NAD <-> 34DHMA + NADH | alcohol dehydrogenase |
R560 | Phenylalanine metabolism | VV12248 OR VV13174 OR VV20334 OR VV12918 | 2.6.1.1OR2.6.1.9 | PHE + AKG <-> PHPYR + GLU | aspartate aminotransferase |
R561 | Phenylalanine metabolism | VV12768 | 1.13.11.27 | PHPYR + O2 -> 2HPA + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R562 | Phenylalanine metabolism | VV10414 | 1.4.99.1 | DPHE -> PHPYR + NH3 | D-amino-acid dehydrogenase |
R563 | Tryptophan metabolism | VV20854 | 4.1.99.1 | TRP -> INDOLE + PYR + NH3 | tryptophanase |
R564 | Tryptophan metabolism | VV11307 | 6.1.1.2 | ATP + TRP + TRNATRP -> AMP + PPI + TRPTRNATRP | tryptophanyl-tRNA synthetase |
R565 | Tryptophan metabolism | VV20869 | 1.2.1.3 | 5HIAA + NAD -> 5HIAC + NADH | aldehyde dehydrogenase |
R566 | Tryptophan metabolism | VV20869 | 1.2.1.3 | I3AA + NAD -> I3AC + NADH | aldehyde dehydrogenase |
R567 | Tryptophan metabolism | VV12755 OR VV21473 | 1.11.1.6 | 2 3HAN + 2 O2 -> CVN + 2 H2O2 | catalase |
R568 | Tryptophan metabolism | VV10157 | 1.2.4.2 | 2OAD + COA + NAD -> GLUTCOA + CO2 + NADH | 2-oxoglutarate dehydrogenase E1 component |
R569 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10495 OR VV12654 OR VV20558 OR VV20833 | 2.5.1.54 | E4P + PEP -> PI + 3DDAH7P | 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase |
R570 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11383 | 4.2.3.4 | 3DDAH7P -> DQT + PI | 3-dehydroquinate synthetase |
R571 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11236 | 4.2.1.10 | DQT -> DHSK | 3-dehydroquinate dehydratase II |
R572 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11236 | 4.2.1.10 | DHSK <-> 34DHB | 3-dehydroquinate dehydratase II |
R573 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11057 | 1.1.1.25 | DHSK + NADPH -> SME + NADP | shikimate5-dehydrogenase |
R574 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11382 | 2.7.1.71 | SME + ATP -> ADP + SME3P | shikimate kinase |
R575 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV12126 AND VV12127 | 2.5.1.19 | SME3P + PEP -> 3PSME + PI | 3-phosphoshikimate 1-carboxyvinyltransferase |
R576 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11981 | 4.2.3.5 | 3PSME -> PI + CHOR | chorismate synthase |
R577 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13064 AND VV13065 | 4.1.3.27 | CHOR + GLN -> GLU + PYR + AN | anthranilate synthase |
R578 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13064 AND VV13065 | 4.1.3.27 | CHOR + NH3 -> AN + PYR | anthranilate synthase |
R579 | Phenylalanine,tyrosineandtryptophanbiosynthesis | VV13066 | 2.4.2.18 | AN + PRPP -> PPI + NPRAN | anthranilate phosphoribosyltransferase |
R580 | Phenylalanine,tyrosineandtryptophanbiosynthesis | VV13067 | 5.3.1.24 | NPRAN -> CPAD5P | phosphoribosylanthranilate isomerase |
R581 | Phenylalanine,tyrosineandtryptophanbiosynthesis | VV13067 | 4.1.1.48 | CPAD5P -> CO2 + IGP | indole-3-glycerolphosphatesynthase |
R582 | Phenylalanine,tyrosineandtryptophanbiosynthesis | VV13068 AND VV13069 | 4.2.1.20 | IGP + SER -> G3P + TRP | tryptophansynthase |
R583 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13068 AND VV13069 | 4.2.1.20 | SER + INDOLE -> TRP | tryptophansynthase |
R584 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13068 AND VV13069 | 4.2.1.20 | INDOLE + G3P <-> IGP | tryptophansynthase |
R585 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10487 OR VV10494 | 5.4.99.5 | CHOR <-> PHEN | chorismatemutase |
R586 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10487 | 4.2.1.51 | PHEN -> CO2 + PHPYR | prephenate dehydratase |
R587 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV12370 AND VV12371 | 6.1.1.20 | ATP + PHE + TRNAPHE -> AMP + PPI + PHETRNAPHE | phenylalanyl-tRNA synthetase |
R588 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10494 | 1.3.1.12 | PHEN + NAD -> 4HPP + CO2 + NADH | prephenatedehydrogenase |
R589 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV12918 | 2.6.1.9 | 4HPP + GLU -> AKG + TYR | histidinol-phosphate aminotransferase |
R590 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11683 OR VV20878 | 6.1.1.1 | ATP + TYR + TRNATYR -> AMP + PPI + TRYTRNATYR | tyrosyl-tRNA synthetase |
R591 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10487 | 4.2.1.51 | AG -> PHE + CO2 | prephenate dehydratase |
R592 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV20455 | 1.14.16.1 | THBPT + PHE + O2 -> DHBPT + TYR | phenylalanine-4-hydroxylase |
R593 | Urea cycle and metabolism of amino groups | VV10326 | 2.7.2.11 | GLU + ATP -> ADP + GLUP | glutamate 5-kinase |
R594 | Urea cycle and metabolism of amino groups | VV10325 | 1.2.1.41 | GLUP + NADPH -> NADP + PI + GLUGSAL | gamma-glutamyl phosphate reductase |
R595 | Urea cycle and metabolism of amino groups | GLUGSAL <-> P5C | spontaneous | ||
R596 | Urea cycle and metabolism of amino groups | VV11524 | 1.5.1.2 | P5C + NADPH <-> PRO + NADP | pyrroline-5-carboxylate reductase |
R597 | Urea cycle and metabolism of amino groups | VV11524 | 1.5.1.2 | PRO + NAD <-> P5C + NADH | pyrroline-5-carboxylate reductase |
R598 | Urea cycle and metabolism of amino groups | VV11799 | 2.3.1.1 | GLU + ACCOA -> COA + NAGLU | amino-acid N-acetyltransferase |
R599 | Urea cycle and metabolism of amino groups | VV11372 | 2.7.2.8 | NAGLU + ATP -> ADP + NAGLUP | acetylglutamate kinase |
R600 | Urea cycle and metabolism of amino groups | VV11371 | 1.2.1.38 | NAGLUP + NADPH -> NADP + PI + NAGLUS | N-acetyl-gamma-glutamyl-phosphate reductase |
R401 | Glutamate metabolism | VV11606 | 6.3.2.2 | ATP + GLU + CYS-> ADP + PI + GCYS | glutamate--cysteine ligase |
R402 | Glutamate metabolism | VV10236 | 6.1.1.17 | TRNAGLU + GLU + ATP-> GLUTRNAGLU + PPI + AMP | glutamyl-tRNAsynthetase |
R403 | Glutamate metabolism | VV10176 AND VV10177 | 6.1.1.18 | ATP + GLN + TRNAGLN-> AMP + PPI + GTRNA | glutaminyl-tRNAsynthetase |
R404 | Glutamate metabolism | VV11530 OR VV21204 | 6.3.2.3 | ATP + GCYS + GLY-> ADP + PI + RGT | glutathionesynthase |
R405 | Glutamate metabolism | VV11105 | 1.8.1.7 | NAD + 2 RGT <-> OGT + NADH | glutathione reductase |
R406 | Glutamate metabolism | VV11105 | 1.8.1.7 | NADP + 2 RGT <-> OGT + NADPH | glutathione reductase |
R407 | Alanine and aspartate metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | OA + GLU <-> ASP + AKG | aspartateaminotransferase |
R408 | Alanine and aspartate metabolism | VV12156 | 6.1.1.12 | ATP + ASP + TRNAASP-> AMP + PPI + ASPTRNAASP | aspartyl-tRNAsynthetase |
R409 | Alanine and aspartate metabolism | VV11593 | 6.1.1.7 | ATP + ALA + TRNAALA <-> AMP + PPI + ALATRNA | alanyl-tRNA synthetase |
R410 | Alanine and aspartate metabolism | VV12254 | 6.1.1.22 | ATP + ASN + TRNAASN-> AMP + PPI + ASNTRNAASN | asparaginyl-tRNAsynthetase |
R411 | Alanine and aspartate metabolism | VV10183 | 6.3.5.4 | ASP + ATP + GLN-> GLU + ASN + AMP + PPI | asparaginesynthase |
R412 | Alanine and aspartate metabolism | VV11328 OR VV13135 | 3.5.1.1 | ASN-> ASP + NH3 | L-asparaginase |
R413 | Alanine and aspartate metabolism | 2.6.1.2 | PYR + GLU <-> AKG + ALA | alanine dehydrogenase | |
R414 | Alanine and aspartate metabolism | VV12824 | 4.1.1.15 | ASP-> bALA + CO2 | glutamate decarboxylase |
R415 | Alanine and aspartate metabolism | VV10333 | 3.4.13.3 | CNS-> bALA + HIS | aminoacylhistidinedipeptidase |
R416 | Glycine, serine and threonine metabolism | VV10545 OR VV11365 OR VV11424 OR VV11594 | 2.7.2.4 | ASP + ATP-> ADP + BASP | aspartate kinase |
R417 | Glycine, serine and threonine metabolism | VV11989 OR VV13115 | 1.2.1.11 | BASP + NADPH-> NADP + PI + ASPSA | aspartate-semialdehyde dehydrogenase |
R418 | Glycine, serine and threonine metabolism | VV10545 OR VV11365 | 1.1.1.3 | ASPSA + NADH <-> NAD + HSER | homoserinedehydrogenase |
R419 | Glycine, serine and threonine metabolism | VV10545 OR VV11365 | 1.1.1.3 | ASPSA + NADPH <-> NADP + HSER | homoserinedehydrogenase |
R420 | Glycine, serine and threonine metabolism | VV10544 | 2.7.1.39 | HSER + ATP-> ADP + PHSER | homoserine kinase |
R421 | Glycine, serine and threonine metabolism | VV10543 | 4.2.3.1 | PHSER-> THR + PI | threonine synthase |
R422 | Glycine, serine and threonine metabolism | VV11546 | 1.1.1.95 | 3PG + NAD-> NADH + PHP | D-3-phosphoglycerate dehydrogenase |
R423 | Glycine, serine and threonine metabolism | VV12813 | 2.6.1.52 | PHP + GLU-> AKG + 3PSER | phosphoserine aminotransferase |
R424 | Glycine, serine and threonine metabolism | VV11730 | 3.1.3.3 | 3PSER-> PI + SER | phosphoserinephosphatase |
R425 | Glycine, serine and threonine metabolism | VV10286 OR VV20188 | 2.1.2.1 | THF + SER <-> GLY + METTHF | serine hydroxymethyltransferase |
R426 | Glycine, serine and threonine metabolism | VV20053 | 4.1.2.5 | THR <-> GLY + ACAL | threoninealdolase |
R427 | Glycine, serine and threonine metabolism | VV20053 | 4.1.2.5 | ATHR <-> GLY + ACAL | threoninealdolase |
R428 | Glycine, serine and threonine metabolism | VV21484 | 2.3.1.29 | ACCOA + GLY <-> COA + 2A3OB | 2-amino-3-ketobutyrate coenzyme A ligase |
R429 | Glycine, serine and threonine metabolism | VV21485 | 1.1.1.103 | THR + NAD-> 2A3OB + NADH | threonine 3-dehydrogenase |
R430 | Glycine, serine and threonine metabolism | VV20190 | 2.1.2.10 | THF + SAP-> METTHF + NH3 + DHLIPOYLPROTEIN | aminomethyltransferase |
R431 | Glycine, serine and threonine metabolism | VV20186 | 1.4.4.2 | GLY + LIPOYLPROTEIN-> SAP + CO2 | glycine cleavage system protein P |
R432 | Glycine, serine and threonine metabolism | VV11632 | 1.8.1.4 | DHLIPOYLPROTEIN + NAD-> NADH + LIPOYLPROTEIN | dihydrolipoamide dehydrogenase |
R433 | Glycine, serine and threonine metabolism | VV12260 OR VV21677 | 4.3.1.17 | SER-> PYR + NH3 | L-serine dehydratase 1 |
R434 | Glycine, serineandthreoninemetabolism | VV11028 | 4.3.1.19 | SER <-> PYR + NH3 | serine deaminase |
R435 | Glycine, serineandthreoninemetabolism | VV11028 | 4.3.1.19 | THR-> OBUT + NH3 | threoninedehydratase |
R436 | Glycine, serine and threonine metabolism | VV12378 | 2.1.2.- | THMNP + SER <-> MTHMNP + GLY | phosphoribosylglycinamide formyltransferase 2 |
R437 | Glycine, serine and threonine metabolism | VV12397 | 6.1.1.3 | ATP + THR + TRNATHR-> AMP + PPI + THRTRNATHR | threonyl-tRNA synthetase |
R438 | Glycine, serine and threonine metabolism | VV12946 | 6.1.1.11 | ATP + SER + TRNASER-> AMP + PPI + SERTRNASER | seryl-tRNAsynthetase |
R439 | Glycine, serine and threonine metabolism | VV10989 AND VV10990 | 6.1.1.14 | ATP + GLY + TRNAGLY-> AMP + PPI + GLYTRNAGLY | glycyl-tRNA synthetase |
R440 | Glycine, serine and threonine metabolism | VV13050 | 2.6.1.76 | GLU + ASPSA-> AKG + 24DAB | glutamate decarboxylase |
R441 | Glycine, serine and threonine metabolism | VV21688 | 1.1.99.1 | BAL + FAD-> FADH2 + BETAINE | choline dehydrogenase |
R442 | Glycine, serine and threonine metabolism | VV21687 | 1.2.1.8 | BAL + NAD-> BETAINE + NADH | NAD-dependent aldehyde dehydrogenase |
R443 | Glycine, serine and threonine metabolism | VV12826 | 1.1.1.- | MTG + NADPH-> HAC + NADP | alcohol dehydrogenase |
R444 | Methionine metabolism | VV12772 | 2.3.1.46 | HSER + SUCCOA <-> OSLHSER + COA | homoserine O-succinyltransferase |
R445 | Methionine metabolism | VV11364 | 2.5.1.48 | CYS + OSLHSER-> LLCT + SUCC | cystathionine beta-lyase |
R446 | Methionine metabolism | VV11364 | 2.5.1.48 | OSLHSER + H2S-> HCYS + SUCC | cystathionine beta-lyase |
R447 | Methionine metabolism | VV11364 | 2.5.1.48 | OSLHSER-> SUCC + OBUT + NH3 | cystathionine beta-lyase |
R448 | Methionine metabolism | VV11364 | 2.5.1.48 | OAHSER + CYS <-> LLCT + AC | cystathionine beta-lyase |
R449 | Methionine metabolism | VV11364 | 2.5.1.48 | OAHSER + H2S-> HCYS + AC | cystathionine beta-lyase |
R450 | Methionine metabolism | VV11364 | 2.5.1.48 | OAHSER + HO3S2 + RTHIO-> HCYS + H2SO3 + OTHIO + AC | cystathionine beta-lyase |
R451 | Methionine metabolism | VV12872 | 4.4.1.8 | LLCT-> HCYS + PYR + NH3 | cystathionine beta-lyase |
R452 | Methionine metabolism | VV11423 | 2.1.1.13 | HCYS + MTHF <-> THF + MET | methionine synthase I |
R453 | Methionine metabolism | VV12219 OR VV20996 | 2.1.1.14 | 5MTGLU + HCYS-> TGLU + MET | 5-methyltetrahydropteroyltriglutamate-homocysteinemethyltransferase |
R454 | Methionine metabolism | VV11608 | 4.4.1.21 | SRLH <-> RIB + HCYS | luxS protein involved in autoinducer AI2 synthesis |
R455 | Methionine metabolism | VV13028 | 6.1.1.10 | ATP + MET + TRNAMET-> AMP + PPI + METTRNA | methionyl-tRNA synthetase |
R456 | Methionine metabolism | VV11047 | 2.1.2.9 | METTRNA + FTHF-> THF + FMETTRNA | methionyl-tRNA formyltransferase |
R457 | Methionine metabolism | VV11536 | 2.5.1.6 | MET + ATP-> PPI + PI + SAM | S-adenosylmethionine synthetase |
R458 | Methionine metabolism | VV10558 | 3.2.2.9 | SAH <-> SRLH + AD | S-adenosylhomocysteine nucleosidase |
R459 | Cysteine metabolism | VV12872 | 4.4.1.8 | H2S + PYR + NH3-> CYS | cystathioninebeta-lyase |
R460 | Cysteine metabolism | VV12872 | 4.4.1.8 | CYST-> PYR + NH3 + TCYS | cystathioninebeta-lyase |
R461 | Cysteine metabolism | VV11276 | 2.3.1.30 | SER + ACCOA <-> COA + ASER | serine O-acetyltransferase |
R462 | Cysteine metabolism | VV10209 OR VV13153 | 2.5.1.47 | ASER + H2S-> CYS + AC | cysteine synthase |
R463 | Cysteine metabolism | VV21457 | 1.1.1.27 | MPYR + NADH-> 3MLAC + NAD | L-lactate dehydrogenase |
R464 | Cysteine metabolism | VV10209 OR VV13153 | 2.5.1.47 | ASER + HO3S2 + RTHIO-> CYS + H2SO3 + OTHIO + AC | cysteine synthase |
R465 | Cysteine metabolism | VV10209 OR VV13153 OR VV11364 * | 2.5.1.47 OR 2.5.1.48 * | ASER + HO3S2-> SSLCYS + AC | cysteine synthase |
R466 | Cysteine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | CYSTEATE + AKG <-> 3SPYR + GLU | aspartate aminotransferase |
R467 | Cysteine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | 3SLALA + AKG-> 3SFPYR + GLU | aspartate aminotransferase |
R468 | Cysteine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | MPYR + GLU-> CYS + AKG | aspartate aminotransferase |
R469 | Cysteine metabolism | VV12260 OR VV21677 | 4.3.1.17 | SER-> 2AA | L-serine dehydratase |
R470 | Cysteine metabolism | VV12908 | 6.1.1.16 | ATP + CYS + TRNACYS-> AMP + PPI + CYSTRNACYS | cysteinyl-tRNA synthetase |
R471 | Valine, leucine and isoleucine degradation | VV20489 OR VV21637 | 1.1.1.31 | HIBUT + NAD-> 3OPP + NADH | 3-hydroxyisobutyrate dehydrogenase |
R472 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | S (3MB) DHL + COA-> 3MBCOA + DLIPO | acetyltransferase |
R473 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | OIVAL + LIPO-> S (2MP) DHL + CO2 | acetyltransferase |
R474 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | S (2MP) DHL + COA-> 2MPPACOA + DLIPO | acetyltransferase |
R475 | Valine, leucine and isoleucine degradation | VV11716 OR VV12448 OR VV21136 OR VV21651 | 2.3.1.- | S (2MB) DHL + COA-> 2MBCOA + DLIPO | acetyltransferase |
R476 | Valine, leucine and isoleucine degradation | VV20496 | 1.3.99.10 | 3MBCOA + FAD-> 3MCCOA + FADH2 | acyl-CoA dehydrogenase |
R477 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3HIVCOA <-> 3MCCOA | enoyl-CoA hydratase |
R478 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 2MP2ECOA-> 3HIBCOA | enoyl-CoA hydratase |
R479 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 OR VV20490 OR VV20491 OR VV20498 | 4.2.1.17 | 3H2MBCOA-> 2MB2ECOA | enoyl-CoA hydratase |
R480 | Valine, leucine and isoleucine degradation | VV20497 | 6.4.1.4 | ATP + 3MCCOA + HCO3-> ADP + PI + 3MGCOA | 3-methylcrotonyl-CoA carboxylase |
R481 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 | 1.1.1.35 | HIBUT + NAD <-> MMSA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R482 | Valine, leucine and isoleucine degradation | VV10981 OR VV11976 | 1.1.1.35 | 3H2MBCOA + NAD <-> 2MAACCOA + NADH | 3-hydroxyacyl-CoA dehydrogenase |
R483 | Valine, leucine and isoleucine degradation | VV20869 | 1.2.1.3 | MMSA + NAD-> MM + NADH | aldehyde dehydrogenase |
R484 | Valine, leucine and isoleucine degradation | VV10982 OR VV11975 | 2.3.1.16 | COA + 2MAACCOA-> PPACOA + ACCOA | acetyl-CoA acyltransferase |
R485 | Valine, leucineandisoleucinebiosynthesis | VV11077 | 1.1.1.86 | ACLAC + NADPH-> NADP + DHMVA | ketol-acid reductoisomerase |
R486 | Valine, leucineandisoleucinebiosynthesis | VV11029 | 4.2.1.9 | DHMVA-> OIVAL | dihydroxy-acid dehydratase |
R487 | Valine, leucineandisoleucinebiosynthesis | VV11030 | 2.6.1.42 | OIVAL + GLU <-> AKG + VAL | branched-chain amino acid aminotransferase |
R488 | Valine, leucine and isoleucine biosynthesis | VV10992 | 2.6.1.66 | OIVAL + ALA-> VAL + PYR | valine-pyruvate aminotransferase |
R489 | Valine, leucine and isoleucine biosynthesis | (VV10647 AND VV10648) OR (VV11031 AND VV11032) | 2.2.1.6 | OBUT + 2 (HE) TPP-> ABUT + THMPP | acetolactate synthase |
R490 | Valine, leucine and isoleucine biosynthesis | VV11077 | 1.1.1.86 | ABUT + NADPH-> NADP + DHMP | ketol-acid reductoisomerase |
R491 | Valine, leucine and isoleucine biosynthesis | VV11029 | 4.2.1.9 | DHMP-> 3MOP | dihydroxy-acid dehydratase |
R492 | Valine, leucine and isoleucine biosynthesis | VV11030 | 2.6.1.42 | 3MOP + GLU <-> AKG + ILE | branched-chain amino acid aminotransferase |
R493 | Valine, leucine and isoleucine biosynthesis | VV10654 | 2.3.3.13 | ACCOA + OIVAL-> COA + IPPMAL | isopropylmalate synthase |
R494 | Valine, leucine and isoleucine biosynthesis | VV10656 AND VV10657 | 4.2.1.33 | IPPMAL <-> CBHCAP | 3-isopropylmalatedehydratase |
R495 | Valine, leucine and isoleucine biosynthesis | VV10655 | 1.1.1.85 | CBHCAP + NAD-> NADH + OICAP | isopropylmalatedehydrogenase |
R496 | Valine, leucine and isoleucine biosynthesis | OICAP-> 4MOP + CO2 | spontaneous | ||
R497 | Valine, leucine and isoleucine biosynthesis | VV11030 | 2.6.1.42 | 4MOP + GLU <-> AKG + LEU | branched-chain amino acid aminotransferase |
R498 | Valine, leucine and isoleucine biosynthesis | VV10272 | 6.1.1.4 | ATP + LEU + TRNALEU-> AMP + PPI + LEUTRNA | leucyl-tRNA synthetase |
R499 | Valine, leucine and isoleucine biosynthesis | VV11474 | 6.1.1.9 | ATP + VAL + TRNAVAL-> AMP + PPI + VALTRNAVAL | valyl-tRNA synthetase |
R500 | Valine, leucine and isoleucine biosynthesis | VV10507 | 6.1.1.5 | ATP + ILE + TRNAILE-> AMP + PPI + ILETRNAILE | isoleucyl-tRNA synthetase |
R501 | Lysine biosynthesis | VV11912 | 4.2.1.52 | ASPSA + PYR-> DHDP | dihydrodipicolinate synthase |
R502 | Lysine biosynthesis | VV10567 | 1.3.1.26 | DHDP + NADPH-> NADP + TDHDP | dihydrodipicolinate reductase |
R503 | Lysine biosynthesis | VV10567 | 1.3.1.26 | DHDP + NADH-> NAD + TDHDP | dihydrodipicolinate reductase |
R504 | Lysine biosynthesis | VV11790 | 2.3.1.117 | TDHDP + SUCCOA-> SAOPIM + COA | tetrahydrodipicolinate N-succinyltransferase |
R505 | Lysine biosynthesis | 2.6.1.17 | SAOPIM + GLU-> SDAPIM + AKG | succinyldiaminopimelate transaminase | |
R506 | Lysine biosynthesis | VV11916 | 3.5.1.18 | SDAPIM-> DAPIM + SUCC | succinyl-diaminopimelate desuccinylase |
R507 | Lysine biosynthesis | VV11127 | 5.1.1.7 | DAPIM <-> MDAPIM | diaminopimelate epimerase |
R508 | Lysine biosynthesis | VV11126 | 4.1.1.20 | MDAPIM-> LYS + CO2 | diaminopimelate decarboxylase |
R509 | Lysine biosynthesis | VV10526 OR VV11270 | 6.1.1.6 | ATP + LYS + TRNALYS-> AMP + PPI + LYSTRNA | lysyl-tRNAsynthetase |
R510 | Lysine degradation | VV10157 | 1.2.4.2 | 2OAD + LIPO-> SGDHL + CO2 | 2-oxoglutarate dehydrogenase E1 component |
R511 | Lysine degradation | VV10156 | 2.3.1.61 | GLUTCOA + DLIPO <-> COA + SGDHL | 2-oxoglutarate dehydrogenase E2 component |
R512 | Arginine and proline metabolism | VV11467 | 3.5.3.6 | ARG-> CITR + NH3 | arginine deiminase |
R513 | Arginine and proline metabolism | VV11314 | 2.3.1.109 | SUCCOA + ARG <-> COA + N2SUCCARG | arginine N-succinyltransferase |
R514 | Arginine and proline metabolism | VV10145 | 6.1.1.19 | ATP + ARG + TRNAARG <-> AMP + PPI + ARGTRNAARG | arginyl-tRNA synthetase |
R515 | Arginine and proline metabolism | VV21030 OR VV21235 | 4.1.1.17 | ORN-> PTRC + CO2 | diaminopimelate decarboxylase |
R516 | Arginine and proline metabolism | VV12355 | 3.5.3.11 | AGMATINE-> PTRC + UREA | agmatinase |
R517 | Arginine and proline metabolism | VV12356 AND VV12357 | 4.1.1.19 | ARG-> AGMATINE + CO2 | biosynthetic arginine decarboxylase |
R518 | Arginine and proline metabolism | VV11315 | 1.2.1.- | N2SUCCGLU5SA + NAD <-> N2SUCCGLU + NADH | aldehydedehydrogenase |
R519 | Arginine and proline metabolism | VV12783 | 3.5.1.- | N2SUCCGLU-> GLU + SUCC | succinylglutamate desuccinylase |
R520 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | P5C + NAD-> NADH + GLU | 1-pyrroline-5-carboxylatedehydrogenase |
R521 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | P5C + NADP-> NADPH + GLU | 1-pyrroline-5-carboxylatedehydrogenase |
R522 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | GLUGSAL + NAD-> NADH + GLU | 1-pyrroline-5-carboxylate dehydrogenase |
R523 | Arginine and proline metabolism | VV21118 | 1.5.99.8 | PRO + FAD-> P5C + FADH2 | proline dehydrogenase |
R524 | Arginine and proline metabolism | VV11838 | 6.1.1.15 | ATP + PRO + TRNAPRO-> AMP + PPI + PROTRNAPRO | prolyl-tRNA synthetase |
R525 | Arginine and proline metabolism | VV21118 | 1.5.99.8 OR 1.5.1.12 | 4HPRO + FAD-> L1P3H5C + FADH2 | proline dehydrogenase |
R526 | Arginine and proline metabolism | VV11524 | 1.5.1.2 | L1P3H5C + NADH-> 4HPRO + NAD | pyrroline-5-carboxylate reductase |
R527 | Arginine and proline metabolism | VV11524 | 1.5.1.2 | L1P3H5C + NADPH-> 4HPRO + NADP | pyrroline-5-carboxylate reductase |
R528 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | L1P3H5C + NAD-> E4HGLU + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R529 | Arginine and proline metabolism | VV21118 | 1.5.1.12 | L1P3H5C + NADP-> E4HGLU + NADPH | 1-pyrroline-5-carboxylate dehydrogenase |
R530 | Arginine and proline metabolism | VV21118 | 1.5.1.12 OR 1.5.99.8 | E4HGLU + NAD <-> 4HGLUSA + NADH | 1-pyrroline-5-carboxylate dehydrogenase |
R531 | Arginine and proline metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | E4HGLU + AKG-> HYDROXYAKG + GLU | aspartate aminotransferase |
R532 | Arginine and proline metabolism | VV11102 OR VV20904 OR VV21072 | 4.1.2.14 | HYDROXYAKG <-> PYR + GLX | 4-hydroxy-2-oxoglutaratealdolase |
R533 | Arginine and proline metabolism | VV20869 | 1.2.1.3 | N4AAB + NAD-> 4AABUT + NADH | aldehyde dehydrogenase |
R534 | Arginine and proline metabolism | VV20869 | 1.2.1.3 | 4AB + NADP-> GABA + NADPH | aldehyde dehydrogenase |
R535 | Arginine and proline metabolism | VV21635 | 2.5.1.16 | SAMA + PTRC-> 5MTA + SPRMD | spermidine synthase |
R536 | Arginine and proline metabolism | VV10333 | 3.4.13.3 | HCNS-> GABA + HIS | aminoacylhistidinedipeptidase |
R537 | Arginine and proline metabolism | VV10558 | 3.2.2.16 | 5MTA-> AD + 5MDR | 5'-methylthioadenosine nucleosidase |
R538 | Arginine and proline metabolism | VV11600 AND VV11601 AND VV11602 OR VV11102 OR VV20904 OR VV21072 | 4.1.1.3 OR 4.1.3.16 | HYDROXYAKG-> PYR + GLX | oxaloacetatedecarboxylaseOR4-hydroxy-2-oxoglutaratealdolase |
R539 | Histidine metabolism | VV12920 | 2.4.2.17 | PRPP + ATP-> PPI + PRBATP | ATP phosphoribosyltransferase |
R540 | Histidine metabolism | VV12913 | 3.6.1.31 | PRBATP-> PPI + PRBAMP | phosphoribosyl-ATP pyrophosphohydrolase |
R541 | Histidine metabolism | VV12913 | 3.5.4.19 | PRBAMP-> PRFP | phosphoribosyl-AMP cyclohydrolase |
R542 | Histidine metabolism | VV12915 | 5.3.1.16 | PRFP-> PRLP | phosphoribosylformimino-5-aminoimidazolecarboxamideribotideisomerase |
R543 | Histidine metabolism | VV12914 AND VV12916 | 2.4.2.- | PRLP + GLN-> GLU + AICAR + DIMGP | imidazoleglycerol-phosphatesynthase / glutamineamidotransferase |
R544 | Histidine metabolism | VV12917 | 4.2.1.19 | DIMGP-> IMACP | imidazoleglycerol-phosphate dehydratase |
R545 | Histidine metabolism | VV12918 | 2.6.1.9 | IMACP + GLU-> AKG + HISOLP | histidinol-phosphate aminotransferase |
R546 | Histidine metabolism | VV12917 | 3.1.3.15 | HISOLP-> PI + HISOL | histidinol-phosphatase |
R547 | Histidine metabolism | VV12919 | 1.1.1.23 | HISOL + 2NAD-> HIS + 2NADH | histidinol dehydrogenase |
R548 | Histidine metabolism | VV11153 | 2.1.1.- | HIS + SAM-> NMHIS + SAH | N6-adenine-specific methylase |
R549 | Histidine metabolism | VV10426 | 6.1.1.21 | ATP + HIS + TRNAHIS-> AMP + PPI + HISTRNAHIS | histidyl-tRNA synthetase |
R550 | Histidine metabolism | VV10053 OR VV12389 | 4.3.1.3 | HIS-> UC + NH3 | histidine ammonia-lyase |
R551 | Histidine metabolism | VV12390 | 4.2.1.49 | UC-> 4I5P | urocanate hydratase |
R552 | Histidine metabolism | VV12392 | 3.5.2.7 | 4I5P-> NFGLU | imidazolonepropionase |
R553 | Histidine metabolism | VV12391 | 3.5.3.8 | NFGLU-> GLU + FA | formiminoglutamase |
R554 | Histidine metabolism | VV20869 | 1.2.1.3 | I4AA + NAD-> I4AC + NADH | aldehyde dehydrogenase |
R555 | Tyrosine metabolism | VV11345 | 5.3.3.10 | 5CM2HM-> 5C2O3E | 5-carboxymethyl-2-hydroxymuconate isomerase |
R556 | Tyrosine metabolism | VV12248 OR VV13174 OR VV20334 | 2.6.1.1 | AKG + TYR <-> 4HPP + GLU | aspartate aminotransferase |
R557 | Tyrosine metabolism | VV12768 | 1.13.11.27 | 4HPP + O2-> HOMOGEN + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R558 | Tyrosine metabolism | VV12765 | 5.2.1.2 | 4MAAC-> 4FAAC | maleylacetoacetate isomerase |
R559 | Tyrosine metabolism | VV10344 OR VV13111 OR VV20019 | 1.1.1.1 | 34DHPEG + NAD <-> 34DHMA + NADH | alcohol dehydrogenase |
R560 | Phenylalanine metabolism | VV12248 OR VV13174 OR VV20334 OR VV12918 | 2.6.1.1OR2.6.1.9 | PHE + AKG <-> PHPYR + GLU | aspartate aminotransferase |
R561 | Phenylalanine metabolism | VV12768 | 1.13.11.27 | PHPYR + O2-> 2HPA + CO2 | 4-hydroxyphenylpyruvate dioxygenase |
R562 | Phenylalanine metabolism | VV10414 | 1.4.99.1 | DPHE-> PHPYR + NH3 | D-amino-acid dehydrogenase |
R563 | Tryptophan metabolism | VV20854 | 4.1.99.1 | TRP-> INDOLE + PYR + NH3 | tryptophanase |
R564 | Tryptophan metabolism | VV11307 | 6.1.1.2 | ATP + TRP + TRNATRP-> AMP + PPI + TRPTRNATRP | tryptophanyl-tRNA synthetase |
R565 | Tryptophan metabolism | VV20869 | 1.2.1.3 | 5HIAA + NAD-> 5HIAC + NADH | aldehyde dehydrogenase |
R566 | Tryptophan metabolism | VV20869 | 1.2.1.3 | I3AA + NAD-> I3AC + NADH | aldehyde dehydrogenase |
R567 | Tryptophan metabolism | VV12755 OR VV21473 | 1.11.1.6 | 2 3HAN + 2 O2-> CVN + 2 H2O2 | catalase |
R568 | Tryptophan metabolism | VV10157 | 1.2.4.2 | 2OAD + COA + NAD-> GLUTCOA + CO2 + NADH | 2-oxoglutarate dehydrogenase E1 component |
R569 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10495 OR VV12654 OR VV20558 OR VV20833 | 2.5.1.54 | E4P + PEP-> PI + 3DDAH7P | 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase |
R570 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11383 | 4.2.3.4 | 3DDAH7P-> DQT + PI | 3-dehydroquinate synthetase |
R571 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11236 | 4.2.1.10 | DQT-> DHSK | 3-dehydroquinate dehydratase II |
R572 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11236 | 4.2.1.10 | DHSK <-> 34DHB | 3-dehydroquinate dehydratase II |
R573 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11057 | 1.1.1.25 | DHSK + NADPH-> SME + NADP | shikimate5-dehydrogenase |
R574 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11382 | 2.7.1.71 | SME + ATP-> ADP + SME3P | shikimate kinase |
R575 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV12126 AND VV12127 | 2.5.1.19 | SME3P + PEP-> 3PSME + PI | 3-phosphoshikimate 1-carboxyvinyltransferase |
R576 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11981 | 4.2.3.5 | 3PSME-> PI + CHOR | chorismate synthase |
R577 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13064 AND VV13065 | 4.1.3.27 | CHOR + GLN-> GLU + PYR + AN | anthranilate synthase |
R578 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13064 AND VV13065 | 4.1.3.27 | CHOR + NH3-> AN + PYR | anthranilate synthase |
R579 | Phenylalanine, tyrosineandtryptophanbiosynthesis | VV13066 | 2.4.2.18 | AN + PRPP-> PPI + NPRAN | anthranilate phosphoribosyltransferase |
R580 | Phenylalanine, tyrosineandtryptophanbiosynthesis | VV13067 | 5.3.1.24 | NPRAN-> CPAD5P | phosphoribosylanthranilate isomerase |
R581 | Phenylalanine, tyrosineandtryptophanbiosynthesis | VV13067 | 4.1.1.48 | CPAD5P-> CO2 + IGP | indole-3-glycerolphosphatesynthase |
R582 | Phenylalanine, tyrosineandtryptophanbiosynthesis | VV13068 AND VV13069 | 4.2.1.20 | IGP + SER-> G3P + TRP | tryptophansynthase |
R583 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13068 AND VV13069 | 4.2.1.20 | SER + INDOLE-> TRP | tryptophansynthase |
R584 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV13068 AND VV13069 | 4.2.1.20 | INDOLE + G3P <-> IGP | tryptophansynthase |
R585 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10487 OR VV10494 | 5.4.99.5 | CHOR <-> PHEN | chorismatemutase |
R586 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10487 | 4.2.1.51 | PHEN-> CO2 + PHPYR | prephenate dehydratase |
R587 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV12370 AND VV12371 | 6.1.1.20 | ATP + PHE + TRNAPHE-> AMP + PPI + PHETRNAPHE | phenylalanyl-tRNA synthetase |
R588 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10494 | 1.3.1.12 | PHEN + NAD-> 4HPP + CO2 + NADH | prephenatedehydrogenase |
R589 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV12918 | 2.6.1.9 | 4HPP + GLU-> AKG + TYR | histidinol-phosphate aminotransferase |
R590 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV11683 OR VV20878 | 6.1.1.1 | ATP + TYR + TRNATYR-> AMP + PPI + TRYTRNATYR | tyrosyl-tRNA synthetase |
R591 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV10487 | 4.2.1.51 | AG-> PHE + CO2 | prephenate dehydratase |
R592 | Phenylalanine, tyrosine and tryptophan biosynthesis | VV20455 | 1.14.16.1 | THBPT + PHE + O2-> DHBPT + TYR | phenylalanine-4-hydroxylase |
R593 | Urea cycle and metabolism of amino groups | VV10326 | 2.7.2.11 | GLU + ATP-> ADP + GLUP | glutamate 5-kinase |
R594 | Urea cycle and metabolism of amino groups | VV10325 | 1.2.1.41 | GLUP + NADPH-> NADP + PI + GLUGSAL | gamma-glutamyl phosphate reductase |
R595 | Urea cycle and metabolism of amino groups | GLUGSAL <-> P5C | spontaneous | ||
R596 | Urea cycle and metabolism of amino groups | VV11524 | 1.5.1.2 | P5C + NADPH <-> PRO + NADP | pyrroline-5-carboxylate reductase |
R597 | Urea cycle and metabolism of amino groups | VV11524 | 1.5.1.2 | PRO + NAD <-> P5C + NADH | pyrroline-5-carboxylate reductase |
R598 | Urea cycle and metabolism of amino groups | VV11799 | 2.3.1.1 | GLU + ACCOA-> COA + NAGLU | amino-acid N-acetyltransferase |
R599 | Urea cycle and metabolism of amino groups | VV11372 | 2.7.2.8 | NAGLU + ATP-> ADP + NAGLUP | acetylglutamate kinase |
R600 | Urea cycle and metabolism of amino groups | VV11371 | 1.2.1.38 | NAGLUP + NADPH-> NADP + PI + NAGLUS | N-acetyl-gamma-glutamyl-phosphate reductase |
표 6
Table 6
R601 | Urea cycle and metabolism of amino groups | VV11313 | 2.6.1.11 | NAGLUS + GLU -> AKG + NAORN | acetylornithine aminotransferase |
R602 | Urea cycle and metabolism of amino groups | VV11370 | 3.5.1.16 | NAORN -> AC + ORN | acetylornithinedeacetylase |
R603 | Urea cycle and metabolism of amino groups | VV11466 | 2.1.3.3 | ORN + CAP <-> CITR + PI | ornithine carbamoyltransferase |
R604 | Urea cycle and metabolism of amino groups | VV11373 | 6.3.4.5 | CITR + ASP + ATP <-> AMP + PPI + ARGSUCC | argininosuccinate synthase |
R605 | Urea cycle and metabolism of amino groups | VV11374 | 4.3.2.1 | ARGSUCC <-> FUM + ARG | argininosuccinatelyase |
R606 | beta-Alanine metabolism | VV20869 | 1.2.1.3 | bAPA + NAD -> bALA + NADH | aldehyde dehydrogenase (NAD+) |
R607 | beta-Alanine metabolism | VV21635 | 2.5.1.16 | 5MTA + SPRM -> SAMA + SPRMD | spermidine synthase |
R608 | Taurine and hypotaurine metabolism | VV12824 | 4.1.1.15 | 3SLALA -> HTR + CO2 | glutamate decarboxylase |
R609 | Taurine and hypotaurine metabolism | VV12824 | 4.1.1.15 | CYSTEATE -> TR + CO2 | glutamate decarboxylase |
R610 | Taurine and hypotaurine metabolism | VV21395 | 1.14.11.17 | TR + AKG + O2 -> H2SO3 + AAA + SUCC + CO2 | taurine dioxygenase |
R611 | Taurine and hypotaurine metabolism | VV12952 | 1.4.1.1 | ALA + NAD -> PYR + NH3 + NADH | alanine dehydrogenase |
R612 | Aminophosphonate metabolism | VV11425 OR VV21062 | 2.6.1.- | PPYR + GLU <-> 2A3PP + AKG | aminotransferase |
R613 | Aminophosphonate metabolism | VV21664 | 2.6.1.37 | (2AE)P + PYR <-> PPAC + ALA | 2-aminoethylphosphonate-pyruvate transaminase |
R614 | Aminophosphonate metabolism | VV11153 | 2.1.1.- | MCB + PPAC -> 2HPP + VB12 | N6-adenine-specificmethylase |
R615 | Selenoamino acid metabolism | VV11364 | 2.5.1.48 | OPHSER + SCYS -> SLLCT + PI | cystathionine gamma-synthase |
R616 | Selenoamino acid metabolism | VV11364 | 2.5.1.48 | AHSER + SCYS -> SLLCT + AC | cystathionine gamma-synthase |
R617 | Selenoamino acid metabolism | VV11364 | 2.5.1.48 | SHSER + SCYS -> SLLCT + SUCC | cystathionine gamma-synthase |
R618 | Selenoamino acid metabolism | VV12872 | 4.4.1.8 | SLLCT -> SHCYS + NH3 + PYR | cystathionine beta-lyase |
R619 | Selenoamino acid metabolism | SHCYS -> SMET | |||
R620 | Selenoamino acid metabolism | VV13028 | 6.1.1.10 | ATP + SMET + TRNAMET -> AMP + PPI + SMETTRNAMET | methionyl-tRNA synthetase |
R621 | Selenoamino acid metabolism | VV11536 | 2.5.1.6 | ATP + SMET -> PI + PPI + SeASMET | S-adenosylmethionine synthetase |
R622 | Selenoamino acid metabolism | VV10209 OR VV13153 | 2.5.1.47 | ASER + SELD -> SCYS + AC | cysteine synthase |
R623 | Selenoamino acid metabolism | VV10725 AND VV10726 | 2.7.7.4 | ATP + SELNT <-> PPI + ASELNT | sulfateadenylyltransferase |
R624 | Selenoamino acid metabolism | VV10723 | 2.7.1.25 | ATP + ASELNT -> ADP + 3PASELNT | adenylylsulfate kinase |
R625 | Cyanoamino acid metabolism | VV21287 | 3.2.1.21 | CGS -> CHD + GLC | beta-glucosidase |
R626 | D-Glutamine and D-glutamate metabolism | VV11517 | 3.5.1.2 | GLN -> GLU + NH3 | glutaminase |
R627 | D-Glutamine and D-glutamate metabolism | VV11517 | 3.5.1.2 | DGLN -> DGLU + NH3 | glutaminase |
R628 | D-Glutamine and D-glutamate metabolism | VV11175 | 5.1.1.3 | DGLU <-> GLU | glutamateracemase |
R629 | D-Alanine metabolism | VV11393 OR VV20478 | 5.1.1.1 | ALA <-> DALA | alanine racemase |
R630 | D-Alanine metabolism | VV20280 | 6.3.2.4 | 2 DALA + ATP -> ALAALA + ADP + PI | D-alanine-D-alanineligase |
R631 | Glutathione metabolism | VV12641 | 3.4.11.2 | CYSGLY -> CYS + GLY | membrane alanyl aminopeptidase |
R632 | Glutathione metabolism | VV20532 | 3.4.11.4 | RGT -> CYSGLY + GLU | tripeptide aminopeptidase |
R633 | Lipopolysaccharide biosynthesis | VV11872 | 2.3.1.129 | C140ACP + UDPNAG -> ACP + UDPG2AA | UDP-N-acetylglucosamine acyltransferase |
R634 | Lipopolysaccharide biosynthesis | VV10571 | 3.5.1.- | UDPG2AA -> UDPG2A + AC | UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase |
R635 | Lipopolysaccharide biosynthesis | VV11870 | 2.3.1.- | UDPG2A + C140ACP -> ACP + UDPG23A | UDP-3-O-[3-hydroxymyristoyl]glucosamineN-acyltransferase |
R636 | Lipopolysaccharide biosynthesis | VV12910 | 3.6.1.- | UDPG23A -> UMP + LIPX | UDP-2,3-diacylglucosamine hydrolase |
R637 | Lipopolysaccharide biosynthesis | VV11873 | 2.4.1.182 | LIPX + UDPG23A -> UDP + DISAC1P | lipid-A-disaccharidesynthase |
R638 | Lipopolysaccharide biosynthesis | VV12086 | 2.7.1.130 | DISAC1P + ATP -> ADP + LIPIV | tetraacyldisaccharide 4'-kinase |
R639 | Lipopolysaccharide biosynthesis | VV10799 | 2.-.-.- | LIPIV + CMPKDO -> KDOLIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R640 | Lipopolysaccharide biosynthesis | VV10799 | 2.-.-.- | KDOLIPIV + CMPKDO -> K2LIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R641 | Lipopolysaccharide biosynthesis | VV10830 | 2.3.1.- | C120ACP + K2LIPIV -> LK2LIPIV + ACP | lipid A biosynthesis lauroyl acyltransferase |
R642 | Lipopolysaccharide biosynthesis | VV10797 | 2.3.1.- | C140ACP + LK2LIPIV -> K2LIPA + ACP | lipidAbiosynthesis(KDO)2-(lauroyl)-lipidivaacyltransferase |
R643 | Lipopolysaccharide biosynthesis | VV10249 | 2.5.1.55 | PEP + A5P -> KDOP + PI | 2-dehydro-3-deoxyphosphooctonate aldolase (KDO 8-P synthase) |
R644 | Lipopolysaccharide biosynthesis | VV10688 | 3.1.3.45 | KDOP -> KDO + PI | 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase |
R645 | Lipopolysaccharide biosynthesis | VV12088 | 2.7.7.38 | KDO + CTP -> PPI + CMPKDO | 3-deoxy-manno-octulosonatecytidylyltransferase |
R646 | Lipopolysaccharide biosynthesis | VV10591 OR VV11897 | 5.-.-.- | S7P -> DGDMH7P | phosphoheptose isomerase |
R647 | Lipopolysaccharide biosynthesis | VV10613 | 2.7.-.- | ATP + DGDMH7P -> ADP + DGDMH17BP | ADP-heptose synthase |
R648 | Lipopolysaccharide biosynthesis | VV10291 | 3.1.1.- | DGDMH17BP -> DGDMH1P + PI | D-glycero-D-manno-heptose 1,7-bisphosphate phosphatase |
R649 | Lipopolysaccharide biosynthesis | VV10613 | 2.7.-.- | ATP + DGDMH1P -> PPI + ADPDGDMHEP | ADP-heptose synthase |
R650 | Lipopolysaccharide biosynthesis | VV10796 | 5.1.3.20 | ADPDGDMHEP -> ADPHEP | ADP-L-glycero-D-manno-heptose 6-epimerase |
R651 | Lipopolysaccharide biosynthesis | 1.149 UDPG + 0.09 F6P + 0.387 ADPHEP + 0.142 UDPNAG -> LPS + 1.291 UDP + 0.09 PI + 0.387 ADP | Lipopolysaccharide biosynthesis | ||
R652 | Peptidoglycan biosynthesis | VV10577 | 6.3.2.8 | UDPNAM + ALA + ATP -> ADP + PI + UDPNAMA | UDP-N-acetylmuramate--alanine ligase |
R653 | Peptidoglycan biosynthesis | VV10580 | 6.3.2.9 | UDPNAMA + DGLU + ATP -> UDPNAMAG + ADP + PI | UDP-N-acetylmuramoylalanine--D-glutamate ligase |
R654 | Peptidoglycan biosynthesis | VV10583 | 6.3.2.13 | UDPNAMAG + MDAPIM + ATP -> UDPMNLADGMD + ADP + PI | UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase |
R655 | Peptidoglycan biosynthesis | VV10582 | 6.3.2.10 | UDPMNLADGMD + ALAALA + ATP -> UDPMNLADGMDDADA + ADP + PI | UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6diaminopimelate--D-alanyl-D-alanineligase |
R656 | Peptidoglycan biosynthesis | VV10581 | 2.7.8.13 | UDPMNLADGMDDADA + UDCP -> UPPMNLADGMDDADA + UMP | phospho-N-acetylmuramoyl-pentapeptide-transferase |
R657 | Peptidoglycan biosynthesis | VV10578 | 2.4.1.227 | UPPMNLADGMDDADA + UDPNAG -> UPPMN(GN)LADGMDDADA + UDP | UDP-N-acetylglucosamine--Nacetylmuramyl-(pentapeptide)pyrophosphoryl-undecaprenolN-acetylglucosaminetransferase |
R658 | Peptidoglycan biosynthesis | VV10889 | 6.3.1.2 | UPPMN(GN)LADGMDDADA + ATP + NH3 -> UPPMN(GN)LADGNMDDADA + ADP + PI | glutamine synthetase |
R659 | Peptidoglycan biosynthesis | 2.3.2.10 | 5 GLY + UPPMN(GN)LADGNMDDADA -> UPPMN(GN)LADGNMD(G)5DADA | L-Alanyl-tRNA:UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanineN6-alanyltransferase | |
R660 | Peptidoglycan biosynthesis | UPPMN(GN)LADGNMD(G)5DADA -> UDCPP + PPEPTIDO | |||
R661 | Peptidoglycan biosynthesis | 2.6.1.21 | PPEPTIDO + DALA -> PEPTIDO + DALAxt | D-Alanine:2-oxoglutarate aminotransferase | |
R662 | Peptidoglycan biosynthesis | VV10623 | 3.6.1.27 | UDCPP -> UDCP + PI | undecaprenyl-diphosphatase |
R663 | Peptidoglycan biosynthesis | VV11291 | 3.5.1.28 | ACALA -> ACMUR + ALA | N-acetylmuramoyl-L-alanine amidase |
R664 | Thiamine metabolism | VV10964 | thiC | AIR -> AHM | thiamine biosynthesis protein ThiC |
R665 | Thiamine metabolism | VV21433 | 2.7.1.49 | AHM + ATP -> AHMP + ADP | hydroxymethylpyrimidine kinase |
R666 | Thiamine metabolism | VV21433 | 2.7.4.7 | AHMP + ATP -> AHMPP + ADP | phosphomethylpyrimidine kinase |
R667 | Thiamine metabolism | VV10963 | 2.5.1.3 | THZP + AHMPP -> THMP + PPI | thiamine-phosphate pyrophosphorylase |
R668 | Thiamine metabolism | VV20752 | 3.1.3.- | THMP <-> THIAMIN + PI | phosphatase |
R669 | Thiamine metabolism | VV10317 | 2.7.4.16 | THMP + ATP <-> THMPP + ADP | thiamine-monophosphatekinase |
R670 | Riboflavin metabolism | VV10321 OR VV12234 OR VV21180 | 3.5.4.25 | GTP -> D6RP5P + FORMATE + PPI | GTP cyclohydrolase II |
R671 | Riboflavin metabolism | VV10323 | 3.5.4.26 | D6RP5P -> A6RP5P + NH3 | diaminohydroxyphosphoribosylaminopyrimidine deaminase |
R672 | Riboflavin metabolism | VV10323 | 1.1.1.193 | A6RP5P + NADPH -> A6RP5P2 + NADP | 5-amino-6-(5-phosphoribosylamino)uracil reductase |
R673 | Riboflavin metabolism | VV20752 | 3.1.3- | A6RP5P2 -> A6RP + PI | phosphatase |
R674 | Riboflavin metabolism | VV21426 | RIBB | RL5P -> DB4P + FORMATE | 3,4-dihydroxy-2-butanone 4-phosphate synthase |
R675 | Riboflavin metabolism | VV10319 | RIBH | DB4P + A6RP -> D8RL + PI | riboflavinsynthase |
R676 | Riboflavin metabolism | VV10322 OR VV12560 | 2.5.1.9 | 2 D8RL -> RIBFLAV + A6RP | riboflavinsynthase |
R677 | Riboflavin metabolism | VV10508 | 2.7.1.26 | RIBFLAV + ATP -> FMN + ADP | riboflavin kinase |
R678 | Riboflavin metabolism | VV10508 | 2.7.7.2 | FMN + ATP -> FAD + PPI | FMN adenylyltransferase |
R679 | Riboflavin metabolism | VV11585 | 3.1.3.2 | FMN -> RIBFLAV + PI | acid phosphatase |
R680 | Riboflavin metabolism | VV12788 | 2.4.2.21 | NACN + DMB -> NAC + N1(5PADR)DMB | nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase |
R681 | Vitamin B6 metabolism | VV11539 | 1.2.1.72 | E4P + NAD <-> ER4P + NADH | D-erythrose 4-phosphate dehydrogenase |
R682 | Vitamin B6 metabolism | VV11988 | 1.1.1.290 | ER4P + NAD <-> OHB + NADH | erythronate-4-phosphate dehydrogenase |
R683 | Vitamin B6 metabolism | VV12813 | 2.6.1.52 | OHB + GLU <-> PHT + AKG | phosphoserine aminotransferase |
R684 | Vitamin B6 metabolism | VV10543 | 4.2.3.1 | PHT-> 4HLT + PI | threonine synthase |
R685 | Vitamin B6 metabolism | VV10662 | 1.1.1.262 | PHT + NAD -> 3A2OP + NADH + CO2 | 4-hydroxythreonine-4-phosphate dehydrogenase |
R686 | Vitamin B6 metabolism | VV11568 | PdxJ | 3A2OP + DX5P -> P5P + PI | pyridoxine 5-phosphate synthase |
R687 | Vitamin B6 metabolism | VV21237 | 2.7.1.35 | PYRDX + ATP-> P5P + ADP | pyridoxine kinase |
R688 | Vitamin B6 metabolism | VV20752 | 3.1.3.- | P5P-> PYRDX + PI | phosphatase |
R689 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | P5P + O2 -> PL5P + H2O2 | pyridoxamine 5'-phosphate oxidase |
R690 | Vitamin B6 metabolism | VV20752 | 3.1.3.- | PL5P-> PL + PI | phosphatase |
R691 | Vitamin B6 metabolism | VV21237 | 2.7.1.35 | PL + ATP-> PL5P + ADP | pyridoxine kinase |
R692 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | PDLA5P + O2-> PL5P + NH3 + H2O2 | pyridoxamine 5'-phosphate oxidase |
R693 | Vitamin B6 metabolism | VV21237 | 2.7.1.35 | PDLA + ATP-> PDLA5P + ADP | pyridoxine kinase |
R694 | Vitamin B6 metabolism | VV20752 | 3.1.3.- | PDLA5P-> PDLA + PI | phosphatase |
R695 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | PYRDX + O2 <-> PL + H2O2 | pyridoxamine 5'-phosphate oxidase |
R696 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | PL + O2 + NH3 <-> PDLA + H2O2 | pyridoxamine 5'-phosphate oxidase |
R697 | Nicotinate and nicotinamide metabolism | VV11558 | 1.4.3.16 | ASP + FUM -> IASP + SUCC | L-aspartateoxidase |
R698 | Nicotinate and nicotinamide metabolism | VV11558 | 1.4.3.16 | ASP + O2 -> IASP + H2O2 | L-aspartate oxidase |
R699 | Nicotinate and nicotinamide metabolism | VV12173 | NadA | IASP + DHAP -> QA + PI | quinolinate synthase |
R700 | Nicotinate and nicotinamide metabolism | VV11627 | 2.4.2.19 | QA + PRPP -> NACN + CO2 + PPI | nicotinate-nucleotide pyrophosphorylase (carboxylating) |
R701 | Nicotinate and nicotinamide metabolism | VV10248 OR VV20237 | 3.1.3.5 | NACN -> NACD + PI | 5'-nucleotidase |
R702 | Nicotinate and nicotinamide metabolism | VV10248 OR VV20237 | 3.1.3.5 | NAMN -> NAMD + PI | 5'-nucleotidase |
R703 | Nicotinate and nicotinamide metabolism | VV10814 | 2.7.1.- | NACD + ATP -> NACN + ADP | putativeKDOkinaseWavC |
R704 | Nicotinate and nicotinamide metabolism | VV12372 | 2.4.2.11 | NAC + PRPP -> NACN + PPI | nicotinate phosphoribosyltransferase |
R705 | Nicotinate and nicotinamide metabolism | 2.7.7.18 | NACN + ATP -> PPI + NAAD | nicotinate-nucleotide adenylyltransferase | |
R706 | Nicotinate and nicotinamide metabolism | VV21599 | 6.3.5.1 | NAAD + ATP + GLN -> NAD + AMP + PPI + GLU | NAD+ synthetase (glutamine-hydrolysing) |
R707 | Nicotinate and nicotinamide metabolism | VV11728 OR VV21540 | 2.4.2.1 | NAC + R1P -> PI + NACD | purine-nucleoside phosphorylase |
R708 | Nicotinate and nicotinamide metabolism | VV11728 OR VV21540 | 2.4.2.1 | NAM + R1P -> PI + NAMD | purine-nucleoside phosphorylase |
R709 | Nicotinate and nicotinamide metabolism | VV12374 | 3.5.1.19 | NAM -> NAC + NH3 | nicotinamidase |
R710 | Nicotinate and nicotinamide metabolism | VV20315 AND VV20316 AND VV20317 | 1.6.1.2 | NADP + NADH -> NADPH + NAD | NAD(P)transhydrogenase |
R711 | Nicotinate and nicotinamide metabolism | VV10366 | 2.7.1.23 | NAD + ATP -> NADP + ADP | NAD kinase |
R712 | Nicotinate and nicotinamide metabolism | VV20752 | 3.1.3.- | NADP -> NAD + PI | phosphatase |
R713 | Nicotinate and nicotinamide metabolism | VV11168 | 1.6.1.1 | NADPH + NAD <-> NADP + NADH | NAD(P) transhydrogenase |
R714 | Pantothenate and CoA biosynthesis | (VV10647 AND VV10648) OR (VV11031 AND VV11032) | 2.2.1.6 | 2 PYR -> ACLAC + CO2 | acetolactatesynthase |
R715 | Pantothenate and CoA biosynthesis | VV11643 | 2.1.2.11 | OIVAL + METTHF -> DHPANT + THF | 3-methyl-2-oxobutanoate hydroxymethyltransferase |
R716 | Pantothenate and CoA biosynthesis | VV11810 | 1.1.1.169 | DHPANT + NADPH -> NADP + PANT | 2-dehydropantoate 2-reductase |
R717 | Pantothenate and CoA biosynthesis | VV11642 | 6.3.2.1 | PANT + bALA + ATP -> AMP + PPI + PNTO | pantoate-beta-alanine ligase |
R718 | Pantothenate and CoA biosynthesis | VV11200 | 2.7.1.33 | PNTO + ATP -> ADP + 4PPNTO | pantothenate kinase |
R719 | Pantothenate and CoA biosynthesis | VV11200 | 2.7.1.33 | ATP + N(P)CYS -> ADP + 4PPNCYS | pantothenate kinase |
R720 | Pantothenate and CoA biosynthesis | VV11200 | 2.7.1.33 | ATP + PTT -> ADP + 4PPNTE | pantothenate kinase |
R721 | Pantothenate and CoA biosynthesis | VV10828 | 6.3.2.5 | 4PPNTO + CTP + CYS -> CMP + PPI + 4PPNCYS | phosphopantothenate-cysteine ligase |
R722 | Pantothenate and CoA biosynthesis | VV10828 | 4.1.1.36 | 4PPNCYS -> CO2 + 4PPNTE | phosphopantothenoylcysteine decarboxylase |
R723 | Pantothenate and CoA biosynthesis | VV10819 | 2.7.7.3 | 4PPNTE + ATP -> PPI + DPCOA | pantetheine-phosphate adenylyltransferase |
R724 | Pantothenate and CoA biosynthesis | VV11621 AND VV11622 | 2.7.1.24 | DPCOA + ATP -> ADP + COA | dephospho-CoA kinase |
R725 | Pantothenate and CoA biosynthesis | VV11569 | 2.7.8.7 | COA + AACP -> PAP + ACP | holo-[acyl-carrier protein] synthase |
R726 | Pantothenate and CoA biosynthesis | VV12341 | 3.1.4.14 | ACP -> 4PPNTE + AACP | acyl carrier protein phosphodiesterase |
R727 | Pantothenate and CoA biosynthesis | VV12599 | 3.5.1.- | PTT -> PNTO + CA | NAD-dependentproteindeacetylases |
R728 | Biotin metabolism | VV12942 | 2.3.1.47 | ALA+CHCOA<->CO2+COA+AONA | 8-amino-7-oxononanoate synthase |
R729 | Biotin metabolism | VV12944 AND VV12945 | 2.6.1.62 | SAM+AONA<->SAMOB+DANNA | adenosylmethionine-8-amino-7-oxononanoateaminotransferase |
R730 | Biotin metabolism | VV12940 | 6.3.3.3 | CO2+DANNA+ATP<->DTB+PI+ADP | dethiobiotin synthetase |
R731 | Biotin metabolism | VV12943 | 2.8.1.6 | DTB + S -> BT | biotin synthase |
R732 | Biotin metabolism | VV11198 AND VV11199 | 6.3.4.15 | ATP + BT -> PPI + B5AMP | biotin-[acetyl-CoA-carboxylase] ligase |
R733 | Biotin metabolism | VV11198 AND VV11199 | 6.3.4.15 | B5AMP + A[C] -> AMP + H[C] | biotin-[acetyl-CoA-carboxylase] ligase |
R734 | Folate biosynthesis | VV20543 | 3.5.4.16 | GTP -> FORMATE + AHTD | GTP cyclohydrolase I |
R735 | Folate biosynthesis | VV10854 OR VV11083 OR VV12614 | 3.6.1.- | AHTD -> DHP + PPI + PI | recG-likehelicase |
R736 | Folate biosynthesis | VV10625 | 4.1.2.25 | DHP -> AHHMP + GLAL | dihydroneopterin aldolase |
R737 | Folate biosynthesis | VV11644 | 2.7.6.3 | AHHMP + ATP -> AMP + AHHMD | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase |
R738 | Folate biosynthesis | VV11311 AND VV11312 AND VV12265 | 2.6.1.85 | CHOR + GLN -> ADCHOR + GLU | para-aminobenzoate synthase |
R739 | Folate biosynthesis | VV13005 | 4.1.3.38 | ADCHOR -> PYR + PABA | 4-amino-4-deoxychorismate lyase |
R740 | Folate biosynthesis | VV11691 | 2.5.1.15 | PABA + AHHMD -> PPI + DHPT | dihydropteroate synthase |
R741 | Folate biosynthesis | VV11691 | 2.5.1.15 | PABA + AHHMP -> DHPT | dihydropteroate synthase |
R742 | Folate biosynthesis | VV11994 | 6.3.2.12 OR 6.3.2.17 | DHPT + ATP + GLU -> ADP + PI + DHF | dihydrofolate synthase |
R743 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NADPH -> NADP + THF | dihydrofolate reductase |
R744 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NADH -> NAD + THF | dihydrofolate reductase |
R745 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NAD <-> FL + NADH | dihydrofolate reductase |
R746 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NADP <-> FL + NADPH | dihydrofolate reductase |
R747 | Folate biosynthesis | VV10666 | 1.5.1.3 | FL + NADH -> THF + NAD | dihydrofolate reductase |
R748 | Folate biosynthesis | VV10666 | 1.5.1.3 | FL + NADPH -> THF + NADP | dihydrofolate reductase |
R749 | Folate biosynthesis | VV11994 | 6.3.2.17 | THF + ATP + GLU <-> ADP + PI + THFG | folylpolyglutamate synthase |
R750 | Folate biosynthesis | VV12257 | 4.2.3.12 | AHTD -> PYTHP + H5P3O10 | 6-pyruvoyl tetrahydrobiopterin synthase |
R751 | Folate biosynthesis | VV20966 | 1.5.1.34 | DHBPT + NADH <-> THBPT + NAD | dihydropteridine reductase |
R752 | Folate biosynthesis | VV20966 | 1.5.1.34 | DHBPT + NADPH <-> THBPT + NADP | dihydropteridine reductase |
R753 | One carbon pool by folate | VV11899 | 2.1.2.2 | GAR + METHF -> FGAR + THF | phosphoribosylglycinamide formyltransferase |
R754 | One carbon pool by folate | VV12022 | 3.5.4.9 | METHF -> FTHF | formate--tetrahydrofolate ligase |
R755 | One carbon pool by folate | VV20190 | 2.1.2.10 | METHF -> 5FTHF | aminomethyltransferase |
R756 | One carbon pool by folate | VV12022 | 1.5.1.5 | METTHF + NADP <-> METHF + NADPH | methylenetetrahydrofolate dehydrogenase (NADP+) |
R757 | One carbon pool by folate | VV12022 | 3.5.4.9 | METHF <-> FTHF | methenyltetrahydrofolatecyclohydrolase |
R758 | One carbon pool by folate | VV11366 | 1.5.1.20 | METTHF+ NADPH -> MTHF + NADP | methylenetetrahydrofolatereductase |
R759 | One carbon pool by folate | VV11366 | 1.5.1.20 | METTHF+ FADH2 <-> MTHF + FAD | methylenetetrahydrofolatereductase |
R760 | One carbon pool by folate | VV10516 | 2.1.1.45 | DUMP + METTHF <-> DHF + DTMP | thymidylatesynthase |
R761 | One carbon pool by folate | VV10143 | 3.5.1.10 | FTHF <-> FORMATE + THF | formyltetrahydrofolate hydrolase |
R762 | Porphyrin and chlorophyll metabolism | VV10254 | 1.2.1.70 | GTRNA + NADPH -> GSA + NADP | glutamyl-tRNA reductase |
R763 | Porphyrin and chlorophyll metabolism | VV11678 | 5.4.3.8 | GSA -> ALAV | glutamate-1-semialdehyde 2,1-aminomutase |
R764 | Porphyrin and chlorophyll metabolism | VV10902 | 4.2.1.24 | 2ALAV-> PBG | porphobilinogen synthase |
R765 | Porphyrin and chlorophyll metabolism | VV11122 | 2.5.1.61 | 4 PBG -> HMB + 4 NH3 | hydroxymethylbilane synthase |
R766 | Porphyrin and chlorophyll metabolism | VV11121 | 4.2.1.75 | HMB->UPRG | uroporphyrinogen-III synthase |
R767 | Porphyrin and chlorophyll metabolism | VV10727 OR VV11120 OR VV20367 OR VV20397 | 2.1.1.107 | 2 SAM + UPRG -> 2 SAH + PC2 | uroporphyrinogen-III methylase |
R768 | Porphyrin and chlorophyll metabolism | VV12702 | 1.3.1.76 | PC2 + NAD -> NADH + SHCL | precorrin-2 dehydrogenase |
R769 | Porphyrin and chlorophyll metabolism | VV12702 | 4.99.1.4 | SHCL -> SHEME | sirohydrochlorin ferrochelatase |
R770 | Porphyrin and chlorophyll metabolism | VV11218 | 4.1.1.37 | UPRG -> 4 CO2 + CPP | uroporphyrinogen decarboxylase |
R771 | Porphyrin and chlorophyll metabolism | VV10894 OR VV11519 OR VV21615 | 1.3.99.22 | CPP + 2 SAM -> PPHG + 2 CO2 + 2 MET + 2 DA | oxygen-independent coproporphyrinogen III oxidase |
R772 | Porphyrin and chlorophyll metabolism | VV11056 | 1.3.3.3 | CPP + O2 -> PPHG + 2 CO2 | coproporphyrinogen III oxidase |
R773 | Porphyrin and chlorophyll metabolism | VV10978 | 1.3.3.4 | 1.5O2+PPHG-> PPIX | protoporphyrinogen oxidase |
R774 | Porphyrin and chlorophyll metabolism | VV10187 | 4.99.1.1 | PPIX -> PTH | ferrochelatase |
R775 | Porphyrin and chlorophyll metabolism | VV13022 | 2.5.1.17 | C(I)DA + ATP -> ACDA + PPI + PI | cob(I)alamin adenosyltransferase |
R776 | Porphyrin and chlorophyll metabolism | VV20330 | 6.3.5.10 | ACDA + 4 GLN + 4 ATP -> ACHA + 4 GLU + 4 PI + 4 ADP | cobyric acid synthase |
R777 | Porphyrin and chlorophyll metabolism | VV10559 | 6.3.1.10 | ACHA + 1AP2O -> ADCBA | adenosylcobinamidesynthase |
R778 | Porphyrin and chlorophyll metabolism | VV10559 | 6.3.1.10 | ACHA + D1AP2OOP + ATP -> ADCBAP + ADP + PI | adenosylcobinamide-phosphatesynthase |
R779 | Porphyrin and chlorophyll metabolism | VV12786 | 2.7.1.156 | ADCBA + ATP -> ADCBAP + ADP | adenosylcobinamidekinase |
R780 | Porphyrin and chlorophyll metabolism | VV12786 | 2.7.1.156 | ADCBA + GTP -> ADCBAP + GDP | adenosylcobinamidekinase |
R781 | Porphyrin and chlorophyll metabolism | VV12786 | 2.7.7.62 | ADCBAP + GTP -> AGDPCBA + PPI | adenosylcobinamide-phosphate guanylyltransferase |
R782 | Porphyrin and chlorophyll metabolism | VV12785 OR VV20752 | 3.1.3.73 OR 3.1.3.- | N1(5PADR)DMB -> ARBZ + PI | alpha-ribazolephosphataseORphosphatase |
R783 | Porphyrin and chlorophyll metabolism | VV12787 | 2.7.8.26 | AGDPCBA + ARBZ -> CBCO + GMP | adenosylcobinamide-GDP ribazoletransferase |
R784 | Porphyrin and chlorophyll metabolism | VV10933 | 1.16.1.3 | NADH + 2 AC(III)A -> NAD + 2 C(II)A | aquacobalamin reductase |
R785 | Ubiquinone biosynthesis | VV13173 OR VV20835 | 5.4.4.2 | CHOR <-> ICHOR | menaquinone-specific isochorismate synthase |
R786 | Ubiquinone biosynthesis | VV11163 | 4.1.3.- | CHOR <-> 4HB + PYR | chorismate--pyruvate lyase |
R787 | Ubiquinone biosynthesis | VV11164 | 2.5.1.- | OPP + 4HB -> 3OP4HB + PPI | 4-hydroxybenzoate octaprenyltransferase |
R788 | Ubiquinone biosynthesis | VV10705 OR VV10935 | 4.1.1.- | 3OP4HB -> 2OPP + CO2 | 3-octaprenyl-4-hydroxybenzoatecarboxy-lyase |
R789 | Ubiquinone biosynthesis | VV10907 | UbiB | 2OPP + O2 + NADPH -> 2OP6HP + NADP | ubiquinone biosynthesis protein |
R790 | Ubiquinone biosynthesis | VV13040 | 2.1.1.64 | 2OP6HP + SAM -> 2OP6MP + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R791 | Ubiquinone biosynthesis | VV11552 | 1.14.13.- | 2OP6MP + O2 + NADPH -> 2OP6M14BQ + NADP | 2-octaprenyl-6-methoxyphenol hydroxylase |
R792 | Ubiquinone biosynthesis | VV10909 | 2.1.1.- | 2OP6M14BQ + SAM -> 2OP3M6M14BQ + SAH | ubiquinone methyltransferase |
R793 | Ubiquinone biosynthesis | VV10265 | 1.14.13.- | 2OP3M6M14BQ + O2 + NADPH -> 2OP3M5H6M14BQ + NADP | 2-polyprenyl-6-methoxyphenol hydroxylase |
R794 | Ubiquinone biosynthesis | VV13040 | 2.1.1.64 | 2OP3M5H6M14BQ + SAM -> UQ + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R795 | Ubiquinone biosynthesis | VV13172 | 2.5.1.64 | ICHOR + AKG -> SHCHC + PYR + CO2 | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylatesynthase |
R796 | Ubiquinone biosynthesis | VV13169 | 4.2.1.- | SHCHC -> OSB | O-succinylbenzoate-CoA synthase |
R797 | Ubiquinone biosynthesis | VV13168 | 6.2.1.26 | OSB + ATP + COA -> AMP + PPI + OSBCOA | O-succinylbenzoic acid--CoA ligase |
R798 | Ubiquinone biosynthesis | VV13170 | 4.1.3.36 | OSBCOA -> DHN + COA | dihydroxynaphthoic acid synthase |
R799 | Ubiquinone biosynthesis | VV11353 | 2.5.1.- | DHN + OPP -> PPI + CO2 + DMK | 1,4-dihydroxy-2-naphthoate octaprenyltransferase |
R800 | Ubiquinone biosynthesis | VV10909 | 2.1.1.- | DMK + SAM -> MKH2 + SAH | menaquinone biosynthesis methyltransferase |
R601 | Urea cycle and metabolism of amino groups | VV11313 | 2.6.1.11 | NAGLUS + GLU-> AKG + NAORN | acetylornithine aminotransferase |
R602 | Urea cycle and metabolism of amino groups | VV11370 | 3.5.1.16 | NAORN-> AC + ORN | acetylornithinedeacetylase |
R603 | Urea cycle and metabolism of amino groups | VV11466 | 2.1.3.3 | ORN + CAP <-> CITR + PI | ornithine carbamoyltransferase |
R604 | Urea cycle and metabolism of amino groups | VV11373 | 6.3.4.5 | CITR + ASP + ATP <-> AMP + PPI + ARGSUCC | argininosuccinate synthase |
R605 | Urea cycle and metabolism of amino groups | VV11374 | 4.3.2.1 | ARGSUCC <-> FUM + ARG | argininosuccinatelyase |
R606 | beta-Alanine metabolism | VV20869 | 1.2.1.3 | bAPA + NAD-> bALA + NADH | aldehyde dehydrogenase (NAD +) |
R607 | beta-Alanine metabolism | VV21635 | 2.5.1.16 | 5MTA + SPRM-> SAMA + SPRMD | spermidine synthase |
R608 | Taurine and hypotaurine metabolism | VV12824 | 4.1.1.15 | 3SLALA-> HTR + CO2 | glutamate decarboxylase |
R609 | Taurine and hypotaurine metabolism | VV12824 | 4.1.1.15 | CYSTEATE-> TR + CO2 | glutamate decarboxylase |
R610 | Taurine and hypotaurine metabolism | VV21395 | 1.14.11.17 | TR + AKG + O2-> H2SO3 + AAA + SUCC + CO2 | taurine dioxygenase |
R611 | Taurine and hypotaurine metabolism | VV12952 | 1.4.1.1 | ALA + NAD-> PYR + NH3 + NADH | alanine dehydrogenase |
R612 | Aminophosphonate metabolism | VV11425 OR VV21062 | 2.6.1.- | PPYR + GLU <-> 2A3PP + AKG | aminotransferase |
R613 | Aminophosphonate metabolism | VV21664 | 2.6.1.37 | (2AE) P + PYR <-> PPAC + ALA | 2-aminoethylphosphonate-pyruvate transaminase |
R614 | Aminophosphonate metabolism | VV11153 | 2.1.1.- | MCB + PPAC-> 2HPP + VB12 | N6-adenine-specificmethylase |
R615 | Selenoamino acid metabolism | VV11364 | 2.5.1.48 | OPHSER + SCYS-> SLLCT + PI | cystathionine gamma-synthase |
R616 | Selenoamino acid metabolism | VV11364 | 2.5.1.48 | AHSER + SCYS-> SLLCT + AC | cystathionine gamma-synthase |
R617 | Selenoamino acid metabolism | VV11364 | 2.5.1.48 | SHSER + SCYS-> SLLCT + SUCC | cystathionine gamma-synthase |
R618 | Selenoamino acid metabolism | VV12872 | 4.4.1.8 | SLLCT-> SHCYS + NH3 + PYR | cystathionine beta-lyase |
R619 | Selenoamino acid metabolism | SHCYS-> SMET | |||
R620 | Selenoamino acid metabolism | VV13028 | 6.1.1.10 | ATP + SMET + TRNAMET-> AMP + PPI + SMETTRNAMET | methionyl-tRNA synthetase |
R621 | Selenoamino acid metabolism | VV11536 | 2.5.1.6 | ATP + SMET-> PI + PPI + SeASMET | S-adenosylmethionine synthetase |
R622 | Selenoamino acid metabolism | VV10209 OR VV13153 | 2.5.1.47 | ASER + SELD-> SCYS + AC | cysteine synthase |
R623 | Selenoamino acid metabolism | VV10725 AND VV10726 | 2.7.7.4 | ATP + SELNT <-> PPI + ASELNT | sulfateadenylyltransferase |
R624 | Selenoamino acid metabolism | VV10723 | 2.7.1.25 | ATP + ASELNT-> ADP + 3PASELNT | adenylylsulfate kinase |
R625 | Cyanoamino acid metabolism | VV21287 | 3.2.1.21 | CGS-> CHD + GLC | beta-glucosidase |
R626 | D-Glutamine and D-glutamate metabolism | VV11517 | 3.5.1.2 | GLN-> GLU + NH3 | glutaminase |
R627 | D-Glutamine and D-glutamate metabolism | VV11517 | 3.5.1.2 | DGLN-> DGLU + NH3 | glutaminase |
R628 | D-Glutamine and D-glutamate metabolism | VV11175 | 5.1.1.3 | DGLU <-> GLU | glutamateracemase |
R629 | D-Alanine metabolism | VV11393 OR VV20478 | 5.1.1.1 | ALA <-> DALA | alanine racemase |
R630 | D-Alanine metabolism | VV20280 | 6.3.2.4 | 2 DALA + ATP-> ALAALA + ADP + PI | D-alanine-D-alanineligase |
R631 | Glutathione metabolism | VV12641 | 3.4.11.2 | CYSGLY-> CYS + GLY | membrane alanyl aminopeptidase |
R632 | Glutathione metabolism | VV20532 | 3.4.11.4 | RGT-> CYSGLY + GLU | tripeptide aminopeptidase |
R633 | Lipopolysaccharide biosynthesis | VV11872 | 2.3.1.129 | C140ACP + UDPNAG-> ACP + UDPG2AA | UDP-N-acetylglucosamine acyltransferase |
R634 | Lipopolysaccharide biosynthesis | VV10571 | 3.5.1.- | UDPG2AA-> UDPG2A + AC | UDP-3-O- [3-hydroxymyristoyl] N-acetylglucosamine deacetylase |
R635 | Lipopolysaccharide biosynthesis | VV11870 | 2.3.1.- | UDPG2A + C140ACP-> ACP + UDPG23A | UDP-3-O- [3-hydroxymyristoyl] glucosamine N-acyltransferase |
R636 | Lipopolysaccharide biosynthesis | VV12910 | 3.6.1.- | UDPG23A-> UMP + LIPX | UDP-2,3-diacylglucosamine hydrolase |
R637 | Lipopolysaccharide biosynthesis | VV11873 | 2.4.1.182 | LIPX + UDPG23A-> UDP + DISAC1P | lipid-A-disaccharide synthase |
R638 | Lipopolysaccharide biosynthesis | VV12086 | 2.7.1.130 | DISAC1P + ATP-> ADP + LIPIV | tetraacyldisaccharide 4'-kinase |
R639 | Lipopolysaccharide biosynthesis | VV10799 | 2.-.-.- | LIPIV + CMPKDO-> KDOLIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R640 | Lipopolysaccharide biosynthesis | VV10799 | 2.-.-.- | KDOLIPIV + CMPKDO-> K2LIPIV + CMP | 3-deoxy-D-manno-octulosonic-acid transferase |
R641 | Lipopolysaccharide biosynthesis | VV10830 | 2.3.1.- | C120ACP + K2LIPIV-> LK2LIPIV + ACP | lipid A biosynthesis lauroyl acyltransferase |
R642 | Lipopolysaccharide biosynthesis | VV10797 | 2.3.1.- | C140ACP + LK2LIPIV-> K2LIPA + ACP | lipidAbiosynthesis (KDO) 2- (lauroyl) -lipidivaacyltransferase |
R643 | Lipopolysaccharide biosynthesis | VV10249 | 2.5.1.55 | PEP + A5P-> KDOP + PI | 2-dehydro-3-deoxyphosphooctonate aldolase (KDO 8-P synthase) |
R644 | Lipopolysaccharide biosynthesis | VV10688 | 3.1.3.45 | KDOP-> KDO + PI | 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase |
R645 | Lipopolysaccharide biosynthesis | VV12088 | 2.7.7.38 | KDO + CTP-> PPI + CMPKDO | 3-deoxy-manno-octulosonatecytidylyltransferase |
R646 | Lipopolysaccharide biosynthesis | VV10591 OR VV11897 | 5 .-.-.- | S7P-> DGDMH7P | phosphoheptose isomerase |
R647 | Lipopolysaccharide biosynthesis | VV10613 | 2.7 .-.- | ATP + DGDMH7P-> ADP + DGDMH17BP | ADP-heptose synthase |
R648 | Lipopolysaccharide biosynthesis | VV10291 | 3.1.1.- | DGDMH17BP-> DGDMH1P + PI | D-glycero-D-manno-heptose 1,7-bisphosphate phosphatase |
R649 | Lipopolysaccharide biosynthesis | VV10613 | 2.7 .-.- | ATP + DGDMH1P-> PPI + ADPDGDMHEP | ADP-heptose synthase |
R650 | Lipopolysaccharide biosynthesis | VV10796 | 5.1.3.20 | ADPDGDMHEP-> ADPHEP | ADP-L-glycero-D-manno-heptose 6-epimerase |
R651 | Lipopolysaccharide biosynthesis | 1.149 UDPG + 0.09 F6P + 0.387 ADPHEP + 0.142 UDPNAG-> LPS + 1.291 UDP + 0.09 PI + 0.387 ADP | Lipopolysaccharide biosynthesis | ||
R652 | Peptidoglycan biosynthesis | VV10577 | 6.3.2.8 | UDPNAM + ALA + ATP-> ADP + PI + UDPNAMA | UDP-N-acetylmuramate--alanine ligase |
R653 | Peptidoglycan biosynthesis | VV10580 | 6.3.2.9 | UDPNAMA + DGLU + ATP-> UDPNAMAG + ADP + PI | UDP-N-acetylmuramoylalanine--D-glutamate ligase |
R654 | Peptidoglycan biosynthesis | VV10583 | 6.3.2.13 | UDPNAMAG + MDAPIM + ATP-> UDPMNLADGMD + ADP + PI | UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase |
R655 | Peptidoglycan biosynthesis | VV10582 | 6.3.2.10 | UDPMNLADGMD + ALAALA + ATP-> UDPMNLADGMDDADA + ADP + PI | UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6diaminopimelate--D-alanyl-D-alanineligase |
R656 | Peptidoglycan biosynthesis | VV10581 | 2.7.8.13 | UDPMNLADGMDDADA + UDCP-> UPPMNLADGMDDADA + UMP | phospho-N-acetylmuramoyl-pentapeptide-transferase |
R657 | Peptidoglycan biosynthesis | VV10578 | 2.4.1.227 | UPPMNLADGMDDADA + UDPNAG-> UPPMN (GN) LADGMDDADA + UDP | UDP-N-acetylglucosamine--Nacetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenolN-acetylglucosaminetransferase |
R658 | Peptidoglycan biosynthesis | VV10889 | 6.3.1.2 | UPPMN (GN) LADGMDDADA + ATP + NH3-> UPPMN (GN) LADGNMDDADA + ADP + PI | glutamine synthetase |
R659 | Peptidoglycan biosynthesis | 2.3.2.10 | 5 GLY + UPPMN (GN) LADGNMDDADA-> UPPMN (GN) LADGNMD (G) 5DADA | L-Alanyl-tRNA: UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanineN6-alanyltransferase | |
R660 | Peptidoglycan biosynthesis | UPPMN (GN) LADGNMD (G) 5DADA-> UDCPP + PPEPTIDO | |||
R661 | Peptidoglycan biosynthesis | 2.6.1.21 | PPEPTIDO + DALA-> PEPTIDO + DALAxt | D-Alanine: 2-oxoglutarate aminotransferase | |
R662 | Peptidoglycan biosynthesis | VV10623 | 3.6.1.27 | UDCPP-> UDCP + PI | undecaprenyl-diphosphatase |
R663 | Peptidoglycan biosynthesis | VV11291 | 3.5.1.28 | ACALA-> ACMUR + ALA | N-acetylmuramoyl-L-alanine amidase |
R664 | Thiamine metabolism | VV10964 | thiC | AIR-> AHM | thiamine biosynthesis protein ThiC |
R665 | Thiamine metabolism | VV21433 | 2.7.1.49 | AHM + ATP-> AHMP + ADP | hydroxymethylpyrimidine kinase |
R666 | Thiamine metabolism | VV21433 | 2.7.4.7 | AHMP + ATP-> AHMPP + ADP | phosphomethylpyrimidine kinase |
R667 | Thiamine metabolism | VV10963 | 2.5.1.3 | THZP + AHMPP-> THMP + PPI | thiamine-phosphate pyrophosphorylase |
R668 | Thiamine metabolism | VV20752 | 3.1.3.- | THMP <-> THIAMIN + PI | phosphatase |
R669 | Thiamine metabolism | VV10317 | 2.7.4.16 | THMP + ATP <-> THMPP + ADP | thiamine-monophosphatekinase |
R670 | Riboflavin metabolism | VV10321 OR VV12234 OR VV21180 | 3.5.4.25 | GTP-> D6RP5P + FORMATE + PPI | GTP cyclohydrolase II |
R671 | Riboflavin metabolism | VV10323 | 3.5.4.26 | D6RP5P-> A6RP5P + NH3 | diaminohydroxyphosphoribosylaminopyrimidine deaminase |
R672 | Riboflavin metabolism | VV10323 | 1.1.1.193 | A6RP5P + NADPH-> A6RP5P2 + NADP | 5-amino-6- (5-phosphoribosylamino) uracil reductase |
R673 | Riboflavin metabolism | VV20752 | 3.1.3- | A6RP5P2-> A6RP + PI | phosphatase |
R674 | Riboflavin metabolism | VV21426 | RIBB | RL5P-> DB4P + FORMATE | 3,4-dihydroxy-2-butanone 4-phosphate synthase |
R675 | Riboflavin metabolism | VV10319 | RIBH | DB4P + A6RP-> D8RL + PI | riboflavinsynthase |
R676 | Riboflavin metabolism | VV10322 OR VV12560 | 2.5.1.9 | 2 D8RL-> RIBFLAV + A6RP | riboflavinsynthase |
R677 | Riboflavin metabolism | VV10508 | 2.7.1.26 | RIBFLAV + ATP-> FMN + ADP | riboflavin kinase |
R678 | Riboflavin metabolism | VV10508 | 2.7.7.2 | FMN + ATP-> FAD + PPI | FMN adenylyltransferase |
R679 | Riboflavin metabolism | VV11585 | 3.1.3.2 | FMN-> RIBFLAV + PI | acid phosphatase |
R680 | Riboflavin metabolism | VV12788 | 2.4.2.21 | NACN + DMB-> NAC + N1 (5PADR) DMB | nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase |
R681 | Vitamin B6 metabolism | VV11539 | 1.2.1.72 | E4P + NAD <-> ER4P + NADH | D-erythrose 4-phosphate dehydrogenase |
R682 | Vitamin B6 metabolism | VV11988 | 1.1.1.290 | ER4P + NAD <-> OHB + NADH | erythronate-4-phosphate dehydrogenase |
R683 | Vitamin B6 metabolism | VV12813 | 2.6.1.52 | OHB + GLU <-> PHT + AKG | phosphoserine aminotransferase |
R684 | Vitamin B6 metabolism | VV10543 | 4.2.3.1 | PHT-> 4HLT + PI | threonine synthase |
R685 | Vitamin B6 metabolism | VV10662 | 1.1.1.262 | PHT + NAD-> 3A2OP + NADH + CO2 | 4-hydroxythreonine-4-phosphate dehydrogenase |
R686 | Vitamin B6 metabolism | VV11568 | PdxJ | 3A2OP + DX5P-> P5P + PI | pyridoxine 5-phosphate synthase |
R687 | Vitamin B6 metabolism | VV21237 | 2.7.1.35 | PYRDX + ATP-> P5P + ADP | pyridoxine kinase |
R688 | Vitamin B6 metabolism | VV20752 | 3.1.3.- | P5P-> PYRDX + PI | phosphatase |
R689 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | P5P + O2-> PL5P + H2O2 | pyridoxamine 5'-phosphate oxidase |
R690 | Vitamin B6 metabolism | VV20752 | 3.1.3.- | PL5P-> PL + PI | phosphatase |
R691 | Vitamin B6 metabolism | VV21237 | 2.7.1.35 | PL + ATP-> PL5P + ADP | pyridoxine kinase |
R692 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | PDLA5P + O2-> PL5P + NH3 + H2O2 | pyridoxamine 5'-phosphate oxidase |
R693 | Vitamin B6 metabolism | VV21237 | 2.7.1.35 | PDLA + ATP-> PDLA5P + ADP | pyridoxine kinase |
R694 | Vitamin B6 metabolism | VV20752 | 3.1.3.- | PDLA5P-> PDLA + PI | phosphatase |
R695 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | PYRDX + O2 <-> PL + H2O2 | pyridoxamine 5'-phosphate oxidase |
R696 | Vitamin B6 metabolism | VV21122 | 1.4.3.5 | PL + O2 + NH3 <-> PDLA + H2O2 | pyridoxamine 5'-phosphate oxidase |
R697 | Nicotinate and nicotinamide metabolism | VV11558 | 1.4.3.16 | ASP + FUM-> IASP + SUCC | L-aspartateoxidase |
R698 | Nicotinate and nicotinamide metabolism | VV11558 | 1.4.3.16 | ASP + O2-> IASP + H2O2 | L-aspartate oxidase |
R699 | Nicotinate and nicotinamide metabolism | VV12173 | NadA | IASP + DHAP-> QA + PI | quinolinate synthase |
R700 | Nicotinate and nicotinamide metabolism | VV11627 | 2.4.2.19 | QA + PRPP-> NACN + CO2 + PPI | nicotinate-nucleotide pyrophosphorylase (carboxylating) |
R701 | Nicotinate and nicotinamide metabolism | VV10248 OR VV20237 | 3.1.3.5 | NACN-> NACD + PI | 5'-nucleotidase |
R702 | Nicotinate and nicotinamide metabolism | VV10248 OR VV20237 | 3.1.3.5 | NAMN-> NAMD + PI | 5'-nucleotidase |
R703 | Nicotinate and nicotinamide metabolism | VV10814 | 2.7.1.- | NACD + ATP-> NACN + ADP | putativeKDOkinaseWavC |
R704 | Nicotinate and nicotinamide metabolism | VV12372 | 2.4.2.11 | NAC + PRPP-> NACN + PPI | nicotinate phosphoribosyltransferase |
R705 | Nicotinate and nicotinamide metabolism | 2.7.7.18 | NACN + ATP-> PPI + NAAD | nicotinate-nucleotide adenylyltransferase | |
R706 | Nicotinate and nicotinamide metabolism | VV21599 | 6.3.5.1 | NAAD + ATP + GLN-> NAD + AMP + PPI + GLU | NAD + synthetase (glutamine-hydrolysing) |
R707 | Nicotinate and nicotinamide metabolism | VV11728 OR VV21540 | 2.4.2.1 | NAC + R1P-> PI + NACD | purine-nucleoside phosphorylase |
R708 | Nicotinate and nicotinamide metabolism | VV11728 OR VV21540 | 2.4.2.1 | NAM + R1P-> PI + NAMD | purine-nucleoside phosphorylase |
R709 | Nicotinate and nicotinamide metabolism | VV12374 | 3.5.1.19 | NAM-> NAC + NH3 | nicotinamidase |
R710 | Nicotinate and nicotinamide metabolism | VV20315 AND VV20316 AND VV20317 | 1.6.1.2 | NADP + NADH-> NADPH + NAD | NAD (P) transhydrogenase |
R711 | Nicotinate and nicotinamide metabolism | VV10366 | 2.7.1.23 | NAD + ATP-> NADP + ADP | NAD kinase |
R712 | Nicotinate and nicotinamide metabolism | VV20752 | 3.1.3.- | NADP-> NAD + PI | phosphatase |
R713 | Nicotinate and nicotinamide metabolism | VV11168 | 1.6.1.1 | NADPH + NAD <-> NADP + NADH | NAD (P) transhydrogenase |
R714 | Pantothenate and CoA biosynthesis | (VV10647 AND VV10648) OR (VV11031 AND VV11032) | 2.2.1.6 | 2 PYR-> ACLAC + CO2 | acetolactatesynthase |
R715 | Pantothenate and CoA biosynthesis | VV11643 | 2.1.2.11 | OIVAL + METTHF-> DHPANT + THF | 3-methyl-2-oxobutanoate hydroxymethyltransferase |
R716 | Pantothenate and CoA biosynthesis | VV11810 | 1.1.1.169 | DHPANT + NADPH-> NADP + PANT | 2-dehydropantoate 2-reductase |
R717 | Pantothenate and CoA biosynthesis | VV11642 | 6.3.2.1 | PANT + bALA + ATP-> AMP + PPI + PNTO | pantoate-beta-alanine ligase |
R718 | Pantothenate and CoA biosynthesis | VV11200 | 2.7.1.33 | PNTO + ATP-> ADP + 4PPNTO | pantothenate kinase |
R719 | Pantothenate and CoA biosynthesis | VV11200 | 2.7.1.33 | ATP + N (P) CYS-> ADP + 4PPNCYS | pantothenate kinase |
R720 | Pantothenate and CoA biosynthesis | VV11200 | 2.7.1.33 | ATP + PTT-> ADP + 4PPNTE | pantothenate kinase |
R721 | Pantothenate and CoA biosynthesis | VV10828 | 6.3.2.5 | 4PPNTO + CTP + CYS-> CMP + PPI + 4PPNCYS | phosphopantothenate-cysteine ligase |
R722 | Pantothenate and CoA biosynthesis | VV10828 | 4.1.1.36 | 4PPNCYS-> CO2 + 4PPNTE | phosphopantothenoylcysteine decarboxylase |
R723 | Pantothenate and CoA biosynthesis | VV10819 | 2.7.7.3 | 4PPNTE + ATP-> PPI + DPCOA | pantetheine-phosphate adenylyltransferase |
R724 | Pantothenate and CoA biosynthesis | VV11621 AND VV11622 | 2.7.1.24 | DPCOA + ATP-> ADP + COA | dephospho-CoA kinase |
R725 | Pantothenate and CoA biosynthesis | VV11569 | 2.7.8.7 | COA + AACP-> PAP + ACP | holo- [acyl-carrier protein] synthase |
R726 | Pantothenate and CoA biosynthesis | VV12341 | 3.1.4.14 | ACP-> 4PPNTE + AACP | acyl carrier protein phosphodiesterase |
R727 | Pantothenate and CoA biosynthesis | VV12599 | 3.5.1.- | PTT-> PNTO + CA | NAD-dependentproteindeacetylases |
R728 | Biotin metabolism | VV12942 | 2.3.1.47 | ALA + CHCOA <-> CO2 + COA + AONA | 8-amino-7-oxononanoate synthase |
R729 | Biotin metabolism | VV12944 AND VV12945 | 2.6.1.62 | SAM + AONA <-> SAMOB + DANNA | adenosylmethionine-8-amino-7-oxononanoateaminotransferase |
R730 | Biotin metabolism | VV12940 | 6.3.3.3 | CO2 + DANNA + ATP <-> DTB + PI + ADP | dethiobiotin synthetase |
R731 | Biotin metabolism | VV12943 | 2.8.1.6 | DTB + S-> BT | biotin synthase |
R732 | Biotin metabolism | VV11198 AND VV11199 | 6.3.4.15 | ATP + BT-> PPI + B5AMP | biotin- [acetyl-CoA-carboxylase] ligase |
R733 | Biotin metabolism | VV11198 AND VV11199 | 6.3.4.15 | B5AMP + A [C]-> AMP + H [C] | biotin- [acetyl-CoA-carboxylase] ligase |
R734 | Folate biosynthesis | VV20543 | 3.5.4.16 | GTP-> FORMATE + AHTD | GTP cyclohydrolase I |
R735 | Folate biosynthesis | VV10854 OR VV11083 OR VV12614 | 3.6.1.- | AHTD-> DHP + PPI + PI | recG-likehelicase |
R736 | Folate biosynthesis | VV10625 | 4.1.2.25 | DHP-> AHHMP + GLAL | dihydroneopterin aldolase |
R737 | Folate biosynthesis | VV11644 | 2.7.6.3 | AHHMP + ATP-> AMP + AHHMD | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase |
R738 | Folate biosynthesis | VV11311 AND VV11312 AND VV12265 | 2.6.1.85 | CHOR + GLN-> ADCHOR + GLU | para-aminobenzoate synthase |
R739 | Folate biosynthesis | VV13005 | 4.1.3.38 | ADCHOR-> PYR + PABA | 4-amino-4-deoxychorismate lyase |
R740 | Folate biosynthesis | VV11691 | 2.5.1.15 | PABA + AHHMD-> PPI + DHPT | dihydropteroate synthase |
R741 | Folate biosynthesis | VV11691 | 2.5.1.15 | PABA + AHHMP-> DHPT | dihydropteroate synthase |
R742 | Folate biosynthesis | VV11994 | 6.3.2.12 OR 6.3.2.17 | DHPT + ATP + GLU-> ADP + PI + DHF | dihydrofolate synthase |
R743 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NADPH-> NADP + THF | dihydrofolate reductase |
R744 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NADH-> NAD + THF | dihydrofolate reductase |
R745 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NAD <-> FL + NADH | dihydrofolate reductase |
R746 | Folate biosynthesis | VV10666 | 1.5.1.3 | DHF + NADP <-> FL + NADPH | dihydrofolate reductase |
R747 | Folate biosynthesis | VV10666 | 1.5.1.3 | FL + NADH-> THF + NAD | dihydrofolate reductase |
R748 | Folate biosynthesis | VV10666 | 1.5.1.3 | FL + NADPH-> THF + NADP | dihydrofolate reductase |
R749 | Folate biosynthesis | VV11994 | 6.3.2.17 | THF + ATP + GLU <-> ADP + PI + THFG | folylpolyglutamate synthase |
R750 | Folate biosynthesis | VV12257 | 4.2.3.12 | AHTD-> PYTHP + H5P3O10 | 6-pyruvoyl tetrahydrobiopterin synthase |
R751 | Folate biosynthesis | VV20966 | 1.5.1.34 | DHBPT + NADH <-> THBPT + NAD | dihydropteridine reductase |
R752 | Folate biosynthesis | VV20966 | 1.5.1.34 | DHBPT + NADPH <-> THBPT + NADP | dihydropteridine reductase |
R753 | One carbon pool by folate | VV11899 | 2.1.2.2 | GAR + METHF-> FGAR + THF | phosphoribosylglycinamide formyltransferase |
R754 | One carbon pool by folate | VV12022 | 3.5.4.9 | METHF-> FTHF | formate--tetrahydrofolate ligase |
R755 | One carbon pool by folate | VV20190 | 2.1.2.10 | METHF-> 5FTHF | aminomethyltransferase |
R756 | One carbon pool by folate | VV12022 | 1.5.1.5 | METTHF + NADP <-> METHF + NADPH | methylenetetrahydrofolate dehydrogenase (NADP +) |
R757 | One carbon pool by folate | VV12022 | 3.5.4.9 | METHF <-> FTHF | methenyltetrahydrofolatecyclohydrolase |
R758 | One carbon pool by folate | VV11366 | 1.5.1.20 | METTHF + NADPH-> MTHF + NADP | methylenetetrahydrofolatereductase |
R759 | One carbon pool by folate | VV11366 | 1.5.1.20 | METTHF + FADH2 <-> MTHF + FAD | methylenetetrahydrofolatereductase |
R760 | One carbon pool by folate | VV10516 | 2.1.1.45 | DUMP + METTHF <-> DHF + DTMP | thymidylatesynthase |
R761 | One carbon pool by folate | VV10143 | 3.5.1.10 | FTHF <-> FORMATE + THF | formyltetrahydrofolate hydrolase |
R762 | Porphyrin and chlorophyll metabolism | VV10254 | 1.2.1.70 | GTRNA + NADPH-> GSA + NADP | glutamyl-tRNA reductase |
R763 | Porphyrin and chlorophyll metabolism | VV11678 | 5.4.3.8 | GSA-> ALAV | glutamate-1-semialdehyde 2,1-aminomutase |
R764 | Porphyrin and chlorophyll metabolism | VV10902 | 4.2.1.24 | 2ALAV-> PBG | porphobilinogen synthase |
R765 | Porphyrin and chlorophyll metabolism | VV11122 | 2.5.1.61 | 4 PBG-> HMB + 4 NH3 | hydroxymethylbilane synthase |
R766 | Porphyrin and chlorophyll metabolism | VV11121 | 4.2.1.75 | HMB-> UPRG | uroporphyrinogen-III synthase |
R767 | Porphyrin and chlorophyll metabolism | VV10727 OR VV11120 OR VV20367 OR VV20397 | 2.1.1.107 | 2 SAM + UPRG-> 2 SAH + PC2 | uroporphyrinogen-III methylase |
R768 | Porphyrin and chlorophyll metabolism | VV12702 | 1.3.1.76 | PC2 + NAD-> NADH + SHCL | precorrin-2 dehydrogenase |
R769 | Porphyrin and chlorophyll metabolism | VV12702 | 4.99.1.4 | SHCL-> SHEME | sirohydrochlorin ferrochelatase |
R770 | Porphyrin and chlorophyll metabolism | VV11218 | 4.1.1.37 | UPRG-> 4 CO2 + CPP | uroporphyrinogen decarboxylase |
R771 | Porphyrin and chlorophyll metabolism | VV10894 OR VV11519 OR VV21615 | 1.3.99.22 | CPP + 2 SAM-> PPHG + 2 CO2 + 2 MET + 2 DA | oxygen-independent coproporphyrinogen III oxidase |
R772 | Porphyrin and chlorophyll metabolism | VV11056 | 1.3.3.3 | CPP + O2-> PPHG + 2 CO2 | coproporphyrinogen III oxidase |
R773 | Porphyrin and chlorophyll metabolism | VV10978 | 1.3.3.4 | 1.5O2 + PPHG-> PPIX | protoporphyrinogen oxidase |
R774 | Porphyrin and chlorophyll metabolism | VV10187 | 4.99.1.1 | PPIX-> PTH | ferrochelatase |
R775 | Porphyrin and chlorophyll metabolism | VV13022 | 2.5.1.17 | C (I) DA + ATP-> ACDA + PPI + PI | cob (I) alamin adenosyltransferase |
R776 | Porphyrin and chlorophyll metabolism | VV20330 | 6.3.5.10 | ACDA + 4 GLN + 4 ATP-> ACHA + 4 GLU + 4 PI + 4 ADP | cobyric acid synthase |
R777 | Porphyrin and chlorophyll metabolism | VV10559 | 6.3.1.10 | ACHA + 1AP2O-> ADCBA | adenosylcobinamidesynthase |
R778 | Porphyrin and chlorophyll metabolism | VV10559 | 6.3.1.10 | ACHA + D1AP2OOP + ATP-> ADCBAP + ADP + PI | adenosylcobinamide-phosphatesynthase |
R779 | Porphyrin and chlorophyll metabolism | VV12786 | 2.7.1.156 | ADCBA + ATP-> ADCBAP + ADP | adenosylcobinamidekinase |
R780 | Porphyrin and chlorophyll metabolism | VV12786 | 2.7.1.156 | ADCBA + GTP-> ADCBAP + GDP | adenosylcobinamidekinase |
R781 | Porphyrin and chlorophyll metabolism | VV12786 | 2.7.7.62 | ADCBAP + GTP-> AGDPCBA + PPI | adenosylcobinamide-phosphate guanylyltransferase |
R782 | Porphyrin and chlorophyll metabolism | VV12785 OR VV20752 | 3.1.3.73 OR 3.1.3.- | N1 (5PADR) DMB-> ARBZ + PI | alpha-ribazolephosphatase ORphosphatase |
R783 | Porphyrin and chlorophyll metabolism | VV12787 | 2.7.8.26 | AGDPCBA + ARBZ-> CBCO + GMP | adenosylcobinamide-GDP ribazoletransferase |
R784 | Porphyrin and chlorophyll metabolism | VV10933 | 1.16.1.3 | NADH + 2 AC (III) A-> NAD + 2 C (II) A | aquacobalamin reductase |
R785 | Ubiquinone biosynthesis | VV13173 OR VV20835 | 5.4.4.2 | CHOR <-> ICHOR | menaquinone-specific isochorismate synthase |
R786 | Ubiquinone biosynthesis | VV11163 | 4.1.3.- | CHOR <-> 4HB + PYR | chorismate--pyruvate lyase |
R787 | Ubiquinone biosynthesis | VV11164 | 2.5.1.- | OPP + 4HB-> 3OP4HB + PPI | 4-hydroxybenzoate octaprenyltransferase |
R788 | Ubiquinone biosynthesis | VV10705 OR VV10935 | 4.1.1.- | 3OP4HB-> 2OPP + CO2 | 3-octaprenyl-4-hydroxybenzoatecarboxy-lyase |
R789 | Ubiquinone biosynthesis | VV10907 | Ubib | 2OPP + O2 + NADPH-> 2OP6HP + NADP | ubiquinone biosynthesis protein |
R790 | Ubiquinone biosynthesis | VV13040 | 2.1.1.64 | 2OP6HP + SAM-> 2OP6MP + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R791 | Ubiquinone biosynthesis | VV11552 | 1.14.13.- | 2OP6MP + O2 + NADPH-> 2OP6M14BQ + NADP | 2-octaprenyl-6-methoxyphenol hydroxylase |
R792 | Ubiquinone biosynthesis | VV10909 | 2.1.1.- | 2OP6M14BQ + SAM-> 2OP3M6M14BQ + SAH | ubiquinone methyltransferase |
R793 | Ubiquinone biosynthesis | VV10265 | 1.14.13.- | 2OP3M6M14BQ + O2 + NADPH-> 2OP3M5H6M14BQ + NADP | 2-polyprenyl-6-methoxyphenol hydroxylase |
R794 | Ubiquinone biosynthesis | VV13040 | 2.1.1.64 | 2OP3M5H6M14BQ + SAM-> UQ + SAH | 3-demethylubiquinone-9 3-methyltransferase |
R795 | Ubiquinone biosynthesis | VV13172 | 2.5.1.64 | ICHOR + AKG-> SHCHC + PYR + CO2 | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylatesynthase |
R796 | Ubiquinone biosynthesis | VV13169 | 4.2.1.- | SHCHC-> OSB | O-succinylbenzoate-CoA synthase |
R797 | Ubiquinone biosynthesis | VV13168 | 6.2.1.26 | OSB + ATP + COA-> AMP + PPI + OSBCOA | O-succinylbenzoic acid--CoA ligase |
R798 | Ubiquinone biosynthesis | VV13170 | 4.1.3.36 | OSBCOA-> DHN + COA | dihydroxynaphthoic acid synthase |
R799 | Ubiquinone biosynthesis | VV11353 | 2.5.1.- | DHN + OPP-> PPI + CO2 + DMK | 1,4-dihydroxy-2-naphthoate octaprenyltransferase |
R800 | Ubiquinone biosynthesis | VV10909 | 2.1.1.- | DMK + SAM-> MKH2 + SAH | menaquinone biosynthesis methyltransferase |
표 7
TABLE 7
R801 | Ubiquinone biosynthesis | VV11353 | 2.5.1.- | DHN + PPP -> 2P14NQ + CO2 + PPI | 1,4-dihydroxy-2-naphthoate octaprenyltransferase |
R802 | Ubiquinone biosynthesis | VV10909 | 2.1.1.- | 2P14NQ + SAM -> PQ + SAH | menaquinone biosynthesis methyltransferase |
R803 | Protein | 1.521ALA+0.384ARG+0.438ASN+0.438ASP+0.108CYS+0.645GLN+0.645GLU+1.002GLY+0.196HIS+0.479ILE+0.673LEU+0.373LYS+0.126MET+0.283PHE+0.392PRO+0.407SER+0.500THR+0.109TRP+0.115TYR+0.712VAL+40ATP->40ADP+40PI+ PROTEIN | |||
R804 | DNA | 2.7.7.7 | 0.863 DATP + 0.756 DGTP + 0.756 DCTP + 0.863 DTTP + 4.4 ATP -> 4.4 ADP + 4.4 PI + 3.237 PPI + DNA | ||
R805 | RNA | 2.7.7.6 | 2.023 ATP + 0.946 GTP + 0.696 CTP + 0.675 UTP -> 1.25 ADP + 1.25 PI + 3.09 PPI + RNA | ||
R806 | Phospholipid | 0.1552AG3PE+0.908PE+0.268PG-> PHOSPHOLIPID | |||
R807 | Cofactors and vitamins (CAV) | 0.163COA+0.159FAD+0.274FMN+0.405MK+0.188NAD+0.168NADP+0.739PYRDX+0.281THF-> CAV | |||
R808 | Biomass | 0.55PROTEIN+0.031DNA+0.205RNA+0.091PHOSPHOLIPID+0.03CAV+0.034LPS+0.025PEPTIDO+0.025GLYCOGEN+46ATP-> BIOMASS + 46 ADP + 46 PI | |||
R809 | Maintenance | ATP -> ADP + PI | |||
R810 | IMAL_transport | VV12614 | 3.6.1.- | IMALxt + ATP <-> IMAL + PI + ADP | |
R811 | FRU_transport | VV20198 AND VV20200 OR (VV21349 AND VV21352 AND VV21353) OR (VV21356 AND VV21357) | 2.7.1.69 | FRUxt + PEP -> F1P + PYR | |
R812 | GLC_transport | VV10212 AND VV12999 | 2.7.1.69 | GLCxt + PEP -> G6P + PYR | |
R813 | GLUC_transport | GLUCxt+ Hxt -> GLUC | |||
R814 | MLT_transport | MLTxt + ATP -> MLT + ADP + PI | |||
R815 | MELI_transport | MELIxt+ Hxt -> MELI | |||
R816 | MELI_transport | MELIxt+ Naxt -> MELI + Na | |||
R817 | MNT_transport | VV10638 | 2.7.1.69 | MNTxt + PEP -> MNT1P + PYR | |
R818 | NAGA_transport | VV10179 | 2.7.1.69 | NAGAxt + PEP -> NAGA6P + PYR | |
R819 | SUC_transport | VV21142 | 2.7.1.69 | SUCxt + PEP -> SUC6P + PYR | |
R820 | TRE_transport | VV10289 | 2.7.1.69 | TRExt + PEP -> TRE6P + PYR | |
R821 | 2PG_transport | 2PGxt + ATP -> 2PG + ADP + PI | |||
R822 | 3PG_transport | 3PGxt + ATP -> 3PG + ADP + PI | |||
R823 | AC_transport | AC<-> ACxt + Hxt | |||
R824 | AKG_transport | AKGxt + Hxt -> AKG | |||
R825 | CIT_transport | CITxt<-> CIT | |||
R826 | CIT_transport | CITxt + Naxt -> CIT + Na | |||
R827 | FORMATE_transport | FORMATE -> FORMATExt | |||
R828 | FUM_transport | FUMxt + Hxt -> FUM | |||
R829 | FUM_transport | FUMxt + Naxt -> FUM + Na | |||
R830 | FUM_transport | FUMxt+ SUCC <-> FUM + SUCCxt | |||
R831 | ICIT_transport | ICITxt + Naxt -> ICIT + Na | |||
R832 | MAL_transport | MALxt + Hxt -> MAL | |||
R833 | MAL_transport | MALxt + Naxt -> MAL + Na | |||
R834 | MAL_transport | MALxt+ SUCC <-> MAL + SUCCxt | |||
R835 | SLAC_transport | SLACxt+ Hxt -> SLAC | |||
R836 | SUCC_transport | SUCCxt + Hxt -> SUCC | |||
R837 | SUCC_transport | SUCCxt + Naxt -> SUCC + Na | |||
R838 | GL3P_transport | GL3Pxt + PI <-> GL3P + PIxt | |||
R839 | GL3P_transport | GL3Pxt + ATP -> GL3P + ADP + PI | |||
R840 | GLYCOLATE_transport | GLYCOLATExt <-> GLYCOLATE | |||
R841 | ATP_transport | ATP <-> Hxt + ADP + PI | |||
R842 | CO2_transport | CO2xt <-> CO2 | |||
R843 | Na_transport | Naxt<-> Na + Hxt | |||
R844 | Na_transport | Na + 2 Hxt <-> Naxt | |||
R845 | Na_transport | Na + 3 Hxt <-> Naxt | |||
R846 | Na_transport | 2 Na + 3 Hxt <-> 2 Naxt | |||
R847 | NH3_transport | NH3xt<-> NH3 | |||
R848 | NO2_transport | NO2 -> NO2xt | |||
R849 | NO3_transport | NO3xt + ATP -> NO3 + ADP + PI | |||
R850 | O2_transport | O2xt <-> O2 | |||
R851 | PI_transport | PIxt + Hxt <-> PI | |||
R852 | PI_transport | PIxt + 3 Naxt <-> PI + 3 Na | |||
R853 | PI_transport | PIxt + ATP -> 2 PI + ADP | |||
R854 | SLF_transport | SLFxt + Naxt -> SLF + Na | |||
R855 | SLF_transport | SLFxt + Hxt -> SLF | |||
R856 | SLF_transport | SLFxt + ATP -> SLF + ADP + PI | |||
R857 | THIAMIN_transport | THIAMINxt + ATP -> THIAMIN + ADP + PI | |||
R858 | ALA_transport | ALA + Hxt <-> ALAxt | |||
R859 | ALA_transport | ALAxt+ ATP -> ALA + ADP + PI | |||
R860 | ALA_transport | ALAxt+ Hxt -> ALA | |||
R861 | ALA_transport | ALAxt+ Naxt -> ALA + Na | |||
R862 | ARG_transport | ARG + Hxt <-> ARGxt | |||
R863 | ARG_transport | ARGxt+ ATP -> ARG + ADP + PI | |||
R864 | ARG_transport | ARGxt+ Hxt -> ARG | |||
R865 | ASN_transport | ASN + Hxt <-> ASNxt | |||
R866 | ASN_transport | ASNxt+ ATP -> ASN + ADP + PI | |||
R867 | ASN_transport | ASNxt+ Hxt -> ASN | |||
R868 | ASP_transport | ASP + Hxt <-> ASPxt | |||
R869 | ASP_transport | ASPxt+ ATP -> ASP + ADP + PI | |||
R870 | ASP_transport | ASPxt+ Hxt -> ASP | |||
R871 | CYS_transport | CYS + Hxt <-> CYSxt | |||
R872 | CYS_transport | CYSxt+ ATP -> CYS + ADP + PI | |||
R873 | CYS_transport | CYSxt+ Hxt -> CYS | |||
R874 | DALA_transport | DALAxt+ Hxt -> DALA | |||
R875 | DGLU_transport | DGLUxt+ Hxt -> DGLU | |||
R876 | GLN_transport | GLN + Hxt <-> GLNxt | |||
R877 | GLN_transport | GLNxt+ ATP -> GLN + ADP + PI | |||
R878 | GLN_transport | GLNxt+ Hxt -> GLN | |||
R879 | GLU_transport | GLU + Hxt <-> GLUxt | |||
R880 | GLU_transport | GLUxt+ ATP -> GLU + ADP + PI | |||
R881 | GLU_transport | GLUxt+ Hxt -> GLU | |||
R882 | GLU_transport | GLUxt+ Naxt -> GLU + Na | |||
R883 | GLY_transport | GLY + Hxt <-> GLYxt | |||
R884 | GLY_transport | GLYxt+ ATP -> GLY + ADP + PI | |||
R885 | GLY_transport | GLYxt+ Hxt -> GLY | |||
R886 | GLY_transport | GLYxt+ Naxt -> GLY + Na | |||
R887 | HIS_transport | HIS + Hxt <-> HISxt | |||
R888 | HIS_transport | HISxt+ ATP -> HIS + ADP + PI | |||
R889 | HIS_transport | HISxt+ Hxt -> HIS | |||
R890 | ILE_transport | ILE+ Hxt <-> ILExt | |||
R891 | ILE_transport | ILExt+ ATP -> ILE + ADP + PI | |||
R892 | ILE_transport | ILExt+ Hxt -> ILE | |||
R893 | LEU_transport | LEU+ Hxt <-> LEUxt | |||
R894 | LEU_transport | LEUxt+ ATP -> LEU + ADP + PI | |||
R895 | LEU_transport | LEUxt+ Hxt -> LEU | |||
R896 | LYS_transport | LYS+ Hxt <-> LYSxt | |||
R897 | LYS_transport | LYS+ Hxt -> LYSxt | |||
R898 | LYS_transport | LYSxt+ ATP -> LYS + ADP + PI | |||
R899 | LYS_transport | LYSxt+ Hxt -> LYS | |||
R900 | MET_transport | MET+ Hxt <-> METxt | |||
R901 | MET_transport | METxt+ ATP -> MET + ADP + PI | |||
R902 | MET_transport | METxt+ Hxt -> MET | |||
R903 | PHE_transport | PHE+ Hxt <-> PHExt | |||
R904 | PHE_transport | PHExt+ ATP -> PHE + ADP + PI | |||
R905 | PHE_transport | PHExt+ Hxt -> PHE | |||
R906 | PRO_transport | PRO+ Hxt <-> PROxt | |||
R907 | PRO_transport | PROxt+ ATP -> PRO + ADP + PI | |||
R908 | PRO_transport | PROxt+ Hxt -> PRO | |||
R909 | PRO_transport | PROxt + Naxt -> PRO + Na | |||
R910 | SER_transport | SER+ Hxt <-> SERxt | |||
R911 | SER_transport | SERxt+ ATP -> SER + ADP + PI | |||
R912 | SER_transport | SERxt+ Hxt -> SER | |||
R913 | THR_transport | THR + Hxt <-> THRxt | |||
R914 | THR_transport | THRxt+ ATP -> THR + ADP + PI | |||
R915 | THR_transport | THRxt+ Hxt -> THR | |||
R916 | TRP_transport | TRP+ Hxt <-> TRPxt | |||
R917 | TRP_transport | TRPxt+ ATP -> TRP + ADP + PI | |||
R918 | TRP_transport | TRPxt+ Hxt -> TRP | |||
R919 | TYR_transport | TYR+ Hxt <-> TYRxt | |||
R920 | TYR_transport | TYRxt+ ATP -> TYR + ADP + PI | |||
R921 | TYR_transport | TYRxt+ Hxt -> TYR | |||
R922 | VAL_transport | VAL+ Hxt <-> VALxt | |||
R923 | VAL_transport | VALxt+ ATP -> VAL + ADP + PI | |||
R924 | VAL_transport | VALxt+ Hxt -> VAL | |||
R925 | HSER_transport | HSER + Hxt <-> HSERxt | |||
R926 | ORN_transport | ORNxt + ATP -> ORN + ADP + PI | |||
R927 | PTRC/ORN_transport | PTRCxt + ORN <-> PTRC + ORNxt | |||
R928 | PTRC_transport | PTRCxt + ATP -> PTRC + ADP + PI | |||
R929 | SPRMD_transport | SPRMDxt + ATP -> SPRMD + ADP + PI | |||
R930 | UREA_transport | UREAxt + ATP -> UREA + ADP + PI | |||
R931 | CHOLINE_transport | CHOLINExt + Hxt -> CHOLINE | |||
R932 | GL_transport | GLxt <-> GL | |||
R933 | ADN_transport | ADNxt+ Hxt -> ADN | |||
R934 | CYTD_transport | CYTDxt+ Hxt -> CYTD | |||
R935 | DA_transport | DAxt+ Hxt -> DA | |||
R936 | DC_transport | DCxt+ Hxt -> DC | |||
R937 | DG_transport | DGxt+ Hxt -> DG | |||
R938 | DT_transport | DTxt+ Hxt -> DT | |||
R939 | DU_transport | DUxt+ Hxt -> DU | |||
R940 | GSN_transport | GSNxt+ Hxt -> GSN | |||
R941 | URI_transport | URIxt+ Hxt -> URI | |||
R942 | CT_transport | CTxt + Hxt -> CT | |||
R943 | XAN_transport | XANxt + Hxt -> XAN | |||
R944 | URA_transport | URAxt + Hxt -> URA | |||
R945 | VB12_transport | VB12xt + ATP -> VB12 + ADP + PI |
R801 | Ubiquinone biosynthesis | VV11353 | 2.5.1.- | DHN + PPP-> 2P14NQ + CO2 + PPI | 1,4-dihydroxy-2-naphthoate octaprenyltransferase |
R802 | Ubiquinone biosynthesis | VV10909 | 2.1.1.- | 2P14NQ + SAM-> PQ + SAH | menaquinone biosynthesis methyltransferase |
R803 | Protein | 1.521ALA + 0.384ARG + 0.438ASN + 0.438ASP + 0.108CYS + 0.645GLN + 0.645GLU + 1.002GLY + 0.196HIS + 0.479ILE + 0.673LEU + 0.373LYS + 0.126MET + 0.283PHE + 0.392PRO + 0.407SER + 0.500THR + 0.109TRP + 0.115TYR + 0.712VAL + 40ATP-> 40ADP + 40PI + PROTEIN | |||
R804 | DNA | 2.7.7.7 | 0.863 DATP + 0.756 DGTP + 0.756 DCTP + 0.863 DTTP + 4.4 ATP-> 4.4 ADP + 4.4 PI + 3.237 PPI + DNA | ||
R805 | RNA | 2.7.7.6 | 2.023 ATP + 0.946 GTP + 0.696 CTP + 0.675 UTP-> 1.25 ADP + 1.25 PI + 3.09 PPI + RNA | ||
R806 | Phospholipid | 0.1552AG3PE + 0.908PE + 0.268PG-> PHOSPHOLIPID | |||
R807 | Cofactors and vitamins (CAV) | 0.163COA + 0.159FAD + 0.274FMN + 0.405MK + 0.188NAD + 0.168NADP + 0.739PYRDX + 0.281THF-> CAV | |||
R808 | Biomass | 0.55PROTEIN + 0.031DNA + 0.205RNA + 0.091PHOSPHOLIPID + 0.03CAV + 0.034LPS + 0.025PEPTIDO + 0.025GLYCOGEN + 46ATP-> BIOMASS + 46 ADP + 46 PI | |||
R809 | Maintenance | ATP-> ADP + PI | |||
R810 | IMAL_transport | VV12614 | 3.6.1.- | IMALxt + ATP <-> IMAL + PI + ADP | |
R811 | FRU_transport | VV20198 AND VV20200 OR (VV21349 AND VV21352 AND VV21353) OR (VV21356 AND VV21357) | 2.7.1.69 | FRUxt + PEP-> F1P + PYR | |
R812 | GLC_transport | VV10212 AND VV12999 | 2.7.1.69 | GLCxt + PEP-> G6P + PYR | |
R813 | GLUC_transport | GLUCxt + Hxt-> GLUC | |||
R814 | MLT_transport | MLTxt + ATP-> MLT + ADP + PI | |||
R815 | MELI_transport | MELIxt + Hxt-> MELI | |||
R816 | MELI_transport | MELIxt + Naxt-> MELIx Na | |||
R817 | MNT_transport | VV10638 | 2.7.1.69 | MNTxt + PEP-> MNT1P + PYR | |
R818 | NAGA_transport | VV10179 | 2.7.1.69 | NAGAxt + PEP-> NAGA6P + PYR | |
R819 | SUC_transport | VV21142 | 2.7.1.69 | SUCxt + PEP-> SUC6P + PYR | |
R820 | TRE_transport | VV10289 | 2.7.1.69 | TRExt + PEP-> TRE6P + PYR | |
R821 | 2PG_transport | 2PGxt + ATP-> 2PG + ADP + PI | |||
R822 | 3PG_transport | 3PGxt + ATP-> 3PG + ADP + PI | |||
R823 | AC_transport | AC <-> ACxt + Hxt | |||
R824 | AKG_transport | AKGxt + Hxt-> AKG | |||
R825 | CIT_transport | CITxt <-> CIT | |||
R826 | CIT_transport | CITxt + Naxt-> CIT + Na | |||
R827 | FORMATE_transport | FORMATE-> FORMATExt | |||
R828 | FUM_transport | FUMxt + Hxt-> FUM | |||
R829 | FUM_transport | FUMxt + Naxt-> FUM + Na | |||
R830 | FUM_transport | FUMxt + SUCC <-> FUM + SUCCxt | |||
R831 | ICIT_transport | ICITxt + Naxt-> ICIT + Na | |||
R832 | MAL_transport | MALxt + Hxt-> MAL | |||
R833 | MAL_transport | MALxt + Naxt-> MAL + Na | |||
R834 | MAL_transport | MALxt + SUCC <-> MAL + SUCCxt | |||
R835 | SLAC_transport | SLACxt + Hxt-> SLAC | |||
R836 | SUCC_transport | SUCCxt + Hxt-> SUCC | |||
R837 | SUCC_transport | SUCCxt + Naxt-> SUCC + Na | |||
R838 | GL3P_transport | GL3Pxt + PI <-> GL3P + PIxt | |||
R839 | GL3P_transport | GL3Pxt + ATP-> GL3P + ADP + PI | |||
R840 | GLYCOLATE_transport | GLYCOLATExt <-> GLYCOLATE | |||
R841 | ATP_transport | ATP <-> Hxt + ADP + PI | |||
R842 | CO2_transport | CO2xt <-> CO2 | |||
R843 | Na_transport | Naxt <-> Na + Hxt | |||
R844 | Na_transport | Na + 2 Hxt <-> Naxt | |||
R845 | Na_transport | Na + 3 Hxt <-> Naxt | |||
R846 | Na_transport | 2 Na + 3 Hxt <-> 2 Naxt | |||
R847 | NH3_transport | NH3xt <-> NH3 | |||
R848 | NO2_transport | NO2-> NO2xt | |||
R849 | NO3_transport | NO3xt + ATP-> NO3 + ADP + PI | |||
R850 | O2_transport | O2xt <-> O2 | |||
R851 | PI_transport | PIxt + Hxt <-> PI | |||
R852 | PI_transport | PIxt + 3 Naxt <-> PI + 3 Na | |||
R853 | PI_transport | PIxt + ATP-> 2 PI + ADP | |||
R854 | SLF_transport | SLFxt + Naxt-> SLF + Na | |||
R855 | SLF_transport | SLFxt + Hxt-> SLF | |||
R856 | SLF_transport | SLFxt + ATP-> SLF + ADP + PI | |||
R857 | THIAMIN_transport | THIAMINxt + ATP-> THIAMIN + ADP + PI | |||
R858 | ALA_transport | ALA + Hxt <-> ALAxt | |||
R859 | ALA_transport | ALAxt + ATP-> ALA + ADP + PI | |||
R860 | ALA_transport | ALAxt + Hxt-> ALA | |||
R861 | ALA_transport | ALAxt + Naxt-> ALA + Na | |||
R862 | ARG_transport | ARG + Hxt <-> ARGxt | |||
R863 | ARG_transport | ARGxt + ATP-> ARG + ADP + PI | |||
R864 | ARG_transport | ARGxt + Hxt-> ARG | |||
R865 | ASN_transport | ASN + Hxt <-> ASNxt | |||
R866 | ASN_transport | ASNxt + ATP-> ASN + ADP + PI | |||
R867 | ASN_transport | ASNxt + Hxt-> ASN | |||
R868 | ASP_transport | ASP + Hxt <-> ASPxt | |||
R869 | ASP_transport | ASPxt + ATP-> ASP + ADP + PI | |||
R870 | ASP_transport | ASPxt + Hxt-> ASP | |||
R871 | CYS_transport | CYS + Hxt <-> CYSxt | |||
R872 | CYS_transport | CYSxt + ATP-> CYS + ADP + PI | |||
R873 | CYS_transport | CYSxt + Hxt-> CYS | |||
R874 | DALA_transport | DALAxt + Hxt-> DALA | |||
R875 | DGLU_transport | DGLUxt + Hxt-> DGLU | |||
R876 | GLN_transport | GLN + Hxt <-> GLNxt | |||
R877 | GLN_transport | GLNxt + ATP-> GLN + ADP + PI | |||
R878 | GLN_transport | GLNxt + Hxt-> GLN | |||
R879 | GLU_transport | GLU + Hxt <-> GLUxt | |||
R880 | GLU_transport | GLUxt + ATP-> GLU + ADP + PI | |||
R881 | GLU_transport | GLUxt + Hxt-> GLU | |||
R882 | GLU_transport | GLUxt + Naxt-> GLU + Na | |||
R883 | GLY_transport | GLY + Hxt <-> GLYxt | |||
R884 | GLY_transport | GLYxt + ATP-> GLY + ADP + PI | |||
R885 | GLY_transport | GLYxt + Hxt-> GLY | |||
R886 | GLY_transport | GLYxt + Naxt-> GLY + Na | |||
R887 | HIS_transport | HIS + Hxt <-> HISxt | |||
R888 | HIS_transport | HISxt + ATP-> HIS + ADP + PI | |||
R889 | HIS_transport | HISxt + Hxt-> HIS | |||
R890 | ILE_transport | ILE + Hxt <-> ILExt | |||
R891 | ILE_transport | ILExt + ATP-> ILE + ADP + PI | |||
R892 | ILE_transport | ILExt + Hxt-> ILE | |||
R893 | LEU_transport | LEU + Hxt <-> LEUxt | |||
R894 | LEU_transport | LEUxt + ATP-> LEU + ADP + PI | |||
R895 | LEU_transport | LEUxt + Hxt-> LEU | |||
R896 | LYS_transport | LYS + Hxt <-> LYSxt | |||
R897 | LYS_transport | LYS + Hxt-> LYSxt | |||
R898 | LYS_transport | LYSxt + ATP-> LYS + ADP + PI | |||
R899 | LYS_transport | LYSxt + Hxt-> LYS | |||
R900 | MET_transport | MET + Hxt <-> METxt | |||
R901 | MET_transport | METxt + ATP-> MET + ADP + PI | |||
R902 | MET_transport | METxt + Hxt-> MET | |||
R903 | PHE_transport | PHE + Hxt <-> PHExt | |||
R904 | PHE_transport | PHExt + ATP-> PHE + ADP + PI | |||
R905 | PHE_transport | PHExt + Hxt-> PHE | |||
R906 | PRO_transport | PRO + Hxt <-> PROxt | |||
R907 | PRO_transport | PROxt + ATP-> PRO + ADP + PI | |||
R908 | PRO_transport | PROxt + Hxt-> PRO | |||
R909 | PRO_transport | PROxt + Naxt-> PRO + Na | |||
R910 | SER_transport | SER + Hxt <-> SERxt | |||
R911 | SER_transport | SERxt + ATP-> SER + ADP + PI | |||
R912 | SER_transport | SERxt + Hxt-> SER | |||
R913 | THR_transport | THR + Hxt <-> THRxt | |||
R914 | THR_transport | THRxt + ATP-> THR + ADP + PI | |||
R915 | THR_transport | THRxt + Hxt-> THR | |||
R916 | TRP_transport | TRP + Hxt <-> TRPxt | |||
R917 | TRP_transport | TRPxt + ATP-> TRP + ADP + PI | |||
R918 | TRP_transport | TRPxt + Hxt-> TRP | |||
R919 | TYR_transport | TYR + Hxt <-> TYRxt | |||
R920 | TYR_transport | TYRxt + ATP-> TYR + ADP + PI | |||
R921 | TYR_transport | TYRxt + Hxt-> TYR | |||
R922 | VAL_transport | VAL + Hxt <-> VALxt | |||
R923 | VAL_transport | VALxt + ATP-> VAL + ADP + PI | |||
R924 | VAL_transport | VALxt + Hxt-> VAL | |||
R925 | HSER_transport | HSER + Hxt <-> HSERxt | |||
R926 | ORN_transport | ORNxt + ATP-> ORN + ADP + PI | |||
R927 | PTRC / ORN_transport | PTRCxt + ORN <-> PTRCx ORNxt | |||
R928 | PTRC_transport | PTRCxt + ATP-> PTRC + ADP + PI | |||
R929 | SPRMD_transport | SPRMDxt + ATP-> SPRMD + ADP + PI | |||
R930 | UREA_transport | UREAxt + ATP-> UREA + ADP + PI | |||
R931 | CHOLINE_transport | CHOLINExt + Hxt-> CHOLINE | |||
R932 | GL_transport | GLxt <-> GL | |||
R933 | ADN_transport | ADNxt + Hxt-> ADN | |||
R934 | CYTD_transport | CYTDxt + Hxt-> CYTD | |||
R935 | DA_transport | DAxt + Hxt-> DA | |||
R936 | DC_transport | DCxt + Hxt-> DC | |||
R937 | DG_transport | DGxt + Hxt-> DG | |||
R938 | DT_transport | DTxt + Hxt-> DT | |||
R939 | DU_transport | DUxt + Hxt-> DU | |||
R940 | GSN_transport | GSNxt + Hxt-> GSN | |||
R941 | URI_transport | URIxt + Hxt-> URI | |||
R942 | CT_transport | CTxt + Hxt-> CT | |||
R943 | XAN_transport | XANxt + Hxt-> XAN | |||
R944 | URA_transport | URAxt + Hxt-> URA | |||
R945 | VB12_transport | VB12xt + ATP-> VB12 + ADP + PI |
상기 표 3 내지 7에서 R002, R150, R196, R201, R233, R237, R238, R239, R240, R241, R413, R505, R619, R659, R660, R661, R705는 게놈 정보에 할당된 유전자가 없는 반응식In Tables 3 to 7, R002, R150, R196, R201, R233, R237, R238, R239, R240, R241, R413, R505, R619, R659, R660, R661, and R705 have no genes assigned to genomic information.
대사산물Metabolite
표 8
Table 8
(2AE)P | (2-Aminoethyl)phosphonate |
13PDG | 3-Phospho-D-glyceroyl phosphate |
1AP2O | 1-Aminopropan-2-ol |
1BOH | 1-Butanol |
2(HE)TPP | 2-(alpha-Hydroxyethyl)thiamine diphosphate |
23cAMP | 2',3'-Cyclic AMP |
23cCMP | 2',3'-Cyclic CMP |
23cGMP | 2',3'-Cyclic GMP |
23cUMP | 2',3'-Cyclic UMP |
24DAB | L-2,4-Diaminobutanoate |
2A3OB | L-2-Amino-3-oxobutanoic acid |
2A3PP | 2-Amino-3-phosphonopropanoate |
2AA | 2-Aminoacrylate |
2AG3PC | 2-Acyl-sn-glycero-3-phosphocholine |
2AG3PE | 2-Acyl-sn-glycero-3-phosphoethanolamine; L-1-Lysophosphatidylethanolamine |
2AG3PS | 2-Acyl-sn-glycero-3-phosphoserine |
2AGL3P | 2-Acyl-sn-glycerol 3-phosphate |
2D3DDX | 2-Dehydro-3-deoxy-D-xylonate |
2HBA | 2-Hydroxybutanoic acid |
2HPA | 2-Hydroxyphenylacetate |
2HPP | 2-Hydroxypropylphosphonate |
2MAACCOA | 2-Methylacetoacetyl-CoA |
2MB2ECOA | 2-Methylbut-2-enoyl-CoA |
2MBCOA | 2-Methylbutanoyl-CoA |
2MCIT | 2-Methylcitrate |
2MP2ECOA | 2-Methylprop-2-enoyl-CoA |
2MPPACOA | 2-Methylpropanoyl-CoA |
2OAD | 2-Oxoadipate |
2OP3M5H6M14BQ | 2-Octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone |
2OP3M6M14BQ | 2-Octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone |
2OP6HP | 2-Octaprenyl-6-hydroxyphenol |
2OP6M14BQ | 2-Octaprenyl-6-methoxy-1,4-benzoquinone |
2OP6MP | 2-Octaprenyl-6-methoxyphenol |
2OPP | 2-Octaprenylphenol |
2P14NQ | 2-Phytyl-1,4-naphthoquinone |
2P1A | 2-Propyn-1-al |
2PCDPMDE | 2-Phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol |
2PG | 2-Phospho-D-glycerate |
2PPG | 2-Phosphoglycolate |
34DHB | 3,4-Dihydroxybenzoate |
34DHMA | 3,4-Dihydroxymandelaldehyde |
34DHPEG | 3,4-Dihydroxyphenylethyleneglycol |
3A2OP | 3-Amino-2-oxopropyl phosphate |
3AMP | 3'-AMP |
3B1A | 3-Butyn-1-al |
3BUT | 3-Butynoate |
3CMP | 3'-CMP |
3DDAH7P | 2-Dehydro-3-deoxy-D-arabino-heptonate7-phosphate |
3DG6P | 3-Dehydro-L-gulonate 6-phosphate |
3GMP | Guanosine 3'-phosphate |
3H2MBCOA | (2S,3S)-3-Hydroxy-2-methylbutanoyl-CoA |
3H3MGCOA | (S)-3-Hydroxy-3-methylglutaryl-CoA |
3HAN | 3-Hydroxyanthranilate |
3HB123TC | (2S,3R)-3-Hydroxybutane-1,2,3-tricarboxylate |
3HBCOA | (S)-3-Hydroxybutanoyl-CoA |
3HIBCOA | (S)-3-Hydroxyisobutyryl-CoA |
3HIVCOA | 3-Hydroxyisovaleryl-CoA |
3HPCOA | 3-Hydroxypropionyl-CoA |
3KBDG | 3-Keto-beta-D-galactose |
3KL | 3-Ketolactose |
3MBCOA | 3-Methylbutanoyl-CoA |
3MCCOA | 3-Methylcrotonyl-CoA |
3MGCOA | 3-Methylglutaconyl-CoA |
3MLAC | 3-Mercaptolactate |
3MOP | 3-Methyl-2-oxopentanoate |
3OP4HB | 3-Octaprenyl-4-hydroxybenzoate |
3OPP | 3-Oxopropanoate |
3PASELNT | 3'-Phosphoadenylylselenate |
3PG | 3-Phospho-D-glycerate |
3PSER | 3-Phosphoserine |
3PSME | 5-O-(1-Carboxyvinyl)-3-phosphoshikimate |
3SFPYR | 3-Sulfinylpyruvate |
3SLALA | 3-Sulfino-L-alanine |
3SPYR | 3-Sulfopyruvate |
3UMP | 3'-UMP |
4AABUT | 4-Acetamidobutanoate |
4AB | 4-Aminobutanal |
4FAAC | 4-Fumarylacetoacetate |
4HB | 4-Hydroxybenzoate |
4HGLUSA | L-4-Hydroxyglutamate semialdehyde |
4HLT | 4-Hydroxy-L-threonine |
4HPP | 3-(4-Hydroxyphenyl)pyruvate |
4HPRO | trans-4-Hydroxy-L-proline |
4I5P | 4-Imidazolone-5-propanoate |
4MAAC | 4-Maleylacetoacetate |
4MOP | 4-Methyl-2-oxopentanoate |
4PPNCYS | (R)-4'-Phosphopantothenoyl-L-cysteine |
4PPNTE | Pantetheine 4'-phosphate |
4PPNTO | D-4'-Phosphopantothenate |
5A4IC | 5-Amino-4-imidazolecarboxyamide |
5C2O3E | 5-Carboxy-2-oxohept-3-enedioate |
5CM2HM | 5-Carboxymethyl-2-hydroxymuconate |
5FTHF | 5-Formyltetrahydrofolate |
5H24DP | (4S)-5-Hydroxy-2,4-dioxopentanoate |
5HIAA | 5-Hydroxyindoleacetaldehyde |
5HIAC | 5-Hydroxyindoleacetate |
5MC | 5-Methylcytosine |
5MDR | 5-Methylthio-D-ribose |
5MTA | 5'-Methylthioadenosine |
5MTGLU | 5-Methyltetrahydropteroyltri-L-glutamate |
A[C] | Apo-[carboxylase] |
A5P | D-Arabinose 5-phosphate |
A6P | Arbutin 6-phosphate |
A6RP | 5-Amino-6-ribitylamino-2,4 (1H, 3H)-pyrimidinedione; 4-(1-D-Ribitylamino)-5-amino-2,6-dihydroxypyrimidine; 4-(1-D-Ribitylamino)-5-aminouracil |
A6RP5P | 5-Amino-6-(5'-phosphoribosylamino)uracil |
A6RP5P2 | 5-Amino-6-(5'-phosphoribitylamino)uracil |
AAA | Aminoacetaldehyde |
AAC | Acetoacetate |
AACCOA | Acetoacetyl-CoA |
AACP | Apo-[acyl-carrier protein] |
AAD | Acetyl adenylate |
ABUT | (S)-2-Aceto-2-hydroxybutanoate |
AC | Acetate |
AC(III)A | Aquacob(III)alamin |
(2AE) P | (2-Aminoethyl) phosphonate |
13PDG | 3-Phospho-D-glyceroyl phosphate |
1AP2O | 1-Aminopropan-2-ol |
1BOH | 1-Butanol |
2 (HE) TPP | 2- (alpha-Hydroxyethyl) thiamine diphosphate |
23cAMP | 2 ', 3'-Cyclic AMP |
23cCMP | 2 ', 3'-Cyclic CMP |
23cGMP | 2 ', 3'-Cyclic GMP |
23cUMP | 2 ', 3'-Cyclic UMP |
24DAB | L-2,4-Diaminobutanoate |
2A3OB | L-2-Amino-3-oxobutanoic acid |
2A3PP | 2-Amino-3-phosphonopropanoate |
2AA | 2-Aminoacrylate |
2AG3PC | 2-Acyl-sn-glycero-3-phosphocholine |
2AG3PE | 2-Acyl-sn-glycero-3-phosphoethanolamine; L-1-Lysophosphatidylethanolamine |
2AG3PS | 2-Acyl-sn-glycero-3-phosphoserine |
2AGL3P | 2-Acyl-sn-glycerol 3-phosphate |
2D3DDX | 2-Dehydro-3-deoxy-D-xylonate |
2HBA | 2-Hydroxybutanoic acid |
2HPA | 2-Hydroxyphenylacetate |
2HPP | 2-Hydroxypropylphosphonate |
2MAACCOA | 2-Methylacetoacetyl-CoA |
2MB2ECOA | 2-Methylbut-2-enoyl-CoA |
2MBCOA | 2-Methylbutanoyl-CoA |
2MCIT | 2-Methylcitrate |
2MP2ECOA | 2-Methylprop-2-enoyl-CoA |
2MPPACOA | 2-Methylpropanoyl-CoA |
2OAD | 2-Oxoadipate |
2OP3M5H6M14BQ | 2-Octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone |
2OP3M6M14BQ | 2-Octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone |
2OP6HP | 2-Octaprenyl-6-hydroxyphenol |
2OP6M14BQ | 2-Octaprenyl-6-methoxy-1,4-benzoquinone |
2OP6MP | 2-Octaprenyl-6-methoxyphenol |
2OPP | 2-Octaprenylphenol |
2P14NQ | 2-Phytyl-1,4-naphthoquinone |
2P1A | 2-Propyn-1-al |
2PCDPMDE | 2-Phospho-4- (cytidine 5'-diphospho) -2-C-methyl-D-erythritol |
2PG | 2-Phospho-D-glycerate |
2PPG | 2-Phosphoglycolate |
34DHB | 3,4-Dihydroxybenzoate |
34DHMA | 3,4-Dihydroxymandelaldehyde |
34DHPEG | 3,4-Dihydroxyphenylethyleneglycol |
3A2OP | 3-Amino-2-oxopropyl phosphate |
3AMP | 3'-AMP |
3B1A | 3-Butyn-1-al |
3BUT | 3-Butynoate |
3CMP | 3'-CMP |
3DDAH7P | 2-Dehydro-3-deoxy-D-arabino-heptonate7-phosphate |
3DG6P | 3-Dehydro-L-gulonate 6-phosphate |
3GMP | Guanosine 3'-phosphate |
3H2MBCOA | (2S, 3S) -3-Hydroxy-2-methylbutanoyl-CoA |
3H3MGCOA | (S) -3-Hydroxy-3-methylglutaryl-CoA |
3HAN | 3-Hydroxyanthranilate |
3HB123TC | (2S, 3R) -3-Hydroxybutane-1,2,3-tricarboxylate |
3HBCOA | (S) -3-Hydroxybutanoyl-CoA |
3HIBCOA | (S) -3-Hydroxyisobutyryl-CoA |
3HIVCOA | 3-Hydroxyisovaleryl-CoA |
3HPCOA | 3-Hydroxypropionyl-CoA |
3KBDG | 3-Keto-beta-D-galactose |
3KL | 3-Ketolactose |
3MBCOA | 3-Methylbutanoyl-CoA |
3MCCOA | 3-Methylcrotonyl-CoA |
3MGCOA | 3-Methylglutaconyl-CoA |
3MLAC | 3-Mercaptolactate |
3MOP | 3-Methyl-2-oxopentanoate |
3OP4HB | 3-Octaprenyl-4-hydroxybenzoate |
3OPP | 3-Oxopropanoate |
3PASELNT | 3'-Phosphoadenylylselenate |
3PG | 3-Phospho-D-glycerate |
3PSER | 3-Phosphoserine |
3PSME | 5-O- (1-Carboxyvinyl) -3-phosphoshikimate |
3SFPYR | 3-Sulfinylpyruvate |
3SLALA | 3-Sulfino-L-alanine |
3SPYR | 3-Sulfopyruvate |
3UMP | 3'-UMP |
4AABUT | 4-Acetamidobutanoate |
4AB | 4-Aminobutanal |
4FAAC | 4-Fumarylacetoacetate |
4HB | 4-Hydroxybenzoate |
4HGLUSA | L-4-Hydroxyglutamate semialdehyde |
4HLT | 4-Hydroxy-L-threonine |
4HPP | 3- (4-Hydroxyphenyl) pyruvate |
4HPRO | trans-4-Hydroxy-L-proline |
4I5P | 4-Imidazolone-5-propanoate |
4MAAC | 4-Maleylacetoacetate |
4MOP | 4-Methyl-2-oxopentanoate |
4PPNCYS | (R) -4'-Phosphopantothenoyl-L-cysteine |
4PPNTE | Pantetheine 4'-phosphate |
4PPNTO | D-4'-Phosphopantothenate |
5A4IC | 5-Amino-4-imidazolecarboxyamide |
5C2O3E | 5-Carboxy-2-oxohept-3-enedioate |
5CM2HM | 5-Carboxymethyl-2-hydroxymuconate |
5FTHF | 5-Formyltetrahydrofolate |
5H24DP | (4S) -5-Hydroxy-2,4-dioxopentanoate |
5HIAA | 5-Hydroxyindoleacetaldehyde |
5HIAC | 5-Hydroxyindoleacetate |
5MC | 5-Methylcytosine |
5MDR | 5-Methylthio-D-ribose |
5MTA | 5'-Methylthioadenosine |
5MTGLU | 5-Methyltetrahydropteroyltri-L-glutamate |
A [C] | Apo- [carboxylase] |
A5P | D-Arabinose 5-phosphate |
A6P | Arbutin 6-phosphate |
A6RP | 5-Amino-6-ribitylamino-2,4 (1H, 3H) -pyrimidinedione; 4- (1-D-Ribitylamino) -5-amino-2,6-dihydroxypyrimidine; 4- (1-D-Ribitylamino) -5-aminouracil |
A6RP5P | 5-Amino-6- (5'-phosphoribosylamino) uracil |
A6RP5P2 | 5-Amino-6- (5'-phosphoribitylamino) uracil |
AAA | Aminoacetaldehyde |
AAC | Acetoacetate |
AACCOA | Acetoacetyl-CoA |
AACP | Apo- [acyl-carrier protein] |
AAD | Acetyl adenylate |
ABUT | (S) -2-Aceto-2-hydroxybutanoate |
AC | Acetate |
AC (III) A | Aquacob (III) alamin |
표 9
Table 9
ACACP | Acetyl-[acyl-carrier protein] |
ACAL | Acetaldehyde |
ACALA | N-Acetylmuramoyl-Ala |
ACCOA | Acetyl-CoA |
ACDA | Adenosyl cobyrinate a,c diamide |
ACETYLP | Acetyl-P |
ACHA | Adenosyl cobyrinate hexaamide |
ACLAC | 2-Acetolactate |
ACMUR | N-Acetyl-D-muramoate |
ACOA | Acyl-CoA |
ACP | Acyl-carrier protein |
AD | Adenine |
ADCBA | Adenosyl cobinamide |
ADCBAP | Adenosyl cobinamide phosphate |
ADCHOR | 4-amino-4-deoxychorismate |
ADLIPO | 6-S-Acetyldihydrolipoamide |
ADN | Adenosine |
ADP | ADP |
ADPDGDMHEP | ADP-D-glycero-D-manno-heptose |
ADPG | ADPglucose |
ADPHEP | ADP-L-glycero-D-manno-heptose |
AG | L-Arogenate |
AGDPCBA | Adenosine-GDP-cobinamide |
AGL | Acylglycerol |
AGL3P | Acyl-sn-glycerol 3-phosphate |
AGMATINE | Agmatine |
AHHMD | 2-Amino-7,8-dihydro-4-hydroxy-6-(diphosphooxymethyl)pteridine |
AHHMP | 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine |
AHM | 4-Amino-5-hydroxymethyl-2-methylpyrimidine |
AHMP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-phosphate |
AHMPP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-pyrophosphate |
AHSER | O-Acetylhomoserine |
AHTD | 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)-dihydropteridine triphosphate |
AICAR | 1-(5'-Phosphoribosyl)-5-amino-4-imidazolecarboxamide |
AIR | Aminoimidazole ribotide |
AKG | 2-Oxoglutarate |
ALA | L-Alanine |
ALAALA | D-alanyl-D-alanine |
ALATRNA | L-Alanyl-tRNA |
ALAV | D-Aminolevulinate |
AMP | AMP |
AN | Anthranilate |
AONA | 8-amino-7-oxononanoate |
AppppA | P1,P4-Bis(5'-adenosyl) tetraphosphate |
APS | Adenylylsulfate |
ARBZ | alpha-Ribazole; N1-(alpha-D-ribosyl)-5,6-dimethylbenzimidazole |
ARG | L-Arginine |
ARGSUCC | N-(L-Arginino)succinate |
ARGTRNAARG | L-Arginyl-tRNA(Arg) |
ARIB | ADPribose |
ASELNT | Adenylylselenate |
ASER | O-Acetyl-L-serine |
ASN | L-Asparagine |
ASNTRNAASN | L-Asparaginyl-tRNA(Asn) |
ASP | L-Aspartate |
ASPSA | L-Aspartate 4-semialdehyde |
ASPTRNAASP | L-Aspartyl-tRNA(Asp) |
ASUC | N6-(1,2-Dicarboxyethyl)-AMP |
ATHR | L-Allothreonine |
ATP | ATP |
B5AMP | Biotinyl-5'-AMP |
BAL | Betaine aldehyde |
bALA | beta-Alanine |
bAPA | beta-Aminopropion aldehyde |
BASP | 4-Phospho-L-aspartate |
bDG6P | beta-D-Glucose 6-phosphate |
bDGLC | beta-D-Glucose |
BETAINE | Betaine |
bGLAC | beta-D-Galactose |
BIOMASS | Biomass |
BT | Biotin |
BUTANAL | Butanal |
C(I)DA | Cob(I)yrinate a,c diamide |
C(II)A | Cob(II)alamin |
C040COA | Butanoyl-CoA |
C090ACP | Nonanoyl-[acyl-carrier protein] |
C100ACP | Decanoyl-[acyl-carrier protein] |
C110ACP | Undecanoyl-[acyl-carrier protein] |
C120 | Dodecanoic acid |
C120ACP | Dodecanoyl-[acyl-carrier protein] |
C130ACP | Tridecanoyl-[acyl-carrier protein] |
C140 | Tetradecanoic acid |
C140ACP | Tetradecanoyl-[acyl-carrier protein] |
C150 | Pentadecanoic acid |
C150ACP | Pentadecanoyl-[acyl-carrier protein] |
C151ACP | Pentadecenoyl-[acyl-carrier protein] |
C160 | Hexadecanoic acid |
C160ACP | Hexadecanoyl-[acyl-carrier protein] |
C161 | Hexadecenoic acid |
C161ACP | Hexadecenoyl-[acyl-carrier protein] |
C170ACP | Heptadecanoyl-[acyl-carrier protein] |
C171ACP | Heptadecenoyl-[acyl-carrier protein] |
C180 | Octadecanoic acid |
C180ACP | Octadecanoyl-[acyl-carrier protein] |
C181 | Octadecenoic acid |
C181ACP | Octadecenoyl-[acyl-carrier protein] |
C190ACP | Nonadecanoyl-[acyl-carrier protein] |
C191ACP | Nonadecenoyl-[acyl-carrier protein] |
C200ACP | Eicosanoyl-[acyl-carrier protein] |
CA | Cysteamine |
CAASP | N-Carbamoyl-L-aspartate |
CAIR | 1-(5-Phospho-D-ribosyl)-5-amino-4-imidazolecarboxylate |
cAMP | 3',5'-Cyclic AMP |
CAP | Carbamoyl phosphate |
CAV | Cofactors and vitamins |
CB | Cellobiose |
CBCO | Cobamide coenzyme |
CBHCAP | 3-Isopropylmalate |
CCOA | Crotonoyl-CoA |
CDP | CDP |
CDPDG | CDP-diacylglycerol |
CDPMDE | 4-(Cytidine5'-diphospho)-2-C-methyl-D-erythritol |
cGMP | 3',5'-Cyclic GMP |
CGS | Cyanoglycoside |
CHCOA | 6-carboxyhexanoyl-CoA; Pimeloyl-CoA |
CHD | Cyanohydrin |
CHOLINE | Choline |
CHOR | Chorismate |
CIT | Citrate |
CITR | L-Citrulline |
CL | Cardiolipin (biomass component) |
CMP | CMP |
CMPKDO | CMP-2-keto-3-deoxyoctanoate |
CMPNANEU | CMP-N-acetylneuraminate |
CMPNGNEU | CMP-N-glycoloylneuraminate |
CNS | Carnosine |
CO2 | CO2 |
COA | CoA; coenzyme A |
CPAD5P | 1-(2-Carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate |
CPP | Coproporphyrinogen III |
CT | Cytosine |
CTP | CTP |
CVN | Cinnavalininate |
CYS | L-Cysteine |
CYSGLY | Cys-Gly |
CYST | L-Cystine |
CYSTEATE | L-Cysteate |
CYSTRNACYS | L-Cysteinyl-tRNA(Cys) |
CYTD | Cytidine |
D1AP2OOP | D-1-Aminopropan-2-ol O-phosphate |
D6PGC | 6-Phospho-D-gluconate |
D6PGL | D-Glucono-1,5-lactone 6-phosphate |
D6RP5P | 2,5-Diamino-6-hydroxy-4-(5'-phosphoribosylamino)-pyrimidine |
D8RL | 6,7-Dimethyl-8-(1-D-ribityl)lumazine |
DA | Deoxyadenosine |
DADP | dADP |
DALA | D-alanine |
DAMP | dAMP |
DANNA | 7,8-Diaminononanoate |
DAPIM | L,L-2,6-Diaminopimelate |
DATP | dATP |
DB4P | L-3,4-Dihydroxy-2-butanone 4-phosphate |
DC | Deoxycytidine |
DCDP | dCDP |
DCMP | dCMP |
DCTP | dCTP |
DDOH | (4S)-4,6-Dihydroxy-2,5-dioxohexanoate |
DEXTRIN | Dextrin |
DFRUC | D-Fructuronate |
DG | Deoxyguanosine |
DGALAC | D-Galacturonate |
DGDMH17BP | D-glycero-D-manno-Heptose 1,7-bisphosphate |
DGDMH1P | D-glycero-D-manno-Heptose 1-phosphate |
DGDMH7P | D-glycero-D-manno-Heptose 7-phosphate |
DGDP | dGDP |
DGLN | D-Glutamine |
DGLU | D-Glutamate |
DGLUC | D-Glucuronate |
DGLUCA | D-Glucarate |
DGLUCL | D-Glucuronolactone |
DGLYCERATE | D-glycerate |
DGMP | dGMP |
DGR | 1,2-Diacyl-sn-glycerol; 1,2-Diacylglycerol |
DGTP | dGTP |
DHAP | Glycerone phosphate |
DHBPT | Dihydrobiopterin |
DHDP | 2,3-Dihydrodipicolinate |
DHF | Dihydrofolate |
DHLIPOYLPROTEIN | Dihydrolipoylprotein |
DHMP | (R)-2,3-dihydroxy-3-methylpentanoate |
DHMVA | (R)-2,3-dihydroxy-3-methylbutanoate |
DHN | 1,4-dihydroxy-2-naphthoate |
DHP | 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine |
DHPANT | 2-Dehydropantoate |
DHPT | Dihydropteroate |
DHSK | 3-Dehydroshikimate |
DIDP | dIDP |
DIMGP | D-erythro-1-(Imidazol-4-yl)glycerol 3-phosphate |
DIN | Deoxyinosine |
DISAC1P | 2,3-bis(3-hydroxytetradecanoyl)-D-glucosaminyl-1,6-beta-D-2,3-bis(3-hydroxytetradecanoyl)-beta-D-glucosaminyl 1-phosphate or dissacharide 1-P |
DITP | dITP |
DLIPO | Dihydrolipoamide |
DMAN | D-Mannonate |
DMB | Dimethylbenzimidazole |
DMK | 2-Demethylmenaquinone |
DMKH2 | 2-Demethylmenaquinol |
DMPP | Dimethylallyl diphosphate |
DNA | DNA (biomass component) |
DOROA | (S)-Dihydroorotate |
DPCOA | Dephospho-CoA |
DPHE | D-Phenylalanine |
DQT | 3-Dehydroquinate |
DR1P | 2-Deoxy-D-ribose 1-phosphate |
DR5P | 2-Deoxy-D-ribose 5-phosphate |
DRIB | Deoxyribose |
DT | Thymidine |
DTAGA | D-Tagaturonate |
DTB | Dethiobiotin |
DTDP | dTDP |
DTDPDGLUC | dTDP-D-glucuronate |
DTDPGLAC | dTDPgalactose |
DTDPGLU | dTDPglucose |
DTMP | dTMP |
DTTP | dTTP |
DU | Deoxyuridine |
DUDP | dUDP |
DUMP | dUMP |
DUTP | dUTP |
DX5P | 1-Deoxy-D-xylulose5-phosphate |
E4HGLU | L-erythro-4-Hydroxyglutamate |
E4P | D-Erythrose 4-phosphate |
EPM | Epimelibiose |
ER4P | 4-Phospho-D-erythronate; 4-Phosphoerythronate |
ETH | Ethanol |
ETHA | Ethanolamine |
F1P | D-Fructose 1-phosphate |
F2P | D-Fructose 2-phosphate |
F6P | beta-D-Fructose 6-phosphate |
FA | Formamide |
FAD | Flavin adenine dinucleotide; FAD |
FADH2 | FADH2 |
FDP | beta-D-Fructose 1,6-bisphosphate |
FERIC | Ferricytochrome c |
FEROC | Ferrocytochrome c |
FGAM | 2-(Formamido)-N1-(5'-phosphoribosyl)acetamidine |
FGAR | 5'-Phosphoribosyl-N-formylglycinamide |
FL | Folate |
FMETTRNA | N-Formylmethionyl-tRNA |
FMN | FMN; Riboflavin-5-phosphate; Flavin mononucleotide |
FORMATE | Formate |
FPP | trans,trans-Farnesyl diphosphate |
FRU | D-Fructose |
FTHF | 10-Formyltetrahydrofolate |
FUM | Fumarate |
G1P | D-Glucose 1-phosphate |
G3P | D-Glyceraldehyde3-phosphate; (2R)-2-Hydroxy-3-(phosphonooxy)-propanal |
G3PC | sn-glycero-3-Phosphocholine |
G3PE | sn-glycero-3-Phosphoethanolamine |
G6GG | D-Gal alpha 1->6D-Gal alpha 1->6D-Glucose |
G6P | alpha-D-Glucose 6-phosphate |
GA1P | D-Glucosamine 1-phosphate |
GA6P | D-Glucosamine 6-phosphate |
GABA | 4-Aminobutanoate |
GAL1P | alpha-D-Galactose 1-phosphate |
GALACTINOL | Galactinol |
GAR | 5'-Phosphoribosylglycinamide |
GCYS | gamma-L-Glutamyl-L-cysteine |
GDP | GDP |
GDPMAN | GDPmannose |
GGL | Galactosylglycerol |
GGPP | Geranylgeranyl diphosphate |
GL | Glycerol |
GL3P | sn-Glycerol 3-phosphate |
GLAC | D-Galactose |
GLAL | Glycolaldehyde |
GLC | alpha-D-Glucose |
GLN | L-Glutamine |
GLU | L-Glutamate |
GLUC | D-Gluconate |
GLUGSAL | L-Glutamate 5-semialdehyde |
GLUP | alpha-D-Glutamyl phosphate |
GLUTCOA | Glutaryl-CoA |
GLUTRNAGLU | L-Glutamyl-tRNA(Glu) |
GLX | Glyoxylate |
GLY | Glycine |
GLYCOGEN | Glycogen |
GLYCOLATE | Glycolate |
GLYTRNAGLY | Glycyl-tRNA(Gly) |
GMP | GMP |
GN | Guanine |
GPP | Geranyl diphosphate |
GSA | Glutamate-1-semialdehyde |
GSN | Guanosine |
GTP | GTP |
GTRNA | Glutaminyl-tRNA |
H[C] | Holo-[carboxylase] |
H2CO3 | Carbonic acid |
H2O2 | H2O2 |
H2S | Hydrogen sulfide |
H2SO3 | Sulfite |
H5P3O10 | Triphosphate |
HAC | Hydroxyacetone |
HCNS | Homocarnosine |
HCO3 | HCO3 |
HCYS | L-Homocysteine |
HEPPP | all-trans-Heptaprenyl diphosphate |
HIBUT | (S)-3-Hydroxyisobutyrate |
HIS | L-Histidine |
HISOL | L-Histidinol |
HISOLP | L-Histidinol phosphate |
HISTRNAHIS | L-Histidyl-tRNA(His) |
HMB | Hydroxymethylbilane |
HMB4PP | 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate |
HO3S2 | Thiosulfate |
HOMOGEN | Homogentisate |
HPPP | all-trans-Hexaprenyl diphosphate |
HQ | Hydroquinone |
HSER | L-Homoserine |
HTR | Hypotaurine |
Hxt | External proton |
HYDROXYAKG | D-4-Hydroxy-2-oxoglutarate |
HYXN | Hypoxanthine |
I3AA | Indole-3-acetaldehyde |
I3AC | Indole-3-acetate |
I4AA | Imidazole-4-acetaldehyde |
I4AC | Imidazole-4-acetate |
IASP | Iminoaspartate |
ICHOR | Isochorismate |
ICIT | Isocitrate |
IDP | IDP |
IGP | Indoleglycerol phosphate |
ILE | L-Isoleucine |
ILETRNAILE | L-Isoleucyl-tRNA(Ile) |
IMACP | 3-(Imidazol-4-yl)-2-oxopropyl phosphate |
IMAL | Isomaltose |
IMP | IMP |
INDOLE | Indole |
INS | Inosine |
IPP | Isopentenyl diphosphate |
IPPMAL | 2-Isopropylmalate |
ITP | ITP |
K2LIPA | KDO2-lipid (A); Di[3-deoxy-D-manno-octulosonyl]-lipid A |
K2LIPIV | KDO2-lipid IV(A); Di[3-deoxy-D-manno-octulosonyl]-lipid IV(A); |
KDG | 2-Dehydro-3-deoxy-D-gluconate |
KDO | 2-Dehydro-3-deoxy-D-octonate |
KDOLIPIV | KDO-lipid IV(A) |
KDOP | 2-Dehydro-3-deoxy-D-octonate 8-phosphate |
KDPG | 2-Dehydro-3-deoxy-6-phospho-D-gluconate |
L1P3H5C | L-1-Pyrroline-3-hydroxy-5-carboxylate |
L6P | Lactose 6-phosphate |
LAC | (R)-Lactate, D-Lactate |
LACTOSE | Lactose |
LEU | L-Leucine |
LEUTRNA | L-Leucyl-tRNA |
LIPIV | Lipid IV(A) |
LIPO | Lipoamide |
LIPOYLPROTEIN | Lipoylprotein |
LIPX | Lipid X |
LK2LIPIV | Lauroyl-KDO2-lipid IV(A) |
LLCT | L-Cystathionine |
LPS | Lippolysaccharide |
LRIBULOSE5P | L-Ribulose 5-phosphate |
LTG | (R)-S-Lactoylglutathione |
LXYLULOSE5P | L-Xylulose 5-phosphate |
LYS | L-Lysine |
LYSTRNA | L-Lysyl-tRNA |
MAL | (S)-Malate |
MALACP | Malonyl-[acyl-carrier protein] |
MALCOA | Malonyl-CoA |
MAN | alpha-D-Mannose |
MAN1P | alpha-D-Mannose 1-phosphate |
MAN6P | D-Mannose 6-phosphate |
MCB | Methylcobalamin |
MDAPIM | meso-2,6-Diaminopimelate |
MDE4P | 2-C-Methyl-D-erythritol 4-phosphate |
MDECPP | 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate |
MELI | Melibiose |
MELT | Melibiitol |
MET | L-Methionine |
METHF | 5,10-Methenyltetrahydrofolate |
METTHF | 5,10-Methylenetetrahydrofolate |
METTRNA | L-Methionyl-tRNA |
MI | myo-Inositol |
MK | menaquinone |
MKH2 | menaquinol |
MLT | Maltose |
MLTHPT | maltoheptaose |
MLTHX | maltohexaose |
MLTPT | maltopentaose |
MLTTR | maltotriose |
MLTTTR | maltotetraose |
MM | Methylmalonate |
MMSA | (S)-Methylmalonate semialdehyde |
MNT | D-Mannitol |
MNT1P | D-Mannitol 1-phosphate |
MPYR | Mercaptopyruvate |
MTG | Methylglyoxal |
MTHF | 5-Methyltetrahydrofolate |
MTHMNP | 5,10-Methylenetetrahydromethanopterin |
MVLN | (R)-Mevalonate |
N(P)CYS | N-((R)-Pantothenoyl)-L-cysteine |
N1(5PADR)DMB | N1-(5-Phospho-alpha-D-ribosyl)-5,6-dimethylbenzimidazole |
N2SUCCARG | N2-Succinyl-L-arginine |
N2SUCCGLU | N2-Succinyl-L-glutamate |
N2SUCCGLU5SA | N2-Succinyl-L-glutamate 5-semialdehyde |
N4AAB | N4-Acetylaminobutanal |
Na | Sodium |
NAAD | Deamido-NAD+ |
NAC | Nicotinate |
NACD | Nicotinate D-ribonucleoside |
NACN | Nicotinate D-ribonucleotide |
NAD | NAD+; Nicotinamide adenine dinucleotide |
NADH | NADH |
NADMA | N-Acetyl-D-mannosamine |
NADMA6P | N-Acetyl-D-mannosamine 6-phosphate |
NADP | NADP+; Nicotinamide adenine dinucleotide phosphate |
NADPH | NADPH |
NAGA | N-Acetyl-D-glucosamine |
NAGA1P | N-Acetyl-D-glucosamine 1-phosphate |
NAGA6P | N-Acetyl-D-glucosamine 6-phosphate |
NAGLU | N-Acetyl-L-glutamate |
NAGLUP | N-Acetyl-L-glutamate 5-phosphate |
NAGLUS | N-Acetyl-L-glutamate 5-semialdehyde |
NAM | Nicotinamide |
NAMD | N-Ribosylnicotinamide |
NAMN | Nicotinamide D-ribonucleotide |
NANEU | N-Acetylneuraminate |
NANEU9P | N-Acetylneuraminate 9-phosphate |
NAORN | N2-Acetyl-L-ornithine |
NFGLU | N-Formimino-L-glutamate |
NGNEU | N-Glycoloyl-neuraminate |
NH3 | NH3 |
NMHIS | N(pi)-Methyl-L-Histidine |
NO2 | Nitrite |
NO3 | Nitrate |
NPRAN | N-(5-Phospho-D-ribosyl)anthranilate |
O2 | Oxygen |
OA | Oxaloacetate |
OAHSER | O-Acetyl-L-homoserine |
OBUT | 2-Oxobutanoate |
OGT | Oxidized glutathione |
OHB | 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate |
OICAP | 3-Carboxy-4-methyl-2-oxopentanoate |
OIVAL | 3-Methyl-2-oxobutanoic acid |
OMP | Orotidine 5'-phosphate |
OPHSER | O-Phosphorylhomoserine |
OPP | all-trans-Octaprenyl diphosphate |
ORN | L-Ornithine |
OROA | Orotate |
OSB | O-succinylbenzoate |
OSBCOA | O-succinylbenzoate-CoA |
OSLHSER | O-Succinyl-L-homoserine |
OTHIO | Oxidized thioredoxin |
P5C | (S)-1-Pyrroline-5-carboxylate |
P5P | Pyridoxine 5'-phosphate; Pyridoxine phosphate |
PA | Phosphatidate; 1,2-Diacyl-sn-glycerol 3-phosphate |
PABA | 4-Aminobenzoate |
PANT | (R)-pantoate |
PAP | Adenosine 3',5'-bisphosphate |
PAPS | 3'-Phosphoadenylyl sulfate |
PBG | Porphobilinogen |
PC | Phosphatidylcholine |
PC2 | Percorrin 2 |
PDLA | Pyridoxamine |
PDLA5P | Pyridoxamine-5-phosphate |
PE | Phosphatidylethanolamine |
PEP | Phosphoenolpyruvate |
PEPTIDO | Peptidoglycan (biomass component) |
PG | Phosphatidylglycerol |
PGP | Phosphatidylglycerophosphate |
PHE | L-Phenylalanine |
PHEN | Prephenate |
PHETRNAPHE | L-Phenylalanyl-tRNA(Phe) |
PHOSPHOLIPID | Phospholipids (biomass component) |
PHP | 3-Phosphonooxypyruvate |
PHPYR | Phenylpyruvate |
PHSER | O-Phospho-L-homoserine |
PHT | O-Phospho-4-hydroxy-L-threonine |
PI | Orthophosphate |
PL | Pyridoxal |
PL5P | Pyridoxal 5'-phosphate |
PNTO | (R)-Pantothenate; Pantothenate |
PPA | Propinol adenylate |
PPAACP | Propanoyl-[acyl-carrier protein]; Propionyl-[acyl-carrier protein] |
PPAC | Phosphonoacetaldehyde |
PPACOA | Propanoyl-CoA; Propionyl-CoA |
PPCOA | Propenoyl-CoA; Acryloyl-CoA |
PPEPTIDO | Peptidoglycan precursor |
ppGpp | Guanosine 3',5'-bis(diphosphate) |
PPHG | Protoporphyrinogen IX |
PPI | Pyrophosphate |
PPIX | Protoporphyrin IX |
PPN | Propynoate |
PPP | Phytyl diphosphate |
pppGpp | Guanosine 3'-diphosphate 5'-triphosphate |
PPPP | all-trans-Pentaprenyl diphosphate |
PPYR | 3-Phosphonopyruvate |
PQ | Phylloquinone |
PRAM | 5-Phosphoribosylamine |
PRBAMP | N1-(5-Phospho-D-ribosyl)-AMP |
PRBATP | N1-(5-Phospho-D-ribosyl)-ATP |
PRFICA | 1-(5'-Phosphoribosyl)-5-formamido-4-imidazolecarboxamide |
PRFP | 5-(5-Phospho-D-ribosylaminoformimino)-1-(5-phosphoribosyl)-imidazole-4-carboxamide |
PRLP | N-(5'-Phospho-D-1'-ribulosylformimino)-5-amino-1-(5"-phospho-D-ribosyl)-4-imidazolecarboxamide |
PRO | L-Proline |
PROPANOATE | Propanoate |
PROPIONYLP | Propanoyl phosphate |
PROTEIN | Proteins |
PROTRNAPRO | L-Prolyl-tRNA(Pro) |
PRPP | 5-Phospho-alpha-D-ribose 1-diphosphate |
PS | Phosphatidylserine |
PTH | Protoheme |
PTRC | Putrescine |
PTT | Pantetheine |
PURI5P | Pseudouridine 5'-phosphate |
PYR | Pyruvate |
PYRDX | Pyridoxine |
PYTHP | 6-Pyruvoyltetrahydropterin |
QA | Quinolinate; Pyridine-2,3-dicarboxylate |
R1P | D-Ribose 1-phosphate |
R3HBCOA | (R)-3-Hydroxybutanoyl-CoA |
R5P | D-Ribose 5-phosphate |
RAF | Raffinose |
RGT | Glutathione |
RIB | D-Ribose |
RIBFLAV | Riboflavin |
RL5P | D-Ribulose 5-phosphate |
RNA | RNA |
RTHIO | Thioredoxin |
S | Sulfur |
S(2MB)DHL | S-(2-Methylbutanoyl)-dihydrolipoamide |
S(2MP)DHL | S-(2-Methylpropanoyl)-dihydrolipoamide |
S(3MB)DHL | S-(3-Methylbutanoyl)-dihydrolipoamide |
S6P | Sorbitol 6-phosphate |
S7P | Sedoheptulose 7-phosphate |
SAH | S-Adenosyl-L-homocysteine |
SAICAR | 1-(5'-Phosphoribosyl)-5-amino-4-(N-succinocarboxamide)-imidazole |
SAM | S-Adenosyl-L-methionine |
SAMA | S-Adenosylmethioninamine |
SAMOB | S-adenosyl-4-methylthio-2-oxobutanoate |
SAOPIM | N-Succinyl-2-amino-6-oxopimelate |
SAP | S-Aminomethyldihydrolipoylprotein |
SB1P | Sorbose 1-phosphate |
SCYS | Selenocysteine |
SDAPIM | N-Succinyl-L-2,6-diaminopimelate |
SDLIPO | S-Succinyldihydrolipoamide |
SeASMET | Se-Adenosylselenomethionine |
SELD | Selenide |
SELNT | Selenate |
SELT | Selenite |
SER | L-Serine |
SERTRNASER | L-Seryl-tRNA(Ser) |
SGDHL | S-Glutaryldihydrolipoamide |
SHCHC | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate |
SHCL | Sirohydrochlorin |
SHCYS | Selenohomocysteine |
SHEME | Siroheme |
SHSER | O-Succinylhomoserine |
SLAC | (S)-Lactate |
SLF | Sulfate |
SLLCT | Selenocystathionine |
SME | Shikimate |
SME3P | Shikimate 3-phosphate |
SMET | Selenomethionine |
SMETTRNAMET | Selenomethionyl-tRNA(Met) |
SOT | D-Sorbitol |
SPRM | Spermine |
SPRMD | Spermidine |
SRLH | S-Ribosyl-L-homocysteine |
SSLCYS | S-Sulfo-L-cysteine |
STA | Starch |
STACHYOSE | Stachyose |
SUC | Sucrose |
SUC6P | Sucrose 6-phosphate |
SUCC | Succinate |
SUCCOA | Succinyl-CoA |
SUCCSA | Succinate semialdehyde |
T16B | D-Tagatose 1,6-bisphosphate |
T3 | D-Glyceraldehyde |
T6P | D-Tagatose 6-phosphate |
TCYS | Thiocysteine |
TDHDP | 2,3,4,5-Tetrahydrodipicolinate |
TGL | Triacylglycerol |
TGLU | Tetrahydropteroyltri-L-glutamate |
THBPT | Tetrahydrobiopterin; 5,6,7,8-Tetrahydrobiopterin; 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone |
THF | Tetrahydrofolate |
THFG | Tetrahydrofolyl-[Glu](n) |
THIAMIN | Thiamin |
THMNP | 5,6,7,8-Tetrahydromethanopterin |
THMP | Thiamin monophosphate |
THMPP | Thiamin diphosphate |
THR | L-Threonine |
THRTRNATHR | L-Threonyl-tRNA(Thr) |
THZP | 4-Methyl-5-(beta-hydroxyethyl)thiazole phosphate |
TM | Thymine |
TR | Taurine |
TRE | alpha,alpha-Trehalose |
TRE6P | alpha,alpha'-Trehalose 6-phosphate |
TRNAALA | tRNA(Ala) |
TRNAARG | tRNA(Arg) |
TRNAASN | tRNA(Asn) |
TRNAASP | tRNA(Asp) |
TRNACYS | tRNA(Cys) |
TRNAGLN | tRNA(Gln) |
TRNAGLU | tRNA(Glu) |
TRNAGLY | tRNA(Gly) |
TRNAHIS | tRNA(His) |
TRNAILE | tRNA(Ile) |
TRNALEU | tRNA(Leu) |
TRNALYS | tRNA(Lys) |
TRNAMET | tRNA(Met) |
TRNAPHE | tRNA(Phe) |
TRNAPRO | tRNA(Pro) |
TRNASER | tRNA(Ser) |
TRNATHR | tRNA(Thr) |
TRNATRP | tRNA(Trp) |
TRNATYR | tRNA(Tyr) |
TRNAVAL | tRNA(Val) |
TRP | L-Tryptophan |
TRPTRNATRP | L-Tryptophanyl-tRNA(Trp) |
TRYTRNATYR | L-Tyrosyl-tRNA(Tyr) |
TYR | L-Tyrosine |
UC | Urocanate |
UDCP | Undecaprenyl phosphate |
UDCPP | Undecaprenyl diphosphate |
UDP | UDP |
UDPDGALAC | UDP-D-galacturonate |
UDPG | UDPglucose |
UDPG23A | UDP-2,3-bis(3-hydroxytetradecanoyl)glucosamine |
UDPG2A | UDP-3-O-(3-hydroxytetradecanoyl)glucosamine |
UDPG2AA | UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine |
UDPGAL | UDP-D-galactose |
UDPGLUC | UDPglucuronate |
UDPMNLADGMD | UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate |
UDPMNLADGMDDADA | UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine |
UDPNADMA | UDP-N-acetyl-D-mannosamine |
UDPNADMAU | UDP-N-acetyl-D-mannosaminouronate |
UDPNAG | UDP-N-acetyl-D-glucosamine |
UDPNAGEP | UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine |
UDPNAM | UDP-N-acetylmuramate |
UDPNAMA | UDP-N-acetylmuramoyl-L-alanine |
UDPNAMAG | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate |
UMP | UMP |
UPPMN(GN)LADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMN(GN)LADGNMD(G)5DADA | Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-(glycyl)5-D-alanyl-D-alanine |
UPPMN(GN)LADGNMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMNLADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPRG | Uroporphyrinogen III |
UQ | Ubiquinone |
UQH2 | Ubiquinol |
URA | Uracil |
UREA | Urea |
URI | Uridine |
UTP | UTP |
VAL | L-Valine |
VALTRNAVAL | L-Valyl-tRNA(Val) |
VB12 | Vitamin B12 |
X5P | D-Xylulose-5-phosphate |
XAN | Xanthine |
XMP | Xanthosine 5'-phosphate |
XTSINE | Xanthosine |
ACACP | Acetyl- [acyl-carrier protein] |
ACAL | Acetaldehyde |
ACALA | N-Acetylmuramoyl-Ala |
ACCOA | Acetyl-CoA |
ACDA | Adenosyl cobyrinate a, c diamide |
ACETYLP | Acetyl-P |
ACHA | Adenosyl cobyrinate hexaamide |
ACLAC | 2-Acetolactate |
ACMUR | N-Acetyl-D-muramoate |
ACOA | Acyl-CoA |
ACP | Acyl-carrier protein |
AD | Adenine |
ADCBA | Adenosyl cobinamide |
ADCBAP | Adenosyl cobinamide phosphate |
ADCHOR | 4-amino-4-deoxychorismate |
ADLIPO | 6-S-Acetyldihydrolipoamide |
ADN | Adenosine |
ADP | ADP |
ADPDGDMHEP | ADP-D-glycero-D-manno-heptose |
ADPG | ADPglucose |
ADPHEP | ADP-L-glycero-D-manno-heptose |
AG | L-Arogenate |
AGDPCBA | Adenosine-GDP-cobinamide |
AGL | Acylglycerol |
AGL3P | Acyl-sn-glycerol 3-phosphate |
AGMATINE | Agmatine |
AHHMD | 2-Amino-7,8-dihydro-4-hydroxy-6- (diphosphooxymethyl) pteridine |
AHHMP | 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine |
AHM | 4-Amino-5-hydroxymethyl-2-methylpyrimidine |
AHMP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-phosphate |
AHMPP | 4-Amino-5-hydroxymethyl-2-methylpyrimidine-pyrophosphate |
AHSER | O-Acetylhomoserine |
AHTD | 2-Amino-4-hydroxy-6- (erythro-1,2,3-trihydroxypropyl) -dihydropteridine triphosphate |
AICAR | 1- (5'-Phosphoribosyl) -5-amino-4-imidazolecarboxamide |
AIR | Aminoimidazole ribotide |
AKG | 2-Oxoglutarate |
ALA | L-Alanine |
ALAALA | D-alanyl-D-alanine |
ALATRNA | L-Alanyl-tRNA |
ALAV | D-Aminolevulinate |
AMP | AMP |
AN | Anthranilate |
AONA | 8-amino-7-oxononanoate |
AppppA | P1, P4-Bis (5'-adenosyl) tetraphosphate |
APS | Adenylylsulfate |
ARBZ | alpha-Ribazole; N1- (alpha-D-ribosyl) -5,6-dimethylbenzimidazole |
ARG | L-Arginine |
ARGSUCC | N- (L-Arginino) succinate |
ARGTRNAARG | L-Arginyl-tRNA (Arg) |
ARIB | ADPribose |
ASELNT | Adenylylselenate |
ASER | O-Acetyl-L-serine |
ASN | L-Asparagine |
ASNTRNAASN | L-Asparaginyl-tRNA (Asn) |
ASP | L-Aspartate |
ASPSA | L-Aspartate 4-semialdehyde |
ASPTRNAASP | L-Aspartyl-tRNA (Asp) |
ASUC | N6- (1,2-Dicarboxyethyl) -AMP |
ATHR | L-Allothreonine |
ATP | ATP |
B5AMP | Biotinyl-5'-AMP |
BAL | Betaine aldehyde |
bALA | beta-Alanine |
bAPA | beta-Aminopropion aldehyde |
BASP | 4-Phospho-L-aspartate |
bDG6P | beta-D-Glucose 6-phosphate |
bDGLC | beta-D-Glucose |
BETAINE | Betaine |
bGLAC | beta-D-Galactose |
BIOMASS | Biomass |
BT | Biotin |
BUTANAL | Butanal |
C (I) DA | Cob (I) yrinate a, c diamide |
C (II) A | Cob (II) alamin |
C040COA | Butanoyl-coa |
C090ACP | Nonanoyl- [acyl-carrier protein] |
C100ACP | Decanoyl- [acyl-carrier protein] |
C110ACP | Undecanoyl- [acyl-carrier protein] |
C120 | Dodecanoic acid |
C120ACP | Dodecanoyl- [acyl-carrier protein] |
C130ACP | Tridecanoyl- [acyl-carrier protein] |
C140 | Tetradecanoic acid |
C140ACP | Tetradecanoyl- [acyl-carrier protein] |
C150 | Pentadecanoic acid |
C150ACP | Pentadecanoyl- [acyl-carrier protein] |
C151ACP | Pentadecenoyl- [acyl-carrier protein] |
C160 | Hexadecanoic acid |
C160ACP | Hexadecanoyl- [acyl-carrier protein] |
C161 | Hexadecenoic acid |
C161ACP | Hexadecenoyl- [acyl-carrier protein] |
C170ACP | Heptadecanoyl- [acyl-carrier protein] |
C171ACP | Heptadecenoyl- [acyl-carrier protein] |
C180 | Octadecanoic acid |
C180ACP | Octadecanoyl- [acyl-carrier protein] |
C181 | Octadecenoic acid |
C181ACP | Octadecenoyl- [acyl-carrier protein] |
C190ACP | Nonadecanoyl- [acyl-carrier protein] |
C191ACP | Nonadecenoyl- [acyl-carrier protein] |
C200ACP | Eicosanoyl- [acyl-carrier protein] |
CA | Cysteamine |
CAASP | N-Carbamoyl-L-aspartate |
CAIR | 1- (5-Phospho-D-ribosyl) -5-amino-4-imidazolecarboxylate |
cAMP | 3 ', 5'-Cyclic AMP |
CAP | Carbamoyl phosphate |
CAV | Cofactors and vitamins |
CB | Cellobiose |
CBCO | Cobamide coenzyme |
CBHCAP | 3-Isopropylmalate |
CCOA | Crotonoyl-coa |
CDP | CDP |
CDPDG | CDP-diacylglycerol |
CDPMDE | 4- (Cytidine5'-diphospho) -2-C-methyl-D-erythritol |
cGMP | 3 ', 5'-Cyclic GMP |
CGS | Cyanoglycoside |
CHCOA | 6-carboxyhexanoyl-CoA; Pimeloyl-coa |
CHD | Cyanohydrin |
CHOLINE | Choline |
CHOR | Chorismate |
CIT | Citrate |
CITR | L-Citrulline |
CL | Cardiolipin (biomass component) |
CMP | CMP |
CMPKDO | CMP-2-keto-3-deoxyoctanoate |
CMPNANEU | CMP-N-acetylneuraminate |
CMPNGNEU | CMP-N-glycoloylneuraminate |
CNS | Carnosine |
CO2 | CO2 |
COA | CoA; coenzyme A |
CPAD5P | 1- (2-Carboxyphenylamino) -1-deoxy-D-ribulose 5-phosphate |
CPP | Coproporphyrinogen III |
CT | Cytosine |
CTP | CTP |
CVN | Cinnavalininate |
CYS | L-Cysteine |
CYSGLY | Cys-gly |
CYST | L-Cystine |
CYSTEATE | L-Cysteate |
CYSTRNACYS | L-Cysteinyl-tRNA (Cys) |
CYTD | Cytidine |
D1AP2OOP | D-1-Aminopropan-2-ol O-phosphate |
D6PGC | 6-Phospho-D-gluconate |
D6PGL | D-Glucono-1,5-lactone 6-phosphate |
D6RP5P | 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine |
D8RL | 6,7-Dimethyl-8- (1-D-ribityl) lumazine |
DA | Deoxyadenosine |
DADP | dADP |
DALA | D-alanine |
DAMP | dAMP |
Danna | 7,8-Diaminononanoate |
DAPIM | L, L-2,6-Diaminopimelate |
DATP | dATP |
DB4P | L-3,4-Dihydroxy-2-butanone 4-phosphate |
DC | Deoxycytidine |
DCDP | dCDP |
DCMP | dCMP |
DCTP | dCTP |
DDOH | (4S) -4,6-Dihydroxy-2,5-dioxohexanoate |
DEXTRIN | Dextrin |
DFRUC | D-Fructuronate |
DG | Deoxyguanosine |
DGALAC | D-Galacturonate |
DGDMH17BP | D-glycero-D-manno-Heptose 1,7-bisphosphate |
DGDMH1P | D-glycero-D-manno-Heptose 1-phosphate |
DGDMH7P | D-glycero-D-manno-Heptose 7-phosphate |
DGDP | dGDP |
DGLN | D-Glutamine |
DGLU | D-Glutamate |
DGLUC | D-Glucuronate |
DGLUCA | D-Glucarate |
DGLUCL | D-Glucuronolactone |
DGLYCERATE | D-glycerate |
DGMP | dGMP |
DGR | 1,2-Diacyl-sn-glycerol; 1,2-Diacylglycerol |
DGTP | dGTP |
DHAP | Glycerone phosphate |
DHBPT | Dihydrobiopterin |
DHDP | 2,3-Dihydrodipicolinate |
DHF | Dihydrofolate |
DHLIPOYLPROTEIN | Dihydrolipoylprotein |
DHMP | (R) -2,3-dihydroxy-3-methylpentanoate |
DHMVA | (R) -2,3-dihydroxy-3-methylbutanoate |
DHN | 1,4-dihydroxy-2-naphthoate |
DHP | 2-Amino-4-hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine |
DHPANT | 2-Dehydropantoate |
DHPT | Dihydropteroate |
DHSK | 3-Dehydroshikimate |
DIDP | dIDP |
DIMGP | D-erythro-1- (Imidazol-4-yl) glycerol 3-phosphate |
DIN | Deoxyinosine |
DISAC1P | 2,3-bis (3-hydroxytetradecanoyl) -D-glucosaminyl-1,6-beta-D-2,3-bis (3-hydroxytetradecanoyl) -beta-D-glucosaminyl 1-phosphate or dissacharide 1-P |
DITP | dITP |
DLIPO | Dihydrolipoamide |
DMAN | D-Mannonate |
DMB | Dimethylbenzimidazole |
DMK | 2-Demethylmenaquinone |
DMKH2 | 2-Demethylmenaquinol |
DMPP | Dimethylallyl diphosphate |
DNA | DNA (biomass component) |
DOROA | (S) -Dihydroorotate |
DPCOA | Dephospho-CoA |
DPHE | D-Phenylalanine |
DQT | 3-Dehydroquinate |
DR1P | 2-Deoxy-D-ribose 1-phosphate |
DR5P | 2-Deoxy-D-ribose 5-phosphate |
DRIB | Deoxyribose |
DT | Thymidine |
DTAGA | D-Tagaturonate |
DTB | Dethiobiotin |
DTDP | dTDP |
DTDPDGLUC | dTDP-D-glucuronate |
DTDPGLAC | dTDPgalactose |
DTDPGLU | dTDPglucose |
DTMP | dTMP |
DTTP | dTTP |
DU | Deoxyuridine |
DUDP | dUDP |
DUMP | dUMP |
DUTP | dUTP |
DX5P | 1-Deoxy-D-xylulose5-phosphate |
E4HGLU | L-erythro-4-Hydroxyglutamate |
E4P | D-Erythrose 4-phosphate |
EPM | Epimelibiose |
ER4P | 4-Phospho-D-erythronate; 4-Phosphoerythronate |
ETH | Ethanol |
ETHA | Ethanolamine |
F1P | D-Fructose 1-phosphate |
F2P | D-Fructose 2-phosphate |
F6P | beta-D-Fructose 6-phosphate |
FA | Formamide |
FAD | Flavin adenine dinucleotide; FAD |
FADH2 | FADH2 |
FDP | beta-D-Fructose 1,6-bisphosphate |
FERIC | Ferricytochrome c |
FEROC | Ferrocytochrome c |
FGAM | 2- (Formamido) -N1- (5'-phosphoribosyl) acetamidine |
FGAR | 5'-Phosphoribosyl-N-formylglycinamide |
FL | Folate |
FMETTRNA | N-Formylmethionyl-tRNA |
FMN | FMN; Riboflavin-5-phosphate; Flavin mononucleotide |
FORMATE | Formate |
FPP | trans, trans-Farnesyl diphosphate |
FRU | D-Fructose |
FTHF | 10-Formyltetrahydrofolate |
FUM | Fumarate |
G1P | D-Glucose 1-phosphate |
G3P | D-Glyceraldehyde3-phosphate; (2R) -2-Hydroxy-3- (phosphonooxy) -propanal |
G3PC | sn-glycero-3-Phosphocholine |
G3PE | sn-glycero-3-Phosphoethanolamine |
G6GG | D-Gal alpha 1-> 6D-Gal alpha 1-> 6D-Glucose |
G6P | alpha-D-Glucose 6-phosphate |
GA1P | D-Glucosamine 1-phosphate |
GA6P | D-Glucosamine 6-phosphate |
GABA | 4-Aminobutanoate |
GAL1P | alpha-D-Galactose 1-phosphate |
GALACTINOL | Galactinol |
GAR | 5'-Phosphoribosylglycinamide |
GCYS | gamma-L-Glutamyl-L-cysteine |
GDP | GDP |
GDPMAN | GDPmannose |
GGL | Galactosylglycerol |
GGPP | Geranylgeranyl diphosphate |
GL | Glycerol |
GL3P | sn-Glycerol 3-phosphate |
GLAC | D-Galactose |
GLAL | Glycolaldehyde |
GLC | alpha-D-Glucose |
GLN | L-Glutamine |
GLU | L-Glutamate |
GLUC | D-Gluconate |
GLUGSAL | L-Glutamate 5-semialdehyde |
GLUP | alpha-D-Glutamyl phosphate |
GLUTCOA | Glutaryl-CoA |
GLUTRNAGLU | L-Glutamyl-tRNA (Glu) |
GLX | Glyoxylate |
GLY | Glycine |
GLYCOGEN | Glycogen |
GLYCOLATE | Glycolate |
GLYTRNAGLY | Glycyl-tRNA (Gly) |
GMP | GMP |
GN | Guanine |
GPP | Geranyl diphosphate |
GSA | Glutamate-1-semialdehyde |
GSN | Guanosine |
GTP | GTP |
GTRNA | Glutaminyl-tRNA |
H [C] | Holo- [carboxylase] |
H2CO3 | Carbonic acid |
H2O2 | H2O2 |
H2S | Hydrogen sulfide |
H2SO3 | Sulfite |
H5P3O10 | Triphosphate |
HAC | Hydroxyacetone |
HCNS | Homocarnosine |
HCO3 | HCO3 |
HCYS | L-Homocysteine |
HEPPP | all-trans-Heptaprenyl diphosphate |
HIBUT | (S) -3-Hydroxyisobutyrate |
HIS | L-Histidine |
HISOL | L-Histidinol |
HISOLP | L-Histidinol phosphate |
HISTRNAHIS | L-Histidyl-tRNA (His) |
HMB | Hydroxymethylbilane |
HMB4PP | 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate |
HO3S2 | Thiosulfate |
HOMOGEN | Homogentisate |
HPPP | all-trans-Hexaprenyl diphosphate |
HQ | Hydroquinone |
HSER | L-Homoserine |
HTR | Hypotaurine |
Hxt | External proton |
HYDROXYAKG | D-4-Hydroxy-2-oxoglutarate |
HYXN | Hypoxanthine |
I3AA | Indole-3-acetaldehyde |
I3AC | Indole-3-acetate |
I4AA | Imidazole-4-acetaldehyde |
I4AC | Imidazole-4-acetate |
IASP | Iminoaspartate |
ICHOR | Isochorismate |
ICIT | Isocitrate |
IDP | IDP |
IGP | Indoleglycerol phosphate |
ILE | L-Isoleucine |
ILETRNAILE | L-Isoleucyl-tRNA (Ile) |
IMACP | 3- (Imidazol-4-yl) -2-oxopropyl phosphate |
IMAL | Isomaltose |
IMP | IMP |
INDOLE | Indole |
INS | Inosine |
IPP | Isopentenyl diphosphate |
IPPMAL | 2-Isopropylmalate |
ITP | ITP |
K2LIPA | KDO2-lipid (A); Di [3-deoxy-D-manno-octulosonyl] -lipid A |
K2LIPIV | KDO2-lipid IV (A); Di [3-deoxy-D-manno-octulosonyl] -lipid IV (A); |
KDG | 2-Dehydro-3-deoxy-D-gluconate |
KDO | 2-Dehydro-3-deoxy-D-octonate |
KDOLIPIV | KDO-lipid IV (A) |
KDOP | 2-Dehydro-3-deoxy-D-octonate 8-phosphate |
KDPG | 2-Dehydro-3-deoxy-6-phospho-D-gluconate |
L1P3H5C | L-1-Pyrroline-3-hydroxy-5-carboxylate |
L6P | Lactose 6-phosphate |
LAC | (R) -Lactate, D-Lactate |
LACTOSE | Lactose |
LEU | L-Leucine |
LEUTRNA | L-Leucyl-tRNA |
LIPIV | Lipid IV (A) |
LIPO | Lipoamide |
LIPOYLPROTEIN | Lipoylprotein |
LIPX | Lipid X |
LK2LIPIV | Lauroyl-KDO2-lipid IV (A) |
LLCT | L-Cystathionine |
LPS | Lippolysaccharide |
LRIBULOSE5P | L-Ribulose 5-phosphate |
LTG | (R) -S-Lactoylglutathione |
LXYLULOSE5P | L-Xylulose 5-phosphate |
LYS | L-Lysine |
LYSTRNA | L-Lysyl-tRNA |
MAL | (S) -Malate |
MALACP | Malonyl- [acyl-carrier protein] |
MALCOA | Malonyl-CoA |
MAN | alpha-D-Mannose |
MAN1P | alpha-D-Mannose 1-phosphate |
MAN6P | D-Mannose 6-phosphate |
MCB | Methylcobalamin |
MDAPIM | meso-2,6-Diaminopimelate |
MDE4P | 2-C-Methyl-D-erythritol 4-phosphate |
MDECPP | 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate |
MELI | Melibiose |
MELT | Melibiitol |
MET | L-Methionine |
METHF | 5,10-Methenyltetrahydrofolate |
METTHF | 5,10-Methylenetetrahydrofolate |
METTRNA | L-Methionyl-tRNA |
MI | myo-Inositol |
MK | menaquinone |
MKH2 | menaquinol |
MLT | Maltose |
MLTHPT | maltoheptaose |
MLTHX | maltohexaose |
MLTPT | maltopentaose |
MLTTR | maltotriose |
MLTTTR | maltotetraose |
MM | Methylmalonate |
MMSA | (S) -Methylmalonate semialdehyde |
MNT | D-Mannitol |
MNT1P | D-Mannitol 1-phosphate |
MPYR | Meraptopyruvate |
MTG | Methylglyoxal |
MTHF | 5-Methyltetrahydrofolate |
MTHMNP | 5,10-Methylenetetrahydromethanopterin |
MVLN | (R) -Mevalonate |
N (P) CYS | N-((R) -Pantothenoyl) -L-cysteine |
N1 (5PADR) DMB | N1- (5-Phospho-alpha-D-ribosyl) -5,6-dimethylbenzimidazole |
N2SUCCARG | N2-Succinyl-L-arginine |
N2SUCCGLU | N2-Succinyl-L-glutamate |
N2SUCCGLU5SA | N2-Succinyl-L-glutamate 5-semialdehyde |
N4AAB | N4-Acetylaminobutanal |
Na | Sodium |
NAAD | Deamido-NAD + |
NAC | Nicotinate |
NACD | Nicotinate D-ribonucleoside |
NACN | Nicotinate D-ribonucleotide |
NAD | NAD +; Nicotinamide adenine dinucleotide |
NADH | NADH |
NADMA | N-Acetyl-D-mannosamine |
NADMA6P | N-Acetyl-D-mannosamine 6-phosphate |
NADP | NADP +; Nicotinamide adenine dinucleotide phosphate |
NADPH | NADPH |
NAGA | N-Acetyl-D-glucosamine |
NAGA1P | N-Acetyl-D-glucosamine 1-phosphate |
NAGA6P | N-Acetyl-D-glucosamine 6-phosphate |
NAGLU | N-Acetyl-L-glutamate |
NAGLUP | N-Acetyl-L-glutamate 5-phosphate |
NAGLUS | N-Acetyl-L-glutamate 5-semialdehyde |
NAM | Nicotinamide |
NAMD | N-Ribosylnicotinamide |
NAMN | Nicotinamide D-ribonucleotide |
NANEU | N-Acetylneuraminate |
NANEU9P | N-Acetylneuraminate 9-phosphate |
NAORN | N2-Acetyl-L-ornithine |
NFGLU | N-Formimino-L-glutamate |
NGNEU | N-Glycoloyl-neuraminate |
NH3 | NH3 |
NMHIS | N (pi) -Methyl-L-Histidine |
NO2 | Nitrite |
NO3 | Nitrate |
NPRAN | N- (5-Phospho-D-ribosyl) anthranilate |
O2 | Oxygen |
OA | Oxaloacetate |
OAHSER | O-Acetyl-L-homoserine |
OBUT | 2-Oxobutanoate |
OGT | Oxidized glutathione |
OHB | 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate |
OICAP | 3-Carboxy-4-methyl-2-oxopentanoate |
OIVAL | 3-Methyl-2-oxobutanoic acid |
OMP | Orotidine 5'-phosphate |
OPHSER | O-Phosphorylhomoserine |
OPP | all-trans-Octaprenyl diphosphate |
ORN | L-Ornithine |
OROA | Orrotate |
OSB | O-succinylbenzoate |
OSBCOA | O-succinylbenzoate-CoA |
OSLHSER | O-Succinyl-L-homoserine |
OTHIO | Oxidized thioredoxin |
P5C | (S) -1-Pyrroline-5-carboxylate |
P5P | Pyridoxine 5'-phosphate; Pyridoxine phosphate |
PA | Phosphatidate; 1,2-Diacyl-sn-glycerol 3-phosphate |
PABA | 4-Aminobenzoate |
PANT | (R) -pantoate |
PAP | Adenosine 3 ', 5'-bisphosphate |
PAPS | 3'-Phosphoadenylyl sulfate |
PBG | Porphobilinogen |
PC | Phosphatidylcholine |
PC2 | Percorrin 2 |
PDLA | Pyridoxamine |
PDLA5P | Pyridoxamine-5-phosphate |
PE | Phosphatidylethanolamine |
PEP | Phosphoenolpyruvate |
PEPTIDO | Peptidoglycan (biomass component) |
PG | Phosphatidylglycerol |
PGP | Phosphatidylglycerophosphate |
PHE | L-Phenylalanine |
PHEN | Prephenate |
PHETRNAPHE | L-Phenylalanyl-tRNA (Phe) |
PHOSPHOLIPID | Phospholipids (biomass component) |
PHP | 3-Phosphonooxypyruvate |
PHPYR | Phenylpyruvate |
PHSER | O-Phospho-L-homoserine |
PHT | O-Phospho-4-hydroxy-L-threonine |
PI | Orthophosphate |
PL | Pyridoxal |
PL5P | Pyridoxal 5'-phosphate |
PNTO | (R) -Pantothenate; Pantothenate |
PPA | Propinol adenylate |
PPAACP | Propanoyl- [acyl-carrier protein]; Propionyl- [acyl-carrier protein] |
PPAC | Phosphonoacetaldehyde |
PPACOA | Propanoyl-CoA; Propionyl-coa |
PPCOA | Propenoyl-CoA; Acryloyl-coa |
PPEPTIDO | Peptidoglycan precursor |
ppGpp | Guanosine 3 ', 5'-bis (diphosphate) |
PPHG | Protoporphyrinogen IX |
PPI | Pyrophosphate |
PPIX | Protoporphyrin IX |
PPN | Propynoate |
PPP | Phytyl diphosphate |
pppGpp | Guanosine 3'-diphosphate 5'-triphosphate |
PPPP | all-trans-Pentaprenyl diphosphate |
PPYR | 3-Phosphonopyruvate |
PQ | Phylloquinone |
PRAM | 5-Phosphoribosylamine |
PRBAMP | N1- (5-Phospho-D-ribosyl) -AMP |
PRBATP | N1- (5-Phospho-D-ribosyl) -ATP |
PRFICA | 1- (5'-Phosphoribosyl) -5-formamido-4-imidazolecarboxamide |
PRFP | 5- (5-Phospho-D-ribosylaminoformimino) -1- (5-phosphoribosyl) -imidazole-4-carboxamide |
PRLP | N- (5'-Phospho-D-1'-ribulosylformimino) -5-amino-1- (5 "-phospho-D-ribosyl) -4-imidazolecarboxamide |
PRO | L-Proline |
PROPANOATE | Propanoate |
PROPIONYLP | Propanoyl phosphate |
PROTEIN | Proteins |
PROTRNAPRO | L-Prolyl-tRNA (Pro) |
PRPP | 5-Phospho-alpha-D-ribose 1-diphosphate |
PS | Phosphatidylserine |
PTH | Protoheme |
PTRC | Putrescine |
PTT | Pantetheine |
PURI5P | Pseudouridine 5'-phosphate |
PYR | Pyruvate |
PYRDX | Pyridoxine |
PYTHP | 6-Pyruvoyltetrahydropterin |
QA | Quinolinate; Pyridine-2,3-dicarboxylate |
R1P | D-Ribose 1-phosphate |
R3HBCOA | (R) -3-Hydroxybutanoyl-CoA |
R5P | D-Ribose 5-phosphate |
RAF | Raffinose |
RGT | Glutathione |
RIB | D-Ribose |
RIBFLAV | Riboflavin |
RL5P | D-Ribulose 5-phosphate |
RNA | RNA |
RTHIO | Thioredoxin |
S | Sulfur |
S (2MB) DHL | S- (2-Methylbutanoyl) -dihydrolipoamide |
S (2MP) DHL | S- (2-Methylpropanoyl) -dihydrolipoamide |
S (3MB) DHL | S- (3-Methylbutanoyl) -dihydrolipoamide |
S6P | Sorbitol 6-phosphate |
S7P | Sedoheptulose 7-phosphate |
SAH | S-Adenosyl-L-homocysteine |
SAICAR | 1- (5'-Phosphoribosyl) -5-amino-4- (N-succinocarboxamide) -imidazole |
SAM | S-Adenosyl-L-methionine |
SAMA | S-Adenosylmethioninamine |
SAMOB | S-adenosyl-4-methylthio-2-oxobutanoate |
SAOPIM | N-Succinyl-2-amino-6-oxopimelate |
SAP | S-Aminomethyldihydrolipoylprotein |
SB1P | Sorbose 1-phosphate |
SCYS | Selenocysteine |
SDAPIM | N-Succinyl-L-2,6-diaminopimelate |
SDLIPO | S-Succinyldihydrolipoamide |
SeASMET | Se-Adenosylselenomethionine |
SELD | Selenide |
SELNT | Selenate |
SELT | Selenite |
SER | L-Serine |
SERTRNASER | L-Seryl-tRNA (Ser) |
SGDHL | S-Glutaryldihydrolipoamide |
SHCHC | 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate |
SHCL | Sirohydrochlorin |
SHCYS | Selenohomocysteine |
SHEME | Siroheme |
SHSER | O-succinylhomoserine |
SLAC | (S) -Lactate |
SLF | Sulfate |
SLLCT | Selenocystathionine |
SME | Shikimate |
SME3P | Shikimate 3-phosphate |
SMET | Selenomethionine |
SMETTRNAMET | Selenomethionyl-tRNA (Met) |
SOT | D-Sorbitol |
SPRM | Spermine |
SPRMD | Spermidine |
SRLH | S-Ribosyl-L-homocysteine |
SSLCYS | S-Sulfo-L-cysteine |
STA | Starch |
STACHYOSE | Stachyose |
SUC | Sucrose |
SUC6P | Sucrose 6-phosphate |
SUCC | Succinate |
SUCCOA | Succinyl-CoA |
SUCCSA | Succinate semialdehyde |
T16B | D-Tagatose 1,6-bisphosphate |
T3 | D-Glyceraldehyde |
T6P | D-Tagatose 6-phosphate |
TCYS | Thiocysteine |
TDHDP | 2,3,4,5-Tetrahydrodipicolinate |
TGL | Triacylglycerol |
TGLU | Tetrahydropteroyltri-L-glutamate |
THBPT | Tetrahydrobiopterin; 5,6,7,8-Tetrahydrobiopterin; 2-Amino-6- (1,2-dihydroxypropyl) -5,6,7,8-tetrahydoro-4 (1H) -pteridinone |
THF | Tetrahydrofolate |
THFG | Tetrahydrofolyl- [Glu] (n) |
THIAMIN | Thiamin |
THMNP | 5,6,7,8-Tetrahydromethanopterin |
THMP | Thiamin monophosphate |
THMPP | Thiamin diphosphate |
THR | L-Threonine |
THRTRNATHR | L-Threonyl-tRNA (Thr) |
THZP | 4-Methyl-5- (beta-hydroxyethyl) thiazole phosphate |
TM | Thymine |
TR | Taurine |
TRE | alpha, alpha-Trehalose |
TRE6P | alpha, alpha'-Trehalose 6-phosphate |
TRNAALA | tRNA (Ala) |
TRNAARG | tRNA (Arg) |
TRNAASN | tRNA (Asn) |
TRNAASP | tRNA (Asp) |
TRNACYS | tRNA (Cys) |
TRNAGLN | tRNA (Gln) |
TRNAGLU | tRNA (Glu) |
TRNAGLY | tRNA (Gly) |
TRNAHIS | tRNA (His) |
TRNAILE | tRNA (Ile) |
TRNALEU | tRNA (Leu) |
TRNALYS | tRNA (Lys) |
TRNAMET | tRNA (Met) |
TRNAPHE | tRNA (Phe) |
TRNAPRO | tRNA (Pro) |
TRNASER | tRNA (Ser) |
TRNATHR | tRNA (Thr) |
TRNATRP | tRNA (Trp) |
TRNATYR | tRNA (Tyr) |
TRNAVAL | tRNA (Val) |
TRP | L-Tryptophan |
TRPTRNATRP | L-Tryptophanyl-tRNA (Trp) |
TRYTRNATYR | L-Tyrosyl-tRNA (Tyr) |
TYR | L-Tyrosine |
UC | Urocanate |
UDCP | Undecaprenyl phosphate |
UDCPP | Undecaprenyl diphosphate |
UDP | UDP |
UDPDGALAC | UDP-D-galacturonate |
UDPG | UDPglucose |
UDPG23A | UDP-2,3-bis (3-hydroxytetradecanoyl) glucosamine |
UDPG2A | UDP-3-O- (3-hydroxytetradecanoyl) glucosamine |
UDPG2AA | UDP-3-O- (3-hydroxytetradecanoyl) -N-acetylglucosamine |
UDPGAL | UDP-D-galactose |
UDPGLUC | UDPglucuronate |
UDPMNLADGMD | UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate |
UDPMNLADGMDDADA | UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine |
UDPNADMA | UDP-N-acetyl-D-mannosamine |
UDPNADMAU | UDP-N-acetyl-D-mannosaminouronate |
UDPNAG | UDP-N-acetyl-D-glucosamine |
UDPNAGEP | UDP-N-acetyl-3- (1-carboxyvinyl) -D-glucosamine |
UDPNAM | UDP-N-acetylmuramate |
UDPNAMA | UDP-N-acetylmuramoyl-L-alanine |
UDPNAMAG | UDP-N-acetylmuramoyl-L-alanyl-D-glutamate |
UMP | UMP |
UPPMN (GN) LADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMN (GN) LADGNMD (G) 5DADA | Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl- (glycyl) 5-D-alanyl-D-alanine |
UPPMN (GN) LADGNMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPPMNLADGMDDADA | Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine |
UPRG | Uroporphyrinogen III |
UQ | Ubiquinone |
UQH2 | Ubiquinol |
URA | Uracil |
UREA | Urea |
URI | Uridine |
UTP | UTP |
VAL | L-Valine |
VALTRNAVAL | L-Valyl-tRNA (Val) |
VB12 | Vitamin b12 |
X5P | D-Xylulose-5-phosphate |
XAN | Xanthine |
XMP | Xanthosine 5'-phosphate |
XTSINE | Xanthosine |
실시예 2: 대사흐름분석을 이용한 필수 대사산물 분석 및 1차 필수 대사산물 결정Example 2 Analysis of Essential Metabolites and Determination of Primary Essential Metabolites Using Metabolic Flow Analysis
(1) 상기 실시예 1에서 구축한 대사 네트워크에서, A. baumanii AYE의 778개의 대사산물을 대상으로, 대사흐름분석을 통하여, 세포가 각 대사산물을 대사반응을 통해 소비하지 않을 때 세포의 성장에 미치는 영향을 조사함으로써 대사산물의 필수도(essentiality)를 구하였다. (1) In the metabolic network constructed in Example 1, 778 metabolites of A. baumanii AYE were subjected to metabolic flow analysis, and the growth of cells when the cells did not consume each metabolite through metabolic reactions. The essentiality of the metabolite was determined by investigating its effect.
즉, 대상 미생물의 대사 네트워크를 구성하는 대사산물들의 대사흐름분석 과정 중 각 대사산물을 소비하는 모든 대사반응을 결실시킨 상태에서, 즉 해당 소비반응식의 대사흐름값을 0(=νj)으로 고정하고, 목적함수는 세포성장속도를 최대화하는 것으로 설정하였을 때, 이때의 세포의 성장속도가 0인 경우를 필수 대사산물로 선별하였다.That is, in the metabolic flow analysis process of metabolites constituting the metabolic network of the target microorganism, all metabolic reactions consuming each metabolite are deleted, that is, the metabolic flow value of the corresponding reaction equation is fixed to 0 (= νj). When the objective function was set to maximize the cell growth rate, the cell growth rate of 0 was selected as an essential metabolite.
영양분들을 섭취하는 반응식들은 모두 -2 (=vj)로 고정함으로써, 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2-Oxoglutarate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, Betaine, Benzoate, Choline, Citrate, CO2, Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine, Formate, D-fructose, Fumarate, alpha-D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Guanosine, L-Histidine, L-Homoserine, Isocitrate, L-Isoleucine, Isomaltose, L-Leucine, L-Lysine, (S)-Malate, L-Methionine, Maltose, D-Mannitol, N-Acetyl-D-glucosamine, Sodium, NH3, Nitrite, Nitrate, O2, L-Ornithine, L-Phenylalanine, Orthophosphate, L-Proline, Putrescine, L-Serine, (S)-Lactate, Sulfate, Spermidine, Succinate, Sucrose, L-Threonine, alpha,alpha-Trehalose, L-Tryptophan, Taurine, L-Tyrosine, Uracil, Urea, Uridine, L-Valine, Xanthine 등의 영양분을 모두 섭취 가능하도록 하였다. The nutrient intake equations are all fixed at -2 (= vj), so 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2-Oxoglutarate, L-Alanine, L-Arginine, L -Asparagine, L-Aspartate, Betaine, Benzoate, Choline, Citrate, CO 2 , Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine Formate, D-fructose, Fumarate, alpha-D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Guanosine, L-Histidine, L-Homoserine, Isocitrate, L-Isoleucine, Isomaltose, L- Leucine, L-Lysine, (S) -Malate, L-Methionine, Maltose, D-Mannitol, N-Acetyl-D-glucosamine, Sodium, NH 3 , Nitrite, Nitrate, O 2 , L-Ornithine, L-Phenylalanine, Orthophosphate, L-Proline, Putrescine, L-Serine, (S) -Lactate, Sulfate, Spermidine, Succinate, Sucrose, L-Threonine, alpha, alpha-Trehalose, L-Tryptophan, Taurine, L-Tyrosine, Uracil, Urea, Uridine, L-Valine, Xanthine It was taken to be.
그 결과, 대사흐름분석을 통하여 하기 표 10의 총 211개의 1차 필수 대사산물들이 결정되었다. As a result, a total of 211 primary essential metabolites of Table 10 were determined through metabolic flow analysis.
표 10
Table 10
C180ACP, DMK, C171ACP, NAGA1P, D8RL, DHPANT, 5MC, 4PPNCYS, G3P, UMP, SME3P, DTDPRMNS, C170ACP, CAV, TYR, G1P, PGP, CDP, PI, PL, 3PSME, C140OH, PA, PG, PE, PS, UPPMN(GN)LADGMDDADA, OBUT, DUMP, TRP, C161ACP, UDP, DHSK, ACCOA, DTTP, HCO3, bALA, DHPT, TM, FMN, SDAPIM, H2O2, DATP, PEP, QA, DNA, ALAALA, MALCOA, OIVAL, bDGLC, ASUC, A5P, PYR, ILE, NADP, DQT, GDPMAN, NADPH, PRO, ASPSA, NACN, C120ACP, EXOPOLYS, IMP, NAAD, PPEPTIDO, OHB, O2, UDPNAMAG, DHP, DHF, CL, DHN, FAD, OSBCOA, CDPDG, MK, UTP, UDPG, DALA, DTDP4ORMNS, KDO, ATP, DT, PROTEIN, GL3P, DPCOA, PEPTIDO, C120OH, PANT, MKH2, ACACP, PHT, PYRDX, UDPGAL, DB4P, GLU, DADP, SHCHC, CHOR, PABA, UDPNAGEP, LPS, DAPIM, 3A2OP, MDAPIM, DTDPGLU, UPPMN(GN)LADGNMD(G)5DADA, 2AG3PE, ASN, MAN6P, ASP, ICHOR, PRPP, OTHIO, CTP, MAN1P, XMP, ADCHOR, SME, AGL3P, DHDP, GA6P, NAD, ARG, DHAP, PNTO, LYS, C100ACP, SAOPIM, A6RP, SAM, GA1P, RTHIO, UDPAGLACA, DX5P, GTP, AKG, F6P, LEU, PPACOA, NH3, C150ACP, SER, DTMP, UPPMNLADGMDDADA, C160ACP, METTHF, DCDP, IASP, 4PPNTO, ALA, PHOSPHOLIPID, D6RP5P, GLY, ACP, GLC, GLN, DGTP, UDPMNLADGMDDADA, CYS, UDCPP, RIBFLAV, AMP, 4PPNTE, E4P, GMP, UDPNAMA, RL5P, PPAACP, G6P, P5P, FDP, DCTP, UPPMN(GN)LADGNMDDADA, A6RP5P2, A6RP5P, ADP, DTDP, DGLU, GDP, THF, VAL, R5P, THR, SUCCOA, AHHMP, DTDP4O6DG, RNA, PL5P, MET, C181ACP, C140ACP, MALACP, KDOP, AHTD, LIPID, 3DDAH7P, HIS, TDHDP, OPP, DGDP, OSB, UDPNAG, UDPNAM, ER4P, PHE, UDCP, COA, UDPMNLADGMD, CO2 |
C180ACP, DMK, C171ACP, NAGA1P, D8RL, DHPANT, 5MC, 4PPNCYS, G3P, UMP, SME3P, DTDPRMNS, C170ACP, CAV, TYR, G1P, PGP, CDP, PI, PL, 3PSME, C140OH, PA, PG, PE, PS, UPPMN (GN) LADGMDDADA, OBUT, DUMP, TRP, C161ACP, UDP, DHSK, ACCOA, DTTP, HCO3, bALA, DHPT, TM, FMN, SDAPIM, H2O2, DATP, PEP, QA, DNA, ALAALA, MALCOA, OIVAL, bDGLC, ASUC, A5P, PYR, ILE, NADP, DQT, GDPMAN, NADPH, PRO, ASPSA, NACN, C120ACP, EXOPOLYS, IMP, NAAD, PPEPTIDO, OHB, O2, UDPNAMAG, DHP, DHF, CL, DHN, FAD, OSBCOA, CDPDG, MK, UTP, UDPG, DALA, DTDP4ORMNS, KDO, ATP, DT, PROTEIN, GL3P, DPCOA, PEPTIDO, C120OH, PANT, MKH2, ACACP, PHT, PYRDX, UDPGAL, DB4P, GLU, DADP, SHCHC, CHOR, PABA, UDPNAGEP, LPS, DAPIM, 3A2OP, MDAPIM, DTDPGLU, UPPMN (GN) LADGNMD (G) 5DADA, 2AG3PE, ASN, MAN6P, ASP, ICHOR, PRPP, OTHIO, CTP, MAN1P, XMP, ADCHOR, SME, AGL3P, DHDP, GA6P, NAD, ARG, DHAP, PNTO, LYS, C100ACP, SAOPIM, A6RP, SAM, GA1P, RTHIO, UDPAGLACA, DX5P, GTP, AKG, F6P, LEU, PPACOA, NH3, C150ACP, SER, DTMP, UPPMNLADGMDDADA, C160ACP, METTHF, DCDP, IASP, 4PPNT O, ALA, PHOSPHOLIPID, D6RP5P, GLY, ACP, GLC, GLN, DGTP, UDPMNLADGMDDADA, CYS, UDCPP, RIBFLAV, AMP, 4PPNTE, E4P, GMP, UDPNAMA, RL5P, PPAACP, G6P, P5P, FDP, DCTP, UPPN GN) LADGNMDDADA, A6RP5P2, A6RP5P, ADP, DTDP, DGLU, GDP, THF, VAL, R5P, THR, SUCCOA, AHHMP, DTDP4O6DG, RNA, PL5P, MET, C181ACP, C140ACP, MALACP, KDIP, AHTDAH HIS, TDHDP, OPP, DGDP, OSB, UDPNAG, UDPNAM, ER4P, PHE, UDCP, COA, UDPMNLADGMD, CO2 |
(2) 상기 실시예 1에서 구축한 대사 네트워크에서, V. vulnificus CMCP6의 765개의 대사산물을 대상으로, 대사흐름분석을 통하여, 세포가 각 대사산물을 대사반응을 통해 소비하지 않을 때 세포의 성장에 미치는 영향을 조사함으로써 대사산물의 필수도(essentiality)를 구하였다. (2) In the metabolic network constructed in Example 1, 765 metabolites of V. vulnificus CMCP6 were subjected to metabolic flow analysis, and the growth of cells when the cells did not consume each metabolite through metabolic reactions. The essentiality of the metabolite was determined by investigating its effect.
즉, 대상 미생물의 대사 네트워크를 구성하는 대사산물들의 대사흐름분석 과정 중 각 대사산물을 소비하는 모든 대사반응을 결실시킨 상태에서, 즉 해당 소비반응식의 대사흐름값을 0(=νj)으로 고정하고, 목적함수는 세포성장속도를 최대화하는 것으로 설정하였을 때, 이때의 세포의 성장속도가 0인 경우를 필수 대사산물로 선별하였다.That is, in the metabolic flow analysis process of metabolites constituting the metabolic network of the target microorganism, all metabolic reactions consuming each metabolite are deleted, that is, the metabolic flow value of the corresponding reaction equation is fixed to 0 (= νj). When the objective function was set to maximize the cell growth rate, the cell growth rate of 0 was selected as an essential metabolite.
영양분들을 섭취하는 반응식들은 모두 -2 (=vj)로 고정함으로써, (S)-Lactate, (S)-Malate, 2-Oxoglutarate, 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, alpha,alpha-Trehalose, alpha-D-Glucose, Choline, Citrate, CO2, Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D-Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, L-Homoserine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Ornithine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Maltose, Melibiose, N-Acetyl-D-glucosamine, NH3, Nitrate, Nitrite, Orthophosphate, Oxygen, Putrescine, sn-Glycerol 3-phosphate, Sodium, Spermidine, Succinate, Sucrose, Sulfate, Thiamin, Thymidine, Uracil, Urea, Uridine, Xanthine 등의 영양분을 모두 섭취 가능하도록 하였다. The nutrient intake equations are all fixed at -2 (= vj), so that (S) -Lactate, (S) -Malate, 2-Oxoglutarate, 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate , Adenosine, alpha, alpha-Trehalose, alpha-D-Glucose, Choline, Citrate, CO2, Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D -Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, L-Homoserine , L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Ornithine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Maltose , Melibiose, N-Acetyl-D-glucosamine, NH3, Nitrate, Nitrite, Orthophosphate, Oxygen, Putrescine, sn-Glycerol 3-phosphate, Sodium, Spermidine, Succinate, Sucrose, Sulfate, Thiamin, Thymidine, Uracil, Urea, Uridine, You can take all the nutrients, such as Xanthine It was.
그 결과, 대사흐름분석을 통하여 하기 표 11의 총 192개의 1차 필수 대사산물들이 결정되었다. As a result, a total of 192 primary essential metabolites of Table 11 were determined through metabolic flow analysis.
표 11
Table 11
2AG3PE, 2PCDPMDE, 3A2OP, 3DDAH7P, 3PSME, 4PPNCYS, 4PPNTE, 4PPNTO, A6RP, A6RP5P, A6RP5P2, ACACP, ACCOA, ACP, ADCHOR, ADP, ADPDGDMHEP, ADPG, ADPHEP, AGL3P, AHHMP, AHTD, AKG, ALA, ALAALA, AMP, ARG, ASN, ASP, ASPSA, ATP, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CAV, CDPDG, CDPMDE, CHOR, CO2, COA, CTP, CYS, D6RP5P, D8RL, DALA, DAPIM, DATP, DB4P, DCTP, DGDMH17BP, DGDMH1P, DGDMH7P, DGLU, DGTP, DHAP, DHDP, DHF, DHN, DHP, DHPANT, DHPT, DHSK, DMK, DMPP, DNA, DPCOA, DQT, DTDP, DTMP, DTTP, DX5P, E4P, ER4P, F6P, FAD, FMN, FPP, FUM, G1P, G3P, GDP, GGPP, GL3P, GLN, GLU, GLY, GLYCOGEN, GMP, GPP, GTP, HEPPP, HIS, HMB4PP, HPPP, IASP, ICHOR, ILE, IPP, LEU, LPS, LYS, MALACP, MALCOA, MDAPIM, MDE4P, MDECPP, MET, METTHF, MK, MKH2, MTHF, NAAD, NACN, NAD, NADH, NADP, NADPH, NH3, OBUT, OHB, OIVAL, OPP, OSB, OSBCOA, OTHIO, P5P, PA, PABA, PANT, PE, PEP, PEPTIDO, PG, PGP, PHE, PHOSPHOLIPID, PHT, PI, PNTO, PPAACP, PPACOA, PPEPTIDO, PPPP, PRO, PROTEIN, PRPP, PS, PYR, PYRDX, QA, R5P, RIBFLAV, RL5P, RNA, RTHIO, S7P, SAM, SAOPIM, SDAPIM, SER, SHCHC, SME, SME3P, SUCCOA, TDHDP, THF, THR, TRP, TYR, UDCP, UDCPP, UDP, UDPG, UDPMNLADGMD, UDPMNLADGMDDADA, UDPNAG, UDPNAGEP, UDPNAM, UDPNAMA, UDPNAMAG, UMP, UPPMNGNLADGMDDADA, UPPMNGNLADGNMDDADA, UPPMNGNLADGNMDG5DADA, UPPMNLADGMDDADA, UTP, VAL |
2AG3PE, 2PCDPMDE, 3A2OP, 3DDAH7P, 3PSME, 4PPNCYS, 4PPNTE, 4PPNTO, A6RP, A6RP5P, A6RP5P2, ACACP, ACCOA, ACP, ADCHOR, ADP, ADPDGDMHEP, ADPG, ADPHEP, AGLMPLA AHH AMP, ARG, ASN, ASP, ASPSA, ATP, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CAV, CDPDG, CDPMDE, CHOR, CO2, COA, CTP, CYS, D6RP5P, D8RL, DALA, DALA, DAPIM, DATP, DB4P, DCTP, DGDMH17BP, DGDMH1P, DGDMH7P, DGLU, DGTP, DHAP, DHDP, DHF, DHN, DHP, DHPANT, DHPT, DHSK, DMK, DMPP, DNA, DPCOA, DQT, DTDP, DTMP, DTMP DX5P, E4P, ER4P, F6P, FAD, FMN, FPP, FUM, G1P, G3P, GDP, GGPP, GL3P, GLN, GLU, GLY, GLYCOGEN, GMP, GPP, GTP, HEPPP, HIS, HMB4PP, HPPP, IASP, ICHOR, ILE, IPP, LEU, LPS, LYS, MALACP, MALCOA, MDAPIM, MDE4P, MDECPP, MET, METTHF, MK, MKH2, MTHF, NAAD, NACN, NAD, NADH, NADP, NADPH, NH3, OBUT, OHB, OIVAL, OPP, OSB, OSBCOA, OTHIO, P5P, PA, PABA, PANT, PE, PEP, PEPTIDO, PG, PGP, PHE, PHOSPHOLIPID, PHT, PI, PNTO, PPAACP, PPACOA, PPEPTIDO, PPPP, PRO, PROTEIN, PRPP, PS, PYR, PYRDX, QA, R5P, RIBFL AV, RL5P, RNA, RTHIO, S7P, SAM, SAOPIM, SDAPIM, SER, SHCHC, SME, SME3P, SUCCOA, TDHDP, THF, THR, TRP, TYR, UDCP, UDCPP, UDP, UDPG, UDPMNLADGMD, UDPMNLADGMDDADA, UDPNAG UDPNAGEP, UDPNAM, UDPNAMA, UDPNAMAG, UMP, UPPMNGNLADGMDDADA, UPPMNGNLADGNMDDADA, UPPMNGNLADGNMDG5DADA, UPPMNLADGMDDADA, UTP, VAL |
실시예 3: 필수 대사산물의 추가 스크리닝Example 3: Additional Screening of Essential Metabolites
(1) 실시예 2-(1)에서 대사흐름분석을 통해 결정된 필수 대사산물에 대해서, 유통 대사산물에 해당하는 것들을 제거하여 179개의 2차 필수 대사산물을 얻었다.(1) For essential metabolites determined through metabolic flow analysis in Example 2- (1), those corresponding to the distribution metabolites were removed to obtain 179 secondary essential metabolites.
표 12
Table 12
AHHMP, DGLU, DHDP, DHP, DHSK, DX5P, DQT, KDO, PABA, ASPSA, C120OH, C140OH, C171ACP, CHOR, DMK, MDAPIM, MK, MKH2, OPP, PHT, PPAACP, SME, ACACP, ACCOA, ACP, AHTD, ARG, ASN, ASP, bALA, bDGLC, C100ACP, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C170ACP, C180ACP, C181ACP, CDPDG, CYS, DADP, DALA, DCDP, DCTP, DGDP, DGTP, DHAP, DHF, DTDP, DTDPGLU, DTDPRMNS, DTMP, DTTP, DUMP, E4P, F6P, FDP, FMN, G1P, G3P, G6P, GL3P, GLC, GLY, HCO3, HIS, ILE, LEU, LYS, MALACP, MET, NAAD, NACN, OBUT, OIVAL, PE, PEP, PG, PHE, PL, PPACOA, PRO, PRPP, PS, R5P, RL5P, SER, SUCCOA, THR, TRP, TYR, UDPG, UDPNAG, VAL, XMP, 2AG3PE, 3A2OP, 3DDAH7P, 3PSME, 4PPNCYS, 4PPNTE, 4PPNTO, 5MC, A5P, A6RP, A6RP5P, A6RP5P2, ADCHOR, AGL3P, ALAALA, ASUC, CAV, CL, D6RP5P, D8RL, DAPIM, DATP, DB4P, DHN, DHPANT, DHPT, DNA, DPCOA, DT, DTDP4O6DG, DTDP4ORMNS, ER4P, EXOPOLYS, GA1P, GA6P, GDPMAN, IASP, ICHOR, KDOP, LIPID, LPS, MALCOA, MAN1P, MAN6P, NAGA1P, OHB, OSB, OSBCOA, P5P, PA, PANT, PEPTIDO, PGP, PHOSPHOLIPID, PL5P, PNTO, PPEPTIDO, PROTEIN, PYRDX, QA, RIBFLAV, RNA, SAOPIM, SDAPIM, SHCHC, SME3P, TDHDP, TM, UDCP, UDCPP, UDPAGLACA, UDPGAL, UDPMNLADGMD, UDPMNLADGMDDADA, UDPNAGEP, UDPNAM, UDPNAMA, UDPNAMAG, UPPMN(GN)LADGMDDADA, UPPMN(GN)LADGNMD(G)5DADA, UPPMN(GN)LADGNMDDADA, UPPMNLADGMDDADA |
AHHMP, DGLU, DHDP, DHP, DHSK, DX5P, DQT, KDO, PABA, ASPSA, C120OH, C140OH, C171ACP, CHOR, DMK, MDAPIM, MK, MKH2, OPP, PHT, PPAACP, SME, ACACP, ACCOA, ACP, AHTD, ARG, ASN, ASP, bALA, bDGLC, C100ACP, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C170ACP, C180ACP, C181ACP, CDPDG, CYS, DADP, DALA, DCDP, DCTP, DGDP, DGTP, DHAP DTDP, DTDPGLU, DTDPRMNS, DTMP, DTTP, DUMP, E4P, F6P, FDP, FMN, G1P, G3P, G6P, GL3P, GLC, GLY, HCO3, HIS, ILE, LEU, LYS, MALACP, MET, NAAD, NACN, OBUT, OIVAL, PE, PEP, PG, PHE, PL, PPACOA, PRO, PRPP, PS, R5P, RL5P, SER, SUCCOA, THR, TRP, TYR, UDPG, UDPNAG, VAL, XMP, 2AG3PE, 3A2OP, 3DDAH7P, 3PSME, 4PPNCYS, 4PPNTE, 4PPNTO, 5MC, A5P, A6RP, A6RP5P, A6RP5P2, ADCHOR, AGL3P, ALAALA, ASUC, CAV, CL, D6RP5P, D8RL, DAPIM, DATP, DB4P, DHN, DHPANT, DCOA, DNA DT, DTDP4O6DG, DTDP4ORMNS, ER4P, EXOPOLYS, GA1P, GA6P, GDPMAN, IASP, ICHOR, KDOP, LIPID, LPS, MALCOA, MAN1P, MAN6P, NAGA1P, OHB, OSB, OSBCOA, P5P, PA, PANTGP PHOSPHOLIPID, PL5P, PNTO, PPEPTIDO, PROTEIN , PYRDX, QA, RIBFLAV, RNA, SAOPIM, SDAPIM, SHCHC, SME3P, TDHDP, TM, UDCP, UDCPP, UDPAGLACA, UDPGAL, UDPMNLADGMD, UDPMNLADGMDDADA, UDPNAGEP, UDPNAM, UDPNAMA, UDPNAMAG, UPPMN (GN) LADGN ) LADGNMD (G) 5DADA, UPPMN (GN) LADGNMDDADA, UPPMNLADGMDDADA |
그리고, 상기 2차 필수 대사산물 중 이들이 최소한 3개 이상의 반응식과 관여하되 2개 이상의 반응식은 해당 필수 대사산물을 소비하는 것들인 것만을 추가 선별하여 97개의 3차 필수 대사산물을 얻었다In addition, among the secondary essential metabolites, they were associated with at least three or more reaction schemes, but two or more reaction schemes were further selected only to consume those essential metabolites, thereby obtaining 97 tertiary essential metabolites.
표 13
Table 13
AHHMP, DGLU, DHDP, DHP, DHSK, DX5P, DQT, KDO, PABA, ASPSA, C120OH, C140OH, C171ACP, CHOR, DMK, MDAPIM, MK, MKH2, OPP, PHT, PPAACP, SME, ACACP, ACCOA, ACP, AHTD, ARG, ASN, ASP, bALA, bDGLC, C100ACP, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C170ACP, C180ACP, C181ACP, CDPDG, CYS, DADP, DALA, DCDP, DCTP, DGDP, DGTP, DHAP, DHF, DTDP, DTDPGLU, DTDPRMNS, DTMP, DTTP, DUMP, E4P, F6P, FDP, FMN, G1P, G3P, G6P, GL3P, GLC, GLY, HCO3, HIS, ILE, LEU, LYS, MALACP, MET, NAAD, NACN, OBUT, OIVAL, PE, PEP, PG, PHE, PL, PPACOA, PRO, PRPP, PS, R5P, RL5P, SER, SUCCOA, THR, TRP, TYR, UDPG, UDPNAG, VAL, XMP |
AHHMP, DGLU, DHDP, DHP, DHSK, DX5P, DQT, KDO, PABA, ASPSA, C120OH, C140OH, C171ACP, CHOR, DMK, MDAPIM, MK, MKH2, OPP, PHT, PPAACP, SME, ACACP, ACCOA, ACP, AHTD, ARG, ASN, ASP, bALA, bDGLC, C100ACP, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C170ACP, C180ACP, C181ACP, CDPDG, CYS, DADP, DALA, DCDP, DCTP, DGDP, DGTP, DHAP DTDP, DTDPGLU, DTDPRMNS, DTMP, DTTP, DUMP, E4P, F6P, FDP, FMN, G1P, G3P, G6P, GL3P, GLC, GLY, HCO3, HIS, ILE, LEU, LYS, MALACP, MET, NAAD, NACN, OBUT, OIVAL, PE, PEP, PG, PHE, PL, PPACOA, PRO, PRPP, PS, R5P, RL5P, SER, SUCCOA, THR, TRP, TYR, UDPG, UDPNAG, VAL, XMP |
그리고, 마지막으로 남은 필수 대사산물이 인체에 존재하지 않는 것들만 선별하여 22개의 4차 대사산물을 얻었다.Finally, the remaining essential metabolites were selected only those that do not exist in the human body to obtain 22 quaternary metabolites.
표 14
Table 14
AHHMP, DGLU, DHDP, DHP, DHSK, DX5P, DQT, KDO, PABA, ASPSA, C120OH, C140OH, C171ACP, CHOR, DMK, MDAPIM, MK, MKH2, OPP, PHT, PPAACP, SME |
AHHMP, DGLU, DHDP, DHP, DHSK, DX5P, DQT, KDO, PABA, ASPSA, C120OH, C140OH, C171ACP, CHOR, DMK, MDAPIM, MK, MKH2, OPP, PHT, PPAACP, SME |
마지막으로 이들의 소비 반응식을 인간과의 상동관계를 기준으로 추가 스크링하여 차기 가능성 있는 필수 대사산물의 수를 더욱 줄였다. 만일 필수 대사산물 중 소비 반응식들의 효소가 한 개라도 인간의 단백질과 통계적으로 유사할 경우, 해당 필수 대사산물 및 그의 소비 반응식은 더 이상 약물 표적으로서 고려하지 않았다. Finally, their consumption equations were further screened based on homology with humans to further reduce the number of possible essential metabolites. If any of the enzymes in the consumption schemes of the essential metabolites are statistically similar to human proteins, the essential metabolites and their consumption schemes are no longer considered as drug targets.
그 결과, 차기 선별된 각 필수 대사산물의 모든 소비 반응식과 관련된 유전자 및 아미노산 서열은 인간 단백질의 것과 현저히 다르게 되어 인간 단백질과 구조적기능적으로도 상이하다고 할 수 있다.As a result, the genes and amino acid sequences associated with all consumption schemes of each of the essential metabolites selected next are significantly different from those of human proteins, which are structurally different from human proteins.
이와 같이, 본 발명의 방법에 의해 스크리닝된 효소군 또는 유전자군들 중에서, 당업자가 약물표적으로 임의 선택하여 사용할 수 있다. As such, among the enzyme groups or gene groups screened by the method of the present invention, those skilled in the art can optionally use the drug target.
(2) 실시예 2-(2)에서 대사흐름분석을 통해 결정된 필수 대사산물에 대해서, 유통 대사산물에 해당하는 것들을 제거하여 162개의 2차 필수 대사산물을 얻었다.(2) For the essential metabolite determined through metabolic flow analysis in Example 2- (2), those corresponding to the distribution metabolite were removed to obtain 162 secondary essential metabolites.
표 16
Table 16
2AG3PE, 2PCDPMDE, 3A2OP, 3DDAH7P, 3PSME, 4PPNCYS, 4PPNTE, 4PPNTO, A6RP, A6RP5P, A6RP5P2, ACACP, ACCOA, ACP, ADCHOR, ADPDGDMHEP, ADPG, ADPHEP, AGL3P, AHHMP, AHTD, ALAALA, ARG, ASN, ASP, ASPSA, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CAV, CDPDG, CDPMDE, CHOR, CYS, D6RP5P, D8RL, DALA, DAPIM, DATP, DB4P, DCTP, DGDMH17BP, DGDMH1P, DGDMH7P, DGLU, DGTP, DHAP, DHDP, DHF, DHN, DHP, DHPANT, DHPT, DHSK, DMK, DMPP, DNA, DPCOA, DQT, DTDP, DTMP, DTTP, DX5P, E4P, ER4P, F6P, FMN, FPP, FUM, G1P, G3P, GGPP, GL3P, GLY, GLYCOGEN, GPP, HEPPP, HIS, HMB4PP, HPPP, IASP, ICHOR, ILE, IPP, LEU, LPS, LYS, MALACP, MALCOA, MDAPIM, MDE4P, MDECPP, MET, MK, MKH2, NAAD, NACN, OBUT, OHB, OIVAL, OPP, OSB, OSBCOA, P5P, PA, PABA, PANT, PE, PEP, PEPTIDO, PG, PGP, PHE, PHOSPHOLIPID, PHT, PNTO, PPAACP, PPACOA, PPEPTIDO, PPPP, PRO, PROTEIN, PRPP, PS, PYRDX, QA, R5P, RIBFLAV, RL5P, RNA, S7P, SAOPIM, SDAPIM, SER, SHCHC, SME, SME3P, SUCCOA, TDHDP, THR, TRP, TYR, UDCP, UDCPP, UDPG, UDPMNLADGMD, UDPMNLADGMDDADA, UDPNAG, UDPNAGEP, UDPNAM, UDPNAMA, UDPNAMAG, UPPMNGNLADGMDDADA, UPPMNGNLADGNMDDADA, UPPMNGNLADGNMDG5DADA, UPPMNLADGMDDADA, VAL |
2AG3PE, 2PCDPMDE, 3A2OP, 3DDAH7P, 3PSME, 4PPNCYS, 4PPNTE, 4PPNTO, A6RP, A6RP5P, A6RP5P2, ACACP, ACCOA, ACP, ADCHOR, ADPDGDMHEP, ADPG, ADPHEP, AGL3P, ARGHMP ASPSA, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CAV, CDPDG, CDPMDE, CHOR, CYS, D6RP5P, D8RL, DALA, DAPIM, DATP, DB4P, DCTP, DGDMH1BP, DGDMH7 DGTP, DHAP, DHDP, DHF, DHN, DHP, DHPANT, DHPT, DHSK, DMK, DMPP, DNA, DPCOA, DQT, DTDP, DTMP, DTTP, DX5P, E4P, ER4P, F6P, FMN, FPP, FUM, G1P, G3P, GGPP, GL3P, GLY, GLYCOGEN, GPP, HEPPP, HIS, HMB4PP, HPPP, IASP, ICHOR, ILE, IPP, LEU, LPS, LYS, MALACP, MALCOA, MDAPIM, MDE4P, MDECPP, MET, MK, MKH2, NAAD, NACN, OBUT, OHB, OIVAL, OPP, OSB, OSBCOA, P5P, PA, PABA, PANT, PE, PEP, PEPTIDO, PG, PGP, PHE, PHOSPHOLIPID, PHT, PNTO, PPAACP, PPACOA, PPEPTIDO, PPPP, PRO, PROTEIN, PRPP, PS, PYRDX, QA, R5P, RIBFLAV, RL5P, RNA, S7P, SAOPIM, SDAPIM, SER, SHCHC, SME, SME3P, SUCCOA, TDHDP, THR, TRP, TYR, UDCP, UDCPP, UDPG, UDPMNLADGMD, UDPMNLA DGMDDADA, UDPNAG, UDPNAGEP, UDPNAM, UDPNAMA, UDPNAMAG, UPPMNGNLADGMDDADA, UPPMNGNLADGNMDDADA, UPPMNGNLADGNMDG5DADA, UPPMNLADGMDDADA, VAL |
그리고, 상기 2차 필수 대사산물 중 이들이 최소한 3개 이상의 반응식과 관여하되 2개 이상의 반응식은 해당 필수 대사산물을 소비하는 것들인 것만을 추가 선별하여 81개의 3차 필수 대사산물을 얻었다.Of these secondary essential metabolites, they were associated with at least three or more reaction schemes, but two or more reaction schemes were further selected only to consume those essential metabolites, thereby obtaining 81 tertiary essential metabolites.
표 17
Table 17
ACACP, ACCOA, ACP, AHHMP, AHTD, ARG, ASN, ASP, ASPSA, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CDPDG, CHOR, CYS, DALA, DATP, DCTP, DGLU, DGTP, DHAP, DHDP, DHF, DHN, DHSK, DMK, DTMP, DTTP, DX5P, E4P, F6P, FMN, FUM, G1P, G3P, GL3P, GLY, GLYCOGEN, HIS, ILE, IPP, LEU, LYS, MALACP, MDAPIM, MET, MK, MKH2, NACN, OBUT, OIVAL, OPP, P5P, PABA, PE, PEP, PG, PHE, PHT, PPAACP, PPACOA, PRO, PRPP, PS, PYRDX, R5P, RL5P, S7P, SER, SUCCOA, THR, TRP, TYR, UDPG, UDPNAG, VAL |
ACACP, ACCOA, ACP, AHHMP, AHTD, ARG, ASN, ASP, ASPSA, bALA, C120ACP, C140ACP, C150ACP, C160ACP, C161ACP, C180ACP, C181ACP, CDPDG, CHOR, CYS, DALA, DATP, DCTP, DGLU, DGTP DHAP, DHDP, DHF, DHN, DHSK, DMK, DTMP, DTTP, DX5P, E4P, F6P, FMN, FUM, G1P, G3P, GL3P, GLY, GLYCOGEN, HIS, ILE, IPP, LEU, LYS, MALACP, MDAPIM, MET, MK, MKH2, NACN, OBUT, OIVAL, OPP, P5P, PABA, PE, PEP, PG, PHE, PHT, PPAACP, PPACOA, PRO, PRPP, PS, PYRDX, R5P, RL5P, S7P, SER, SUCCOA, THR, TRP, TYR, UDPG, UDPNAG, VAL |
그리고, 마지막으로 남은 필수 대사산물이 인체에 존재하지 않는 것들만 선별하여 16개의 4차 대사산물을 얻었다.Finally, the remaining essential metabolites were selected only those that do not exist in the human body to obtain 16 quaternary metabolites.
표 18
Table 18
AHHMP, ASPSA, CHOR, DGLU, DHDP, DHN, DHSK, DMK, DX5P, MDAPIM, MK, MKH2, OPP, PABA, PHT, PPAACP |
AHHMP, ASPSA, CHOR, DGLU, DHDP, DHN, DHSK, DMK, DX5P, MDAPIM, MK, MKH2, OPP, PABA, PHT, PPAACP |
마지막으로 이들의 소비 반응식을 인간과의 상동관계를 기준으로 추가 스크링하여 차기 가능성 있는 필수 대사산물의 수를 더욱 줄였다. 만일 필수 대사산물 중 소비 반응식들의 효소가 한 개라도 인간의 단백질과 통계적으로 유사할 경우, 해당 필수 대사산물 및 그의 소비 반응식은 더 이상 약물 표적으로서 고려하지 않았다. Finally, their consumption equations were further screened based on homology with humans to further reduce the number of possible essential metabolites. If any of the enzymes in the consumption schemes of the essential metabolites are statistically similar to human proteins, the essential metabolites and their consumption schemes are no longer considered as drug targets.
그 결과, 차기 선별된 각 필수 대사산물의 모든 소비 반응식과 관련된 유전자 및 아미노산 서열은 인간 단백질의 것과 현저히 다르게 되어 인간 단백질과 구조적·기능적으로도 상이하다고 할 수 있다.As a result, the genes and amino acid sequences associated with all consumption reactions of each of the essential metabolites selected next are significantly different from those of human proteins, which are structurally and functionally different from human proteins.
표 19
Table 19
Essential metabolites | ORFs | Metabolism | E.C.No. | Enzyme |
AHHMP | VV11644 | Folate biosynthesis | 2.7.6.3 | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase |
AHHMP, PABAa | VV11691 | Folate biosynthesis | 2.5.1.15 | dihydropteroate synthase |
DGLU | VV11175 | D-Glutamine and D-glutamate metabolism | 5.1.1.3 | glutamate racemase |
DGLU | VV10580 | Peptidoglycan biosynthesis | 6.3.2.9 | UDP-N-acetylmuramoylalanine--D-glutamate ligase |
DHDPb | VV10567 | Lysine biosynthesis | 1.3.1.26 | dihydrodipicolinate reductase |
DX5P | VV11866 | Biosynthesis of steroids | 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
DX5P | VV11568 | Vitamin B6 metabolism | - | pyridoxine 5-phosphate synthase |
Essential metabolites | ORFs | Metabolism | ECNo. | Enzyme |
AHHMP | VV11644 | Folate biosynthesis | 2.7.6.3 | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase |
AHHMP, PABA a | VV11691 | Folate biosynthesis | 2.5.1.15 | dihydropteroate synthase |
DGLU | VV11175 | D-Glutamine and D-glutamate metabolism | 5.1.1.3 | glutamate racemase |
DGLU | VV10580 | Peptidoglycan biosynthesis | 6.3.2.9 | UDP-N-acetylmuramoylalanine--D-glutamate ligase |
DHDP b | VV10567 | Lysine biosynthesis | 1.3.1.26 | dihydrodipicolinate reductase |
DX5P | VV11866 | Biosynthesis of steroids | 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
DX5P | VV11568 | Vitamin B6 metabolism | - | pyridoxine 5-phosphate synthase |
이와 같이, 본 발명의 방법에 의해 스크리닝된 효소군 또는 유전자군들 중에서, 당업자가 약물표적으로 임의 선택하여 사용할 수 있다. As such, among the enzyme groups or gene groups screened by the method of the present invention, those skilled in the art can optionally use the drug target.
실시예 4: 5차 필수 대사산물과 구조적으로 유사한 화합물의 선별 및 미생물 성장 억제 실험을 통한 약물 스크리닝 Example 4 Screening of Drugs Through Screening of Compounds Structurally Similar to the 5th Essential Metabolite and Inhibition of Microbial Growth
상기 실시예 3-(2)에서 최종적으로 선별된 5개의 5차 필수 대사산물과 구조적으로 유사한 화합물을 한국화합물은행에 있는 17만개 이상으로 구성된 화합물 라이브러리부터 선별하여, 미생물의 성장 억제 실험을 실시하였다.Compounds structurally similar to the five fifth essential metabolites finally selected in Example 3- (2) were selected from a compound library consisting of 170,000 or more in the Korea Compound Bank, and microbial growth inhibition experiments were performed. .
pipeline을 통한 유사 구조의 화합물 검색 결과, 상기 화합물 라이브러리로부터 타니모토 계수 0.5~1.0의 총 352 개의 구조 유사 화합물이 약물 후보군으로써 선별되었으며, 이들 화합물들에 대하여, 100-well plate의 각 well에는 100 ㎕의 Mueller Hinton이라는 복합 액체 배지를 넣으며, 대사 미생물을 각 well에서 배양하였다. As a result of the compound search through the pipeline, a total of 352 structure-like compounds having a Tanimoto coefficient of 0.5 to 1.0 were selected as drug candidates from the compound library. For these compounds, 100 µl was added to each well of a 100-well plate. Mueller Hinton's complex liquid medium was added, and metabolic microorganisms were cultured in each well.
배양은 20시간동안 이루어졌으며, 미생물의 농도는 매 시간마다 OD600를 측정해주는 BioScreen C를 이용하였다. 상기 화합물들을 화합물 처리가 전혀 안된 대조 표준 미생물의 최고 농도 대비 미생물 농도의 80% 이상을 억제할 경우, 이러한 화합물을 항병원균 약물로써 효력이 있는 것으로 선별하였다. Incubation was performed for 20 hours, and the concentration of microorganisms was measured using BioScreen C, which measures OD600 every hour. These compounds were selected to be effective as anti-pathogen drugs when they inhibited at least 80% of the microbial concentration relative to the highest concentration of the control standard microorganisms that were not treated with the compound.
총 352 개의 선별된 구조 유사 화합물로부터, 미생물 성장 억제 실험 결과, 이들 중 가장 성공적으로 비브리오 불니피커스 (Vibrio vulnificus)를 억제한 화합물은 화학식 1의 구조를 가지는 화합물로,From a total of 352 selected structure-like compounds, microbial growth inhibition experiments showed that the most successfully inhibited Vibrio vulnificus was a compound having the structure of Formula 1.
화학식 1Formula 1
최소 억제 농도 (Minimal inhibitory concentration, MIC)는 2 ㎍/㎖이었다.Minimal inhibitory concentration (MIC) was 2 μg / ml.
본 발명은 미생물의 약물 표적을 예측하고, 미생물 성장을 효율적으로 억제할 수 있는 신약 후보 화합물을 스크리닝 하는 방법에 관한 것으로, 대사흐름분석에 기반한 필수 대사산물 분석에 따른 결과를 바탕으로, 병원균을 비롯한 다양한 미생물에 의한 질병에 대한 차기 가능성 있는 효과적인 약물 표적 후보군들만을 얻게 되어, 상기 병원균 미생물에 의한 질병의 치료 및 예방에 유용하다. 특히, 다약제 내성을 가지고 있는 병원균체, 예컨대, 아시네토박터 바우마니, 비브리오 불니피커스 등에 대한 신약 화합물을 스크리닝함으로써, 이러한 병원성 미생물에 의한 질병의 치료 및 예방에 유용하다.The present invention relates to a method for predicting a drug target of a microorganism and screening for a drug candidate compound capable of efficiently inhibiting microbial growth. The present invention is based on the results of essential metabolite analysis based on metabolic flow analysis, including pathogens. Only potential next effective drug target candidates for diseases caused by various microorganisms are obtained, which is useful for the treatment and prevention of diseases caused by the pathogen microorganisms. In particular, it is useful for the treatment and prevention of diseases caused by such pathogenic microorganisms by screening new drug compounds against pathogens that are multi-drug resistant, such as Acinetobacter Baumani, Vibrio Bulnipicus, and the like.
Claims (47)
- 다음의 단계를 포함하는, 미생물에 대한 약물 표적 효소의 스크리닝 방법:A method for screening a drug target enzyme for a microorganism, comprising the following steps:(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, (c) of the primary essential metabolites determined in step (b),대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하는 단계 및 숙주의 대사에 존재하지 않는 것들만을 선별하는 단계를, 각각 또는 모두 실시하는 단계; 및Removing a current metabolite having no specificity with the microorganism of interest and selecting only those that are not present in the host's metabolism, each or all; And(d) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 최종 필수 대사산물로 결정하고, 상기 최종 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계.(d) If all of the enzymes consuming the essential metabolites determined in the previous step do not have homology with the host protein, determine the essential metabolites as the final essential metabolite, and determine the enzymes involved in the final essential metabolite. Selecting a drug target enzyme.
- 제1항에 있어서, 상기 (c)단계 이후 결정된 필수 대사산물 중, 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 대사산물을 선별하는 단계를 추가로 수행하는 것을 특징으로 하는 스크리닝 방법.The method of claim 1, wherein the step of selecting a metabolite in the case where at least two or more of the essential metabolites determined after step (c) is involved in at least three or more enzyme reaction schemes and at the same time consumes the essential metabolites. The screening method, characterized in that further performing.
- 다음의 단계를 포함하는, 미생물에 대한 약물 스크리닝 방법:A drug screening method for microorganisms, comprising the following steps:(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming specific metabolites in the established microbial metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하는 단계 및 숙주의 대사에 존재하지 않는 것들만을 선별하는 단계를, 각각 또는 모두 실시하는 단계;(c) screening only those that are not present in the metabolism of the host and removing the circulation metabolite having no specificity with the target microorganism among the primary essential metabolites determined in step (b) Performing each or all of the steps;(d) 앞 단계에서 결정된 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 최종 필수 대사산물로 결정하는 단계;(d) if all enzymes consuming the essential metabolites determined in the previous step are not homologous to the host protein, determining those essential metabolites as the final essential metabolite;(e) 상기 (d)단계에서 결정된 최종 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 화합물 라이브러리에서 타니모토 계수를 이용하여 선별하는 단계; 및(e) selecting a compound candidate group having structural similarity to the final essential metabolite determined in step (d) using the Tanimoto coefficient in the compound library; And(f) 상기 선별된 화합물 후보군을 각각 대상 미생물에 투여하여, 미생물의 성장 억제 여부를 확인함으로써, 미생물에 대한 약물을 스크리닝 하는 단계.(f) screening drugs against the microorganisms by administering each of the selected compound candidate groups to the target microorganisms to determine whether the microorganisms inhibit growth.
- 제3항에 있어서, 상기 (c)단계 이후 결정된 필수 대사산물 중, 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 대사산물을 선별하는 단계를 추가로 수행하는 것을 특징으로 하는 스크리닝 방법.4. The method of claim 3, wherein the step of selecting a metabolite when the at least two or more of the essential metabolites determined after step (c) is involved in at least three or more enzyme reaction schemes and at the same time consumes the essential metabolites. The screening method, characterized in that further performing.
- 다음의 단계를 포함하는, 미생물에 대한 약물 표적 효소의 스크리닝 방법:A method for screening a drug target enzyme for a microorganism, comprising the following steps:(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계; (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 대상 미생물의 약물 표적 효소로 선정하는 단계.(f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the target microorganism.
- 다음의 단계를 포함하는, 미생물에 대한 약물의 스크리닝 방법:A method for screening a drug against a microorganism, comprising the following steps:(a) 대상 미생물을 선정하고, 선정된 미생물의 대사 네트워크 모델을 구축하는 단계; (a) selecting a target microorganism and building a metabolic network model of the selected microorganism;(b) 상기 구축된 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 대상 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계; (c) determining a secondary essential metabolite by removing a circulation metabolite having no specificity with the target microorganism among the first essential metabolites determined in step (b);(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정 하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;(g) 상기 (e)단계에서 결정된 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 화합물 라이브러리에서 타니모토 계수(Tanimoto coefficient)를 이용하여 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite determined in step (e) using the Tanimoto coefficient in the compound library; And(h) 상기 선별된 화합물 후보군을 각각 대상 미생물에 투여하여, 미생물의 성장 억제 여부를 확인함으로써, 미생물에 대한 약물을 스크리닝 하는 단계.(h) screening drugs against the microorganisms by administering each of the selected compound candidate groups to the target microorganisms to determine whether the microorganisms inhibit growth.
- 제1항, 제3항, 제5항 및 제6항 중 어느 한 항에 있어서, 상기 대상 미생물은 대장균 또는 병원성 미생물인 것을 특징으로 하는 방법.The method of any one of claims 1, 3, 5 and 6, wherein the subject microorganism is E. coli or pathogenic microorganism.
- 제1항, 제3항, 제5항 및 제6항 중 어느 한 항에 있어서, 상기 숙주는 인간인 것을 특징으로 하는 방법.7. The method of any one of claims 1, 3, 5 and 6, wherein said host is a human.
- 제1항, 제3항, 제5항 및 제6항 중 어느 한 항에 있어서, (a)단계에서 미생물의 상기 대사 네트워크는 게놈 수준인 것을 특징으로 하는 방법.7. The method of any one of claims 1, 3, 5 and 6, wherein in step (a) said metabolic network of microorganisms is at the genome level.
- 제1항, 제3항, 제5항 및 제6항 중 어느 한 항에 있어서, (b)단계의 수행은, The method of any one of claims 1, 3, 5 and 6, wherein performing step (b) comprises:(i) 상기 구축된 미생물 대사 네트워크를 이하의 수학식으로 표현하여 선형계획법을 이용하는 단계; 및(i) the constructed microorganism Expressing a metabolic network by the following equation to use a linear programming method; And수학식 1Equation 1(여기서, S : 시간에 따른 X의 변화량, X: 대사산물의 농도, t: 시간)(here,S: Over timeXChange in,X= Concentration of metabolite,t: time)(ii) 이하의 수학식2를 이용하여, 대사산물 소비 반응식의 대사흐름값을 0으로 고정시킨 후 세포의 성장속도가 0인 경우를 1차 필수 대사산물로 결정하는 것을 특징으로 하는 방법:(ii) using Equation 2 below, after fixing the metabolite flow value of the metabolite consumption equation to 0 and determining the growth rate of the cell as 0, the first essential metabolite:수학식 2Equation 2(여기서 j m 은 각 대사산물의 소비 반응식; V jm 은 해당 소비 반응식의 대사흐름값).Where j m is the consumption equation of each metabolite; V jm is the metabolic flow value of the corresponding consumption equation.
- 제10항에 있어서, 상기 선형계획법을 적용할 때, 목적함수를 세포 성장 속도를 최대화하는 것으로 설정하는 것을 특징으로 하는 방법.The method of claim 10, wherein, when applying the linear programming method, the objective function is set to maximize the cell growth rate.
- 제10항에 있어서, 상기 선형계획법의 적용은 세포의 성장에 필요한 모든 영양분 조건을 반영하여 이루어지는 것을 특징으로 하는 방법.The method of claim 10, wherein the application of the linear programming method reflects all the nutrient conditions necessary for cell growth.
- 제5항 또는 제6항에 있어서, (d)단계에서 2차 필수 대사산물들 중 적어도 3개 이상의 효소 반응식에 관여하면서, 동시에 적어도 2개 이상은 해당 필수 대사산물을 소비하는 경우의 대사산물을 3차 필수 대사산물로 결정하는 것을 특징으로 하는 방법.The method according to claim 5 or 6, wherein in step (d), at least two or more of the secondary essential metabolites are involved in the enzymatic reaction, while at least two or more of the metabolites are consumed when the essential metabolites are consumed. Characterized in that it is determined as a tertiary essential metabolite.
- 제1항, 제3항, 제5항 및 제6항 중 어느 한 항에 있어서, 상기 상동관계의 검토는 아미노산 서열 또는 유전자 서열을 이용하는 것을 특징으로 하는 방법.7. The method of any one of claims 1, 3, 5 and 6, wherein the examination of homology uses amino acid sequences or gene sequences.
- 제14항에 있어서, 상기 상동관계의 검토는 BLASTP 프로그램 또는 BLAST 프로그램을 이용하여 이루어지는 것을 특징으로 하는 방법.15. The method of claim 14, wherein examining the homology is made using a BLASTP program or a BLAST program.
- 제1항 또는 제5항에서 선정된 대상 미생물의 약물 표적 효소를 코딩하는 유전자군들을 대상 미생물의 약물 표적 유전자로 결정하는 것을 특징으로 하는, 미생물에 대한 약물 표적 유전자의 스크리닝 방법.A method of screening a drug target gene for a microorganism, characterized in that a group of genes encoding a drug target enzyme of the target microorganism selected from claim 1 or 5 is determined as a drug target gene of the target microorganism.
- 제1항 또는 제5항에서 선정된 대상 미생물의 효소들; 또는 제16항에서 결정된 대상 미생물의 유전자군들을, 대상 미생물의 약물 표적으로 이용하는 방법.Enzymes of the target microorganism selected from claim 1 or 5; Or using the gene groups of the subject microorganism determined in claim 16 as drug targets of the subject microorganism.
- 제3항에 있어서, 상기 필수 대사산물과 구조적 유사성을 가진 화합물 후보군은 타니모토 계수가 0.5∼1인 화합물인 것을 특징으로 하는 방법.4. The method of claim 3, wherein the compound candidate group having structural similarity to the essential metabolite is a compound having a Tanimoto coefficient of 0.5 to 1.
- 제6항에 있어서, 상기 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군은 타니모토 계수가 0.5∼1인 화합물인 것을 특징으로 하는 방법.The method of claim 6, wherein the compound candidate group having structural similarity to the fifth essential metabolite is a compound having a Tanimoto coefficient of 0.5 to 1.
- 제3항 또는 제6항에 있어서, 상기 화합물 후보군을 대상 미생물에 투여하여 성장 억제 여부를 확인함으로써, 미생물에 대한 약물을 스크리닝 하는 단계는, 화합물 후보군을 처리한 시험군이 화합물 후보군이 처리되지 않은 대조군에 비해, 대상 미생물의 농도를 80% 이상 억제하는 화합물을 미생물에 대한 약물로써 스크리닝 하는 것을 특징으로 하는 방법. The method of claim 3 or 6, wherein the step of screening the drug against the microorganisms by administering the compound candidate group to the target microorganism to confirm growth inhibition, wherein the test group treated with the compound candidate group is not treated with the compound candidate group. Compared to the control, a method for screening a compound that inhibits the concentration of the target microorganism by 80% or more as a drug against the microorganism.
- 다음의 단계를 포함하는, 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소의 스크리닝 방법:A method for screening a drug target enzyme of a microorganism of the genus Acinetobacter , comprising the following steps:(a) 아시네토박터(Acinetobacter) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) building a metabolic network model of the genus Acinetobacter ;(b) 상기 구축된 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed acinetobacter (Acinetobacter)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 아시네토박터(Acinetobacter) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Of the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter. Determining;(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소로 선정하는 단계.(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, the corresponding essential metabolites are determined as the fifth essential metabolite and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the genus Acinetobacter ( Acinetobacter) .
- 다음의 단계를 포함하는, 아시네토박터(Acinetobacter) 속 미생물에 대한 약물 스크리닝 방법:A drug screening method for Acinetobacter spp. Microorganisms comprising the following steps:(a) 아시네토박터(Acinetobacter) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) building a metabolic network model of the genus Acinetobacter ;(b) 상기 구축된 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed acinetobacter (Acinetobacter)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 아시네토박터(Acinetobacter) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Of the primary essential metabolites determined in step (b), the secondary essential metabolite is removed by removing a circulation metabolite having no specificity with the microorganisms of the genus Acinetobacter. Determining;(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; (e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite;(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;(g) 상기 (f)단계에서 결정된 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 화합물 라이브러리에서 타니모토 계수를 이용하여 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite determined in step (f) using the Tanimoto coefficient in the compound library; And(h) 상기 화합물 후보군을 각각 아시네토박터(Acinetobacter) 속 미생물에 투여하여 미생물의 성장 억제 여부를 확인함으로써, 미생물에 대한 약물을 스크리닝 하는 단계.(h) screening drugs against the microorganisms by administering the compound candidate groups to the microorganisms of the genus Acinetobacter to determine whether the microorganisms inhibit growth.
- 제21항 또는 제22항 있어서, 상기 아시네토박터(Acinetobacter) 속 미생물은 아시네토박터 바우마니 (Acinetobacter baumannii)인 것을 특징으로 하는 방법.Claim 21 or claim 22 wherein the Acinetobacter (Acinetobacter) in the microorganism is characterized in that the Acinetobacter baumannii (Acinetobacter baumannii).
- 제21항 또는 제22항에 있어서, 상기 숙주는 인간인 것을 특징으로 하는 방법.23. The method of claim 21 or 22, wherein said host is a human.
- 제21항 또는 제22항 있어서, (a) 단계에서의 상기 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크 구축은 ABAYE0014, ABAYE0022, ABAYE0023, ABAYE0028, ABAYE0036, ABAYE0043, ABAYE0056, ABAYE0058, ABAYE0059, ABAYE0064, ABAYE0067, ABAYE0068, ABAYE0075, ABAYE0076, ABAYE0078, ABAYE0079, ABAYE0081, ABAYE0082, ABAYE0084, ABAYE0089, ABAYE0090, ABAYE0091, ABAYE0093, ABAYE0095, ABAYE0096, ABAYE0098, ABAYE0102, ABAYE0104, ABAYE0109, ABAYE0116, ABAYE0127, ABAYE0128, ABAYE0129, ABAYE0144, ABAYE0147, ABAYE0148, ABAYE0149, ABAYE0150, ABAYE0154, ABAYE0157, ABAYE0158, ABAYE0166, ABAYE0167, ABAYE0168, ABAYE0175, ABAYE0179, ABAYE0200, ABAYE0209, ABAYE0210, ABAYE0243, ABAYE0244, ABAYE0250, ABAYE0253, ABAYE0254, ABAYE0262, ABAYE0264, ABAYE0277, ABAYE0283, ABAYE0284, ABAYE0285, ABAYE0295, ABAYE0296, ABAYE0298, ABAYE0299, ABAYE0310, ABAYE0312, ABAYE0313, ABAYE0325, ABAYE0332, ABAYE0351, ABAYE0352, ABAYE0353, ABAYE0354, ABAYE0355, ABAYE0356, ABAYE0367, ABAYE0368, ABAYE0377, ABAYE0378, ABAYE0379, ABAYE0381, ABAYE0397, ABAYE0405, ABAYE0435, ABAYE0436, ABAYE0465, ABAYE0470, ABAYE0476, ABAYE0479, ABAYE0480, ABAYE0482, ABAYE0483, ABAYE0489, ABAYE0491, ABAYE0497, ABAYE0505, ABAYE0524, ABAYE0577, ABAYE0588, ABAYE0604, ABAYE0605, ABAYE0607, ABAYE0608, ABAYE0613, ABAYE0614, ABAYE0615, ABAYE0619, ABAYE0624, ABAYE0625, ABAYE0628, ABAYE0629, ABAYE0634, ABAYE0638, ABAYE0663, ABAYE0674, ABAYE0676, ABAYE0682, ABAYE0691, ABAYE0697, ABAYE0698, ABAYE0699, ABAYE0708, ABAYE0709, ABAYE0716, ABAYE0722, ABAYE0740, ABAYE0749, ABAYE0757, ABAYE0758, ABAYE0763, ABAYE0773, ABAYE0774, ABAYE0775, ABAYE0776, ABAYE0777, ABAYE0780, ABAYE0781, ABAYE0782, ABAYE0783, ABAYE0784, ABAYE0788, ABAYE0800, ABAYE0801, ABAYE0807, ABAYE0811, ABAYE0812, ABAYE0816, ABAYE0817, ABAYE0818, ABAYE0824, ABAYE0826, ABAYE0849, ABAYE0850, ABAYE0853, ABAYE0854, ABAYE0860, ABAYE0861, ABAYE0877, ABAYE0885, ABAYE0888, ABAYE0889, ABAYE0899, ABAYE0911, ABAYE0912, ABAYE0915, ABAYE0916, ABAYE0923, ABAYE0931, ABAYE0933, ABAYE0935, ABAYE0945, ABAYE0951, ABAYE0958, ABAYE0962, ABAYE0966, ABAYE0969, ABAYE0977, ABAYE0980, ABAYE0982, ABAYE1010, ABAYE1011, ABAYE1026, ABAYE1027, ABAYE1028, ABAYE1030, ABAYE1039, ABAYE1047, ABAYE1052, ABAYE1066, ABAYE1067, ABAYE1083, ABAYE1094, ABAYE1098, ABAYE1103, ABAYE1104, ABAYE1106, ABAYE1113, ABAYE1114, ABAYE1115, ABAYE1118, ABAYE1119, ABAYE1123, ABAYE1126, ABAYE1127, ABAYE1128, ABAYE1138, ABAYE1141, ABAYE1142, ABAYE1145, ABAYE1147, ABAYE1171, ABAYE1199, ABAYE1204, ABAYE1206, ABAYE1207, ABAYE1209, ABAYE1223, ABAYE1278, ABAYE1280, ABAYE1295, ABAYE1296, ABAYE1354, ABAYE1356, ABAYE1362, ABAYE1366, ABAYE1367, ABAYE1380, ABAYE1385, ABAYE1386, ABAYE1387, ABAYE1388, ABAYE1389, ABAYE1391, ABAYE1411, ABAYE1413, ABAYE1417, ABAYE1418, ABAYE1425, ABAYE1427, ABAYE1432, ABAYE1445, ABAYE1453, ABAYE1455, ABAYE1456, ABAYE1457, ABAYE1458, ABAYE1460, ABAYE1463, ABAYE1465, ABAYE1466, ABAYE1469, ABAYE1477, ABAYE1510, ABAYE1513, ABAYE1514, ABAYE1520, ABAYE1522, ABAYE1526, ABAYE1537, ABAYE1538, ABAYE1539, ABAYE1544, ABAYE1546, ABAYE1562, ABAYE1563, ABAYE1567, ABAYE1569, ABAYE1571, ABAYE1577, ABAYE1580, ABAYE1581, ABAYE1585, ABAYE1586, ABAYE1587, ABAYE1599, ABAYE1613, ABAYE1625, ABAYE1636, ABAYE1637, ABAYE1646, ABAYE1649, ABAYE1650, ABAYE1653, ABAYE1658, ABAYE1667, ABAYE1668, ABAYE1669, ABAYE1672, ABAYE1675, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE1700, ABAYE1706, ABAYE1710, ABAYE1712, ABAYE1715, ABAYE1724, ABAYE1736, ABAYE1742, ABAYE1781, ABAYE1786, ABAYE1789, ABAYE1792, ABAYE1811, ABAYE1861, ABAYE1886, ABAYE1896, ABAYE1897, ABAYE1909, ABAYE1913, ABAYE1914, ABAYE1916, ABAYE1921, ABAYE1937, ABAYE1940, ABAYE1943, ABAYE1944, ABAYE1945, ABAYE1946, ABAYE1947, ABAYE1948, ABAYE1953, ABAYE1955, ABAYE1970, ABAYE1983, ABAYE1989, ABAYE1990, ABAYE1993, ABAYE1994, ABAYE2013, ABAYE2014, ABAYE2053, ABAYE2058, ABAYE2062, ABAYE2065, ABAYE2067, ABAYE2076, ABAYE2077, ABAYE2088, ABAYE2090, ABAYE2108, ABAYE2116, ABAYE2118, ABAYE2129, ABAYE2153, ABAYE2179, ABAYE2181, ABAYE2184, ABAYE2188, ABAYE2191, ABAYE2209, ABAYE2219, ABAYE2220, ABAYE2227, ABAYE2246, ABAYE2248, ABAYE2250, ABAYE2270, ABAYE2288, ABAYE2290, ABAYE2291, ABAYE2292, ABAYE2304, ABAYE2306, ABAYE2307, ABAYE2310, ABAYE2311, ABAYE2317, ABAYE2318, ABAYE2329, ABAYE2333, ABAYE2342, ABAYE2344, ABAYE2366, ABAYE2367, ABAYE2368, ABAYE2369, ABAYE2370, ABAYE2377, ABAYE2385, ABAYE2388, ABAYE2396, ABAYE2422, ABAYE2438, ABAYE2439, ABAYE2457, ABAYE2460, ABAYE2481, ABAYE2483, ABAYE2491, ABAYE2493, ABAYE2533, ABAYE2562, ABAYE2566, ABAYE2577, ABAYE2578, ABAYE2589, ABAYE2592, ABAYE2593, ABAYE2594, ABAYE2595, ABAYE2596, ABAYE2601, ABAYE2606, ABAYE2607, ABAYE2613, ABAYE2614, ABAYE2618, ABAYE2628, ABAYE2630, ABAYE2631, ABAYE2641, ABAYE2646, ABAYE2663, ABAYE2666, ABAYE2678, ABAYE2764, ABAYE2767, ABAYE2771, ABAYE2776, ABAYE2777, ABAYE2778, ABAYE2783, ABAYE2790, ABAYE2791, ABAYE2794, ABAYE2799, ABAYE2803, ABAYE2809, ABAYE2810, ABAYE2819, ABAYE2822, ABAYE2823, ABAYE2824, ABAYE2829, ABAYE2832, ABAYE2836, ABAYE2837, ABAYE2838, ABAYE2843, ABAYE2845, ABAYE2852, ABAYE2867, ABAYE2868, ABAYE2869, ABAYE2871, ABAYE2878, ABAYE2905, ABAYE2909, ABAYE2910, ABAYE2927, ABAYE2928, ABAYE2929, ABAYE2940, ABAYE2951, ABAYE2955, ABAYE2958, ABAYE2964, ABAYE2969, ABAYE2976, ABAYE2981, ABAYE2984, ABAYE2987, ABAYE2988, ABAYE2989, ABAYE2992, ABAYE2993, ABAYE3001, ABAYE3003, ABAYE3004, ABAYE3006, ABAYE3007, ABAYE3015, ABAYE3016, ABAYE3025, ABAYE3028, ABAYE3031, ABAYE3037, ABAYE3047, ABAYE3048, ABAYE3049, ABAYE3050, ABAYE3051, ABAYE3052, ABAYE3053, ABAYE3054, ABAYE3055, ABAYE3056, ABAYE3057, ABAYE3058, ABAYE3059, ABAYE3060, ABAYE3065, ABAYE3067, ABAYE3078, ABAYE3079, ABAYE3086, ABAYE3097, ABAYE3101, ABAYE3104, ABAYE3105, ABAYE3114, ABAYE3129, ABAYE3130, ABAYE3131, ABAYE3132, ABAYE3133, ABAYE3151, ABAYE3153, ABAYE3154, ABAYE3159, ABAYE3160, ABAYE3169, ABAYE3174, ABAYE3175, ABAYE3176, ABAYE3179, ABAYE3181, ABAYE3184, ABAYE3186, ABAYE3187, ABAYE3188, ABAYE3191, ABAYE3192, ABAYE3193, ABAYE3228, ABAYE3238, ABAYE3239, ABAYE3240, ABAYE3244, ABAYE3250, ABAYE3258, ABAYE3262, ABAYE3263, ABAYE3267, ABAYE3269, ABAYE3272, ABAYE3276, ABAYE3278, ABAYE3280, ABAYE3281, ABAYE3282, ABAYE3283, ABAYE3284, ABAYE3292, ABAYE3293, ABAYE3296, ABAYE3314, ABAYE3315, ABAYE3322, ABAYE3343, ABAYE3348, ABAYE3351, ABAYE3357, ABAYE3359, ABAYE3360, ABAYE3366, ABAYE3373, ABAYE3378, ABAYE3379, ABAYE3393, ABAYE3395, ABAYE3424, ABAYE3426, ABAYE3428, ABAYE3429, ABAYE3443, ABAYE3447, ABAYE3463, ABAYE3470, ABAYE3471, ABAYE3497, ABAYE3498, ABAYE3507, ABAYE3508, ABAYE3511, ABAYE3518, ABAYE3519, ABAYE3524, ABAYE3530, ABAYE3531, ABAYE3537, ABAYE3540, ABAYE3544, ABAYE3546, ABAYE3568, ABAYE3572, ABAYE3588, ABAYE3612, ABAYE3614, ABAYE3616, ABAYE3644, ABAYE3661, ABAYE3670, ABAYE3671, ABAYE3675, ABAYE3678, ABAYE3696, ABAYE3697, ABAYE3713, ABAYE3715, ABAYE3716, ABAYE3717, ABAYE3718, ABAYE3719, ABAYE3720, ABAYE3721, ABAYE3723, ABAYE3731, ABAYE3732, ABAYE3740, ABAYE3750, ABAYE3763, ABAYE3764, ABAYE3766, ABAYE3767, ABAYE3768, ABAYE3773, ABAYE3774, ABAYE3791, ABAYE3792, ABAYE3793, ABAYE3795, ABAYE3796, ABAYE3797, ABAYE3800, ABAYE3801, ABAYE3802, ABAYE3803, ABAYE3804, ABAYE3807, ABAYE3814, ABAYE3815, ABAYE3823, ABAYE3825, ABAYE3834, ABAYE3835, ABAYE3839, ABAYE3846, ABAYE3851, ABAYE3852, ABAYE3871, ABAYE3872, ABAYE3885, ABAYE3887, p2ABAYE0004, p3ABAYE0020, p3ABAYE0024, p3ABAYE0029으로 구성된 유전자 군에 기반한 것을 특징으로 하는 방법.The method of claim 21 or 22, wherein the Acinetobacter genus microbial metabolic network construction in step (a) is ABAYE0014, ABAYE0022, ABAYE0023, ABAYE0028, ABAYE0036, ABAYE0043, ABAYE0056, ABAYE0058, ABAYE0059, ABAYE0064, ABA ABAYE0068, ABAYE0075, ABAYE0076, ABAYE0078, ABAYE0079, ABAYE0081, ABAYE0082, ABAYE0084, ABAYE0089, ABAYE0090, ABAYE0091, ABAYE0093, ABAYE0095, ABAYE0096, ABAYE0098, ABAYE0102, ABAYE0104, ABAYE0109, ABAYE0116, ABAYE0127, ABAYE0128, ABAYE0129, ABAYE0144, ABAYE0147, ABAYE0148, ABAYE0149, ABAYE0150, ABAYE0154, ABAYE0157, ABAYE0158, ABAYE0166, ABAYE0167, ABAYE0168, ABAYE0175, ABAYE0179, ABAYE0200, ABAYE0209, ABAYE0210, ABAYE0243, ABAYE0244, ABAYE0250, ABAYE0253, ABAYE0254, ABAYE0262, ABAYE0264, ABAYE0277, ABAYE0283, ABAYE0284, ABAYE0285, ABAYE0295, ABAYE0296, ABAYE0298, ABAYE0299, ABAYE0310, ABAYE0312, ABAYE0313, ABAYE0325, ABAYE0332, ABAYE0351, ABAYE0352, ABAYE0353, ABAYE0354, ABAYE0355, ABAYE0356, ABAYE0367, ABAYE0376 BAYE0378, ABAYE0379, ABAYE0381, ABAYE0397, ABAYE0405, ABAYE0435, ABAYE0436, ABAYE0465, ABAYE0470, ABAYE0476, ABAYE0479, ABAYE0480, ABAYE0482, ABAYE0483, ABAYE0489, ABAYE0491, ABAYE0497, ABAYE0505, ABAYE0524, ABAYE0577, ABAYE0588, ABAYE0604, ABAYE0605, ABAYE0607, ABAYE0608, ABAYE0613, ABAYE0614, ABAYE0615, ABAYE0619, ABAYE0624, ABAYE0625, ABAYE0628, ABAYE0629, ABAYE0634, ABAYE0638, ABAYE0663, ABAYE0674, ABAYE0676, ABAYE0682, ABAYE0691, ABAYE0697, ABAYE0698, ABAYE0699, ABAYE0708, ABAYE0709, ABAYE0716, ABAYE0722, ABAYE0740, ABAYE0749, ABAYE0757, ABAYE0758, ABAYE0763, ABAYE0773, ABAYE0774, ABAYE0775, ABAYE0776, ABAYE0777, ABAYE0780, ABAYE0781, ABAYE0782, ABAYE0783, ABAYE0784, ABAYE0788, ABAYE0800, ABAYE0801, ABAYE0807, ABAYE0811, ABAYE0812, ABAYE0816, ABAYE0817, ABAYE0818, ABAYE0824, ABAYE0826, ABAYE0849, ABAYE0850, ABAYE0853, ABAYE0854, ABAYE0860, ABAYE0861, ABAYE0877, ABAYE0885, ABAYE0888, ABAYE0889, ABAYE0899, ABAYE0911, ABAYE0912, ABAYE0915, ABAYE0916, ABAYE0923, ABAYE0931, ABAYE0933, ABAYE0935, ABAYE0945, ABAYE0951, ABAYE0958, ABAYE0962, ABAYE0966, ABAYE0969, ABAYE0977, ABAYE0980, ABAYE0982, ABAYE1010, ABAYE1011, ABAYE1026, ABAYE1027, ABAYE1028, ABAYE1030, ABAYE1039, ABAYE1047, ABAYE1052, ABAYE1066, ABAYE1067, ABAYE1083, ABAYE1094, ABAYE1098, ABAYE1103, ABAYE1104, ABAYE1106, ABAYE1113, ABAYE1114, ABAYE1115, ABAYE1118, ABAYE1119, ABAYE1123, ABAYE1126, ABAYE1127, ABAYE1128, ABAYE1138, ABAYE1141, ABAYE1142, ABAYE1145, ABAYE1147, ABAYE1171, ABAYE1199, ABAYE1204, ABAYE1206, ABAYE1207, ABAYE1209, ABAYE1223, ABAYE1278, ABAYE1280, ABAYE1295, ABAYE1296, ABAYE1354, ABAYE1356, ABAYE1362, ABAYE1366, ABAYE1367, ABAYE1380, ABAYE1385, ABAYE1386, ABAYE1387, ABAYE1388, ABAYE1389, ABAYE1391, ABAYE1411, ABAYE1413, ABAYE1417, ABAYE1418, ABAYE1425, ABAYE1427, ABAYE1432, ABAYE1445, ABAYE1453, ABAYE1455, ABAYE1456, ABAYE1457, ABAYE1458, ABAYE1460, ABAYE1463, ABAYE1465, ABAYE1466, ABAYE1469, ABAYE1477, ABAYE1510, ABAYE1513, ABAYE1514, ABAYE1520, ABAYE1522, ABAYE1526, ABAYE1537, ABAYE1538, ABAYE1539, ABAYE1544, ABAYE1546, ABAYE1562, ABAYE1563, ABAYE1567, ABAYE1569, ABAYE1571, ABAYE1577, ABAYE1580, ABAYE1581, ABAYE1585, ABAYE1586, ABAYE1587, ABAYE1599, ABAYE1613, ABAYE1625, ABAYE1636, ABAYE1637, ABAYE1646, ABAYE1649, ABAYE1650, ABAYE1653, ABAYE1658, ABAYE1667, ABAYE1668, ABAYE1669, ABAYE1672, ABAYE1675, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE1700, ABAYE1706, ABAYE1710, ABAYE1712, ABAYE1715, ABAYE1724, ABAYE1736, ABAYE1742, ABAYE1781, ABAYE1786, ABAYE1789, ABAYE1792, ABAYE1811, ABAYE1861, ABAYE1886, ABAYE1896, ABAYE1897, ABAYE1909, ABAYE1913, ABAYE1914, ABAYE1916, ABAYE1921, ABAYE1937, ABAYE1940, ABAYE1943, ABAYE1944, ABAYE1945, ABAYE1946, ABAYE1947, ABAYE1948, ABAYE1953, ABAYE1955, ABAYE1970, ABAYEBA A93, A1989 A1919 ABAYE2065, ABAYE2067, ABAYE2076, ABAYE2077, ABAYE2088, ABAYE2090, ABAYE2108, ABAYE2116, ABAYE2118, ABAYE2129, ABAYE2153, ABAYE2179, ABAYE2181, ABAYE2184, ABAYE2188, ABAYE2191 , ABAYE2209, ABAYE2219, ABAYE2220, ABAYE2227, ABAYE2246, ABAYE2248, ABAYE2250, ABAYE2270, ABAYE2288, ABAYE2290, ABAYE2291, ABAYE2292, ABAYE2304, ABAYE2306, ABAYE2307, ABAYE2310, ABAYE2311, ABAYE2317, ABAYE2318, ABAYE2329, ABAYE2333, ABAYE2342, ABAYE2344, ABAYE2366, ABAYE2367 , ABAYE2368, ABAYE2369, ABAYE2370, ABAYE2377, ABAYE2385, ABAYE2388, ABAYE2396, ABAYE2422, ABAYE2438, ABAYE2439, ABAYE2457, ABAYE2460, ABAYE2481, ABAYE2483, ABAYE2491, ABAYE2493, ABAYE2533, ABAYE2562, ABAYE2566, ABAYE2577, ABAYE2578, ABAYE2589, ABAYE2592, ABAYE2593, ABAYE2594 , ABAYE2595, ABAYE2596, ABAYE2601, ABAYE2606, ABAYE2607, ABAYE2613, ABAYE2614, ABAYE2618, ABAYE2628, ABAYE2630, ABAYE2631, ABAYE2641, ABAYE2646, ABAYE2663, ABAYE2666, ABAYE2678, ABAYE2764, ABAYE2767, ABAYE2771, ABAYE2776, ABAYE2777, ABAYE2778, ABAYE2783, ABAYE2790, ABAYE2791 , ABAYE2794, ABAYE2799, ABAYE2803, ABAYE2809, ABAYE2810, ABAYE2819, ABAYE2822, ABAYE2823, ABAYE2824, ABAYE2829, ABAYE2832, ABAYE2836, ABAYE2837, ABAYE2838, ABAYE2843, ABAYE284 5, ABAYE2852, ABAYE2867, ABAYE2868, ABAYE2869, ABAYE2871, ABAYE2878, ABAYE2905, ABAYE2909, ABAYE2910, ABAYE2927, ABAYE2928, ABAYE29, ABAYE2940, ABAYE2951, ABAYE2955, ABAYE29, ABAYE2992, ABAYE2993, ABAYE3001, ABAYE3003, ABAYE3004, ABAYE3006, ABAYE3007, ABAYE3015, ABAYE3016, ABAYE3025, ABAYE3028, ABAYE3031, ABAYE3037, ABAYE3047, ABAYE3048, ABAYE3049, ABAYE3050, ABAYE3051, ABAYE3052, ABAYE3053, ABAYE3054, ABAYE3055, ABAYE3056, ABAYE3057, ABAYE3058, ABAYE3059, ABAYE3060, ABAYE3065, ABAYE3067, ABAYE3078, ABAYE3079, ABAYE3086, ABAYE3097, ABAYE3101, ABAYE3104, ABAYE3105, ABAYE3114, ABAYE3129, ABAYE3130, ABAYE3131, ABAYE3132, ABAYE3133, ABAYE3151, ABAYE3153, ABAYE3154, ABAYE3159, ABAYE3160, ABAYE3169, ABAYE3174, ABAYE3175, ABAYE3176, ABAYE3179, ABAYE3181, ABAYE3184, ABAYE3186, ABAYE3187, ABAYE3188, ABAYE3191, ABAYE3192, ABAYE3193, ABAYE3228, ABAYE3238, ABAYE3239, ABAYE3240, ABAYE3244, ABAYE32250, ABAYE32250 58, ABAYE3262, ABAYE3263, ABAYE3267, ABAYE3269, ABAYE3272, ABAYE3276, ABAYE3278, ABAYE3280, ABAYE3281, ABAYE3282, ABAYE3283, ABAYE3284, ABAYE3292, ABAYE3293, ABAYE3296, ABAYE3314 ABAYE3366, ABAYE3373, ABAYE3378, ABAYE3379, ABAYE3393, ABAYE3395, ABAYE3424, ABAYE3426, ABAYE3428, ABAYE3429, ABAYE3443, ABAYE3447, ABAYE3463, ABAYE3470, ABAYE3471, ABAYE3497, ABAYE3498, ABAYE3507, ABAYE3508, ABAYE3511, ABAYE3518, ABAYE3519, ABAYE3524, ABAYE3530, ABAYE3531, ABAYE3537, ABAYE3540, ABAYE3544, ABAYE3546, ABAYE3568, ABAYE3572, ABAYE3588, ABAYE3612, ABAYE3614, ABAYE3616, ABAYE3644, ABAYE3661, ABAYE3670, ABAYE3671, ABAYE3675, ABAYE3678, ABAYE3696, ABAYE3697, ABAYE3713, ABAYE3715, ABAYE3716, ABAYE3717, ABAYE3718, ABAYE3719, ABAYE3720, ABAYE3721, ABAYE3723, ABAYE3731, ABAYE3732, ABAYE3740, ABAYE3750, ABAYE3763, ABAYE3764, ABAYE3766, ABAYE3767, ABAYE3768, ABAYE3773, ABAYE3774, ABAYE3791, ABAYE3792, ABAYE393, ABAYE3793 795, ABAYE3796, ABAYE3797, ABAYE3800, ABAYE3801, ABAYE3802, ABAYE3803, ABAYE3804, ABAYE3807, ABAYE3814, ABAYE3815, ABAYE3823, ABAYE3825, ABAYE3834, ABAYE3835, ABAYE3839, ABAYE3846, ABAYE3851, ABAYE3852, ABAYE3871, ABAYE3872, ABAYE3885, ABAYE3887, p2ABAYE0004, p3ABAYE0020, Method based on the gene group consisting of p3ABAYE0024, p3ABAYE0029.
- 제21항 또는 제22항 있어서, 상기 (b)단계의 수행은, The method of claim 21 or 22, wherein performing the step (b),(i) 상기 구축된 아시네토박터(Acinetobacter) 속 미생물 대사 네트워크를 이하의 수학식으로 표현하여 선형계획법을 이용하는 단계, 이 때, 상기 선형계획법의 적용은 세포의 성장에 필요한 모든 영양분 조건을 반영하여 이루어지는 것을 특징으로 함; 및(i) the constructed acinetobacter (Acinetobacter) Microorganisms Expressing the metabolic network by the following equation to use the linear programming, wherein the application of the linear programming is characterized by reflecting all the nutrient conditions necessary for the growth of the cells; And수학식 1Equation 1(여기서, S : 시간에 따른 X의 변화량, X: 대사산물의 농도, t: 시간)(here,S: Over timeXChange in,X= Concentration of metabolite,t: time)(ii) 이하의 수학식2를 이용하여, 대사산물 소비 반응식의 대사흐름값을 0으로 고정시킨 후 세포의 성장속도가 0인 경우를 1차 필수 대사산물로 결정하는 것을 특징으로 하는 방법:(ii) using Equation 2 below, after fixing the metabolite flow value of the metabolite consumption equation to 0 and determining the growth rate of the cell as 0, the first essential metabolite:수학식 2Equation 2(여기서 j m 은 각 대사산물의 소비 반응식; V jm 은 해당 소비 반응식의 대사흐름값).Where j m is the consumption equation of each metabolite; V jm is the metabolic flow value of the corresponding consumption equation.
- 제26항에 있어서, 상기 영양분은 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2-Oxoglutarate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, Betaine, Benzoate, Choline, Citrate, CO2, Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine, Formate, D-fructose, Fumarate, alpha-D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Guanosine, L-Histidine, L-Homoserine, Isocitrate, L-Isoleucine, Isomaltose, L-Leucine, L-Lysine, (S)-Malate, L-Methionine, Maltose, D-Mannitol, N-Acetyl-D-glucosamine, Sodium, NH3, Nitrite, Nitrate, O2, L-Ornithine, L-Phenylalanine, Orthophosphate, L-Proline, Putrescine, L-Serine, (S)-Lactate, Sulfate, Spermidine, Succinate, Sucrose, L-Threonine, alpha,alpha-Trehalose, L-Tryptophan, Taurine, L-Tyrosine, Uracil, Urea, Uridine, L-Valine 및 Xanthine으로 구성된 군에서 선택되는 것을 특징으로 하는 방법.The method of claim 26, wherein the nutrient is 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, 2-Oxoglutarate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, Betaine , Benzoate, Choline, Citrate, CO2, Cytosine, L-Cysteine, Cytidine, D-alanine, Deoxyadenosine, Deoxycytidine, D-Glutamate, Deoxyguanosine, D-Serine, Thymidine, Deoxyuridine, Ethanolamine, Formate, D-fructose, Fumarate, alpha -D-Glucose, L-Glutamine, D-Gluconate, L-Glutamate, Glycolate, Glycine, Guanosine, L-Histidine, L-Homoserine, Isocitrate, L-Isoleucine, Isomaltose, L-Leucine, L-Lysine, (S) -Malate, L-Methionine, Maltose, D-Mannitol, N-Acetyl-D-glucosamine, Sodium, NH3, Nitrite, Nitrate, O2, L-Ornithine, L-Phenylalanine, Orthophosphate, L-Proline, Putrescine, L-Serine , (S) -Lactate, Sulfate, Spermidine, Succinate, Sucrose, L-Threonine, alpha, alpha-Trehalose, L-Tryptophan, Taurine, L-Tyrosine, Uracil, Urea, Uridine, L-Valine, and Xanthine Method characterized by being selected .
- 제21항 또는 제22항 있어서, 상기 (b)단계에서 수득된 1차 필수 대사산물은 (R)-4'-Phosphopantothenoyl-L-cysteine, (R)-pantoate, (R)-Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Acyl-sn-glycerol 3-phosphate, 1-Deoxy-D-xylulose 5-phosphate, 2,3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4-(5'-phosphoribosylamino)-pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine, 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine triphosphate, 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate , 2-Dehydro-3-deoxy-D-octonate, 2-Dehydro-3-deoxy-D-octonate 8-phosphate, 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3-Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4,6-Dideoxy-4-oxo-dTDP-D-glucose, 4-amino-4-deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate, 5,10-Methylenetetrahydrofolate, 5-Amino-6-(5'-phosphoribitylamino)uracil, 5-Amino-6-(5'-phosphoribosylamino)uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H)-pyrimidinedione, 5-O-(1-Carboxyvinyl)-3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, Acetyl-[acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, ADP, all-trans-Octaprenyl diphosphate, alpha-D-Glucose, alpha-D-Glucose 6-phosphate, alpha-D-Mannose 1-phosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 1,6-bisphosphate, beta-D-Fructose 6-phosphate, beta-D-Glucose, beta-hydroxy dodecanoic acid, beta-hydroxy tetradecanoic acid, Cardiolipin (biomass component), CDP, CDP-diacylglycerol, Chorismate, CO2, CoA, Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, dADP, D-alanine, D-alanyl-D-alanine, D-Arabinose 5-phosphate, dATP, dCDP, dCTP, Deamino-NAD+, Decanoyl-[acyl-carrier protein], Dephospho-CoA, D-Erythrose 4-phosphate, dGDP, D-Glucosamine 1-phosphate, D-Glucosamine 6-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate, dGTP, Dihydrofolate, Dihydropteroate, D-Mannose 6-phosphate, DNA (biomass component), DNA 5-methylcytosine, Dodecanoyl-[acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTDP-4-dehydro-6-deoxy-L-mannose, dTDP-6-deoxy-L-mannose, dTDP-glucose, dTMP, dTTP, dUMP, Exopolysaccharide, Flavin adenine dinucleotide, FMN, GDP, GDP-mannose, Glycerone phosphate, Glycine, GMP, GTP, H2O2, HCO3, Heptadecanoyl-[acyl-carrier protein], Heptadecenoyl-[acyl-carrier protein], Hexadecanoyl-[acyl-carrier protein], Hexadecenoyl-[acyl-carrier protein], Iminoaspartate, IMP, Isochorismate, L,L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspartate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lipids other than phospholipid, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl-[acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminoheptanedioate, N6-(1,2-Dicarboxyethyl)-AMP, N-Acetyl-D-glucosamine 1-phosphate, NAD+, NADP+, NADPH, NH3, Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L-2,6-diaminopimelate, Octadecanoyl-[acyl-carrier protein], Octadecenoyl-[acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxygen, Pantetheine 4'-phosphate, Pentadecanoyl-[acyl-carrier protein], Peptidoglycan (biomass component), Peptidoglycan precursor, Phosphatidate, Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphoenolpyruvate, Phospholipids (biomass component), Propanoyl-[acyl-carrier protein], Propanoyl-CoA, Proteins , Pyridoxal, Pyridoxal 5'-phosphate, Pyridoxine, Pyridoxine 5'-phosphate, Pyruvate, Quinolinate, Riboflavin, RNA , S-Adenosyl-L-methionine, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl-[acyl-carrier protein], Tetrahydrofolate, Thioredoxin, Thioredoxin disulfide, Thymidine, Thymine, UDP, UDP-D-galactose, UDP-glucose, UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine, UDP-N-acetyl-D-galactosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-(glycyl)5-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, UTP, 및 Xanthosine 5'-phosphate로 구성된 군에서 선택되는 것을 특징으로 하는 방법.The method according to claim 21 or 22, wherein the primary essential metabolite obtained in step (b) is (R) -4'-Phosphopantothenoyl-L-cysteine, (R) -pantoate, (R) -Pantothenate, 1, 4-dihydroxy-2-naphthoate, 1-Acyl-sn-glycerol 3-phosphate, 1-Deoxy-D-xylulose 5-phosphate, 2,3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5- Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine, 2-Amino-4-hydroxy-6- (D-erythro-1,2,3- trihydroxypropyl) -7,8-dihydropteridine, 2-Amino-4-hydroxy-6- (erythro-1,2,3-trihydroxypropyl) dihydropteridine triphosphate, 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine , 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate, 2-Dehydro-3-deoxy-D-octonate, 2-Dehydro-3-deoxy-D-octonate 8-phosphate, 2-Dehydropantoate, 2 -Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3-Dehydroshikimate, 3-Hydroxy- 4-phospho-hydroxy-alpha-ketobutyr ate, 3-Methyl-2-oxobutanoic acid, 4,6-Dideoxy-4-oxo-dTDP-D-glucose, 4-amino-4-deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate, 5,10 -Methylenetetrahydrofolate, 5-Amino-6- (5'-phosphoribitylamino) uracil, 5-Amino-6- (5'-phosphoribosylamino) uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H) -pyrimidinedione, 5-O- (1-Carboxyvinyl) -3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl-8- (1-D-ribityl) lumazine, Acetyl- [acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, ADP, all-trans-Octaprenyl diphosphate, alpha-D-Glucose, alpha-D-Glucose 6-phosphate, alpha-D-Mannose 1-phosphate, AMP, ATP, beta -Alanine, beta-D-Fructose 1,6-bisphosphate, beta-D-Fructose 6-phosphate, beta-D-Glucose, beta-hydroxy dodecanoic acid, beta-hydroxy tetradecanoic acid, Cardiolipin (biomass component), CDP, CDP -diacylglycerol, Chorismate, CO 2 , CoA, Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, dADP, D-alanine, D-alanyl-D-alanine, D-Arabinose 5-phosphate, dATP, dCDP, dCTP, Deamino-NAD +, Decanoyl- [acyl-carrier protein], Dephospho-CoA, D-Erythrose 4-phosphate, dGDP, D-Glucosamine 1-phosphate, D-Glucosamine 6-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate, dGTP, Dihydrofolate, Dihydropteroate, D-Mannose 6-phosphate, DNA (biomass component), DNA 5-methylcytosine, Dodecanoyl- [acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate , dTDP, dTDP-4-dehydro-6-deoxy-L-mannose, dTDP-6-deoxy-L-mannose, dTDP-glucose, dTMP, dTTP, dUMP, Exopolysaccharide, Flavin adenine dinucleotide, FMN, GDP, GDP-mannose , Glycerone phosphate, Glycine, GMP, GTP, H 2 O 2 , HCO 3 , Heptadecanoyl- [acyl-carrier protein], Heptadecenoyl- [acyl-carrier protein], Hexadecanoyl- [acyl-carrier protein], Hexadecenoyl- [acyl- carrier protein], Iminoaspartate, IMP, Isochorismate, L, L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate , L-Aspartate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lipids other than phospholipid, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl- [acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminoheptanedioate, N6- (1,2-Dicarboxyethyl) -AMP, N-Acetyl-D-glucosamine 1-phosphate, NAD +, NADP +, NADPH, NH 3 , Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L-2,6-diaminopimelate, Octadecanoyl- [acyl-carrier protein], Octadecenoyl- [acyl- carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxygen, Pantetheine 4'-phosphate, Pentadecanoyl- [acyl-carrier protein], Peptidoglycan (biomass component) , Peptidoglycan precursor, Phosphatidate, Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphoenolpyruvate, Phospholipids (biomass component), Propanoyl- [acyl-carrier protein], Propanoyl-CoA, Protein yridoxal, Pyridoxal 5'-phosphate, Pyridoxine, Pyridoxine 5'-phosphate, Pyruvate, Quinolinate, Riboflavin, RNA, S-Adenosyl-L-methionine, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl- [acyl-carrier protein], Tetrahydrofolate, Thioredoxin, Thioredoxin disulfide, Thymidine, Thymine, UDP, UDP-D-galactose, UDP-glucose, UDP-N-acetyl-3- (1-carboxyvinyl) -D-glucosamine, UDP-N-acetyl-D-galactosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma- glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl- D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl- (glycyl) 5-D-alanyl -D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-di aminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl- diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, UTP, and Xanthosine 5'-phosphate.
- 제21항 또는 제22항에 있어서, 상기 5차 필수 대사산물은 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, D-Glutamate, 2,3-Dihydrodipicolinate, 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, 3-Dehydroshikimate, 1-Deoxy-D-xylulose 5-phosphate, 3-Dehydroquinate, 2-Dehydro-3-deoxy-D-octonate, 및 4-Aminobenzoate으로 구성된 군에서 선택되는 것을 특징으로 하는 방법.The method of claim 21 or 22, wherein the fifth essential metabolite is 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, D-Glutamate, 2,3-Dihydrodipicolinate, 2-Amino-4 -hydroxy-6- (D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 3-Dehydroshikimate, 1-Deoxy-D-xylulose 5-phosphate, 3-Dehydroquinate, 2-Dehydro-3- deoxy-D-octonate, and 4-Aminobenzoate.
- 제21항의 방법에 따라 선정된 아시네토박터(Acinetobacter) 속 미생물의 약물 표적 효소인 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase(3-dehydroquinase), shikimate 5-dehydrogenase, quinate/shikimate dehydrogenase, 3-dehydroshikimate dehydratase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, 및 dihydropteroate synthase로 구성된 군에서 선택되는 1종 이상의 효소, 또는 상기 효소를 코딩하는 유전자를 아시네토박터(Acinetobacter) 속 미생물에 대한 약물 표적으로 이용하는 방법.Drug targeting enzymes of Acinetobacter genus microorganism selected according to the method of claim 21, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine, pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D- glutamate ligase, dihydrodipicolinate reductase, dihydroneopterin aldolase, alkaline phosphatase D precursor, 3-dehydroquinate dehydratase II, catabolic 3-dehydroquinate dehydratase (3-dehydroquinase), shikimate 5-dehydrogenase, quinate / shikimate dehydrogenase, 3-dehydroshikimate dedeoxyatase One or more enzymes selected from the group consisting of D-xylulose-5-phosphate reductoisomerase, pyridoxine 5-phosphate synthase, 3-deoxy-manno-octulosonate cytidylyltransferase, and dihydropteroate synthase, or genes encoding the enzymes may be represented by acinetobacter ( Acinetobacter) as a drug target for microorganisms.
- 제30항에 있어서, 상기 효소를 코딩하는 유전자는, ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE2076, ABAYE3176, ABAYE3395, ABAYE3524, ABAYE3568, ABAYE3612 및 ABAYE3616으로 구성된 군에서 선택되는 1종 이상인 것을 특징으로 하는 방법.The gene encoding the enzyme is ABAYE0036, ABAYE0082, ABAYE0377, ABAYE0807, ABAYE0811, ABAYE0945, ABAYE1417, ABAYE1418, ABAYE1539, ABAYE1581, ABAYE1682, ABAYE1683, ABAYE1685, ABAYE376, ABAYE376 At least one selected from the group consisting of ABAYE3612 and ABAYE3616.
- 제22항에 있어서, 상기 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군은 타니모토 계수가 0.5~1인 화합물인 것을 특징으로 하는 방법.The method of claim 22, wherein the compound candidate group having structural similarity to the fifth essential metabolite is a compound having a Tanimoto coefficient of 0.5 to 1.
- 제22항에 있어서, 상기 화합물 후보군을 아시네토박터(Acinetobacter) 속 미생물에 투여하여 성장 억제 여부를 확인함으로써, 약물을 스크리닝 하는 단계는 화합물이 처리되지 않은 대조군에 비해, 화합물을 처리한 시험군의 아시네토박터(Acinetobacter) 속 미생물의 농도를 80% 이상 억제하는 화합물을 미생물에 대한 약물로써 스크리닝 하는 것을 특징으로 하는 방법. 23. The method of claim 22, wherein the step of screening the drug by administering the compound candidate group to Acinetobacter genus microorganisms to determine whether to inhibit the growth, compared to the control group without the compound, A method for screening a compound that inhibits the concentration of at least 80% of the genus Acinetobacter as a drug against the microorganism.
- 다음의 단계를 포함하는, 비브리오(Vibrio) 속 미생물의 약물 표적 효소의 스크리닝 방법:A method for screening a drug target enzyme of Vibrio sp. Microorganism, comprising the following steps:(a) 비브리오(Vibrio) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of Vibrio genus microorganisms;(b) 상기 구축된 비브리오(Vibrio) 속 미생물 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed Vibrio (Vibrio)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 비브리오(Vibrio) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하고, 상기 5차 필수 대사산물에 관여하는 효소를 비브리오(Vibrio) 속 미생물의 약물 표적 효소로 선정하는 단계.(f) if all of the enzymes consuming the fourth essential metabolites determined in step (e) do not have homology with the host protein, the corresponding metabolites are determined as the fifth essential metabolite, and the fifth essential metabolite Selecting an enzyme involved in the drug target enzyme of the microorganism of Vibrio genus.
- 다음의 단계를 포함하는, 비브리오(Vibrio) 속 미생물에 대한 약물 스크리닝 방법:Drug screening method for Vibrio spp. Microorganisms comprising the following steps:(a) 비브리오(Vibrio) 속 미생물의 대사 네트워크 모델을 구축하는 단계; (a) establishing a metabolic network model of Vibrio genus microorganisms;(b) 상기 구축된 비브리오(Vibrio) 속 미생물 미생물 대사 네트워크에서 특정 대사산물들을 소비하는 효소 반응을 동시에 차단시킨 상태에서, 세포의 성장속도가 0인 경우의 상기 특정 대사산물들을 1차 필수 대사산물들로 결정하는 단계;(b) the constructed Vibrio (Vibrio)Genus microorganism Determining the specific metabolites as primary essential metabolites when the growth rate of the cell is zero while simultaneously blocking the enzymatic reaction of consuming the specific metabolites in the metabolic network;(c) 상기 (b) 단계에서 결정된 1차 필수 대사산물들 중, 비브리오(Vibrio) 속 미생물과의 특이성(specificity)이 없는 유통 대사산물 (currency metabolite)을 제거하여 2차 필수 대사산물을 결정하는 단계;(c) Among the primary essential metabolites determined in step (b), the secondary essential metabolite is determined by removing a circulation metabolite having no specificity with Vibrio genus microorganisms. step;(d) 상기 (c) 단계에서 결정된 2차 필수 대사산물들 중, 관여하는 효소 반응식의 수 및 소비하는 효소 반응식의 수를 고려하여 3차 필수 대사산물로 결정하는 단계;(d) determining the third essential metabolite in consideration of the number of enzymatic schemes involved and the number of enzymatic schemes consumed among the secondary essential metabolites determined in step (c);(e) 상기 (d) 단계에서 결정된 3차 필수 대사산물들 중 숙주의 대사에 존재하지 않는 것들만을 선별하여 4차 필수 대사산물로 결정하는 단계; 및(e) selecting only those which are not present in the metabolism of the host among the third essential metabolites determined in step (d) and determining the fourth essential metabolite; And(f) 상기 (e) 단계에서 결정된 4차 필수 대사산물들을 소비하는 모든 효소들이 숙주 단백질과 상동관계가 없는 경우, 해당 필수 대사산물들을 5차 필수 대사산물로 결정하는 단계;(f) if all the enzymes consuming the fourth essential metabolites determined in step (e) do not have a homology with the host protein, determining those essential metabolites as the fifth essential metabolite;(g) 상기 (f)단계에서 결정된 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군을 화합물 라이브러리에서 타니모토 계수를 이용하여 선별하는 단계; 및(g) selecting a compound candidate group having structural similarity to the fifth essential metabolite determined in step (f) using the Tanimoto coefficient in the compound library; And(h) 상기 선별된 화합물 후보군을 각각 비브리오(Vibrio) 속 미생물에 투여하여 미생물의 성장 억제 여부를 확인함으로써, 미생물에 대한 약물을 스크리닝 하는 단계.(h) screening drugs against the microorganisms by administering each of the selected compound candidate groups to the microorganisms of Vibrio genus to determine whether they inhibit the growth of the microorganisms.
- 제34항 또는 제35항에 있어서, 상기 비브리오(Vibrio) 속 미생물은 비브리오 불니피커스 (Vibrio vulnificus)인 것을 특징으로 하는 방법.36. The method of claim 34 or 35, wherein the Vibrio genus microorganism is Vibrio vulnificus.
- 제34항 또는 제35항에 있어서, 상기 숙주는 인간인 것을 특징으로 하는 방법.36. The method of claim 34 or 35, wherein said host is a human.
- 제34항 또는 제35항에 있어서, (a) 단계에서의 상기 비브리오(Vibrio) 속 미생물 대사 네트 구축은 VV10014, VV10053, VV10060, VV10061, VV10136, VV10143, VV10145, VV10154, VV10155, VV10156, VV10157, VV10158, VV10159, VV10160, VV10161, VV10162, VV10169, VV10176, VV10177, VV10179, VV10180, VV10183, VV10187, VV10188, VV10209, VV10212, VV10236, VV10246, VV10248, VV10249, VV10254, VV10256, VV10257, VV10265, VV10272, VV10286, VV10288, VV10289, VV10291, VV10314, VV10315, VV10316, VV10317, VV10319, VV10321, VV10322, VV10323, VV10325, VV10326, VV10329, VV10333, VV10340, VV10344, VV10366, VV10414, VV10418, VV10419, VV10426, VV10427, VV10430, VV10449, VV10450, VV10465, VV10484, VV10487, VV10494, VV10495, VV10504, VV10507, VV10508, VV10516, VV10526, VV10543, VV10544, VV10545, VV10553, VV10554, VV10555, VV10556, VV10558, VV10559, VV10565, VV10566, VV10567, VV10571, VV10577, VV10578, VV10580, VV10581, VV10582, VV10583, VV10591, VV10595, VV10596, VV10597, VV10610, VV10613, VV10623, VV10625, VV10638, VV10639, VV10641, VV10644, VV10647, VV10648, VV10649, VV10654, VV10655, VV10656, VV10657, VV10662, VV10665, VV10666, VV10673, VV10678, VV10679, VV10688, VV10705, VV10707, VV10708, VV10723, VV10725, VV10726, VV10727, VV10728, VV10774, VV10779, VV10780, VV10796, VV10797, VV10799, VV10803, VV10804, VV10808, VV10814, VV10815, VV10819, VV10828, VV10830, VV10831, VV10850, VV10852, VV10854, VV10881, VV10889, VV10894, VV10902, VV10907, VV10909, VV10933, VV10935, VV10940, VV10963, VV10964, VV10978, VV10981, VV10982, VV10989, VV10990, VV10992, VV11015, VV11016, VV11017, VV11018, VV11019, VV11020, VV11021, VV11022, VV11023, VV11028, VV11029, VV11030, VV11031, VV11032, VV11047, VV11053, VV11054, VV11056, VV11057, VV11077, VV11083, VV11099, VV11100, VV11102, VV11105, VV11120, VV11121, VV11122, VV11123, VV11126, VV11127, VV11141, VV11153, VV11163, VV11164, VV11165, VV11168, VV11175, VV11195, VV11197, VV11198, VV11199, VV11200, VV11218, VV11226, VV11227, VV11234, VV11235, VV11236, VV11237, VV11249, VV11257, VV11266, VV11267, VV11268, VV11269, VV11270, VV11276, VV11277, VV11281, VV11284, VV11291, VV11299, VV11306, VV11307, VV11311, VV11312, VV11313, VV11314, VV11315, VV11328, VV11342, VV11343, VV11345, VV11349, VV11353, VV11361, VV11364, VV11364*, VV11365, VV11366, VV11369, VV11370, VV11371, VV11372, VV11373, VV11374, VV11382, VV11383, VV11386, VV11393, VV11396, VV11402, VV11403, VV11404, VV11423, VV11424, VV11425, VV11428, VV11453, VV11461, VV11464, VV11465, VV11466, VV11467, VV11474, VV11485, VV11517, VV11519, VV11524, VV11530, VV11536, VV11537, VV11539, VV11540, VV11541, VV11546, VV11547, VV11552, VV11558, VV11568, VV11569, VV11575, VV11576, VV11578, VV11579, VV11582, VV11583, VV11584, VV11585, VV11593, VV11594, VV11600, VV11601, VV11602, VV11606, VV11608, VV11621, VV11622, VV11627, VV11630, VV11631, VV11632, VV11635, VV11636, VV11637, VV11642, VV11643, VV11644, VV11653, VV11654, VV11664, VV11678, VV11683, VV11691, VV11692, VV11698, VV11716, VV11725, VV11726, VV11727, VV11728, VV11730, VV11766, VV11767, VV11770, VV11771, VV11772, VV11773, VV11785, VV11787, VV11790, VV11799, VV11810, VV11838, VV11846, VV11855, VV11861, VV11865, VV11866, VV11870, VV11872, VV11873, VV11876, VV11883, VV11896, VV11897, VV11899, VV11900, VV11901, VV11912, VV11916, VV11975, VV11976, VV11978, VV11981, VV11986, VV11988, VV11989, VV11992, VV11993, VV11994, VV11997, VV12002, VV12016, VV12022, VV12064, VV12074, VV12075, VV12086, VV12088, VV12098, VV12116, VV12118, VV12126, VV12127, VV12131, VV12132, VV12156, VV12162, VV12163, VV12173, VV12200, VV12219, VV12220, VV12221, VV12227, VV12234, VV12248, VV12254, VV12257, VV12260, VV12265, VV12266, VV12341, VV12349, VV12355, VV12356, VV12357, VV12370, VV12371, VV12372, VV12374, VV12378, VV12379, VV12389, VV12390, VV12391, VV12392, VV12397, VV12448, VV12560, VV12590, VV12591, VV12592, VV12599, VV12614, VV12617, VV12618, VV12619, VV12620, VV12637, VV12641, VV12654, VV12682, VV12683, VV12684, VV12699, VV12702, VV12711, VV12730, VV12731, VV12732, VV12754, VV12755, VV12765, VV12768, VV12771, VV12772, VV12783, VV12785, VV12786, VV12787, VV12788, VV12797, VV12799, VV12801, VV12810, VV12813, VV12824, VV12826, VV12843, VV12871, VV12872, VV12888, VV12890, VV12907, VV12908, VV12910, VV12913, VV12914, VV12915, VV12916, VV12917, VV12918, VV12919, VV12920, VV12924, VV12928, VV12940, VV12942, VV12943, VV12944, VV12945, VV12946, VV12952, VV12977, VV12983, VV12992, VV12999, VV13002, VV13005, VV13006, VV13007, VV13009, VV13010, VV13011, VV13016, VV13018, VV13022, VV13025, VV13028, VV13035, VV13040, VV13041, VV13042, VV13050, VV13052, VV13060, VV13064, VV13065, VV13066, VV13067, VV13068, VV13069, VV13100, VV13111, VV13115, VV13135, VV13140, VV13153, VV13168, VV13169, VV13170, VV13172, VV13173, VV13174, VV20005, VV20010, VV20011, VV20012, VV20019, VV20053, VV20065, VV20117, VV20123, VV20148, VV20186, VV20188, VV20190, VV20198, VV20199, VV20200, VV20206, VV20214, VV20216, VV20217, VV20218, VV20237, VV20256, VV20280, VV20315, VV20316, VV20317, VV20330, VV20334, VV20337, VV20349, VV20367, VV20369, VV20370, VV20389, VV20390, VV20397, VV20398, VV20400, VV20407, VV20455, VV20456, VV20468, VV20469, VV20470, VV20471, VV20478, VV20488, VV20489, VV20490, VV20491, VV20493, VV20494, VV20496, VV20497, VV20498, VV20499, VV20500, VV20514, VV20515, VV20531, VV20532, VV20543, VV20552, VV20553, VV20558, VV20560, VV20561, VV20565, VV20566, VV20567, VV20568, VV20569, VV20712, VV20721, VV20730, VV20734, VV20735, VV20736, VV20741, VV20742, VV20752, VV20768, VV20789, VV20833, VV20835, VV20854, VV20869, VV20878, VV20903, VV20904, VV20905, VV20914, VV20966, VV20996, VV21024, VV21030, VV21050, VV21062, VV21064, VV21069, VV21070, VV21071, VV21072, VV21084, VV21085, VV21093, VV21094, VV21095, VV21118, VV21122, VV21136, VV21142, VV21180, VV21200, VV21204, VV21235, VV21237, VV21250, VV21251, VV21266, VV21287, VV21318, VV21327, VV21330, VV21348, VV21349, VV21352, VV21353, VV21356, VV21357, VV21373, VV21395, VV21412, VV21426, VV21432, VV21433, VV21457, VV21473, VV21484, VV21485, VV21520, VV21540, VV21596, VV21599, VV21615, VV21622, VV21635, VV21637, VV21651, VV21663, VV21664, VV21677, VV21687, VV21688 으로 구성된 유전자 군에 기반한 것을 특징으로 하는 방법.36. The method according to claim 34 or 35, wherein the microbial metabolic net construction of Vibrio genus in step (a) is VV10014, VV10053, VV10060, VV10061, VV10136, VV10143, VV10145, VV10154, VV10155, VV10156, VV10157, VV10158 , VV10159, VV10160, VV10161, VV10162, VV10169, VV10176, VV10177, VV10179, VV10180, VV10183, VV10187, VV10188, VV10209, VV10212, VV10236, VV10246, VV10248, VV10249, VV1022 , VV10289, VV10291, VV10314, VV10315, VV10316, VV10317, VV10319, VV10321, VV10322, VV10323, VV10325, VV10326, VV10329, VV10333, VV10340, VV10344, VV10366, VV10414, VV10418, VV10418, VV104 , VV10465, VV10484, VV10487, VV10494, VV10495, VV10504, VV10507, VV10508, VV10516, VV10526, VV10543, VV10544, VV10545, VV10553, VV10554, VV10555, VV10556, VV10558, VV10559, V105 105, V565 , VV10580, VV10581, VV10582, VV10583, VV10591, VV10595, VV10596, VV10597, VV10610, VV10613, VV 10623, VV10625, VV10638, VV10639, VV10641, VV10644, VV10647, VV10648, VV10649, VV10654, VV10655, VV10656, VV10657, VV10662, VV10665, VV10666, VV10673, VV10678, VV10679, V707 V107 V10 VV10726, VV10727, VV10728, VV10774, VV10779, VV10780, VV10796, VV10797, VV10799, VV10803, VV10804, VV10808, VV10814, VV10815, VV10819, VV10828, VV10830, VV10831, V852 10, V108, V108, V10 VV10907, VV10909, VV10933, VV10935, VV10940, VV10963, VV10964, VV10978, VV10981, VV10982, VV10989, VV10990, VV10992, VV11015, VV11016, VV11017, VV11018, VV11019, VV11020, V110, V110 VV11031, VV11032, VV11047, VV11053, VV11054, VV11056, VV11057, VV11077, VV11083, VV11099, VV11100, VV11102, VV11105, VV11120, VV11121, VV11122, VV11123, VV11126, VV11127, V11 V11, V11 VV11175, VV11195, VV11197, VV11198, VV11199, VV11200, VV11218, VV11226, VV11227, VV11234, VV11235, VV1 1236, VV11237, VV11249, VV11257, VV11266, VV11267, VV11268, VV11269, VV11270, VV11276, VV11277, VV11281, VV11284, VV11291, VV11299, VV11306, VV11307, VV11311, VV11312, V113V11 V11 VV11345, VV11349, VV11353, VV11361, VV11364, VV11364 *, VV11365, VV11366, VV11369, VV11370, VV11371, VV11372, VV11373, VV11374, VV11382, VV11383, VV11386, VV11393, VV11386, VV24, V11 V11 , VV11428, VV11453, VV11461, VV11464, VV11465, VV11466, VV11467, VV11474, VV11485, VV11517, VV11519, VV11524, VV11530, VV11536, VV11537, VV11539, VV11540, VV11541, VV11 V, V115, V11 , VV11576, VV11578, VV11579, VV11582, VV11583, VV11584, VV11585, VV11593, VV11594, VV11600, VV11601, VV11602, VV11606, VV11608, VV11621, VV11622, VV11627, VV11630, VV11631, V116 V, V11631, V116 , VV11644, VV11653, VV11654, VV11664, VV11678, VV11683, VV11691, VV11692, VV11698, VV11716, VV11725, VV1 1726, VV11727, VV11728, VV11730, VV11766, VV11767, VV11770, VV11771, VV11772, VV11773, VV11785, VV11787, VV11790, VV11799, VV11810, VV11838, VV11846, VV11855, VV11861, V118 V11 V870 V11 V870 V11 VV11883, VV11896, VV11897, VV11899, VV11900, VV11901, VV11912, VV11916, VV11975, VV11976, VV11978, VV11981, VV11986, VV11988, VV11989, VV11992, VV11993, VV11994, VV11997, V2 V1201, V2 VV12086, VV12088, VV12098, VV12116, VV12118, VV12126, VV12127, VV12131, VV12132, VV12156, VV12162, VV12163, VV12173, VV12200, VV12219, VV12220, VV12221, VV12227, VV12221, VV1222, VV12234, V12212, V1222, V1212, V1212, V1212, V1212, V1212, V1212, V1212, V1212, V1224 VV12341, VV12349, VV12355, VV12356, VV12357, VV12370, VV12371, VV12372, VV12374, VV12378, VV12379, VV12389, VV12390, VV12391, VV12392, VV12397, VV12448, VV12560, VV12590 V125 V12 VV12619, VV12620, VV12637, VV12641, VV12654, VV12682, VV12683, VV12684, VV12699, VV12702, VV12711, VV12 730, VV12731, VV12732, VV12754, VV12755, VV12765, VV12768, VV12771, VV12772, VV12783, VV12785, VV12786, VV12787, VV12788, VV12797, VV12799, VV12801, VV12810, VV12813, V12128, V128 V12 VV12890, VV12907, VV12908, VV12910, VV12913, VV12914, VV12915, VV12916, VV12917, VV12918, VV12919, VV12920, VV12924, VV12928, VV12940, VV12942, VV12943, VV12944, VV1292, V1292, V1292, V1292, V1292 VV13002, VV13005, VV13006, VV13007, VV13009, VV13010, VV13011, VV13016, VV13018, VV13022, VV13025, VV13028, VV13035, VV13040, VV13041, VV13042, VV13050, VV13052, VV13060, V13060, V130 VV13100, VV13111, VV13115, VV13135, VV13140, VV13153, VV13168, VV13169, VV13170, VV13172, VV13173, VV13174, VV20005, VV20010, VV20011, VV20012, VV20019, VV20053, VV20065, V117, V20 VV20198, VV20199, VV20200, VV20206, VV20214, VV20216, VV20217, VV20218, VV20237, VV20256, VV20280, VV203 15, VV20316, VV20317, VV20330, VV20334, VV20337, VV20349, VV20367, VV20369, VV20370, VV20389, VV20390, VV20397, VV20398, VV20400, VV20407, VV20455, VV20456, VV20468, VV204 V20, V71 VV20490, VV20491, VV20493, VV20494, VV20496, VV20497, VV20498, VV20499, VV20500, VV20514, VV20515, VV20531, VV20532. VV20721, VV20730, VV20734, VV20735, VV20736, VV20741, VV20742, VV20752, VV20768, VV20789, VV20833, VV20835, VV20854, VV20869, VV20878, VV20903, VV20904, VV20905, VV20914, V210 V220 VV21064, VV21069, VV21070, VV21071, VV21072, VV21084, VV21085, VV21093, VV21094, VV21095, VV21118, VV21122, VV21136, VV21142, VV21180, VV21200, VV21204, VV21235, VV21237, V21 V21, V21, V21, V21, V21 VV21330, VV21348, VV21349, VV21352, VV21353, VV21356, VV21357, VV21373, VV21395, VV21412, VV21426, VV2143 2, VV21433, VV21457, VV21473, VV21484, VV21485, VV21520, VV21540, VV21596, VV21599, VV21615, VV21622, VV21635, VV21637, VV21651, VV21663, VV21664, VV21677, VV21687, and VV21688 based on a gene based method .
- 제34항 또는 제35항에 있어서, 상기 (b)단계의 수행은, 36. The method of claim 34 or 35, wherein performing step (b) comprises:(i) 상기 구축된 비브리오(Vibrio) 속 미생물 대사 네트워크를 이하의 수학식으로 표현하여 선형계획법을 이용하는 단계, 이 때, 상기 선형계획법의 적용은 세포의 성장에 필요한 모든 영양분 조건을 반영하여 이루어지는 것을 특징으로 함; 및(i) Vibrio spp. Expressing the metabolic network by the following equation to use the linear programming, wherein the application of the linear programming is characterized by reflecting all the nutrient conditions necessary for the growth of the cells; And수학식 1Equation 1(여기서, S : 시간에 따른 X의 변화량, X: 대사산물의 농도, t: 시간)(here,S: Over timeXChange in,X= Concentration of metabolite,t: time)(ii) 이하의 수학식2를 이용하여, 대사산물 소비 반응식의 대사흐름값을 0으로 고정시킨 후 세포의 성장속도가 0인 경우를 1차 필수 대사산물로 결정하는 단계로 이루어지는 것을 특징으로 하는 방법:(ii) using the following Equation 2, after fixing the metabolite flow value of the metabolite consumption reaction equation to 0, determining the case where the cell growth rate is 0 as the primary essential metabolite. Way:수학식 2Equation 2(여기서 jm은 각 대사산물의 소비 반응식; Vjm은 해당 소비 반응식의 대사흐름값).Where jm is the consumption equation of each metabolite; Vjm is the metabolic flow value of the corresponding consumption equation.
- 제39항에 있어서, 상기 영양분은 (S)-Lactate, (S)-Malate, 2-Oxoglutarate, 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, alpha,alpha-Trehalose, alpha-D-Glucose, Choline, Citrate, CO2, Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D-Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, L-Homoserine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Ornithine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Maltose, Melibiose, N-Acetyl-D-glucosamine, NH3, Nitrate, Nitrite, Orthophosphate, Oxygen, Putrescine, sn-Glycerol 3-phosphate, Sodium, Spermidine, Succinate, Sucrose, Sulfate, Thiamin, Thymidine, Uracil, Urea, Uridine, 및 Xanthine 으로 구성된 군에서 선택되는 것을 특징으로 하는 방법.40. The method of claim 39, wherein the nutrient is (S) -Lactate, (S) -Malate, 2-Oxoglutarate, 2-Phospho-D-glycerate, 3-Phospho-D-glycerate, Acetate, Adenosine, alpha, alpha-Trehalose , alpha-D-Glucose, Choline, Citrate, CO 2 , Cytidine, Cytosine, D-alanine, Deoxyadenosine, Deoxycytidine, Deoxyguanosine, Deoxyuridine, D-Fructose, D-Gluconate, D-Glutamate, D-Mannitol, Fumarate, Glycerol, Glycine, Guanosine, Isocitrate, Isomaltose, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, L-Homoserine, L-Isoleucine, L- Leucine, L-Lysine, L-Methionine, L-Ornithine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Maltose, Melibiose, N-Acetyl- D-glucosamine, NH 3 , Nitrate, Nitrite, Orthophosphate, Oxygen, Putrescine, sn-Glycerol 3-phosphate, Sodium, Spermidine, Succinate, Sucrose, Sulfate, Thiamin, Thymidine, Uracil, Urea, Uridine, and Xanthine Selected method.
- 제34항 또는 제35항에 있어서, 상기 (b)단계에서 수득된 1차 필수 대사산물은 (R)-4'-Phosphopantothenoyl-L-cysteine, (R)-pantoate, (R)-Pantothenate, 1,4-dihydroxy-2-naphthoate, 1-Deoxy-D-xylulose 5-phosphate , 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate, 2,3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate, 2,5-Diamino-6-hydroxy-4-(5'-phosphoribosylamino)-pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine (L-1-Lysophosphatidylethanolamine), 2-Amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine, 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)-dihydropteridine triphosphate, 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate, 2-C-Methyl-D-erythritol 4-phosphate, 2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate , 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-Phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3-Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4-(Cytidine 5'-diphospho)-2-C-methyl-D-erythritol , 4-amino-4-deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate (4-Phosphoerythronate), 5,10-Methylenetetrahydrofolate, 5-Amino-6-(5'-phosphoribitylamino)uracil, 5-Amino-6-(5'-phosphoribosylamino)uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H)-pyrimidinedione (4-(1-D-Ribitylamino)-5-amino-2,6-dihydroxypyrimidine (4-(1-D-Ribitylamino)-5-aminouracil)), 5-Methyltetrahydrofolate, 5-O-(1-Carboxyvinyl)-3-phosphoshikimate, 5-Phospho-alpha-D-ribose 1-diphosphate, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, Acetyl-[acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, Acyl-sn-glycerol 3-phosphate, ADP, ADP-D-glycero-D-manno-heptose, ADPglucose, ADP-L-glycero-D-manno-heptose, all-trans-Heptaprenyl diphosphate, all-trans-Hexaprenyl diphosphate, all-trans-Octaprenyl diphosphate, all-trans-Pentaprenyl diphosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 6-phosphate, CDP-diacylglycerol, Chorismate, CO2, CoA (coenzyme A), Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, D-alanine, D-alanyl-D-alanine, dATP, dCTP, Deamido-NAD+, Dephospho-CoA, D-Erythrose 4-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate ((2R)-2-Hydroxy-3-(phosphonooxy)-propanal), D-glycero-D-manno-Heptose 1,7-bisphosphate, D-glycero-D-manno-Heptose 1-phosphate, D-glycero-D-manno-Heptose 7-phosphate, dGTP, Dihydrofolate, Dihydropteroate, Dimethylallyl diphosphate, DNA (biomass component), Dodecanoyl-[acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTMP, dTTP, Flavin adenine dinucleotide (FAD), FMN (Riboflavin-5-phosphate, Flavin mononucleotide), Fumarate, GDP, Geranyl diphosphate, Geranylgeranyl diphosphate, Glycerone phosphate, Glycine, Glycogen, GMP, GTP, Hexadecanoyl-[acyl-carrier protein], Hexadecenoyl-[acyl-carrier protein], Iminoaspartate, Isochorismate, Isopentenyl diphosphate, L,L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspartate 4-semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl-[acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminopimelate, NAD+ (Nicotinamide adenine dinucleotide), NADH, NADP+ (Nicotinamide adenine dinucleotide phosphate), NADPH, NH3, Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L-2,6-diaminopimelate, Octadecanoyl-[acyl-carrier protein], Octadecenoyl-[acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxidized thioredoxin, Pantetheine 4'-phosphate, Pentadecanoyl-[acyl-carrier protein], Peptidoglycan (biomass component), Peptidoglycan precursor, Phosphatidate (1,2-Diacyl-sn-glycerol 3-phosphate), Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphoenolpyruvate, Phospholipids (biomass component), Propanoyl-[acyl-carrier protein] (Propionyl-[acyl-carrier protein]), Propanoyl-CoA (Propionyl-CoA), Proteins , Pyridoxine, Pyridoxine 5'-phosphate (Pyridoxine phosphate), Pyruvate, Quinolinate (Pyridine-2,3-dicarboxylate), Riboflavin, RNA , S-Adenosyl-L-methionine, Sedoheptulose 7-phosphate, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl-[acyl-carrier protein], Tetrahydrofolate, Thioredoxin, trans,trans-Farnesyl diphosphate, UDP, UDPglucose, UDP-N-acetyl-3-(1-carboxyvinyl)-D-glucosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-(glycyl)5-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-(N-acetylglucosamine)-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, 및 UTP로 구성된 군에서 선택되는 것을 특징으로 하는 방법. The method of claim 34 or 35, wherein the primary essential metabolite obtained in step (b) is (R) -4'-Phosphopantothenoyl-L-cysteine, (R) -pantoate, (R) -Pantothenate, 1 , 4-dihydroxy-2-naphthoate, 1-Deoxy-D-xylulose 5-phosphate, 1-Hydroxy-2-methyl-2-butenyl 4-diphosphate, 2,3,4,5-Tetrahydrodipicolinate, 2,3-Dihydrodipicolinate , 2,5-Diamino-6-hydroxy-4- (5'-phosphoribosylamino) -pyrimidine, 2-Acyl-sn-glycero-3-phosphoethanolamine (L-1-Lysophosphatidylethanolamine), 2-Amino-4-hydroxy-6 -(D-erythro-1,2,3-trihydroxypropyl) -7,8-dihydropteridine, 2-Amino-4-hydroxy-6- (erythro-1,2,3-trihydroxypropyl) -dihydropteridine triphosphate, 2-Amino- 4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate, 2-C-Methyl-D-erythritol 4-phosphate, 2-Dehydro-3-deoxy- D-arabino-heptonate 7-phosphate, 2-Dehydropantoate, 2-Demethylmenaquinone, 2-Oxobutanoate, 2-Oxoglutarate, 2-Phospho-4- (cytidine 5'-diphospho) -2-C-methyl-D-erythritol, 2 -succinyl-6-hydroxy-2,4-cyclohexadiene-1-c arboxylate, 3-Amino-2-oxopropyl phosphate, 3-Dehydroquinate, 3-Dehydroshikimate, 3-Hydroxy-4-phospho-hydroxy-alpha-ketobutyrate, 3-Methyl-2-oxobutanoic acid, 4- (Cytidine 5'-diphospho ) -2-C-methyl-D-erythritol, 4-amino-4-deoxychorismate, 4-Aminobenzoate, 4-Phospho-D-erythronate (4-Phosphoerythronate), 5,10-Methylenetetrahydrofolate, 5-Amino-6- ( 5'-phosphoribitylamino) uracil, 5-Amino-6- (5'-phosphoribosylamino) uracil, 5-Amino-6-ribitylamino-2,4 (1H, 3H) -pyrimidinedione (4- (1-D-Ribitylamino)- 5-amino-2,6-dihydroxypyrimidine (4- (1-D-Ribitylamino) -5-aminouracil)), 5-Methyltetrahydrofolate, 5-O- (1-Carboxyvinyl) -3-phosphoshikimate, 5-Phospho-alpha- D-ribose 1-diphosphate, 6,7-Dimethyl-8- (1-D-ribityl) lumazine, Acetyl- [acyl-carrier protein], Acetyl-CoA, Acyl-carrier protein, Acyl-sn-glycerol 3-phosphate , ADP, ADP-D-glycero-D-manno-heptose, ADPglucose, ADP-L-glycero-D-manno-heptose, all-trans-Heptaprenyl diphosphate, all-trans-Hexaprenyl diphosphate, all-trans-Octaprenyl diphosphate, all-trans-Penta prenyl diphosphate, AMP, ATP, beta-Alanine, beta-D-Fructose 6-phosphate, CDP-diacylglycerol, Chorismate, CO 2 , CoA (coenzyme A), Cofactors and vitamins, CTP, D-4'-Phosphopantothenate, D- alanine, D-alanyl-D-alanine, dATP, dCTP, Deamido-NAD +, Dephospho-CoA, D-Erythrose 4-phosphate, D-Glucose 1-phosphate, D-Glutamate, D-Glyceraldehyde 3-phosphate ((2R) 2-Hydroxy-3- (phosphonooxy) -propanal), D-glycero-D-manno-Heptose 1,7-bisphosphate, D-glycero-D-manno-Heptose 1-phosphate, D-glycero-D-manno- Heptose 7-phosphate, dGTP, Dihydrofolate, Dihydropteroate, Dimethylallyl diphosphate, DNA (biomass component), Dodecanoyl- [acyl-carrier protein], D-Ribose 5-phosphate, D-Ribulose 5-phosphate, dTDP, dTMP, dTTP, Flavin adenine dinucleotide (FAD), FMN (Riboflavin-5-phosphate, Flavin mononucleotide), Fumarate, GDP, Geranyl diphosphate, Geranylgeranyl diphosphate, Glycerone phosphate, Glycine, Glycogen, GMP, GTP, Hexadecanoyl- [acyl-carrier protein], Hexadecenoyl- [acyl-carrier protein], Iminoaspartate, Isocho rismate, Isopentenyl diphosphate, L, L-2,6-Diaminopimelate, L-3,4-Dihydroxy-2-butanone 4-phosphate, L-Alanine, L-Arginine, L-Asparagine, L-Aspartate, L-Aspartate 4 -semialdehyde, L-Cysteine, L-Glutamate, L-Glutamine, L-Histidine, Lippolysaccharide, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L -Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Malonyl- [acyl-carrier protein], Malonyl-CoA, menaquinol, menaquinone, meso-2,6-Diaminopimelate, NAD + (Nicotinamide adenine dinucleotide), NADH, NADP + (Nicotinamide adenine dinucleotide phosphate), NADPH, NH 3 , Nicotinate D-ribonucleotide, N-Succinyl-2-amino-6-oxopimelate, N-Succinyl-L-2,6-diaminopimelate, Octadecanoyl- [acyl-carrier protein], Octadecenoyl- [acyl-carrier protein], O-Phospho-4-hydroxy-L-threonine, Orthophosphate, O-succinylbenzoate, O-succinylbenzoate-CoA, Oxidized thioredoxin, Pantetheine 4'-phosphate, Pentadecanoyl- [acyl-carrier protein] , Peptidoglycan (biomass component), Peptidoglycan precurs or, Phosphatidate (1,2-Diacyl-sn-glycerol 3-phosphate), Phosphatidylethanolamine, Phosphatidylglycerol, Phosphatidylglycerophosphate, Phosphatidylserine, Phosphoenolpyruvate, Phospholipids (biomass component), Propanoyl- [acyl-p-carrierprotein ]), Propanoyl-CoA (Propionyl-CoA), Proteins, Pyridoxine, Pyridoxine 5'-phosphate (Pyridoxine phosphate), Pyruvate, Quinolinate (Pyridine-2,3-dicarboxylate), Riboflavin, RNA, S-Adenosyl-L-methionine , Sedoheptulose 7-phosphate, Shikimate, Shikimate 3-phosphate, sn-Glycerol 3-phosphate, Succinyl-CoA, Tetradecanoyl- [acyl-carrier protein], Tetrahydrofolate, Thioredoxin, trans, trans-Farnesyl diphosphate, UDP, UDPglucose, UDP- N-acetyl-3- (1-carboxyvinyl) -D-glucosamine, UDP-N-acetyl-D-glucosamine, UDP-N-acetylmuramate, UDP-N-acetylmuramoyl-L-alanine, UDP-N-acetylmuramoyl-L- alanyl-D-gamma-glutamyl-meso-2,6-diaminopimelate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate, UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L- lysyl- D-alanyl-D-alanine, UMP, Undecaprenyl diphosphate, Undecaprenyl phosphate, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl- (glycyl) 5 -D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutaminyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho -N-acetylmuramoyl- (N-acetylglucosamine) -L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, Undecaprenyl-diphospho-N-acetylmuramoyl-L-alanyl-D-glutamyl -meso-2,6-diaminopimeloyl-D-alanyl-D-alanine, and UTP.
- 제34항 또는 제35항에 있어서, 상기 5차 필수 대사산물은 1-deoxy-D-xylulose 5-phosphate, 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2,3-dihydrodipicolinate, 4-aminobenzoate 및 D-glutamate으로 구성된 군에서 선택되는 것을 특징으로 하는 방법.36. The method of claim 34 or 35, wherein the fifth essential metabolite is 1-deoxy-D-xylulose 5-phosphate, 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine, 2,3- dihydrodipicolinate, 4-aminobenzoate and D-glutamate.
- 제34항의 방법에 따라 선정된 비브리오(Vibrio) 속 미생물의 약물 표적 효소인 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, 및 pyridoxine 5-phosphate synthase로 구성된 군에서 선택되는 1종 이상의 효소 또는 상기 효소를 코딩하는 유전자를, 비브리오(Vibrio) 속 미생물에 대한 약물 표적으로 이용하는 방법.Vibrio selected in accordance with the method of claim 34Vibrio) 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase, dihydropteroate synthase, glutamate racemase, UDP-N-acetylmuramoylalanine--D-glutamate ligase, dihydrodipicolinate reductase, 1-deoxy-D-xylulose-5 A method of using at least one enzyme selected from the group consisting of -phosphate reductoisomerase, and pyridoxine 5-phosphate synthase, or a gene encoding the enzyme, as a drug target for Vibrio spp.
- 제43항에 있어서, 상기 효소를 코딩하는 유전자는 VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, 및 VV11866으로 구성된 군에서 선택되는 1종 이상인 것을 특징으로 하는 방법.The method of claim 43, wherein the gene encoding the enzyme is at least one selected from the group consisting of VV10567, VV10580, VV11175, VV11568, VV11644, VV11691, and VV11866.
- 제35항에 있어서, 상기 5차 필수 대사산물과 구조적 유사성을 가진 화합물 후보군은 타니모토 계수가 0.5~ 1인 화합물인 것을 특징으로 하는 방법.36. The method of claim 35, wherein the compound candidate group having structural similarity to the fifth essential metabolite is a compound having a Tanimoto coefficient of 0.5 to 1.
- 제35항에 있어서, 상기 화합물 후보군을 비브리오(Vibrio) 속 미생물에 투여하여 성장 억제 여부를 확인함으로써, 미생물에 대한 약물을 스크리닝 하는 단계는, 화합물 후보군을 처리한 시험군이 비브리오(Vibrio) 속 미생물의 농도를 80% 이상 억제하는 화합물을 미생물에 대한 약물로써 스크리닝 하는 것을 특징으로 하는 방법. The method of claim 35, wherein the compound candidate group is Vibrio (Vibrio) By screening the growth inhibitory by administering to the genus microorganisms, the step of screening the drug for the microorganism, the test group treated with the compound candidate group Vibrio (Vibrio) A method for screening a compound that inhibits the concentration of the genus microorganism by 80% or more as a drug against the microorganism.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0088502 | 2009-09-18 | ||
KR20090088502 | 2009-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011034397A2 true WO2011034397A2 (en) | 2011-03-24 |
WO2011034397A3 WO2011034397A3 (en) | 2011-10-06 |
Family
ID=43758840
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/000162 WO2011034263A1 (en) | 2009-09-18 | 2010-01-11 | Method for predicting a drug target in pathogenic microorganisms using an essential metabolite |
PCT/KR2010/006469 WO2011034397A2 (en) | 2009-09-18 | 2010-09-20 | Method for predicting drug targets and screening for drugs for pathogenic microorganisms using essential metabolites |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/000162 WO2011034263A1 (en) | 2009-09-18 | 2010-01-11 | Method for predicting a drug target in pathogenic microorganisms using an essential metabolite |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101243378B1 (en) |
WO (2) | WO2011034263A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102663214A (en) * | 2012-05-09 | 2012-09-12 | 四川大学 | Construction and prediction method of integrated drug target prediction system |
KR20140019424A (en) * | 2011-04-01 | 2014-02-14 | 로레알 | Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117095741B (en) * | 2023-10-19 | 2024-01-30 | 华东交通大学 | Graph self-attention-based microorganism-drug association prediction method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168654A1 (en) * | 2001-01-10 | 2002-11-14 | Maranas Costas D. | Method and system for modeling cellular metabolism |
WO2008078911A1 (en) * | 2006-12-22 | 2008-07-03 | Korea Advanced Institute Of Science And Technology | Method for screening essential metabolites in growth of microorganisms |
US7440855B2 (en) * | 2001-08-11 | 2008-10-21 | The Regents Of The University Of California | Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7869957B2 (en) * | 2002-10-15 | 2011-01-11 | The Regents Of The University Of California | Methods and systems to identify operational reaction pathways |
WO2005010794A2 (en) * | 2003-07-29 | 2005-02-03 | Ajinomoto Co., Inc. | Method for determining metabolic flux affecting substance production |
KR100655495B1 (en) * | 2005-07-11 | 2006-12-08 | 한국과학기술원 | - Method of In-silico Improvement of Organisms Using the Flux Sum of Metabolites |
KR101132395B1 (en) * | 2008-03-24 | 2012-04-03 | 한국과학기술원 | Systems-oriented Approach for Predicting Drug Targets in Vibrio family |
-
2010
- 2010-01-11 WO PCT/KR2010/000162 patent/WO2011034263A1/en active Application Filing
- 2010-09-17 KR KR1020100092052A patent/KR101243378B1/en active IP Right Grant
- 2010-09-20 WO PCT/KR2010/006469 patent/WO2011034397A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168654A1 (en) * | 2001-01-10 | 2002-11-14 | Maranas Costas D. | Method and system for modeling cellular metabolism |
US7440855B2 (en) * | 2001-08-11 | 2008-10-21 | The Regents Of The University Of California | Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis |
WO2008078911A1 (en) * | 2006-12-22 | 2008-07-03 | Korea Advanced Institute Of Science And Technology | Method for screening essential metabolites in growth of microorganisms |
Non-Patent Citations (2)
Title |
---|
DUROT M. ET AL.: 'Genome-scale models of bacterial metabolism: reconstruction and applications.' FEMS MICROBIOL. REV. vol. 33, 2009, pages 164 - 190 * |
LEE S Y ET AL.: 'Systems biotechnology for strain improvement.' TRENDS BIOTECHNOL. vol. 23, no. 7, 2005, pages 349 - 358 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140019424A (en) * | 2011-04-01 | 2014-02-14 | 로레알 | Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone |
KR102129242B1 (en) | 2011-04-01 | 2020-07-02 | 로레알 | Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone |
CN102663214A (en) * | 2012-05-09 | 2012-09-12 | 四川大学 | Construction and prediction method of integrated drug target prediction system |
Also Published As
Publication number | Publication date |
---|---|
WO2011034263A1 (en) | 2011-03-24 |
KR101243378B1 (en) | 2013-03-25 |
KR20110031143A (en) | 2011-03-24 |
WO2011034397A3 (en) | 2011-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011034397A2 (en) | Method for predicting drug targets and screening for drugs for pathogenic microorganisms using essential metabolites | |
US8635031B2 (en) | Methods for identifying drug targets based on genomic sequence data | |
Moolamalla et al. | Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems biology approach | |
Ouzounis et al. | A minimal estimate for the gene content of the last universal common ancestor—exobiology from a terrestrial perspective | |
Nei et al. | Drift variances of FSTand GST statistics obtained from a finite number of isolated populations | |
EP2463654B1 (en) | Compositions and methods for modeling saccharomyces cerevisiae metabolism | |
Manna et al. | Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans | |
Yoo et al. | Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs | |
Williams et al. | Running energetics of the North American river otter: do short legs necessarily reduce efficiency on land? | |
Papamichael et al. | FIST: A fast, lightweight, FPGA-friendly packet latency estimator for NoC modeling in full-system simulations | |
Contador et al. | Metabolic analyses of nitrogen fixation in the soybean microsymbiont Sinorhizobium fredii using constraint-based modeling | |
US7869957B2 (en) | Methods and systems to identify operational reaction pathways | |
US8311790B2 (en) | Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems | |
Fawcett et al. | A slater parameter optimization method applied to the computation of collision strengths for Fe xiii | |
WO2008078911A1 (en) | Method for screening essential metabolites in growth of microorganisms | |
Cooper et al. | Database guided conformation selection in crystal structure prediction of alanine | |
KR20140015998A (en) | Genome-scale metabolic network model reconstruction of kluyveromyces marxianus and strategies for engineering non-native pathways for 3-hydroxypropionate production in kluyveromyces marxianus | |
Chen et al. | DFT study of binding energies between acetohydroxyacid synthase and its sulfonylurea inhibitors: An application of quantum pseudoreceptor model | |
Bujnicki et al. | RNA:(guanine-N2) methyltransferases RsmC/RsmD and their homologs revisited–bioinformatic analysis and prediction of the active site based on the uncharacterized Mj0882 protein structure | |
Zhang et al. | Tests of association for quantitative traits in nuclear families using principal components to correct for population stratification | |
Olson et al. | Interaction potential for the X1Σ state of Li++ Ar | |
Kämpfer et al. | Flavobacterium panici sp. nov. isolated from the rhizosphere of the switchgrass Panicum virgatum | |
Jordan | Optimization, resolution and application of composite compact finite difference templates | |
Sha et al. | Analytical correction for multiple testing in admixture mapping | |
Aglietti et al. | The teraflop supercomputer APEmille: architecture, software and project status report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10817466 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10817466 Country of ref document: EP Kind code of ref document: A2 |